data_2mry_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mry _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 121.105 0.479 . . . . 0.0 111.325 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.34 129.36 35.89 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.525 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.46 153.58 40.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.187 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.566 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 4.5 pt20 -80.74 135.53 36.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.185 0.517 . . . . 0.0 111.279 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 19.7 mt-30 -94.05 112.39 24.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.601 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.42 -154.28 0.4 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.389 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -81.95 75.81 8.87 Favored 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.12 -5.36 63.23 Favored Glycine 0 CA--C 1.522 0.518 0 C-N-CA 120.772 -0.728 . . . . 0.0 114.121 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 26.9 p90 -144.35 163.76 32.79 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 117.063 0.431 . . . . 0.0 110.958 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.13 154.81 28.26 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.991 0.424 . . . . 0.0 111.452 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.566 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.6 tt0 -145.26 141.59 28.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.515 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.405 ' CG2' HD12 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -143.63 128.59 14.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.863 179.024 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.3 109.97 21.26 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.207 0.527 . . . . 0.0 111.117 179.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 44.9 t -98.22 103.37 14.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.488 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.408 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.8 OUTLIER -70.93 114.23 8.78 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.792 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.3 t -96.61 97.73 6.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.461 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.455 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.2 ptm -144.25 86.98 1.86 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.52 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.47 -0.53 89.06 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.833 -0.698 . . . . 0.0 111.434 -178.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.424 ' N ' HD13 ' A' ' 75' ' ' LEU . . . 161.9 -170.33 37.55 Favored Glycine 0 N--CA 1.448 -0.522 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -93.07 124.24 36.9 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.793 0.297 . . . . 0.0 110.213 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.454 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 37.1 m -63.42 -63.65 3.8 Favored Pre-proline 0 CA--C 1.539 0.527 0 CA-C-O 119.642 -0.218 . . . . 0.0 111.431 -179.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.454 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 60.7 Cg_endo -74.99 96.58 1.02 Allowed 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 121.312 1.341 . . . . 0.0 111.055 177.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.65 -43.44 57.17 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.069 -179.351 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.39 118.68 19.68 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.654 179.443 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.3 pt -97.8 126.78 50.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.913 0.387 . . . . 0.0 110.929 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 95.9 t -100.09 127.24 53.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.953 0.406 . . . . 0.0 111.557 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 2.3 mt -136.87 166.92 22.48 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.279 -179.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -89.62 176.89 6.69 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 120.745 0.307 . . . . 0.0 110.897 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.9 ttpp -107.55 149.53 27.9 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 111.972 0.36 . . . . 0.0 111.972 -179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.7 t 65.55 19.51 11.51 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.725 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.436 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.5 p -123.82 136.26 27.19 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.11 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -64.26 122.61 10.62 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.247 1.965 . . . . 0.0 111.641 178.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.66 138.34 54.31 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.926 0.394 . . . . 0.0 111.723 -179.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.411 HH11 ' HD2' ' A' ' 63' ' ' ARG . 0.1 OUTLIER -120.49 127.42 52.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.643 0.735 . . . . 0.0 111.626 179.825 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.432 HD12 HG23 ' A' ' 64' ' ' ILE . 3.4 mm -100.2 114.23 38.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.623 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 2.8 t -90.64 107.41 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.739 0.304 . . . . 0.0 111.492 -179.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -94.77 102.62 14.51 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.918 0.39 . . . . 0.0 111.279 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -91.17 106.94 18.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.435 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -77.46 105.28 8.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.287 0.565 . . . . 0.0 111.903 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.3 tptp -97.76 -34.28 10.96 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.256 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.455 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.7 t70 -110.27 134.38 20.8 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.848 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -81.42 40.1 0.94 Allowed 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.111 2.54 . . . . 0.0 112.995 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.61 135.37 90.47 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.387 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.27 -32.88 61.41 Favored 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 122.772 2.315 . . . . 0.0 112.802 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.1 p -77.09 -2.15 32.73 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.364 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.424 HD13 ' N ' ' A' ' 48' ' ' GLY . 33.4 mt -119.29 13.56 12.8 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.242 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.14 -36.38 72.06 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.078 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.84 152.67 48.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.896 0.379 . . . . 0.0 111.503 -179.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -132.79 128.48 57.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.103 0.478 . . . . 0.0 110.727 179.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.4 130.61 65.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 121.258 0.551 . . . . 0.0 111.346 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -93.17 102.12 6.72 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.715 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.55 -14.36 41.96 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.621 2.214 . . . . 0.0 113.593 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -100.65 -7.57 23.77 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 111.809 0.299 . . . . 0.0 111.809 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -122.63 -22.77 5.3 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 112.058 0.392 . . . . 0.0 112.058 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.25 25.75 50.44 Favored Glycine 0 C--N 1.331 0.302 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.025 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.7 t -106.5 117.79 52.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.887 0.375 . . . . 0.0 111.71 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -121.67 118.52 29.37 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.388 179.323 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.38 162.53 34.19 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.084 0.468 . . . . 0.0 112.257 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 14.2 p-10 -104.19 148.28 26.48 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.679 179.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 29.5 mt -107.18 130.8 22.33 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.938 0.399 . . . . 0.0 111.716 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -82.34 127.99 5.37 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.743 2.296 . . . . 0.0 112.434 179.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.5 tpt -66.62 125.4 25.65 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-O 121.025 0.441 . . . . 0.0 111.693 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.81 1.37 80.21 Favored Glycine 0 CA--C 1.52 0.344 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.842 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -134.24 177.17 7.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.895 0.379 . . . . 0.0 110.787 -179.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -118.14 133.33 56.0 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.197 0.522 . . . . 0.0 111.639 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.1 t80 -112.16 123.28 49.92 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.127 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.424 ' O ' HG11 ' A' ' 96' ' ' VAL . 1.5 p -97.78 135.24 33.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.609 0.719 . . . . 0.0 112.304 -179.207 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 62.6 t -112.49 109.69 29.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.027 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -92.08 117.17 29.58 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.228 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -131.58 165.8 30.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.237 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.3 m -128.1 96.22 32.04 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.426 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.4 Cg_endo -72.2 98.88 0.95 Allowed 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.803 2.336 . . . . 0.0 112.454 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -95.27 7.78 45.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.832 0.349 . . . . 0.0 111.838 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.39 130.97 31.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.753 0.311 . . . . 0.0 110.931 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -85.3 124.8 32.34 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.199 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 171.71 -166.53 39.51 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.863 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.76 114.89 27.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.036 0.446 . . . . 0.0 110.732 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -110.49 174.84 5.67 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.233 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 91.6 p -153.45 164.15 38.69 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.419 0.525 . . . . 0.0 112.419 -178.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 36.8 p90 -150.85 137.67 19.0 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.481 178.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.261 0 CA-C-O 120.982 0.42 . . . . 0.0 111.708 -179.311 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.8 ttmm . . . . . 0 CA--C 1.53 0.177 0 CA-C-O 121.235 0.54 . . . . 0.0 111.891 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 2.2 ttm -134.65 136.26 42.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.797 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -120.99 118.2 55.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.006 0.432 . . . . 0.0 110.804 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 71.9 t -102.82 121.33 53.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.177 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.254 1.306 0 CA-C-O 118.335 -0.84 . . . . 0.0 111.396 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.531 0.217 0 CA-C-O 121.018 0.437 . . . . 0.0 111.289 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -90.49 126.67 35.99 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.787 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.26 151.88 43.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.15 179.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.574 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 7.7 pt20 -82.24 140.18 33.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.178 0.513 . . . . 0.0 111.545 -179.183 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 6.8 mp0 -95.46 113.25 24.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.488 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 6.1 mmtt -93.2 -148.68 0.25 Allowed 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.474 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -81.64 72.81 8.69 Favored 'General case' 0 CA--C 1.535 0.373 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.19 -5.71 68.37 Favored Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.845 178.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -141.27 160.46 40.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.864 0.332 . . . . 0.0 110.751 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.98 156.23 19.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.197 0.522 . . . . 0.0 111.351 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.574 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 4.2 tt0 -145.9 142.44 28.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.445 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.5 129.61 16.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.194 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -90.23 106.56 18.57 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.012 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 46.1 t -97.81 103.01 14.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.604 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.47 117.48 14.18 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.974 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 42.3 t -100.4 99.04 7.69 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 CA-C-O 121.535 0.683 . . . . 0.0 111.484 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.406 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.5 ptp -141.27 85.63 1.98 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.222 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 87.56 -14.65 57.6 Favored Glycine 0 CA--C 1.519 0.313 0 N-CA-C 111.104 -0.798 . . . . 0.0 111.104 -177.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 176.89 -152.5 12.37 Favored Glycine 0 N--CA 1.449 -0.452 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -104.91 127.98 52.96 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.82 0.31 . . . . 0.0 110.56 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.451 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 43.0 m -69.15 -63.72 1.97 Allowed Pre-proline 0 CA--C 1.539 0.535 0 CA-C-O 119.571 -0.252 . . . . 0.0 111.368 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.451 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 61.9 Cg_endo -74.39 98.09 1.08 Allowed 'Trans proline' 0 C--N 1.357 1.012 0 C-N-CA 121.295 1.33 . . . . 0.0 111.121 177.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.25 -43.86 61.62 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.991 -0.549 . . . . 0.0 112.326 -179.181 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -133.89 118.53 18.05 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.559 0.218 . . . . 0.0 110.776 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.694 HD12 ' SD ' ' A' ' 120' ' ' MET . 8.6 pt -97.33 127.55 49.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.1 0.476 . . . . 0.0 111.004 179.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.5 t -96.04 126.43 48.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.472 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 24.3 mt -133.44 166.4 22.62 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.425 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 18.6 mttt -96.74 166.75 11.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.563 179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.3 ttpp -97.52 147.74 23.95 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.9 t 66.73 18.8 10.74 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.861 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.441 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 6.0 p -123.56 135.16 25.82 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.914 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -64.58 122.73 10.71 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.051 1.834 . . . . 0.0 111.611 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.24 138.94 54.34 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.834 0.35 . . . . 0.0 111.561 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.48 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.5 ptt180 -121.15 126.76 50.54 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.638 0.732 . . . . 0.0 111.394 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.425 HD13 HG23 ' A' ' 64' ' ' ILE . 4.8 mm -98.64 114.36 36.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.822 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.2 t -91.47 109.84 21.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.375 -179.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -96.15 117.37 30.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.132 0.491 . . . . 0.0 111.332 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.6 t0 -99.94 100.31 11.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.412 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.37 93.0 3.41 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 121.225 0.536 . . . . 0.0 111.455 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -88.74 -37.43 15.49 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.752 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.406 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.2 t70 -101.75 129.44 26.61 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.763 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -79.23 38.63 0.74 Allowed 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 123.088 2.525 . . . . 0.0 113.014 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -70.52 135.35 86.27 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.015 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -63.47 -31.57 71.68 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.789 2.326 . . . . 0.0 112.888 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -75.85 -9.45 58.61 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.46 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 36.7 mt -113.22 13.99 19.3 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.466 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -70.13 -38.44 75.55 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.782 0.325 . . . . 0.0 111.709 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -122.64 158.82 29.17 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.113 0.482 . . . . 0.0 111.435 -179.586 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.86 130.12 35.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.444 178.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.433 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 2.0 p -133.27 132.3 58.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.314 0.578 . . . . 0.0 111.43 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -94.08 101.89 7.21 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.516 178.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -67.32 -14.03 41.44 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.589 2.193 . . . . 0.0 113.566 -178.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 33.1 m-20 -100.23 -9.14 22.75 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -122.87 -20.07 5.96 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.76 30.65 42.91 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.353 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 49.8 t -110.8 116.44 52.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.828 0.347 . . . . 0.0 111.733 -179.018 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -119.86 121.12 38.37 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.47 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.92 172.19 13.38 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 -112.66 142.36 45.36 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.461 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 41.0 mt -105.73 122.79 41.39 Favored Pre-proline 0 CA--C 1.531 0.246 0 CA-C-O 121.094 0.473 . . . . 0.0 111.544 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 67.2 Cg_endo -78.13 132.72 11.72 Favored 'Trans proline' 0 CA--C 1.531 0.326 0 C-N-CA 122.921 2.414 . . . . 0.0 112.713 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.8 tpt -68.55 124.89 24.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.082 0.467 . . . . 0.0 111.733 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.06 9.23 85.52 Favored Glycine 0 C--N 1.333 0.395 0 CA-C-N 115.863 -0.608 . . . . 0.0 113.101 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -134.28 176.82 8.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.979 0.419 . . . . 0.0 111.13 -179.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -115.2 133.31 56.15 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.137 0.494 . . . . 0.0 111.647 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 14.1 t80 -119.89 123.64 44.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.977 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.2 p -102.99 137.21 32.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.65 0.738 . . . . 0.0 112.643 -178.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 54.9 t -112.86 112.03 38.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.18 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -93.16 119.52 32.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.507 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -136.49 155.6 34.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.227 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 2.9 m -119.37 97.81 50.3 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.514 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.441 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 73.2 Cg_endo -74.24 100.82 1.34 Allowed 'Trans proline' 0 CA--C 1.531 0.344 0 C-N-CA 122.86 2.373 . . . . 0.0 112.503 179.719 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -95.63 3.76 53.7 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.919 0.39 . . . . 0.0 111.657 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -130.4 133.63 46.52 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.867 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -90.07 128.8 36.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.908 0.385 . . . . 0.0 111.255 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 168.05 -166.75 39.67 Favored Glycine 0 CA--C 1.517 0.185 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.813 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -99.89 112.83 25.08 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.168 0.509 . . . . 0.0 110.746 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -110.67 168.61 9.34 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.009 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 63.5 p -150.64 160.89 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.138 0.494 . . . . 0.0 112.047 -179.379 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 36.3 p90 -146.21 136.08 23.41 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.913 179.083 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.157 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.231 -179.673 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.17 0 CA-C-O 120.966 0.412 . . . . 0.0 111.083 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.694 ' SD ' HD12 ' A' ' 54' ' ' ILE . 8.9 ttp -131.71 119.52 21.46 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.012 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.7 mp -107.16 116.24 50.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.031 0.443 . . . . 0.0 110.793 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.2 t -101.23 120.43 50.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.168 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 . . . . . 0 C--O 1.252 1.224 0 CA-C-O 118.146 -0.93 . . . . 0.0 111.458 -179.646 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 121.161 0.505 . . . . 0.0 111.066 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.82 129.23 35.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.606 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.71 156.1 39.3 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.403 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.55 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 5.9 pt20 -82.0 142.81 32.05 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.125 0.488 . . . . 0.0 111.259 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -98.47 112.99 24.84 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.657 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 5.6 mmtt -95.34 -150.28 0.31 Allowed 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.557 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -80.71 74.99 7.63 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.98 -5.82 76.11 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.867 -0.682 . . . . 0.0 113.974 178.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.4 p90 -140.59 163.96 31.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.923 0.361 . . . . 0.0 110.85 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.65 154.57 27.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.975 0.417 . . . . 0.0 111.457 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.55 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 4.0 tt0 -143.82 141.3 30.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.572 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.403 ' CG2' HD13 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -142.71 128.97 17.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.915 179.109 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 ttt180 -90.73 110.9 22.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.253 0.549 . . . . 0.0 111.123 179.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 45.2 t -101.04 103.87 15.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.517 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -71.49 117.01 12.5 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.029 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.2 t -98.76 99.93 9.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.451 -178.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.515 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.3 ptm -147.09 90.77 1.92 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.568 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 79.28 1.04 85.25 Favored Glycine 0 CA--C 1.52 0.396 0 C-N-CA 120.774 -0.727 . . . . 0.0 111.733 -178.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.411 ' N ' HD12 ' A' ' 75' ' ' LEU . . . 163.54 -148.61 15.19 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 111.314 -0.715 . . . . 0.0 111.314 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -115.64 129.65 56.57 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.718 0.259 . . . . 0.0 110.309 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.452 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 41.0 m -68.76 -64.6 1.65 Allowed Pre-proline 0 CA--C 1.538 0.515 0 CA-C-O 119.468 -0.301 . . . . 0.0 111.497 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.452 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 62.4 Cg_endo -74.9 98.88 1.19 Allowed 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.271 1.314 . . . . 0.0 111.119 177.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -51.84 -44.55 63.64 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.917 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.85 119.09 20.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.864 179.78 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.2 pt -97.1 126.98 49.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 121.08 0.467 . . . . 0.0 110.943 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 60.1 t -98.58 126.67 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.642 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.3 mt -136.22 165.37 25.91 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.363 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -88.85 176.01 7.22 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.82 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.6 ttpt -106.7 147.95 28.98 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 111.872 -179.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.0 t 65.13 20.2 11.95 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.737 179.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.437 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.3 p -123.61 136.4 27.22 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.989 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -64.47 123.43 11.76 Favored 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.099 1.866 . . . . 0.0 111.736 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.05 139.37 53.86 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.954 0.407 . . . . 0.0 111.682 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.502 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.6 ptt180 -121.78 127.06 50.21 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.744 0.783 . . . . 0.0 111.335 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.453 HD13 HG21 ' A' ' 64' ' ' ILE . 3.5 mm -99.87 115.78 41.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.838 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.2 t -91.24 107.59 18.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.853 0.359 . . . . 0.0 111.463 -179.229 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -95.09 103.57 15.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.909 0.385 . . . . 0.0 111.466 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -90.59 105.9 18.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.377 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.55 100.1 7.6 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.157 0.503 . . . . 0.0 111.882 -179.197 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.0 tmtt? -91.42 -39.19 12.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.852 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.515 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 0.1 OUTLIER -107.1 137.8 19.66 Favored Pre-proline 0 CA--C 1.534 0.354 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.149 -179.913 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -81.87 39.66 0.88 Allowed 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 123.229 2.619 . . . . 0.0 113.405 -179.279 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -67.73 135.66 92.48 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.991 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -62.42 -34.3 76.93 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.872 2.382 . . . . 0.0 113.106 -179.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.02 -3.29 38.33 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.518 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.411 HD12 ' N ' ' A' ' 48' ' ' GLY . 56.3 mt -120.01 12.88 12.07 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.446 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -68.78 -39.27 80.25 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 120.915 0.388 . . . . 0.0 111.379 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 31.0 mt-30 -123.66 166.15 16.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.034 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -140.93 130.45 25.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.296 0.57 . . . . 0.0 110.836 178.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.577 ' O ' ' HD3' ' A' ' 81' ' ' PRO . 0.2 OUTLIER -133.9 132.33 56.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.216 0.532 . . . . 0.0 110.981 179.68 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 -96.01 101.72 9.01 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.721 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.577 ' HD3' ' O ' ' A' ' 79' ' ' VAL . 23.2 Cg_exo -63.46 -19.02 67.1 Favored 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.072 2.515 . . . . 0.0 113.791 -178.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -100.66 -5.94 25.88 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -121.44 -23.03 5.76 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.11 22.8 56.69 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.151 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.1 t -102.53 120.34 52.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.674 0.274 . . . . 0.0 111.552 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -125.74 119.69 28.62 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.633 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.78 169.35 17.94 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.112 0.482 . . . . 0.0 112.249 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -109.05 140.67 42.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.548 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 38.6 mt -100.69 129.44 27.6 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.851 0.358 . . . . 0.0 111.356 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -80.64 128.25 6.76 Favored 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.813 2.342 . . . . 0.0 112.452 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -66.16 124.85 23.74 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.087 0.47 . . . . 0.0 111.681 -179.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 87.11 3.46 82.56 Favored Glycine 0 CA--C 1.521 0.446 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.951 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -134.65 177.05 8.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.009 0.433 . . . . 0.0 110.913 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -117.27 133.35 56.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.211 0.529 . . . . 0.0 111.564 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -113.21 125.49 54.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.222 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 96' ' ' VAL . 1.7 p -98.09 135.19 33.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.715 0.769 . . . . 0.0 112.334 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.0 t -112.82 112.92 42.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.199 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -93.73 119.76 33.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.035 0.445 . . . . 0.0 111.518 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -136.4 156.44 36.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.125 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.26 97.74 48.99 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.452 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.437 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 58.6 Cg_endo -71.14 98.42 0.82 Allowed 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.734 2.289 . . . . 0.0 112.618 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -97.6 22.72 8.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.004 0.43 . . . . 0.0 111.482 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.35 131.23 14.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.539 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.11 127.1 35.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.071 0.462 . . . . 0.0 111.41 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 164.99 -157.6 30.13 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.714 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -101.55 126.01 48.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.172 0.51 . . . . 0.0 111.535 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.413 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 87.9 m-85 -119.58 171.93 8.02 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.783 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 84.8 p -157.81 160.54 37.88 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.211 0.529 . . . . 0.0 112.418 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -143.77 140.46 29.94 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.496 178.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.282 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.662 -179.196 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.459 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.529 0.143 0 CA-C-O 120.884 0.373 . . . . 0.0 111.112 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.413 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -132.56 140.12 48.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.059 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.5 118.74 54.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 121.048 0.451 . . . . 0.0 110.823 179.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.3 t -100.21 123.86 53.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.062 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.251 1.168 0 CA-C-O 118.155 -0.926 . . . . 0.0 111.973 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.158 0 CA-C-O 121.155 0.502 . . . . 0.0 111.375 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -88.57 126.59 35.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.626 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.27 153.84 41.32 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.297 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.72 140.67 34.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.243 0.544 . . . . 0.0 111.187 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 22.0 mt-30 -96.38 116.83 29.69 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.595 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.1 -153.07 0.41 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.119 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -83.73 76.82 9.96 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -179.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.6 -8.84 64.2 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.767 -0.73 . . . . 0.0 114.007 178.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -141.21 164.99 28.77 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 117.093 0.446 . . . . 0.0 111.091 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.44 154.28 27.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.924 0.392 . . . . 0.0 111.177 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -143.28 142.07 31.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.891 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.406 ' CG2' HD13 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -143.54 128.69 15.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.972 179.027 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -90.18 110.18 21.22 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.208 0.528 . . . . 0.0 110.93 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.9 t -102.37 107.2 21.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.663 -0.698 . . . . 0.0 110.74 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.403 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.7 OUTLIER -75.93 117.76 17.99 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.002 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 50.6 t -96.62 99.03 8.31 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.416 -178.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.45 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.4 ptm -144.72 90.3 2.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.487 179.023 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 81.85 2.05 90.43 Favored Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.72 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 159.61 -131.28 2.67 Favored Glycine 0 N--CA 1.449 -0.471 0 N-CA-C 111.601 -0.6 . . . . 0.0 111.601 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -126.09 134.57 51.33 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.729 -0.277 . . . . 0.0 110.754 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.465 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 32.4 m -73.57 -63.98 0.87 Allowed Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 121.066 -0.253 . . . . 0.0 110.93 179.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.465 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 61.2 Cg_endo -74.53 100.51 1.33 Allowed 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 121.409 1.406 . . . . 0.0 111.226 177.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.63 -45.42 63.27 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.28 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.76 119.06 19.82 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.561 0.22 . . . . 0.0 110.999 179.783 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.1 pt -96.58 126.04 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.128 0.489 . . . . 0.0 110.896 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 84.0 t -97.8 126.43 50.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.567 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.5 mt -136.15 164.37 28.21 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.248 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.74 170.9 10.04 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 120.757 0.313 . . . . 0.0 110.935 179.24 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 12.7 ttpt -100.65 147.81 25.57 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.7 t 65.72 19.63 11.42 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.936 179.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.441 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.5 p -123.63 135.74 26.49 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.964 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_endo -64.11 123.28 11.64 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.133 1.889 . . . . 0.0 111.722 178.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.23 136.56 54.24 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.938 0.399 . . . . 0.0 111.542 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.53 125.51 50.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.855 0.836 . . . . 0.0 111.545 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.438 HD13 HG22 ' A' ' 64' ' ' ILE . 3.1 mm -98.38 114.93 37.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.626 179.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.5 t -91.34 107.83 19.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.768 0.318 . . . . 0.0 111.357 -179.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -94.16 118.53 31.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.081 0.467 . . . . 0.0 111.381 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -102.18 106.97 17.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.469 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.7 tpt180 -76.35 96.69 4.05 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 121.13 0.491 . . . . 0.0 111.42 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 23.4 tptt -91.89 -35.91 13.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.451 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.45 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.7 t70 -107.08 131.15 21.92 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.731 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -80.18 38.48 0.75 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.001 2.467 . . . . 0.0 113.027 -179.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -68.91 132.74 90.37 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.945 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -64.32 -30.92 63.5 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.668 2.245 . . . . 0.0 112.894 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.75 -3.13 42.78 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.544 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 16.6 mt -117.67 10.15 13.29 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 120.751 0.31 . . . . 0.0 111.19 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.18 -42.61 79.71 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -179.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -116.83 138.01 51.81 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.829 0.347 . . . . 0.0 111.584 -179.56 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -118.21 131.7 70.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.654 179.432 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -137.42 129.44 41.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.397 0.618 . . . . 0.0 111.579 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -89.95 102.18 4.39 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.252 178.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -64.99 -14.16 43.72 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.606 2.204 . . . . 0.0 113.637 -178.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -101.02 -11.25 19.82 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -119.15 -24.29 6.52 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 111.945 0.35 . . . . 0.0 111.945 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 88.84 1.17 80.46 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.143 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.8 t -80.36 117.02 25.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.886 0.374 . . . . 0.0 111.396 -178.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 19.2 p-80 -132.05 122.59 25.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.835 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.48 174.23 10.94 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 121.112 0.482 . . . . 0.0 111.91 -178.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -108.23 141.89 39.31 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.656 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 33.9 mt -100.71 124.49 42.06 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 120.906 0.384 . . . . 0.0 111.467 -179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.403 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 63.6 Cg_endo -78.57 128.63 8.82 Favored 'Trans proline' 0 CA--C 1.53 0.313 0 C-N-CA 122.786 2.324 . . . . 0.0 112.684 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 12.3 tpt -66.19 124.94 23.99 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.151 0.501 . . . . 0.0 111.677 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.38 6.76 85.69 Favored Glycine 0 CA--C 1.52 0.398 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.923 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.403 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 48.3 mm-40 -134.13 176.78 8.28 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-O 120.943 0.401 . . . . 0.0 111.292 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -114.58 132.32 56.38 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.983 0.42 . . . . 0.0 111.834 -179.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.6 t80 -118.06 121.63 41.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.778 178.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 1.4 p -98.52 138.46 23.04 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 CA-C-O 121.629 0.728 . . . . 0.0 112.577 -178.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 43.8 t -115.6 110.34 31.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.053 178.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -93.98 117.39 30.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.034 0.445 . . . . 0.0 111.551 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -132.73 156.52 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.18 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.3 m -119.9 96.74 49.55 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.437 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.441 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.1 Cg_endo -72.07 99.49 1.0 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.706 2.271 . . . . 0.0 112.494 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -97.3 22.92 8.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.023 0.439 . . . . 0.0 111.553 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.17 127.76 11.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.749 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -83.84 122.96 29.4 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.975 0.417 . . . . 0.0 111.326 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 169.2 -158.76 31.44 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.729 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -101.99 126.7 48.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.182 0.515 . . . . 0.0 111.576 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.419 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 85.7 m-85 -119.69 169.7 9.86 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.918 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 99.1 p -149.81 157.38 43.15 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -148.29 138.48 22.6 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.995 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.38 0 CA-C-O 121.05 0.452 . . . . 0.0 111.655 -179.73 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 14.6 ttpt . . . . . 0 CA--C 1.528 0.119 0 CA-C-O 121.03 0.443 . . . . 0.0 111.098 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.419 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.7 ttm -128.39 136.22 50.61 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.908 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -120.02 118.42 56.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.981 0.42 . . . . 0.0 110.846 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 76.0 t -99.78 121.78 50.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.146 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.103 -0.951 . . . . 0.0 111.531 -179.702 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 . . . . . 0 N--CA 1.462 0.168 0 CA-C-O 121.207 0.527 . . . . 0.0 111.477 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 3.1 ttpt -90.17 129.5 36.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.747 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.22 153.51 40.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.422 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 3.7 pt20 -84.48 139.33 32.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.132 0.491 . . . . 0.0 111.393 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -94.82 115.29 27.31 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.769 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.89 -151.14 0.32 Allowed 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.248 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.6 m120 -82.94 73.29 9.98 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.68 -4.76 61.75 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 120.817 -0.706 . . . . 0.0 114.061 178.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 30.2 p90 -143.62 162.57 35.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.909 0.355 . . . . 0.0 110.915 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.42 153.33 27.51 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.006 0.432 . . . . 0.0 111.475 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.422 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.6 tt0 -142.14 142.81 32.78 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.567 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.56 129.07 13.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -90.74 110.12 21.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.239 0.542 . . . . 0.0 110.939 179.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 43.5 t -102.16 103.91 15.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.774 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.452 ' HG2' ' SD ' ' A' ' 46' ' ' MET . 0.8 OUTLIER -75.25 118.13 17.82 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.614 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.5 t -96.9 98.41 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.649 -178.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.452 ' SD ' ' HG2' ' A' ' 44' ' ' GLU . 6.4 ptm -142.55 90.81 2.26 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.642 179.124 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 81.7 0.72 89.68 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.901 -0.666 . . . . 0.0 111.684 -178.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 162.79 -133.66 3.16 Favored Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -124.8 130.77 53.04 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.743 0.272 . . . . 0.0 110.599 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.48 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 49.7 m -70.15 -64.99 1.2 Allowed Pre-proline 0 CA--C 1.538 0.51 0 CA-C-O 119.508 -0.282 . . . . 0.0 111.391 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.48 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 58.7 Cg_endo -73.95 100.32 1.27 Allowed 'Trans proline' 0 C--N 1.358 1.058 0 C-N-CA 121.278 1.319 . . . . 0.0 111.249 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.84 -47.16 60.25 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.951 -0.568 . . . . 0.0 112.285 -179.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.56 119.06 20.01 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.638 0.256 . . . . 0.0 110.752 179.897 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.4 pt -97.04 129.37 47.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.093 0.473 . . . . 0.0 111.062 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 96.3 t -96.18 124.95 49.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.509 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.0 157.24 42.87 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.087 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -89.85 168.99 11.63 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 110.163 -0.31 . . . . 0.0 110.163 178.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.9 ttpp -98.77 146.95 25.39 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 112.305 0.484 . . . . 0.0 112.305 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.6 t 65.66 19.78 11.48 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.86 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.445 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.95 135.9 26.84 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.976 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -64.29 122.74 10.8 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.128 1.885 . . . . 0.0 111.812 178.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.7 134.68 53.67 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.856 0.36 . . . . 0.0 111.47 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.59 126.32 53.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.776 0.798 . . . . 0.0 111.585 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.451 HD12 HG21 ' A' ' 64' ' ' ILE . 3.5 mm -99.5 114.88 38.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.67 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.1 t -90.45 108.2 19.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.714 0.292 . . . . 0.0 111.383 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -95.08 113.67 25.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.147 0.499 . . . . 0.0 111.326 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 21.8 t0 -99.32 103.72 15.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.5 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.25 97.66 4.24 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.176 0.512 . . . . 0.0 111.723 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.66 -42.1 10.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.482 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.411 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.2 t70 -99.47 131.75 24.39 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.837 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -80.73 39.63 0.88 Allowed 'Trans proline' 0 C--N 1.348 0.526 0 C-N-CA 123.16 2.573 . . . . 0.0 113.162 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 30.7 t -69.77 136.18 87.84 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.326 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -63.95 -27.95 66.63 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.576 2.184 . . . . 0.0 112.443 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 80.6 m -81.05 -6.89 59.33 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.059 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 50.9 mt -118.31 14.92 13.92 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.208 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -68.37 -35.89 78.39 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 120.95 0.405 . . . . 0.0 111.557 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -129.34 165.68 21.0 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.047 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.08 131.82 42.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.245 0.545 . . . . 0.0 110.98 179.156 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.9 128.63 43.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.455 0.645 . . . . 0.0 111.179 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -90.81 102.21 4.95 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.422 178.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -65.24 -14.2 43.83 Favored 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.583 2.188 . . . . 0.0 113.583 -178.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -101.05 -10.24 20.68 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 111.906 0.335 . . . . 0.0 111.906 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 59.0 m-85 -119.84 -23.69 6.37 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -179.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 87.92 1.28 82.57 Favored Glycine 0 CA--C 1.521 0.458 0 C-N-CA 121.291 -0.48 . . . . 0.0 112.175 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.6 t -81.48 116.27 25.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.892 0.377 . . . . 0.0 111.348 -178.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 20.3 p-80 -131.51 120.86 23.53 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.959 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -140.18 173.79 11.16 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.759 -179.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 8.1 p-10 -106.54 145.54 31.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.738 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 36.2 mt -103.97 130.17 23.89 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 120.924 0.393 . . . . 0.0 111.203 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -80.86 126.11 5.69 Favored 'Trans proline' 0 CA--C 1.532 0.382 0 C-N-CA 122.706 2.271 . . . . 0.0 112.325 179.26 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.0 tpt -64.01 123.95 20.34 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.092 0.473 . . . . 0.0 111.764 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.02 3.59 87.62 Favored Glycine 0 CA--C 1.522 0.508 0 CA-C-N 115.866 -0.606 . . . . 0.0 113.283 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -131.86 176.86 7.99 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 120.886 0.374 . . . . 0.0 111.196 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -113.38 135.55 53.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.083 0.468 . . . . 0.0 111.985 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -120.07 124.26 45.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.807 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 1.4 p -98.7 137.94 24.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.63 0.728 . . . . 0.0 112.666 -178.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 46.1 t -114.99 110.46 32.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.055 178.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -93.56 117.09 29.64 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.854 0.359 . . . . 0.0 111.481 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 pt -132.05 158.05 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.213 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -121.38 96.24 47.97 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.501 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.445 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.7 Cg_endo -71.19 99.59 0.91 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.724 2.283 . . . . 0.0 112.276 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -94.22 3.65 54.96 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -132.01 135.95 46.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.79 0.329 . . . . 0.0 110.754 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.46 124.11 34.19 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.962 179.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 168.76 -159.44 32.56 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.839 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -100.61 125.93 47.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.155 0.503 . . . . 0.0 111.556 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.437 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 95.5 m-85 -121.42 164.86 16.44 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.831 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -151.21 157.43 42.63 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.251 0.548 . . . . 0.0 112.244 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -142.92 140.42 31.14 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.913 179.099 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.356 -179.757 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 4.1 ttmm . . . . . 0 CA--C 1.528 0.097 0 CA-C-O 120.947 0.403 . . . . 0.0 111.209 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.437 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 3.4 ttm -131.1 135.13 47.24 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.926 179.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.16 117.87 55.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.045 0.45 . . . . 0.0 110.527 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.1 t -99.95 123.58 52.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.349 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 118.186 -0.912 . . . . 0.0 111.46 -179.844 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 . . . . . 0 CA--C 1.53 0.177 0 CA-C-O 121.069 0.461 . . . . 0.0 111.268 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 5.3 mtpt -90.12 129.25 36.43 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.733 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.99 149.21 43.49 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.636 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.6 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.8 pt20 -74.81 138.02 42.3 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.907 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -97.55 113.36 25.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.871 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -95.41 -156.17 0.5 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.368 -179.682 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -81.89 79.26 8.47 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 112.29 0.478 . . . . 0.0 112.29 -179.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.74 -9.98 66.36 Favored Glycine 0 CA--C 1.522 0.508 0 C-N-CA 120.799 -0.715 . . . . 0.0 114.298 178.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 28.9 p90 -142.01 164.07 31.17 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 117.098 0.449 . . . . 0.0 111.193 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.13 155.41 26.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.012 0.434 . . . . 0.0 111.182 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.6 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.9 tt0 -144.49 143.19 30.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.33 -179.28 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.11 129.44 17.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.082 0.468 . . . . 0.0 111.327 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 ttm180 -88.7 106.97 18.69 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.221 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 45.6 t -100.39 102.31 13.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.496 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -73.6 119.38 17.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.711 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.2 t -98.86 99.44 8.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.517 -178.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.451 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.2 ptm -143.8 88.24 1.97 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.537 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.31 -0.36 84.61 Favored Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.575 -178.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.409 ' N ' HD13 ' A' ' 75' ' ' LEU . . . 163.41 -163.45 35.6 Favored Glycine 0 N--CA 1.447 -0.586 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -98.58 126.36 44.13 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.768 0.284 . . . . 0.0 110.321 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.484 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 47.8 m -65.24 -64.3 2.73 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 121.196 -0.202 . . . . 0.0 111.267 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.484 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 60.8 Cg_endo -74.62 96.58 1.0 Allowed 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 121.358 1.372 . . . . 0.0 111.198 177.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.36 -42.86 61.61 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.096 -0.502 . . . . 0.0 112.195 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.48 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.88 118.68 20.16 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.696 0.284 . . . . 0.0 110.606 179.513 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.9 pt -98.0 127.48 50.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-O 121.03 0.443 . . . . 0.0 111.092 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.1 t -98.68 126.72 51.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.597 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.0 mt -136.41 165.32 26.08 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.264 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -90.97 171.42 9.29 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.797 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.5 ttpp -101.74 148.47 25.24 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.999 0.428 . . . . 0.0 112.066 -179.325 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.0 t 65.42 20.14 11.71 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.931 179.567 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.426 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.8 p -123.78 135.91 26.77 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.866 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -64.36 122.2 10.06 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.202 1.935 . . . . 0.0 111.68 178.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.46 138.65 54.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.995 0.426 . . . . 0.0 111.546 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.471 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.2 ptt180 -120.72 126.85 51.21 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-O 121.776 0.798 . . . . 0.0 111.343 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.8 mm -97.73 115.01 36.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.81 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.6 t -91.99 110.52 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.376 -179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -96.2 114.69 26.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.041 0.448 . . . . 0.0 111.289 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -100.38 104.5 15.93 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.181 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -76.64 104.66 7.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.289 0.566 . . . . 0.0 111.958 -179.093 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.73 -39.84 9.26 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.093 179.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.451 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.1 t70 -105.71 133.86 19.99 Favored Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.929 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -80.97 39.53 0.87 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.994 2.463 . . . . 0.0 112.861 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.07 133.87 91.74 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.451 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.67 -32.37 57.67 Favored 'Trans proline' 0 C--N 1.348 0.527 0 C-N-CA 122.771 2.314 . . . . 0.0 112.63 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.15 -2.69 32.3 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.56 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.409 HD13 ' N ' ' A' ' 48' ' ' GLY . 34.9 mt -118.74 12.99 13.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.275 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -70.55 -43.46 69.46 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.931 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.55 140.14 51.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.026 0.441 . . . . 0.0 111.54 -179.476 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -120.64 127.64 75.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.525 178.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -130.11 130.58 65.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.349 0.595 . . . . 0.0 111.475 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -92.65 102.12 6.26 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.374 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -66.67 -16.66 51.18 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.667 2.245 . . . . 0.0 113.7 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -100.57 -7.44 24.06 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -120.58 -21.82 6.61 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.9 29.82 45.53 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.077 -179.369 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.1 t -110.85 117.98 56.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.81 0.338 . . . . 0.0 111.753 -178.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -119.93 121.0 38.03 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.226 179.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.48 158.92 43.37 Favored 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 112.521 0.564 . . . . 0.0 112.521 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -104.01 137.0 42.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.477 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 45.0 mt -99.76 127.84 32.8 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.968 0.413 . . . . 0.0 111.466 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.409 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 70.8 Cg_endo -82.05 130.36 6.46 Favored 'Trans proline' 0 CA--C 1.533 0.426 0 C-N-CA 122.689 2.259 . . . . 0.0 112.441 179.241 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.7 tpt -68.06 125.57 26.77 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-O 121.072 0.463 . . . . 0.0 111.644 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.51 13.11 79.16 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-N 115.855 -0.611 . . . . 0.0 112.866 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.409 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.5 mm-40 -138.5 176.93 8.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.878 0.371 . . . . 0.0 111.125 -179.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -114.0 134.21 55.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.049 0.452 . . . . 0.0 111.661 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.7 t80 -123.05 124.84 44.03 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.029 178.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.428 ' O ' HG12 ' A' ' 96' ' ' VAL . 2.1 p -105.04 136.73 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 CA-C-O 121.544 0.688 . . . . 0.0 112.439 -178.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.7 t -113.17 112.92 42.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.113 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -93.84 119.49 32.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.951 0.405 . . . . 0.0 111.476 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -135.46 156.6 38.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.145 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -119.96 97.57 49.45 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.614 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.426 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.4 Cg_endo -72.75 100.28 1.16 Allowed 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 122.806 2.338 . . . . 0.0 112.309 179.502 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -95.46 5.34 51.85 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -131.97 133.29 44.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.798 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.89 127.74 35.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.0 0.429 . . . . 0.0 111.223 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 162.47 -156.56 28.25 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.764 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.02 126.13 48.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.198 0.523 . . . . 0.0 111.488 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.409 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 84.0 m-85 -118.15 173.41 6.81 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.904 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 83.2 p -151.22 158.13 43.51 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -178.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -149.69 130.46 14.15 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.334 178.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.215 0 CA-C-O 120.964 0.411 . . . . 0.0 112.001 -179.381 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 12.4 ttmt . . . . . 0 CA--C 1.532 0.271 0 CA-C-O 121.106 0.479 . . . . 0.0 111.898 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.409 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -134.52 139.79 45.69 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.735 179.479 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.0 mp -123.24 120.16 59.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.997 0.427 . . . . 0.0 110.81 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 85.2 t -104.16 123.19 57.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.202 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.237 0 CA-C-O 118.102 -0.951 . . . . 0.0 111.505 -179.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.135 0 CA-C-O 121.042 0.449 . . . . 0.0 111.237 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.2 mtpt -91.34 129.24 37.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.874 179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.65 152.36 40.51 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.317 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.553 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.5 pt20 -80.84 141.26 34.83 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-O 121.152 0.501 . . . . 0.0 111.444 -179.352 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 58.4 mt-30 -96.9 114.84 26.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.594 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.39 -149.82 0.31 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.456 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -82.01 72.72 9.06 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -179.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.76 -5.21 66.57 Favored Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.788 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.4 p90 -141.36 160.3 40.41 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.905 0.352 . . . . 0.0 110.746 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.18 155.66 21.68 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.988 0.423 . . . . 0.0 111.423 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.553 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.7 tt0 -144.53 143.84 31.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.545 -179.317 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -145.15 129.63 12.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.2 179.144 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 7.3 ttt180 -89.96 108.14 19.53 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.071 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 49.0 t -99.99 107.85 21.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.705 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -73.6 122.46 22.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.013 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.8 t -103.08 95.33 3.77 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-O 121.535 0.683 . . . . 0.0 111.052 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.406 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 3.8 ptm -146.16 89.45 1.87 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.405 179.562 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.55 0.24 89.8 Favored Glycine 0 CA--C 1.521 0.454 0 C-N-CA 120.811 -0.709 . . . . 0.0 111.545 -178.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.438 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.66 -140.6 6.81 Favored Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 111.649 -0.581 . . . . 0.0 111.649 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -121.86 129.46 52.61 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.741 0.27 . . . . 0.0 110.543 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.428 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 20.8 m -68.84 -62.0 3.17 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 120.997 -0.281 . . . . 0.0 111.176 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.428 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 63.5 Cg_endo -75.62 97.6 1.11 Allowed 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 121.417 1.411 . . . . 0.0 111.064 177.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -52.11 -43.34 63.9 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.125 -0.489 . . . . 0.0 112.062 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -134.17 118.45 17.67 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.711 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.7 HD13 ' SD ' ' A' ' 120' ' ' MET . 9.6 pt -96.91 127.35 49.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.134 0.492 . . . . 0.0 110.939 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 98.9 t -95.51 125.86 48.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.601 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . 0.416 HD12 ' SD ' ' A' ' 120' ' ' MET . 23.6 mt -133.69 167.68 20.07 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.263 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.2 mttt -96.59 168.84 10.29 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.685 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -98.67 146.72 25.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.928 0.395 . . . . 0.0 111.927 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.5 t 66.06 19.7 11.19 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.89 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.438 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 5.7 p -123.53 135.2 25.84 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.002 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -64.3 122.7 10.74 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.051 1.834 . . . . 0.0 111.711 178.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.1 138.98 54.36 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.79 0.328 . . . . 0.0 111.622 -179.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -120.92 125.33 47.17 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.719 0.771 . . . . 0.0 111.494 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 5.7 mm -97.66 115.25 37.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.654 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.5 t -91.9 109.8 21.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.375 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -95.5 111.81 23.65 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.016 0.436 . . . . 0.0 111.296 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -98.11 106.03 18.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.52 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -78.19 105.16 9.24 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.282 0.563 . . . . 0.0 111.91 -179.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.05 -37.36 9.38 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.19 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.406 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 5.2 t70 -103.78 129.88 24.48 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.922 179.544 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -80.52 39.13 0.81 Allowed 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.113 2.542 . . . . 0.0 112.881 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.2 m -72.04 135.84 82.46 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.349 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -64.08 -31.21 65.65 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.617 2.211 . . . . 0.0 112.583 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 5.2 p -76.79 -5.29 47.58 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.587 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.438 HD11 ' N ' ' A' ' 48' ' ' GLY . 30.2 mt -120.12 15.94 12.38 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.964 179.642 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -67.82 -35.56 78.82 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 116.096 -0.502 . . . . 0.0 112.243 -179.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 -133.7 165.91 23.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.914 0.388 . . . . 0.0 111.583 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . 0.403 HG13 ' N ' ' A' ' 79' ' ' VAL . 0.5 OUTLIER -137.72 141.37 39.22 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.115 179.858 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.403 ' N ' HG13 ' A' ' 78' ' ' ILE . 0.2 OUTLIER -139.9 134.14 36.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.364 0.602 . . . . 0.0 111.359 179.054 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -97.57 101.68 10.97 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.84 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.56 -13.79 40.14 Favored 'Trans proline' 0 C--N 1.347 0.481 0 C-N-CA 122.613 2.209 . . . . 0.0 113.431 -178.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -100.57 -9.11 22.32 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -123.02 -19.93 5.92 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.71 28.97 49.7 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.86 -0.685 . . . . 0.0 112.226 -179.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.4 t -110.75 116.87 53.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.745 0.307 . . . . 0.0 111.535 -179.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 4.3 t60 -127.12 117.72 22.95 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.87 0.367 . . . . 0.0 110.45 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.12 170.48 15.61 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 121.09 0.471 . . . . 0.0 111.858 -179.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -106.24 145.84 31.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.477 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 34.8 mt -105.47 129.35 24.85 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.867 0.365 . . . . 0.0 111.412 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.414 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.7 Cg_endo -81.86 129.21 6.18 Favored 'Trans proline' 0 CA--C 1.532 0.409 0 C-N-CA 122.752 2.301 . . . . 0.0 112.486 179.265 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.3 tpt -67.07 125.27 25.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.138 0.494 . . . . 0.0 111.699 -179.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.66 6.37 85.64 Favored Glycine 0 C--N 1.333 0.367 0 CA-C-N 115.864 -0.607 . . . . 0.0 113.077 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.414 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 45.7 mt-10 -134.29 176.82 8.26 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 120.988 0.423 . . . . 0.0 111.018 -179.533 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -115.06 132.49 56.58 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.0 0.429 . . . . 0.0 111.767 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.4 t80 -116.47 123.9 48.64 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.968 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 96' ' ' VAL . 1.6 p -101.28 137.1 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 CA-C-O 121.651 0.739 . . . . 0.0 112.51 -178.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.98 110.21 31.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.154 178.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -92.67 118.82 31.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.373 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -135.84 154.52 34.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.361 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -119.22 97.43 50.46 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.272 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.438 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 74.2 Cg_endo -73.47 101.92 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.845 2.363 . . . . 0.0 112.72 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -97.71 19.9 12.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.984 0.421 . . . . 0.0 111.483 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -146.97 129.93 16.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.774 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -86.1 126.28 34.08 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.903 0.382 . . . . 0.0 111.269 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.09 -168.29 41.36 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.816 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -99.76 112.02 24.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.141 0.496 . . . . 0.0 110.774 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -110.94 172.4 6.9 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.292 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 54.2 p -153.69 163.39 40.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.132 0.491 . . . . 0.0 112.274 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 31.2 p90 -145.58 140.63 27.54 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.518 179.067 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.371 0 CA-C-O 121.332 0.587 . . . . 0.0 112.273 -179.222 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 1.2 ttpt . . . . . 0 CA--C 1.53 0.175 0 CA-C-O 120.957 0.408 . . . . 0.0 111.476 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.7 ' SD ' HD13 ' A' ' 54' ' ' ILE . 9.2 ttp -133.96 122.18 22.71 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.048 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -109.69 116.08 51.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.101 0.477 . . . . 0.0 110.88 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 98.3 t -100.05 120.07 48.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.077 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 24.1 mt-10 . . . . . 0 C--O 1.253 1.247 0 CA-C-O 118.13 -0.938 . . . . 0.0 111.491 -179.542 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 19.8 mp0 . . . . . 0 C--O 1.232 0.164 0 CA-C-O 121.175 0.512 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 3.4 ttmt -89.5 127.52 35.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.909 -179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.16 155.95 39.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.052 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.567 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 10.9 pt20 -79.68 132.8 36.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.295 0.569 . . . . 0.0 111.248 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.0 mt-30 -92.79 109.11 20.53 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.83 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.03 -157.07 0.47 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.352 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -83.09 80.3 9.09 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.05 -7.18 67.01 Favored Glycine 0 CA--C 1.523 0.534 0 C-N-CA 120.846 -0.692 . . . . 0.0 114.178 178.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . 0.431 ' HB2' ' O ' ' A' ' 61' ' ' PRO . 24.6 p90 -144.15 165.53 27.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 117.191 0.496 . . . . 0.0 111.075 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.89 154.96 33.61 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.901 0.382 . . . . 0.0 111.201 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.567 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.5 tt0 -145.21 143.13 30.12 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.43 -179.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.71 129.2 13.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.93 0.395 . . . . 0.0 110.714 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.58 111.45 22.76 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.317 0.58 . . . . 0.0 111.127 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 42.6 t -100.05 102.82 13.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.571 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.402 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.4 OUTLIER -72.56 113.61 9.79 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.607 179.874 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 43.1 t -94.66 97.45 6.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.674 -0.693 . . . . 0.0 111.336 -178.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.433 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.7 ptm -141.68 85.27 1.94 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.532 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.94 1.42 90.63 Favored Glycine 0 CA--C 1.521 0.41 0 C-N-CA 120.958 -0.639 . . . . 0.0 111.516 -178.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 160.94 -166.95 35.79 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -93.75 123.75 37.29 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.86 0.33 . . . . 0.0 110.44 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.442 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 25.5 m -63.67 -62.17 5.81 Favored Pre-proline 0 CA--C 1.538 0.489 0 CA-C-O 119.594 -0.241 . . . . 0.0 111.07 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.442 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 61.2 Cg_endo -75.23 98.73 1.19 Allowed 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 121.211 1.274 . . . . 0.0 110.974 177.366 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.54 -45.31 62.94 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.3 -179.066 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.452 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -133.18 118.28 18.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.53 179.704 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.624 HD12 ' SD ' ' A' ' 120' ' ' MET . 5.0 pt -96.92 126.12 49.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.141 0.495 . . . . 0.0 111.273 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 88.9 t -99.07 125.65 52.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.413 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 2.3 mt -136.27 166.19 24.0 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.354 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.0 177.18 7.67 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.263 179.382 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 12.2 ttpt -106.05 147.36 28.99 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 111.842 0.312 . . . . 0.0 111.842 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.8 t 62.35 26.9 16.08 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.646 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -123.57 137.06 27.97 Favored Pre-proline 0 CA--C 1.538 0.508 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.435 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . 0.431 ' O ' ' HB2' ' A' ' 38' ' ' TYR . 36.2 Cg_endo -67.25 93.44 0.35 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.773 2.316 . . . . 0.0 112.206 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -97.99 138.78 34.8 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.911 0.386 . . . . 0.0 111.988 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -121.51 129.09 52.71 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 121.736 0.779 . . . . 0.0 111.644 179.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.412 HG22 HD12 ' A' ' 64' ' ' ILE . 4.6 mm -100.63 114.78 40.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.285 -0.871 . . . . 0.0 110.695 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.3 t -91.65 109.86 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.677 -0.238 . . . . 0.0 111.411 -179.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -95.44 113.63 25.32 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.034 0.445 . . . . 0.0 111.278 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -100.18 106.6 18.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.142 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.05 105.98 9.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.312 0.577 . . . . 0.0 112.12 -179.143 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.2 tptp -99.9 -34.56 10.07 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.084 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.433 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.6 t70 -109.6 132.68 21.2 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.779 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -81.13 40.43 0.99 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.085 2.524 . . . . 0.0 113.306 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.2 t -68.65 134.7 90.41 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.331 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -64.43 -27.96 62.56 Favored 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 122.652 2.234 . . . . 0.0 112.647 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.1 m -78.92 -10.75 59.91 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.168 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 40.9 mt -110.57 10.21 23.04 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.497 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -68.23 -40.53 82.0 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 120.87 0.367 . . . . 0.0 111.81 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -123.54 148.64 46.11 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.359 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -130.53 129.88 64.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.13 0.49 . . . . 0.0 110.374 178.653 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 2.4 p -133.98 132.45 56.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.2 0.524 . . . . 0.0 111.18 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -93.07 101.76 5.99 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.259 178.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.57 -15.71 48.52 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.662 2.241 . . . . 0.0 113.527 -178.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -100.58 -7.59 23.87 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -121.36 -20.9 6.5 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 112.026 0.38 . . . . 0.0 112.026 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.95 29.43 46.84 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.105 -179.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 50.9 t -110.89 115.71 50.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.881 0.372 . . . . 0.0 111.753 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.6 p80 -118.75 124.95 48.53 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.429 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.04 160.06 41.09 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -104.08 139.55 39.02 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.471 179.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 42.3 mt -101.63 127.23 31.87 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.904 0.383 . . . . 0.0 111.438 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.411 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 68.9 Cg_endo -81.0 128.14 6.4 Favored 'Trans proline' 0 CA--C 1.532 0.383 0 C-N-CA 122.667 2.245 . . . . 0.0 112.479 179.441 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.0 tpt -66.75 125.49 26.01 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.993 0.425 . . . . 0.0 111.583 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.84 7.88 83.4 Favored Glycine 0 CA--C 1.52 0.393 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.889 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.411 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 52.4 mm-40 -135.58 176.9 8.25 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.014 0.435 . . . . 0.0 111.14 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -114.63 134.34 55.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.033 0.444 . . . . 0.0 111.669 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -121.95 126.15 47.96 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.108 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 1.4 p -103.81 139.28 25.21 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 CA-C-O 121.516 0.674 . . . . 0.0 112.674 -178.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.8 t -116.41 110.82 32.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.123 178.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -93.67 119.37 32.6 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.255 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -133.31 157.57 42.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.086 0.469 . . . . 0.0 111.186 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.5 m -122.3 95.57 46.99 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.317 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.68 101.2 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.816 2.344 . . . . 0.0 112.649 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -95.02 23.73 5.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.922 0.391 . . . . 0.0 111.64 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -149.25 130.43 14.54 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.764 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.51 127.21 35.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.04 0.448 . . . . 0.0 111.438 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 165.01 -160.38 33.66 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.659 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -101.58 125.58 48.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.051 0.453 . . . . 0.0 111.275 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.407 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 91.7 m-85 -118.31 167.54 11.45 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.198 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.6 p -143.53 154.88 44.07 Favored 'General case' 0 C--O 1.234 0.26 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -148.73 129.46 14.16 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.916 178.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.249 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.116 -179.703 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.9 ttpt . . . . . 0 CA--C 1.53 0.184 0 CA-C-O 121.304 0.573 . . . . 0.0 111.729 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.624 ' SD ' HD12 ' A' ' 54' ' ' ILE . 12.0 ttp -133.93 135.16 43.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.734 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.1 mp -119.38 119.29 60.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.952 0.406 . . . . 0.0 110.856 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 89.6 t -104.12 120.16 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.135 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.227 -0.892 . . . . 0.0 111.464 -179.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.16 0 CA-C-O 121.134 0.493 . . . . 0.0 111.223 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.42 126.1 37.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.808 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.36 153.19 42.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.24 179.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -81.42 141.2 34.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.163 0.506 . . . . 0.0 111.52 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -97.16 115.71 28.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.596 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.51 -149.88 0.34 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.513 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -81.74 73.0 8.8 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -179.149 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.68 -6.54 67.62 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.65 -0.786 . . . . 0.0 113.898 179.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 38.9 p90 -139.89 163.7 31.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.767 0.283 . . . . 0.0 110.799 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.92 153.1 29.83 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.111 0.481 . . . . 0.0 111.283 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.413 ' HG3' ' HE ' ' A' ' 63' ' ' ARG . 3.3 tt0 -142.16 141.6 32.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.606 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.19 128.95 22.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.116 179.203 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -89.1 107.46 19.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.159 0.504 . . . . 0.0 111.017 179.574 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.3 t -100.28 103.29 14.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.416 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -73.29 116.87 14.35 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.025 -179.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 42.0 t -98.01 99.08 8.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 CA-C-O 121.52 0.676 . . . . 0.0 111.423 -179.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.453 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.0 ptm -143.88 86.93 1.88 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.462 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.98 2.28 90.67 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 160.65 -154.01 24.97 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 65.3 m-85 -107.43 127.62 53.76 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.85 0.325 . . . . 0.0 110.407 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.46 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 40.7 m -66.92 -64.46 2.16 Favored Pre-proline 0 CA--C 1.539 0.522 0 CA-C-O 119.529 -0.272 . . . . 0.0 111.389 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.46 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 65.1 Cg_endo -75.0 98.65 1.18 Allowed 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.329 1.353 . . . . 0.0 111.028 177.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.89 -44.67 59.92 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.33 -179.346 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.499 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.04 119.2 20.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.645 0.259 . . . . 0.0 110.913 179.788 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.1 pt -97.1 125.71 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 120.976 0.417 . . . . 0.0 111.102 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 88.4 t -98.27 126.77 51.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.535 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 2.9 mt -136.93 166.79 22.82 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.384 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.2 mtmm -90.38 172.49 8.71 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.915 179.322 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.6 ttpp -103.38 148.76 25.49 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 37.3 t 65.45 20.12 11.68 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.779 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' HG11 ' A' ' 60' ' ' VAL . 8.9 p -123.73 136.01 26.85 Favored Pre-proline 0 CA--C 1.535 0.371 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.868 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -64.2 122.9 11.03 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.105 1.87 . . . . 0.0 111.561 178.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.46 137.85 54.4 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.007 0.432 . . . . 0.0 111.632 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.413 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.6 ptt180 -119.65 125.55 49.01 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.714 0.769 . . . . 0.0 111.286 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.457 HD12 HG23 ' A' ' 64' ' ' ILE . 3.5 mm -98.35 115.58 38.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.61 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.5 t -91.79 109.21 20.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.558 -179.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -97.83 107.8 20.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.898 0.38 . . . . 0.0 111.386 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -93.47 107.28 19.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.533 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.2 tpt180 -77.07 101.3 6.01 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.183 0.516 . . . . 0.0 111.776 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 21.0 tptt -96.38 -34.28 11.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.413 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.453 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.8 t70 -108.93 131.39 21.82 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.693 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -79.6 39.54 0.84 Allowed 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 123.163 2.575 . . . . 0.0 113.246 -179.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 30.0 t -68.23 136.05 91.37 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.095 179.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.29 -26.98 55.95 Favored 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 122.684 2.256 . . . . 0.0 112.584 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -81.65 -7.98 59.65 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.243 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 40.5 mt -115.02 8.28 15.72 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.472 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.61 -38.18 90.14 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.899 0.38 . . . . 0.0 111.933 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 3.9 mp0 -124.86 160.35 29.0 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.092 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -135.95 131.8 50.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.167 0.508 . . . . 0.0 110.83 179.202 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 1.0 OUTLIER -135.79 130.53 49.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.279 0.561 . . . . 0.0 111.199 179.757 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -93.89 101.9 7.05 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.393 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.7 -15.94 48.92 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.616 2.211 . . . . 0.0 113.578 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 55.7 m-20 -100.53 -7.13 24.46 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -121.17 -23.45 5.77 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.26 26.94 41.82 Favored Glycine 0 CA--C 1.52 0.363 0 C-N-CA 120.892 -0.671 . . . . 0.0 112.234 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 50.1 t -107.62 119.58 57.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.772 0.32 . . . . 0.0 111.605 -178.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -124.14 120.59 32.77 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.667 179.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -139.6 173.57 11.4 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-O 121.004 0.431 . . . . 0.0 112.109 -179.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -114.92 142.18 46.94 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.972 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 31.0 mt -102.77 124.09 40.12 Favored Pre-proline 0 CA--C 1.531 0.25 0 CA-C-O 120.949 0.404 . . . . 0.0 111.53 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -77.07 129.48 10.56 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.753 2.302 . . . . 0.0 112.725 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.2 tpt -66.36 125.01 24.3 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.039 0.447 . . . . 0.0 111.803 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.03 1.25 82.35 Favored Glycine 0 C--N 1.332 0.336 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.838 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -133.93 177.13 7.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.955 0.407 . . . . 0.0 110.802 -179.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -119.01 134.73 55.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.135 0.493 . . . . 0.0 111.596 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 12.5 t80 -113.77 127.91 56.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.171 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.402 ' O ' HG11 ' A' ' 96' ' ' VAL . 1.8 p -99.87 136.3 31.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.588 0.708 . . . . 0.0 112.504 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 65.7 t -113.84 112.17 39.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.203 178.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -93.53 118.89 31.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.584 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.88 158.05 41.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.255 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -120.48 97.08 48.94 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.663 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.432 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 65.8 Cg_endo -72.5 99.73 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.915 2.41 . . . . 0.0 112.336 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -95.07 3.73 54.5 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 111.868 0.321 . . . . 0.0 111.868 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -130.82 133.37 45.89 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.77 0.319 . . . . 0.0 110.812 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.75 128.08 35.62 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.98 0.419 . . . . 0.0 111.241 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.11 -157.9 30.1 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.709 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -101.42 125.64 48.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.21 0.528 . . . . 0.0 111.605 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.423 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 85.8 m-85 -118.46 172.81 7.22 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.868 179.602 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 93.4 p -155.03 158.74 39.59 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.1 p90 -147.23 133.43 19.42 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.542 -0.754 . . . . 0.0 111.088 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.309 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.994 -179.887 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.499 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 13.4 ttmt . . . . . 0 CA--C 1.53 0.204 0 CA-C-O 120.958 0.409 . . . . 0.0 110.852 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.423 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -131.25 138.48 49.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.062 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.1 mp -121.84 118.49 55.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.964 0.411 . . . . 0.0 110.775 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.5 t -102.06 121.84 53.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.301 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 . . . . . 0 C--O 1.252 1.235 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.441 -179.802 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.181 0 CA-C-O 121.107 0.479 . . . . 0.0 111.166 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.2 ttmt -91.93 125.48 36.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.995 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -70.94 150.89 45.25 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.189 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.545 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 3.8 pt20 -80.71 139.68 36.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.131 0.491 . . . . 0.0 111.422 -179.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 6.9 mp0 -95.66 115.33 27.28 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.776 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.75 -149.79 0.3 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.256 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -83.6 75.84 10.01 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 94.75 -5.97 69.92 Favored Glycine 0 CA--C 1.523 0.536 0 C-N-CA 120.88 -0.676 . . . . 0.0 113.928 179.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -142.32 160.54 40.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.912 0.356 . . . . 0.0 110.859 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -109.98 157.29 19.44 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.094 0.473 . . . . 0.0 111.45 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.545 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.0 OUTLIER -145.88 143.13 29.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.474 -179.539 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -142.7 129.05 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.064 0.459 . . . . 0.0 111.024 179.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.5 ttt180 -89.45 106.98 18.81 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.192 0.52 . . . . 0.0 111.028 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.0 t -99.82 103.0 14.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.474 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.07 116.66 13.85 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.08 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.5 t -97.52 98.91 7.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.466 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.402 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.6 ptm -143.06 85.83 1.89 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.453 179.111 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.04 3.37 87.75 Favored Glycine 0 CA--C 1.52 0.356 0 C-N-CA 120.941 -0.647 . . . . 0.0 111.509 -178.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 159.81 -143.32 8.99 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -116.2 127.89 55.16 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.687 0.244 . . . . 0.0 110.56 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.465 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 42.6 m -67.7 -64.67 1.85 Allowed Pre-proline 0 CA--C 1.54 0.58 0 CA-C-O 119.548 -0.263 . . . . 0.0 111.481 -179.649 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.465 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 66.7 Cg_endo -75.0 98.88 1.2 Allowed 'Trans proline' 0 C--N 1.356 0.941 0 C-N-CA 121.288 1.325 . . . . 0.0 111.044 177.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -51.45 -44.51 62.41 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.333 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.72 118.99 20.71 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.635 0.255 . . . . 0.0 110.944 179.77 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.0 pt -97.65 125.08 50.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.033 0.444 . . . . 0.0 111.087 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.7 t -95.98 126.38 48.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.497 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 10.2 mt -134.83 169.61 17.1 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.403 -179.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -97.66 166.98 11.24 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.56 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.3 ttpp -96.92 147.87 23.54 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -179.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.6 t 65.92 20.2 11.33 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.953 179.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.441 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 5.6 p -123.59 134.93 25.61 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.991 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -64.41 123.77 12.3 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.1 1.867 . . . . 0.0 111.596 178.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.95 137.23 53.68 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.908 0.385 . . . . 0.0 111.748 -179.527 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -117.5 125.9 51.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.705 0.764 . . . . 0.0 111.414 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.441 HD13 HG23 ' A' ' 64' ' ' ILE . 3.1 mm -98.08 114.78 36.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.726 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.1 t -90.53 107.73 18.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.35 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 61.9 m-85 -95.71 102.78 14.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.912 0.387 . . . . 0.0 111.479 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -89.66 105.84 18.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.178 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.77 101.98 8.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.237 0.541 . . . . 0.0 112.12 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.3 tppt? -96.49 -36.65 10.71 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.636 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.402 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.6 t70 -102.32 130.52 23.99 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.932 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -80.62 39.25 0.83 Allowed 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.089 2.526 . . . . 0.0 113.112 -179.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -70.07 137.77 87.2 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.299 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -63.01 -33.55 73.75 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 122.814 2.343 . . . . 0.0 112.982 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.9 p -75.54 -9.87 58.95 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.388 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 57.3 mt -112.93 14.62 19.77 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.469 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -68.33 -35.35 77.65 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-O 120.91 0.386 . . . . 0.0 111.461 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -131.62 165.9 22.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.932 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -139.13 133.68 40.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.945 0.402 . . . . 0.0 111.116 179.301 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -136.46 132.27 48.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.34 0.59 . . . . 0.0 111.403 179.378 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -94.35 102.08 7.85 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.136 -0.938 . . . . 0.0 109.466 178.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -65.92 -16.4 52.57 Favored 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.696 2.264 . . . . 0.0 113.696 -178.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -100.46 -7.38 24.31 Favored 'General case' 0 CA--C 1.535 0.394 0 N-CA-C 111.933 0.345 . . . . 0.0 111.933 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -120.44 -22.04 6.62 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.69 31.0 41.84 Favored Glycine 0 C--N 1.333 0.378 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.922 -179.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.3 t -114.46 117.06 54.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.633 0.254 . . . . 0.0 111.659 -178.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 -126.13 122.76 36.61 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.892 0.377 . . . . 0.0 110.617 179.244 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.77 171.21 14.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.655 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -106.32 143.54 34.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.73 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 38.7 mt -104.65 128.3 27.15 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.972 0.415 . . . . 0.0 111.359 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -80.64 126.7 6.08 Favored 'Trans proline' 0 CA--C 1.532 0.421 0 C-N-CA 122.726 2.284 . . . . 0.0 112.507 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.4 tpt -65.35 124.93 23.55 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-O 120.974 0.416 . . . . 0.0 111.64 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.29 1.66 81.15 Favored Glycine 0 CA--C 1.52 0.387 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.959 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -134.04 177.37 7.79 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 120.885 0.374 . . . . 0.0 110.857 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -117.55 134.24 55.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.179 0.514 . . . . 0.0 111.658 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -113.78 126.84 55.65 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.142 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.411 ' O ' HG11 ' A' ' 96' ' ' VAL . 1.4 p -98.4 136.92 27.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 CA-C-O 121.55 0.69 . . . . 0.0 112.613 -179.053 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 62.0 t -115.52 111.4 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.132 178.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -92.66 118.42 31.03 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.52 -179.305 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.68 157.07 40.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.142 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.8 m -121.14 98.3 47.2 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.533 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.441 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.1 Cg_endo -72.79 100.62 1.21 Allowed 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.781 2.321 . . . . 0.0 112.376 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -95.34 6.7 48.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.791 0.329 . . . . 0.0 111.783 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.12 133.75 43.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.528 -0.305 . . . . 0.0 110.706 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.32 127.49 35.8 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.918 0.39 . . . . 0.0 111.29 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.08 -157.08 29.09 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.716 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -101.68 125.13 48.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.166 0.508 . . . . 0.0 111.684 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.425 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 82.6 m-85 -117.64 172.27 7.47 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.666 179.495 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 86.9 p -153.72 158.62 41.27 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -178.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -148.71 134.46 18.88 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.87 178.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.264 0 CA-C-O 120.903 0.383 . . . . 0.0 111.564 -179.72 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.49 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 0.9 OUTLIER . . . . . 0 CA--C 1.53 0.182 0 CA-C-O 120.955 0.407 . . . . 0.0 111.033 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.425 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 3.0 ttm -130.58 137.68 49.78 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.09 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -120.92 118.32 55.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.024 0.44 . . . . 0.0 110.639 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 88.9 t -101.79 122.96 54.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.307 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 . . . . . 0 C--O 1.253 1.249 0 CA-C-O 118.163 -0.922 . . . . 0.0 111.462 -179.645 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.53 0.196 0 CA-C-O 121.163 0.506 . . . . 0.0 111.579 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.1 ttmt -101.38 129.62 47.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.619 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.09 152.84 39.83 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 111.187 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.508 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 22.8 pt20 -85.49 142.96 28.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.155 0.502 . . . . 0.0 111.791 -179.25 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -94.96 114.92 26.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.785 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -94.97 -150.72 0.31 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.024 0.44 . . . . 0.0 111.362 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -82.69 70.54 9.69 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.55 -9.83 59.05 Favored Glycine 0 CA--C 1.521 0.411 0 C-N-CA 120.771 -0.728 . . . . 0.0 113.713 178.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 32.8 p90 -137.93 165.64 26.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.953 0.376 . . . . 0.0 110.895 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.7 152.45 31.96 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.912 0.387 . . . . 0.0 111.103 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.508 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.9 tt0 -143.27 139.94 30.41 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.576 -179.325 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.0 128.42 22.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.975 179.185 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 11.0 ttt180 -89.28 108.85 19.85 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.297 0.57 . . . . 0.0 111.114 179.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 44.3 t -100.1 103.61 15.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.583 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -72.91 117.03 14.13 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.979 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 52.3 t -99.59 99.18 8.03 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.558 -178.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.442 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.7 ptm -145.86 86.68 1.73 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.182 179.112 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.22 -0.42 88.75 Favored Glycine 0 CA--C 1.52 0.368 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -178.243 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.463 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.8 -161.4 32.76 Favored Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 47.4 m-85 -101.99 126.39 48.91 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 117.046 0.423 . . . . 0.0 110.418 179.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.456 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 40.3 m -63.82 -63.49 3.87 Favored Pre-proline 0 CA--C 1.54 0.569 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.566 -179.547 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.456 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 68.2 Cg_endo -75.48 95.86 1.02 Allowed 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 121.301 1.334 . . . . 0.0 111.036 177.653 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -49.6 -43.54 46.47 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.32 -179.371 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.94 118.69 19.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.476 179.56 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.8 pt -97.45 126.4 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 121.086 0.469 . . . . 0.0 111.172 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 78.0 t -96.07 127.31 48.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.283 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 10.4 mt -135.0 171.51 14.33 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.558 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -97.13 173.26 7.34 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.739 179.453 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.0 ttpp -104.8 147.93 27.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.829 0.347 . . . . 0.0 111.926 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.4 t 65.49 20.7 11.74 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.751 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.429 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.95 136.46 27.49 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.169 -179.769 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -64.28 122.46 10.42 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.096 1.864 . . . . 0.0 111.47 178.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.91 138.04 54.26 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.99 0.424 . . . . 0.0 111.775 -179.45 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.407 HH11 ' HD2' ' A' ' 63' ' ' ARG . 6.7 ptt85 -120.67 126.55 50.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.789 0.804 . . . . 0.0 111.081 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.428 HG21 ' CZ ' ' A' ' 66' ' ' PHE . 3.4 mm -100.07 114.16 37.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.759 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.0 t -89.93 107.49 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.467 -179.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.428 ' CZ ' HG21 ' A' ' 64' ' ' ILE . 72.6 m-85 -96.53 106.96 19.3 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.918 0.389 . . . . 0.0 111.318 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -91.54 105.79 18.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.633 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.45 96.2 5.32 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.204 0.526 . . . . 0.0 111.596 -179.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 17.4 tptt -90.95 -37.92 13.19 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.69 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.442 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.6 t70 -102.73 130.95 22.86 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.785 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -79.75 38.57 0.75 Allowed 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 123.151 2.567 . . . . 0.0 113.235 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.9 t -69.67 135.55 88.1 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.046 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.33 -28.21 63.4 Favored 'Trans proline' 0 C--N 1.349 0.556 0 C-N-CA 122.63 2.22 . . . . 0.0 112.42 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 22.7 m -78.75 -9.23 59.36 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.081 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.463 HD11 ' N ' ' A' ' 48' ' ' GLY . 46.0 mt -116.05 17.27 15.9 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.456 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -71.7 -32.19 67.55 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -133.29 165.87 23.81 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.967 0.413 . . . . 0.0 111.393 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -140.57 130.14 26.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.98 179.296 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -130.27 132.7 64.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.481 0.657 . . . . 0.0 111.157 179.349 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -95.91 101.96 9.43 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.662 179.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.56 -15.19 46.93 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.59 2.193 . . . . 0.0 113.624 -178.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -100.71 -7.16 24.09 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -122.45 -22.06 5.58 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 112.017 0.376 . . . . 0.0 112.017 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.49 31.4 41.39 Favored Glycine 0 C--N 1.332 0.355 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.028 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.1 t -114.69 119.62 62.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.654 0.264 . . . . 0.0 111.657 -178.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 13.7 t-80 -126.37 119.8 28.23 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.841 0.353 . . . . 0.0 110.427 179.251 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.8 173.23 11.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.754 -179.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -110.07 151.44 27.2 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.046 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 28.0 mt -111.25 125.04 31.31 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-O 120.945 0.402 . . . . 0.0 111.386 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -78.18 131.06 10.57 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 122.826 2.351 . . . . 0.0 112.708 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.6 tpt -66.81 124.43 22.92 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.799 -179.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 86.64 3.59 83.65 Favored Glycine 0 CA--C 1.52 0.345 0 CA-C-N 115.814 -0.63 . . . . 0.0 113.012 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -134.96 177.09 8.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.862 0.363 . . . . 0.0 110.905 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.56 134.8 54.82 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.231 0.539 . . . . 0.0 111.546 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -113.54 125.35 54.1 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.221 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.403 ' O ' HG12 ' A' ' 96' ' ' VAL . 2.3 p -99.08 135.2 35.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.552 0.691 . . . . 0.0 112.489 -178.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 66.7 t -110.77 112.24 39.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.055 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -94.09 118.6 31.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.95 0.405 . . . . 0.0 111.475 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.99 166.5 28.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.146 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.2 m -129.66 97.51 24.32 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.486 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.429 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 70.2 Cg_endo -72.99 100.58 1.22 Allowed 'Trans proline' 0 CA--C 1.532 0.423 0 C-N-CA 122.844 2.363 . . . . 0.0 112.447 179.774 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -95.32 3.8 54.09 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.665 -179.586 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -132.16 134.68 45.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.735 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.32 124.24 34.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.974 0.416 . . . . 0.0 111.272 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 171.42 -165.34 38.32 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.884 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.25 115.47 27.67 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.19 0.519 . . . . 0.0 110.721 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -111.4 173.03 6.54 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.971 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 85.5 p -152.58 165.1 36.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.307 0.575 . . . . 0.0 112.549 -178.573 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.2 p90 -152.07 136.86 17.09 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.441 178.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.256 0 CA-C-O 120.834 0.349 . . . . 0.0 111.825 -179.32 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.423 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.0 ttmm . . . . . 0 CA--C 1.529 0.164 0 CA-C-O 121.069 0.462 . . . . 0.0 111.828 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 2.6 ttm -134.74 131.22 37.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.773 179.413 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.7 mp -116.03 117.79 56.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.024 0.44 . . . . 0.0 110.67 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 74.8 t -101.8 122.53 54.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.288 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 . . . . . 0 C--O 1.252 1.213 0 CA-C-O 118.112 -0.947 . . . . 0.0 111.387 -179.583 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.53 0.203 0 CA-C-O 121.096 0.474 . . . . 0.0 111.402 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.8 mtpt -91.67 130.85 37.4 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.79 179.56 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.25 151.37 39.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.488 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.579 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.6 pt20 -79.04 139.4 38.16 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.142 0.496 . . . . 0.0 111.089 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -97.31 114.47 26.24 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.766 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -94.89 -154.5 0.43 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.256 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -82.11 74.23 9.1 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.14 -9.14 59.48 Favored Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.655 -0.783 . . . . 0.0 113.986 178.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 27.5 p90 -140.96 164.66 29.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 117.036 0.418 . . . . 0.0 111.066 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.67 153.65 29.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.974 0.416 . . . . 0.0 111.353 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.579 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.9 tt0 -143.36 143.08 31.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.46 -179.579 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.51 128.53 17.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.011 0.434 . . . . 0.0 111.08 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.63 106.12 18.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.213 0.53 . . . . 0.0 111.168 179.71 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 46.1 t -99.01 103.29 14.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.65 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.402 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.9 OUTLIER -73.09 118.2 15.75 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.789 -179.961 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.9 t -100.23 97.82 6.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.472 -178.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.431 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.9 ptm -143.27 85.02 1.84 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.372 179.273 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.08 0.24 88.9 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 -178.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 160.38 -169.29 36.15 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -92.17 125.73 36.96 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.924 0.362 . . . . 0.0 110.348 179.511 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.468 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 43.3 m -65.27 -63.97 3.02 Favored Pre-proline 0 CA--C 1.54 0.587 0 CA-C-O 119.557 -0.259 . . . . 0.0 111.293 -179.657 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.468 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 64.3 Cg_endo -75.03 96.55 1.03 Allowed 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 121.244 1.296 . . . . 0.0 111.205 177.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -51.36 -42.51 61.36 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.182 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.502 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -130.96 118.74 21.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.763 179.617 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.2 pt -99.16 126.93 52.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.951 0.405 . . . . 0.0 111.098 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 85.2 t -98.25 127.03 51.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.473 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.2 mt -135.95 165.52 25.47 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.318 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.6 mttt -90.12 176.26 6.84 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.728 179.164 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.2 ttpp -107.0 148.64 28.44 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -179.108 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.9 t 64.93 20.38 12.1 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.771 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.441 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.0 p -123.93 136.75 27.82 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.064 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.75 122.46 10.31 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.164 1.91 . . . . 0.0 111.639 178.607 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.45 139.8 53.65 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.969 0.414 . . . . 0.0 111.53 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.449 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.8 ptt180 -121.5 126.92 50.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.764 0.792 . . . . 0.0 111.344 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.7 mm -98.4 114.71 36.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.726 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.5 t -90.62 113.44 26.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.35 -179.391 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -100.31 114.87 28.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.077 0.465 . . . . 0.0 111.5 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -99.45 102.99 14.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.065 179.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.55 98.42 6.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.176 0.513 . . . . 0.0 111.998 -179.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.9 tptp -94.29 -35.69 12.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.536 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.431 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.8 t70 -106.17 130.79 22.43 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.931 179.579 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -81.2 39.39 0.85 Allowed 'Trans proline' 0 C--N 1.349 0.598 0 C-N-CA 123.059 2.506 . . . . 0.0 113.302 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -70.4 138.33 86.49 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.186 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -62.75 -32.73 78.08 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 122.924 2.416 . . . . 0.0 113.257 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.4 p -76.08 -8.06 56.13 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.779 0.323 . . . . 0.0 111.5 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 53.0 mt -114.88 13.67 17.15 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.356 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -68.49 -36.88 79.56 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-O 120.913 0.387 . . . . 0.0 111.643 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -132.23 161.58 33.08 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.066 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -136.96 131.22 46.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.038 0.446 . . . . 0.0 111.083 179.521 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -133.09 132.96 58.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 121.362 0.601 . . . . 0.0 111.31 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -94.76 102.14 8.39 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.509 178.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.25 -16.55 52.14 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.67 2.246 . . . . 0.0 113.668 -178.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -100.38 -7.04 24.83 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -120.52 -20.78 7.03 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 77.37 32.31 48.02 Favored Glycine 0 C--N 1.333 0.398 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.944 -179.198 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.1 t -116.72 117.98 57.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 -178.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 22.3 t-80 -123.79 122.03 36.98 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.802 0.334 . . . . 0.0 110.402 179.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.9 163.64 28.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.704 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.88 139.04 40.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.481 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 45.7 mt -101.34 128.45 29.22 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 120.856 0.36 . . . . 0.0 111.541 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.409 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 72.7 Cg_endo -82.91 128.65 5.19 Favored 'Trans proline' 0 CA--C 1.532 0.415 0 C-N-CA 122.71 2.273 . . . . 0.0 112.388 179.198 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -66.45 125.12 24.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.08 0.467 . . . . 0.0 111.725 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.88 11.77 80.9 Favored Glycine 0 CA--C 1.52 0.364 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.98 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.409 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.6 mm-40 -137.64 176.97 8.23 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.89 0.376 . . . . 0.0 111.083 -179.604 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -113.37 134.73 54.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.025 0.441 . . . . 0.0 111.733 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.1 t80 -123.98 127.86 48.54 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.935 178.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.3 p -107.0 137.18 39.16 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 CA-C-O 121.417 0.627 . . . . 0.0 112.628 -178.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 67.2 t -112.93 113.19 43.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.134 178.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -94.11 120.15 33.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.95 0.405 . . . . 0.0 111.516 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -136.0 157.9 38.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.82 97.79 48.14 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.682 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.441 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 67.1 Cg_endo -72.82 101.31 1.29 Allowed 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.814 2.343 . . . . 0.0 112.15 179.539 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -95.51 1.96 54.15 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -179.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -129.81 134.84 47.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.762 0.315 . . . . 0.0 110.74 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.93 124.25 34.56 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.007 0.432 . . . . 0.0 111.273 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 166.82 -157.3 29.71 Favored Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.63 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -101.64 125.72 48.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.187 0.518 . . . . 0.0 111.487 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.413 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 84.9 m-85 -117.34 171.44 7.97 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.013 179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.3 p -150.22 158.31 44.02 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 -178.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -150.4 131.46 14.37 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.957 178.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.075 -179.858 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.7 ttpt . . . . . 0 CA--C 1.53 0.181 0 CA-C-O 121.204 0.526 . . . . 0.0 111.904 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.413 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.6 ttm -132.4 139.15 47.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.686 179.439 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -122.39 119.72 59.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.116 0.484 . . . . 0.0 110.854 179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 90.9 t -102.97 123.08 56.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.272 -179.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 . . . . . 0 C--O 1.252 1.201 0 CA-C-O 118.169 -0.92 . . . . 0.0 111.42 -179.774 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 18.4 mm-40 . . . . . 0 C--O 1.233 0.195 0 CA-C-O 121.128 0.489 . . . . 0.0 111.328 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -89.97 125.59 35.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.709 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -70.93 152.07 44.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.238 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.52 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 17.2 pt20 -81.27 137.99 35.77 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.214 0.531 . . . . 0.0 111.448 -179.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.2 mp0 -94.53 113.2 25.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.865 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.63 -151.32 0.28 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.191 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -83.81 77.51 9.87 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 112.03 0.382 . . . . 0.0 112.03 -179.223 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.15 -6.49 68.98 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 120.812 -0.709 . . . . 0.0 114.047 178.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.7 p90 -143.54 161.34 38.72 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.045 0.423 . . . . 0.0 111.072 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.19 156.63 21.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.058 0.456 . . . . 0.0 111.349 179.744 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.52 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.4 tt0 -145.75 144.45 30.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.434 -179.566 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.404 ' CG2' HD11 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -146.96 129.04 7.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.732 179.135 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . 0.404 HH11 ' HD2' ' A' ' 42' ' ' ARG . 0.1 OUTLIER -90.9 110.18 21.41 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.252 0.548 . . . . 0.0 110.938 179.305 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 60.6 t -100.42 108.21 22.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.757 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -72.68 124.97 26.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.648 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.7 t -104.64 96.44 4.6 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 CA-C-O 121.475 0.655 . . . . 0.0 111.262 -179.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.44 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.0 ptp -141.97 87.74 2.06 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.373 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.11 -15.88 36.27 Favored Glycine 0 CA--C 1.522 0.482 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.127 -178.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 178.79 -138.72 3.71 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.483 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -121.09 129.59 53.38 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.862 0.331 . . . . 0.0 110.59 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.425 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 20.2 m -65.84 -60.93 6.34 Favored Pre-proline 0 CA--C 1.538 0.519 0 C-N-CA 121.027 -0.269 . . . . 0.0 110.911 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.425 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 74.4 Cg_endo -76.79 95.77 1.07 Allowed 'Trans proline' 0 C--N 1.358 1.045 0 C-N-CA 121.333 1.355 . . . . 0.0 110.968 177.575 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.77 -42.73 58.11 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.331 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.476 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.73 118.52 20.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.782 179.52 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.8 pt -97.32 124.45 50.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.085 0.469 . . . . 0.0 110.888 179.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.5 t -97.25 126.73 49.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.509 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.3 mt -134.21 170.12 16.17 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.357 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.28 173.73 7.57 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.684 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.6 ttpt -104.29 146.7 28.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.779 0.323 . . . . 0.0 111.844 -179.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.4 t 64.97 20.86 12.21 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.832 179.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.44 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 7.9 p -123.44 135.61 26.26 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.935 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.6 Cg_endo -64.34 122.49 10.45 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 122.076 1.85 . . . . 0.0 111.668 178.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.25 138.86 54.35 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.877 0.37 . . . . 0.0 111.577 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.57 126.79 49.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.769 0.795 . . . . 0.0 111.439 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.404 HD11 ' CG2' ' A' ' 41' ' ' ILE . 4.0 mm -99.0 115.82 40.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.836 -179.85 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.2 t -91.71 110.25 22.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.216 -179.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -95.59 114.77 26.56 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.076 0.465 . . . . 0.0 111.467 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -99.93 104.48 16.11 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.398 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.6 106.54 9.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.274 0.559 . . . . 0.0 112.144 -179.155 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -101.23 -33.83 9.91 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.415 179.293 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.44 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.0 t70 -110.6 133.87 21.04 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.862 179.799 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -81.67 40.29 0.96 Allowed 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 123.086 2.524 . . . . 0.0 112.975 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.41 137.29 93.56 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.308 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -63.03 -35.02 68.24 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.938 2.426 . . . . 0.0 112.941 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.35 -6.68 54.16 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.595 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 58.2 mt -114.32 7.75 16.5 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.426 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -66.18 -38.46 88.09 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.089 0.471 . . . . 0.0 111.451 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 16.5 mt-30 -124.74 158.72 32.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.576 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -133.23 127.79 54.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.379 0.609 . . . . 0.0 110.937 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.68 129.63 58.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.294 0.568 . . . . 0.0 111.105 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -92.9 102.02 6.29 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.402 178.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.26 -16.35 51.42 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.626 2.217 . . . . 0.0 113.77 -178.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 46.5 m-20 -100.71 -6.83 24.48 Favored 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.0 m-85 -120.97 -22.54 6.14 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 81.7 25.45 53.37 Favored Glycine 0 C--N 1.332 0.348 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.07 -179.442 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.1 t -106.48 117.95 53.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.844 0.354 . . . . 0.0 111.663 -178.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -121.16 118.9 30.84 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.598 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.79 167.17 21.36 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.172 0.51 . . . . 0.0 111.945 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -109.38 138.66 45.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.621 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 51.8 mt -101.13 128.46 29.39 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.89 0.376 . . . . 0.0 111.39 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.405 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 74.4 Cg_endo -82.0 128.15 5.68 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 122.768 2.312 . . . . 0.0 112.428 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.4 tpt -66.3 124.55 23.0 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.046 0.451 . . . . 0.0 111.623 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.53 9.3 81.74 Favored Glycine 0 CA--C 1.521 0.418 0 CA-C-N 115.857 -0.611 . . . . 0.0 113.075 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.405 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 50.1 mm-40 -136.9 176.75 8.43 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.903 0.382 . . . . 0.0 111.342 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -112.9 136.32 52.68 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.036 0.446 . . . . 0.0 111.744 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -124.23 126.25 45.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.039 178.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 1.8 p -102.99 138.19 28.2 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-O 121.58 0.705 . . . . 0.0 112.511 -178.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 64.5 t -115.51 112.34 39.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.188 178.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -93.8 118.99 32.18 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.934 0.397 . . . . 0.0 111.576 -179.307 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.11 156.33 39.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.073 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.4 m -120.03 98.32 49.21 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.461 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.44 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.9 Cg_endo -71.88 99.14 0.94 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.713 2.275 . . . . 0.0 112.561 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -97.7 22.79 8.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.09 0.471 . . . . 0.0 111.515 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.15 131.78 14.89 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.464 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.29 127.29 35.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.983 0.421 . . . . 0.0 111.407 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 164.42 -157.33 29.64 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.759 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.18 126.59 49.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.168 0.509 . . . . 0.0 111.544 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.417 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 86.4 m-85 -119.32 171.99 7.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.891 179.641 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 87.8 p -153.73 159.85 42.11 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -150.53 131.14 13.95 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.093 178.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.325 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.295 -179.774 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 4.5 ttmm . . . . . 0 CA--C 1.531 0.244 0 CA-C-O 121.053 0.454 . . . . 0.0 111.229 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.417 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -132.83 140.42 47.95 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.994 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.95 119.77 56.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.061 0.458 . . . . 0.0 110.877 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.9 t -101.89 124.68 55.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.079 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.251 1.158 0 CA-C-O 118.045 -0.979 . . . . 0.0 111.898 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.232 0.168 0 CA-C-O 121.187 0.517 . . . . 0.0 111.168 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -88.27 126.58 35.24 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.631 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.03 150.56 45.47 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.141 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.541 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 19.8 pt20 -79.44 137.5 37.27 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.297 0.57 . . . . 0.0 111.283 -179.323 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.5 mp0 -94.52 114.02 25.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.963 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -93.03 -156.08 0.46 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.072 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -83.56 76.91 9.92 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-O 120.851 0.358 . . . . 0.0 111.948 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.25 -12.71 57.19 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 120.806 -0.712 . . . . 0.0 114.151 178.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -140.69 167.47 22.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 117.16 0.48 . . . . 0.0 111.353 -179.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.93 155.0 28.78 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.863 0.363 . . . . 0.0 111.119 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.541 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 5.8 tt0 -145.35 142.23 29.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.562 -179.271 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.39 129.84 17.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.312 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -91.67 110.22 21.54 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.239 0.542 . . . . 0.0 111.058 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 46.4 t -100.48 104.01 15.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.589 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.413 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.9 OUTLIER -73.16 116.98 14.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.845 -179.91 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 41.1 t -97.41 98.46 7.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.365 -178.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.418 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.8 ptp -139.6 81.93 1.85 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.383 179.383 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 88.01 -8.98 76.39 Favored Glycine 0 CA--C 1.521 0.429 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 -178.342 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 172.85 -153.36 18.35 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -105.42 125.65 51.23 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.825 0.313 . . . . 0.0 110.54 179.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.462 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 45.2 m -65.13 -64.48 2.61 Favored Pre-proline 0 CA--C 1.538 0.518 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.407 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.462 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 60.1 Cg_endo -74.11 97.91 1.05 Allowed 'Trans proline' 0 C--N 1.358 1.039 0 C-N-CA 121.266 1.311 . . . . 0.0 111.001 177.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.63 -44.04 57.18 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.163 -179.236 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.449 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.6 118.99 19.88 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.605 0.241 . . . . 0.0 110.959 179.57 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.0 pt -97.07 126.96 49.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 121.054 0.454 . . . . 0.0 110.747 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 84.6 t -98.09 126.93 50.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.505 -179.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.8 mt -135.63 166.52 23.05 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.567 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.7 tttt -93.1 170.24 9.8 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.709 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.5 ttpp -100.45 148.25 24.96 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.403 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.2 t 65.84 20.14 11.38 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.917 179.393 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.428 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.2 p -123.8 135.88 26.74 Favored Pre-proline 0 CA--C 1.537 0.445 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.977 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -64.4 122.77 10.8 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.198 1.932 . . . . 0.0 111.575 178.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.67 138.51 53.9 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.956 0.408 . . . . 0.0 111.728 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.421 ' CG ' ' HG3' ' A' ' 40' ' ' GLU . 0.0 OUTLIER -121.06 129.4 53.33 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.767 0.794 . . . . 0.0 111.517 179.739 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.452 HD11 HG22 ' A' ' 64' ' ' ILE . 3.4 mm -100.76 115.69 42.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.817 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.5 t -91.77 111.69 24.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 120.766 0.317 . . . . 0.0 111.326 -179.3 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -97.7 113.22 24.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.053 0.454 . . . . 0.0 111.354 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -98.96 105.19 17.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.215 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -79.09 104.8 9.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.29 0.566 . . . . 0.0 112.22 -178.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.2 tppt? -99.35 -36.09 9.72 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.086 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.418 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 6.4 t70 -103.79 129.86 24.53 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.852 179.562 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -80.49 39.47 0.85 Allowed 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.998 2.465 . . . . 0.0 112.939 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.1 m -69.95 135.67 87.47 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.382 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -64.05 -29.9 66.06 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.901 2.401 . . . . 0.0 112.811 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.71 -9.38 58.63 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.599 179.761 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 29.1 mt -113.17 12.52 19.07 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 120.784 0.326 . . . . 0.0 111.321 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -67.44 -35.18 78.72 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.785 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -129.48 160.68 32.42 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.805 0.336 . . . . 0.0 111.21 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.67 129.01 33.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.181 0.515 . . . . 0.0 110.85 179.292 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.5 p -132.04 132.4 61.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.276 0.56 . . . . 0.0 111.257 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 15.7 m-85 -94.93 101.92 8.11 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.725 179.032 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -67.09 -15.23 46.05 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.722 2.281 . . . . 0.0 113.562 -178.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 -99.62 -7.34 25.88 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -122.67 -22.13 5.46 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.092 0.405 . . . . 0.0 112.092 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 81.45 26.43 51.33 Favored Glycine 0 CA--C 1.52 0.374 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.044 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.6 t -107.69 117.37 53.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.746 0.307 . . . . 0.0 111.709 -178.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -119.12 117.94 30.05 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.519 179.214 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.67 167.54 19.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.156 0.503 . . . . 0.0 112.222 -179.157 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -111.69 141.2 45.6 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.319 179.562 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 53.1 mt -103.56 127.75 28.89 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.005 0.431 . . . . 0.0 111.566 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.419 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 72.5 Cg_endo -82.94 129.85 5.53 Favored 'Trans proline' 0 CA--C 1.532 0.411 0 C-N-CA 122.846 2.364 . . . . 0.0 112.481 179.271 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.5 tpt -67.58 125.24 25.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.008 0.432 . . . . 0.0 111.71 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 83.29 11.61 80.3 Favored Glycine 0 CA--C 1.52 0.405 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.877 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.419 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 53.7 mm-40 -137.46 176.86 8.33 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.007 0.432 . . . . 0.0 111.157 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -113.37 132.77 55.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.78 -179.716 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -121.75 125.11 45.8 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.967 178.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.2 p -105.16 137.06 36.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.549 0.69 . . . . 0.0 112.472 -178.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -112.79 112.11 39.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.153 178.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -93.67 119.22 32.4 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.953 0.406 . . . . 0.0 111.416 -179.469 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.91 158.24 38.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.339 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -121.67 96.81 47.11 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.469 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.428 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.9 Cg_endo -71.59 99.44 0.94 Allowed 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.823 2.349 . . . . 0.0 112.294 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -94.07 4.47 53.85 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.995 0.368 . . . . 0.0 111.995 -179.3 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -133.88 135.63 43.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.756 0.313 . . . . 0.0 110.933 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.59 124.9 34.5 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.837 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.35 -167.56 40.51 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.796 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -97.9 114.72 26.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.105 0.479 . . . . 0.0 110.631 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 20.7 m-85 -111.4 172.42 6.9 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.177 -179.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 87.1 p -158.17 164.88 36.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.155 0.502 . . . . 0.0 112.196 -178.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -148.26 137.39 21.92 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.762 179.017 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.219 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.277 -179.719 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.8 ttmt . . . . . 0 CA--C 1.53 0.194 0 CA-C-O 120.974 0.416 . . . . 0.0 111.359 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 2.8 ttm -133.68 133.62 42.1 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.896 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.13 117.36 53.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.071 0.463 . . . . 0.0 110.753 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 94.7 t -101.65 121.94 53.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.155 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.277 -0.868 . . . . 0.0 111.538 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.233 0.235 0 CA-C-O 120.959 0.409 . . . . 0.0 111.502 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.6 ttmt -90.37 126.71 35.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.501 179.565 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.36 151.11 46.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.028 0.442 . . . . 0.0 111.464 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.569 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.7 pt20 -78.28 143.52 36.95 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.379 -179.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -98.68 115.33 28.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.855 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.63 -151.62 0.36 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.484 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -81.65 75.52 8.6 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -179.171 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.4 -7.47 68.82 Favored Glycine 0 CA--C 1.523 0.573 0 C-N-CA 120.72 -0.753 . . . . 0.0 114.047 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -141.35 161.48 37.78 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.959 0.38 . . . . 0.0 110.981 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.06 155.71 22.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.102 0.477 . . . . 0.0 111.154 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.569 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.9 tt0 -144.53 143.89 31.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.616 -179.382 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.411 ' CG2' HD11 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -143.17 128.71 16.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.081 0.467 . . . . 0.0 110.963 178.926 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.69 109.03 20.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.33 0.586 . . . . 0.0 110.962 179.535 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.75 103.95 15.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.599 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.402 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 1.1 tp10 -73.17 117.62 15.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.857 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.3 t -99.52 98.55 7.18 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.526 -178.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.45 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.3 ptm -145.25 86.97 1.78 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.4 179.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 83.66 -2.51 87.25 Favored Glycine 0 CA--C 1.521 0.407 0 C-N-CA 120.824 -0.703 . . . . 0.0 111.468 -178.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.433 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 162.9 -171.17 38.63 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 30.3 m-85 -91.78 124.94 36.29 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.816 0.308 . . . . 0.0 110.354 179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.471 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 45.0 m -63.99 -64.35 2.95 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 119.638 -0.22 . . . . 0.0 111.407 -179.42 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.471 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 62.1 Cg_endo -74.98 96.88 1.04 Allowed 'Trans proline' 0 C--N 1.357 0.977 0 C-N-CA 121.299 1.333 . . . . 0.0 111.075 177.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.84 -43.19 59.12 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.261 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.433 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.36 118.52 20.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.622 -0.263 . . . . 0.0 110.708 179.667 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.7 pt -98.3 125.43 51.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.031 0.443 . . . . 0.0 111.15 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 75.9 t -98.62 126.71 51.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.425 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.4 mt -132.74 171.5 13.79 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.472 -179.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.95 170.02 9.72 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.549 179.403 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.6 ttpp -102.43 147.06 27.19 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.86 0.362 . . . . 0.0 111.909 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.4 t 65.27 20.46 11.89 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.527 -0.76 . . . . 0.0 111.701 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.417 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 7.4 p -123.66 136.41 27.26 Favored Pre-proline 0 CA--C 1.534 0.356 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.003 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -64.33 122.7 10.72 Favored 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 121.984 1.79 . . . . 0.0 111.412 178.442 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.29 138.49 54.08 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.017 0.437 . . . . 0.0 111.582 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.439 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.9 ptt180 -120.55 127.74 52.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.727 0.775 . . . . 0.0 111.418 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.431 HD11 HG23 ' A' ' 64' ' ' ILE . 3.0 mm -99.4 114.68 38.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.628 179.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.3 t -92.01 110.53 22.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.697 0.284 . . . . 0.0 111.553 -179.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -97.1 120.05 36.72 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.013 0.435 . . . . 0.0 111.233 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -103.93 105.18 15.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.433 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.0 tpt180 -77.77 97.81 5.32 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.161 0.505 . . . . 0.0 111.605 -179.427 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.8 tptp -93.71 -32.93 13.83 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.412 179.428 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.45 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.9 t70 -111.28 131.66 22.13 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.741 179.661 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -80.24 39.33 0.83 Allowed 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 123.075 2.516 . . . . 0.0 112.978 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.13 135.76 91.57 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.159 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.26 -33.28 60.34 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.764 2.309 . . . . 0.0 112.875 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -77.37 -1.97 32.71 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.55 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.433 HD11 ' N ' ' A' ' 48' ' ' GLY . 28.8 mt -119.01 9.13 11.76 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.457 -179.749 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.9 -41.04 78.76 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -122.09 149.37 43.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.028 0.442 . . . . 0.0 111.591 -179.495 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -131.51 129.18 61.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.54 179.238 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 p -132.7 131.35 59.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.439 0.637 . . . . 0.0 111.44 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -92.86 101.93 6.1 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.448 178.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.41 -15.52 45.64 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.631 2.221 . . . . 0.0 113.657 -178.465 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -100.12 -9.61 22.38 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.5 m-85 -119.46 -21.41 7.43 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 80.95 28.33 46.34 Favored Glycine 0 CA--C 1.52 0.346 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.074 -179.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.4 t -109.44 117.58 54.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.786 0.327 . . . . 0.0 111.731 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -120.59 119.74 33.76 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.428 179.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.72 167.92 20.72 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 121.182 0.515 . . . . 0.0 112.344 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -113.3 143.27 44.72 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.316 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 30.7 mt -103.53 124.35 38.34 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.451 . . . . 0.0 111.599 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.09 130.38 9.33 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.771 2.314 . . . . 0.0 112.662 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.2 tpt -67.47 124.77 24.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.138 0.494 . . . . 0.0 111.748 -179.597 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 83.53 9.68 82.98 Favored Glycine 0 CA--C 1.521 0.411 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.975 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 51.4 mm-40 -136.21 176.69 8.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.865 0.364 . . . . 0.0 111.284 -179.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -114.07 134.72 54.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.013 0.435 . . . . 0.0 111.574 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.7 t80 -122.52 124.09 42.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.036 178.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.2 p -104.37 136.99 35.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 CA-C-O 121.563 0.697 . . . . 0.0 112.533 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 54.2 t -112.98 112.11 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.16 179.02 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -93.52 119.57 32.75 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.517 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.6 158.28 39.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.207 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 m -121.51 96.79 47.44 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.525 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.417 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.8 Cg_endo -72.93 101.18 1.29 Allowed 'Trans proline' 0 CA--C 1.532 0.399 0 C-N-CA 122.855 2.37 . . . . 0.0 112.349 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -95.51 5.53 51.31 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 111.898 0.333 . . . . 0.0 111.898 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -132.4 133.97 44.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.763 0.316 . . . . 0.0 110.751 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -90.61 128.26 36.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.983 0.42 . . . . 0.0 111.301 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 162.64 -155.88 27.36 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.694 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -102.19 126.91 49.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.21 0.529 . . . . 0.0 111.468 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.405 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 89.9 m-85 -120.69 173.28 7.3 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.885 179.733 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 14.9 m -154.9 156.91 36.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.197 0.523 . . . . 0.0 112.399 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -146.26 142.21 28.12 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.726 179.246 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.215 0 CA-C-O 120.961 0.41 . . . . 0.0 111.68 -179.487 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.433 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.1 ttpt . . . . . 0 CA--C 1.531 0.222 0 CA-C-O 121.122 0.487 . . . . 0.0 112.054 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.405 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.4 ttm -135.73 139.76 43.86 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.805 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.32 120.64 59.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.027 0.441 . . . . 0.0 110.667 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 90.2 t -102.88 123.31 56.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.272 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 . . . . . 0 C--O 1.252 1.191 0 CA-C-O 118.184 -0.913 . . . . 0.0 111.416 -179.554 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.139 0 CA-C-O 121.026 0.441 . . . . 0.0 111.297 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.22 126.12 35.72 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.753 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.4 148.97 46.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.257 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.575 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 18.6 pt20 -76.49 140.21 41.12 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.269 0.557 . . . . 0.0 111.217 -179.461 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -97.45 115.94 28.72 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.92 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -95.33 -151.91 0.35 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.522 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -82.46 72.88 9.52 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -179.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.12 -8.74 61.06 Favored Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.678 -0.773 . . . . 0.0 113.902 178.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -139.1 165.29 27.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 117.03 0.415 . . . . 0.0 110.932 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.2 153.07 31.52 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.994 0.426 . . . . 0.0 111.058 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.575 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 6.7 tt0 -144.42 140.49 29.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.412 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.01 130.24 24.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.131 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -90.6 110.06 21.21 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.178 0.513 . . . . 0.0 110.999 179.463 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 53.1 t -102.1 109.84 27.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.738 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.98 123.16 23.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.727 179.793 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.2 t -104.25 95.78 4.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-O 121.479 0.656 . . . . 0.0 111.376 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.421 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 6.2 ptm -146.58 87.89 1.74 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.281 179.27 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.52 -0.84 89.22 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.432 -178.321 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 160.57 -144.36 9.88 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 111.5 -0.64 . . . . 0.0 111.5 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -119.1 128.61 54.46 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.774 0.287 . . . . 0.0 110.636 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.441 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 22.0 m -65.61 -61.66 5.52 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-O 119.572 -0.252 . . . . 0.0 110.958 179.775 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.441 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 68.9 Cg_endo -75.91 95.75 1.03 Allowed 'Trans proline' 0 C--N 1.357 0.998 0 C-N-CA 121.325 1.35 . . . . 0.0 111.038 177.742 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.6 -42.13 55.56 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.162 -179.206 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.433 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -133.8 118.99 18.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.83 179.477 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.648 HD12 ' SD ' ' A' ' 120' ' ' MET . 6.0 pt -96.67 126.62 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-O 121.062 0.458 . . . . 0.0 110.969 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 94.8 t -97.72 125.94 50.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.443 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 3.5 mt -135.67 165.03 26.52 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.307 -179.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.6 mmtt -89.01 176.41 7.01 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 120.769 0.318 . . . . 0.0 111.046 179.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.8 ttpp -106.93 148.26 28.84 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.834 0.349 . . . . 0.0 111.929 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.4 t 64.73 20.85 12.26 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.644 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.402 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.8 p -123.88 136.17 27.13 Favored Pre-proline 0 CA--C 1.537 0.457 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.998 -179.776 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -63.57 120.87 8.43 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.111 1.874 . . . . 0.0 111.688 178.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.82 138.29 54.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.845 0.355 . . . . 0.0 111.598 -179.425 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -123.19 128.42 50.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.784 0.802 . . . . 0.0 111.537 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.445 HD12 HG23 ' A' ' 64' ' ' ILE . 4.2 mm -99.69 116.31 42.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.883 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.6 t -91.63 112.56 25.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.812 0.339 . . . . 0.0 111.246 -179.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -98.21 116.84 31.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.116 0.484 . . . . 0.0 111.528 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -100.78 103.31 14.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.387 179.468 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.54 102.85 7.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.247 0.546 . . . . 0.0 112.157 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.5 tptp -97.44 -38.37 9.63 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.588 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.421 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.0 t70 -103.0 130.72 23.13 Favored Pre-proline 0 CA--C 1.535 0.375 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.95 179.68 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -81.31 39.43 0.86 Allowed 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 123.099 2.532 . . . . 0.0 113.209 -179.394 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 29.1 t -70.5 135.16 86.35 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.263 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.15 -26.85 64.91 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.673 2.249 . . . . 0.0 112.519 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.3 m -80.24 -10.93 59.77 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.131 179.631 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 24.0 mt -113.9 13.7 18.39 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.213 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -70.21 -34.15 72.57 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.575 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -127.21 161.88 27.5 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.969 0.414 . . . . 0.0 111.511 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -138.76 127.97 30.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.338 178.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.404 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 1.5 p -131.72 130.08 61.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.282 0.563 . . . . 0.0 111.545 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -92.65 101.84 5.8 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.279 178.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.94 -13.32 38.04 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 122.566 2.177 . . . . 0.0 113.64 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -100.49 -11.72 19.92 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 111.929 0.344 . . . . 0.0 111.929 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -120.77 -17.82 7.85 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -178.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.78 29.24 52.68 Favored Glycine 0 C--N 1.333 0.371 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.541 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 54.2 t -109.06 113.59 44.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.81 0.338 . . . . 0.0 111.748 -179.113 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -117.93 117.44 29.27 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.401 179.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.57 167.59 20.19 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-O 121.342 0.591 . . . . 0.0 112.44 -179.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -110.1 139.8 44.86 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.257 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 46.3 mt -102.89 126.61 32.08 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.943 0.402 . . . . 0.0 111.481 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.416 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 70.1 Cg_endo -81.03 128.79 6.63 Favored 'Trans proline' 0 CA--C 1.532 0.393 0 C-N-CA 122.794 2.33 . . . . 0.0 112.414 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -65.92 124.83 23.56 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 121.042 0.449 . . . . 0.0 111.837 -179.497 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.94 9.6 84.17 Favored Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.923 -0.581 . . . . 0.0 113.055 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.416 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 47.5 mt-10 -135.14 176.79 8.34 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-O 120.94 0.4 . . . . 0.0 111.08 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -113.12 134.63 54.46 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.981 0.42 . . . . 0.0 111.799 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.9 t80 -123.22 126.59 47.23 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.899 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.2 p -106.15 138.87 29.47 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 CA-C-O 121.527 0.679 . . . . 0.0 112.64 -178.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.8 t -114.22 112.3 39.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.164 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -94.76 119.1 32.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.018 0.437 . . . . 0.0 111.626 -179.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.03 157.57 40.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.273 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.8 m -120.73 96.67 48.75 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.326 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.402 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 71.6 Cg_endo -73.31 102.68 1.5 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.81 2.34 . . . . 0.0 112.434 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -97.71 10.6 39.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.902 0.382 . . . . 0.0 111.9 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.26 130.25 30.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.851 0.358 . . . . 0.0 110.874 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.07 128.22 35.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.372 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 165.79 -155.15 26.26 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.847 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -107.96 125.63 51.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.122 0.487 . . . . 0.0 111.012 -179.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -124.29 166.92 15.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.305 -179.74 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.19 157.9 43.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.182 0.515 . . . . 0.0 112.29 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -146.36 135.57 22.75 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.623 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.278 0 CA-C-O 120.799 0.333 . . . . 0.0 111.406 -179.627 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.433 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.0 ttpt . . . . . 0 CA--C 1.53 0.199 0 CA-C-O 121.223 0.535 . . . . 0.0 111.783 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.648 ' SD ' HD12 ' A' ' 54' ' ' ILE . 10.1 ttp -134.36 130.73 37.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.657 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -117.61 118.78 59.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.038 0.447 . . . . 0.0 111.097 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 57.8 t -101.29 119.83 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.886 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.005 -0.998 . . . . 0.0 112.063 -179.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.174 0 CA-C-O 121.066 0.46 . . . . 0.0 111.454 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 8.4 ttmt -91.43 128.45 37.26 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.788 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.8 152.22 41.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.163 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 -82.75 141.51 32.32 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.206 0.527 . . . . 0.0 111.555 -179.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -95.34 115.69 27.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.805 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.71 -150.87 0.33 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.245 -179.831 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -83.11 78.0 9.66 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.85 -6.34 73.31 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.94 -0.648 . . . . 0.0 114.111 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -143.35 161.88 37.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 117.039 0.419 . . . . 0.0 111.094 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.11 155.56 21.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.982 0.42 . . . . 0.0 111.081 179.603 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -146.01 140.31 26.76 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.7 -179.17 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . 0.405 ' CG2' HD13 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -142.06 130.12 21.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.791 179.108 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . 0.407 HH11 ' HD2' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -91.5 111.05 22.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.192 0.52 . . . . 0.0 111.113 179.535 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 44.9 t -100.54 103.8 15.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.681 -179.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -72.27 115.31 11.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.602 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.8 t -97.68 98.74 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.489 0.662 . . . . 0.0 111.432 -178.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.51 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.6 ptm -145.76 89.51 1.91 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.502 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.3 -0.89 83.26 Favored Glycine 0 CA--C 1.521 0.418 0 C-N-CA 120.869 -0.681 . . . . 0.0 111.59 -178.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . 0.407 ' N ' HD13 ' A' ' 75' ' ' LEU . . . 161.83 -173.29 38.16 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -90.14 124.66 35.01 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.896 0.348 . . . . 0.0 110.17 179.479 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.458 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 31.7 m -63.36 -63.9 3.54 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 119.648 -0.215 . . . . 0.0 111.317 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.458 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 63.5 Cg_endo -75.63 96.97 1.07 Allowed 'Trans proline' 0 C--N 1.358 1.038 0 C-N-CA 121.267 1.312 . . . . 0.0 111.068 177.506 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.61 -43.31 56.77 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 116.057 -0.519 . . . . 0.0 112.38 -179.222 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.457 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.39 118.58 19.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.655 179.684 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.609 HD13 ' SD ' ' A' ' 120' ' ' MET . 5.6 pt -97.67 125.72 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-O 121.085 0.469 . . . . 0.0 111.037 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 83.9 t -97.76 126.67 50.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.36 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 3.3 mt -135.76 171.42 14.49 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.494 -179.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 14.5 mttt -93.63 174.58 7.12 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.978 179.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.8 ttpt -106.46 147.88 28.81 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.852 0.358 . . . . 0.0 111.891 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.0 t 65.08 19.72 11.88 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.641 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.413 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.5 135.93 26.64 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -63.45 122.35 10.47 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.118 1.878 . . . . 0.0 111.464 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.85 139.41 54.0 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.931 0.396 . . . . 0.0 111.728 -179.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.412 HH11 ' HD2' ' A' ' 63' ' ' ARG . 3.3 ptt180 -122.3 128.29 50.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.769 0.795 . . . . 0.0 111.389 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.431 HD13 HG21 ' A' ' 64' ' ' ILE . 3.6 mm -101.58 113.62 38.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.759 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.0 t -88.82 106.91 17.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.507 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -94.03 113.24 25.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.016 0.436 . . . . 0.0 111.258 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -99.52 104.35 16.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.522 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.7 94.97 5.17 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.231 0.539 . . . . 0.0 111.498 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -88.6 -35.05 17.09 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.829 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.51 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 0.2 OUTLIER -111.55 136.82 21.03 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.083 179.906 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -81.01 39.47 0.87 Allowed 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 123.105 2.537 . . . . 0.0 113.288 -179.371 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.9 m -67.46 133.68 92.94 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.175 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -63.03 -32.23 75.89 Favored 'Trans proline' 0 C--N 1.348 0.551 0 C-N-CA 122.693 2.262 . . . . 0.0 112.776 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.58 -2.48 32.73 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.547 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . 0.407 HD13 ' N ' ' A' ' 48' ' ' GLY . 49.9 mt -121.21 13.77 11.23 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.291 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -70.63 -41.59 72.01 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.764 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -124.72 138.48 54.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.892 0.377 . . . . 0.0 111.586 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -118.78 130.35 73.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.593 179.287 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . 0.603 ' O ' ' HD3' ' A' ' 81' ' ' PRO . 0.2 OUTLIER -134.83 131.79 53.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.386 0.612 . . . . 0.0 111.316 179.978 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -92.84 101.59 5.53 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.42 178.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . 0.603 ' HD3' ' O ' ' A' ' 79' ' ' VAL . 25.5 Cg_exo -61.82 -17.66 56.42 Favored 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 123.024 2.482 . . . . 0.0 113.748 -178.716 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -101.2 -10.22 20.58 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -119.55 -21.38 7.39 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 85.66 1.49 87.43 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 121.248 -0.501 . . . . 0.0 112.226 -179.449 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.9 t -80.72 115.24 22.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.893 0.378 . . . . 0.0 111.41 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 20.5 p-80 -131.29 121.63 25.06 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.602 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -141.15 161.91 36.75 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -99.53 127.11 45.6 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.115 179.208 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 57.5 mt -84.4 130.22 54.71 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-O 121.059 0.457 . . . . 0.0 111.844 -178.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -79.04 123.54 5.72 Favored 'Trans proline' 0 CA--C 1.533 0.461 0 C-N-CA 122.704 2.27 . . . . 0.0 112.236 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.1 tpt -64.16 124.96 23.01 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.7 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.86 6.25 85.43 Favored Glycine 0 CA--C 1.521 0.426 0 CA-C-N 115.886 -0.597 . . . . 0.0 113.081 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -132.96 176.87 8.11 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.984 0.421 . . . . 0.0 111.081 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.6 mp0 -115.97 132.17 56.73 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.478 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -120.51 117.95 28.98 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.333 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 3.4 p -96.0 130.34 44.83 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 CA-C-O 121.764 0.792 . . . . 0.0 112.062 -179.429 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 52.9 t -106.17 115.24 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.426 179.167 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -95.81 119.17 33.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.871 0.367 . . . . 0.0 111.631 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -134.09 157.15 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.107 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.4 m -120.0 97.06 49.5 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.517 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.413 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.9 Cg_endo -73.22 98.06 0.99 Allowed 'Trans proline' 0 CA--C 1.532 0.402 0 C-N-CA 122.78 2.32 . . . . 0.0 112.531 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -96.51 23.44 6.83 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.014 0.435 . . . . 0.0 111.481 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.5 131.91 14.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.521 179.66 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.71 128.46 36.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.986 0.422 . . . . 0.0 111.495 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.57 -158.64 31.15 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.632 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -101.82 123.46 45.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.048 0.452 . . . . 0.0 111.352 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.401 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 88.2 m-85 -115.9 166.19 12.24 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.019 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 95.5 p -141.57 155.73 45.75 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -178.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -151.57 129.56 11.78 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.389 178.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.188 0 CA-C-O 121.123 0.487 . . . . 0.0 111.904 -179.346 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.457 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 6.8 ttpt . . . . . 0 CA--C 1.53 0.207 0 CA-C-O 121.265 0.555 . . . . 0.0 111.785 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.609 ' SD ' HD13 ' A' ' 54' ' ' ILE . 17.2 ttp -133.02 133.65 43.37 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.701 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -118.82 119.66 61.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.111 0.481 . . . . 0.0 111.08 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 92.5 t -102.61 121.86 54.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.946 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.25 1.106 0 CA-C-O 118.147 -0.93 . . . . 0.0 111.937 -179.428 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.157 0 CA-C-O 121.321 0.582 . . . . 0.0 111.527 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.4 mtpt -89.19 130.17 35.65 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.736 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.41 151.85 41.01 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.388 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLN . . . . . 0.567 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.6 pt20 -80.33 141.06 35.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.036 0.445 . . . . 0.0 111.4 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 56.4 mt-30 -96.83 115.03 26.73 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.73 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.76 -149.99 0.31 Allowed 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.454 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -81.58 72.68 8.63 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -179.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.03 -6.11 66.44 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 120.806 -0.711 . . . . 0.0 113.875 178.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -140.92 160.67 39.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.894 0.347 . . . . 0.0 110.788 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.15 156.08 21.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.136 0.493 . . . . 0.0 111.379 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.567 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.5 tt0 -144.31 143.2 30.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.513 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -143.73 128.42 14.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.065 0.459 . . . . 0.0 111.053 179.089 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.75 106.5 18.5 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.152 0.501 . . . . 0.0 111.078 179.689 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 49.0 t -98.09 101.99 12.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.557 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -71.59 117.81 13.63 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.796 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 31.8 t -99.49 98.22 6.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.394 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' MET . . . . . 0.448 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 10.8 ptp -140.38 82.3 1.85 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.333 179.499 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 88.0 -12.14 64.97 Favored Glycine 0 CA--C 1.517 0.194 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -178.017 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 173.27 -171.43 44.46 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -88.41 123.02 32.55 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.973 0.386 . . . . 0.0 110.265 179.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' THR . . . . . 0.457 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 35.5 m -61.99 -63.45 4.23 Favored Pre-proline 0 CA--C 1.54 0.558 0 CA-C-O 119.559 -0.257 . . . . 0.0 111.359 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' PRO . . . . . 0.457 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 73.6 Cg_endo -75.76 96.74 1.06 Allowed 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 121.296 1.331 . . . . 0.0 111.013 177.501 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -50.57 -43.13 56.26 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -179.252 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . 0.431 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -130.41 118.8 21.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.659 0.266 . . . . 0.0 110.866 179.775 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.0 pt -98.8 126.31 52.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.079 0.466 . . . . 0.0 110.984 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 91.9 t -97.13 126.46 49.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.925 0.393 . . . . 0.0 111.532 -179.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 8.3 mt -133.98 168.33 18.99 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.38 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.6 tttt -95.09 168.28 10.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.508 179.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 4.6 ttpp -99.18 147.89 24.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 111.964 -179.423 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.4 t 65.78 19.83 11.39 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.874 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.443 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 6.3 p -123.71 135.63 26.41 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.895 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -64.52 123.36 11.64 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.104 1.869 . . . . 0.0 111.53 178.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.61 138.82 54.29 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.893 0.378 . . . . 0.0 111.703 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' ARG . . . . . 0.406 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.8 ptt180 -120.4 126.63 50.94 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-O 121.706 0.765 . . . . 0.0 111.274 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ILE . . . . . 0.463 HD11 HG22 ' A' ' 64' ' ' ILE . 3.2 mm -99.42 115.48 40.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.801 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.0 t -91.17 109.55 21.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.825 0.345 . . . . 0.0 111.287 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -96.78 112.23 24.07 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.075 0.464 . . . . 0.0 111.431 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -96.74 101.63 13.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.281 179.517 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.77 97.91 4.64 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 121.281 0.563 . . . . 0.0 111.918 -179.12 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -95.98 -29.56 14.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.828 179.715 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ASP . . . . . 0.448 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.8 t70 -111.75 131.79 22.23 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.922 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -80.63 39.45 0.86 Allowed 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.085 2.523 . . . . 0.0 113.121 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.7 m -69.75 139.1 88.33 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.289 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -62.61 -33.85 76.41 Favored 'Trans proline' 0 C--N 1.348 0.553 0 C-N-CA 122.883 2.389 . . . . 0.0 112.863 -179.6 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 10.7 p -78.59 -2.57 39.56 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.45 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 37.9 mt -121.14 9.94 10.59 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.32 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.93 -37.29 78.8 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.059 0.457 . . . . 0.0 111.118 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -129.34 160.06 34.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.515 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -133.49 128.5 54.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.339 0.59 . . . . 0.0 111.018 179.44 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -132.39 128.83 58.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 121.312 0.577 . . . . 0.0 111.071 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -92.54 102.08 6.1 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.47 -0.787 . . . . 0.0 109.537 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.79 -16.24 49.58 Favored 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.581 2.187 . . . . 0.0 113.598 -178.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -100.68 -6.37 25.22 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 111.984 0.364 . . . . 0.0 111.984 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -121.38 -22.98 5.8 Favored 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.25 25.33 51.95 Favored Glycine 0 CA--C 1.52 0.355 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.032 -179.473 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.0 t -106.6 117.7 52.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.813 0.339 . . . . 0.0 111.684 -178.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -121.1 117.52 27.38 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.52 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.82 165.83 24.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.138 0.494 . . . . 0.0 112.025 -179.292 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -107.38 140.56 40.11 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.474 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 58.9 mt -102.07 129.56 26.11 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.986 0.422 . . . . 0.0 111.363 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' PRO . . . . . 0.409 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 74.3 Cg_endo -82.7 126.2 4.53 Favored 'Trans proline' 0 CA--C 1.533 0.426 0 C-N-CA 122.723 2.282 . . . . 0.0 112.341 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.7 tpt -64.72 124.23 21.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.023 0.439 . . . . 0.0 111.789 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.65 5.23 84.6 Favored Glycine 0 CA--C 1.521 0.424 0 CA-C-N 115.87 -0.605 . . . . 0.0 113.195 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.409 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 44.8 mt-10 -133.29 176.78 8.21 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.959 0.409 . . . . 0.0 111.181 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.74 132.63 55.13 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.834 -179.747 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -118.98 125.43 49.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.982 178.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' VAL . . . . . 0.404 ' O ' HG12 ' A' ' 96' ' ' VAL . 1.8 p -101.68 136.31 34.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.672 0.749 . . . . 0.0 112.462 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 61.5 t -113.26 112.31 39.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.069 178.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -93.27 118.72 31.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.511 -179.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -135.23 156.98 39.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.215 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.36 97.4 48.97 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.573 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' PRO . . . . . 0.443 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 66.7 Cg_endo -72.19 100.06 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.794 2.329 . . . . 0.0 112.36 179.544 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -96.11 10.36 37.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.854 0.359 . . . . 0.0 111.9 -179.521 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.03 132.45 32.22 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.51 -0.314 . . . . 0.0 110.779 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.38 127.3 35.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.018 0.437 . . . . 0.0 111.314 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.78 -157.24 29.41 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.624 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -101.73 126.81 48.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.127 0.489 . . . . 0.0 111.668 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' PHE . . . . . 0.414 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 86.0 m-85 -119.64 173.76 6.82 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.67 -0.696 . . . . 0.0 109.815 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 41.9 p -154.7 160.86 41.64 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -178.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.8 p90 -152.79 133.99 14.23 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.89 178.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.39 0 CA-C-O 121.05 0.452 . . . . 0.0 111.879 179.758 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' LYS . . . . . 0.431 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.4 ttpt . . . . . 0 CA--C 1.531 0.233 0 CA-C-O 121.071 0.463 . . . . 0.0 111.568 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' MET . . . . . 0.414 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -134.22 141.01 46.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.043 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.7 mp -124.66 120.22 58.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.984 0.421 . . . . 0.0 110.706 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.0 t -103.25 124.34 57.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.238 -179.675 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 . . . . . 0 C--O 1.252 1.216 0 CA-C-O 118.106 -0.949 . . . . 0.0 111.46 -179.601 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.667 0 N-CA-C 112.452 -0.259 . . . . 0.0 112.452 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -82.38 75.08 9.31 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.109 0.48 . . . . 0.0 111.471 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -89.92 142.24 27.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.366 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -86.57 170.1 41.9 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.887 -0.673 . . . . 0.0 113.041 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -118.6 128.74 54.83 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.105 0.479 . . . . 0.0 111.325 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.34 129.36 35.89 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.525 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.46 153.58 40.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.187 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.566 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 4.5 pt20 -80.74 135.53 36.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.185 0.517 . . . . 0.0 111.279 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 19.7 mt-30 -94.05 112.39 24.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.601 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.42 -154.28 0.4 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.389 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -81.95 75.81 8.87 Favored 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.12 -5.36 63.23 Favored Glycine 0 CA--C 1.522 0.518 0 C-N-CA 120.772 -0.728 . . . . 0.0 114.121 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 26.9 p90 -144.35 163.76 32.79 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 117.063 0.431 . . . . 0.0 110.958 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.13 154.81 28.26 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.991 0.424 . . . . 0.0 111.452 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.566 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.6 tt0 -145.26 141.59 28.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.515 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.405 ' CG2' HD12 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -143.63 128.59 14.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.863 179.024 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.3 109.97 21.26 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.207 0.527 . . . . 0.0 111.117 179.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 44.9 t -98.22 103.37 14.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.488 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.408 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.8 OUTLIER -70.93 114.23 8.78 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.792 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 49.3 t -96.61 97.73 6.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.461 -178.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.455 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.2 ptm -144.25 86.98 1.86 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.52 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.47 -0.53 89.06 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.833 -0.698 . . . . 0.0 111.434 -178.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.424 ' N ' HD13 ' A' ' 75' ' ' LEU . . . 161.9 -170.33 37.55 Favored Glycine 0 N--CA 1.448 -0.522 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -93.07 124.24 36.9 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.793 0.297 . . . . 0.0 110.213 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.454 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 37.1 m -63.42 -63.65 3.8 Favored Pre-proline 0 CA--C 1.539 0.527 0 CA-C-O 119.642 -0.218 . . . . 0.0 111.431 -179.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.454 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 60.7 Cg_endo -74.99 96.58 1.02 Allowed 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 121.312 1.341 . . . . 0.0 111.055 177.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.65 -43.44 57.17 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.069 -179.351 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.466 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.39 118.68 19.68 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.654 179.443 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.3 pt -97.8 126.78 50.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.913 0.387 . . . . 0.0 110.929 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 95.9 t -100.09 127.24 53.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.953 0.406 . . . . 0.0 111.557 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 2.3 mt -136.87 166.92 22.48 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.279 -179.633 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -89.62 176.89 6.69 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 120.745 0.307 . . . . 0.0 110.897 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.9 ttpp -107.55 149.53 27.9 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 111.972 0.36 . . . . 0.0 111.972 -179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.7 t 65.55 19.51 11.51 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.725 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.436 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.5 p -123.82 136.26 27.19 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.11 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -64.26 122.61 10.62 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.247 1.965 . . . . 0.0 111.641 178.528 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.66 138.34 54.31 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.926 0.394 . . . . 0.0 111.723 -179.337 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.411 HH11 ' HD2' ' A' ' 63' ' ' ARG . 0.1 OUTLIER -120.49 127.42 52.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.643 0.735 . . . . 0.0 111.626 179.825 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.432 HD12 HG23 ' A' ' 64' ' ' ILE . 3.4 mm -100.2 114.23 38.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.623 179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 2.8 t -90.64 107.41 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.739 0.304 . . . . 0.0 111.492 -179.24 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -94.77 102.62 14.51 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.918 0.39 . . . . 0.0 111.279 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -91.17 106.94 18.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.435 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -77.46 105.28 8.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.287 0.565 . . . . 0.0 111.903 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.3 tptp -97.76 -34.28 10.96 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.256 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.455 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.7 t70 -110.27 134.38 20.8 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.848 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -81.42 40.1 0.94 Allowed 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.111 2.54 . . . . 0.0 112.995 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.61 135.37 90.47 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.387 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.27 -32.88 61.41 Favored 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 122.772 2.315 . . . . 0.0 112.802 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.1 p -77.09 -2.15 32.73 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.364 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.424 HD13 ' N ' ' A' ' 48' ' ' GLY . 33.4 mt -119.29 13.56 12.8 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.242 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.14 -36.38 72.06 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.078 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.84 152.67 48.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.896 0.379 . . . . 0.0 111.503 -179.447 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -132.79 128.48 57.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.103 0.478 . . . . 0.0 110.727 179.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.4 130.61 65.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 121.258 0.551 . . . . 0.0 111.346 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -93.17 102.12 6.72 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.715 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.55 -14.36 41.96 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.621 2.214 . . . . 0.0 113.593 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -100.65 -7.57 23.77 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 111.809 0.299 . . . . 0.0 111.809 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -122.63 -22.77 5.3 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 112.058 0.392 . . . . 0.0 112.058 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.25 25.75 50.44 Favored Glycine 0 C--N 1.331 0.302 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.025 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.7 t -106.5 117.79 52.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.887 0.375 . . . . 0.0 111.71 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -121.67 118.52 29.37 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.388 179.323 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.38 162.53 34.19 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.084 0.468 . . . . 0.0 112.257 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 14.2 p-10 -104.19 148.28 26.48 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.679 179.604 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 29.5 mt -107.18 130.8 22.33 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.938 0.399 . . . . 0.0 111.716 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -82.34 127.99 5.37 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.743 2.296 . . . . 0.0 112.434 179.176 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.5 tpt -66.62 125.4 25.65 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-O 121.025 0.441 . . . . 0.0 111.693 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.81 1.37 80.21 Favored Glycine 0 CA--C 1.52 0.344 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.842 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -134.24 177.17 7.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.895 0.379 . . . . 0.0 110.787 -179.484 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -118.14 133.33 56.0 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.197 0.522 . . . . 0.0 111.639 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.1 t80 -112.16 123.28 49.92 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.127 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.424 ' O ' HG11 ' A' ' 96' ' ' VAL . 1.5 p -97.78 135.24 33.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.609 0.719 . . . . 0.0 112.304 -179.207 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 62.6 t -112.49 109.69 29.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.027 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -92.08 117.17 29.58 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.228 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -131.58 165.8 30.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.237 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.3 m -128.1 96.22 32.04 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.426 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.4 Cg_endo -72.2 98.88 0.95 Allowed 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.803 2.336 . . . . 0.0 112.454 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -95.27 7.78 45.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.832 0.349 . . . . 0.0 111.838 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.39 130.97 31.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.753 0.311 . . . . 0.0 110.931 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -85.3 124.8 32.34 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.199 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 171.71 -166.53 39.51 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.863 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.76 114.89 27.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.036 0.446 . . . . 0.0 110.732 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -110.49 174.84 5.67 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.233 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 91.6 p -153.45 164.15 38.69 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.419 0.525 . . . . 0.0 112.419 -178.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 36.8 p90 -150.85 137.67 19.0 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.481 178.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.22 178.65 8.55 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.982 0.42 . . . . 0.0 111.708 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 41.6 t -115.55 127.84 55.55 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 179.309 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 87.71 -115.31 4.32 Favored Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.837 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 3.8 mtm -137.97 -90.85 0.22 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.868 0.366 . . . . 0.0 111.058 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -88.85 58.82 4.78 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.017 0.437 . . . . 0.0 111.342 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -149.38 165.52 31.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.109 -179.71 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 77.7 mmm 66.17 -177.51 0.19 Allowed 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.097 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -159.31 104.93 1.67 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.446 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -145.93 122.31 1.64 Allowed Glycine 0 CA--C 1.52 0.346 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.108 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.8 ttmm -121.36 150.82 40.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.235 0.54 . . . . 0.0 111.891 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 2.2 ttm -134.65 136.26 42.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.797 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -120.99 118.2 55.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.006 0.432 . . . . 0.0 110.804 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 71.9 t -102.82 121.33 53.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.177 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.254 1.306 0 CA-C-O 118.335 -0.84 . . . . 0.0 111.396 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.613 0 CA-C-O 121.112 0.285 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -83.19 71.0 10.2 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.183 0.516 . . . . 0.0 111.562 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 1.9 mtm -82.15 64.29 6.76 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.359 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.38 -168.83 28.5 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.797 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.27 127.93 20.25 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.018 0.437 . . . . 0.0 111.289 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -90.49 126.67 35.99 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.787 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.26 151.88 43.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.15 179.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.574 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 7.7 pt20 -82.24 140.18 33.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.178 0.513 . . . . 0.0 111.545 -179.183 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 6.8 mp0 -95.46 113.25 24.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.488 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 6.1 mmtt -93.2 -148.68 0.25 Allowed 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.474 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -81.64 72.81 8.69 Favored 'General case' 0 CA--C 1.535 0.373 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.19 -5.71 68.37 Favored Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.845 178.978 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -141.27 160.46 40.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.864 0.332 . . . . 0.0 110.751 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.98 156.23 19.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.197 0.522 . . . . 0.0 111.351 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.574 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 4.2 tt0 -145.9 142.44 28.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.445 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.5 129.61 16.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.194 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -90.23 106.56 18.57 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.012 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 46.1 t -97.81 103.01 14.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.604 -179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.47 117.48 14.18 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.974 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 42.3 t -100.4 99.04 7.69 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 CA-C-O 121.535 0.683 . . . . 0.0 111.484 -178.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.406 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.5 ptp -141.27 85.63 1.98 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.222 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 87.56 -14.65 57.6 Favored Glycine 0 CA--C 1.519 0.313 0 N-CA-C 111.104 -0.798 . . . . 0.0 111.104 -177.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 176.89 -152.5 12.37 Favored Glycine 0 N--CA 1.449 -0.452 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -104.91 127.98 52.96 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.82 0.31 . . . . 0.0 110.56 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.451 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 43.0 m -69.15 -63.72 1.97 Allowed Pre-proline 0 CA--C 1.539 0.535 0 CA-C-O 119.571 -0.252 . . . . 0.0 111.368 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.451 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 61.9 Cg_endo -74.39 98.09 1.08 Allowed 'Trans proline' 0 C--N 1.357 1.012 0 C-N-CA 121.295 1.33 . . . . 0.0 111.121 177.817 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.25 -43.86 61.62 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.991 -0.549 . . . . 0.0 112.326 -179.181 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -133.89 118.53 18.05 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.559 0.218 . . . . 0.0 110.776 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.694 HD12 ' SD ' ' A' ' 120' ' ' MET . 8.6 pt -97.33 127.55 49.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.1 0.476 . . . . 0.0 111.004 179.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.5 t -96.04 126.43 48.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.472 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 24.3 mt -133.44 166.4 22.62 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.425 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 18.6 mttt -96.74 166.75 11.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.563 179.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.3 ttpp -97.52 147.74 23.95 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.9 t 66.73 18.8 10.74 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.861 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.441 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 6.0 p -123.56 135.16 25.82 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.914 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -64.58 122.73 10.71 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.051 1.834 . . . . 0.0 111.611 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.24 138.94 54.34 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.834 0.35 . . . . 0.0 111.561 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.48 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.5 ptt180 -121.15 126.76 50.54 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.638 0.732 . . . . 0.0 111.394 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.425 HD13 HG23 ' A' ' 64' ' ' ILE . 4.8 mm -98.64 114.36 36.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.822 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.2 t -91.47 109.84 21.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.375 -179.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -96.15 117.37 30.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.132 0.491 . . . . 0.0 111.332 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.6 t0 -99.94 100.31 11.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.412 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.37 93.0 3.41 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 121.225 0.536 . . . . 0.0 111.455 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -88.74 -37.43 15.49 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.752 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.406 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.2 t70 -101.75 129.44 26.61 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.763 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -79.23 38.63 0.74 Allowed 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 123.088 2.525 . . . . 0.0 113.014 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -70.52 135.35 86.27 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.015 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -63.47 -31.57 71.68 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.789 2.326 . . . . 0.0 112.888 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -75.85 -9.45 58.61 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.46 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 36.7 mt -113.22 13.99 19.3 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.466 -179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -70.13 -38.44 75.55 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.782 0.325 . . . . 0.0 111.709 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -122.64 158.82 29.17 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.113 0.482 . . . . 0.0 111.435 -179.586 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.86 130.12 35.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.444 178.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.433 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 2.0 p -133.27 132.3 58.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.314 0.578 . . . . 0.0 111.43 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -94.08 101.89 7.21 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.516 178.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -67.32 -14.03 41.44 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.589 2.193 . . . . 0.0 113.566 -178.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 33.1 m-20 -100.23 -9.14 22.75 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -122.87 -20.07 5.96 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.76 30.65 42.91 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.353 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 49.8 t -110.8 116.44 52.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.828 0.347 . . . . 0.0 111.733 -179.018 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -119.86 121.12 38.37 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.47 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.92 172.19 13.38 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 -112.66 142.36 45.36 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.461 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 41.0 mt -105.73 122.79 41.39 Favored Pre-proline 0 CA--C 1.531 0.246 0 CA-C-O 121.094 0.473 . . . . 0.0 111.544 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 67.2 Cg_endo -78.13 132.72 11.72 Favored 'Trans proline' 0 CA--C 1.531 0.326 0 C-N-CA 122.921 2.414 . . . . 0.0 112.713 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.8 tpt -68.55 124.89 24.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.082 0.467 . . . . 0.0 111.733 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.06 9.23 85.52 Favored Glycine 0 C--N 1.333 0.395 0 CA-C-N 115.863 -0.608 . . . . 0.0 113.101 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 45.4 mt-10 -134.28 176.82 8.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.979 0.419 . . . . 0.0 111.13 -179.527 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -115.2 133.31 56.15 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.137 0.494 . . . . 0.0 111.647 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 14.1 t80 -119.89 123.64 44.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.977 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.2 p -102.99 137.21 32.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.65 0.738 . . . . 0.0 112.643 -178.759 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 54.9 t -112.86 112.03 38.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.18 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -93.16 119.52 32.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.507 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -136.49 155.6 34.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.227 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 2.9 m -119.37 97.81 50.3 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.514 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.441 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 73.2 Cg_endo -74.24 100.82 1.34 Allowed 'Trans proline' 0 CA--C 1.531 0.344 0 C-N-CA 122.86 2.373 . . . . 0.0 112.503 179.719 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -95.63 3.76 53.7 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.919 0.39 . . . . 0.0 111.657 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -130.4 133.63 46.52 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.867 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -90.07 128.8 36.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.908 0.385 . . . . 0.0 111.255 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 168.05 -166.75 39.67 Favored Glycine 0 CA--C 1.517 0.185 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.813 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -99.89 112.83 25.08 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.168 0.509 . . . . 0.0 110.746 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 22.6 m-85 -110.67 168.61 9.34 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.009 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 63.5 p -150.64 160.89 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.138 0.494 . . . . 0.0 112.047 -179.379 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 36.3 p90 -146.21 136.08 23.41 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.913 179.083 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.15 156.2 21.56 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.231 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 4.8 t -160.97 165.89 29.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.004 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 83.55 -77.65 2.1 Favored Glycine 0 CA--C 1.52 0.398 0 C-N-CA 120.934 -0.65 . . . . 0.0 113.308 179.494 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -127.83 153.72 46.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.929 0.395 . . . . 0.0 111.4 -179.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -83.51 54.53 2.87 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.474 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -126.94 -92.6 0.49 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.62 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -68.37 141.93 55.6 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-O 120.971 0.415 . . . . 0.0 110.279 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 34.2 p-80 -155.08 158.05 38.47 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.495 -0.32 . . . . 0.0 111.488 -179.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -110.73 145.99 17.46 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.497 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.85 149.69 31.44 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.966 0.412 . . . . 0.0 111.083 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.694 ' SD ' HD12 ' A' ' 54' ' ' ILE . 8.9 ttp -131.71 119.52 21.46 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.012 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.7 mp -107.16 116.24 50.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.031 0.443 . . . . 0.0 110.793 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.2 t -101.23 120.43 50.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.168 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 . . . . . 0 C--O 1.252 1.224 0 CA-C-O 118.146 -0.93 . . . . 0.0 111.458 -179.646 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.631 0 N-CA-C 112.168 -0.373 . . . . 0.0 112.168 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -70.95 -18.54 62.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.795 0.331 . . . . 0.0 111.655 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 50.7 mmm -86.77 -10.03 54.52 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.303 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.05 164.56 20.42 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.868 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -112.4 123.23 49.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.161 0.505 . . . . 0.0 111.066 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.82 129.23 35.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.606 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.71 156.1 39.3 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.403 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.55 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 5.9 pt20 -82.0 142.81 32.05 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.125 0.488 . . . . 0.0 111.259 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -98.47 112.99 24.84 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.657 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 5.6 mmtt -95.34 -150.28 0.31 Allowed 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.557 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -80.71 74.99 7.63 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.98 -5.82 76.11 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.867 -0.682 . . . . 0.0 113.974 178.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.4 p90 -140.59 163.96 31.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.923 0.361 . . . . 0.0 110.85 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.65 154.57 27.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.975 0.417 . . . . 0.0 111.457 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.55 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 4.0 tt0 -143.82 141.3 30.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.572 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.403 ' CG2' HD13 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -142.71 128.97 17.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.915 179.109 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 ttt180 -90.73 110.9 22.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.253 0.549 . . . . 0.0 111.123 179.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 45.2 t -101.04 103.87 15.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.517 -179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -71.49 117.01 12.5 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.029 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.2 t -98.76 99.93 9.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.451 -178.76 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.515 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.3 ptm -147.09 90.77 1.92 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.568 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 79.28 1.04 85.25 Favored Glycine 0 CA--C 1.52 0.396 0 C-N-CA 120.774 -0.727 . . . . 0.0 111.733 -178.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.411 ' N ' HD12 ' A' ' 75' ' ' LEU . . . 163.54 -148.61 15.19 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 111.314 -0.715 . . . . 0.0 111.314 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -115.64 129.65 56.57 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.718 0.259 . . . . 0.0 110.309 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.452 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 41.0 m -68.76 -64.6 1.65 Allowed Pre-proline 0 CA--C 1.538 0.515 0 CA-C-O 119.468 -0.301 . . . . 0.0 111.497 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.452 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 62.4 Cg_endo -74.9 98.88 1.19 Allowed 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.271 1.314 . . . . 0.0 111.119 177.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -51.84 -44.55 63.64 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.917 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.459 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.85 119.09 20.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.864 179.78 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.2 pt -97.1 126.98 49.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 121.08 0.467 . . . . 0.0 110.943 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 60.1 t -98.58 126.67 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.642 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.3 mt -136.22 165.37 25.91 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.363 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -88.85 176.01 7.22 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.82 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.6 ttpt -106.7 147.95 28.98 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 111.872 -179.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.0 t 65.13 20.2 11.95 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.737 179.596 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.437 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.3 p -123.61 136.4 27.22 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.989 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -64.47 123.43 11.76 Favored 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.099 1.866 . . . . 0.0 111.736 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.05 139.37 53.86 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.954 0.407 . . . . 0.0 111.682 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.502 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.6 ptt180 -121.78 127.06 50.21 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.744 0.783 . . . . 0.0 111.335 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.453 HD13 HG21 ' A' ' 64' ' ' ILE . 3.5 mm -99.87 115.78 41.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.838 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.2 t -91.24 107.59 18.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.853 0.359 . . . . 0.0 111.463 -179.229 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -95.09 103.57 15.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.909 0.385 . . . . 0.0 111.466 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -90.59 105.9 18.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.377 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.55 100.1 7.6 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.157 0.503 . . . . 0.0 111.882 -179.197 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.0 tmtt? -91.42 -39.19 12.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.852 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.515 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 0.1 OUTLIER -107.1 137.8 19.66 Favored Pre-proline 0 CA--C 1.534 0.354 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.149 -179.913 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -81.87 39.66 0.88 Allowed 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 123.229 2.619 . . . . 0.0 113.405 -179.279 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -67.73 135.66 92.48 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.991 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -62.42 -34.3 76.93 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.872 2.382 . . . . 0.0 113.106 -179.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.02 -3.29 38.33 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.518 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.411 HD12 ' N ' ' A' ' 48' ' ' GLY . 56.3 mt -120.01 12.88 12.07 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.446 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -68.78 -39.27 80.25 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 120.915 0.388 . . . . 0.0 111.379 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 31.0 mt-30 -123.66 166.15 16.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.034 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -140.93 130.45 25.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.296 0.57 . . . . 0.0 110.836 178.764 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.577 ' O ' ' HD3' ' A' ' 81' ' ' PRO . 0.2 OUTLIER -133.9 132.33 56.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.216 0.532 . . . . 0.0 110.981 179.68 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 -96.01 101.72 9.01 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.721 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.577 ' HD3' ' O ' ' A' ' 79' ' ' VAL . 23.2 Cg_exo -63.46 -19.02 67.1 Favored 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.072 2.515 . . . . 0.0 113.791 -178.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -100.66 -5.94 25.88 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -121.44 -23.03 5.76 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.11 22.8 56.69 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.151 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.1 t -102.53 120.34 52.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.674 0.274 . . . . 0.0 111.552 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -125.74 119.69 28.62 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.633 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.78 169.35 17.94 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.112 0.482 . . . . 0.0 112.249 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -109.05 140.67 42.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.548 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 38.6 mt -100.69 129.44 27.6 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.851 0.358 . . . . 0.0 111.356 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -80.64 128.25 6.76 Favored 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.813 2.342 . . . . 0.0 112.452 179.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -66.16 124.85 23.74 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.087 0.47 . . . . 0.0 111.681 -179.541 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 87.11 3.46 82.56 Favored Glycine 0 CA--C 1.521 0.446 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.951 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -134.65 177.05 8.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.009 0.433 . . . . 0.0 110.913 -179.593 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -117.27 133.35 56.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.211 0.529 . . . . 0.0 111.564 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -113.21 125.49 54.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.222 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 96' ' ' VAL . 1.7 p -98.09 135.19 33.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.715 0.769 . . . . 0.0 112.334 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.0 t -112.82 112.92 42.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.199 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -93.73 119.76 33.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.035 0.445 . . . . 0.0 111.518 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -136.4 156.44 36.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.125 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.26 97.74 48.99 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.452 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.437 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 58.6 Cg_endo -71.14 98.42 0.82 Allowed 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.734 2.289 . . . . 0.0 112.618 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -97.6 22.72 8.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.004 0.43 . . . . 0.0 111.482 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.35 131.23 14.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.539 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.11 127.1 35.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.071 0.462 . . . . 0.0 111.41 -179.859 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 164.99 -157.6 30.13 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.714 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -101.55 126.01 48.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.172 0.51 . . . . 0.0 111.535 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.413 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 87.9 m-85 -119.58 171.93 8.02 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.783 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 84.8 p -157.81 160.54 37.88 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.211 0.529 . . . . 0.0 112.418 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -143.77 140.46 29.94 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.496 178.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -157.43 177.84 10.98 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.662 -179.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 7.3 t -163.41 138.87 6.55 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.301 179.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 84.84 -78.8 1.97 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.833 -0.698 . . . . 0.0 113.413 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -116.54 -178.74 3.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.066 0.46 . . . . 0.0 111.455 -179.409 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -85.89 -22.45 27.5 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.189 179.649 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.3 157.56 19.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.541 179.527 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' MET . . . . . 0.428 ' O ' ' HE2' ' A' ' 116' ' ' MET . 11.0 ttp 61.75 73.22 0.48 Allowed 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 121.295 0.569 . . . . 0.0 110.922 -179.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 18.8 p80 -133.67 169.86 16.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.685 -179.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -106.5 160.92 14.26 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.178 179.499 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.459 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 0.2 OUTLIER -128.51 149.85 50.42 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.884 0.373 . . . . 0.0 111.112 179.68 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.413 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -132.56 140.12 48.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.059 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.5 118.74 54.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 121.048 0.451 . . . . 0.0 110.823 179.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.3 t -100.21 123.86 53.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.062 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.251 1.168 0 CA-C-O 118.155 -0.926 . . . . 0.0 111.973 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.988 ' N ' ' HZ3' ' A' ' 31' ' ' LYS . . . . . . . . 0 N--CA 1.498 2.784 0 CA-C-O 121.159 0.311 . . . . 0.0 112.457 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -93.8 -27.14 16.63 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.93 0.395 . . . . 0.0 111.441 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 4.9 tpt -133.51 93.35 3.13 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.039 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.28 -162.84 12.48 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.615 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.29 125.12 19.65 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.155 0.502 . . . . 0.0 111.375 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.988 ' HZ3' ' N ' ' A' ' 26' ' ' GLY . 0.5 OUTLIER -88.57 126.59 35.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.626 179.784 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.27 153.84 41.32 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.297 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.72 140.67 34.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.243 0.544 . . . . 0.0 111.187 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 22.0 mt-30 -96.38 116.83 29.69 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.595 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.1 -153.07 0.41 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.119 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -83.73 76.82 9.96 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -179.271 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.6 -8.84 64.2 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.767 -0.73 . . . . 0.0 114.007 178.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -141.21 164.99 28.77 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 117.093 0.446 . . . . 0.0 111.091 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.44 154.28 27.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.924 0.392 . . . . 0.0 111.177 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -143.28 142.07 31.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.891 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.406 ' CG2' HD13 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -143.54 128.69 15.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.972 179.027 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -90.18 110.18 21.22 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.208 0.528 . . . . 0.0 110.93 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.9 t -102.37 107.2 21.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.663 -0.698 . . . . 0.0 110.74 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.403 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.7 OUTLIER -75.93 117.76 17.99 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.002 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 50.6 t -96.62 99.03 8.31 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.416 -178.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.45 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.4 ptm -144.72 90.3 2.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.487 179.023 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 81.85 2.05 90.43 Favored Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.72 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 159.61 -131.28 2.67 Favored Glycine 0 N--CA 1.449 -0.471 0 N-CA-C 111.601 -0.6 . . . . 0.0 111.601 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.422 ' HH ' ' HG ' ' A' ' 111' ' ' CYS . 76.9 m-85 -126.09 134.57 51.33 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.729 -0.277 . . . . 0.0 110.754 179.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.465 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 32.4 m -73.57 -63.98 0.87 Allowed Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 121.066 -0.253 . . . . 0.0 110.93 179.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.465 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 61.2 Cg_endo -74.53 100.51 1.33 Allowed 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 121.409 1.406 . . . . 0.0 111.226 177.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.63 -45.42 63.27 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.28 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.503 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.76 119.06 19.82 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.561 0.22 . . . . 0.0 110.999 179.783 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.1 pt -96.58 126.04 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.128 0.489 . . . . 0.0 110.896 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 84.0 t -97.8 126.43 50.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.567 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.5 mt -136.15 164.37 28.21 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.248 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.74 170.9 10.04 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 120.757 0.313 . . . . 0.0 110.935 179.24 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 12.7 ttpt -100.65 147.81 25.57 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.7 t 65.72 19.63 11.42 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.936 179.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.441 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.5 p -123.63 135.74 26.49 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.964 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_endo -64.11 123.28 11.64 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.133 1.889 . . . . 0.0 111.722 178.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.23 136.56 54.24 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.938 0.399 . . . . 0.0 111.542 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.53 125.51 50.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.855 0.836 . . . . 0.0 111.545 179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.438 HD13 HG22 ' A' ' 64' ' ' ILE . 3.1 mm -98.38 114.93 37.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.626 179.779 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.5 t -91.34 107.83 19.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.768 0.318 . . . . 0.0 111.357 -179.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -94.16 118.53 31.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.081 0.467 . . . . 0.0 111.381 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -102.18 106.97 17.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.469 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.7 tpt180 -76.35 96.69 4.05 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 121.13 0.491 . . . . 0.0 111.42 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 23.4 tptt -91.89 -35.91 13.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.451 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.45 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.7 t70 -107.08 131.15 21.92 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.731 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -80.18 38.48 0.75 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.001 2.467 . . . . 0.0 113.027 -179.631 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -68.91 132.74 90.37 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.945 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -64.32 -30.92 63.5 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.668 2.245 . . . . 0.0 112.894 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.75 -3.13 42.78 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.544 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 16.6 mt -117.67 10.15 13.29 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 120.751 0.31 . . . . 0.0 111.19 -179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.18 -42.61 79.71 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -179.412 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . 0.429 ' O ' ' HB3' ' A' ' 111' ' ' CYS . 16.8 mt-30 -116.83 138.01 51.81 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.829 0.347 . . . . 0.0 111.584 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -118.21 131.7 70.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.654 179.432 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -137.42 129.44 41.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.397 0.618 . . . . 0.0 111.579 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -89.95 102.18 4.39 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.252 178.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_endo -64.99 -14.16 43.72 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.606 2.204 . . . . 0.0 113.637 -178.396 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -101.02 -11.25 19.82 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -119.15 -24.29 6.52 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 111.945 0.35 . . . . 0.0 111.945 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 88.84 1.17 80.46 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.143 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.8 t -80.36 117.02 25.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.886 0.374 . . . . 0.0 111.396 -178.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 19.2 p-80 -132.05 122.59 25.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.835 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.48 174.23 10.94 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 121.112 0.482 . . . . 0.0 111.91 -178.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -108.23 141.89 39.31 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.656 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 33.9 mt -100.71 124.49 42.06 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 120.906 0.384 . . . . 0.0 111.467 -179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.403 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 63.6 Cg_endo -78.57 128.63 8.82 Favored 'Trans proline' 0 CA--C 1.53 0.313 0 C-N-CA 122.786 2.324 . . . . 0.0 112.684 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 12.3 tpt -66.19 124.94 23.99 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.151 0.501 . . . . 0.0 111.677 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.38 6.76 85.69 Favored Glycine 0 CA--C 1.52 0.398 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.923 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.403 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 48.3 mm-40 -134.13 176.78 8.28 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-O 120.943 0.401 . . . . 0.0 111.292 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -114.58 132.32 56.38 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.983 0.42 . . . . 0.0 111.834 -179.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.6 t80 -118.06 121.63 41.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.778 178.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 1.4 p -98.52 138.46 23.04 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 CA-C-O 121.629 0.728 . . . . 0.0 112.577 -178.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 43.8 t -115.6 110.34 31.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.053 178.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -93.98 117.39 30.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.034 0.445 . . . . 0.0 111.551 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -132.73 156.52 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.18 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.3 m -119.9 96.74 49.55 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.437 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.441 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.1 Cg_endo -72.07 99.49 1.0 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.706 2.271 . . . . 0.0 112.494 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -97.3 22.92 8.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.023 0.439 . . . . 0.0 111.553 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.17 127.76 11.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.749 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -83.84 122.96 29.4 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.975 0.417 . . . . 0.0 111.326 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 169.2 -158.76 31.44 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.729 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -101.99 126.7 48.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.182 0.515 . . . . 0.0 111.576 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.419 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 85.7 m-85 -119.69 169.7 9.86 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.918 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 99.1 p -149.81 157.38 43.15 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.928 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -148.29 138.48 22.6 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.995 178.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.42 178.27 8.79 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.05 0.452 . . . . 0.0 111.655 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.429 ' HB3' ' O ' ' A' ' 77' ' ' GLN . 0.0 OUTLIER -123.9 126.74 46.91 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.882 179.407 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 62.22 -103.75 0.65 Allowed Glycine 0 CA--C 1.522 0.484 0 C-N-CA 121.179 -0.534 . . . . 0.0 113.066 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -139.3 -107.06 0.17 Allowed 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 110.504 -0.184 . . . . 0.0 110.504 179.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 59.05 -160.13 0.28 Allowed 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 121.099 0.476 . . . . 0.0 111.923 179.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -113.9 -27.87 7.59 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.19 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 1.2 ptm -68.39 117.77 10.6 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.032 0.444 . . . . 0.0 111.219 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 53.1 p-80 -150.18 152.91 35.4 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.164 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -105.64 148.3 16.46 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.251 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.503 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 14.6 ttpt -117.62 146.14 43.86 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.03 0.443 . . . . 0.0 111.098 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.419 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.7 ttm -128.39 136.22 50.61 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.908 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -120.02 118.42 56.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.981 0.42 . . . . 0.0 110.846 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 76.0 t -99.78 121.78 50.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.146 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.103 -0.951 . . . . 0.0 111.531 -179.702 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.646 0 CA-C-O 121.259 0.366 . . . . 0.0 112.241 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.18 0.21 11.17 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.511 -0.344 . . . . 0.0 111.415 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.95 -74.36 0.61 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.441 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.4 171.09 39.49 Favored Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.801 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -133.1 128.17 35.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.207 0.527 . . . . 0.0 111.477 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 3.1 ttpt -90.17 129.5 36.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.747 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.22 153.51 40.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.422 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 3.7 pt20 -84.48 139.33 32.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.132 0.491 . . . . 0.0 111.393 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -94.82 115.29 27.31 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.769 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.89 -151.14 0.32 Allowed 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.248 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.6 m120 -82.94 73.29 9.98 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.68 -4.76 61.75 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 120.817 -0.706 . . . . 0.0 114.061 178.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 30.2 p90 -143.62 162.57 35.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.909 0.355 . . . . 0.0 110.915 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.42 153.33 27.51 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.006 0.432 . . . . 0.0 111.475 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.422 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.6 tt0 -142.14 142.81 32.78 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.567 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.56 129.07 13.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -90.74 110.12 21.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.239 0.542 . . . . 0.0 110.939 179.639 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 43.5 t -102.16 103.91 15.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.774 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.452 ' HG2' ' SD ' ' A' ' 46' ' ' MET . 0.8 OUTLIER -75.25 118.13 17.82 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.614 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.5 t -96.9 98.41 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.649 -178.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.452 ' SD ' ' HG2' ' A' ' 44' ' ' GLU . 6.4 ptm -142.55 90.81 2.26 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.642 179.124 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 81.7 0.72 89.68 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.901 -0.666 . . . . 0.0 111.684 -178.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 162.79 -133.66 3.16 Favored Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 179.911 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -124.8 130.77 53.04 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.743 0.272 . . . . 0.0 110.599 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.48 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 49.7 m -70.15 -64.99 1.2 Allowed Pre-proline 0 CA--C 1.538 0.51 0 CA-C-O 119.508 -0.282 . . . . 0.0 111.391 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.48 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 58.7 Cg_endo -73.95 100.32 1.27 Allowed 'Trans proline' 0 C--N 1.358 1.058 0 C-N-CA 121.278 1.319 . . . . 0.0 111.249 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.84 -47.16 60.25 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.951 -0.568 . . . . 0.0 112.285 -179.365 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.468 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.56 119.06 20.01 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.638 0.256 . . . . 0.0 110.752 179.897 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.4 pt -97.04 129.37 47.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.093 0.473 . . . . 0.0 111.062 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 96.3 t -96.18 124.95 49.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.509 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.0 157.24 42.87 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.087 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -89.85 168.99 11.63 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 110.163 -0.31 . . . . 0.0 110.163 178.31 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.9 ttpp -98.77 146.95 25.39 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 112.305 0.484 . . . . 0.0 112.305 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.6 t 65.66 19.78 11.48 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.86 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.445 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.95 135.9 26.84 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.976 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -64.29 122.74 10.8 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.128 1.885 . . . . 0.0 111.812 178.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.7 134.68 53.67 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.856 0.36 . . . . 0.0 111.47 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -116.59 126.32 53.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.776 0.798 . . . . 0.0 111.585 -179.918 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.451 HD12 HG21 ' A' ' 64' ' ' ILE . 3.5 mm -99.5 114.88 38.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.67 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.1 t -90.45 108.2 19.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.714 0.292 . . . . 0.0 111.383 -179.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -95.08 113.67 25.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.147 0.499 . . . . 0.0 111.326 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 21.8 t0 -99.32 103.72 15.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.5 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.25 97.66 4.24 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.176 0.512 . . . . 0.0 111.723 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.66 -42.1 10.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.482 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.411 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.2 t70 -99.47 131.75 24.39 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.837 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -80.73 39.63 0.88 Allowed 'Trans proline' 0 C--N 1.348 0.526 0 C-N-CA 123.16 2.573 . . . . 0.0 113.162 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 30.7 t -69.77 136.18 87.84 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.326 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -63.95 -27.95 66.63 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.576 2.184 . . . . 0.0 112.443 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 80.6 m -81.05 -6.89 59.33 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.059 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 50.9 mt -118.31 14.92 13.92 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.208 179.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -68.37 -35.89 78.39 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 120.95 0.405 . . . . 0.0 111.557 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -129.34 165.68 21.0 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.047 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.08 131.82 42.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.245 0.545 . . . . 0.0 110.98 179.156 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.9 128.63 43.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.455 0.645 . . . . 0.0 111.179 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -90.81 102.21 4.95 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.422 178.848 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -65.24 -14.2 43.83 Favored 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.583 2.188 . . . . 0.0 113.583 -178.547 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -101.05 -10.24 20.68 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 111.906 0.335 . . . . 0.0 111.906 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 59.0 m-85 -119.84 -23.69 6.37 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -179.644 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 87.92 1.28 82.57 Favored Glycine 0 CA--C 1.521 0.458 0 C-N-CA 121.291 -0.48 . . . . 0.0 112.175 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.6 t -81.48 116.27 25.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.892 0.377 . . . . 0.0 111.348 -178.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 20.3 p-80 -131.51 120.86 23.53 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.959 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -140.18 173.79 11.16 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.759 -179.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 8.1 p-10 -106.54 145.54 31.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.738 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 36.2 mt -103.97 130.17 23.89 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 120.924 0.393 . . . . 0.0 111.203 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.7 Cg_endo -80.86 126.11 5.69 Favored 'Trans proline' 0 CA--C 1.532 0.382 0 C-N-CA 122.706 2.271 . . . . 0.0 112.325 179.26 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.0 tpt -64.01 123.95 20.34 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.092 0.473 . . . . 0.0 111.764 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.02 3.59 87.62 Favored Glycine 0 CA--C 1.522 0.508 0 CA-C-N 115.866 -0.606 . . . . 0.0 113.283 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 47.8 mt-10 -131.86 176.86 7.99 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 120.886 0.374 . . . . 0.0 111.196 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -113.38 135.55 53.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.083 0.468 . . . . 0.0 111.985 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -120.07 124.26 45.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.807 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 1.4 p -98.7 137.94 24.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.63 0.728 . . . . 0.0 112.666 -178.879 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 46.1 t -114.99 110.46 32.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.055 178.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -93.56 117.09 29.64 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.854 0.359 . . . . 0.0 111.481 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 pt -132.05 158.05 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.213 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -121.38 96.24 47.97 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.501 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.445 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.7 Cg_endo -71.19 99.59 0.91 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.724 2.283 . . . . 0.0 112.276 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -94.22 3.65 54.96 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -132.01 135.95 46.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.79 0.329 . . . . 0.0 110.754 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.46 124.11 34.19 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.962 179.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 168.76 -159.44 32.56 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.839 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -100.61 125.93 47.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.155 0.503 . . . . 0.0 111.556 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.437 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 95.5 m-85 -121.42 164.86 16.44 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.831 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -151.21 157.43 42.63 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.251 0.548 . . . . 0.0 112.244 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -142.92 140.42 31.14 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.913 179.099 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.21 177.69 9.42 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.356 -179.757 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 39.1 t -143.68 128.18 17.99 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 120.849 0.356 . . . . 0.0 111.262 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 72.85 -142.55 32.19 Favored Glycine 0 CA--C 1.521 0.415 0 C-N-CA 121.08 -0.581 . . . . 0.0 113.196 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -131.01 104.23 6.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.846 0.355 . . . . 0.0 110.923 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.25 -179.91 6.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.984 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.66 -28.82 30.41 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.441 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 1.6 ptm -67.85 116.87 9.01 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.156 0.503 . . . . 0.0 111.221 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 49.6 p-80 -151.82 157.73 42.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.771 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -114.23 148.84 18.79 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.468 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.468 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 4.1 ttmm -120.85 147.3 45.57 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.947 0.403 . . . . 0.0 111.209 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.437 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 3.4 ttm -131.1 135.13 47.24 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.926 179.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.16 117.87 55.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.045 0.45 . . . . 0.0 110.527 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.1 t -99.95 123.58 52.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.349 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 118.186 -0.912 . . . . 0.0 111.46 -179.844 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.647 0 CA-C-O 121.282 0.379 . . . . 0.0 112.28 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.87 2.79 17.2 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.439 -0.381 . . . . 0.0 111.383 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 19.6 mtm -82.9 52.05 2.06 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-O 121.007 0.432 . . . . 0.0 111.623 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.65 160.39 35.74 Favored Glycine 0 CA--C 1.518 0.278 0 C-N-CA 121.051 -0.595 . . . . 0.0 113.007 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -124.04 129.31 50.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.069 0.461 . . . . 0.0 111.268 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 5.3 mtpt -90.12 129.25 36.43 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.733 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.99 149.21 43.49 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.636 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.6 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.8 pt20 -74.81 138.02 42.3 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.907 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -97.55 113.36 25.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.871 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -95.41 -156.17 0.5 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.368 -179.682 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -81.89 79.26 8.47 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 112.29 0.478 . . . . 0.0 112.29 -179.182 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.74 -9.98 66.36 Favored Glycine 0 CA--C 1.522 0.508 0 C-N-CA 120.799 -0.715 . . . . 0.0 114.298 178.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 28.9 p90 -142.01 164.07 31.17 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 117.098 0.449 . . . . 0.0 111.193 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.13 155.41 26.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.012 0.434 . . . . 0.0 111.182 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.6 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.9 tt0 -144.49 143.19 30.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.33 -179.28 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.11 129.44 17.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.082 0.468 . . . . 0.0 111.327 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 ttm180 -88.7 106.97 18.69 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.221 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 45.6 t -100.39 102.31 13.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.496 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -73.6 119.38 17.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.711 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.2 t -98.86 99.44 8.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.517 -178.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.451 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.2 ptm -143.8 88.24 1.97 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.537 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.31 -0.36 84.61 Favored Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.575 -178.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.409 ' N ' HD13 ' A' ' 75' ' ' LEU . . . 163.41 -163.45 35.6 Favored Glycine 0 N--CA 1.447 -0.586 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -98.58 126.36 44.13 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.768 0.284 . . . . 0.0 110.321 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.484 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 47.8 m -65.24 -64.3 2.73 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 121.196 -0.202 . . . . 0.0 111.267 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.484 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 60.8 Cg_endo -74.62 96.58 1.0 Allowed 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 121.358 1.372 . . . . 0.0 111.198 177.693 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.36 -42.86 61.61 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.096 -0.502 . . . . 0.0 112.195 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.48 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.88 118.68 20.16 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.696 0.284 . . . . 0.0 110.606 179.513 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.9 pt -98.0 127.48 50.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-O 121.03 0.443 . . . . 0.0 111.092 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.1 t -98.68 126.72 51.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.597 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.0 mt -136.41 165.32 26.08 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.264 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -90.97 171.42 9.29 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.797 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.5 ttpp -101.74 148.47 25.24 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.999 0.428 . . . . 0.0 112.066 -179.325 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.0 t 65.42 20.14 11.71 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.931 179.567 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.426 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.8 p -123.78 135.91 26.77 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.866 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -64.36 122.2 10.06 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.202 1.935 . . . . 0.0 111.68 178.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.46 138.65 54.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.995 0.426 . . . . 0.0 111.546 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.471 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.2 ptt180 -120.72 126.85 51.21 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-O 121.776 0.798 . . . . 0.0 111.343 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.8 mm -97.73 115.01 36.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.81 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.6 t -91.99 110.52 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.376 -179.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -96.2 114.69 26.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.041 0.448 . . . . 0.0 111.289 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -100.38 104.5 15.93 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.181 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -76.64 104.66 7.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.289 0.566 . . . . 0.0 111.958 -179.093 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.73 -39.84 9.26 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.093 179.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.451 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.1 t70 -105.71 133.86 19.99 Favored Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.929 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -80.97 39.53 0.87 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.994 2.463 . . . . 0.0 112.861 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.07 133.87 91.74 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.451 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.67 -32.37 57.67 Favored 'Trans proline' 0 C--N 1.348 0.527 0 C-N-CA 122.771 2.314 . . . . 0.0 112.63 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.15 -2.69 32.3 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.56 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.409 HD13 ' N ' ' A' ' 48' ' ' GLY . 34.9 mt -118.74 12.99 13.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.275 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -70.55 -43.46 69.46 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.931 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.55 140.14 51.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.026 0.441 . . . . 0.0 111.54 -179.476 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -120.64 127.64 75.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.525 178.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -130.11 130.58 65.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.349 0.595 . . . . 0.0 111.475 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -92.65 102.12 6.26 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.374 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -66.67 -16.66 51.18 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.667 2.245 . . . . 0.0 113.7 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -100.57 -7.44 24.06 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -120.58 -21.82 6.61 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.9 29.82 45.53 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.077 -179.369 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.1 t -110.85 117.98 56.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.81 0.338 . . . . 0.0 111.753 -178.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -119.93 121.0 38.03 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.226 179.117 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.48 158.92 43.37 Favored 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 112.521 0.564 . . . . 0.0 112.521 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -104.01 137.0 42.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.477 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 45.0 mt -99.76 127.84 32.8 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.968 0.413 . . . . 0.0 111.466 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.409 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 70.8 Cg_endo -82.05 130.36 6.46 Favored 'Trans proline' 0 CA--C 1.533 0.426 0 C-N-CA 122.689 2.259 . . . . 0.0 112.441 179.241 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.7 tpt -68.06 125.57 26.77 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-O 121.072 0.463 . . . . 0.0 111.644 -179.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.51 13.11 79.16 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-N 115.855 -0.611 . . . . 0.0 112.866 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.409 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.5 mm-40 -138.5 176.93 8.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.878 0.371 . . . . 0.0 111.125 -179.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -114.0 134.21 55.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.049 0.452 . . . . 0.0 111.661 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.7 t80 -123.05 124.84 44.03 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.029 178.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.428 ' O ' HG12 ' A' ' 96' ' ' VAL . 2.1 p -105.04 136.73 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 CA-C-O 121.544 0.688 . . . . 0.0 112.439 -178.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.7 t -113.17 112.92 42.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.113 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -93.84 119.49 32.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.951 0.405 . . . . 0.0 111.476 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -135.46 156.6 38.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.145 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -119.96 97.57 49.45 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.614 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.426 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.4 Cg_endo -72.75 100.28 1.16 Allowed 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 122.806 2.338 . . . . 0.0 112.309 179.502 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -95.46 5.34 51.85 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -131.97 133.29 44.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.798 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.89 127.74 35.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.0 0.429 . . . . 0.0 111.223 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 162.47 -156.56 28.25 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.764 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.02 126.13 48.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.198 0.523 . . . . 0.0 111.488 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.409 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 84.0 m-85 -118.15 173.41 6.81 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.904 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 83.2 p -151.22 158.13 43.51 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -178.859 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -149.69 130.46 14.15 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.334 178.756 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.33 172.91 14.9 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.964 0.411 . . . . 0.0 112.001 -179.381 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 41.2 t -120.58 130.41 54.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.627 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -77.0 70.34 2.34 Favored Glycine 0 CA--C 1.522 0.489 0 C-N-CA 120.923 -0.655 . . . . 0.0 113.084 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.86 -31.53 0.55 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.777 0.322 . . . . 0.0 111.593 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -156.14 -159.78 0.93 Allowed 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.116 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 1.7 ttp -78.16 77.94 4.65 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-O 120.999 0.428 . . . . 0.0 111.302 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.19 149.56 24.54 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.151 -179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.4 105.21 3.58 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.8 0.333 . . . . 0.0 111.822 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -146.06 121.15 1.42 Allowed Glycine 0 CA--C 1.521 0.444 0 C-N-CA 121.185 -0.531 . . . . 0.0 112.269 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 12.4 ttmt -123.09 151.57 41.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.106 0.479 . . . . 0.0 111.898 -179.255 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.409 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -134.52 139.79 45.69 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.735 179.479 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.0 mp -123.24 120.16 59.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.997 0.427 . . . . 0.0 110.81 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 85.2 t -104.16 123.19 57.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.202 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.237 0 CA-C-O 118.102 -0.951 . . . . 0.0 111.505 -179.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.699 0 N-CA-C 112.237 -0.345 . . . . 0.0 112.237 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -114.15 8.71 17.0 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.934 0.397 . . . . 0.0 111.464 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -88.01 89.94 8.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.985 0.421 . . . . 0.0 111.274 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.98 -168.59 12.64 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.788 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.11 128.41 24.13 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.042 0.449 . . . . 0.0 111.237 179.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.2 mtpt -91.34 129.24 37.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.874 179.794 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.65 152.36 40.51 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.317 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.553 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.5 pt20 -80.84 141.26 34.83 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-O 121.152 0.501 . . . . 0.0 111.444 -179.352 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 58.4 mt-30 -96.9 114.84 26.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.594 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.39 -149.82 0.31 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.456 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -82.01 72.72 9.06 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -179.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.76 -5.21 66.57 Favored Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.788 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.4 p90 -141.36 160.3 40.41 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.905 0.352 . . . . 0.0 110.746 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.18 155.66 21.68 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.988 0.423 . . . . 0.0 111.423 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.553 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.7 tt0 -144.53 143.84 31.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.545 -179.317 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -145.15 129.63 12.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.2 179.144 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 7.3 ttt180 -89.96 108.14 19.53 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.071 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 49.0 t -99.99 107.85 21.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.705 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -73.6 122.46 22.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.013 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.8 t -103.08 95.33 3.77 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-O 121.535 0.683 . . . . 0.0 111.052 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.406 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 3.8 ptm -146.16 89.45 1.87 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.405 179.562 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.55 0.24 89.8 Favored Glycine 0 CA--C 1.521 0.454 0 C-N-CA 120.811 -0.709 . . . . 0.0 111.545 -178.705 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.438 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.66 -140.6 6.81 Favored Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 111.649 -0.581 . . . . 0.0 111.649 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -121.86 129.46 52.61 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.741 0.27 . . . . 0.0 110.543 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.428 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 20.8 m -68.84 -62.0 3.17 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 120.997 -0.281 . . . . 0.0 111.176 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.428 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 63.5 Cg_endo -75.62 97.6 1.11 Allowed 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 121.417 1.411 . . . . 0.0 111.064 177.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -52.11 -43.34 63.9 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.125 -0.489 . . . . 0.0 112.062 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -134.17 118.45 17.67 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.711 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.7 HD13 ' SD ' ' A' ' 120' ' ' MET . 9.6 pt -96.91 127.35 49.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.134 0.492 . . . . 0.0 110.939 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 98.9 t -95.51 125.86 48.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.601 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . 0.416 HD12 ' SD ' ' A' ' 120' ' ' MET . 23.6 mt -133.69 167.68 20.07 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.263 -179.943 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.2 mttt -96.59 168.84 10.29 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.685 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -98.67 146.72 25.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.928 0.395 . . . . 0.0 111.927 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.5 t 66.06 19.7 11.19 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.89 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.438 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 5.7 p -123.53 135.2 25.84 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.002 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -64.3 122.7 10.74 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.051 1.834 . . . . 0.0 111.711 178.761 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.1 138.98 54.36 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.79 0.328 . . . . 0.0 111.622 -179.628 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -120.92 125.33 47.17 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.719 0.771 . . . . 0.0 111.494 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 5.7 mm -97.66 115.25 37.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.654 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.5 t -91.9 109.8 21.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.375 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -95.5 111.81 23.65 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.016 0.436 . . . . 0.0 111.296 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -98.11 106.03 18.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.52 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -78.19 105.16 9.24 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.282 0.563 . . . . 0.0 111.91 -179.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.05 -37.36 9.38 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.19 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.406 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 5.2 t70 -103.78 129.88 24.48 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.922 179.544 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -80.52 39.13 0.81 Allowed 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.113 2.542 . . . . 0.0 112.881 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.2 m -72.04 135.84 82.46 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.349 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -64.08 -31.21 65.65 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.617 2.211 . . . . 0.0 112.583 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 5.2 p -76.79 -5.29 47.58 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.587 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.438 HD11 ' N ' ' A' ' 48' ' ' GLY . 30.2 mt -120.12 15.94 12.38 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.964 179.642 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -67.82 -35.56 78.82 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 116.096 -0.502 . . . . 0.0 112.243 -179.332 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 -133.7 165.91 23.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.914 0.388 . . . . 0.0 111.583 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . 0.403 HG13 ' N ' ' A' ' 79' ' ' VAL . 0.5 OUTLIER -137.72 141.37 39.22 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.115 179.858 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.403 ' N ' HG13 ' A' ' 78' ' ' ILE . 0.2 OUTLIER -139.9 134.14 36.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.364 0.602 . . . . 0.0 111.359 179.054 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -97.57 101.68 10.97 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.84 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.56 -13.79 40.14 Favored 'Trans proline' 0 C--N 1.347 0.481 0 C-N-CA 122.613 2.209 . . . . 0.0 113.431 -178.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -100.57 -9.11 22.32 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -123.02 -19.93 5.92 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.353 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.71 28.97 49.7 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.86 -0.685 . . . . 0.0 112.226 -179.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.4 t -110.75 116.87 53.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.745 0.307 . . . . 0.0 111.535 -179.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 4.3 t60 -127.12 117.72 22.95 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.87 0.367 . . . . 0.0 110.45 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.12 170.48 15.61 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 121.09 0.471 . . . . 0.0 111.858 -179.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -106.24 145.84 31.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.477 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 34.8 mt -105.47 129.35 24.85 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.867 0.365 . . . . 0.0 111.412 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.414 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.7 Cg_endo -81.86 129.21 6.18 Favored 'Trans proline' 0 CA--C 1.532 0.409 0 C-N-CA 122.752 2.301 . . . . 0.0 112.486 179.265 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.3 tpt -67.07 125.27 25.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.138 0.494 . . . . 0.0 111.699 -179.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.66 6.37 85.64 Favored Glycine 0 C--N 1.333 0.367 0 CA-C-N 115.864 -0.607 . . . . 0.0 113.077 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.414 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 45.7 mt-10 -134.29 176.82 8.26 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 120.988 0.423 . . . . 0.0 111.018 -179.533 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -115.06 132.49 56.58 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.0 0.429 . . . . 0.0 111.767 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.4 t80 -116.47 123.9 48.64 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.968 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 96' ' ' VAL . 1.6 p -101.28 137.1 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 CA-C-O 121.651 0.739 . . . . 0.0 112.51 -178.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.98 110.21 31.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.154 178.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -92.67 118.82 31.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.373 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -135.84 154.52 34.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.361 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -119.22 97.43 50.46 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.272 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.438 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 74.2 Cg_endo -73.47 101.92 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.845 2.363 . . . . 0.0 112.72 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -97.71 19.9 12.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.984 0.421 . . . . 0.0 111.483 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -146.97 129.93 16.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.774 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -86.1 126.28 34.08 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.903 0.382 . . . . 0.0 111.269 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.09 -168.29 41.36 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.816 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -99.76 112.02 24.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.141 0.496 . . . . 0.0 110.774 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -110.94 172.4 6.9 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.292 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 54.2 p -153.69 163.39 40.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.132 0.491 . . . . 0.0 112.274 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 31.2 p90 -145.58 140.63 27.54 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.518 179.067 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.39 178.48 8.62 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 121.332 0.587 . . . . 0.0 112.273 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 49.6 t -122.35 137.18 54.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.108 178.818 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -73.93 74.16 1.19 Allowed Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.008 -0.615 . . . . 0.0 113.474 -179.365 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 3.4 ttm -164.3 -39.26 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.275 0 CA-C-O 120.694 0.283 . . . . 0.0 111.443 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -114.69 177.19 4.74 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.205 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -95.77 -16.08 22.15 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.491 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.9 146.38 44.06 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-O 121.008 0.432 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 22.9 p80 -153.54 157.98 40.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.92 0.39 . . . . 0.0 111.611 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -107.49 151.92 16.92 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 179.381 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 1.2 ttpt -115.94 151.9 34.5 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.957 0.408 . . . . 0.0 111.476 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.7 ' SD ' HD13 ' A' ' 54' ' ' ILE . 9.2 ttp -133.96 122.18 22.71 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.048 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -109.69 116.08 51.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.101 0.477 . . . . 0.0 110.88 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 98.3 t -100.05 120.07 48.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.077 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 24.1 mt-10 . . . . . 0 C--O 1.253 1.247 0 CA-C-O 118.13 -0.938 . . . . 0.0 111.491 -179.542 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.684 0 CA-C-O 121.227 0.348 . . . . 0.0 112.315 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.9 24.59 9.55 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.98 0.419 . . . . 0.0 111.26 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.53 72.2 10.29 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 121.041 0.448 . . . . 0.0 111.443 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 118.19 167.36 14.04 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.88 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 19.8 mp0 -117.14 123.85 47.74 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.175 0.512 . . . . 0.0 111.114 -179.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 3.4 ttmt -89.5 127.52 35.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.909 -179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.16 155.95 39.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.052 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.567 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 10.9 pt20 -79.68 132.8 36.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.295 0.569 . . . . 0.0 111.248 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.0 mt-30 -92.79 109.11 20.53 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.83 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.03 -157.07 0.47 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.352 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -83.09 80.3 9.09 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.203 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.05 -7.18 67.01 Favored Glycine 0 CA--C 1.523 0.534 0 C-N-CA 120.846 -0.692 . . . . 0.0 114.178 178.762 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . 0.431 ' HB2' ' O ' ' A' ' 61' ' ' PRO . 24.6 p90 -144.15 165.53 27.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 117.191 0.496 . . . . 0.0 111.075 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.89 154.96 33.61 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.901 0.382 . . . . 0.0 111.201 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.567 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.5 tt0 -145.21 143.13 30.12 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.43 -179.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.71 129.2 13.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.93 0.395 . . . . 0.0 110.714 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.58 111.45 22.76 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.317 0.58 . . . . 0.0 111.127 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 42.6 t -100.05 102.82 13.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.571 -179.877 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.402 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.4 OUTLIER -72.56 113.61 9.79 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.607 179.874 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 43.1 t -94.66 97.45 6.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.674 -0.693 . . . . 0.0 111.336 -178.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.433 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.7 ptm -141.68 85.27 1.94 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.532 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.94 1.42 90.63 Favored Glycine 0 CA--C 1.521 0.41 0 C-N-CA 120.958 -0.639 . . . . 0.0 111.516 -178.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 160.94 -166.95 35.79 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.733 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -93.75 123.75 37.29 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.86 0.33 . . . . 0.0 110.44 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.442 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 25.5 m -63.67 -62.17 5.81 Favored Pre-proline 0 CA--C 1.538 0.489 0 CA-C-O 119.594 -0.241 . . . . 0.0 111.07 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.442 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 61.2 Cg_endo -75.23 98.73 1.19 Allowed 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 121.211 1.274 . . . . 0.0 110.974 177.366 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.54 -45.31 62.94 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.3 -179.066 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.452 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -133.18 118.28 18.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.53 179.704 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.624 HD12 ' SD ' ' A' ' 120' ' ' MET . 5.0 pt -96.92 126.12 49.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.141 0.495 . . . . 0.0 111.273 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 88.9 t -99.07 125.65 52.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.413 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 2.3 mt -136.27 166.19 24.0 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.354 -179.588 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.0 177.18 7.67 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.263 179.382 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 12.2 ttpt -106.05 147.36 28.99 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 111.842 0.312 . . . . 0.0 111.842 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.8 t 62.35 26.9 16.08 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.646 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -123.57 137.06 27.97 Favored Pre-proline 0 CA--C 1.538 0.508 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.435 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . 0.431 ' O ' ' HB2' ' A' ' 38' ' ' TYR . 36.2 Cg_endo -67.25 93.44 0.35 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.773 2.316 . . . . 0.0 112.206 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -97.99 138.78 34.8 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.911 0.386 . . . . 0.0 111.988 -179.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -121.51 129.09 52.71 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 121.736 0.779 . . . . 0.0 111.644 179.747 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.412 HG22 HD12 ' A' ' 64' ' ' ILE . 4.6 mm -100.63 114.78 40.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.285 -0.871 . . . . 0.0 110.695 179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.3 t -91.65 109.86 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.677 -0.238 . . . . 0.0 111.411 -179.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -95.44 113.63 25.32 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.034 0.445 . . . . 0.0 111.278 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -100.18 106.6 18.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.142 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.05 105.98 9.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.312 0.577 . . . . 0.0 112.12 -179.143 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.2 tptp -99.9 -34.56 10.07 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.084 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.433 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.6 t70 -109.6 132.68 21.2 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.779 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -81.13 40.43 0.99 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.085 2.524 . . . . 0.0 113.306 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.2 t -68.65 134.7 90.41 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.331 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -64.43 -27.96 62.56 Favored 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 122.652 2.234 . . . . 0.0 112.647 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.1 m -78.92 -10.75 59.91 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.168 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 40.9 mt -110.57 10.21 23.04 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.497 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -68.23 -40.53 82.0 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 120.87 0.367 . . . . 0.0 111.81 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -123.54 148.64 46.11 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.359 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -130.53 129.88 64.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.13 0.49 . . . . 0.0 110.374 178.653 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 2.4 p -133.98 132.45 56.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.2 0.524 . . . . 0.0 111.18 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -93.07 101.76 5.99 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.259 178.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.57 -15.71 48.52 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.662 2.241 . . . . 0.0 113.527 -178.391 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -100.58 -7.59 23.87 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -121.36 -20.9 6.5 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 112.026 0.38 . . . . 0.0 112.026 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.95 29.43 46.84 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.105 -179.524 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 50.9 t -110.89 115.71 50.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.881 0.372 . . . . 0.0 111.753 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.6 p80 -118.75 124.95 48.53 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.429 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.04 160.06 41.09 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -104.08 139.55 39.02 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.471 179.594 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 42.3 mt -101.63 127.23 31.87 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.904 0.383 . . . . 0.0 111.438 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.411 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 68.9 Cg_endo -81.0 128.14 6.4 Favored 'Trans proline' 0 CA--C 1.532 0.383 0 C-N-CA 122.667 2.245 . . . . 0.0 112.479 179.441 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.0 tpt -66.75 125.49 26.01 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.993 0.425 . . . . 0.0 111.583 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.84 7.88 83.4 Favored Glycine 0 CA--C 1.52 0.393 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.889 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.411 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 52.4 mm-40 -135.58 176.9 8.25 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.014 0.435 . . . . 0.0 111.14 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -114.63 134.34 55.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.033 0.444 . . . . 0.0 111.669 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -121.95 126.15 47.96 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.108 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 1.4 p -103.81 139.28 25.21 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 CA-C-O 121.516 0.674 . . . . 0.0 112.674 -178.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.8 t -116.41 110.82 32.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.123 178.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -93.67 119.37 32.6 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.255 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -133.31 157.57 42.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.086 0.469 . . . . 0.0 111.186 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.5 m -122.3 95.57 46.99 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.317 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.68 101.2 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.816 2.344 . . . . 0.0 112.649 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -95.02 23.73 5.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.922 0.391 . . . . 0.0 111.64 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -149.25 130.43 14.54 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.764 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.51 127.21 35.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.04 0.448 . . . . 0.0 111.438 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 165.01 -160.38 33.66 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.659 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -101.58 125.58 48.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.051 0.453 . . . . 0.0 111.275 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.407 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 91.7 m-85 -118.31 167.54 11.45 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.198 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.6 p -143.53 154.88 44.07 Favored 'General case' 0 C--O 1.234 0.26 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 44.4 p90 -148.73 129.46 14.16 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.916 178.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.81 158.09 22.3 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.116 -179.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 6.7 t -156.51 162.82 39.93 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.921 0.391 . . . . 0.0 111.188 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 87.08 -77.29 1.99 Allowed Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.924 -0.655 . . . . 0.0 113.237 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -135.0 177.59 7.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.005 0.431 . . . . 0.0 111.418 -179.674 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -85.2 2.03 45.52 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.508 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 6.9 mtm -85.26 -7.66 58.91 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-O 120.875 0.369 . . . . 0.0 111.324 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -76.34 155.95 33.73 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.119 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -144.89 106.25 4.22 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.987 0.423 . . . . 0.0 111.858 -179.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -141.34 115.69 1.03 Allowed Glycine 0 CA--C 1.519 0.316 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.969 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.452 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.9 ttpt -119.4 149.7 41.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.304 0.573 . . . . 0.0 111.729 -179.181 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.624 ' SD ' HD12 ' A' ' 54' ' ' ILE . 12.0 ttp -133.93 135.16 43.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.734 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.1 mp -119.38 119.29 60.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.952 0.406 . . . . 0.0 110.856 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 89.6 t -104.12 120.16 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.135 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.227 -0.892 . . . . 0.0 111.464 -179.773 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.706 0 N-CA-C 112.529 -0.229 . . . . 0.0 112.529 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . 63.47 -91.23 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 123.408 0.683 . . . . 0.0 112.127 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -137.15 111.23 8.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.951 0.405 . . . . 0.0 111.39 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -84.67 167.8 42.96 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.993 -0.623 . . . . 0.0 112.962 179.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.09 132.19 55.99 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.134 0.493 . . . . 0.0 111.223 -179.768 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.42 126.1 37.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.808 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.36 153.19 42.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.24 179.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -81.42 141.2 34.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.163 0.506 . . . . 0.0 111.52 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -97.16 115.71 28.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.596 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.51 -149.88 0.34 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.513 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -81.74 73.0 8.8 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -179.149 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.68 -6.54 67.62 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.65 -0.786 . . . . 0.0 113.898 179.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 38.9 p90 -139.89 163.7 31.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.767 0.283 . . . . 0.0 110.799 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.92 153.1 29.83 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.111 0.481 . . . . 0.0 111.283 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.413 ' HG3' ' HE ' ' A' ' 63' ' ' ARG . 3.3 tt0 -142.16 141.6 32.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.606 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.19 128.95 22.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.116 179.203 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -89.1 107.46 19.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.159 0.504 . . . . 0.0 111.017 179.574 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.3 t -100.28 103.29 14.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.416 -179.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -73.29 116.87 14.35 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.025 -179.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 42.0 t -98.01 99.08 8.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 CA-C-O 121.52 0.676 . . . . 0.0 111.423 -179.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.453 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.0 ptm -143.88 86.93 1.88 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.462 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.98 2.28 90.67 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 160.65 -154.01 24.97 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 65.3 m-85 -107.43 127.62 53.76 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.85 0.325 . . . . 0.0 110.407 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.46 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 40.7 m -66.92 -64.46 2.16 Favored Pre-proline 0 CA--C 1.539 0.522 0 CA-C-O 119.529 -0.272 . . . . 0.0 111.389 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.46 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 65.1 Cg_endo -75.0 98.65 1.18 Allowed 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.329 1.353 . . . . 0.0 111.028 177.789 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.89 -44.67 59.92 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.33 -179.346 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.499 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.04 119.2 20.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.645 0.259 . . . . 0.0 110.913 179.788 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.1 pt -97.1 125.71 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 120.976 0.417 . . . . 0.0 111.102 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 88.4 t -98.27 126.77 51.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.535 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 2.9 mt -136.93 166.79 22.82 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.384 -179.602 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.2 mtmm -90.38 172.49 8.71 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.915 179.322 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.6 ttpp -103.38 148.76 25.49 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 37.3 t 65.45 20.12 11.68 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.779 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' HG11 ' A' ' 60' ' ' VAL . 8.9 p -123.73 136.01 26.85 Favored Pre-proline 0 CA--C 1.535 0.371 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.868 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -64.2 122.9 11.03 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.105 1.87 . . . . 0.0 111.561 178.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.46 137.85 54.4 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.007 0.432 . . . . 0.0 111.632 -179.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.413 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.6 ptt180 -119.65 125.55 49.01 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.714 0.769 . . . . 0.0 111.286 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.457 HD12 HG23 ' A' ' 64' ' ' ILE . 3.5 mm -98.35 115.58 38.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.61 -179.927 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.5 t -91.79 109.21 20.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.558 -179.177 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -97.83 107.8 20.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.898 0.38 . . . . 0.0 111.386 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -93.47 107.28 19.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.533 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 1.2 tpt180 -77.07 101.3 6.01 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.183 0.516 . . . . 0.0 111.776 -179.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 21.0 tptt -96.38 -34.28 11.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.413 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.453 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.8 t70 -108.93 131.39 21.82 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.693 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -79.6 39.54 0.84 Allowed 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 123.163 2.575 . . . . 0.0 113.246 -179.374 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 30.0 t -68.23 136.05 91.37 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.095 179.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.29 -26.98 55.95 Favored 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 122.684 2.256 . . . . 0.0 112.584 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -81.65 -7.98 59.65 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.243 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 40.5 mt -115.02 8.28 15.72 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.472 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.61 -38.18 90.14 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.899 0.38 . . . . 0.0 111.933 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 3.9 mp0 -124.86 160.35 29.0 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.092 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -135.95 131.8 50.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.167 0.508 . . . . 0.0 110.83 179.202 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 1.0 OUTLIER -135.79 130.53 49.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.279 0.561 . . . . 0.0 111.199 179.757 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -93.89 101.9 7.05 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.393 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.7 -15.94 48.92 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.616 2.211 . . . . 0.0 113.578 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 55.7 m-20 -100.53 -7.13 24.46 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -121.17 -23.45 5.77 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.26 26.94 41.82 Favored Glycine 0 CA--C 1.52 0.363 0 C-N-CA 120.892 -0.671 . . . . 0.0 112.234 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 50.1 t -107.62 119.58 57.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.772 0.32 . . . . 0.0 111.605 -178.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -124.14 120.59 32.77 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.667 179.569 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -139.6 173.57 11.4 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-O 121.004 0.431 . . . . 0.0 112.109 -179.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -114.92 142.18 46.94 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.972 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 31.0 mt -102.77 124.09 40.12 Favored Pre-proline 0 CA--C 1.531 0.25 0 CA-C-O 120.949 0.404 . . . . 0.0 111.53 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 61.1 Cg_endo -77.07 129.48 10.56 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.753 2.302 . . . . 0.0 112.725 -179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.2 tpt -66.36 125.01 24.3 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.039 0.447 . . . . 0.0 111.803 -179.46 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.03 1.25 82.35 Favored Glycine 0 C--N 1.332 0.336 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.838 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 42.1 mt-10 -133.93 177.13 7.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.955 0.407 . . . . 0.0 110.802 -179.568 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -119.01 134.73 55.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.135 0.493 . . . . 0.0 111.596 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 12.5 t80 -113.77 127.91 56.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.171 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.402 ' O ' HG11 ' A' ' 96' ' ' VAL . 1.8 p -99.87 136.3 31.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.588 0.708 . . . . 0.0 112.504 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 65.7 t -113.84 112.17 39.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.203 178.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -93.53 118.89 31.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.584 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.88 158.05 41.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.255 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -120.48 97.08 48.94 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.663 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.432 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 65.8 Cg_endo -72.5 99.73 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.915 2.41 . . . . 0.0 112.336 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -95.07 3.73 54.5 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 111.868 0.321 . . . . 0.0 111.868 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -130.82 133.37 45.89 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.77 0.319 . . . . 0.0 110.812 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.75 128.08 35.62 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.98 0.419 . . . . 0.0 111.241 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.11 -157.9 30.1 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.709 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -101.42 125.64 48.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.21 0.528 . . . . 0.0 111.605 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.423 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 85.8 m-85 -118.46 172.81 7.22 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.868 179.602 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 93.4 p -155.03 158.74 39.59 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.1 p90 -147.23 133.43 19.42 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.542 -0.754 . . . . 0.0 111.088 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.43 162.56 27.71 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.994 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 5.8 t -143.97 135.22 25.68 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 120.875 0.369 . . . . 0.0 111.562 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.59 -172.67 54.58 Favored Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.173 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 4.1 tpt -103.39 88.43 3.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.03 0.443 . . . . 0.0 110.733 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -148.48 175.8 10.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.181 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -88.09 -30.38 19.92 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.275 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.53 121.43 14.89 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 121.104 0.478 . . . . 0.0 111.295 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 56.2 p-80 -149.94 154.14 37.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.879 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -109.46 146.68 16.9 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.757 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.499 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 13.4 ttmt -118.05 148.8 41.91 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.958 0.409 . . . . 0.0 110.852 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.423 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -131.25 138.48 49.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.062 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.1 mp -121.84 118.49 55.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.964 0.411 . . . . 0.0 110.775 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.5 t -102.06 121.84 53.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.301 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 . . . . . 0 C--O 1.252 1.235 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.441 -179.802 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.609 0 CA-C-O 121.155 0.308 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -83.42 66.18 8.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.1 0.476 . . . . 0.0 111.472 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 1.4 mpp? -95.69 90.88 5.85 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.204 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.74 -176.69 19.52 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.981 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.69 129.73 53.79 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.107 0.479 . . . . 0.0 111.166 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.2 ttmt -91.93 125.48 36.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.995 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -70.94 150.89 45.25 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.189 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.545 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 3.8 pt20 -80.71 139.68 36.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.131 0.491 . . . . 0.0 111.422 -179.385 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 6.9 mp0 -95.66 115.33 27.28 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.776 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.75 -149.79 0.3 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.256 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -83.6 75.84 10.01 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 94.75 -5.97 69.92 Favored Glycine 0 CA--C 1.523 0.536 0 C-N-CA 120.88 -0.676 . . . . 0.0 113.928 179.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -142.32 160.54 40.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.912 0.356 . . . . 0.0 110.859 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -109.98 157.29 19.44 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.094 0.473 . . . . 0.0 111.45 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.545 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.0 OUTLIER -145.88 143.13 29.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.474 -179.539 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -142.7 129.05 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.064 0.459 . . . . 0.0 111.024 179.079 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.5 ttt180 -89.45 106.98 18.81 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.192 0.52 . . . . 0.0 111.028 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.0 t -99.82 103.0 14.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.474 -179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -73.07 116.66 13.85 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.08 -179.906 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 48.5 t -97.52 98.91 7.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.466 -179.001 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.402 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.6 ptm -143.06 85.83 1.89 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.453 179.111 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.04 3.37 87.75 Favored Glycine 0 CA--C 1.52 0.356 0 C-N-CA 120.941 -0.647 . . . . 0.0 111.509 -178.522 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 159.81 -143.32 8.99 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -179.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -116.2 127.89 55.16 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.687 0.244 . . . . 0.0 110.56 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.465 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 42.6 m -67.7 -64.67 1.85 Allowed Pre-proline 0 CA--C 1.54 0.58 0 CA-C-O 119.548 -0.263 . . . . 0.0 111.481 -179.649 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.465 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 66.7 Cg_endo -75.0 98.88 1.2 Allowed 'Trans proline' 0 C--N 1.356 0.941 0 C-N-CA 121.288 1.325 . . . . 0.0 111.044 177.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -51.45 -44.51 62.41 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.333 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.49 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.72 118.99 20.71 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.635 0.255 . . . . 0.0 110.944 179.77 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.0 pt -97.65 125.08 50.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.033 0.444 . . . . 0.0 111.087 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.7 t -95.98 126.38 48.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.497 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 10.2 mt -134.83 169.61 17.1 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.403 -179.683 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -97.66 166.98 11.24 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.56 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.3 ttpp -96.92 147.87 23.54 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -179.302 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.6 t 65.92 20.2 11.33 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.953 179.439 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.441 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 5.6 p -123.59 134.93 25.61 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.991 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -64.41 123.77 12.3 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.1 1.867 . . . . 0.0 111.596 178.618 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.95 137.23 53.68 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.908 0.385 . . . . 0.0 111.748 -179.527 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -117.5 125.9 51.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.705 0.764 . . . . 0.0 111.414 179.827 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.441 HD13 HG23 ' A' ' 64' ' ' ILE . 3.1 mm -98.08 114.78 36.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.726 179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.1 t -90.53 107.73 18.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.35 -179.249 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 61.9 m-85 -95.71 102.78 14.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.912 0.387 . . . . 0.0 111.479 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -89.66 105.84 18.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.178 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.77 101.98 8.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.237 0.541 . . . . 0.0 112.12 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.3 tppt? -96.49 -36.65 10.71 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.636 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.402 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.6 t70 -102.32 130.52 23.99 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.932 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -80.62 39.25 0.83 Allowed 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.089 2.526 . . . . 0.0 113.112 -179.543 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -70.07 137.77 87.2 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.299 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -63.01 -33.55 73.75 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 122.814 2.343 . . . . 0.0 112.982 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.9 p -75.54 -9.87 58.95 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.388 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 57.3 mt -112.93 14.62 19.77 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.469 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -68.33 -35.35 77.65 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-O 120.91 0.386 . . . . 0.0 111.461 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -131.62 165.9 22.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.932 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -139.13 133.68 40.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.945 0.402 . . . . 0.0 111.116 179.301 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -136.46 132.27 48.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.34 0.59 . . . . 0.0 111.403 179.378 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -94.35 102.08 7.85 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.136 -0.938 . . . . 0.0 109.466 178.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -65.92 -16.4 52.57 Favored 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.696 2.264 . . . . 0.0 113.696 -178.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -100.46 -7.38 24.31 Favored 'General case' 0 CA--C 1.535 0.394 0 N-CA-C 111.933 0.345 . . . . 0.0 111.933 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -120.44 -22.04 6.62 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.69 31.0 41.84 Favored Glycine 0 C--N 1.333 0.378 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.922 -179.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.3 t -114.46 117.06 54.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.633 0.254 . . . . 0.0 111.659 -178.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 -126.13 122.76 36.61 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.892 0.377 . . . . 0.0 110.617 179.244 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.77 171.21 14.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.655 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -106.32 143.54 34.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.73 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 38.7 mt -104.65 128.3 27.15 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.972 0.415 . . . . 0.0 111.359 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -80.64 126.7 6.08 Favored 'Trans proline' 0 CA--C 1.532 0.421 0 C-N-CA 122.726 2.284 . . . . 0.0 112.507 179.284 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.4 tpt -65.35 124.93 23.55 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-O 120.974 0.416 . . . . 0.0 111.64 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.29 1.66 81.15 Favored Glycine 0 CA--C 1.52 0.387 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.959 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -134.04 177.37 7.79 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 120.885 0.374 . . . . 0.0 110.857 -179.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -117.55 134.24 55.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.179 0.514 . . . . 0.0 111.658 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -113.78 126.84 55.65 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.142 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.411 ' O ' HG11 ' A' ' 96' ' ' VAL . 1.4 p -98.4 136.92 27.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 CA-C-O 121.55 0.69 . . . . 0.0 112.613 -179.053 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 62.0 t -115.52 111.4 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.132 178.837 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -92.66 118.42 31.03 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.52 -179.305 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.68 157.07 40.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.142 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.8 m -121.14 98.3 47.2 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.533 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.441 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.1 Cg_endo -72.79 100.62 1.21 Allowed 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.781 2.321 . . . . 0.0 112.376 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -95.34 6.7 48.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.791 0.329 . . . . 0.0 111.783 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.12 133.75 43.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.528 -0.305 . . . . 0.0 110.706 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.32 127.49 35.8 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.918 0.39 . . . . 0.0 111.29 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.08 -157.08 29.09 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.716 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -101.68 125.13 48.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.166 0.508 . . . . 0.0 111.684 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.425 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 82.6 m-85 -117.64 172.27 7.47 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.666 179.495 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 86.9 p -153.72 158.62 41.27 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -178.795 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 37.5 p90 -148.71 134.46 18.88 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.87 178.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.31 162.92 28.22 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.903 0.383 . . . . 0.0 111.564 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 3.2 t -154.75 157.49 38.09 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.949 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 85.8 -5.56 83.43 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.931 -0.652 . . . . 0.0 113.538 179.655 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 56.82 50.83 11.74 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 121.063 0.459 . . . . 0.0 111.722 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -120.66 -173.11 2.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.361 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -73.82 -34.09 64.42 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.477 -179.846 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -65.32 119.79 11.6 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 121.122 0.487 . . . . 0.0 111.242 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 56.5 p-80 -149.23 151.5 34.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.242 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -110.02 148.8 17.41 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.433 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.49 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 0.9 OUTLIER -119.32 148.81 42.76 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.955 0.407 . . . . 0.0 111.033 -179.926 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.425 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 3.0 ttm -130.58 137.68 49.78 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.09 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -120.92 118.32 55.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.024 0.44 . . . . 0.0 110.639 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 88.9 t -101.79 122.96 54.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.307 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 . . . . . 0 C--O 1.253 1.249 0 CA-C-O 118.163 -0.922 . . . . 0.0 111.462 -179.645 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.753 0 CA-C-O 121.15 0.305 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -84.07 71.19 10.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.032 0.444 . . . . 0.0 111.443 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -116.63 119.05 34.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.173 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.55 -176.89 26.72 Favored Glycine 0 CA--C 1.52 0.377 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.905 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.63 143.6 33.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.163 0.506 . . . . 0.0 111.579 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.1 ttmt -101.38 129.62 47.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.619 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.09 152.84 39.83 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 111.187 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.508 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 22.8 pt20 -85.49 142.96 28.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.155 0.502 . . . . 0.0 111.791 -179.25 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -94.96 114.92 26.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.785 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -94.97 -150.72 0.31 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.024 0.44 . . . . 0.0 111.362 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -82.69 70.54 9.69 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.55 -9.83 59.05 Favored Glycine 0 CA--C 1.521 0.411 0 C-N-CA 120.771 -0.728 . . . . 0.0 113.713 178.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 32.8 p90 -137.93 165.64 26.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.953 0.376 . . . . 0.0 110.895 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.7 152.45 31.96 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.912 0.387 . . . . 0.0 111.103 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.508 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.9 tt0 -143.27 139.94 30.41 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.576 -179.325 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.0 128.42 22.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.975 179.185 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 11.0 ttt180 -89.28 108.85 19.85 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.297 0.57 . . . . 0.0 111.114 179.616 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 44.3 t -100.1 103.61 15.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.583 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -72.91 117.03 14.13 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.979 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 52.3 t -99.59 99.18 8.03 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.558 -178.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.442 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.7 ptm -145.86 86.68 1.73 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.182 179.112 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.22 -0.42 88.75 Favored Glycine 0 CA--C 1.52 0.368 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -178.243 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.463 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.8 -161.4 32.76 Favored Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 47.4 m-85 -101.99 126.39 48.91 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 117.046 0.423 . . . . 0.0 110.418 179.53 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.456 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 40.3 m -63.82 -63.49 3.87 Favored Pre-proline 0 CA--C 1.54 0.569 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.566 -179.547 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.456 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 68.2 Cg_endo -75.48 95.86 1.02 Allowed 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 121.301 1.334 . . . . 0.0 111.036 177.653 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -49.6 -43.54 46.47 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.32 -179.371 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.423 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.94 118.69 19.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.476 179.56 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.8 pt -97.45 126.4 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 121.086 0.469 . . . . 0.0 111.172 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 78.0 t -96.07 127.31 48.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.283 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 10.4 mt -135.0 171.51 14.33 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.558 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -97.13 173.26 7.34 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.739 179.453 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.0 ttpp -104.8 147.93 27.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.829 0.347 . . . . 0.0 111.926 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.4 t 65.49 20.7 11.74 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.751 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.429 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.95 136.46 27.49 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.169 -179.769 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -64.28 122.46 10.42 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.096 1.864 . . . . 0.0 111.47 178.242 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.91 138.04 54.26 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.99 0.424 . . . . 0.0 111.775 -179.45 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.407 HH11 ' HD2' ' A' ' 63' ' ' ARG . 6.7 ptt85 -120.67 126.55 50.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.789 0.804 . . . . 0.0 111.081 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.428 HG21 ' CZ ' ' A' ' 66' ' ' PHE . 3.4 mm -100.07 114.16 37.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.759 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.0 t -89.93 107.49 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.467 -179.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.428 ' CZ ' HG21 ' A' ' 64' ' ' ILE . 72.6 m-85 -96.53 106.96 19.3 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.918 0.389 . . . . 0.0 111.318 -179.923 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -91.54 105.79 18.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.633 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.45 96.2 5.32 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.204 0.526 . . . . 0.0 111.596 -179.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 17.4 tptt -90.95 -37.92 13.19 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.69 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.442 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.6 t70 -102.73 130.95 22.86 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.785 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -79.75 38.57 0.75 Allowed 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 123.151 2.567 . . . . 0.0 113.235 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.9 t -69.67 135.55 88.1 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.046 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.33 -28.21 63.4 Favored 'Trans proline' 0 C--N 1.349 0.556 0 C-N-CA 122.63 2.22 . . . . 0.0 112.42 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 22.7 m -78.75 -9.23 59.36 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.081 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.463 HD11 ' N ' ' A' ' 48' ' ' GLY . 46.0 mt -116.05 17.27 15.9 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.456 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -71.7 -32.19 67.55 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -133.29 165.87 23.81 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.967 0.413 . . . . 0.0 111.393 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -140.57 130.14 26.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.98 179.296 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -130.27 132.7 64.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.481 0.657 . . . . 0.0 111.157 179.349 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -95.91 101.96 9.43 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.662 179.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.56 -15.19 46.93 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.59 2.193 . . . . 0.0 113.624 -178.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -100.71 -7.16 24.09 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -122.45 -22.06 5.58 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 112.017 0.376 . . . . 0.0 112.017 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.49 31.4 41.39 Favored Glycine 0 C--N 1.332 0.355 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.028 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.1 t -114.69 119.62 62.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.654 0.264 . . . . 0.0 111.657 -178.721 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 13.7 t-80 -126.37 119.8 28.23 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.841 0.353 . . . . 0.0 110.427 179.251 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.8 173.23 11.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.754 -179.474 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -110.07 151.44 27.2 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.046 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 28.0 mt -111.25 125.04 31.31 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-O 120.945 0.402 . . . . 0.0 111.386 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 64.5 Cg_endo -78.18 131.06 10.57 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 122.826 2.351 . . . . 0.0 112.708 179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.6 tpt -66.81 124.43 22.92 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.799 -179.415 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 86.64 3.59 83.65 Favored Glycine 0 CA--C 1.52 0.345 0 CA-C-N 115.814 -0.63 . . . . 0.0 113.012 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -134.96 177.09 8.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.862 0.363 . . . . 0.0 110.905 -179.509 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.56 134.8 54.82 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.231 0.539 . . . . 0.0 111.546 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -113.54 125.35 54.1 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.221 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.403 ' O ' HG12 ' A' ' 96' ' ' VAL . 2.3 p -99.08 135.2 35.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.552 0.691 . . . . 0.0 112.489 -178.983 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 66.7 t -110.77 112.24 39.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.055 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -94.09 118.6 31.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.95 0.405 . . . . 0.0 111.475 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.99 166.5 28.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.146 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.2 m -129.66 97.51 24.32 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.486 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.429 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 70.2 Cg_endo -72.99 100.58 1.22 Allowed 'Trans proline' 0 CA--C 1.532 0.423 0 C-N-CA 122.844 2.363 . . . . 0.0 112.447 179.774 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -95.32 3.8 54.09 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.665 -179.586 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -132.16 134.68 45.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.735 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.32 124.24 34.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.974 0.416 . . . . 0.0 111.272 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 171.42 -165.34 38.32 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.884 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.25 115.47 27.67 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.19 0.519 . . . . 0.0 110.721 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 20.5 m-85 -111.4 173.03 6.54 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.971 -179.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 85.5 p -152.58 165.1 36.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.307 0.575 . . . . 0.0 112.549 -178.573 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.2 p90 -152.07 136.86 17.09 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.441 178.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -161.92 176.89 10.33 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.834 0.349 . . . . 0.0 111.825 -179.32 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 48.6 t -131.98 133.15 44.14 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.064 179.195 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 95.67 -135.8 12.54 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.832 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -122.69 -96.98 0.46 Allowed 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 120.649 0.261 . . . . 0.0 110.979 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -86.72 59.82 5.86 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.035 0.445 . . . . 0.0 111.346 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -154.9 179.35 9.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.04 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER 69.5 174.18 0.29 Allowed 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.289 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 56.4 t-80 -164.9 103.74 0.79 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.009 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -150.55 122.59 1.41 Allowed Glycine 0 CA--C 1.517 0.193 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.361 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.423 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.0 ttmm -122.84 151.44 41.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.069 0.462 . . . . 0.0 111.828 -179.4 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 2.6 ttm -134.74 131.22 37.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.773 179.413 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.7 mp -116.03 117.79 56.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.024 0.44 . . . . 0.0 110.67 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 74.8 t -101.8 122.53 54.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.288 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 . . . . . 0 C--O 1.252 1.213 0 CA-C-O 118.112 -0.947 . . . . 0.0 111.387 -179.583 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.688 0 CA-C-O 121.073 0.263 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -82.21 91.66 6.77 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.143 0.497 . . . . 0.0 111.547 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 4.8 tpp -81.4 101.0 9.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.143 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.92 168.34 53.41 Favored Glycine 0 CA--C 1.519 0.304 0 C-N-CA 120.963 -0.637 . . . . 0.0 113.115 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.96 130.43 48.39 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.096 0.474 . . . . 0.0 111.402 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.8 mtpt -91.67 130.85 37.4 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.79 179.56 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.25 151.37 39.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.488 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.579 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.6 pt20 -79.04 139.4 38.16 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.142 0.496 . . . . 0.0 111.089 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -97.31 114.47 26.24 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.766 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -94.89 -154.5 0.43 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.256 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -82.11 74.23 9.1 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.14 -9.14 59.48 Favored Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.655 -0.783 . . . . 0.0 113.986 178.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 27.5 p90 -140.96 164.66 29.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 117.036 0.418 . . . . 0.0 111.066 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.67 153.65 29.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.974 0.416 . . . . 0.0 111.353 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.579 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.9 tt0 -143.36 143.08 31.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.46 -179.579 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.51 128.53 17.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.011 0.434 . . . . 0.0 111.08 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.63 106.12 18.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.213 0.53 . . . . 0.0 111.168 179.71 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 46.1 t -99.01 103.29 14.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.65 -179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.402 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.9 OUTLIER -73.09 118.2 15.75 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.789 -179.961 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.9 t -100.23 97.82 6.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.472 -178.852 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.431 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.9 ptm -143.27 85.02 1.84 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.372 179.273 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.08 0.24 88.9 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 -178.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 160.38 -169.29 36.15 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -92.17 125.73 36.96 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.924 0.362 . . . . 0.0 110.348 179.511 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.468 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 43.3 m -65.27 -63.97 3.02 Favored Pre-proline 0 CA--C 1.54 0.587 0 CA-C-O 119.557 -0.259 . . . . 0.0 111.293 -179.657 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.468 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 64.3 Cg_endo -75.03 96.55 1.03 Allowed 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 121.244 1.296 . . . . 0.0 111.205 177.815 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -51.36 -42.51 61.36 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.182 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.502 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -130.96 118.74 21.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.763 179.617 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.2 pt -99.16 126.93 52.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.951 0.405 . . . . 0.0 111.098 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 85.2 t -98.25 127.03 51.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.473 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.2 mt -135.95 165.52 25.47 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.318 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.6 mttt -90.12 176.26 6.84 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.728 179.164 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.2 ttpp -107.0 148.64 28.44 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -179.108 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.9 t 64.93 20.38 12.1 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.771 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.441 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.0 p -123.93 136.75 27.82 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.064 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.75 122.46 10.31 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.164 1.91 . . . . 0.0 111.639 178.607 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.45 139.8 53.65 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.969 0.414 . . . . 0.0 111.53 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.449 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.8 ptt180 -121.5 126.92 50.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.764 0.792 . . . . 0.0 111.344 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.7 mm -98.4 114.71 36.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.726 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.5 t -90.62 113.44 26.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.35 -179.391 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -100.31 114.87 28.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.077 0.465 . . . . 0.0 111.5 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -99.45 102.99 14.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.065 179.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.55 98.42 6.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.176 0.513 . . . . 0.0 111.998 -179.148 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.9 tptp -94.29 -35.69 12.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.536 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.431 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.8 t70 -106.17 130.79 22.43 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.931 179.579 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -81.2 39.39 0.85 Allowed 'Trans proline' 0 C--N 1.349 0.598 0 C-N-CA 123.059 2.506 . . . . 0.0 113.302 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -70.4 138.33 86.49 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.186 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -62.75 -32.73 78.08 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 122.924 2.416 . . . . 0.0 113.257 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.4 p -76.08 -8.06 56.13 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.779 0.323 . . . . 0.0 111.5 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 53.0 mt -114.88 13.67 17.15 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.356 -179.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -68.49 -36.88 79.56 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-O 120.913 0.387 . . . . 0.0 111.643 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -132.23 161.58 33.08 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.066 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -136.96 131.22 46.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.038 0.446 . . . . 0.0 111.083 179.521 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -133.09 132.96 58.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 121.362 0.601 . . . . 0.0 111.31 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -94.76 102.14 8.39 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.509 178.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.25 -16.55 52.14 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.67 2.246 . . . . 0.0 113.668 -178.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -100.38 -7.04 24.83 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -120.52 -20.78 7.03 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 77.37 32.31 48.02 Favored Glycine 0 C--N 1.333 0.398 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.944 -179.198 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.1 t -116.72 117.98 57.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 -178.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 22.3 t-80 -123.79 122.03 36.98 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.802 0.334 . . . . 0.0 110.402 179.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.9 163.64 28.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.704 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.88 139.04 40.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.481 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 45.7 mt -101.34 128.45 29.22 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 120.856 0.36 . . . . 0.0 111.541 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.409 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 72.7 Cg_endo -82.91 128.65 5.19 Favored 'Trans proline' 0 CA--C 1.532 0.415 0 C-N-CA 122.71 2.273 . . . . 0.0 112.388 179.198 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -66.45 125.12 24.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.08 0.467 . . . . 0.0 111.725 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.88 11.77 80.9 Favored Glycine 0 CA--C 1.52 0.364 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.98 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.409 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.6 mm-40 -137.64 176.97 8.23 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.89 0.376 . . . . 0.0 111.083 -179.604 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -113.37 134.73 54.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.025 0.441 . . . . 0.0 111.733 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.1 t80 -123.98 127.86 48.54 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.935 178.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.3 p -107.0 137.18 39.16 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 CA-C-O 121.417 0.627 . . . . 0.0 112.628 -178.865 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 67.2 t -112.93 113.19 43.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.134 178.907 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -94.11 120.15 33.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.95 0.405 . . . . 0.0 111.516 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -136.0 157.9 38.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.82 97.79 48.14 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.682 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.441 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 67.1 Cg_endo -72.82 101.31 1.29 Allowed 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.814 2.343 . . . . 0.0 112.15 179.539 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -95.51 1.96 54.15 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -179.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -129.81 134.84 47.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.762 0.315 . . . . 0.0 110.74 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.93 124.25 34.56 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.007 0.432 . . . . 0.0 111.273 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 166.82 -157.3 29.71 Favored Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.63 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -101.64 125.72 48.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.187 0.518 . . . . 0.0 111.487 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.413 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 84.9 m-85 -117.34 171.44 7.97 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.013 179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.3 p -150.22 158.31 44.02 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 -178.765 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -150.4 131.46 14.37 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.957 178.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.36 165.09 26.95 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.075 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.446 ' O ' ' HG3' ' A' ' 116' ' ' MET . 4.1 t -147.74 157.68 43.66 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.008 0.432 . . . . 0.0 111.405 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 88.81 -90.77 1.67 Allowed Glycine 0 CA--C 1.52 0.349 0 C-N-CA 120.893 -0.67 . . . . 0.0 113.195 179.658 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -145.09 -170.03 3.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.745 0.307 . . . . 0.0 111.111 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.56 52.38 1.17 Allowed 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 120.925 0.393 . . . . 0.0 111.676 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -126.59 -17.54 5.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.078 179.776 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' MET . . . . . 0.446 ' HG3' ' O ' ' A' ' 111' ' ' CYS . 0.3 OUTLIER -84.93 164.57 18.27 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.169 179.953 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.36 105.47 3.75 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 111.963 0.357 . . . . 0.0 111.963 -179.757 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -142.95 116.96 1.06 Allowed Glycine 0 CA--C 1.52 0.403 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.882 179.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.502 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.7 ttpt -122.15 148.71 44.58 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.204 0.526 . . . . 0.0 111.904 -179.089 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.413 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.6 ttm -132.4 139.15 47.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.686 179.439 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -122.39 119.72 59.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.116 0.484 . . . . 0.0 110.854 179.586 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 90.9 t -102.97 123.08 56.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.272 -179.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 . . . . . 0 C--O 1.252 1.201 0 CA-C-O 118.169 -0.92 . . . . 0.0 111.42 -179.774 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.994 ' N ' ' HZ1' ' A' ' 31' ' ' LYS . . . . . . . . 0 N--CA 1.498 2.789 0 CA-C-O 121.147 0.304 . . . . 0.0 112.387 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -96.49 -12.19 24.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.918 0.39 . . . . 0.0 111.382 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -132.11 -51.32 0.96 Allowed 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.231 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -103.0 -163.15 25.76 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.851 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 18.4 mm-40 -133.14 130.27 38.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.128 0.489 . . . . 0.0 111.328 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . 0.994 ' HZ1' ' N ' ' A' ' 26' ' ' GLY . 0.2 OUTLIER -89.97 125.59 35.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.709 179.823 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -70.93 152.07 44.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.238 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.52 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 17.2 pt20 -81.27 137.99 35.77 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.214 0.531 . . . . 0.0 111.448 -179.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.2 mp0 -94.53 113.2 25.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.865 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.63 -151.32 0.28 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.191 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -83.81 77.51 9.87 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 112.03 0.382 . . . . 0.0 112.03 -179.223 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.15 -6.49 68.98 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 120.812 -0.709 . . . . 0.0 114.047 178.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.7 p90 -143.54 161.34 38.72 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.045 0.423 . . . . 0.0 111.072 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.19 156.63 21.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.058 0.456 . . . . 0.0 111.349 179.744 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.52 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.4 tt0 -145.75 144.45 30.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.434 -179.566 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.404 ' CG2' HD11 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -146.96 129.04 7.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.732 179.135 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.404 HH11 ' HD2' ' A' ' 42' ' ' ARG . 0.1 OUTLIER -90.9 110.18 21.41 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.252 0.548 . . . . 0.0 110.938 179.305 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 60.6 t -100.42 108.21 22.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.757 -179.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -72.68 124.97 26.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.648 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.7 t -104.64 96.44 4.6 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 CA-C-O 121.475 0.655 . . . . 0.0 111.262 -179.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.44 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.0 ptp -141.97 87.74 2.06 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.373 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.11 -15.88 36.27 Favored Glycine 0 CA--C 1.522 0.482 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.127 -178.035 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 178.79 -138.72 3.71 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.483 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -121.09 129.59 53.38 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.862 0.331 . . . . 0.0 110.59 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.425 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 20.2 m -65.84 -60.93 6.34 Favored Pre-proline 0 CA--C 1.538 0.519 0 C-N-CA 121.027 -0.269 . . . . 0.0 110.911 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.425 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 74.4 Cg_endo -76.79 95.77 1.07 Allowed 'Trans proline' 0 C--N 1.358 1.045 0 C-N-CA 121.333 1.355 . . . . 0.0 110.968 177.575 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.77 -42.73 58.11 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.331 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.476 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.73 118.52 20.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.782 179.52 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.8 pt -97.32 124.45 50.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.085 0.469 . . . . 0.0 110.888 179.501 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.5 t -97.25 126.73 49.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.509 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.3 mt -134.21 170.12 16.17 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.357 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.28 173.73 7.57 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.684 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.6 ttpt -104.29 146.7 28.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.779 0.323 . . . . 0.0 111.844 -179.206 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.4 t 64.97 20.86 12.21 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.832 179.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.44 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 7.9 p -123.44 135.61 26.26 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.935 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.6 Cg_endo -64.34 122.49 10.45 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 122.076 1.85 . . . . 0.0 111.668 178.588 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.25 138.86 54.35 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.877 0.37 . . . . 0.0 111.577 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -121.57 126.79 49.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.769 0.795 . . . . 0.0 111.439 179.932 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.404 HD11 ' CG2' ' A' ' 41' ' ' ILE . 4.0 mm -99.0 115.82 40.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.836 -179.85 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.2 t -91.71 110.25 22.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.216 -179.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -95.59 114.77 26.56 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.076 0.465 . . . . 0.0 111.467 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -99.93 104.48 16.11 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.398 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -77.6 106.54 9.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.274 0.559 . . . . 0.0 112.144 -179.155 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -101.23 -33.83 9.91 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.415 179.293 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.44 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.0 t70 -110.6 133.87 21.04 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.862 179.799 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -81.67 40.29 0.96 Allowed 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 123.086 2.524 . . . . 0.0 112.975 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.41 137.29 93.56 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.308 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -63.03 -35.02 68.24 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.938 2.426 . . . . 0.0 112.941 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.35 -6.68 54.16 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.595 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 58.2 mt -114.32 7.75 16.5 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.426 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -66.18 -38.46 88.09 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.089 0.471 . . . . 0.0 111.451 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 16.5 mt-30 -124.74 158.72 32.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.576 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -133.23 127.79 54.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.379 0.609 . . . . 0.0 110.937 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.68 129.63 58.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.294 0.568 . . . . 0.0 111.105 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -92.9 102.02 6.29 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.402 178.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.26 -16.35 51.42 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.626 2.217 . . . . 0.0 113.77 -178.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 46.5 m-20 -100.71 -6.83 24.48 Favored 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.0 m-85 -120.97 -22.54 6.14 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 81.7 25.45 53.37 Favored Glycine 0 C--N 1.332 0.348 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.07 -179.442 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.1 t -106.48 117.95 53.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.844 0.354 . . . . 0.0 111.663 -178.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -121.16 118.9 30.84 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.598 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.79 167.17 21.36 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.172 0.51 . . . . 0.0 111.945 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -109.38 138.66 45.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.621 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 51.8 mt -101.13 128.46 29.39 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.89 0.376 . . . . 0.0 111.39 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.405 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 74.4 Cg_endo -82.0 128.15 5.68 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 122.768 2.312 . . . . 0.0 112.428 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.4 tpt -66.3 124.55 23.0 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.046 0.451 . . . . 0.0 111.623 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.53 9.3 81.74 Favored Glycine 0 CA--C 1.521 0.418 0 CA-C-N 115.857 -0.611 . . . . 0.0 113.075 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.405 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 50.1 mm-40 -136.9 176.75 8.43 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.903 0.382 . . . . 0.0 111.342 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -112.9 136.32 52.68 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.036 0.446 . . . . 0.0 111.744 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -124.23 126.25 45.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.039 178.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 1.8 p -102.99 138.19 28.2 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-O 121.58 0.705 . . . . 0.0 112.511 -178.778 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 64.5 t -115.51 112.34 39.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.188 178.782 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -93.8 118.99 32.18 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.934 0.397 . . . . 0.0 111.576 -179.307 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.11 156.33 39.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.073 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.4 m -120.03 98.32 49.21 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.461 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.44 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.9 Cg_endo -71.88 99.14 0.94 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.713 2.275 . . . . 0.0 112.561 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -97.7 22.79 8.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.09 0.471 . . . . 0.0 111.515 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.15 131.78 14.89 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.464 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.29 127.29 35.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.983 0.421 . . . . 0.0 111.407 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 164.42 -157.33 29.64 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.759 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.18 126.59 49.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.168 0.509 . . . . 0.0 111.544 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.417 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 86.4 m-85 -119.32 171.99 7.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.891 179.641 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 87.8 p -153.73 159.85 42.11 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -150.53 131.14 13.95 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.093 178.866 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.7 168.49 21.49 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.295 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 5.9 t -146.14 128.38 15.76 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.263 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 73.06 -152.97 47.82 Favored Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.936 -0.65 . . . . 0.0 113.15 179.717 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -135.77 110.28 8.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.839 0.352 . . . . 0.0 111.14 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -163.31 -170.38 2.25 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.903 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -85.35 48.86 1.64 Allowed 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.0 0.429 . . . . 0.0 111.916 -179.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -145.22 142.37 29.48 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.053 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -162.21 139.19 8.14 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.851 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -116.75 136.75 13.0 Favored Glycine 0 CA--C 1.52 0.35 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.639 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 4.5 ttmm -120.01 149.48 42.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.053 0.454 . . . . 0.0 111.229 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.417 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -132.83 140.42 47.95 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.994 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.95 119.77 56.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.061 0.458 . . . . 0.0 110.877 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.9 t -101.89 124.68 55.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.079 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.251 1.158 0 CA-C-O 118.045 -0.979 . . . . 0.0 111.898 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.722 0 N-CA-C 112.4 -0.28 . . . . 0.0 112.4 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -82.96 73.94 9.96 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.148 0.499 . . . . 0.0 111.504 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -100.17 160.3 14.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.368 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -91.06 175.18 39.59 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.831 -0.699 . . . . 0.0 113.063 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -118.97 128.62 54.57 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.187 0.517 . . . . 0.0 111.168 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -88.27 126.58 35.24 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.631 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.03 150.56 45.47 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.141 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.541 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 19.8 pt20 -79.44 137.5 37.27 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.297 0.57 . . . . 0.0 111.283 -179.323 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.5 mp0 -94.52 114.02 25.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.963 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -93.03 -156.08 0.46 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.072 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -83.56 76.91 9.92 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-O 120.851 0.358 . . . . 0.0 111.948 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.25 -12.71 57.19 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 120.806 -0.712 . . . . 0.0 114.151 178.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -140.69 167.47 22.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 117.16 0.48 . . . . 0.0 111.353 -179.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.93 155.0 28.78 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.863 0.363 . . . . 0.0 111.119 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.541 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 5.8 tt0 -145.35 142.23 29.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.562 -179.271 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.39 129.84 17.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.312 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -91.67 110.22 21.54 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.239 0.542 . . . . 0.0 111.058 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 46.4 t -100.48 104.01 15.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.589 -179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.413 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.9 OUTLIER -73.16 116.98 14.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.845 -179.91 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 41.1 t -97.41 98.46 7.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.365 -178.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.418 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.8 ptp -139.6 81.93 1.85 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.383 179.383 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 88.01 -8.98 76.39 Favored Glycine 0 CA--C 1.521 0.429 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 -178.342 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 172.85 -153.36 18.35 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -105.42 125.65 51.23 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.825 0.313 . . . . 0.0 110.54 179.648 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.462 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 45.2 m -65.13 -64.48 2.61 Favored Pre-proline 0 CA--C 1.538 0.518 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.407 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.462 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 60.1 Cg_endo -74.11 97.91 1.05 Allowed 'Trans proline' 0 C--N 1.358 1.039 0 C-N-CA 121.266 1.311 . . . . 0.0 111.001 177.684 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.63 -44.04 57.18 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.163 -179.236 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.449 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.6 118.99 19.88 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.605 0.241 . . . . 0.0 110.959 179.57 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.0 pt -97.07 126.96 49.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 121.054 0.454 . . . . 0.0 110.747 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 84.6 t -98.09 126.93 50.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.505 -179.649 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.8 mt -135.63 166.52 23.05 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.567 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.7 tttt -93.1 170.24 9.8 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.709 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.5 ttpp -100.45 148.25 24.96 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.403 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.2 t 65.84 20.14 11.38 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.917 179.393 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.428 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.2 p -123.8 135.88 26.74 Favored Pre-proline 0 CA--C 1.537 0.445 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.977 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -64.4 122.77 10.8 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.198 1.932 . . . . 0.0 111.575 178.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.67 138.51 53.9 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.956 0.408 . . . . 0.0 111.728 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.421 ' CG ' ' HG3' ' A' ' 40' ' ' GLU . 0.0 OUTLIER -121.06 129.4 53.33 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.767 0.794 . . . . 0.0 111.517 179.739 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.452 HD11 HG22 ' A' ' 64' ' ' ILE . 3.4 mm -100.76 115.69 42.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.817 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.5 t -91.77 111.69 24.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 120.766 0.317 . . . . 0.0 111.326 -179.3 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -97.7 113.22 24.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.053 0.454 . . . . 0.0 111.354 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -98.96 105.19 17.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.215 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -79.09 104.8 9.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.29 0.566 . . . . 0.0 112.22 -178.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.2 tppt? -99.35 -36.09 9.72 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.086 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.418 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 6.4 t70 -103.79 129.86 24.53 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.852 179.562 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -80.49 39.47 0.85 Allowed 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.998 2.465 . . . . 0.0 112.939 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.1 m -69.95 135.67 87.47 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.382 -179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -64.05 -29.9 66.06 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.901 2.401 . . . . 0.0 112.811 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.71 -9.38 58.63 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.599 179.761 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 29.1 mt -113.17 12.52 19.07 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 120.784 0.326 . . . . 0.0 111.321 -179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -67.44 -35.18 78.72 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.785 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -129.48 160.68 32.42 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.805 0.336 . . . . 0.0 111.21 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.67 129.01 33.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.181 0.515 . . . . 0.0 110.85 179.292 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.5 p -132.04 132.4 61.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.276 0.56 . . . . 0.0 111.257 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 15.7 m-85 -94.93 101.92 8.11 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.725 179.032 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -67.09 -15.23 46.05 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.722 2.281 . . . . 0.0 113.562 -178.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 -99.62 -7.34 25.88 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -122.67 -22.13 5.46 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.092 0.405 . . . . 0.0 112.092 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 81.45 26.43 51.33 Favored Glycine 0 CA--C 1.52 0.374 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.044 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.6 t -107.69 117.37 53.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.746 0.307 . . . . 0.0 111.709 -178.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -119.12 117.94 30.05 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.519 179.214 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.67 167.54 19.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.156 0.503 . . . . 0.0 112.222 -179.157 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -111.69 141.2 45.6 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.319 179.562 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 53.1 mt -103.56 127.75 28.89 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.005 0.431 . . . . 0.0 111.566 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.419 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 72.5 Cg_endo -82.94 129.85 5.53 Favored 'Trans proline' 0 CA--C 1.532 0.411 0 C-N-CA 122.846 2.364 . . . . 0.0 112.481 179.271 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.5 tpt -67.58 125.24 25.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.008 0.432 . . . . 0.0 111.71 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 83.29 11.61 80.3 Favored Glycine 0 CA--C 1.52 0.405 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.877 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.419 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 53.7 mm-40 -137.46 176.86 8.33 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.007 0.432 . . . . 0.0 111.157 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -113.37 132.77 55.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.78 -179.716 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -121.75 125.11 45.8 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.967 178.876 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.2 p -105.16 137.06 36.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.549 0.69 . . . . 0.0 112.472 -178.887 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -112.79 112.11 39.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.153 178.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -93.67 119.22 32.4 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.953 0.406 . . . . 0.0 111.416 -179.469 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.91 158.24 38.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.339 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -121.67 96.81 47.11 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.469 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.428 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.9 Cg_endo -71.59 99.44 0.94 Allowed 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.823 2.349 . . . . 0.0 112.294 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -94.07 4.47 53.85 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.995 0.368 . . . . 0.0 111.995 -179.3 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -133.88 135.63 43.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.756 0.313 . . . . 0.0 110.933 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.59 124.9 34.5 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.837 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.35 -167.56 40.51 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.796 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -97.9 114.72 26.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.105 0.479 . . . . 0.0 110.631 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 20.7 m-85 -111.4 172.42 6.9 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.177 -179.754 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 87.1 p -158.17 164.88 36.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.155 0.502 . . . . 0.0 112.196 -178.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -148.26 137.39 21.92 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.762 179.017 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -161.85 153.74 19.12 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.277 -179.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 4.7 t -159.22 161.25 36.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.945 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 84.44 -118.87 4.82 Favored Glycine 0 CA--C 1.52 0.378 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.237 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -154.46 -160.9 1.13 Allowed 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 122.013 0.125 . . . . 0.0 110.85 -179.585 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 68.33 -170.63 0.19 Allowed 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 122.898 0.479 . . . . 0.0 111.828 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.21 65.04 0.95 Allowed 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.933 0.396 . . . . 0.0 111.69 -179.626 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -135.9 136.49 40.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.863 0.363 . . . . 0.0 111.066 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 20.2 p80 -165.5 154.47 12.01 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.24 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -113.15 150.31 18.48 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.047 -0.596 . . . . 0.0 112.055 179.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.449 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.8 ttmt -119.09 150.32 40.2 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.974 0.416 . . . . 0.0 111.359 -179.869 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 2.8 ttm -133.68 133.62 42.1 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.896 179.685 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.13 117.36 53.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.071 0.463 . . . . 0.0 110.753 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 94.7 t -101.65 121.94 53.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.155 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.277 -0.868 . . . . 0.0 111.538 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.703 0 CA-C-O 121.192 0.329 . . . . 0.0 112.347 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.99 37.19 3.91 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.1 0.476 . . . . 0.0 111.439 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 14.5 mtp -82.57 66.33 8.12 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-O 121.056 0.455 . . . . 0.0 111.385 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.69 171.83 23.67 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.854 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -123.83 124.88 43.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.959 0.409 . . . . 0.0 111.502 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.6 ttmt -90.37 126.71 35.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.501 179.565 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.36 151.11 46.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.028 0.442 . . . . 0.0 111.464 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.569 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.7 pt20 -78.28 143.52 36.95 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.379 -179.544 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -98.68 115.33 28.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.855 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.63 -151.62 0.36 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.484 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -81.65 75.52 8.6 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -179.171 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.4 -7.47 68.82 Favored Glycine 0 CA--C 1.523 0.573 0 C-N-CA 120.72 -0.753 . . . . 0.0 114.047 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -141.35 161.48 37.78 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.959 0.38 . . . . 0.0 110.981 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.06 155.71 22.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.102 0.477 . . . . 0.0 111.154 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.569 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.9 tt0 -144.53 143.89 31.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.616 -179.382 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.411 ' CG2' HD11 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -143.17 128.71 16.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.081 0.467 . . . . 0.0 110.963 178.926 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.69 109.03 20.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.33 0.586 . . . . 0.0 110.962 179.535 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 45.1 t -99.75 103.95 15.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.599 -179.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.402 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 1.1 tp10 -73.17 117.62 15.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.857 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 54.3 t -99.52 98.55 7.18 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.526 -178.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.45 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.3 ptm -145.25 86.97 1.78 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.4 179.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 83.66 -2.51 87.25 Favored Glycine 0 CA--C 1.521 0.407 0 C-N-CA 120.824 -0.703 . . . . 0.0 111.468 -178.429 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.433 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 162.9 -171.17 38.63 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 30.3 m-85 -91.78 124.94 36.29 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.816 0.308 . . . . 0.0 110.354 179.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.471 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 45.0 m -63.99 -64.35 2.95 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 119.638 -0.22 . . . . 0.0 111.407 -179.42 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.471 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 62.1 Cg_endo -74.98 96.88 1.04 Allowed 'Trans proline' 0 C--N 1.357 0.977 0 C-N-CA 121.299 1.333 . . . . 0.0 111.075 177.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.84 -43.19 59.12 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.261 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.433 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.36 118.52 20.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.622 -0.263 . . . . 0.0 110.708 179.667 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.7 pt -98.3 125.43 51.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.031 0.443 . . . . 0.0 111.15 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 75.9 t -98.62 126.71 51.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.425 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.4 mt -132.74 171.5 13.79 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.472 -179.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.95 170.02 9.72 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.549 179.403 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.6 ttpp -102.43 147.06 27.19 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.86 0.362 . . . . 0.0 111.909 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.4 t 65.27 20.46 11.89 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.527 -0.76 . . . . 0.0 111.701 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.417 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 7.4 p -123.66 136.41 27.26 Favored Pre-proline 0 CA--C 1.534 0.356 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.003 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -64.33 122.7 10.72 Favored 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 121.984 1.79 . . . . 0.0 111.412 178.442 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.29 138.49 54.08 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.017 0.437 . . . . 0.0 111.582 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.439 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.9 ptt180 -120.55 127.74 52.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.727 0.775 . . . . 0.0 111.418 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.431 HD11 HG23 ' A' ' 64' ' ' ILE . 3.0 mm -99.4 114.68 38.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.628 179.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.3 t -92.01 110.53 22.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.697 0.284 . . . . 0.0 111.553 -179.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -97.1 120.05 36.72 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.013 0.435 . . . . 0.0 111.233 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -103.93 105.18 15.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.433 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.0 tpt180 -77.77 97.81 5.32 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.161 0.505 . . . . 0.0 111.605 -179.427 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.8 tptp -93.71 -32.93 13.83 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.412 179.428 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.45 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.9 t70 -111.28 131.66 22.13 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.741 179.661 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -80.24 39.33 0.83 Allowed 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 123.075 2.516 . . . . 0.0 112.978 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.13 135.76 91.57 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.159 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.26 -33.28 60.34 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.764 2.309 . . . . 0.0 112.875 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -77.37 -1.97 32.71 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.55 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.433 HD11 ' N ' ' A' ' 48' ' ' GLY . 28.8 mt -119.01 9.13 11.76 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.457 -179.749 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.9 -41.04 78.76 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -122.09 149.37 43.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.028 0.442 . . . . 0.0 111.591 -179.495 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -131.51 129.18 61.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.54 179.238 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 p -132.7 131.35 59.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.439 0.637 . . . . 0.0 111.44 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -92.86 101.93 6.1 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.448 178.649 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.41 -15.52 45.64 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.631 2.221 . . . . 0.0 113.657 -178.465 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -100.12 -9.61 22.38 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.5 m-85 -119.46 -21.41 7.43 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 80.95 28.33 46.34 Favored Glycine 0 CA--C 1.52 0.346 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.074 -179.589 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.4 t -109.44 117.58 54.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.786 0.327 . . . . 0.0 111.731 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -120.59 119.74 33.76 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.428 179.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.72 167.92 20.72 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 121.182 0.515 . . . . 0.0 112.344 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -113.3 143.27 44.72 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.316 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 30.7 mt -103.53 124.35 38.34 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.451 . . . . 0.0 111.599 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.09 130.38 9.33 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.771 2.314 . . . . 0.0 112.662 179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.2 tpt -67.47 124.77 24.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.138 0.494 . . . . 0.0 111.748 -179.597 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 83.53 9.68 82.98 Favored Glycine 0 CA--C 1.521 0.411 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.975 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 51.4 mm-40 -136.21 176.69 8.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.865 0.364 . . . . 0.0 111.284 -179.537 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -114.07 134.72 54.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.013 0.435 . . . . 0.0 111.574 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.7 t80 -122.52 124.09 42.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.036 178.918 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.2 p -104.37 136.99 35.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 CA-C-O 121.563 0.697 . . . . 0.0 112.533 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 54.2 t -112.98 112.11 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.16 179.02 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -93.52 119.57 32.75 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.517 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.6 158.28 39.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.207 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 m -121.51 96.79 47.44 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.525 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.417 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.8 Cg_endo -72.93 101.18 1.29 Allowed 'Trans proline' 0 CA--C 1.532 0.399 0 C-N-CA 122.855 2.37 . . . . 0.0 112.349 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -95.51 5.53 51.31 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 111.898 0.333 . . . . 0.0 111.898 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -132.4 133.97 44.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.763 0.316 . . . . 0.0 110.751 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -90.61 128.26 36.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.983 0.42 . . . . 0.0 111.301 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 162.64 -155.88 27.36 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.694 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -102.19 126.91 49.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.21 0.529 . . . . 0.0 111.468 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.405 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 89.9 m-85 -120.69 173.28 7.3 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.885 179.733 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 14.9 m -154.9 156.91 36.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.197 0.523 . . . . 0.0 112.399 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -146.26 142.21 28.12 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.726 179.246 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.4 178.19 8.87 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.961 0.41 . . . . 0.0 111.68 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 38.3 t -106.78 127.3 53.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.057 0.456 . . . . 0.0 110.76 179.005 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.15 -2.7 74.91 Favored Glycine 0 CA--C 1.525 0.686 0 C-N-CA 121.1 -0.572 . . . . 0.0 113.417 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.7 mtm 58.13 38.49 26.44 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 122.857 0.463 . . . . 0.0 111.805 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -156.16 -48.24 0.08 Allowed 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.044 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -96.08 -175.58 3.43 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.972 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 79.1 mmm 68.5 -179.36 0.22 Allowed 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.052 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -158.17 105.21 1.91 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.875 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -142.23 123.75 2.27 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 111.776 -0.529 . . . . 0.0 111.776 179.309 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.433 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.1 ttpt -119.9 151.68 38.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.122 0.487 . . . . 0.0 112.054 -178.952 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.405 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.4 ttm -135.73 139.76 43.86 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.805 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.32 120.64 59.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.027 0.441 . . . . 0.0 110.667 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 90.2 t -102.88 123.31 56.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.272 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 . . . . . 0 C--O 1.252 1.191 0 CA-C-O 118.184 -0.913 . . . . 0.0 111.416 -179.554 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.669 0 N-CA-C 112.42 -0.272 . . . . 0.0 112.42 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . 58.59 -124.0 1.39 Allowed 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 123.082 0.553 . . . . 0.0 111.961 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER 56.68 49.98 13.49 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 120.99 0.424 . . . . 0.0 111.735 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.99 174.64 52.83 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.91 -0.662 . . . . 0.0 113.302 -179.65 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.53 130.33 50.37 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.026 0.441 . . . . 0.0 111.297 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.22 126.12 35.72 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.753 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.4 148.97 46.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.257 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.575 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 18.6 pt20 -76.49 140.21 41.12 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.269 0.557 . . . . 0.0 111.217 -179.461 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -97.45 115.94 28.72 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.92 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -95.33 -151.91 0.35 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.522 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -82.46 72.88 9.52 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -179.275 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.12 -8.74 61.06 Favored Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.678 -0.773 . . . . 0.0 113.902 178.971 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -139.1 165.29 27.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 117.03 0.415 . . . . 0.0 110.932 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.2 153.07 31.52 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.994 0.426 . . . . 0.0 111.058 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.575 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 6.7 tt0 -144.42 140.49 29.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.412 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.01 130.24 24.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.131 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -90.6 110.06 21.21 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.178 0.513 . . . . 0.0 110.999 179.463 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 53.1 t -102.1 109.84 27.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.738 -179.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.98 123.16 23.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.727 179.793 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 67.2 t -104.25 95.78 4.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-O 121.479 0.656 . . . . 0.0 111.376 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.421 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 6.2 ptm -146.58 87.89 1.74 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.281 179.27 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.52 -0.84 89.22 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.432 -178.321 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 160.57 -144.36 9.88 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 111.5 -0.64 . . . . 0.0 111.5 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -119.1 128.61 54.46 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.774 0.287 . . . . 0.0 110.636 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.441 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 22.0 m -65.61 -61.66 5.52 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-O 119.572 -0.252 . . . . 0.0 110.958 179.775 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.441 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 68.9 Cg_endo -75.91 95.75 1.03 Allowed 'Trans proline' 0 C--N 1.357 0.998 0 C-N-CA 121.325 1.35 . . . . 0.0 111.038 177.742 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.6 -42.13 55.56 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.162 -179.206 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.433 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -133.8 118.99 18.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.83 179.477 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.648 HD12 ' SD ' ' A' ' 120' ' ' MET . 6.0 pt -96.67 126.62 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-O 121.062 0.458 . . . . 0.0 110.969 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 94.8 t -97.72 125.94 50.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.443 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 3.5 mt -135.67 165.03 26.52 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.307 -179.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.6 mmtt -89.01 176.41 7.01 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 120.769 0.318 . . . . 0.0 111.046 179.415 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.8 ttpp -106.93 148.26 28.84 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.834 0.349 . . . . 0.0 111.929 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.4 t 64.73 20.85 12.26 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.644 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.402 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.8 p -123.88 136.17 27.13 Favored Pre-proline 0 CA--C 1.537 0.457 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.998 -179.776 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -63.57 120.87 8.43 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.111 1.874 . . . . 0.0 111.688 178.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.82 138.29 54.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.845 0.355 . . . . 0.0 111.598 -179.425 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -123.19 128.42 50.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.784 0.802 . . . . 0.0 111.537 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.445 HD12 HG23 ' A' ' 64' ' ' ILE . 4.2 mm -99.69 116.31 42.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.883 179.93 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.6 t -91.63 112.56 25.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.812 0.339 . . . . 0.0 111.246 -179.501 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -98.21 116.84 31.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.116 0.484 . . . . 0.0 111.528 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -100.78 103.31 14.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.387 179.468 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.54 102.85 7.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.247 0.546 . . . . 0.0 112.157 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.5 tptp -97.44 -38.37 9.63 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.588 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.421 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.0 t70 -103.0 130.72 23.13 Favored Pre-proline 0 CA--C 1.535 0.375 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.95 179.68 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -81.31 39.43 0.86 Allowed 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 123.099 2.532 . . . . 0.0 113.209 -179.394 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 29.1 t -70.5 135.16 86.35 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.263 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.15 -26.85 64.91 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.673 2.249 . . . . 0.0 112.519 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.3 m -80.24 -10.93 59.77 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.131 179.631 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 24.0 mt -113.9 13.7 18.39 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.213 -180.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -70.21 -34.15 72.57 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.575 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -127.21 161.88 27.5 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.969 0.414 . . . . 0.0 111.511 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -138.76 127.97 30.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.338 178.477 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.404 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 1.5 p -131.72 130.08 61.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.282 0.563 . . . . 0.0 111.545 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -92.65 101.84 5.8 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.279 178.576 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.94 -13.32 38.04 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 122.566 2.177 . . . . 0.0 113.64 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -100.49 -11.72 19.92 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 111.929 0.344 . . . . 0.0 111.929 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -120.77 -17.82 7.85 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -178.972 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.78 29.24 52.68 Favored Glycine 0 C--N 1.333 0.371 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.541 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 54.2 t -109.06 113.59 44.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.81 0.338 . . . . 0.0 111.748 -179.113 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -117.93 117.44 29.27 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.401 179.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.57 167.59 20.19 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-O 121.342 0.591 . . . . 0.0 112.44 -179.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -110.1 139.8 44.86 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.257 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 46.3 mt -102.89 126.61 32.08 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.943 0.402 . . . . 0.0 111.481 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.416 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 70.1 Cg_endo -81.03 128.79 6.63 Favored 'Trans proline' 0 CA--C 1.532 0.393 0 C-N-CA 122.794 2.33 . . . . 0.0 112.414 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -65.92 124.83 23.56 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 121.042 0.449 . . . . 0.0 111.837 -179.497 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.94 9.6 84.17 Favored Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.923 -0.581 . . . . 0.0 113.055 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.416 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 47.5 mt-10 -135.14 176.79 8.34 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-O 120.94 0.4 . . . . 0.0 111.08 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -113.12 134.63 54.46 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.981 0.42 . . . . 0.0 111.799 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.9 t80 -123.22 126.59 47.23 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.899 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 2.2 p -106.15 138.87 29.47 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 CA-C-O 121.527 0.679 . . . . 0.0 112.64 -178.721 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.8 t -114.22 112.3 39.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.164 178.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -94.76 119.1 32.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.018 0.437 . . . . 0.0 111.626 -179.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.03 157.57 40.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.273 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.8 m -120.73 96.67 48.75 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.326 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.402 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 71.6 Cg_endo -73.31 102.68 1.5 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.81 2.34 . . . . 0.0 112.434 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -97.71 10.6 39.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.902 0.382 . . . . 0.0 111.9 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.26 130.25 30.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.851 0.358 . . . . 0.0 110.874 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.07 128.22 35.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.372 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 165.79 -155.15 26.26 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.847 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -107.96 125.63 51.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.122 0.487 . . . . 0.0 111.012 -179.639 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -124.29 166.92 15.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.305 -179.74 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.19 157.9 43.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.182 0.515 . . . . 0.0 112.29 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -146.36 135.57 22.75 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.623 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.2 164.81 27.57 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 120.799 0.333 . . . . 0.0 111.406 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 1.2 t -151.92 178.84 9.0 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.059 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 97.35 -160.29 21.29 Favored Glycine 0 CA--C 1.519 0.326 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.879 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -100.71 -28.08 13.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.843 0.354 . . . . 0.0 111.506 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.87 178.0 9.33 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.814 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 2.4 ttm 62.8 -141.68 0.39 Allowed 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.43 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 73.35 151.13 0.11 Allowed 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.239 0.616 . . . . 0.0 112.038 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 5.4 t-80 -157.88 105.06 1.96 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.549 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -140.97 115.18 1.0 Allowed Glycine 0 CA--C 1.521 0.434 0 C-N-CA 121.115 -0.564 . . . . 0.0 111.794 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.433 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.0 ttpt -118.28 149.7 40.7 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.223 0.535 . . . . 0.0 111.783 -179.414 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.648 ' SD ' HD12 ' A' ' 54' ' ' ILE . 10.1 ttp -134.36 130.73 37.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.657 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -117.61 118.78 59.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.038 0.447 . . . . 0.0 111.097 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 57.8 t -101.29 119.83 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.886 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.005 -0.998 . . . . 0.0 112.063 -179.622 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.67 0 CA-C-O 121.191 0.328 . . . . 0.0 112.339 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.16 -38.31 12.22 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.904 0.383 . . . . 0.0 111.325 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 4.1 mmm -91.09 57.58 3.49 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 121.071 0.462 . . . . 0.0 111.272 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.2 -172.37 25.35 Favored Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.765 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.91 128.65 26.86 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.066 0.46 . . . . 0.0 111.454 179.819 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 8.4 ttmt -91.43 128.45 37.26 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.788 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.8 152.22 41.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.163 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 -82.75 141.51 32.32 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.206 0.527 . . . . 0.0 111.555 -179.403 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -95.34 115.69 27.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.805 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.71 -150.87 0.33 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.245 -179.831 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -83.11 78.0 9.66 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.85 -6.34 73.31 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.94 -0.648 . . . . 0.0 114.111 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -143.35 161.88 37.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 117.039 0.419 . . . . 0.0 111.094 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.11 155.56 21.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.982 0.42 . . . . 0.0 111.081 179.603 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -146.01 140.31 26.76 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.7 -179.17 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . 0.405 ' CG2' HD13 ' A' ' 64' ' ' ILE . 0.2 OUTLIER -142.06 130.12 21.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.791 179.108 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.407 HH11 ' HD2' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -91.5 111.05 22.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.192 0.52 . . . . 0.0 111.113 179.535 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 44.9 t -100.54 103.8 15.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.681 -179.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -72.27 115.31 11.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.602 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 53.8 t -97.68 98.74 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.489 0.662 . . . . 0.0 111.432 -178.686 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.51 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.6 ptm -145.76 89.51 1.91 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.502 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.3 -0.89 83.26 Favored Glycine 0 CA--C 1.521 0.418 0 C-N-CA 120.869 -0.681 . . . . 0.0 111.59 -178.402 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.407 ' N ' HD13 ' A' ' 75' ' ' LEU . . . 161.83 -173.29 38.16 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -90.14 124.66 35.01 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.896 0.348 . . . . 0.0 110.17 179.479 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.458 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 31.7 m -63.36 -63.9 3.54 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 119.648 -0.215 . . . . 0.0 111.317 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.458 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 63.5 Cg_endo -75.63 96.97 1.07 Allowed 'Trans proline' 0 C--N 1.358 1.038 0 C-N-CA 121.267 1.312 . . . . 0.0 111.068 177.506 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.61 -43.31 56.77 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 116.057 -0.519 . . . . 0.0 112.38 -179.222 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.457 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.39 118.58 19.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.655 179.684 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.609 HD13 ' SD ' ' A' ' 120' ' ' MET . 5.6 pt -97.67 125.72 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-O 121.085 0.469 . . . . 0.0 111.037 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 83.9 t -97.76 126.67 50.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.36 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 3.3 mt -135.76 171.42 14.49 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.494 -179.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 14.5 mttt -93.63 174.58 7.12 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.978 179.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.8 ttpt -106.46 147.88 28.81 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.852 0.358 . . . . 0.0 111.891 -179.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.0 t 65.08 19.72 11.88 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.641 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.413 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.5 135.93 26.64 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -63.45 122.35 10.47 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.118 1.878 . . . . 0.0 111.464 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.85 139.41 54.0 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.931 0.396 . . . . 0.0 111.728 -179.528 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.412 HH11 ' HD2' ' A' ' 63' ' ' ARG . 3.3 ptt180 -122.3 128.29 50.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.769 0.795 . . . . 0.0 111.389 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.431 HD13 HG21 ' A' ' 64' ' ' ILE . 3.6 mm -101.58 113.62 38.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.759 179.93 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 3.0 t -88.82 106.91 17.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.507 -179.192 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -94.03 113.24 25.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.016 0.436 . . . . 0.0 111.258 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -99.52 104.35 16.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.522 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.7 94.97 5.17 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.231 0.539 . . . . 0.0 111.498 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -88.6 -35.05 17.09 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.829 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.51 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 0.2 OUTLIER -111.55 136.82 21.03 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.083 179.906 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -81.01 39.47 0.87 Allowed 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 123.105 2.537 . . . . 0.0 113.288 -179.371 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.9 m -67.46 133.68 92.94 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.175 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -63.03 -32.23 75.89 Favored 'Trans proline' 0 C--N 1.348 0.551 0 C-N-CA 122.693 2.262 . . . . 0.0 112.776 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.58 -2.48 32.73 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.547 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . 0.407 HD13 ' N ' ' A' ' 48' ' ' GLY . 49.9 mt -121.21 13.77 11.23 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.291 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -70.63 -41.59 72.01 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.764 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -124.72 138.48 54.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.892 0.377 . . . . 0.0 111.586 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -118.78 130.35 73.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.593 179.287 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . 0.603 ' O ' ' HD3' ' A' ' 81' ' ' PRO . 0.2 OUTLIER -134.83 131.79 53.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.386 0.612 . . . . 0.0 111.316 179.978 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -92.84 101.59 5.53 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.42 178.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . 0.603 ' HD3' ' O ' ' A' ' 79' ' ' VAL . 25.5 Cg_exo -61.82 -17.66 56.42 Favored 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 123.024 2.482 . . . . 0.0 113.748 -178.716 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -101.2 -10.22 20.58 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -119.55 -21.38 7.39 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 85.66 1.49 87.43 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 121.248 -0.501 . . . . 0.0 112.226 -179.449 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.9 t -80.72 115.24 22.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.893 0.378 . . . . 0.0 111.41 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 20.5 p-80 -131.29 121.63 25.06 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.602 179.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -141.15 161.91 36.75 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -99.53 127.11 45.6 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.115 179.208 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 57.5 mt -84.4 130.22 54.71 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-O 121.059 0.457 . . . . 0.0 111.844 -178.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -79.04 123.54 5.72 Favored 'Trans proline' 0 CA--C 1.533 0.461 0 C-N-CA 122.704 2.27 . . . . 0.0 112.236 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.1 tpt -64.16 124.96 23.01 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.7 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.86 6.25 85.43 Favored Glycine 0 CA--C 1.521 0.426 0 CA-C-N 115.886 -0.597 . . . . 0.0 113.081 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -132.96 176.87 8.11 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.984 0.421 . . . . 0.0 111.081 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.6 mp0 -115.97 132.17 56.73 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.478 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -120.51 117.95 28.98 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.333 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . . . . . . . . . 3.4 p -96.0 130.34 44.83 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 CA-C-O 121.764 0.792 . . . . 0.0 112.062 -179.429 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 52.9 t -106.17 115.24 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.426 179.167 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -95.81 119.17 33.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.871 0.367 . . . . 0.0 111.631 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -134.09 157.15 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.107 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.4 m -120.0 97.06 49.5 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.517 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.413 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.9 Cg_endo -73.22 98.06 0.99 Allowed 'Trans proline' 0 CA--C 1.532 0.402 0 C-N-CA 122.78 2.32 . . . . 0.0 112.531 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -96.51 23.44 6.83 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.014 0.435 . . . . 0.0 111.481 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.5 131.91 14.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.521 179.66 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.71 128.46 36.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.986 0.422 . . . . 0.0 111.495 -179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.57 -158.64 31.15 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.632 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -101.82 123.46 45.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.048 0.452 . . . . 0.0 111.352 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.401 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 88.2 m-85 -115.9 166.19 12.24 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.019 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 95.5 p -141.57 155.73 45.75 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -178.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -151.57 129.56 11.78 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.389 178.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.59 177.77 9.14 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 121.123 0.487 . . . . 0.0 111.904 -179.346 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 34.6 t -116.33 132.12 56.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.615 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -77.24 75.65 1.74 Allowed Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.191 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.78 -60.31 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.774 0.321 . . . . 0.0 111.437 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -151.36 -86.08 0.07 Allowed 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 120.689 0.28 . . . . 0.0 111.458 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 2.1 ttm -124.8 111.99 16.17 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.923 0.392 . . . . 0.0 111.362 -179.72 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 1.8 mmt -131.49 156.81 45.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.835 179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.14 105.34 3.5 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 120.902 0.382 . . . . 0.0 111.874 -179.835 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -144.64 115.05 0.83 Allowed Glycine 0 CA--C 1.519 0.334 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.946 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.457 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 6.8 ttpt -120.88 149.82 42.01 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.265 0.555 . . . . 0.0 111.785 -179.201 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.609 ' SD ' HD13 ' A' ' 54' ' ' ILE . 17.2 ttp -133.02 133.65 43.37 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.701 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -118.82 119.66 61.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.111 0.481 . . . . 0.0 111.08 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 92.5 t -102.61 121.86 54.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.946 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.25 1.106 0 CA-C-O 118.147 -0.93 . . . . 0.0 111.937 -179.428 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.711 0 N-CA-C 112.328 -0.309 . . . . 0.0 112.328 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -89.49 -36.18 15.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.754 -0.223 . . . . 0.0 111.447 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 59.88 -160.62 0.29 Allowed 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.95 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.86 152.54 30.16 Favored Glycine 0 C--N 1.331 0.293 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.663 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -116.32 128.93 55.98 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.321 0.582 . . . . 0.0 111.527 -179.452 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.4 mtpt -89.19 130.17 35.65 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.736 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.41 151.85 41.01 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.388 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLN . . . . . 0.567 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.6 pt20 -80.33 141.06 35.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.036 0.445 . . . . 0.0 111.4 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 56.4 mt-30 -96.83 115.03 26.73 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.73 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.76 -149.99 0.31 Allowed 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.454 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -81.58 72.68 8.63 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -179.132 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.03 -6.11 66.44 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 120.806 -0.711 . . . . 0.0 113.875 178.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -140.92 160.67 39.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.894 0.347 . . . . 0.0 110.788 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.15 156.08 21.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.136 0.493 . . . . 0.0 111.379 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.567 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.5 tt0 -144.31 143.2 30.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.513 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -143.73 128.42 14.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.065 0.459 . . . . 0.0 111.053 179.089 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.75 106.5 18.5 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.152 0.501 . . . . 0.0 111.078 179.689 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 49.0 t -98.09 101.99 12.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.557 -179.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -71.59 117.81 13.63 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.796 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' VAL . . . . . . . . . . . . . 31.8 t -99.49 98.22 6.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.394 -178.782 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' MET . . . . . 0.448 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 10.8 ptp -140.38 82.3 1.85 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.333 179.499 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 88.0 -12.14 64.97 Favored Glycine 0 CA--C 1.517 0.194 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -178.017 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . 0.432 ' HA2' ' SD ' ' A' ' 116' ' ' MET . . . 173.27 -171.43 44.46 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 179.502 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -88.41 123.02 32.55 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.973 0.386 . . . . 0.0 110.265 179.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' THR . . . . . 0.457 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 35.5 m -61.99 -63.45 4.23 Favored Pre-proline 0 CA--C 1.54 0.558 0 CA-C-O 119.559 -0.257 . . . . 0.0 111.359 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' PRO . . . . . 0.457 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 73.6 Cg_endo -75.76 96.74 1.06 Allowed 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 121.296 1.331 . . . . 0.0 111.013 177.501 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -50.57 -43.13 56.26 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -179.252 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.431 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -130.41 118.8 21.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.659 0.266 . . . . 0.0 110.866 179.775 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.0 pt -98.8 126.31 52.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.079 0.466 . . . . 0.0 110.984 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 91.9 t -97.13 126.46 49.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.925 0.393 . . . . 0.0 111.532 -179.704 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 8.3 mt -133.98 168.33 18.99 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.38 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.6 tttt -95.09 168.28 10.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.508 179.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 4.6 ttpp -99.18 147.89 24.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 111.964 -179.423 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.4 t 65.78 19.83 11.39 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.874 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.443 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 6.3 p -123.71 135.63 26.41 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.895 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -64.52 123.36 11.64 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.104 1.869 . . . . 0.0 111.53 178.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.61 138.82 54.29 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.893 0.378 . . . . 0.0 111.703 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' ARG . . . . . 0.406 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.8 ptt180 -120.4 126.63 50.94 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-O 121.706 0.765 . . . . 0.0 111.274 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ILE . . . . . 0.463 HD11 HG22 ' A' ' 64' ' ' ILE . 3.2 mm -99.42 115.48 40.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.801 -179.911 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' VAL . . . . . . . . . . . . . 4.0 t -91.17 109.55 21.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.825 0.345 . . . . 0.0 111.287 -179.342 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -96.78 112.23 24.07 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.075 0.464 . . . . 0.0 111.431 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -96.74 101.63 13.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.281 179.517 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.77 97.91 4.64 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 121.281 0.563 . . . . 0.0 111.918 -179.12 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -95.98 -29.56 14.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.828 179.715 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ASP . . . . . 0.448 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.8 t70 -111.75 131.79 22.23 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.922 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -80.63 39.45 0.86 Allowed 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.085 2.523 . . . . 0.0 113.121 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.7 m -69.75 139.1 88.33 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.289 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -62.61 -33.85 76.41 Favored 'Trans proline' 0 C--N 1.348 0.553 0 C-N-CA 122.883 2.389 . . . . 0.0 112.863 -179.6 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 10.7 p -78.59 -2.57 39.56 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.45 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 37.9 mt -121.14 9.94 10.59 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.32 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.93 -37.29 78.8 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.059 0.457 . . . . 0.0 111.118 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -129.34 160.06 34.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.515 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -133.49 128.5 54.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.339 0.59 . . . . 0.0 111.018 179.44 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -132.39 128.83 58.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 121.312 0.577 . . . . 0.0 111.071 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -92.54 102.08 6.1 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.47 -0.787 . . . . 0.0 109.537 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.79 -16.24 49.58 Favored 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.581 2.187 . . . . 0.0 113.598 -178.436 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -100.68 -6.37 25.22 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 111.984 0.364 . . . . 0.0 111.984 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -121.38 -22.98 5.8 Favored 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.25 25.33 51.95 Favored Glycine 0 CA--C 1.52 0.355 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.032 -179.473 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.0 t -106.6 117.7 52.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.813 0.339 . . . . 0.0 111.684 -178.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -121.1 117.52 27.38 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.52 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.82 165.83 24.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.138 0.494 . . . . 0.0 112.025 -179.292 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -107.38 140.56 40.11 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.474 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 58.9 mt -102.07 129.56 26.11 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.986 0.422 . . . . 0.0 111.363 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' PRO . . . . . 0.409 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 74.3 Cg_endo -82.7 126.2 4.53 Favored 'Trans proline' 0 CA--C 1.533 0.426 0 C-N-CA 122.723 2.282 . . . . 0.0 112.341 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.7 tpt -64.72 124.23 21.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.023 0.439 . . . . 0.0 111.789 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.65 5.23 84.6 Favored Glycine 0 CA--C 1.521 0.424 0 CA-C-N 115.87 -0.605 . . . . 0.0 113.195 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.409 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 44.8 mt-10 -133.29 176.78 8.21 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.959 0.409 . . . . 0.0 111.181 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.74 132.63 55.13 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.834 -179.747 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -118.98 125.43 49.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.982 178.912 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' VAL . . . . . 0.404 ' O ' HG12 ' A' ' 96' ' ' VAL . 1.8 p -101.68 136.31 34.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.672 0.749 . . . . 0.0 112.462 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 61.5 t -113.26 112.31 39.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.069 178.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -93.27 118.72 31.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.511 -179.498 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -135.23 156.98 39.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.215 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.36 97.4 48.97 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.573 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' PRO . . . . . 0.443 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 66.7 Cg_endo -72.19 100.06 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.794 2.329 . . . . 0.0 112.36 179.544 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -96.11 10.36 37.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.854 0.359 . . . . 0.0 111.9 -179.521 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.03 132.45 32.22 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.51 -0.314 . . . . 0.0 110.779 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.38 127.3 35.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.018 0.437 . . . . 0.0 111.314 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.78 -157.24 29.41 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.624 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -101.73 126.81 48.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.127 0.489 . . . . 0.0 111.668 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' PHE . . . . . 0.414 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 86.0 m-85 -119.64 173.76 6.82 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.67 -0.696 . . . . 0.0 109.815 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 41.9 p -154.7 160.86 41.64 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -178.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.8 p90 -152.79 133.99 14.23 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.89 178.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -163.62 177.73 8.52 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-O 121.05 0.452 . . . . 0.0 111.879 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 33.7 t -148.65 127.45 12.59 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.553 179.017 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 68.51 -145.48 44.03 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.949 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 2.7 tpt -153.47 75.55 1.06 Allowed 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 121.043 0.449 . . . . 0.0 111.062 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -119.35 41.3 3.13 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.363 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 1.6 ttp 59.11 37.73 24.06 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.109 0.481 . . . . 0.0 111.714 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' MET . . . . . 0.432 ' SD ' ' HA2' ' A' ' 48' ' ' GLY . 2.5 ttp -139.55 135.64 33.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.654 -179.773 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -158.24 135.31 9.96 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.383 -179.6 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -102.05 150.01 18.12 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 121.087 -0.578 . . . . 0.0 111.748 178.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' LYS . . . . . 0.431 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.4 ttpt -126.84 150.82 49.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.071 0.463 . . . . 0.0 111.568 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' MET . . . . . 0.414 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -134.22 141.01 46.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.043 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.7 mp -124.66 120.22 58.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.984 0.421 . . . . 0.0 110.706 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.0 t -103.25 124.34 57.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.238 -179.675 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 . . . . . 0 C--O 1.252 1.216 0 CA-C-O 118.106 -0.949 . . . . 0.0 111.46 -179.601 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 121.105 0.479 . . . . 0.0 111.325 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.34 129.36 35.89 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.525 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.46 153.58 40.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.187 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.572 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 4.5 pt20 -80.74 135.53 36.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.185 0.517 . . . . 0.0 111.279 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 19.7 mt-30 -94.05 112.39 24.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.601 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.42 -154.28 0.4 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.389 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -81.95 75.81 8.87 Favored 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.12 -5.36 63.23 Favored Glycine 0 CA--C 1.522 0.518 0 C-N-CA 120.772 -0.728 . . . . 0.0 114.121 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 26.9 p90 -144.35 163.76 32.79 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 117.063 0.431 . . . . 0.0 110.958 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.13 154.81 28.26 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.991 0.424 . . . . 0.0 111.452 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.572 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.6 tt0 -145.26 141.59 28.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.515 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.63 128.59 14.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.863 179.024 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.3 109.97 21.26 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.207 0.527 . . . . 0.0 111.117 179.584 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.647 HG13 ' HD2' ' A' ' 51' ' ' PRO . 44.9 t -98.22 103.37 14.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.488 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.424 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.8 OUTLIER -70.93 114.23 8.78 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.792 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.59 HG13 HD22 ' A' ' 75' ' ' LEU . 49.3 t -96.61 97.73 6.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.461 -178.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.496 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.2 ptm -144.25 86.98 1.86 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.52 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.47 -0.53 89.06 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.833 -0.698 . . . . 0.0 111.434 -178.443 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.427 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 161.9 -170.33 37.55 Favored Glycine 0 N--CA 1.448 -0.522 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -93.07 124.24 36.9 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.793 0.297 . . . . 0.0 110.213 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.509 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 37.1 m -63.42 -63.65 3.8 Favored Pre-proline 0 CA--C 1.539 0.527 0 CA-C-O 119.642 -0.218 . . . . 0.0 111.431 -179.589 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.647 ' HD2' HG13 ' A' ' 43' ' ' VAL . 60.7 Cg_endo -74.99 96.58 1.02 Allowed 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 121.312 1.341 . . . . 0.0 111.055 177.612 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.65 -43.44 57.17 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.069 -179.351 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.39 118.68 19.68 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.654 179.443 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.3 pt -97.8 126.78 50.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.913 0.387 . . . . 0.0 110.929 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 95.9 t -100.09 127.24 53.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.953 0.406 . . . . 0.0 111.557 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.438 HD22 ' HB1' ' A' ' 62' ' ' ALA . 2.3 mt -136.87 166.92 22.48 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.279 -179.633 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -89.62 176.89 6.69 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 120.745 0.307 . . . . 0.0 110.897 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.9 ttpp -107.55 149.53 27.9 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 111.972 0.36 . . . . 0.0 111.972 -179.463 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.7 t 65.55 19.51 11.51 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.725 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.44 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.5 p -123.82 136.26 27.19 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.11 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -64.26 122.61 10.62 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.247 1.965 . . . . 0.0 111.641 178.528 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.438 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -124.66 138.34 54.31 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.926 0.394 . . . . 0.0 111.723 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.502 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -120.49 127.42 52.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.643 0.735 . . . . 0.0 111.626 179.825 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.4 mm -100.2 114.23 38.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.623 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.511 HG22 HG23 ' A' ' 96' ' ' VAL . 2.8 t -90.64 107.41 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.739 0.304 . . . . 0.0 111.492 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -94.77 102.62 14.51 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.918 0.39 . . . . 0.0 111.279 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -91.17 106.94 18.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.435 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -77.46 105.28 8.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.287 0.565 . . . . 0.0 111.903 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.3 tptp -97.76 -34.28 10.96 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.256 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.496 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.7 t70 -110.27 134.38 20.8 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.848 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -81.42 40.1 0.94 Allowed 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.111 2.54 . . . . 0.0 112.995 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.61 135.37 90.47 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.387 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.27 -32.88 61.41 Favored 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 122.772 2.315 . . . . 0.0 112.802 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.1 p -77.09 -2.15 32.73 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.364 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.59 HD22 HG13 ' A' ' 45' ' ' VAL . 33.4 mt -119.29 13.56 12.8 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.242 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.14 -36.38 72.06 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.078 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.84 152.67 48.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.896 0.379 . . . . 0.0 111.503 -179.447 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -132.79 128.48 57.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.103 0.478 . . . . 0.0 110.727 179.196 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.4 130.61 65.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 121.258 0.551 . . . . 0.0 111.346 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -93.17 102.12 6.72 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.715 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.55 -14.36 41.96 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.621 2.214 . . . . 0.0 113.593 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -100.65 -7.57 23.77 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 111.809 0.299 . . . . 0.0 111.809 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -122.63 -22.77 5.3 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 112.058 0.392 . . . . 0.0 112.058 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.25 25.75 50.44 Favored Glycine 0 C--N 1.331 0.302 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.025 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.7 t -106.5 117.79 52.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.887 0.375 . . . . 0.0 111.71 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -121.67 118.52 29.37 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.388 179.323 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.38 162.53 34.19 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.084 0.468 . . . . 0.0 112.257 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 14.2 p-10 -104.19 148.28 26.48 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.679 179.604 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 29.5 mt -107.18 130.8 22.33 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.938 0.399 . . . . 0.0 111.716 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.418 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.3 Cg_endo -82.34 127.99 5.37 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.743 2.296 . . . . 0.0 112.434 179.176 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.5 tpt -66.62 125.4 25.65 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-O 121.025 0.441 . . . . 0.0 111.693 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.81 1.37 80.21 Favored Glycine 0 CA--C 1.52 0.344 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.842 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.418 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 41.7 mt-10 -134.24 177.17 7.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.895 0.379 . . . . 0.0 110.787 -179.484 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -118.14 133.33 56.0 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.197 0.522 . . . . 0.0 111.639 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.1 t80 -112.16 123.28 49.92 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.127 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.511 HG23 HG22 ' A' ' 65' ' ' VAL . 1.5 p -97.78 135.24 33.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.609 0.719 . . . . 0.0 112.304 -179.207 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 62.6 t -112.49 109.69 29.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.027 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -92.08 117.17 29.58 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.228 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -131.58 165.8 30.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.237 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.3 m -128.1 96.22 32.04 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.426 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.44 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.4 Cg_endo -72.2 98.88 0.95 Allowed 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.803 2.336 . . . . 0.0 112.454 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -95.27 7.78 45.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.832 0.349 . . . . 0.0 111.838 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.39 130.97 31.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.753 0.311 . . . . 0.0 110.931 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -85.3 124.8 32.34 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.199 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 171.71 -166.53 39.51 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.863 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.76 114.89 27.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.036 0.446 . . . . 0.0 110.732 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -110.49 174.84 5.67 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.233 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 91.6 p -153.45 164.15 38.69 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.419 0.525 . . . . 0.0 112.419 -178.642 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 36.8 p90 -150.85 137.67 19.0 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.481 178.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.261 0 CA-C-O 120.982 0.42 . . . . 0.0 111.708 -179.311 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.8 ttmm . . . . . 0 CA--C 1.53 0.177 0 CA-C-O 121.235 0.54 . . . . 0.0 111.891 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 2.2 ttm -134.65 136.26 42.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.797 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -120.99 118.2 55.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.006 0.432 . . . . 0.0 110.804 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 71.9 t -102.82 121.33 53.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.177 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.254 1.306 0 CA-C-O 118.335 -0.84 . . . . 0.0 111.396 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.531 0.217 0 CA-C-O 121.018 0.437 . . . . 0.0 111.289 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -90.49 126.67 35.99 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.787 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.26 151.88 43.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.15 179.663 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.586 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 7.7 pt20 -82.24 140.18 33.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.178 0.513 . . . . 0.0 111.545 -179.183 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 6.8 mp0 -95.46 113.25 24.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.488 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 6.1 mmtt -93.2 -148.68 0.25 Allowed 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.474 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -81.64 72.81 8.69 Favored 'General case' 0 CA--C 1.535 0.373 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.19 -5.71 68.37 Favored Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.845 178.978 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -141.27 160.46 40.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.864 0.332 . . . . 0.0 110.751 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.98 156.23 19.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.197 0.522 . . . . 0.0 111.351 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.586 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 4.2 tt0 -145.9 142.44 28.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.445 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.5 129.61 16.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.194 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -90.23 106.56 18.57 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.012 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.58 HG13 ' HD2' ' A' ' 51' ' ' PRO . 46.1 t -97.81 103.01 14.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.604 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.47 117.48 14.18 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.974 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.545 HG13 HD22 ' A' ' 75' ' ' LEU . 42.3 t -100.4 99.04 7.69 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 CA-C-O 121.535 0.683 . . . . 0.0 111.484 -178.798 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.448 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.5 ptp -141.27 85.63 1.98 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.222 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 87.56 -14.65 57.6 Favored Glycine 0 CA--C 1.519 0.313 0 N-CA-C 111.104 -0.798 . . . . 0.0 111.104 -177.993 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 176.89 -152.5 12.37 Favored Glycine 0 N--CA 1.449 -0.452 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -104.91 127.98 52.96 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.82 0.31 . . . . 0.0 110.56 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.513 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 43.0 m -69.15 -63.72 1.97 Allowed Pre-proline 0 CA--C 1.539 0.535 0 CA-C-O 119.571 -0.252 . . . . 0.0 111.368 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.58 ' HD2' HG13 ' A' ' 43' ' ' VAL . 61.9 Cg_endo -74.39 98.09 1.08 Allowed 'Trans proline' 0 C--N 1.357 1.012 0 C-N-CA 121.295 1.33 . . . . 0.0 111.121 177.817 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.25 -43.86 61.62 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.991 -0.549 . . . . 0.0 112.326 -179.181 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -133.89 118.53 18.05 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.559 0.218 . . . . 0.0 110.776 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.493 HG13 ' HG3' ' A' ' 120' ' ' MET . 8.6 pt -97.33 127.55 49.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.1 0.476 . . . . 0.0 111.004 179.504 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.5 t -96.04 126.43 48.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.472 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 24.3 mt -133.44 166.4 22.62 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.425 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 18.6 mttt -96.74 166.75 11.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.563 179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.3 ttpp -97.52 147.74 23.95 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.9 t 66.73 18.8 10.74 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.861 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.45 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 6.0 p -123.56 135.16 25.82 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.914 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -64.58 122.73 10.71 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.051 1.834 . . . . 0.0 111.611 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.24 138.94 54.34 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.834 0.35 . . . . 0.0 111.561 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.486 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.5 ptt180 -121.15 126.76 50.54 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.638 0.732 . . . . 0.0 111.394 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.8 mm -98.64 114.36 36.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.822 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.501 HG22 HG23 ' A' ' 96' ' ' VAL . 3.2 t -91.47 109.84 21.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.375 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -96.15 117.37 30.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.132 0.491 . . . . 0.0 111.332 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.6 t0 -99.94 100.31 11.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.412 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.37 93.0 3.41 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 121.225 0.536 . . . . 0.0 111.455 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -88.74 -37.43 15.49 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.752 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.448 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.2 t70 -101.75 129.44 26.61 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.763 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -79.23 38.63 0.74 Allowed 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 123.088 2.525 . . . . 0.0 113.014 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -70.52 135.35 86.27 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.015 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -63.47 -31.57 71.68 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.789 2.326 . . . . 0.0 112.888 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -75.85 -9.45 58.61 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.46 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.545 HD22 HG13 ' A' ' 45' ' ' VAL . 36.7 mt -113.22 13.99 19.3 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.466 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -70.13 -38.44 75.55 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.782 0.325 . . . . 0.0 111.709 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -122.64 158.82 29.17 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.113 0.482 . . . . 0.0 111.435 -179.586 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.86 130.12 35.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.444 178.791 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 2.0 p -133.27 132.3 58.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.314 0.578 . . . . 0.0 111.43 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -94.08 101.89 7.21 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.516 178.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -67.32 -14.03 41.44 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.589 2.193 . . . . 0.0 113.566 -178.445 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 33.1 m-20 -100.23 -9.14 22.75 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -122.87 -20.07 5.96 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.76 30.65 42.91 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.353 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 49.8 t -110.8 116.44 52.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.828 0.347 . . . . 0.0 111.733 -179.018 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -119.86 121.12 38.37 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.47 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.92 172.19 13.38 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 -112.66 142.36 45.36 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.461 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 41.0 mt -105.73 122.79 41.39 Favored Pre-proline 0 CA--C 1.531 0.246 0 CA-C-O 121.094 0.473 . . . . 0.0 111.544 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.426 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 67.2 Cg_endo -78.13 132.72 11.72 Favored 'Trans proline' 0 CA--C 1.531 0.326 0 C-N-CA 122.921 2.414 . . . . 0.0 112.713 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.8 tpt -68.55 124.89 24.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.082 0.467 . . . . 0.0 111.733 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.06 9.23 85.52 Favored Glycine 0 C--N 1.333 0.395 0 CA-C-N 115.863 -0.608 . . . . 0.0 113.101 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 45.4 mt-10 -134.28 176.82 8.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.979 0.419 . . . . 0.0 111.13 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -115.2 133.31 56.15 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.137 0.494 . . . . 0.0 111.647 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 14.1 t80 -119.89 123.64 44.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.977 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.501 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -102.99 137.21 32.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.65 0.738 . . . . 0.0 112.643 -178.759 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 54.9 t -112.86 112.03 38.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.18 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -93.16 119.52 32.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.507 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -136.49 155.6 34.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.227 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 2.9 m -119.37 97.81 50.3 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.514 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 73.2 Cg_endo -74.24 100.82 1.34 Allowed 'Trans proline' 0 CA--C 1.531 0.344 0 C-N-CA 122.86 2.373 . . . . 0.0 112.503 179.719 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -95.63 3.76 53.7 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.919 0.39 . . . . 0.0 111.657 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -130.4 133.63 46.52 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.867 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -90.07 128.8 36.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.908 0.385 . . . . 0.0 111.255 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 168.05 -166.75 39.67 Favored Glycine 0 CA--C 1.517 0.185 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.813 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -99.89 112.83 25.08 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.168 0.509 . . . . 0.0 110.746 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.408 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 22.6 m-85 -110.67 168.61 9.34 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.009 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 63.5 p -150.64 160.89 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.138 0.494 . . . . 0.0 112.047 -179.379 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 36.3 p90 -146.21 136.08 23.41 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.913 179.083 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.157 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.231 -179.673 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.17 0 CA-C-O 120.966 0.412 . . . . 0.0 111.083 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.493 ' HG3' HG13 ' A' ' 54' ' ' ILE . 8.9 ttp -131.71 119.52 21.46 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.012 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.7 mp -107.16 116.24 50.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.031 0.443 . . . . 0.0 110.793 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.2 t -101.23 120.43 50.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.168 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 . . . . . 0 C--O 1.252 1.224 0 CA-C-O 118.146 -0.93 . . . . 0.0 111.458 -179.646 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 121.161 0.505 . . . . 0.0 111.066 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.82 129.23 35.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.606 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.71 156.1 39.3 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.403 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.549 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 5.9 pt20 -82.0 142.81 32.05 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.125 0.488 . . . . 0.0 111.259 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -98.47 112.99 24.84 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.657 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 5.6 mmtt -95.34 -150.28 0.31 Allowed 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.557 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -80.71 74.99 7.63 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.98 -5.82 76.11 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.867 -0.682 . . . . 0.0 113.974 178.869 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.4 p90 -140.59 163.96 31.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.923 0.361 . . . . 0.0 110.85 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.65 154.57 27.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.975 0.417 . . . . 0.0 111.457 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.549 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 4.0 tt0 -143.82 141.3 30.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.572 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.71 128.97 17.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.915 179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 ttt180 -90.73 110.9 22.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.253 0.549 . . . . 0.0 111.123 179.649 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.57 HG13 ' HD2' ' A' ' 51' ' ' PRO . 45.2 t -101.04 103.87 15.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.517 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.411 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 1.3 tp10 -71.49 117.01 12.5 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.029 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.557 HG13 HD22 ' A' ' 75' ' ' LEU . 53.2 t -98.76 99.93 9.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.451 -178.76 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.564 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.3 ptm -147.09 90.77 1.92 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.568 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 79.28 1.04 85.25 Favored Glycine 0 CA--C 1.52 0.396 0 C-N-CA 120.774 -0.727 . . . . 0.0 111.733 -178.501 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.481 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 163.54 -148.61 15.19 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 111.314 -0.715 . . . . 0.0 111.314 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -115.64 129.65 56.57 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.718 0.259 . . . . 0.0 110.309 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.504 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 41.0 m -68.76 -64.6 1.65 Allowed Pre-proline 0 CA--C 1.538 0.515 0 CA-C-O 119.468 -0.301 . . . . 0.0 111.497 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.57 ' HD2' HG13 ' A' ' 43' ' ' VAL . 62.4 Cg_endo -74.9 98.88 1.19 Allowed 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.271 1.314 . . . . 0.0 111.119 177.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -51.84 -44.55 63.64 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.917 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.85 119.09 20.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.864 179.78 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.2 pt -97.1 126.98 49.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 121.08 0.467 . . . . 0.0 110.943 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 60.1 t -98.58 126.67 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.642 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.3 mt -136.22 165.37 25.91 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.363 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -88.85 176.01 7.22 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.82 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.452 ' HD3' ' HB2' ' A' ' 104' ' ' ALA . 2.6 ttpt -106.7 147.95 28.98 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 111.872 -179.339 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.0 t 65.13 20.2 11.95 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.737 179.596 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.444 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.3 p -123.61 136.4 27.22 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.989 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -64.47 123.43 11.76 Favored 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.099 1.866 . . . . 0.0 111.736 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.05 139.37 53.86 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.954 0.407 . . . . 0.0 111.682 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.515 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.6 ptt180 -121.78 127.06 50.21 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.744 0.783 . . . . 0.0 111.335 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.5 mm -99.87 115.78 41.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.838 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.517 HG22 HG23 ' A' ' 96' ' ' VAL . 3.2 t -91.24 107.59 18.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.853 0.359 . . . . 0.0 111.463 -179.229 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -95.09 103.57 15.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.909 0.385 . . . . 0.0 111.466 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -90.59 105.9 18.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.377 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.55 100.1 7.6 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.157 0.503 . . . . 0.0 111.882 -179.197 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.0 tmtt? -91.42 -39.19 12.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.852 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.564 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 0.1 OUTLIER -107.1 137.8 19.66 Favored Pre-proline 0 CA--C 1.534 0.354 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.149 -179.913 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -81.87 39.66 0.88 Allowed 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 123.229 2.619 . . . . 0.0 113.405 -179.279 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -67.73 135.66 92.48 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.991 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -62.42 -34.3 76.93 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.872 2.382 . . . . 0.0 113.106 -179.337 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.02 -3.29 38.33 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.518 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.557 HD22 HG13 ' A' ' 45' ' ' VAL . 56.3 mt -120.01 12.88 12.07 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.446 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -68.78 -39.27 80.25 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 120.915 0.388 . . . . 0.0 111.379 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 31.0 mt-30 -123.66 166.15 16.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.034 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -140.93 130.45 25.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.296 0.57 . . . . 0.0 110.836 178.764 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.582 ' O ' ' HD3' ' A' ' 81' ' ' PRO . 0.2 OUTLIER -133.9 132.33 56.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.216 0.532 . . . . 0.0 110.981 179.68 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 -96.01 101.72 9.01 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.721 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.582 ' HD3' ' O ' ' A' ' 79' ' ' VAL . 23.2 Cg_exo -63.46 -19.02 67.1 Favored 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.072 2.515 . . . . 0.0 113.791 -178.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -100.66 -5.94 25.88 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -121.44 -23.03 5.76 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.11 22.8 56.69 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.151 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.1 t -102.53 120.34 52.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.674 0.274 . . . . 0.0 111.552 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -125.74 119.69 28.62 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.633 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.78 169.35 17.94 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.112 0.482 . . . . 0.0 112.249 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -109.05 140.67 42.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.548 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 38.6 mt -100.69 129.44 27.6 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.851 0.358 . . . . 0.0 111.356 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.426 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.9 Cg_endo -80.64 128.25 6.76 Favored 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.813 2.342 . . . . 0.0 112.452 179.164 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -66.16 124.85 23.74 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.087 0.47 . . . . 0.0 111.681 -179.541 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 87.11 3.46 82.56 Favored Glycine 0 CA--C 1.521 0.446 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.951 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 41.9 mt-10 -134.65 177.05 8.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.009 0.433 . . . . 0.0 110.913 -179.593 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -117.27 133.35 56.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.211 0.529 . . . . 0.0 111.564 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -113.21 125.49 54.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.222 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.517 HG23 HG22 ' A' ' 65' ' ' VAL . 1.7 p -98.09 135.19 33.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.715 0.769 . . . . 0.0 112.334 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.0 t -112.82 112.92 42.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.199 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -93.73 119.76 33.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.035 0.445 . . . . 0.0 111.518 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -136.4 156.44 36.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.125 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.26 97.74 48.99 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.452 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.444 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 58.6 Cg_endo -71.14 98.42 0.82 Allowed 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.734 2.289 . . . . 0.0 112.618 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -97.6 22.72 8.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.004 0.43 . . . . 0.0 111.482 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.35 131.23 14.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.539 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ALA . . . . . 0.452 ' HB2' ' HD3' ' A' ' 58' ' ' LYS . . . -88.11 127.1 35.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.071 0.462 . . . . 0.0 111.41 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 164.99 -157.6 30.13 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.714 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -101.55 126.01 48.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.172 0.51 . . . . 0.0 111.535 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.443 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 87.9 m-85 -119.58 171.93 8.02 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.783 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 84.8 p -157.81 160.54 37.88 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.211 0.529 . . . . 0.0 112.418 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -143.77 140.46 29.94 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.496 178.7 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.282 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.662 -179.196 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.529 0.143 0 CA-C-O 120.884 0.373 . . . . 0.0 111.112 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.443 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -132.56 140.12 48.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.059 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.5 118.74 54.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 121.048 0.451 . . . . 0.0 110.823 179.363 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.3 t -100.21 123.86 53.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.062 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.251 1.168 0 CA-C-O 118.155 -0.926 . . . . 0.0 111.973 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.158 0 CA-C-O 121.155 0.502 . . . . 0.0 111.375 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -88.57 126.59 35.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.626 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.27 153.84 41.32 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.297 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.72 140.67 34.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.243 0.544 . . . . 0.0 111.187 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 22.0 mt-30 -96.38 116.83 29.69 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.595 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.1 -153.07 0.41 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.119 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -83.73 76.82 9.96 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -179.271 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.6 -8.84 64.2 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.767 -0.73 . . . . 0.0 114.007 178.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -141.21 164.99 28.77 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 117.093 0.446 . . . . 0.0 111.091 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.44 154.28 27.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.924 0.392 . . . . 0.0 111.177 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -143.28 142.07 31.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.891 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.54 128.69 15.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.972 179.027 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -90.18 110.18 21.22 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.208 0.528 . . . . 0.0 110.93 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.566 HG13 ' HD2' ' A' ' 51' ' ' PRO . 47.9 t -102.37 107.2 21.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.663 -0.698 . . . . 0.0 110.74 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.42 ' HG2' ' SD ' ' A' ' 46' ' ' MET . 0.7 OUTLIER -75.93 117.76 17.99 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.002 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.491 HG13 HD22 ' A' ' 75' ' ' LEU . 50.6 t -96.62 99.03 8.31 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.416 -178.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.496 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.4 ptm -144.72 90.3 2.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.487 179.023 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 81.85 2.05 90.43 Favored Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.72 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.448 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 159.61 -131.28 2.67 Favored Glycine 0 N--CA 1.449 -0.471 0 N-CA-C 111.601 -0.6 . . . . 0.0 111.601 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -126.09 134.57 51.33 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.729 -0.277 . . . . 0.0 110.754 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.521 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 32.4 m -73.57 -63.98 0.87 Allowed Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 121.066 -0.253 . . . . 0.0 110.93 179.559 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.566 ' HD2' HG13 ' A' ' 43' ' ' VAL . 61.2 Cg_endo -74.53 100.51 1.33 Allowed 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 121.409 1.406 . . . . 0.0 111.226 177.726 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.63 -45.42 63.27 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.28 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.511 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.76 119.06 19.82 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.561 0.22 . . . . 0.0 110.999 179.783 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.1 pt -96.58 126.04 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.128 0.489 . . . . 0.0 110.896 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 84.0 t -97.8 126.43 50.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.567 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.5 mt -136.15 164.37 28.21 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.248 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.74 170.9 10.04 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 120.757 0.313 . . . . 0.0 110.935 179.24 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 12.7 ttpt -100.65 147.81 25.57 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.7 t 65.72 19.63 11.42 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.936 179.419 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.5 p -123.63 135.74 26.49 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.964 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_endo -64.11 123.28 11.64 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.133 1.889 . . . . 0.0 111.722 178.642 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.23 136.56 54.24 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.938 0.399 . . . . 0.0 111.542 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.434 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -118.53 125.51 50.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.855 0.836 . . . . 0.0 111.545 179.965 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.1 mm -98.38 114.93 37.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.626 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.543 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.34 107.83 19.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.768 0.318 . . . . 0.0 111.357 -179.38 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -94.16 118.53 31.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.081 0.467 . . . . 0.0 111.381 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -102.18 106.97 17.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.469 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.7 tpt180 -76.35 96.69 4.05 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 121.13 0.491 . . . . 0.0 111.42 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 23.4 tptt -91.89 -35.91 13.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.451 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.496 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.7 t70 -107.08 131.15 21.92 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.731 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -80.18 38.48 0.75 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.001 2.467 . . . . 0.0 113.027 -179.631 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -68.91 132.74 90.37 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.945 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -64.32 -30.92 63.5 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.668 2.245 . . . . 0.0 112.894 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.75 -3.13 42.78 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.544 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.491 HD22 HG13 ' A' ' 45' ' ' VAL . 16.6 mt -117.67 10.15 13.29 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 120.751 0.31 . . . . 0.0 111.19 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.18 -42.61 79.71 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -179.412 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -116.83 138.01 51.81 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.829 0.347 . . . . 0.0 111.584 -179.56 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -118.21 131.7 70.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.654 179.432 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.416 ' HB ' ' HB3' ' A' ' 86' ' ' HIS . 0.2 OUTLIER -137.42 129.44 41.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.397 0.618 . . . . 0.0 111.579 179.947 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -89.95 102.18 4.39 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.252 178.78 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 109' ' ' PHE . 36.4 Cg_endo -64.99 -14.16 43.72 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.606 2.204 . . . . 0.0 113.637 -178.396 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -101.02 -11.25 19.82 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -119.15 -24.29 6.52 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 111.945 0.35 . . . . 0.0 111.945 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 88.84 1.17 80.46 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.143 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.521 HG11 HG13 ' A' ' 97' ' ' VAL . 54.8 t -80.36 117.02 25.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.886 0.374 . . . . 0.0 111.396 -178.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' HIS . . . . . 0.416 ' HB3' ' HB ' ' A' ' 79' ' ' VAL . 19.2 p-80 -132.05 122.59 25.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.835 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.48 174.23 10.94 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 121.112 0.482 . . . . 0.0 111.91 -178.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -108.23 141.89 39.31 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.656 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 33.9 mt -100.71 124.49 42.06 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 120.906 0.384 . . . . 0.0 111.467 -179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.434 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 63.6 Cg_endo -78.57 128.63 8.82 Favored 'Trans proline' 0 CA--C 1.53 0.313 0 C-N-CA 122.786 2.324 . . . . 0.0 112.684 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 12.3 tpt -66.19 124.94 23.99 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.151 0.501 . . . . 0.0 111.677 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.38 6.76 85.69 Favored Glycine 0 CA--C 1.52 0.398 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.923 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.434 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 48.3 mm-40 -134.13 176.78 8.28 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-O 120.943 0.401 . . . . 0.0 111.292 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -114.58 132.32 56.38 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.983 0.42 . . . . 0.0 111.834 -179.665 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.415 ' HB2' ' HD2' ' A' ' 90' ' ' PRO . 9.6 t80 -118.06 121.63 41.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.778 178.632 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.543 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -98.52 138.46 23.04 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 CA-C-O 121.629 0.728 . . . . 0.0 112.577 -178.715 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.521 HG13 HG11 ' A' ' 85' ' ' VAL . 43.8 t -115.6 110.34 31.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.053 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -93.98 117.39 30.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.034 0.445 . . . . 0.0 111.551 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -132.73 156.52 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.18 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.3 m -119.9 96.74 49.55 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.437 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.449 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.1 Cg_endo -72.07 99.49 1.0 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.706 2.271 . . . . 0.0 112.494 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -97.3 22.92 8.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.023 0.439 . . . . 0.0 111.553 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.17 127.76 11.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.749 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -83.84 122.96 29.4 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.975 0.417 . . . . 0.0 111.326 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 169.2 -158.76 31.44 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.729 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -101.99 126.7 48.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.182 0.515 . . . . 0.0 111.576 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.447 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 85.7 m-85 -119.69 169.7 9.86 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.918 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 99.1 p -149.81 157.38 43.15 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.408 ' HA ' ' HD2' ' A' ' 81' ' ' PRO . 32.9 p90 -148.29 138.48 22.6 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.995 178.778 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.38 0 CA-C-O 121.05 0.452 . . . . 0.0 111.655 -179.73 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 14.6 ttpt . . . . . 0 CA--C 1.528 0.119 0 CA-C-O 121.03 0.443 . . . . 0.0 111.098 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.447 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.7 ttm -128.39 136.22 50.61 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.908 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -120.02 118.42 56.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.981 0.42 . . . . 0.0 110.846 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 76.0 t -99.78 121.78 50.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.146 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.103 -0.951 . . . . 0.0 111.531 -179.702 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 . . . . . 0 N--CA 1.462 0.168 0 CA-C-O 121.207 0.527 . . . . 0.0 111.477 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 3.1 ttpt -90.17 129.5 36.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.747 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.22 153.51 40.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.441 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 3.7 pt20 -84.48 139.33 32.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.132 0.491 . . . . 0.0 111.393 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -94.82 115.29 27.31 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.769 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.89 -151.14 0.32 Allowed 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.248 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.6 m120 -82.94 73.29 9.98 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.131 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.68 -4.76 61.75 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 120.817 -0.706 . . . . 0.0 114.061 178.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 30.2 p90 -143.62 162.57 35.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.909 0.355 . . . . 0.0 110.915 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.42 153.33 27.51 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.006 0.432 . . . . 0.0 111.475 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.441 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.6 tt0 -142.14 142.81 32.78 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.567 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.56 129.07 13.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -90.74 110.12 21.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.239 0.542 . . . . 0.0 110.939 179.639 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.582 HG13 ' HD2' ' A' ' 51' ' ' PRO . 43.5 t -102.16 103.91 15.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.774 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.468 ' HG2' ' SD ' ' A' ' 46' ' ' MET . 0.8 OUTLIER -75.25 118.13 17.82 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.614 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.563 HG13 HD22 ' A' ' 75' ' ' LEU . 53.5 t -96.9 98.41 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.649 -178.614 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.468 ' SD ' ' HG2' ' A' ' 44' ' ' GLU . 6.4 ptm -142.55 90.81 2.26 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.642 179.124 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 81.7 0.72 89.68 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.901 -0.666 . . . . 0.0 111.684 -178.797 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.464 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 162.79 -133.66 3.16 Favored Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -124.8 130.77 53.04 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.743 0.272 . . . . 0.0 110.599 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.537 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 49.7 m -70.15 -64.99 1.2 Allowed Pre-proline 0 CA--C 1.538 0.51 0 CA-C-O 119.508 -0.282 . . . . 0.0 111.391 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.582 ' HD2' HG13 ' A' ' 43' ' ' VAL . 58.7 Cg_endo -73.95 100.32 1.27 Allowed 'Trans proline' 0 C--N 1.358 1.058 0 C-N-CA 121.278 1.319 . . . . 0.0 111.249 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.84 -47.16 60.25 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.951 -0.568 . . . . 0.0 112.285 -179.365 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.56 119.06 20.01 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.638 0.256 . . . . 0.0 110.752 179.897 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.4 pt -97.04 129.37 47.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.093 0.473 . . . . 0.0 111.062 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 96.3 t -96.18 124.95 49.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.509 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.0 157.24 42.87 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.087 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -89.85 168.99 11.63 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 110.163 -0.31 . . . . 0.0 110.163 178.31 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.9 ttpp -98.77 146.95 25.39 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 112.305 0.484 . . . . 0.0 112.305 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.6 t 65.66 19.78 11.48 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.86 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.451 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.95 135.9 26.84 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.976 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -64.29 122.74 10.8 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.128 1.885 . . . . 0.0 111.812 178.629 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.7 134.68 53.67 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.856 0.36 . . . . 0.0 111.47 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.46 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -116.59 126.32 53.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.776 0.798 . . . . 0.0 111.585 -179.918 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.5 mm -99.5 114.88 38.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.67 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.523 HG22 HG23 ' A' ' 96' ' ' VAL . 4.1 t -90.45 108.2 19.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.714 0.292 . . . . 0.0 111.383 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -95.08 113.67 25.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.147 0.499 . . . . 0.0 111.326 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 21.8 t0 -99.32 103.72 15.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.5 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.25 97.66 4.24 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.176 0.512 . . . . 0.0 111.723 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.66 -42.1 10.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.482 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.455 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.2 t70 -99.47 131.75 24.39 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.837 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -80.73 39.63 0.88 Allowed 'Trans proline' 0 C--N 1.348 0.526 0 C-N-CA 123.16 2.573 . . . . 0.0 113.162 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 30.7 t -69.77 136.18 87.84 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.326 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -63.95 -27.95 66.63 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.576 2.184 . . . . 0.0 112.443 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 80.6 m -81.05 -6.89 59.33 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.059 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.563 HD22 HG13 ' A' ' 45' ' ' VAL . 50.9 mt -118.31 14.92 13.92 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.208 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -68.37 -35.89 78.39 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 120.95 0.405 . . . . 0.0 111.557 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -129.34 165.68 21.0 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.047 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.08 131.82 42.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.245 0.545 . . . . 0.0 110.98 179.156 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.9 128.63 43.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.455 0.645 . . . . 0.0 111.179 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -90.81 102.21 4.95 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.422 178.848 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -65.24 -14.2 43.83 Favored 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.583 2.188 . . . . 0.0 113.583 -178.547 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -101.05 -10.24 20.68 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 111.906 0.335 . . . . 0.0 111.906 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 59.0 m-85 -119.84 -23.69 6.37 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -179.644 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 87.92 1.28 82.57 Favored Glycine 0 CA--C 1.521 0.458 0 C-N-CA 121.291 -0.48 . . . . 0.0 112.175 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.506 HG11 HG13 ' A' ' 97' ' ' VAL . 53.6 t -81.48 116.27 25.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.892 0.377 . . . . 0.0 111.348 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 20.3 p-80 -131.51 120.86 23.53 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.959 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -140.18 173.79 11.16 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.759 -179.028 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 8.1 p-10 -106.54 145.54 31.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.738 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 36.2 mt -103.97 130.17 23.89 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 120.924 0.393 . . . . 0.0 111.203 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.425 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.7 Cg_endo -80.86 126.11 5.69 Favored 'Trans proline' 0 CA--C 1.532 0.382 0 C-N-CA 122.706 2.271 . . . . 0.0 112.325 179.26 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.0 tpt -64.01 123.95 20.34 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.092 0.473 . . . . 0.0 111.764 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.02 3.59 87.62 Favored Glycine 0 CA--C 1.522 0.508 0 CA-C-N 115.866 -0.606 . . . . 0.0 113.283 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.425 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 47.8 mt-10 -131.86 176.86 7.99 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 120.886 0.374 . . . . 0.0 111.196 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -113.38 135.55 53.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.083 0.468 . . . . 0.0 111.985 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -120.07 124.26 45.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.807 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.523 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -98.7 137.94 24.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.63 0.728 . . . . 0.0 112.666 -178.879 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.506 HG13 HG11 ' A' ' 85' ' ' VAL . 46.1 t -114.99 110.46 32.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.055 178.78 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -93.56 117.09 29.64 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.854 0.359 . . . . 0.0 111.481 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 pt -132.05 158.05 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.213 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -121.38 96.24 47.97 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.501 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.451 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.7 Cg_endo -71.19 99.59 0.91 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.724 2.283 . . . . 0.0 112.276 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -94.22 3.65 54.96 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -132.01 135.95 46.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.79 0.329 . . . . 0.0 110.754 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.46 124.11 34.19 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.962 179.752 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 168.76 -159.44 32.56 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.839 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -100.61 125.93 47.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.155 0.503 . . . . 0.0 111.556 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.467 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 95.5 m-85 -121.42 164.86 16.44 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.831 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -151.21 157.43 42.63 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.251 0.548 . . . . 0.0 112.244 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -142.92 140.42 31.14 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.913 179.099 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.356 -179.757 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 4.1 ttmm . . . . . 0 CA--C 1.528 0.097 0 CA-C-O 120.947 0.403 . . . . 0.0 111.209 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.467 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 3.4 ttm -131.1 135.13 47.24 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.926 179.496 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.16 117.87 55.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.045 0.45 . . . . 0.0 110.527 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.1 t -99.95 123.58 52.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.349 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 118.186 -0.912 . . . . 0.0 111.46 -179.844 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 . . . . . 0 CA--C 1.53 0.177 0 CA-C-O 121.069 0.461 . . . . 0.0 111.268 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 5.3 mtpt -90.12 129.25 36.43 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.733 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.99 149.21 43.49 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.636 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.602 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.8 pt20 -74.81 138.02 42.3 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.907 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -97.55 113.36 25.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.871 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -95.41 -156.17 0.5 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.368 -179.682 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -81.89 79.26 8.47 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 112.29 0.478 . . . . 0.0 112.29 -179.182 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.74 -9.98 66.36 Favored Glycine 0 CA--C 1.522 0.508 0 C-N-CA 120.799 -0.715 . . . . 0.0 114.298 178.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 28.9 p90 -142.01 164.07 31.17 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 117.098 0.449 . . . . 0.0 111.193 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.13 155.41 26.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.012 0.434 . . . . 0.0 111.182 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.602 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.9 tt0 -144.49 143.19 30.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.33 -179.28 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.11 129.44 17.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.082 0.468 . . . . 0.0 111.327 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 ttm180 -88.7 106.97 18.69 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.221 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.587 HG13 ' HD2' ' A' ' 51' ' ' PRO . 45.6 t -100.39 102.31 13.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.496 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -73.6 119.38 17.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.711 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.552 HG13 HD22 ' A' ' 75' ' ' LEU . 53.2 t -98.86 99.44 8.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.517 -178.723 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.493 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.2 ptm -143.8 88.24 1.97 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.537 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.31 -0.36 84.61 Favored Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.575 -178.555 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.437 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 163.41 -163.45 35.6 Favored Glycine 0 N--CA 1.447 -0.586 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -98.58 126.36 44.13 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.768 0.284 . . . . 0.0 110.321 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.537 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 47.8 m -65.24 -64.3 2.73 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 121.196 -0.202 . . . . 0.0 111.267 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.587 ' HD2' HG13 ' A' ' 43' ' ' VAL . 60.8 Cg_endo -74.62 96.58 1.0 Allowed 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 121.358 1.372 . . . . 0.0 111.198 177.693 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.36 -42.86 61.61 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.096 -0.502 . . . . 0.0 112.195 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.485 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.88 118.68 20.16 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.696 0.284 . . . . 0.0 110.606 179.513 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.9 pt -98.0 127.48 50.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-O 121.03 0.443 . . . . 0.0 111.092 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.1 t -98.68 126.72 51.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.597 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.0 mt -136.41 165.32 26.08 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.264 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -90.97 171.42 9.29 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.797 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.5 ttpp -101.74 148.47 25.24 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.999 0.428 . . . . 0.0 112.066 -179.325 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.0 t 65.42 20.14 11.71 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.931 179.567 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.436 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.8 p -123.78 135.91 26.77 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.866 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -64.36 122.2 10.06 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.202 1.935 . . . . 0.0 111.68 178.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.46 138.65 54.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.995 0.426 . . . . 0.0 111.546 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.474 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.2 ptt180 -120.72 126.85 51.21 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-O 121.776 0.798 . . . . 0.0 111.343 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.8 mm -97.73 115.01 36.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.81 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.452 HG22 HG23 ' A' ' 96' ' ' VAL . 3.6 t -91.99 110.52 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.376 -179.271 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -96.2 114.69 26.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.041 0.448 . . . . 0.0 111.289 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -100.38 104.5 15.93 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.181 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.407 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 0.1 OUTLIER -76.64 104.66 7.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.289 0.566 . . . . 0.0 111.958 -179.093 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.73 -39.84 9.26 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.093 179.212 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.493 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.1 t70 -105.71 133.86 19.99 Favored Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.929 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -80.97 39.53 0.87 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.994 2.463 . . . . 0.0 112.861 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.07 133.87 91.74 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.451 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.67 -32.37 57.67 Favored 'Trans proline' 0 C--N 1.348 0.527 0 C-N-CA 122.771 2.314 . . . . 0.0 112.63 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.15 -2.69 32.3 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.56 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.552 HD22 HG13 ' A' ' 45' ' ' VAL . 34.9 mt -118.74 12.99 13.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.275 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -70.55 -43.46 69.46 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.931 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.55 140.14 51.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.026 0.441 . . . . 0.0 111.54 -179.476 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -120.64 127.64 75.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.525 178.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -130.11 130.58 65.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.349 0.595 . . . . 0.0 111.475 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -92.65 102.12 6.26 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.374 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -66.67 -16.66 51.18 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.667 2.245 . . . . 0.0 113.7 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -100.57 -7.44 24.06 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -120.58 -21.82 6.61 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.9 29.82 45.53 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.077 -179.369 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.1 t -110.85 117.98 56.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.81 0.338 . . . . 0.0 111.753 -178.773 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -119.93 121.0 38.03 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.226 179.117 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.48 158.92 43.37 Favored 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 112.521 0.564 . . . . 0.0 112.521 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -104.01 137.0 42.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.477 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 45.0 mt -99.76 127.84 32.8 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.968 0.413 . . . . 0.0 111.466 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.433 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 70.8 Cg_endo -82.05 130.36 6.46 Favored 'Trans proline' 0 CA--C 1.533 0.426 0 C-N-CA 122.689 2.259 . . . . 0.0 112.441 179.241 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' MET . . . . . 0.407 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 10.7 tpt -68.06 125.57 26.77 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-O 121.072 0.463 . . . . 0.0 111.644 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.51 13.11 79.16 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-N 115.855 -0.611 . . . . 0.0 112.866 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.433 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.5 mm-40 -138.5 176.93 8.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.878 0.371 . . . . 0.0 111.125 -179.482 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -114.0 134.21 55.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.049 0.452 . . . . 0.0 111.661 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.7 t80 -123.05 124.84 44.03 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.029 178.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.452 HG23 HG22 ' A' ' 65' ' ' VAL . 2.1 p -105.04 136.73 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 CA-C-O 121.544 0.688 . . . . 0.0 112.439 -178.909 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.7 t -113.17 112.92 42.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.113 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -93.84 119.49 32.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.951 0.405 . . . . 0.0 111.476 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -135.46 156.6 38.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.145 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -119.96 97.57 49.45 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.614 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.4 Cg_endo -72.75 100.28 1.16 Allowed 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 122.806 2.338 . . . . 0.0 112.309 179.502 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -95.46 5.34 51.85 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -131.97 133.29 44.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.798 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.89 127.74 35.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.0 0.429 . . . . 0.0 111.223 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 162.47 -156.56 28.25 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.764 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.02 126.13 48.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.198 0.523 . . . . 0.0 111.488 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.439 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 84.0 m-85 -118.15 173.41 6.81 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.904 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 83.2 p -151.22 158.13 43.51 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -178.859 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -149.69 130.46 14.15 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.334 178.756 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.215 0 CA-C-O 120.964 0.411 . . . . 0.0 112.001 -179.381 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 12.4 ttmt . . . . . 0 CA--C 1.532 0.271 0 CA-C-O 121.106 0.479 . . . . 0.0 111.898 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.439 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -134.52 139.79 45.69 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.735 179.479 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.0 mp -123.24 120.16 59.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.997 0.427 . . . . 0.0 110.81 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 85.2 t -104.16 123.19 57.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.202 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.237 0 CA-C-O 118.102 -0.951 . . . . 0.0 111.505 -179.691 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.135 0 CA-C-O 121.042 0.449 . . . . 0.0 111.237 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.2 mtpt -91.34 129.24 37.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.874 179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.65 152.36 40.51 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.317 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.563 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.5 pt20 -80.84 141.26 34.83 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-O 121.152 0.501 . . . . 0.0 111.444 -179.352 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 58.4 mt-30 -96.9 114.84 26.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.594 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.39 -149.82 0.31 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.456 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -82.01 72.72 9.06 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -179.104 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.76 -5.21 66.57 Favored Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.788 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.4 p90 -141.36 160.3 40.41 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.905 0.352 . . . . 0.0 110.746 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.18 155.66 21.68 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.988 0.423 . . . . 0.0 111.423 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.563 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.7 tt0 -144.53 143.84 31.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.545 -179.317 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -145.15 129.63 12.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.2 179.144 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 7.3 ttt180 -89.96 108.14 19.53 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.071 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.475 HG13 ' HD2' ' A' ' 51' ' ' PRO . 49.0 t -99.99 107.85 21.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.705 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -73.6 122.46 22.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.013 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.55 HG13 HD22 ' A' ' 75' ' ' LEU . 53.8 t -103.08 95.33 3.77 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-O 121.535 0.683 . . . . 0.0 111.052 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.449 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 3.8 ptm -146.16 89.45 1.87 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.405 179.562 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.55 0.24 89.8 Favored Glycine 0 CA--C 1.521 0.454 0 C-N-CA 120.811 -0.709 . . . . 0.0 111.545 -178.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.478 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.66 -140.6 6.81 Favored Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 111.649 -0.581 . . . . 0.0 111.649 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -121.86 129.46 52.61 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.741 0.27 . . . . 0.0 110.543 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.49 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 20.8 m -68.84 -62.0 3.17 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 120.997 -0.281 . . . . 0.0 111.176 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.49 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 63.5 Cg_endo -75.62 97.6 1.11 Allowed 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 121.417 1.411 . . . . 0.0 111.064 177.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -52.11 -43.34 63.9 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.125 -0.489 . . . . 0.0 112.062 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -134.17 118.45 17.67 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.711 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.488 HG13 ' HG3' ' A' ' 120' ' ' MET . 9.6 pt -96.91 127.35 49.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.134 0.492 . . . . 0.0 110.939 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 98.9 t -95.51 125.86 48.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.601 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 23.6 mt -133.69 167.68 20.07 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.263 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.2 mttt -96.59 168.84 10.29 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.685 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -98.67 146.72 25.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.928 0.395 . . . . 0.0 111.927 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.5 t 66.06 19.7 11.19 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.89 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 5.7 p -123.53 135.2 25.84 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.002 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -64.3 122.7 10.74 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.051 1.834 . . . . 0.0 111.711 178.761 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.1 138.98 54.36 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.79 0.328 . . . . 0.0 111.622 -179.628 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.447 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -120.92 125.33 47.17 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.719 0.771 . . . . 0.0 111.494 179.947 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 5.7 mm -97.66 115.25 37.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.654 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.518 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.9 109.8 21.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.375 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -95.5 111.81 23.65 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.016 0.436 . . . . 0.0 111.296 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -98.11 106.03 18.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.52 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.406 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 0.2 OUTLIER -78.19 105.16 9.24 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.282 0.563 . . . . 0.0 111.91 -179.448 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.05 -37.36 9.38 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.19 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.449 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 5.2 t70 -103.78 129.88 24.48 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.922 179.544 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -80.52 39.13 0.81 Allowed 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.113 2.542 . . . . 0.0 112.881 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.2 m -72.04 135.84 82.46 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.349 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -64.08 -31.21 65.65 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.617 2.211 . . . . 0.0 112.583 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 5.2 p -76.79 -5.29 47.58 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.587 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.55 HD22 HG13 ' A' ' 45' ' ' VAL . 30.2 mt -120.12 15.94 12.38 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.964 179.642 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -67.82 -35.56 78.82 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 116.096 -0.502 . . . . 0.0 112.243 -179.332 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 -133.7 165.91 23.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.914 0.388 . . . . 0.0 111.583 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ILE . . . . . 0.417 HG13 ' N ' ' A' ' 79' ' ' VAL . 0.5 OUTLIER -137.72 141.37 39.22 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.115 179.858 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.417 ' N ' HG13 ' A' ' 78' ' ' ILE . 0.2 OUTLIER -139.9 134.14 36.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.364 0.602 . . . . 0.0 111.359 179.054 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -97.57 101.68 10.97 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.84 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.56 -13.79 40.14 Favored 'Trans proline' 0 C--N 1.347 0.481 0 C-N-CA 122.613 2.209 . . . . 0.0 113.431 -178.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -100.57 -9.11 22.32 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -123.02 -19.93 5.92 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.353 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.71 28.97 49.7 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.86 -0.685 . . . . 0.0 112.226 -179.605 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.4 t -110.75 116.87 53.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.745 0.307 . . . . 0.0 111.535 -179.052 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 4.3 t60 -127.12 117.72 22.95 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.87 0.367 . . . . 0.0 110.45 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.12 170.48 15.61 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 121.09 0.471 . . . . 0.0 111.858 -179.394 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -106.24 145.84 31.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.477 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 34.8 mt -105.47 129.35 24.85 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.867 0.365 . . . . 0.0 111.412 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.445 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.7 Cg_endo -81.86 129.21 6.18 Favored 'Trans proline' 0 CA--C 1.532 0.409 0 C-N-CA 122.752 2.301 . . . . 0.0 112.486 179.265 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' MET . . . . . 0.406 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 10.3 tpt -67.07 125.27 25.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.138 0.494 . . . . 0.0 111.699 -179.575 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.66 6.37 85.64 Favored Glycine 0 C--N 1.333 0.367 0 CA-C-N 115.864 -0.607 . . . . 0.0 113.077 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.445 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 45.7 mt-10 -134.29 176.82 8.26 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 120.988 0.423 . . . . 0.0 111.018 -179.533 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -115.06 132.49 56.58 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.0 0.429 . . . . 0.0 111.767 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.4 t80 -116.47 123.9 48.64 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.968 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.518 HG23 HG22 ' A' ' 65' ' ' VAL . 1.6 p -101.28 137.1 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 CA-C-O 121.651 0.739 . . . . 0.0 112.51 -178.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.98 110.21 31.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.154 178.823 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -92.67 118.82 31.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.373 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -135.84 154.52 34.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.361 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -119.22 97.43 50.46 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.272 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.449 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 74.2 Cg_endo -73.47 101.92 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.845 2.363 . . . . 0.0 112.72 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -97.71 19.9 12.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.984 0.421 . . . . 0.0 111.483 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -146.97 129.93 16.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.774 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -86.1 126.28 34.08 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.903 0.382 . . . . 0.0 111.269 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.09 -168.29 41.36 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.816 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -99.76 112.02 24.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.141 0.496 . . . . 0.0 110.774 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -110.94 172.4 6.9 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.292 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 54.2 p -153.69 163.39 40.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.132 0.491 . . . . 0.0 112.274 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 31.2 p90 -145.58 140.63 27.54 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.518 179.067 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.371 0 CA-C-O 121.332 0.587 . . . . 0.0 112.273 -179.222 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 1.2 ttpt . . . . . 0 CA--C 1.53 0.175 0 CA-C-O 120.957 0.408 . . . . 0.0 111.476 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.488 ' HG3' HG13 ' A' ' 54' ' ' ILE . 9.2 ttp -133.96 122.18 22.71 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.048 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -109.69 116.08 51.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.101 0.477 . . . . 0.0 110.88 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 98.3 t -100.05 120.07 48.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.077 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 24.1 mt-10 . . . . . 0 C--O 1.253 1.247 0 CA-C-O 118.13 -0.938 . . . . 0.0 111.491 -179.542 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 19.8 mp0 . . . . . 0 C--O 1.232 0.164 0 CA-C-O 121.175 0.512 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 3.4 ttmt -89.5 127.52 35.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.909 -179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.16 155.95 39.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.052 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.575 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 10.9 pt20 -79.68 132.8 36.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.295 0.569 . . . . 0.0 111.248 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.0 mt-30 -92.79 109.11 20.53 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.83 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.03 -157.07 0.47 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.352 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -83.09 80.3 9.09 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.203 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.05 -7.18 67.01 Favored Glycine 0 CA--C 1.523 0.534 0 C-N-CA 120.846 -0.692 . . . . 0.0 114.178 178.762 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' TYR . . . . . 0.452 ' HB2' ' O ' ' A' ' 61' ' ' PRO . 24.6 p90 -144.15 165.53 27.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 117.191 0.496 . . . . 0.0 111.075 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.89 154.96 33.61 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.901 0.382 . . . . 0.0 111.201 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.575 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.5 tt0 -145.21 143.13 30.12 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.43 -179.533 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.71 129.2 13.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.93 0.395 . . . . 0.0 110.714 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.58 111.45 22.76 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.317 0.58 . . . . 0.0 111.127 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.652 HG13 ' HD2' ' A' ' 51' ' ' PRO . 42.6 t -100.05 102.82 13.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.571 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.414 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.4 OUTLIER -72.56 113.61 9.79 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.607 179.874 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.604 HG13 HD22 ' A' ' 75' ' ' LEU . 43.1 t -94.66 97.45 6.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.674 -0.693 . . . . 0.0 111.336 -178.87 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.474 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.7 ptm -141.68 85.27 1.94 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.532 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.94 1.42 90.63 Favored Glycine 0 CA--C 1.521 0.41 0 C-N-CA 120.958 -0.639 . . . . 0.0 111.516 -178.598 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.427 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.94 -166.95 35.79 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -93.75 123.75 37.29 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.86 0.33 . . . . 0.0 110.44 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.501 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 25.5 m -63.67 -62.17 5.81 Favored Pre-proline 0 CA--C 1.538 0.489 0 CA-C-O 119.594 -0.241 . . . . 0.0 111.07 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.652 ' HD2' HG13 ' A' ' 43' ' ' VAL . 61.2 Cg_endo -75.23 98.73 1.19 Allowed 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 121.211 1.274 . . . . 0.0 110.974 177.366 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.54 -45.31 62.94 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.3 -179.066 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.461 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -133.18 118.28 18.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.53 179.704 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.435 HG13 ' HG3' ' A' ' 120' ' ' MET . 5.0 pt -96.92 126.12 49.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.141 0.495 . . . . 0.0 111.273 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 88.9 t -99.07 125.65 52.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.413 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.57 HD22 ' HB1' ' A' ' 62' ' ' ALA . 2.3 mt -136.27 166.19 24.0 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.354 -179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.0 177.18 7.67 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.263 179.382 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 12.2 ttpt -106.05 147.36 28.99 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 111.842 0.312 . . . . 0.0 111.842 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.8 t 62.35 26.9 16.08 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.646 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -123.57 137.06 27.97 Favored Pre-proline 0 CA--C 1.538 0.508 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.435 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' PRO . . . . . 0.452 ' O ' ' HB2' ' A' ' 38' ' ' TYR . 36.2 Cg_endo -67.25 93.44 0.35 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.773 2.316 . . . . 0.0 112.206 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.57 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -97.99 138.78 34.8 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.911 0.386 . . . . 0.0 111.988 -179.083 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.491 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.5 OUTLIER -121.51 129.09 52.71 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 121.736 0.779 . . . . 0.0 111.644 179.747 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.6 mm -100.63 114.78 40.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.285 -0.871 . . . . 0.0 110.695 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.501 HG22 HG23 ' A' ' 96' ' ' VAL . 3.3 t -91.65 109.86 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.677 -0.238 . . . . 0.0 111.411 -179.396 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -95.44 113.63 25.32 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.034 0.445 . . . . 0.0 111.278 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -100.18 106.6 18.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.142 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.05 105.98 9.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.312 0.577 . . . . 0.0 112.12 -179.143 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.2 tptp -99.9 -34.56 10.07 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.084 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.474 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.6 t70 -109.6 132.68 21.2 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.779 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -81.13 40.43 0.99 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.085 2.524 . . . . 0.0 113.306 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.514 ' HB3' HD12 ' A' ' 75' ' ' LEU . 36.2 t -68.65 134.7 90.41 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.331 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -64.43 -27.96 62.56 Favored 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 122.652 2.234 . . . . 0.0 112.647 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.1 m -78.92 -10.75 59.91 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.168 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.604 HD22 HG13 ' A' ' 45' ' ' VAL . 40.9 mt -110.57 10.21 23.04 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.497 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -68.23 -40.53 82.0 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 120.87 0.367 . . . . 0.0 111.81 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -123.54 148.64 46.11 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.359 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -130.53 129.88 64.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.13 0.49 . . . . 0.0 110.374 178.653 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 2.4 p -133.98 132.45 56.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.2 0.524 . . . . 0.0 111.18 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -93.07 101.76 5.99 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.259 178.647 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 109' ' ' PHE . 38.2 Cg_endo -66.57 -15.71 48.52 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.662 2.241 . . . . 0.0 113.527 -178.391 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -100.58 -7.59 23.87 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -121.36 -20.9 6.5 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 112.026 0.38 . . . . 0.0 112.026 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.95 29.43 46.84 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.105 -179.524 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 50.9 t -110.89 115.71 50.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.881 0.372 . . . . 0.0 111.753 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.6 p80 -118.75 124.95 48.53 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.429 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.04 160.06 41.09 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -104.08 139.55 39.02 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.471 179.594 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 42.3 mt -101.63 127.23 31.87 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.904 0.383 . . . . 0.0 111.438 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.438 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 68.9 Cg_endo -81.0 128.14 6.4 Favored 'Trans proline' 0 CA--C 1.532 0.383 0 C-N-CA 122.667 2.245 . . . . 0.0 112.479 179.441 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.0 tpt -66.75 125.49 26.01 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.993 0.425 . . . . 0.0 111.583 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.84 7.88 83.4 Favored Glycine 0 CA--C 1.52 0.393 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.889 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.438 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 52.4 mm-40 -135.58 176.9 8.25 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.014 0.435 . . . . 0.0 111.14 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -114.63 134.34 55.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.033 0.444 . . . . 0.0 111.669 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -121.95 126.15 47.96 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.108 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.501 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -103.81 139.28 25.21 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 CA-C-O 121.516 0.674 . . . . 0.0 112.674 -178.873 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.8 t -116.41 110.82 32.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.123 178.68 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -93.67 119.37 32.6 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.255 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -133.31 157.57 42.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.086 0.469 . . . . 0.0 111.186 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.5 m -122.3 95.57 46.99 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.317 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.68 101.2 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.816 2.344 . . . . 0.0 112.649 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -95.02 23.73 5.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.922 0.391 . . . . 0.0 111.64 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -149.25 130.43 14.54 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.764 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.51 127.21 35.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.04 0.448 . . . . 0.0 111.438 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 165.01 -160.38 33.66 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.659 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -101.58 125.58 48.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.051 0.453 . . . . 0.0 111.275 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.439 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 91.7 m-85 -118.31 167.54 11.45 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.198 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.6 p -143.53 154.88 44.07 Favored 'General case' 0 C--O 1.234 0.26 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.415 ' HA ' ' HD2' ' A' ' 81' ' ' PRO . 44.4 p90 -148.73 129.46 14.16 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.916 178.869 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.249 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.116 -179.703 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.461 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.9 ttpt . . . . . 0 CA--C 1.53 0.184 0 CA-C-O 121.304 0.573 . . . . 0.0 111.729 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.439 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 12.0 ttp -133.93 135.16 43.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.734 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.1 mp -119.38 119.29 60.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.952 0.406 . . . . 0.0 110.856 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 89.6 t -104.12 120.16 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.135 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.227 -0.892 . . . . 0.0 111.464 -179.773 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.16 0 CA-C-O 121.134 0.493 . . . . 0.0 111.223 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.42 126.1 37.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.808 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.36 153.19 42.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.24 179.681 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -81.42 141.2 34.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.163 0.506 . . . . 0.0 111.52 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -97.16 115.71 28.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.596 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.51 -149.88 0.34 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.513 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -81.74 73.0 8.8 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -179.149 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.68 -6.54 67.62 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.65 -0.786 . . . . 0.0 113.898 179.006 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 38.9 p90 -139.89 163.7 31.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.767 0.283 . . . . 0.0 110.799 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.92 153.1 29.83 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.111 0.481 . . . . 0.0 111.283 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.409 ' HG3' ' HE ' ' A' ' 63' ' ' ARG . 3.3 tt0 -142.16 141.6 32.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.606 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.19 128.95 22.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.116 179.203 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -89.1 107.46 19.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.159 0.504 . . . . 0.0 111.017 179.574 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.587 HG13 ' HD2' ' A' ' 51' ' ' PRO . 47.3 t -100.28 103.29 14.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.416 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -73.29 116.87 14.35 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.025 -179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.558 HG13 HD22 ' A' ' 75' ' ' LEU . 42.0 t -98.01 99.08 8.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 CA-C-O 121.52 0.676 . . . . 0.0 111.423 -179.013 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.497 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.0 ptm -143.88 86.93 1.88 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.462 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.98 2.28 90.67 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.447 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.65 -154.01 24.97 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 65.3 m-85 -107.43 127.62 53.76 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.85 0.325 . . . . 0.0 110.407 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.517 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 40.7 m -66.92 -64.46 2.16 Favored Pre-proline 0 CA--C 1.539 0.522 0 CA-C-O 119.529 -0.272 . . . . 0.0 111.389 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.587 ' HD2' HG13 ' A' ' 43' ' ' VAL . 65.1 Cg_endo -75.0 98.65 1.18 Allowed 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.329 1.353 . . . . 0.0 111.028 177.789 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.89 -44.67 59.92 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.33 -179.346 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.506 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.04 119.2 20.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.645 0.259 . . . . 0.0 110.913 179.788 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.1 pt -97.1 125.71 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 120.976 0.417 . . . . 0.0 111.102 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 88.4 t -98.27 126.77 51.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.535 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.412 HD22 ' HB1' ' A' ' 62' ' ' ALA . 2.9 mt -136.93 166.79 22.82 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.384 -179.602 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.2 mtmm -90.38 172.49 8.71 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.915 179.322 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.6 ttpp -103.38 148.76 25.49 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 37.3 t 65.45 20.12 11.68 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.779 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.44 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.9 p -123.73 136.01 26.85 Favored Pre-proline 0 CA--C 1.535 0.371 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.868 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -64.2 122.9 11.03 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.105 1.87 . . . . 0.0 111.561 178.7 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.412 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -124.46 137.85 54.4 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.007 0.432 . . . . 0.0 111.632 -179.539 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.423 ' HB2' HG22 ' A' ' 96' ' ' VAL . 5.6 ptt180 -119.65 125.55 49.01 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.714 0.769 . . . . 0.0 111.286 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.5 mm -98.35 115.58 38.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.61 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.538 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.79 109.21 20.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.558 -179.177 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -97.83 107.8 20.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.898 0.38 . . . . 0.0 111.386 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -93.47 107.28 19.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.533 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.404 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 1.2 tpt180 -77.07 101.3 6.01 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.183 0.516 . . . . 0.0 111.776 -179.509 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 21.0 tptt -96.38 -34.28 11.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.413 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.497 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.8 t70 -108.93 131.39 21.82 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.693 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -79.6 39.54 0.84 Allowed 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 123.163 2.575 . . . . 0.0 113.246 -179.374 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.41 ' HB3' HD12 ' A' ' 75' ' ' LEU . 30.0 t -68.23 136.05 91.37 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.095 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.29 -26.98 55.95 Favored 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 122.684 2.256 . . . . 0.0 112.584 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -81.65 -7.98 59.65 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.243 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.558 HD22 HG13 ' A' ' 45' ' ' VAL . 40.5 mt -115.02 8.28 15.72 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.472 -179.811 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.61 -38.18 90.14 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.899 0.38 . . . . 0.0 111.933 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 3.9 mp0 -124.86 160.35 29.0 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.092 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -135.95 131.8 50.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.167 0.508 . . . . 0.0 110.83 179.202 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.417 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 1.0 OUTLIER -135.79 130.53 49.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.279 0.561 . . . . 0.0 111.199 179.757 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -93.89 101.9 7.05 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.393 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.7 -15.94 48.92 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.616 2.211 . . . . 0.0 113.578 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 55.7 m-20 -100.53 -7.13 24.46 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -121.17 -23.45 5.77 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.26 26.94 41.82 Favored Glycine 0 CA--C 1.52 0.363 0 C-N-CA 120.892 -0.671 . . . . 0.0 112.234 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 50.1 t -107.62 119.58 57.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.772 0.32 . . . . 0.0 111.605 -178.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -124.14 120.59 32.77 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.667 179.569 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -139.6 173.57 11.4 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-O 121.004 0.431 . . . . 0.0 112.109 -179.433 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -114.92 142.18 46.94 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.972 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 31.0 mt -102.77 124.09 40.12 Favored Pre-proline 0 CA--C 1.531 0.25 0 CA-C-O 120.949 0.404 . . . . 0.0 111.53 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.414 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 61.1 Cg_endo -77.07 129.48 10.56 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.753 2.302 . . . . 0.0 112.725 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' MET . . . . . 0.404 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 10.2 tpt -66.36 125.01 24.3 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.039 0.447 . . . . 0.0 111.803 -179.46 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.03 1.25 82.35 Favored Glycine 0 C--N 1.332 0.336 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.838 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.414 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 42.1 mt-10 -133.93 177.13 7.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.955 0.407 . . . . 0.0 110.802 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -119.01 134.73 55.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.135 0.493 . . . . 0.0 111.596 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.406 ' HB2' ' HD2' ' A' ' 90' ' ' PRO . 12.5 t80 -113.77 127.91 56.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.171 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.538 HG23 HG22 ' A' ' 65' ' ' VAL . 1.8 p -99.87 136.3 31.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.588 0.708 . . . . 0.0 112.504 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 65.7 t -113.84 112.17 39.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.203 178.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -93.53 118.89 31.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.584 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.88 158.05 41.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.255 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -120.48 97.08 48.94 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.663 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.44 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 65.8 Cg_endo -72.5 99.73 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.915 2.41 . . . . 0.0 112.336 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -95.07 3.73 54.5 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 111.868 0.321 . . . . 0.0 111.868 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -130.82 133.37 45.89 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.77 0.319 . . . . 0.0 110.812 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.75 128.08 35.62 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.98 0.419 . . . . 0.0 111.241 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.11 -157.9 30.1 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.709 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -101.42 125.64 48.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.21 0.528 . . . . 0.0 111.605 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.452 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 85.8 m-85 -118.46 172.81 7.22 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.868 179.602 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 93.4 p -155.03 158.74 39.59 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.1 p90 -147.23 133.43 19.42 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.542 -0.754 . . . . 0.0 111.088 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.309 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.994 -179.887 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.506 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 13.4 ttmt . . . . . 0 CA--C 1.53 0.204 0 CA-C-O 120.958 0.409 . . . . 0.0 110.852 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.452 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -131.25 138.48 49.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.062 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.1 mp -121.84 118.49 55.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.964 0.411 . . . . 0.0 110.775 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.5 t -102.06 121.84 53.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.301 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 . . . . . 0 C--O 1.252 1.235 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.441 -179.802 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.181 0 CA-C-O 121.107 0.479 . . . . 0.0 111.166 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.2 ttmt -91.93 125.48 36.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.995 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -70.94 150.89 45.25 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.189 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.557 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 3.8 pt20 -80.71 139.68 36.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.131 0.491 . . . . 0.0 111.422 -179.385 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 6.9 mp0 -95.66 115.33 27.28 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.776 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.75 -149.79 0.3 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.256 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -83.6 75.84 10.01 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 94.75 -5.97 69.92 Favored Glycine 0 CA--C 1.523 0.536 0 C-N-CA 120.88 -0.676 . . . . 0.0 113.928 179.016 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -142.32 160.54 40.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.912 0.356 . . . . 0.0 110.859 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -109.98 157.29 19.44 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.094 0.473 . . . . 0.0 111.45 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.557 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.0 OUTLIER -145.88 143.13 29.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.474 -179.539 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -142.7 129.05 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.064 0.459 . . . . 0.0 111.024 179.079 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.5 ttt180 -89.45 106.98 18.81 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.192 0.52 . . . . 0.0 111.028 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.584 HG13 ' HD2' ' A' ' 51' ' ' PRO . 47.0 t -99.82 103.0 14.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.474 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.403 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.5 OUTLIER -73.07 116.66 13.85 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.08 -179.906 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.57 HG13 HD22 ' A' ' 75' ' ' LEU . 48.5 t -97.52 98.91 7.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.466 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.446 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.6 ptm -143.06 85.83 1.89 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.453 179.111 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.04 3.37 87.75 Favored Glycine 0 CA--C 1.52 0.356 0 C-N-CA 120.941 -0.647 . . . . 0.0 111.509 -178.522 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.447 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 159.81 -143.32 8.99 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -116.2 127.89 55.16 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.687 0.244 . . . . 0.0 110.56 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.521 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 42.6 m -67.7 -64.67 1.85 Allowed Pre-proline 0 CA--C 1.54 0.58 0 CA-C-O 119.548 -0.263 . . . . 0.0 111.481 -179.649 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.584 ' HD2' HG13 ' A' ' 43' ' ' VAL . 66.7 Cg_endo -75.0 98.88 1.2 Allowed 'Trans proline' 0 C--N 1.356 0.941 0 C-N-CA 121.288 1.325 . . . . 0.0 111.044 177.872 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -51.45 -44.51 62.41 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.333 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.498 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.72 118.99 20.71 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.635 0.255 . . . . 0.0 110.944 179.77 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.0 pt -97.65 125.08 50.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.033 0.444 . . . . 0.0 111.087 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.7 t -95.98 126.38 48.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.497 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 10.2 mt -134.83 169.61 17.1 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.403 -179.683 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -97.66 166.98 11.24 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.56 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.3 ttpp -96.92 147.87 23.54 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -179.302 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.6 t 65.92 20.2 11.33 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.953 179.439 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.451 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 5.6 p -123.59 134.93 25.61 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.991 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -64.41 123.77 12.3 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.1 1.867 . . . . 0.0 111.596 178.618 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.95 137.23 53.68 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.908 0.385 . . . . 0.0 111.748 -179.527 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.485 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -117.5 125.9 51.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.705 0.764 . . . . 0.0 111.414 179.827 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.1 mm -98.08 114.78 36.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.726 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.528 HG22 HG23 ' A' ' 96' ' ' VAL . 4.1 t -90.53 107.73 18.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.35 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 61.9 m-85 -95.71 102.78 14.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.912 0.387 . . . . 0.0 111.479 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -89.66 105.84 18.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.178 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.77 101.98 8.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.237 0.541 . . . . 0.0 112.12 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.3 tppt? -96.49 -36.65 10.71 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.636 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.446 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.6 t70 -102.32 130.52 23.99 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.932 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -80.62 39.25 0.83 Allowed 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.089 2.526 . . . . 0.0 113.112 -179.543 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.428 ' HB2' HD12 ' A' ' 75' ' ' LEU . 2.5 m -70.07 137.77 87.2 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.299 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -63.01 -33.55 73.75 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 122.814 2.343 . . . . 0.0 112.982 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.9 p -75.54 -9.87 58.95 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.388 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.57 HD22 HG13 ' A' ' 45' ' ' VAL . 57.3 mt -112.93 14.62 19.77 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.469 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -68.33 -35.35 77.65 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-O 120.91 0.386 . . . . 0.0 111.461 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -131.62 165.9 22.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.932 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -139.13 133.68 40.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.945 0.402 . . . . 0.0 111.116 179.301 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -136.46 132.27 48.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.34 0.59 . . . . 0.0 111.403 179.378 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -94.35 102.08 7.85 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.136 -0.938 . . . . 0.0 109.466 178.798 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 109' ' ' PHE . 37.6 Cg_endo -65.92 -16.4 52.57 Favored 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.696 2.264 . . . . 0.0 113.696 -178.34 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -100.46 -7.38 24.31 Favored 'General case' 0 CA--C 1.535 0.394 0 N-CA-C 111.933 0.345 . . . . 0.0 111.933 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -120.44 -22.04 6.62 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.69 31.0 41.84 Favored Glycine 0 C--N 1.333 0.378 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.922 -179.325 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.3 t -114.46 117.06 54.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.633 0.254 . . . . 0.0 111.659 -178.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 -126.13 122.76 36.61 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.892 0.377 . . . . 0.0 110.617 179.244 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.77 171.21 14.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.655 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -106.32 143.54 34.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.73 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 38.7 mt -104.65 128.3 27.15 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.972 0.415 . . . . 0.0 111.359 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.417 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.5 Cg_endo -80.64 126.7 6.08 Favored 'Trans proline' 0 CA--C 1.532 0.421 0 C-N-CA 122.726 2.284 . . . . 0.0 112.507 179.284 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.4 tpt -65.35 124.93 23.55 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-O 120.974 0.416 . . . . 0.0 111.64 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.29 1.66 81.15 Favored Glycine 0 CA--C 1.52 0.387 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.959 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.417 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 42.6 mt-10 -134.04 177.37 7.79 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 120.885 0.374 . . . . 0.0 110.857 -179.567 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -117.55 134.24 55.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.179 0.514 . . . . 0.0 111.658 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -113.78 126.84 55.65 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.142 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.528 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -98.4 136.92 27.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 CA-C-O 121.55 0.69 . . . . 0.0 112.613 -179.053 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 62.0 t -115.52 111.4 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.132 178.837 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -92.66 118.42 31.03 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.52 -179.305 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.68 157.07 40.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.142 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.8 m -121.14 98.3 47.2 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.533 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.451 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.1 Cg_endo -72.79 100.62 1.21 Allowed 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.781 2.321 . . . . 0.0 112.376 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -95.34 6.7 48.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.791 0.329 . . . . 0.0 111.783 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.12 133.75 43.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.528 -0.305 . . . . 0.0 110.706 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.32 127.49 35.8 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.918 0.39 . . . . 0.0 111.29 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.08 -157.08 29.09 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.716 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -101.68 125.13 48.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.166 0.508 . . . . 0.0 111.684 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.456 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 82.6 m-85 -117.64 172.27 7.47 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.666 179.495 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 86.9 p -153.72 158.62 41.27 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -178.795 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' PHE . . . . . 0.404 ' HA ' ' HD2' ' A' ' 81' ' ' PRO . 37.5 p90 -148.71 134.46 18.88 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.87 178.666 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.264 0 CA-C-O 120.903 0.383 . . . . 0.0 111.564 -179.72 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 0.9 OUTLIER . . . . . 0 CA--C 1.53 0.182 0 CA-C-O 120.955 0.407 . . . . 0.0 111.033 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.456 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 3.0 ttm -130.58 137.68 49.78 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.09 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -120.92 118.32 55.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.024 0.44 . . . . 0.0 110.639 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 88.9 t -101.79 122.96 54.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.307 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 . . . . . 0 C--O 1.253 1.249 0 CA-C-O 118.163 -0.922 . . . . 0.0 111.462 -179.645 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.53 0.196 0 CA-C-O 121.163 0.506 . . . . 0.0 111.579 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.1 ttmt -101.38 129.62 47.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.619 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.09 152.84 39.83 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 111.187 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.516 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 22.8 pt20 -85.49 142.96 28.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.155 0.502 . . . . 0.0 111.791 -179.25 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -94.96 114.92 26.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.785 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -94.97 -150.72 0.31 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.024 0.44 . . . . 0.0 111.362 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -82.69 70.54 9.69 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.55 -9.83 59.05 Favored Glycine 0 CA--C 1.521 0.411 0 C-N-CA 120.771 -0.728 . . . . 0.0 113.713 178.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 32.8 p90 -137.93 165.64 26.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.953 0.376 . . . . 0.0 110.895 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.7 152.45 31.96 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.912 0.387 . . . . 0.0 111.103 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.516 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.9 tt0 -143.27 139.94 30.41 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.576 -179.325 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.0 128.42 22.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.975 179.185 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 11.0 ttt180 -89.28 108.85 19.85 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.297 0.57 . . . . 0.0 111.114 179.616 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.617 HG13 ' HD2' ' A' ' 51' ' ' PRO . 44.3 t -100.1 103.61 15.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.583 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -72.91 117.03 14.13 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.979 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.537 HG13 HD22 ' A' ' 75' ' ' LEU . 52.3 t -99.59 99.18 8.03 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.558 -178.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.486 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.7 ptm -145.86 86.68 1.73 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.182 179.112 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.22 -0.42 88.75 Favored Glycine 0 CA--C 1.52 0.368 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -178.243 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.441 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.8 -161.4 32.76 Favored Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 47.4 m-85 -101.99 126.39 48.91 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 117.046 0.423 . . . . 0.0 110.418 179.53 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.514 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 40.3 m -63.82 -63.49 3.87 Favored Pre-proline 0 CA--C 1.54 0.569 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.566 -179.547 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.617 ' HD2' HG13 ' A' ' 43' ' ' VAL . 68.2 Cg_endo -75.48 95.86 1.02 Allowed 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 121.301 1.334 . . . . 0.0 111.036 177.653 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -49.6 -43.54 46.47 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.32 -179.371 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.427 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.94 118.69 19.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.476 179.56 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.8 pt -97.45 126.4 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 121.086 0.469 . . . . 0.0 111.172 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 78.0 t -96.07 127.31 48.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.283 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 10.4 mt -135.0 171.51 14.33 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.558 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -97.13 173.26 7.34 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.739 179.453 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.0 ttpp -104.8 147.93 27.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.829 0.347 . . . . 0.0 111.926 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.4 t 65.49 20.7 11.74 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.751 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.438 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.95 136.46 27.49 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.169 -179.769 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -64.28 122.46 10.42 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.096 1.864 . . . . 0.0 111.47 178.242 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.91 138.04 54.26 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.99 0.424 . . . . 0.0 111.775 -179.45 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.418 HH11 ' HD2' ' A' ' 63' ' ' ARG . 6.7 ptt85 -120.67 126.55 50.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.789 0.804 . . . . 0.0 111.081 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.4 mm -100.07 114.16 37.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.759 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.507 HG22 HG23 ' A' ' 96' ' ' VAL . 3.0 t -89.93 107.49 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.467 -179.057 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -96.53 106.96 19.3 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.918 0.389 . . . . 0.0 111.318 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -91.54 105.79 18.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.633 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.45 96.2 5.32 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.204 0.526 . . . . 0.0 111.596 -179.338 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 17.4 tptt -90.95 -37.92 13.19 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.69 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.486 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.6 t70 -102.73 130.95 22.86 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.785 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -79.75 38.57 0.75 Allowed 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 123.151 2.567 . . . . 0.0 113.235 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.9 t -69.67 135.55 88.1 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.046 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.33 -28.21 63.4 Favored 'Trans proline' 0 C--N 1.349 0.556 0 C-N-CA 122.63 2.22 . . . . 0.0 112.42 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 22.7 m -78.75 -9.23 59.36 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.081 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.537 HD22 HG13 ' A' ' 45' ' ' VAL . 46.0 mt -116.05 17.27 15.9 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.456 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -71.7 -32.19 67.55 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -133.29 165.87 23.81 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.967 0.413 . . . . 0.0 111.393 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -140.57 130.14 26.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.98 179.296 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -130.27 132.7 64.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.481 0.657 . . . . 0.0 111.157 179.349 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -95.91 101.96 9.43 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.662 179.05 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.56 -15.19 46.93 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.59 2.193 . . . . 0.0 113.624 -178.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -100.71 -7.16 24.09 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -122.45 -22.06 5.58 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 112.017 0.376 . . . . 0.0 112.017 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.49 31.4 41.39 Favored Glycine 0 C--N 1.332 0.355 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.028 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.1 t -114.69 119.62 62.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.654 0.264 . . . . 0.0 111.657 -178.721 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 13.7 t-80 -126.37 119.8 28.23 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.841 0.353 . . . . 0.0 110.427 179.251 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.8 173.23 11.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.754 -179.474 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -110.07 151.44 27.2 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.046 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 28.0 mt -111.25 125.04 31.31 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-O 120.945 0.402 . . . . 0.0 111.386 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.427 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 64.5 Cg_endo -78.18 131.06 10.57 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 122.826 2.351 . . . . 0.0 112.708 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.6 tpt -66.81 124.43 22.92 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.799 -179.415 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 86.64 3.59 83.65 Favored Glycine 0 CA--C 1.52 0.345 0 CA-C-N 115.814 -0.63 . . . . 0.0 113.012 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.427 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 43.4 mt-10 -134.96 177.09 8.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.862 0.363 . . . . 0.0 110.905 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.56 134.8 54.82 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.231 0.539 . . . . 0.0 111.546 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -113.54 125.35 54.1 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.221 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.507 HG23 HG22 ' A' ' 65' ' ' VAL . 2.3 p -99.08 135.2 35.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.552 0.691 . . . . 0.0 112.489 -178.983 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 66.7 t -110.77 112.24 39.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.055 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -94.09 118.6 31.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.95 0.405 . . . . 0.0 111.475 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.99 166.5 28.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.146 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.2 m -129.66 97.51 24.32 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.486 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.438 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 70.2 Cg_endo -72.99 100.58 1.22 Allowed 'Trans proline' 0 CA--C 1.532 0.423 0 C-N-CA 122.844 2.363 . . . . 0.0 112.447 179.774 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -95.32 3.8 54.09 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.665 -179.586 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -132.16 134.68 45.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.735 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.32 124.24 34.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.974 0.416 . . . . 0.0 111.272 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 171.42 -165.34 38.32 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.884 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.25 115.47 27.67 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.19 0.519 . . . . 0.0 110.721 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.413 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 20.5 m-85 -111.4 173.03 6.54 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.971 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 85.5 p -152.58 165.1 36.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.307 0.575 . . . . 0.0 112.549 -178.573 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.2 p90 -152.07 136.86 17.09 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.441 178.89 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.256 0 CA-C-O 120.834 0.349 . . . . 0.0 111.825 -179.32 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.427 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.0 ttmm . . . . . 0 CA--C 1.529 0.164 0 CA-C-O 121.069 0.462 . . . . 0.0 111.828 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.413 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.6 ttm -134.74 131.22 37.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.773 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.7 mp -116.03 117.79 56.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.024 0.44 . . . . 0.0 110.67 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 74.8 t -101.8 122.53 54.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.288 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 . . . . . 0 C--O 1.252 1.213 0 CA-C-O 118.112 -0.947 . . . . 0.0 111.387 -179.583 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.53 0.203 0 CA-C-O 121.096 0.474 . . . . 0.0 111.402 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.8 mtpt -91.67 130.85 37.4 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.79 179.56 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.25 151.37 39.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.488 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.587 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.6 pt20 -79.04 139.4 38.16 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.142 0.496 . . . . 0.0 111.089 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -97.31 114.47 26.24 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.766 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -94.89 -154.5 0.43 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.256 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -82.11 74.23 9.1 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.14 -9.14 59.48 Favored Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.655 -0.783 . . . . 0.0 113.986 178.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 27.5 p90 -140.96 164.66 29.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 117.036 0.418 . . . . 0.0 111.066 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.67 153.65 29.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.974 0.416 . . . . 0.0 111.353 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.587 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.9 tt0 -143.36 143.08 31.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.46 -179.579 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.51 128.53 17.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.011 0.434 . . . . 0.0 111.08 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.63 106.12 18.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.213 0.53 . . . . 0.0 111.168 179.71 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.604 HG13 ' HD2' ' A' ' 51' ' ' PRO . 46.1 t -99.01 103.29 14.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.65 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.416 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.9 OUTLIER -73.09 118.2 15.75 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.789 -179.961 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.617 HG13 HD22 ' A' ' 75' ' ' LEU . 53.9 t -100.23 97.82 6.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.472 -178.852 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.473 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.9 ptm -143.27 85.02 1.84 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.372 179.273 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.08 0.24 88.9 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 -178.451 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.413 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.38 -169.29 36.15 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -92.17 125.73 36.96 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.924 0.362 . . . . 0.0 110.348 179.511 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.522 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 43.3 m -65.27 -63.97 3.02 Favored Pre-proline 0 CA--C 1.54 0.587 0 CA-C-O 119.557 -0.259 . . . . 0.0 111.293 -179.657 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.604 ' HD2' HG13 ' A' ' 43' ' ' VAL . 64.3 Cg_endo -75.03 96.55 1.03 Allowed 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 121.244 1.296 . . . . 0.0 111.205 177.815 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -51.36 -42.51 61.36 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.182 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.509 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -130.96 118.74 21.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.763 179.617 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.2 pt -99.16 126.93 52.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.951 0.405 . . . . 0.0 111.098 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 85.2 t -98.25 127.03 51.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.473 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.2 mt -135.95 165.52 25.47 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.318 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.6 mttt -90.12 176.26 6.84 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.728 179.164 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.2 ttpp -107.0 148.64 28.44 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -179.108 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.9 t 64.93 20.38 12.1 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.771 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.45 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.0 p -123.93 136.75 27.82 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.064 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.75 122.46 10.31 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.164 1.91 . . . . 0.0 111.639 178.607 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.45 139.8 53.65 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.969 0.414 . . . . 0.0 111.53 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.451 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.8 ptt180 -121.5 126.92 50.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.764 0.792 . . . . 0.0 111.344 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.7 mm -98.4 114.71 36.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.726 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.424 HG22 HG23 ' A' ' 96' ' ' VAL . 4.5 t -90.62 113.44 26.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.35 -179.391 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -100.31 114.87 28.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.077 0.465 . . . . 0.0 111.5 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -99.45 102.99 14.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.065 179.31 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.55 98.42 6.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.176 0.513 . . . . 0.0 111.998 -179.148 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.9 tptp -94.29 -35.69 12.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.536 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.473 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.8 t70 -106.17 130.79 22.43 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.931 179.579 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -81.2 39.39 0.85 Allowed 'Trans proline' 0 C--N 1.349 0.598 0 C-N-CA 123.059 2.506 . . . . 0.0 113.302 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -70.4 138.33 86.49 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.186 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -62.75 -32.73 78.08 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 122.924 2.416 . . . . 0.0 113.257 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.4 p -76.08 -8.06 56.13 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.779 0.323 . . . . 0.0 111.5 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.617 HD22 HG13 ' A' ' 45' ' ' VAL . 53.0 mt -114.88 13.67 17.15 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.356 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -68.49 -36.88 79.56 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-O 120.913 0.387 . . . . 0.0 111.643 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -132.23 161.58 33.08 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.066 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -136.96 131.22 46.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.038 0.446 . . . . 0.0 111.083 179.521 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -133.09 132.96 58.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 121.362 0.601 . . . . 0.0 111.31 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -94.76 102.14 8.39 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.509 178.842 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.25 -16.55 52.14 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.67 2.246 . . . . 0.0 113.668 -178.381 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -100.38 -7.04 24.83 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -120.52 -20.78 7.03 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 77.37 32.31 48.02 Favored Glycine 0 C--N 1.333 0.398 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.944 -179.198 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.1 t -116.72 117.98 57.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 -178.581 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 22.3 t-80 -123.79 122.03 36.98 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.802 0.334 . . . . 0.0 110.402 179.042 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.9 163.64 28.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.704 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.88 139.04 40.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.481 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 45.7 mt -101.34 128.45 29.22 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 120.856 0.36 . . . . 0.0 111.541 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.433 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 72.7 Cg_endo -82.91 128.65 5.19 Favored 'Trans proline' 0 CA--C 1.532 0.415 0 C-N-CA 122.71 2.273 . . . . 0.0 112.388 179.198 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -66.45 125.12 24.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.08 0.467 . . . . 0.0 111.725 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.88 11.77 80.9 Favored Glycine 0 CA--C 1.52 0.364 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.98 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.433 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.6 mm-40 -137.64 176.97 8.23 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.89 0.376 . . . . 0.0 111.083 -179.604 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -113.37 134.73 54.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.025 0.441 . . . . 0.0 111.733 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.1 t80 -123.98 127.86 48.54 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.935 178.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.424 HG23 HG22 ' A' ' 65' ' ' VAL . 2.3 p -107.0 137.18 39.16 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 CA-C-O 121.417 0.627 . . . . 0.0 112.628 -178.865 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 67.2 t -112.93 113.19 43.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.134 178.907 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -94.11 120.15 33.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.95 0.405 . . . . 0.0 111.516 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -136.0 157.9 38.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.82 97.79 48.14 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.682 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 67.1 Cg_endo -72.82 101.31 1.29 Allowed 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.814 2.343 . . . . 0.0 112.15 179.539 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -95.51 1.96 54.15 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -179.393 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -129.81 134.84 47.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.762 0.315 . . . . 0.0 110.74 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.93 124.25 34.56 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.007 0.432 . . . . 0.0 111.273 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 166.82 -157.3 29.71 Favored Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.63 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -101.64 125.72 48.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.187 0.518 . . . . 0.0 111.487 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.446 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 84.9 m-85 -117.34 171.44 7.97 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.013 179.731 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.3 p -150.22 158.31 44.02 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 -178.765 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -150.4 131.46 14.37 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.957 178.821 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.075 -179.858 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.509 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.7 ttpt . . . . . 0 CA--C 1.53 0.181 0 CA-C-O 121.204 0.526 . . . . 0.0 111.904 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.446 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.6 ttm -132.4 139.15 47.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.686 179.439 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -122.39 119.72 59.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.116 0.484 . . . . 0.0 110.854 179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 90.9 t -102.97 123.08 56.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.272 -179.695 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 . . . . . 0 C--O 1.252 1.201 0 CA-C-O 118.169 -0.92 . . . . 0.0 111.42 -179.774 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 18.4 mm-40 . . . . . 0 C--O 1.233 0.195 0 CA-C-O 121.128 0.489 . . . . 0.0 111.328 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -89.97 125.59 35.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.709 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -70.93 152.07 44.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.238 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.53 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 7.3 pt20 -81.27 137.99 35.77 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.214 0.531 . . . . 0.0 111.448 -179.328 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.2 mp0 -94.53 113.2 25.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.865 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.63 -151.32 0.28 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.191 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -83.81 77.51 9.87 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 112.03 0.382 . . . . 0.0 112.03 -179.223 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.15 -6.49 68.98 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 120.812 -0.709 . . . . 0.0 114.047 178.869 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.7 p90 -143.54 161.34 38.72 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.045 0.423 . . . . 0.0 111.072 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.19 156.63 21.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.058 0.456 . . . . 0.0 111.349 179.744 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.53 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.4 tt0 -145.75 144.45 30.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.434 -179.566 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -146.96 129.04 7.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.732 179.135 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.417 HH11 ' HD2' ' A' ' 42' ' ' ARG . 0.1 OUTLIER -90.9 110.18 21.41 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.252 0.548 . . . . 0.0 110.938 179.305 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.491 HG13 ' HD2' ' A' ' 51' ' ' PRO . 60.6 t -100.42 108.21 22.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.757 -179.668 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -72.68 124.97 26.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.648 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.569 HG13 HD22 ' A' ' 75' ' ' LEU . 53.7 t -104.64 96.44 4.6 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 CA-C-O 121.475 0.655 . . . . 0.0 111.262 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.484 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.0 ptp -141.97 87.74 2.06 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.373 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.11 -15.88 36.27 Favored Glycine 0 CA--C 1.522 0.482 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.127 -178.035 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 178.79 -138.72 3.71 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.483 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -121.09 129.59 53.38 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.862 0.331 . . . . 0.0 110.59 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.489 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 20.2 m -65.84 -60.93 6.34 Favored Pre-proline 0 CA--C 1.538 0.519 0 C-N-CA 121.027 -0.269 . . . . 0.0 110.911 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.491 ' HD2' HG13 ' A' ' 43' ' ' VAL . 74.4 Cg_endo -76.79 95.77 1.07 Allowed 'Trans proline' 0 C--N 1.358 1.045 0 C-N-CA 121.333 1.355 . . . . 0.0 110.968 177.575 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.77 -42.73 58.11 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.331 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.482 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.73 118.52 20.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.782 179.52 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.8 pt -97.32 124.45 50.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.085 0.469 . . . . 0.0 110.888 179.501 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.5 t -97.25 126.73 49.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.509 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.3 mt -134.21 170.12 16.17 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.357 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.28 173.73 7.57 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.684 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.6 ttpt -104.29 146.7 28.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.779 0.323 . . . . 0.0 111.844 -179.206 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.4 t 64.97 20.86 12.21 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.832 179.627 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.45 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 7.9 p -123.44 135.61 26.26 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.935 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.6 Cg_endo -64.34 122.49 10.45 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 122.076 1.85 . . . . 0.0 111.668 178.588 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.25 138.86 54.35 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.877 0.37 . . . . 0.0 111.577 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.413 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -121.57 126.79 49.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.769 0.795 . . . . 0.0 111.439 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.0 mm -99.0 115.82 40.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.836 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.483 HG22 HG23 ' A' ' 96' ' ' VAL . 3.2 t -91.71 110.25 22.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.216 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -95.59 114.77 26.56 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.076 0.465 . . . . 0.0 111.467 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -99.93 104.48 16.11 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.398 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.4 ' HA ' ' HB ' ' A' ' 45' ' ' VAL . 0.1 OUTLIER -77.6 106.54 9.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.274 0.559 . . . . 0.0 112.144 -179.155 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -101.23 -33.83 9.91 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.415 179.293 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.484 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.0 t70 -110.6 133.87 21.04 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.862 179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -81.67 40.29 0.96 Allowed 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 123.086 2.524 . . . . 0.0 112.975 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.41 137.29 93.56 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.308 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -63.03 -35.02 68.24 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.938 2.426 . . . . 0.0 112.941 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.35 -6.68 54.16 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.595 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.569 HD22 HG13 ' A' ' 45' ' ' VAL . 58.2 mt -114.32 7.75 16.5 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.426 -179.777 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -66.18 -38.46 88.09 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.089 0.471 . . . . 0.0 111.451 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -124.74 158.72 32.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.576 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -133.23 127.79 54.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.379 0.609 . . . . 0.0 110.937 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.68 129.63 58.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.294 0.568 . . . . 0.0 111.105 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -92.9 102.02 6.29 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.402 178.839 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.26 -16.35 51.42 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.626 2.217 . . . . 0.0 113.77 -178.315 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 46.5 m-20 -100.71 -6.83 24.48 Favored 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.0 m-85 -120.97 -22.54 6.14 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 81.7 25.45 53.37 Favored Glycine 0 C--N 1.332 0.348 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.07 -179.442 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.1 t -106.48 117.95 53.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.844 0.354 . . . . 0.0 111.663 -178.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -121.16 118.9 30.84 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.598 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.79 167.17 21.36 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.172 0.51 . . . . 0.0 111.945 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -109.38 138.66 45.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.621 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 51.8 mt -101.13 128.46 29.39 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.89 0.376 . . . . 0.0 111.39 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.435 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 74.4 Cg_endo -82.0 128.15 5.68 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 122.768 2.312 . . . . 0.0 112.428 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.4 tpt -66.3 124.55 23.0 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.046 0.451 . . . . 0.0 111.623 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.53 9.3 81.74 Favored Glycine 0 CA--C 1.521 0.418 0 CA-C-N 115.857 -0.611 . . . . 0.0 113.075 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.435 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 50.1 mm-40 -136.9 176.75 8.43 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.903 0.382 . . . . 0.0 111.342 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -112.9 136.32 52.68 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.036 0.446 . . . . 0.0 111.744 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -124.23 126.25 45.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.039 178.975 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.483 HG23 HG22 ' A' ' 65' ' ' VAL . 1.8 p -102.99 138.19 28.2 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-O 121.58 0.705 . . . . 0.0 112.511 -178.778 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 64.5 t -115.51 112.34 39.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.188 178.782 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -93.8 118.99 32.18 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.934 0.397 . . . . 0.0 111.576 -179.307 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.11 156.33 39.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.073 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.4 m -120.03 98.32 49.21 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.461 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.9 Cg_endo -71.88 99.14 0.94 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.713 2.275 . . . . 0.0 112.561 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -97.7 22.79 8.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.09 0.471 . . . . 0.0 111.515 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.15 131.78 14.89 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.464 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.29 127.29 35.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.983 0.421 . . . . 0.0 111.407 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 164.42 -157.33 29.64 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.759 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.18 126.59 49.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.168 0.509 . . . . 0.0 111.544 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.446 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 86.4 m-85 -119.32 171.99 7.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.891 179.641 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 87.8 p -153.73 159.85 42.11 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.909 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -150.53 131.14 13.95 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.093 178.866 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.325 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.295 -179.774 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 4.5 ttmm . . . . . 0 CA--C 1.531 0.244 0 CA-C-O 121.053 0.454 . . . . 0.0 111.229 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.446 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -132.83 140.42 47.95 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.994 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.95 119.77 56.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.061 0.458 . . . . 0.0 110.877 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.9 t -101.89 124.68 55.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.079 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.251 1.158 0 CA-C-O 118.045 -0.979 . . . . 0.0 111.898 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.232 0.168 0 CA-C-O 121.187 0.517 . . . . 0.0 111.168 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -88.27 126.58 35.24 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.631 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.03 150.56 45.47 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.141 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.551 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 19.8 pt20 -79.44 137.5 37.27 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.297 0.57 . . . . 0.0 111.283 -179.323 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.5 mp0 -94.52 114.02 25.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.963 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -93.03 -156.08 0.46 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.072 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -83.56 76.91 9.92 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-O 120.851 0.358 . . . . 0.0 111.948 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.25 -12.71 57.19 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 120.806 -0.712 . . . . 0.0 114.151 178.876 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -140.69 167.47 22.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 117.16 0.48 . . . . 0.0 111.353 -179.595 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.93 155.0 28.78 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.863 0.363 . . . . 0.0 111.119 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.551 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 5.8 tt0 -145.35 142.23 29.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.562 -179.271 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.39 129.84 17.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.312 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -91.67 110.22 21.54 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.239 0.542 . . . . 0.0 111.058 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.62 HG13 ' HD2' ' A' ' 51' ' ' PRO . 46.4 t -100.48 104.01 15.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.589 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.427 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.9 OUTLIER -73.16 116.98 14.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.845 -179.91 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.556 HG13 HD22 ' A' ' 75' ' ' LEU . 41.1 t -97.41 98.46 7.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.365 -178.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.466 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.8 ptp -139.6 81.93 1.85 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.383 179.383 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 88.01 -8.98 76.39 Favored Glycine 0 CA--C 1.521 0.429 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 -178.342 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 172.85 -153.36 18.35 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -105.42 125.65 51.23 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.825 0.313 . . . . 0.0 110.54 179.648 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.516 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 45.2 m -65.13 -64.48 2.61 Favored Pre-proline 0 CA--C 1.538 0.518 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.407 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.62 ' HD2' HG13 ' A' ' 43' ' ' VAL . 60.1 Cg_endo -74.11 97.91 1.05 Allowed 'Trans proline' 0 C--N 1.358 1.039 0 C-N-CA 121.266 1.311 . . . . 0.0 111.001 177.684 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.63 -44.04 57.18 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.163 -179.236 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.453 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.6 118.99 19.88 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.605 0.241 . . . . 0.0 110.959 179.57 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.0 pt -97.07 126.96 49.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 121.054 0.454 . . . . 0.0 110.747 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 84.6 t -98.09 126.93 50.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.505 -179.649 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.8 mt -135.63 166.52 23.05 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.567 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.7 tttt -93.1 170.24 9.8 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.709 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.5 ttpp -100.45 148.25 24.96 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.403 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.2 t 65.84 20.14 11.38 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.917 179.393 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.434 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.2 p -123.8 135.88 26.74 Favored Pre-proline 0 CA--C 1.537 0.445 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.977 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -64.4 122.77 10.8 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.198 1.932 . . . . 0.0 111.575 178.637 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.67 138.51 53.9 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.956 0.408 . . . . 0.0 111.728 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.433 ' CG ' ' HG3' ' A' ' 40' ' ' GLU . 0.0 OUTLIER -121.06 129.4 53.33 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.767 0.794 . . . . 0.0 111.517 179.739 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.4 mm -100.76 115.69 42.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.817 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.435 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.77 111.69 24.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 120.766 0.317 . . . . 0.0 111.326 -179.3 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -97.7 113.22 24.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.053 0.454 . . . . 0.0 111.354 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -98.96 105.19 17.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.215 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -79.09 104.8 9.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.29 0.566 . . . . 0.0 112.22 -178.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.2 tppt? -99.35 -36.09 9.72 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.086 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.466 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 6.4 t70 -103.79 129.86 24.53 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.852 179.562 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -80.49 39.47 0.85 Allowed 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.998 2.465 . . . . 0.0 112.939 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.493 ' HB2' HD12 ' A' ' 75' ' ' LEU . 2.1 m -69.95 135.67 87.47 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.382 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -64.05 -29.9 66.06 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.901 2.401 . . . . 0.0 112.811 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.71 -9.38 58.63 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.599 179.761 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.556 HD22 HG13 ' A' ' 45' ' ' VAL . 29.1 mt -113.17 12.52 19.07 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 120.784 0.326 . . . . 0.0 111.321 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -67.44 -35.18 78.72 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.785 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -129.48 160.68 32.42 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.805 0.336 . . . . 0.0 111.21 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.67 129.01 33.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.181 0.515 . . . . 0.0 110.85 179.292 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.5 p -132.04 132.4 61.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.276 0.56 . . . . 0.0 111.257 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 15.7 m-85 -94.93 101.92 8.11 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.725 179.032 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -67.09 -15.23 46.05 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.722 2.281 . . . . 0.0 113.562 -178.653 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 -99.62 -7.34 25.88 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -122.67 -22.13 5.46 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.092 0.405 . . . . 0.0 112.092 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 81.45 26.43 51.33 Favored Glycine 0 CA--C 1.52 0.374 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.044 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.6 t -107.69 117.37 53.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.746 0.307 . . . . 0.0 111.709 -178.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -119.12 117.94 30.05 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.519 179.214 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.67 167.54 19.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.156 0.503 . . . . 0.0 112.222 -179.157 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -111.69 141.2 45.6 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.319 179.562 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 53.1 mt -103.56 127.75 28.89 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.005 0.431 . . . . 0.0 111.566 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.443 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 72.5 Cg_endo -82.94 129.85 5.53 Favored 'Trans proline' 0 CA--C 1.532 0.411 0 C-N-CA 122.846 2.364 . . . . 0.0 112.481 179.271 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.5 tpt -67.58 125.24 25.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.008 0.432 . . . . 0.0 111.71 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 83.29 11.61 80.3 Favored Glycine 0 CA--C 1.52 0.405 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.877 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.443 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 53.7 mm-40 -137.46 176.86 8.33 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.007 0.432 . . . . 0.0 111.157 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -113.37 132.77 55.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.78 -179.716 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -121.75 125.11 45.8 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.967 178.876 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.435 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -105.16 137.06 36.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.549 0.69 . . . . 0.0 112.472 -178.887 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -112.79 112.11 39.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.153 178.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -93.67 119.22 32.4 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.953 0.406 . . . . 0.0 111.416 -179.469 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.91 158.24 38.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.339 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -121.67 96.81 47.11 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.469 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.434 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.9 Cg_endo -71.59 99.44 0.94 Allowed 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.823 2.349 . . . . 0.0 112.294 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -94.07 4.47 53.85 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.995 0.368 . . . . 0.0 111.995 -179.3 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -133.88 135.63 43.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.756 0.313 . . . . 0.0 110.933 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.59 124.9 34.5 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.837 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.35 -167.56 40.51 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.796 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -97.9 114.72 26.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.105 0.479 . . . . 0.0 110.631 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.402 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 20.7 m-85 -111.4 172.42 6.9 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.177 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 87.1 p -158.17 164.88 36.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.155 0.502 . . . . 0.0 112.196 -178.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -148.26 137.39 21.92 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.762 179.017 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.219 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.277 -179.719 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.453 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.8 ttmt . . . . . 0 CA--C 1.53 0.194 0 CA-C-O 120.974 0.416 . . . . 0.0 111.359 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.402 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -133.68 133.62 42.1 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.896 179.685 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.13 117.36 53.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.071 0.463 . . . . 0.0 110.753 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 94.7 t -101.65 121.94 53.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.155 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.277 -0.868 . . . . 0.0 111.538 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.233 0.235 0 CA-C-O 120.959 0.409 . . . . 0.0 111.502 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.6 ttmt -90.37 126.71 35.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.501 179.565 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.36 151.11 46.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.028 0.442 . . . . 0.0 111.464 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.578 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.7 pt20 -78.28 143.52 36.95 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.379 -179.544 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -98.68 115.33 28.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.855 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.63 -151.62 0.36 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.484 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -81.65 75.52 8.6 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -179.171 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.4 -7.47 68.82 Favored Glycine 0 CA--C 1.523 0.573 0 C-N-CA 120.72 -0.753 . . . . 0.0 114.047 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -141.35 161.48 37.78 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.959 0.38 . . . . 0.0 110.981 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.06 155.71 22.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.102 0.477 . . . . 0.0 111.154 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.578 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.9 tt0 -144.53 143.89 31.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.616 -179.382 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.17 128.71 16.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.081 0.467 . . . . 0.0 110.963 178.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.69 109.03 20.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.33 0.586 . . . . 0.0 110.962 179.535 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.628 HG13 ' HD2' ' A' ' 51' ' ' PRO . 45.1 t -99.75 103.95 15.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.599 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.415 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 1.1 tp10 -73.17 117.62 15.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.857 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.592 HG13 HD22 ' A' ' 75' ' ' LEU . 54.3 t -99.52 98.55 7.18 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.526 -178.792 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.491 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.3 ptm -145.25 86.97 1.78 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.4 179.304 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 83.66 -2.51 87.25 Favored Glycine 0 CA--C 1.521 0.407 0 C-N-CA 120.824 -0.703 . . . . 0.0 111.468 -178.429 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.421 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 162.9 -171.17 38.63 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 30.3 m-85 -91.78 124.94 36.29 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.816 0.308 . . . . 0.0 110.354 179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.524 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 45.0 m -63.99 -64.35 2.95 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 119.638 -0.22 . . . . 0.0 111.407 -179.42 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.628 ' HD2' HG13 ' A' ' 43' ' ' VAL . 62.1 Cg_endo -74.98 96.88 1.04 Allowed 'Trans proline' 0 C--N 1.357 0.977 0 C-N-CA 121.299 1.333 . . . . 0.0 111.075 177.729 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.84 -43.19 59.12 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.261 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.36 118.52 20.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.622 -0.263 . . . . 0.0 110.708 179.667 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.7 pt -98.3 125.43 51.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.031 0.443 . . . . 0.0 111.15 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 75.9 t -98.62 126.71 51.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.425 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.423 HD22 ' HB1' ' A' ' 62' ' ' ALA . 5.4 mt -132.74 171.5 13.79 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.472 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.95 170.02 9.72 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.549 179.403 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.6 ttpp -102.43 147.06 27.19 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.86 0.362 . . . . 0.0 111.909 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.4 t 65.27 20.46 11.89 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.527 -0.76 . . . . 0.0 111.701 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.425 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 7.4 p -123.66 136.41 27.26 Favored Pre-proline 0 CA--C 1.534 0.356 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.003 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -64.33 122.7 10.72 Favored 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 121.984 1.79 . . . . 0.0 111.412 178.442 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.423 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -125.29 138.49 54.08 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.017 0.437 . . . . 0.0 111.582 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.438 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.9 ptt180 -120.55 127.74 52.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.727 0.775 . . . . 0.0 111.418 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.0 mm -99.4 114.68 38.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.628 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.495 HG22 HG23 ' A' ' 96' ' ' VAL . 3.3 t -92.01 110.53 22.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.697 0.284 . . . . 0.0 111.553 -179.284 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -97.1 120.05 36.72 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.013 0.435 . . . . 0.0 111.233 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -103.93 105.18 15.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.433 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ARG . . . . . 0.401 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 2.0 tpt180 -77.77 97.81 5.32 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.161 0.505 . . . . 0.0 111.605 -179.427 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.8 tptp -93.71 -32.93 13.83 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.412 179.428 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.491 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.9 t70 -111.28 131.66 22.13 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.741 179.661 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -80.24 39.33 0.83 Allowed 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 123.075 2.516 . . . . 0.0 112.978 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.13 135.76 91.57 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.159 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.26 -33.28 60.34 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.764 2.309 . . . . 0.0 112.875 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -77.37 -1.97 32.71 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.55 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.592 HD22 HG13 ' A' ' 45' ' ' VAL . 28.8 mt -119.01 9.13 11.76 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.457 -179.749 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.9 -41.04 78.76 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -122.09 149.37 43.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.028 0.442 . . . . 0.0 111.591 -179.495 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -131.51 129.18 61.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.54 179.238 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 p -132.7 131.35 59.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.439 0.637 . . . . 0.0 111.44 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -92.86 101.93 6.1 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.448 178.649 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.41 -15.52 45.64 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.631 2.221 . . . . 0.0 113.657 -178.465 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -100.12 -9.61 22.38 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.5 m-85 -119.46 -21.41 7.43 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 80.95 28.33 46.34 Favored Glycine 0 CA--C 1.52 0.346 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.074 -179.589 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.4 t -109.44 117.58 54.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.786 0.327 . . . . 0.0 111.731 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -120.59 119.74 33.76 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.428 179.481 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.72 167.92 20.72 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 121.182 0.515 . . . . 0.0 112.344 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -113.3 143.27 44.72 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.316 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 30.7 mt -103.53 124.35 38.34 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.451 . . . . 0.0 111.599 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.421 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 68.6 Cg_endo -79.09 130.38 9.33 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.771 2.314 . . . . 0.0 112.662 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 91' ' ' MET . . . . . 0.401 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 11.2 tpt -67.47 124.77 24.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.138 0.494 . . . . 0.0 111.748 -179.597 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 83.53 9.68 82.98 Favored Glycine 0 CA--C 1.521 0.411 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.975 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.421 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.4 mm-40 -136.21 176.69 8.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.865 0.364 . . . . 0.0 111.284 -179.537 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -114.07 134.72 54.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.013 0.435 . . . . 0.0 111.574 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' TYR . . . . . 0.4 ' HB2' ' HD2' ' A' ' 90' ' ' PRO . 8.7 t80 -122.52 124.09 42.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.036 178.918 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.495 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -104.37 136.99 35.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 CA-C-O 121.563 0.697 . . . . 0.0 112.533 -178.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 54.2 t -112.98 112.11 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.16 179.02 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -93.52 119.57 32.75 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.517 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.6 158.28 39.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.207 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 m -121.51 96.79 47.44 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.525 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.425 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.8 Cg_endo -72.93 101.18 1.29 Allowed 'Trans proline' 0 CA--C 1.532 0.399 0 C-N-CA 122.855 2.37 . . . . 0.0 112.349 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -95.51 5.53 51.31 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 111.898 0.333 . . . . 0.0 111.898 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -132.4 133.97 44.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.763 0.316 . . . . 0.0 110.751 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -90.61 128.26 36.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.983 0.42 . . . . 0.0 111.301 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 162.64 -155.88 27.36 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.694 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -102.19 126.91 49.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.21 0.529 . . . . 0.0 111.468 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.435 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 89.9 m-85 -120.69 173.28 7.3 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.885 179.733 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 14.9 m -154.9 156.91 36.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.197 0.523 . . . . 0.0 112.399 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -146.26 142.21 28.12 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.726 179.246 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.215 0 CA-C-O 120.961 0.41 . . . . 0.0 111.68 -179.487 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.1 ttpt . . . . . 0 CA--C 1.531 0.222 0 CA-C-O 121.122 0.487 . . . . 0.0 112.054 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.435 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.4 ttm -135.73 139.76 43.86 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.805 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.32 120.64 59.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.027 0.441 . . . . 0.0 110.667 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 90.2 t -102.88 123.31 56.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.272 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 . . . . . 0 C--O 1.252 1.191 0 CA-C-O 118.184 -0.913 . . . . 0.0 111.416 -179.554 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.139 0 CA-C-O 121.026 0.441 . . . . 0.0 111.297 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.22 126.12 35.72 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.753 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.4 148.97 46.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.257 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.585 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 18.6 pt20 -76.49 140.21 41.12 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.269 0.557 . . . . 0.0 111.217 -179.461 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -97.45 115.94 28.72 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.92 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -95.33 -151.91 0.35 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.522 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -82.46 72.88 9.52 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -179.275 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.12 -8.74 61.06 Favored Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.678 -0.773 . . . . 0.0 113.902 178.971 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -139.1 165.29 27.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 117.03 0.415 . . . . 0.0 110.932 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.2 153.07 31.52 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.994 0.426 . . . . 0.0 111.058 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.585 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 6.7 tt0 -144.42 140.49 29.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.412 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.01 130.24 24.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.131 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -90.6 110.06 21.21 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.178 0.513 . . . . 0.0 110.999 179.463 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.511 HG13 ' HD2' ' A' ' 51' ' ' PRO . 53.1 t -102.1 109.84 27.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.738 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.98 123.16 23.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.727 179.793 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.543 HG13 HD22 ' A' ' 75' ' ' LEU . 67.2 t -104.25 95.78 4.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-O 121.479 0.656 . . . . 0.0 111.376 -179.372 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.467 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 6.2 ptm -146.58 87.89 1.74 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.281 179.27 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.52 -0.84 89.22 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.432 -178.321 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.45 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.57 -144.36 9.88 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 111.5 -0.64 . . . . 0.0 111.5 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -119.1 128.61 54.46 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.774 0.287 . . . . 0.0 110.636 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.504 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 22.0 m -65.61 -61.66 5.52 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-O 119.572 -0.252 . . . . 0.0 110.958 179.775 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.511 ' HD2' HG13 ' A' ' 43' ' ' VAL . 68.9 Cg_endo -75.91 95.75 1.03 Allowed 'Trans proline' 0 C--N 1.357 0.998 0 C-N-CA 121.325 1.35 . . . . 0.0 111.038 177.742 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.6 -42.13 55.56 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.162 -179.206 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.441 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -133.8 118.99 18.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.83 179.477 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.472 HG13 ' HG3' ' A' ' 120' ' ' MET . 6.0 pt -96.67 126.62 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-O 121.062 0.458 . . . . 0.0 110.969 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 94.8 t -97.72 125.94 50.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.443 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.461 HD22 ' HB1' ' A' ' 62' ' ' ALA . 3.5 mt -135.67 165.03 26.52 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.307 -179.662 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.6 mmtt -89.01 176.41 7.01 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 120.769 0.318 . . . . 0.0 111.046 179.415 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.8 ttpp -106.93 148.26 28.84 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.834 0.349 . . . . 0.0 111.929 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.4 t 64.73 20.85 12.26 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.644 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.413 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.8 p -123.88 136.17 27.13 Favored Pre-proline 0 CA--C 1.537 0.457 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.998 -179.776 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -63.57 120.87 8.43 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.111 1.874 . . . . 0.0 111.688 178.595 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.461 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -123.82 138.29 54.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.845 0.355 . . . . 0.0 111.598 -179.425 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.414 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.4 OUTLIER -123.19 128.42 50.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.784 0.802 . . . . 0.0 111.537 179.867 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.2 mm -99.69 116.31 42.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.883 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.431 HG22 HG23 ' A' ' 96' ' ' VAL . 3.6 t -91.63 112.56 25.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.812 0.339 . . . . 0.0 111.246 -179.501 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -98.21 116.84 31.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.116 0.484 . . . . 0.0 111.528 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -100.78 103.31 14.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.387 179.468 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.54 102.85 7.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.247 0.546 . . . . 0.0 112.157 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.5 tptp -97.44 -38.37 9.63 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.588 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.467 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.0 t70 -103.0 130.72 23.13 Favored Pre-proline 0 CA--C 1.535 0.375 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.95 179.68 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -81.31 39.43 0.86 Allowed 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 123.099 2.532 . . . . 0.0 113.209 -179.394 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 29.1 t -70.5 135.16 86.35 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.263 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.15 -26.85 64.91 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.673 2.249 . . . . 0.0 112.519 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.3 m -80.24 -10.93 59.77 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.131 179.631 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.543 HD22 HG13 ' A' ' 45' ' ' VAL . 24.0 mt -113.9 13.7 18.39 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.213 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -70.21 -34.15 72.57 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.575 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -127.21 161.88 27.5 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.969 0.414 . . . . 0.0 111.511 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -138.76 127.97 30.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.338 178.477 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 1.5 p -131.72 130.08 61.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.282 0.563 . . . . 0.0 111.545 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -92.65 101.84 5.8 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.279 178.576 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.94 -13.32 38.04 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 122.566 2.177 . . . . 0.0 113.64 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -100.49 -11.72 19.92 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 111.929 0.344 . . . . 0.0 111.929 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -120.77 -17.82 7.85 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -178.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.78 29.24 52.68 Favored Glycine 0 C--N 1.333 0.371 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.541 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 54.2 t -109.06 113.59 44.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.81 0.338 . . . . 0.0 111.748 -179.113 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -117.93 117.44 29.27 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.401 179.368 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.57 167.59 20.19 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-O 121.342 0.591 . . . . 0.0 112.44 -179.044 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -110.1 139.8 44.86 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.257 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 46.3 mt -102.89 126.61 32.08 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.943 0.402 . . . . 0.0 111.481 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.443 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 70.1 Cg_endo -81.03 128.79 6.63 Favored 'Trans proline' 0 CA--C 1.532 0.393 0 C-N-CA 122.794 2.33 . . . . 0.0 112.414 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -65.92 124.83 23.56 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 121.042 0.449 . . . . 0.0 111.837 -179.497 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.94 9.6 84.17 Favored Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.923 -0.581 . . . . 0.0 113.055 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.443 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 47.5 mt-10 -135.14 176.79 8.34 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-O 120.94 0.4 . . . . 0.0 111.08 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -113.12 134.63 54.46 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.981 0.42 . . . . 0.0 111.799 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.9 t80 -123.22 126.59 47.23 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.899 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.431 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -106.15 138.87 29.47 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 CA-C-O 121.527 0.679 . . . . 0.0 112.64 -178.721 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 63' ' ' ARG . 53.8 t -114.22 112.3 39.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.164 178.789 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -94.76 119.1 32.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.018 0.437 . . . . 0.0 111.626 -179.532 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.03 157.57 40.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.273 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.8 m -120.73 96.67 48.75 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.326 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.413 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 71.6 Cg_endo -73.31 102.68 1.5 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.81 2.34 . . . . 0.0 112.434 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -97.71 10.6 39.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.902 0.382 . . . . 0.0 111.9 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.26 130.25 30.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.851 0.358 . . . . 0.0 110.874 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.07 128.22 35.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.372 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 165.79 -155.15 26.26 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.847 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -107.96 125.63 51.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.122 0.487 . . . . 0.0 111.012 -179.639 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -124.29 166.92 15.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.305 -179.74 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.19 157.9 43.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.182 0.515 . . . . 0.0 112.29 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -146.36 135.57 22.75 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.623 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.278 0 CA-C-O 120.799 0.333 . . . . 0.0 111.406 -179.627 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.441 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.0 ttpt . . . . . 0 CA--C 1.53 0.199 0 CA-C-O 121.223 0.535 . . . . 0.0 111.783 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.472 ' HG3' HG13 ' A' ' 54' ' ' ILE . 10.1 ttp -134.36 130.73 37.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.657 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -117.61 118.78 59.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.038 0.447 . . . . 0.0 111.097 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 57.8 t -101.29 119.83 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.886 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.005 -0.998 . . . . 0.0 112.063 -179.622 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.174 0 CA-C-O 121.066 0.46 . . . . 0.0 111.454 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 8.4 ttmt -91.43 128.45 37.26 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.788 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.8 152.22 41.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.163 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 -82.75 141.51 32.32 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.206 0.527 . . . . 0.0 111.555 -179.403 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -95.34 115.69 27.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.805 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.71 -150.87 0.33 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.245 -179.831 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -83.11 78.0 9.66 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.85 -6.34 73.31 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.94 -0.648 . . . . 0.0 114.111 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -143.35 161.88 37.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 117.039 0.419 . . . . 0.0 111.094 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.11 155.56 21.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.982 0.42 . . . . 0.0 111.081 179.603 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -146.01 140.31 26.76 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.7 -179.17 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.06 130.12 21.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.791 179.108 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' ARG . . . . . 0.411 HH11 ' HD2' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -91.5 111.05 22.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.192 0.52 . . . . 0.0 111.113 179.535 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.646 HG13 ' HD2' ' A' ' 51' ' ' PRO . 44.9 t -100.54 103.8 15.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.681 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -72.27 115.31 11.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.602 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.53 HG13 HD22 ' A' ' 75' ' ' LEU . 53.8 t -97.68 98.74 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.489 0.662 . . . . 0.0 111.432 -178.686 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.555 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.6 ptm -145.76 89.51 1.91 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.502 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.3 -0.89 83.26 Favored Glycine 0 CA--C 1.521 0.418 0 C-N-CA 120.869 -0.681 . . . . 0.0 111.59 -178.402 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' GLY . . . . . 0.453 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 161.83 -173.29 38.16 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -90.14 124.66 35.01 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.896 0.348 . . . . 0.0 110.17 179.479 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.515 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 31.7 m -63.36 -63.9 3.54 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 119.648 -0.215 . . . . 0.0 111.317 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.646 ' HD2' HG13 ' A' ' 43' ' ' VAL . 63.5 Cg_endo -75.63 96.97 1.07 Allowed 'Trans proline' 0 C--N 1.358 1.038 0 C-N-CA 121.267 1.312 . . . . 0.0 111.068 177.506 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.61 -43.31 56.77 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 116.057 -0.519 . . . . 0.0 112.38 -179.222 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.465 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.39 118.58 19.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.655 179.684 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.436 HG13 ' HG3' ' A' ' 120' ' ' MET . 5.6 pt -97.67 125.72 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-O 121.085 0.469 . . . . 0.0 111.037 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 83.9 t -97.76 126.67 50.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.36 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' LEU . . . . . 0.442 HD22 ' HB1' ' A' ' 62' ' ' ALA . 3.3 mt -135.76 171.42 14.49 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.494 -179.647 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 14.5 mttt -93.63 174.58 7.12 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.978 179.638 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' LYS . . . . . 0.521 ' HD3' ' HB2' ' A' ' 104' ' ' ALA . 2.8 ttpt -106.46 147.88 28.81 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.852 0.358 . . . . 0.0 111.891 -179.296 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.0 t 65.08 19.72 11.88 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.641 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.421 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.5 135.93 26.64 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -63.45 122.35 10.47 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.118 1.878 . . . . 0.0 111.464 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ALA . . . . . 0.442 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -123.85 139.41 54.0 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.931 0.396 . . . . 0.0 111.728 -179.528 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.473 ' HB2' HG22 ' A' ' 96' ' ' VAL . 3.3 ptt180 -122.3 128.29 50.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.769 0.795 . . . . 0.0 111.389 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.6 mm -101.58 113.62 38.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.759 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.513 HG22 HG23 ' A' ' 96' ' ' VAL . 3.0 t -88.82 106.91 17.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.507 -179.192 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -94.03 113.24 25.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.016 0.436 . . . . 0.0 111.258 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -99.52 104.35 16.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.522 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.7 94.97 5.17 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.231 0.539 . . . . 0.0 111.498 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -88.6 -35.05 17.09 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.829 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.555 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 0.2 OUTLIER -111.55 136.82 21.03 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.083 179.906 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -81.01 39.47 0.87 Allowed 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 123.105 2.537 . . . . 0.0 113.288 -179.371 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.9 m -67.46 133.68 92.94 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.175 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -63.03 -32.23 75.89 Favored 'Trans proline' 0 C--N 1.348 0.551 0 C-N-CA 122.693 2.262 . . . . 0.0 112.776 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.58 -2.48 32.73 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.547 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.53 HD22 HG13 ' A' ' 45' ' ' VAL . 49.9 mt -121.21 13.77 11.23 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.291 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -70.63 -41.59 72.01 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.764 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -124.72 138.48 54.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.892 0.377 . . . . 0.0 111.586 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -118.78 130.35 73.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.593 179.287 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' VAL . . . . . 0.608 ' O ' ' HD3' ' A' ' 81' ' ' PRO . 0.2 OUTLIER -134.83 131.79 53.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.386 0.612 . . . . 0.0 111.316 179.978 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -92.84 101.59 5.53 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.42 178.653 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' PRO . . . . . 0.608 ' HD3' ' O ' ' A' ' 79' ' ' VAL . 25.5 Cg_exo -61.82 -17.66 56.42 Favored 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 123.024 2.482 . . . . 0.0 113.748 -178.716 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -101.2 -10.22 20.58 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -119.55 -21.38 7.39 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 85.66 1.49 87.43 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 121.248 -0.501 . . . . 0.0 112.226 -179.449 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.9 t -80.72 115.24 22.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.893 0.378 . . . . 0.0 111.41 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' HIS . . . . . 0.42 ' HB3' ' HB ' ' A' ' 79' ' ' VAL . 20.5 p-80 -131.29 121.63 25.06 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.602 179.831 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -141.15 161.91 36.75 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.722 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -99.53 127.11 45.6 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.115 179.208 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 57.5 mt -84.4 130.22 54.71 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-O 121.059 0.457 . . . . 0.0 111.844 -178.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -79.04 123.54 5.72 Favored 'Trans proline' 0 CA--C 1.533 0.461 0 C-N-CA 122.704 2.27 . . . . 0.0 112.236 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.1 tpt -64.16 124.96 23.01 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.7 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.86 6.25 85.43 Favored Glycine 0 CA--C 1.521 0.426 0 CA-C-N 115.886 -0.597 . . . . 0.0 113.081 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -132.96 176.87 8.11 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.984 0.421 . . . . 0.0 111.081 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.6 mp0 -115.97 132.17 56.73 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.478 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -120.51 117.95 28.98 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.333 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.513 HG23 HG22 ' A' ' 65' ' ' VAL . 3.4 p -96.0 130.34 44.83 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 CA-C-O 121.764 0.792 . . . . 0.0 112.062 -179.429 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 63' ' ' ARG . 52.9 t -106.17 115.24 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.426 179.167 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -95.81 119.17 33.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.871 0.367 . . . . 0.0 111.631 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -134.09 157.15 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.107 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.4 m -120.0 97.06 49.5 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.517 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.421 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.9 Cg_endo -73.22 98.06 0.99 Allowed 'Trans proline' 0 CA--C 1.532 0.402 0 C-N-CA 122.78 2.32 . . . . 0.0 112.531 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -96.51 23.44 6.83 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.014 0.435 . . . . 0.0 111.481 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.5 131.91 14.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.521 179.66 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ALA . . . . . 0.521 ' HB2' ' HD3' ' A' ' 58' ' ' LYS . . . -89.71 128.46 36.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.986 0.422 . . . . 0.0 111.495 -179.855 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.57 -158.64 31.15 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.632 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -101.82 123.46 45.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.048 0.452 . . . . 0.0 111.352 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.434 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 88.2 m-85 -115.9 166.19 12.24 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.019 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 95.5 p -141.57 155.73 45.75 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -178.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -151.57 129.56 11.78 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.389 178.82 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.188 0 CA-C-O 121.123 0.487 . . . . 0.0 111.904 -179.346 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.465 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 6.8 ttpt . . . . . 0 CA--C 1.53 0.207 0 CA-C-O 121.265 0.555 . . . . 0.0 111.785 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.436 ' HG3' HG13 ' A' ' 54' ' ' ILE . 17.2 ttp -133.02 133.65 43.37 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.701 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -118.82 119.66 61.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.111 0.481 . . . . 0.0 111.08 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 92.5 t -102.61 121.86 54.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.946 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.25 1.106 0 CA-C-O 118.147 -0.93 . . . . 0.0 111.937 -179.428 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.157 0 CA-C-O 121.321 0.582 . . . . 0.0 111.527 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.4 mtpt -89.19 130.17 35.65 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.736 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.41 151.85 41.01 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.388 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLN . . . . . 0.575 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.6 pt20 -80.33 141.06 35.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.036 0.445 . . . . 0.0 111.4 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 56.4 mt-30 -96.83 115.03 26.73 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.73 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.76 -149.99 0.31 Allowed 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.454 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -81.58 72.68 8.63 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -179.132 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.03 -6.11 66.44 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 120.806 -0.711 . . . . 0.0 113.875 178.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -140.92 160.67 39.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.894 0.347 . . . . 0.0 110.788 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.15 156.08 21.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.136 0.493 . . . . 0.0 111.379 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.575 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.5 tt0 -144.31 143.2 30.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.513 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -143.73 128.42 14.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.065 0.459 . . . . 0.0 111.053 179.089 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.75 106.5 18.5 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.152 0.501 . . . . 0.0 111.078 179.689 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.598 HG13 ' HD2' ' A' ' 51' ' ' PRO . 49.0 t -98.09 101.99 12.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.557 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -71.59 117.81 13.63 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.796 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' VAL . . . . . 0.66 HG13 HD22 ' A' ' 75' ' ' LEU . 31.8 t -99.49 98.22 6.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.394 -178.782 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' MET . . . . . 0.492 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 10.8 ptp -140.38 82.3 1.85 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.333 179.499 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 88.0 -12.14 64.97 Favored Glycine 0 CA--C 1.517 0.194 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -178.017 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 173.27 -171.43 44.46 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -88.41 123.02 32.55 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.973 0.386 . . . . 0.0 110.265 179.58 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' THR . . . . . 0.515 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 35.5 m -61.99 -63.45 4.23 Favored Pre-proline 0 CA--C 1.54 0.558 0 CA-C-O 119.559 -0.257 . . . . 0.0 111.359 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' PRO . . . . . 0.598 ' HD2' HG13 ' A' ' 43' ' ' VAL . 73.6 Cg_endo -75.76 96.74 1.06 Allowed 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 121.296 1.331 . . . . 0.0 111.013 177.501 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -50.57 -43.13 56.26 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -179.252 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.439 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -130.41 118.8 21.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.659 0.266 . . . . 0.0 110.866 179.775 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.0 pt -98.8 126.31 52.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.079 0.466 . . . . 0.0 110.984 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 91.9 t -97.13 126.46 49.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.925 0.393 . . . . 0.0 111.532 -179.704 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 8.3 mt -133.98 168.33 18.99 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.38 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.6 tttt -95.09 168.28 10.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.508 179.43 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 4.6 ttpp -99.18 147.89 24.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 111.964 -179.423 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.4 t 65.78 19.83 11.39 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.874 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 6.3 p -123.71 135.63 26.41 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.895 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -64.52 123.36 11.64 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.104 1.869 . . . . 0.0 111.53 178.621 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.61 138.82 54.29 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.893 0.378 . . . . 0.0 111.703 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' ARG . . . . . 0.41 ' HB2' HG22 ' A' ' 96' ' ' VAL . 5.8 ptt180 -120.4 126.63 50.94 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-O 121.706 0.765 . . . . 0.0 111.274 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.2 mm -99.42 115.48 40.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.801 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' VAL . . . . . 0.484 HG22 HG23 ' A' ' 96' ' ' VAL . 4.0 t -91.17 109.55 21.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.825 0.345 . . . . 0.0 111.287 -179.342 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -96.78 112.23 24.07 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.075 0.464 . . . . 0.0 111.431 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -96.74 101.63 13.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.281 179.517 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.77 97.91 4.64 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 121.281 0.563 . . . . 0.0 111.918 -179.12 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -95.98 -29.56 14.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.828 179.715 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ASP . . . . . 0.492 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.8 t70 -111.75 131.79 22.23 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.922 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -80.63 39.45 0.86 Allowed 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.085 2.523 . . . . 0.0 113.121 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.528 ' HB2' HD12 ' A' ' 75' ' ' LEU . 2.7 m -69.75 139.1 88.33 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.289 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -62.61 -33.85 76.41 Favored 'Trans proline' 0 C--N 1.348 0.553 0 C-N-CA 122.883 2.389 . . . . 0.0 112.863 -179.6 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 10.7 p -78.59 -2.57 39.56 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.45 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.66 HD22 HG13 ' A' ' 45' ' ' VAL . 37.9 mt -121.14 9.94 10.59 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.32 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.93 -37.29 78.8 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.059 0.457 . . . . 0.0 111.118 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -129.34 160.06 34.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.515 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -133.49 128.5 54.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.339 0.59 . . . . 0.0 111.018 179.44 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -132.39 128.83 58.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 121.312 0.577 . . . . 0.0 111.071 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -92.54 102.08 6.1 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.47 -0.787 . . . . 0.0 109.537 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.79 -16.24 49.58 Favored 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.581 2.187 . . . . 0.0 113.598 -178.436 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -100.68 -6.37 25.22 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 111.984 0.364 . . . . 0.0 111.984 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -121.38 -22.98 5.8 Favored 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.25 25.33 51.95 Favored Glycine 0 CA--C 1.52 0.355 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.032 -179.473 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.0 t -106.6 117.7 52.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.813 0.339 . . . . 0.0 111.684 -178.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -121.1 117.52 27.38 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.52 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.82 165.83 24.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.138 0.494 . . . . 0.0 112.025 -179.292 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -107.38 140.56 40.11 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.474 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 58.9 mt -102.07 129.56 26.11 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.986 0.422 . . . . 0.0 111.363 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' PRO . . . . . 0.438 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 74.3 Cg_endo -82.7 126.2 4.53 Favored 'Trans proline' 0 CA--C 1.533 0.426 0 C-N-CA 122.723 2.282 . . . . 0.0 112.341 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.7 tpt -64.72 124.23 21.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.023 0.439 . . . . 0.0 111.789 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.65 5.23 84.6 Favored Glycine 0 CA--C 1.521 0.424 0 CA-C-N 115.87 -0.605 . . . . 0.0 113.195 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.438 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 44.8 mt-10 -133.29 176.78 8.21 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.959 0.409 . . . . 0.0 111.181 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.74 132.63 55.13 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.834 -179.747 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -118.98 125.43 49.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.982 178.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' VAL . . . . . 0.484 HG23 HG22 ' A' ' 65' ' ' VAL . 1.8 p -101.68 136.31 34.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.672 0.749 . . . . 0.0 112.462 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 61.5 t -113.26 112.31 39.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.069 178.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -93.27 118.72 31.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.511 -179.498 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -135.23 156.98 39.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.215 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.36 97.4 48.97 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.573 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' PRO . . . . . 0.449 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 66.7 Cg_endo -72.19 100.06 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.794 2.329 . . . . 0.0 112.36 179.544 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -96.11 10.36 37.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.854 0.359 . . . . 0.0 111.9 -179.521 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.03 132.45 32.22 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.51 -0.314 . . . . 0.0 110.779 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.38 127.3 35.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.018 0.437 . . . . 0.0 111.314 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.78 -157.24 29.41 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.624 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -101.73 126.81 48.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.127 0.489 . . . . 0.0 111.668 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' PHE . . . . . 0.443 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 86.0 m-85 -119.64 173.76 6.82 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.67 -0.696 . . . . 0.0 109.815 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 41.9 p -154.7 160.86 41.64 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -178.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.8 p90 -152.79 133.99 14.23 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.89 178.994 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.39 0 CA-C-O 121.05 0.452 . . . . 0.0 111.879 179.758 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 119' ' ' LYS . . . . . 0.439 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.4 ttpt . . . . . 0 CA--C 1.531 0.233 0 CA-C-O 121.071 0.463 . . . . 0.0 111.568 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' MET . . . . . 0.443 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -134.22 141.01 46.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.043 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.7 mp -124.66 120.22 58.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.984 0.421 . . . . 0.0 110.706 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.0 t -103.25 124.34 57.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.238 -179.675 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 . . . . . 0 C--O 1.252 1.216 0 CA-C-O 118.106 -0.949 . . . . 0.0 111.46 -179.601 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.667 0 N-CA-C 112.452 -0.259 . . . . 0.0 112.452 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -82.38 75.08 9.31 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.109 0.48 . . . . 0.0 111.471 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -89.92 142.24 27.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.366 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -86.57 170.1 41.9 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.887 -0.673 . . . . 0.0 113.041 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -118.6 128.74 54.83 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.105 0.479 . . . . 0.0 111.325 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.34 129.36 35.89 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.525 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.46 153.58 40.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.187 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.572 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 4.5 pt20 -80.74 135.53 36.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.185 0.517 . . . . 0.0 111.279 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 19.7 mt-30 -94.05 112.39 24.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.601 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.42 -154.28 0.4 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.389 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -81.95 75.81 8.87 Favored 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.12 -5.36 63.23 Favored Glycine 0 CA--C 1.522 0.518 0 C-N-CA 120.772 -0.728 . . . . 0.0 114.121 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 26.9 p90 -144.35 163.76 32.79 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 117.063 0.431 . . . . 0.0 110.958 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.13 154.81 28.26 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.991 0.424 . . . . 0.0 111.452 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.572 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.6 tt0 -145.26 141.59 28.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.515 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.63 128.59 14.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.863 179.024 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.3 109.97 21.26 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.207 0.527 . . . . 0.0 111.117 179.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.647 HG13 ' HD2' ' A' ' 51' ' ' PRO . 44.9 t -98.22 103.37 14.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.488 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.424 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.8 OUTLIER -70.93 114.23 8.78 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.792 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.59 HG13 HD22 ' A' ' 75' ' ' LEU . 49.3 t -96.61 97.73 6.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.461 -178.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.496 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.2 ptm -144.25 86.98 1.86 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.52 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.47 -0.53 89.06 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.833 -0.698 . . . . 0.0 111.434 -178.443 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.427 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 161.9 -170.33 37.55 Favored Glycine 0 N--CA 1.448 -0.522 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -93.07 124.24 36.9 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.793 0.297 . . . . 0.0 110.213 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.509 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 37.1 m -63.42 -63.65 3.8 Favored Pre-proline 0 CA--C 1.539 0.527 0 CA-C-O 119.642 -0.218 . . . . 0.0 111.431 -179.589 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.647 ' HD2' HG13 ' A' ' 43' ' ' VAL . 60.7 Cg_endo -74.99 96.58 1.02 Allowed 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 121.312 1.341 . . . . 0.0 111.055 177.612 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.65 -43.44 57.17 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.069 -179.351 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.39 118.68 19.68 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.654 179.443 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.3 pt -97.8 126.78 50.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.913 0.387 . . . . 0.0 110.929 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 95.9 t -100.09 127.24 53.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.953 0.406 . . . . 0.0 111.557 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.438 HD22 ' HB1' ' A' ' 62' ' ' ALA . 2.3 mt -136.87 166.92 22.48 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.279 -179.633 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -89.62 176.89 6.69 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 120.745 0.307 . . . . 0.0 110.897 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.9 ttpp -107.55 149.53 27.9 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 111.972 0.36 . . . . 0.0 111.972 -179.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.7 t 65.55 19.51 11.51 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.725 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.44 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.5 p -123.82 136.26 27.19 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.11 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -64.26 122.61 10.62 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.247 1.965 . . . . 0.0 111.641 178.528 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.438 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -124.66 138.34 54.31 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.926 0.394 . . . . 0.0 111.723 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.502 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -120.49 127.42 52.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.643 0.735 . . . . 0.0 111.626 179.825 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.4 mm -100.2 114.23 38.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.623 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.511 HG22 HG23 ' A' ' 96' ' ' VAL . 2.8 t -90.64 107.41 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.739 0.304 . . . . 0.0 111.492 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -94.77 102.62 14.51 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.918 0.39 . . . . 0.0 111.279 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -91.17 106.94 18.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.435 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -77.46 105.28 8.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.287 0.565 . . . . 0.0 111.903 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.3 tptp -97.76 -34.28 10.96 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.256 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.496 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.7 t70 -110.27 134.38 20.8 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.848 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -81.42 40.1 0.94 Allowed 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.111 2.54 . . . . 0.0 112.995 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.61 135.37 90.47 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.387 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.27 -32.88 61.41 Favored 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 122.772 2.315 . . . . 0.0 112.802 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.1 p -77.09 -2.15 32.73 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.364 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.59 HD22 HG13 ' A' ' 45' ' ' VAL . 33.4 mt -119.29 13.56 12.8 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.242 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.14 -36.38 72.06 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.078 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.84 152.67 48.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.896 0.379 . . . . 0.0 111.503 -179.447 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -132.79 128.48 57.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.103 0.478 . . . . 0.0 110.727 179.196 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.4 130.61 65.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 121.258 0.551 . . . . 0.0 111.346 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -93.17 102.12 6.72 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.715 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.55 -14.36 41.96 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.621 2.214 . . . . 0.0 113.593 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -100.65 -7.57 23.77 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 111.809 0.299 . . . . 0.0 111.809 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -122.63 -22.77 5.3 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 112.058 0.392 . . . . 0.0 112.058 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.25 25.75 50.44 Favored Glycine 0 C--N 1.331 0.302 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.025 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.7 t -106.5 117.79 52.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.887 0.375 . . . . 0.0 111.71 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -121.67 118.52 29.37 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.388 179.323 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.38 162.53 34.19 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.084 0.468 . . . . 0.0 112.257 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 14.2 p-10 -104.19 148.28 26.48 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.679 179.604 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 29.5 mt -107.18 130.8 22.33 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.938 0.399 . . . . 0.0 111.716 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.418 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.3 Cg_endo -82.34 127.99 5.37 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.743 2.296 . . . . 0.0 112.434 179.176 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.5 tpt -66.62 125.4 25.65 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-O 121.025 0.441 . . . . 0.0 111.693 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.81 1.37 80.21 Favored Glycine 0 CA--C 1.52 0.344 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.842 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.418 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 41.7 mt-10 -134.24 177.17 7.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.895 0.379 . . . . 0.0 110.787 -179.484 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -118.14 133.33 56.0 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.197 0.522 . . . . 0.0 111.639 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.1 t80 -112.16 123.28 49.92 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.127 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.511 HG23 HG22 ' A' ' 65' ' ' VAL . 1.5 p -97.78 135.24 33.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.609 0.719 . . . . 0.0 112.304 -179.207 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 62.6 t -112.49 109.69 29.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.027 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -92.08 117.17 29.58 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.228 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -131.58 165.8 30.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.237 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.3 m -128.1 96.22 32.04 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.426 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.44 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.4 Cg_endo -72.2 98.88 0.95 Allowed 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.803 2.336 . . . . 0.0 112.454 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -95.27 7.78 45.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.832 0.349 . . . . 0.0 111.838 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.39 130.97 31.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.753 0.311 . . . . 0.0 110.931 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -85.3 124.8 32.34 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.199 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 171.71 -166.53 39.51 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.863 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.76 114.89 27.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.036 0.446 . . . . 0.0 110.732 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -110.49 174.84 5.67 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.233 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 91.6 p -153.45 164.15 38.69 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.419 0.525 . . . . 0.0 112.419 -178.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 36.8 p90 -150.85 137.67 19.0 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.481 178.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.22 178.65 8.55 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.982 0.42 . . . . 0.0 111.708 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 41.6 t -115.55 127.84 55.55 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 179.309 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 87.71 -115.31 4.32 Favored Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.837 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 3.8 mtm -137.97 -90.85 0.22 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.868 0.366 . . . . 0.0 111.058 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -88.85 58.82 4.78 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.017 0.437 . . . . 0.0 111.342 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -149.38 165.52 31.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.109 -179.71 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 77.7 mmm 66.17 -177.51 0.19 Allowed 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.097 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -159.31 104.93 1.67 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.446 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -145.93 122.31 1.64 Allowed Glycine 0 CA--C 1.52 0.346 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.108 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.8 ttmm -121.36 150.82 40.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.235 0.54 . . . . 0.0 111.891 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 2.2 ttm -134.65 136.26 42.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.797 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -120.99 118.2 55.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.006 0.432 . . . . 0.0 110.804 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 71.9 t -102.82 121.33 53.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.177 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.254 1.306 0 CA-C-O 118.335 -0.84 . . . . 0.0 111.396 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.613 0 CA-C-O 121.112 0.285 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -83.19 71.0 10.2 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.183 0.516 . . . . 0.0 111.562 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 1.9 mtm -82.15 64.29 6.76 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.359 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.38 -168.83 28.5 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.797 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.27 127.93 20.25 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.018 0.437 . . . . 0.0 111.289 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -90.49 126.67 35.99 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.787 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.26 151.88 43.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.15 179.663 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.586 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 7.7 pt20 -82.24 140.18 33.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.178 0.513 . . . . 0.0 111.545 -179.183 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 6.8 mp0 -95.46 113.25 24.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.488 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 6.1 mmtt -93.2 -148.68 0.25 Allowed 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.474 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -81.64 72.81 8.69 Favored 'General case' 0 CA--C 1.535 0.373 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.19 -5.71 68.37 Favored Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.845 178.978 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -141.27 160.46 40.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.864 0.332 . . . . 0.0 110.751 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.98 156.23 19.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.197 0.522 . . . . 0.0 111.351 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.586 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 4.2 tt0 -145.9 142.44 28.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.445 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.5 129.61 16.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.194 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -90.23 106.56 18.57 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.012 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.58 HG13 ' HD2' ' A' ' 51' ' ' PRO . 46.1 t -97.81 103.01 14.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.604 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.47 117.48 14.18 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.974 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.545 HG13 HD22 ' A' ' 75' ' ' LEU . 42.3 t -100.4 99.04 7.69 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 CA-C-O 121.535 0.683 . . . . 0.0 111.484 -178.798 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.448 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.5 ptp -141.27 85.63 1.98 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.222 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 87.56 -14.65 57.6 Favored Glycine 0 CA--C 1.519 0.313 0 N-CA-C 111.104 -0.798 . . . . 0.0 111.104 -177.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 176.89 -152.5 12.37 Favored Glycine 0 N--CA 1.449 -0.452 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -104.91 127.98 52.96 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.82 0.31 . . . . 0.0 110.56 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.513 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 43.0 m -69.15 -63.72 1.97 Allowed Pre-proline 0 CA--C 1.539 0.535 0 CA-C-O 119.571 -0.252 . . . . 0.0 111.368 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.58 ' HD2' HG13 ' A' ' 43' ' ' VAL . 61.9 Cg_endo -74.39 98.09 1.08 Allowed 'Trans proline' 0 C--N 1.357 1.012 0 C-N-CA 121.295 1.33 . . . . 0.0 111.121 177.817 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.25 -43.86 61.62 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.991 -0.549 . . . . 0.0 112.326 -179.181 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -133.89 118.53 18.05 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.559 0.218 . . . . 0.0 110.776 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.493 HG13 ' HG3' ' A' ' 120' ' ' MET . 8.6 pt -97.33 127.55 49.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.1 0.476 . . . . 0.0 111.004 179.504 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.5 t -96.04 126.43 48.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.472 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 24.3 mt -133.44 166.4 22.62 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.425 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 18.6 mttt -96.74 166.75 11.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.563 179.346 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.3 ttpp -97.52 147.74 23.95 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.9 t 66.73 18.8 10.74 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.861 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.45 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 6.0 p -123.56 135.16 25.82 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.914 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -64.58 122.73 10.71 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.051 1.834 . . . . 0.0 111.611 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.24 138.94 54.34 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.834 0.35 . . . . 0.0 111.561 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.486 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.5 ptt180 -121.15 126.76 50.54 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.638 0.732 . . . . 0.0 111.394 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.8 mm -98.64 114.36 36.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.822 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.501 HG22 HG23 ' A' ' 96' ' ' VAL . 3.2 t -91.47 109.84 21.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.375 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -96.15 117.37 30.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.132 0.491 . . . . 0.0 111.332 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.6 t0 -99.94 100.31 11.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.412 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.37 93.0 3.41 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 121.225 0.536 . . . . 0.0 111.455 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -88.74 -37.43 15.49 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.752 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.448 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.2 t70 -101.75 129.44 26.61 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.763 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -79.23 38.63 0.74 Allowed 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 123.088 2.525 . . . . 0.0 113.014 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -70.52 135.35 86.27 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.015 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -63.47 -31.57 71.68 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.789 2.326 . . . . 0.0 112.888 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -75.85 -9.45 58.61 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.46 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.545 HD22 HG13 ' A' ' 45' ' ' VAL . 36.7 mt -113.22 13.99 19.3 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.466 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -70.13 -38.44 75.55 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.782 0.325 . . . . 0.0 111.709 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -122.64 158.82 29.17 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.113 0.482 . . . . 0.0 111.435 -179.586 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.86 130.12 35.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.444 178.791 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 2.0 p -133.27 132.3 58.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.314 0.578 . . . . 0.0 111.43 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -94.08 101.89 7.21 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.516 178.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -67.32 -14.03 41.44 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.589 2.193 . . . . 0.0 113.566 -178.445 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 33.1 m-20 -100.23 -9.14 22.75 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -122.87 -20.07 5.96 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.76 30.65 42.91 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.353 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 49.8 t -110.8 116.44 52.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.828 0.347 . . . . 0.0 111.733 -179.018 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -119.86 121.12 38.37 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.47 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.92 172.19 13.38 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 -112.66 142.36 45.36 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.461 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 41.0 mt -105.73 122.79 41.39 Favored Pre-proline 0 CA--C 1.531 0.246 0 CA-C-O 121.094 0.473 . . . . 0.0 111.544 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.426 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 67.2 Cg_endo -78.13 132.72 11.72 Favored 'Trans proline' 0 CA--C 1.531 0.326 0 C-N-CA 122.921 2.414 . . . . 0.0 112.713 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.8 tpt -68.55 124.89 24.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.082 0.467 . . . . 0.0 111.733 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.06 9.23 85.52 Favored Glycine 0 C--N 1.333 0.395 0 CA-C-N 115.863 -0.608 . . . . 0.0 113.101 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 45.4 mt-10 -134.28 176.82 8.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.979 0.419 . . . . 0.0 111.13 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -115.2 133.31 56.15 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.137 0.494 . . . . 0.0 111.647 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 14.1 t80 -119.89 123.64 44.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.977 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.501 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -102.99 137.21 32.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.65 0.738 . . . . 0.0 112.643 -178.759 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 54.9 t -112.86 112.03 38.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.18 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -93.16 119.52 32.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.507 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -136.49 155.6 34.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.227 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 2.9 m -119.37 97.81 50.3 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.514 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 73.2 Cg_endo -74.24 100.82 1.34 Allowed 'Trans proline' 0 CA--C 1.531 0.344 0 C-N-CA 122.86 2.373 . . . . 0.0 112.503 179.719 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -95.63 3.76 53.7 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.919 0.39 . . . . 0.0 111.657 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -130.4 133.63 46.52 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.867 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -90.07 128.8 36.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.908 0.385 . . . . 0.0 111.255 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 168.05 -166.75 39.67 Favored Glycine 0 CA--C 1.517 0.185 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.813 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -99.89 112.83 25.08 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.168 0.509 . . . . 0.0 110.746 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.408 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 22.6 m-85 -110.67 168.61 9.34 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.009 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 63.5 p -150.64 160.89 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.138 0.494 . . . . 0.0 112.047 -179.379 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 36.3 p90 -146.21 136.08 23.41 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.913 179.083 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.15 156.2 21.56 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.231 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 4.8 t -160.97 165.89 29.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.004 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 83.55 -77.65 2.1 Favored Glycine 0 CA--C 1.52 0.398 0 C-N-CA 120.934 -0.65 . . . . 0.0 113.308 179.494 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -127.83 153.72 46.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.929 0.395 . . . . 0.0 111.4 -179.586 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -83.51 54.53 2.87 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.474 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -126.94 -92.6 0.49 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.62 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -68.37 141.93 55.6 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-O 120.971 0.415 . . . . 0.0 110.279 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 34.2 p-80 -155.08 158.05 38.47 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.495 -0.32 . . . . 0.0 111.488 -179.231 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -110.73 145.99 17.46 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.497 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.85 149.69 31.44 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.966 0.412 . . . . 0.0 111.083 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.493 ' HG3' HG13 ' A' ' 54' ' ' ILE . 8.9 ttp -131.71 119.52 21.46 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.012 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.7 mp -107.16 116.24 50.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.031 0.443 . . . . 0.0 110.793 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.2 t -101.23 120.43 50.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.168 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 . . . . . 0 C--O 1.252 1.224 0 CA-C-O 118.146 -0.93 . . . . 0.0 111.458 -179.646 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.631 0 N-CA-C 112.168 -0.373 . . . . 0.0 112.168 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -70.95 -18.54 62.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.795 0.331 . . . . 0.0 111.655 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 50.7 mmm -86.77 -10.03 54.52 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.303 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.05 164.56 20.42 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.868 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -112.4 123.23 49.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.161 0.505 . . . . 0.0 111.066 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.82 129.23 35.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.606 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.71 156.1 39.3 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.403 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.549 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 5.9 pt20 -82.0 142.81 32.05 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.125 0.488 . . . . 0.0 111.259 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -98.47 112.99 24.84 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.657 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 5.6 mmtt -95.34 -150.28 0.31 Allowed 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.557 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -80.71 74.99 7.63 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.98 -5.82 76.11 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.867 -0.682 . . . . 0.0 113.974 178.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.4 p90 -140.59 163.96 31.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.923 0.361 . . . . 0.0 110.85 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.65 154.57 27.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.975 0.417 . . . . 0.0 111.457 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.549 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 4.0 tt0 -143.82 141.3 30.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.572 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.71 128.97 17.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.915 179.109 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 ttt180 -90.73 110.9 22.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.253 0.549 . . . . 0.0 111.123 179.649 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.57 HG13 ' HD2' ' A' ' 51' ' ' PRO . 45.2 t -101.04 103.87 15.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.517 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.411 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 1.3 tp10 -71.49 117.01 12.5 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.029 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.557 HG13 HD22 ' A' ' 75' ' ' LEU . 53.2 t -98.76 99.93 9.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.451 -178.76 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.564 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.3 ptm -147.09 90.77 1.92 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.568 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 79.28 1.04 85.25 Favored Glycine 0 CA--C 1.52 0.396 0 C-N-CA 120.774 -0.727 . . . . 0.0 111.733 -178.501 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.481 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 163.54 -148.61 15.19 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 111.314 -0.715 . . . . 0.0 111.314 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -115.64 129.65 56.57 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.718 0.259 . . . . 0.0 110.309 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.504 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 41.0 m -68.76 -64.6 1.65 Allowed Pre-proline 0 CA--C 1.538 0.515 0 CA-C-O 119.468 -0.301 . . . . 0.0 111.497 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.57 ' HD2' HG13 ' A' ' 43' ' ' VAL . 62.4 Cg_endo -74.9 98.88 1.19 Allowed 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.271 1.314 . . . . 0.0 111.119 177.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -51.84 -44.55 63.64 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.917 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.85 119.09 20.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.864 179.78 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.2 pt -97.1 126.98 49.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 121.08 0.467 . . . . 0.0 110.943 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 60.1 t -98.58 126.67 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.642 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.3 mt -136.22 165.37 25.91 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.363 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -88.85 176.01 7.22 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.82 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.452 ' HD3' ' HB2' ' A' ' 104' ' ' ALA . 2.6 ttpt -106.7 147.95 28.98 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 111.872 -179.339 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.0 t 65.13 20.2 11.95 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.737 179.596 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.444 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.3 p -123.61 136.4 27.22 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.989 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -64.47 123.43 11.76 Favored 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.099 1.866 . . . . 0.0 111.736 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.05 139.37 53.86 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.954 0.407 . . . . 0.0 111.682 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.515 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.6 ptt180 -121.78 127.06 50.21 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.744 0.783 . . . . 0.0 111.335 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.5 mm -99.87 115.78 41.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.838 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.517 HG22 HG23 ' A' ' 96' ' ' VAL . 3.2 t -91.24 107.59 18.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.853 0.359 . . . . 0.0 111.463 -179.229 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -95.09 103.57 15.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.909 0.385 . . . . 0.0 111.466 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -90.59 105.9 18.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.377 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.55 100.1 7.6 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.157 0.503 . . . . 0.0 111.882 -179.197 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.0 tmtt? -91.42 -39.19 12.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.852 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.564 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 0.1 OUTLIER -107.1 137.8 19.66 Favored Pre-proline 0 CA--C 1.534 0.354 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.149 -179.913 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -81.87 39.66 0.88 Allowed 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 123.229 2.619 . . . . 0.0 113.405 -179.279 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -67.73 135.66 92.48 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.991 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -62.42 -34.3 76.93 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.872 2.382 . . . . 0.0 113.106 -179.337 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.02 -3.29 38.33 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.518 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.557 HD22 HG13 ' A' ' 45' ' ' VAL . 56.3 mt -120.01 12.88 12.07 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.446 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -68.78 -39.27 80.25 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 120.915 0.388 . . . . 0.0 111.379 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 31.0 mt-30 -123.66 166.15 16.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.034 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -140.93 130.45 25.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.296 0.57 . . . . 0.0 110.836 178.764 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.582 ' O ' ' HD3' ' A' ' 81' ' ' PRO . 0.2 OUTLIER -133.9 132.33 56.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.216 0.532 . . . . 0.0 110.981 179.68 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 -96.01 101.72 9.01 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.721 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.582 ' HD3' ' O ' ' A' ' 79' ' ' VAL . 23.2 Cg_exo -63.46 -19.02 67.1 Favored 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.072 2.515 . . . . 0.0 113.791 -178.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -100.66 -5.94 25.88 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -121.44 -23.03 5.76 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.11 22.8 56.69 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.151 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.1 t -102.53 120.34 52.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.674 0.274 . . . . 0.0 111.552 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -125.74 119.69 28.62 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.633 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.78 169.35 17.94 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.112 0.482 . . . . 0.0 112.249 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -109.05 140.67 42.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.548 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 38.6 mt -100.69 129.44 27.6 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.851 0.358 . . . . 0.0 111.356 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.426 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.9 Cg_endo -80.64 128.25 6.76 Favored 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.813 2.342 . . . . 0.0 112.452 179.164 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -66.16 124.85 23.74 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.087 0.47 . . . . 0.0 111.681 -179.541 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 87.11 3.46 82.56 Favored Glycine 0 CA--C 1.521 0.446 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.951 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 41.9 mt-10 -134.65 177.05 8.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.009 0.433 . . . . 0.0 110.913 -179.593 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -117.27 133.35 56.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.211 0.529 . . . . 0.0 111.564 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -113.21 125.49 54.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.222 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.517 HG23 HG22 ' A' ' 65' ' ' VAL . 1.7 p -98.09 135.19 33.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.715 0.769 . . . . 0.0 112.334 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.0 t -112.82 112.92 42.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.199 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -93.73 119.76 33.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.035 0.445 . . . . 0.0 111.518 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -136.4 156.44 36.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.125 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.26 97.74 48.99 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.452 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.444 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 58.6 Cg_endo -71.14 98.42 0.82 Allowed 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.734 2.289 . . . . 0.0 112.618 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -97.6 22.72 8.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.004 0.43 . . . . 0.0 111.482 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.35 131.23 14.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.539 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ALA . . . . . 0.452 ' HB2' ' HD3' ' A' ' 58' ' ' LYS . . . -88.11 127.1 35.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.071 0.462 . . . . 0.0 111.41 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 164.99 -157.6 30.13 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.714 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -101.55 126.01 48.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.172 0.51 . . . . 0.0 111.535 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.443 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 87.9 m-85 -119.58 171.93 8.02 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.783 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 84.8 p -157.81 160.54 37.88 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.211 0.529 . . . . 0.0 112.418 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -143.77 140.46 29.94 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.496 178.7 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.602 ' HB2' ' HB2' ' A' ' 117' ' ' HIS . . . -157.43 177.84 10.98 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.662 -179.196 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 7.3 t -163.41 138.87 6.55 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.301 179.344 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 84.84 -78.8 1.97 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.833 -0.698 . . . . 0.0 113.413 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -116.54 -178.74 3.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.066 0.46 . . . . 0.0 111.455 -179.409 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -85.89 -22.45 27.5 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.189 179.649 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.3 157.56 19.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.541 179.527 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 11.0 ttp 61.75 73.22 0.48 Allowed 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 121.295 0.569 . . . . 0.0 110.922 -179.484 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' HIS . . . . . 0.602 ' HB2' ' HB2' ' A' ' 110' ' ' ALA . 18.8 p80 -133.67 169.86 16.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.685 -179.431 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -106.5 160.92 14.26 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.178 179.499 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 0.2 OUTLIER -128.51 149.85 50.42 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.884 0.373 . . . . 0.0 111.112 179.68 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.443 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -132.56 140.12 48.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.059 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.5 118.74 54.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 121.048 0.451 . . . . 0.0 110.823 179.363 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.3 t -100.21 123.86 53.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.062 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.251 1.168 0 CA-C-O 118.155 -0.926 . . . . 0.0 111.973 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.946 ' N ' ' HZ1' ' A' ' 31' ' ' LYS . . . . . . . . 0 N--CA 1.498 2.784 0 CA-C-O 121.159 0.311 . . . . 0.0 112.457 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -93.8 -27.14 16.63 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.93 0.395 . . . . 0.0 111.441 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 4.9 tpt -133.51 93.35 3.13 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.039 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.28 -162.84 12.48 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.615 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.29 125.12 19.65 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.155 0.502 . . . . 0.0 111.375 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.946 ' HZ1' ' N ' ' A' ' 26' ' ' GLY . 0.5 OUTLIER -88.57 126.59 35.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.626 179.784 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.27 153.84 41.32 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.297 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.72 140.67 34.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.243 0.544 . . . . 0.0 111.187 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 22.0 mt-30 -96.38 116.83 29.69 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.595 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.1 -153.07 0.41 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.119 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -83.73 76.82 9.96 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -179.271 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.6 -8.84 64.2 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.767 -0.73 . . . . 0.0 114.007 178.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -141.21 164.99 28.77 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 117.093 0.446 . . . . 0.0 111.091 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.44 154.28 27.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.924 0.392 . . . . 0.0 111.177 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -143.28 142.07 31.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.891 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.54 128.69 15.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.972 179.027 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -90.18 110.18 21.22 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.208 0.528 . . . . 0.0 110.93 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.566 HG13 ' HD2' ' A' ' 51' ' ' PRO . 47.9 t -102.37 107.2 21.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.663 -0.698 . . . . 0.0 110.74 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.42 ' HG2' ' SD ' ' A' ' 46' ' ' MET . 0.7 OUTLIER -75.93 117.76 17.99 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.002 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.491 HG13 HD22 ' A' ' 75' ' ' LEU . 50.6 t -96.62 99.03 8.31 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.416 -178.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.496 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.4 ptm -144.72 90.3 2.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.487 179.023 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 81.85 2.05 90.43 Favored Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.72 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.448 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 159.61 -131.28 2.67 Favored Glycine 0 N--CA 1.449 -0.471 0 N-CA-C 111.601 -0.6 . . . . 0.0 111.601 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -126.09 134.57 51.33 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.729 -0.277 . . . . 0.0 110.754 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.521 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 32.4 m -73.57 -63.98 0.87 Allowed Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 121.066 -0.253 . . . . 0.0 110.93 179.559 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.566 ' HD2' HG13 ' A' ' 43' ' ' VAL . 61.2 Cg_endo -74.53 100.51 1.33 Allowed 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 121.409 1.406 . . . . 0.0 111.226 177.726 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.63 -45.42 63.27 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.28 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.511 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.76 119.06 19.82 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.561 0.22 . . . . 0.0 110.999 179.783 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.1 pt -96.58 126.04 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.128 0.489 . . . . 0.0 110.896 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 84.0 t -97.8 126.43 50.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.567 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.5 mt -136.15 164.37 28.21 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.248 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.74 170.9 10.04 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 120.757 0.313 . . . . 0.0 110.935 179.24 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 12.7 ttpt -100.65 147.81 25.57 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.7 t 65.72 19.63 11.42 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.936 179.419 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.5 p -123.63 135.74 26.49 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.964 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_endo -64.11 123.28 11.64 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.133 1.889 . . . . 0.0 111.722 178.642 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.23 136.56 54.24 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.938 0.399 . . . . 0.0 111.542 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.434 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -118.53 125.51 50.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.855 0.836 . . . . 0.0 111.545 179.965 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.1 mm -98.38 114.93 37.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.626 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.543 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.34 107.83 19.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.768 0.318 . . . . 0.0 111.357 -179.38 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -94.16 118.53 31.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.081 0.467 . . . . 0.0 111.381 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -102.18 106.97 17.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.469 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.7 tpt180 -76.35 96.69 4.05 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 121.13 0.491 . . . . 0.0 111.42 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 23.4 tptt -91.89 -35.91 13.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.451 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.496 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.7 t70 -107.08 131.15 21.92 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.731 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -80.18 38.48 0.75 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.001 2.467 . . . . 0.0 113.027 -179.631 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -68.91 132.74 90.37 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.945 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -64.32 -30.92 63.5 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.668 2.245 . . . . 0.0 112.894 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.75 -3.13 42.78 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.544 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.491 HD22 HG13 ' A' ' 45' ' ' VAL . 16.6 mt -117.67 10.15 13.29 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 120.751 0.31 . . . . 0.0 111.19 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.18 -42.61 79.71 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -179.412 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLN . . . . . 0.426 ' O ' ' HB3' ' A' ' 111' ' ' CYS . 16.8 mt-30 -116.83 138.01 51.81 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.829 0.347 . . . . 0.0 111.584 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -118.21 131.7 70.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.654 179.432 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.416 ' HB ' ' HB3' ' A' ' 86' ' ' HIS . 0.2 OUTLIER -137.42 129.44 41.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.397 0.618 . . . . 0.0 111.579 179.947 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -89.95 102.18 4.39 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.252 178.78 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 109' ' ' PHE . 36.4 Cg_endo -64.99 -14.16 43.72 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.606 2.204 . . . . 0.0 113.637 -178.396 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -101.02 -11.25 19.82 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -119.15 -24.29 6.52 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 111.945 0.35 . . . . 0.0 111.945 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 88.84 1.17 80.46 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.143 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.521 HG11 HG13 ' A' ' 97' ' ' VAL . 54.8 t -80.36 117.02 25.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.886 0.374 . . . . 0.0 111.396 -178.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' HIS . . . . . 0.416 ' HB3' ' HB ' ' A' ' 79' ' ' VAL . 19.2 p-80 -132.05 122.59 25.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.835 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.48 174.23 10.94 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 121.112 0.482 . . . . 0.0 111.91 -178.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -108.23 141.89 39.31 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.656 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 33.9 mt -100.71 124.49 42.06 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 120.906 0.384 . . . . 0.0 111.467 -179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.434 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 63.6 Cg_endo -78.57 128.63 8.82 Favored 'Trans proline' 0 CA--C 1.53 0.313 0 C-N-CA 122.786 2.324 . . . . 0.0 112.684 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 12.3 tpt -66.19 124.94 23.99 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.151 0.501 . . . . 0.0 111.677 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.38 6.76 85.69 Favored Glycine 0 CA--C 1.52 0.398 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.923 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.434 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 48.3 mm-40 -134.13 176.78 8.28 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-O 120.943 0.401 . . . . 0.0 111.292 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -114.58 132.32 56.38 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.983 0.42 . . . . 0.0 111.834 -179.665 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.415 ' HB2' ' HD2' ' A' ' 90' ' ' PRO . 9.6 t80 -118.06 121.63 41.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.778 178.632 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.543 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -98.52 138.46 23.04 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 CA-C-O 121.629 0.728 . . . . 0.0 112.577 -178.715 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.521 HG13 HG11 ' A' ' 85' ' ' VAL . 43.8 t -115.6 110.34 31.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.053 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -93.98 117.39 30.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.034 0.445 . . . . 0.0 111.551 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -132.73 156.52 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.18 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.3 m -119.9 96.74 49.55 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.437 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.449 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.1 Cg_endo -72.07 99.49 1.0 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.706 2.271 . . . . 0.0 112.494 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -97.3 22.92 8.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.023 0.439 . . . . 0.0 111.553 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.17 127.76 11.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.749 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -83.84 122.96 29.4 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.975 0.417 . . . . 0.0 111.326 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 169.2 -158.76 31.44 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.729 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -101.99 126.7 48.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.182 0.515 . . . . 0.0 111.576 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.447 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 85.7 m-85 -119.69 169.7 9.86 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.918 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 99.1 p -149.81 157.38 43.15 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.408 ' HA ' ' HD2' ' A' ' 81' ' ' PRO . 32.9 p90 -148.29 138.48 22.6 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.995 178.778 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.42 178.27 8.79 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.05 0.452 . . . . 0.0 111.655 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.426 ' HB3' ' O ' ' A' ' 77' ' ' GLN . 0.0 OUTLIER -123.9 126.74 46.91 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.882 179.407 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 62.22 -103.75 0.65 Allowed Glycine 0 CA--C 1.522 0.484 0 C-N-CA 121.179 -0.534 . . . . 0.0 113.066 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -139.3 -107.06 0.17 Allowed 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 110.504 -0.184 . . . . 0.0 110.504 179.65 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 59.05 -160.13 0.28 Allowed 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 121.099 0.476 . . . . 0.0 111.923 179.426 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' MET . . . . . 0.409 ' H ' ' HG3' ' A' ' 115' ' ' MET . 0.0 OUTLIER -113.9 -27.87 7.59 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.19 179.408 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 1.2 ptm -68.39 117.77 10.6 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.032 0.444 . . . . 0.0 111.219 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 53.1 p-80 -150.18 152.91 35.4 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.164 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -105.64 148.3 16.46 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.251 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 14.6 ttpt -117.62 146.14 43.86 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.03 0.443 . . . . 0.0 111.098 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.447 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.7 ttm -128.39 136.22 50.61 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.908 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -120.02 118.42 56.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.981 0.42 . . . . 0.0 110.846 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 76.0 t -99.78 121.78 50.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.146 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.103 -0.951 . . . . 0.0 111.531 -179.702 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.646 0 CA-C-O 121.259 0.366 . . . . 0.0 112.241 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.18 0.21 11.17 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.511 -0.344 . . . . 0.0 111.415 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.95 -74.36 0.61 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.441 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.4 171.09 39.49 Favored Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.801 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -133.1 128.17 35.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.207 0.527 . . . . 0.0 111.477 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 3.1 ttpt -90.17 129.5 36.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.747 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.22 153.51 40.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.441 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 3.7 pt20 -84.48 139.33 32.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.132 0.491 . . . . 0.0 111.393 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -94.82 115.29 27.31 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.769 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.89 -151.14 0.32 Allowed 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.248 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.6 m120 -82.94 73.29 9.98 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.131 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.68 -4.76 61.75 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 120.817 -0.706 . . . . 0.0 114.061 178.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 30.2 p90 -143.62 162.57 35.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.909 0.355 . . . . 0.0 110.915 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.42 153.33 27.51 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.006 0.432 . . . . 0.0 111.475 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.441 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.6 tt0 -142.14 142.81 32.78 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.567 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.56 129.07 13.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -90.74 110.12 21.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.239 0.542 . . . . 0.0 110.939 179.639 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.582 HG13 ' HD2' ' A' ' 51' ' ' PRO . 43.5 t -102.16 103.91 15.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.774 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.468 ' HG2' ' SD ' ' A' ' 46' ' ' MET . 0.8 OUTLIER -75.25 118.13 17.82 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.614 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.563 HG13 HD22 ' A' ' 75' ' ' LEU . 53.5 t -96.9 98.41 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.649 -178.614 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.468 ' SD ' ' HG2' ' A' ' 44' ' ' GLU . 6.4 ptm -142.55 90.81 2.26 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.642 179.124 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 81.7 0.72 89.68 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.901 -0.666 . . . . 0.0 111.684 -178.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.464 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 162.79 -133.66 3.16 Favored Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -124.8 130.77 53.04 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.743 0.272 . . . . 0.0 110.599 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.537 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 49.7 m -70.15 -64.99 1.2 Allowed Pre-proline 0 CA--C 1.538 0.51 0 CA-C-O 119.508 -0.282 . . . . 0.0 111.391 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.582 ' HD2' HG13 ' A' ' 43' ' ' VAL . 58.7 Cg_endo -73.95 100.32 1.27 Allowed 'Trans proline' 0 C--N 1.358 1.058 0 C-N-CA 121.278 1.319 . . . . 0.0 111.249 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.84 -47.16 60.25 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.951 -0.568 . . . . 0.0 112.285 -179.365 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.56 119.06 20.01 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.638 0.256 . . . . 0.0 110.752 179.897 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.4 pt -97.04 129.37 47.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.093 0.473 . . . . 0.0 111.062 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 96.3 t -96.18 124.95 49.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.509 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.0 157.24 42.87 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.087 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -89.85 168.99 11.63 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 110.163 -0.31 . . . . 0.0 110.163 178.31 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.9 ttpp -98.77 146.95 25.39 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 112.305 0.484 . . . . 0.0 112.305 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.6 t 65.66 19.78 11.48 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.86 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.451 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.95 135.9 26.84 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.976 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -64.29 122.74 10.8 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.128 1.885 . . . . 0.0 111.812 178.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.7 134.68 53.67 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.856 0.36 . . . . 0.0 111.47 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.46 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -116.59 126.32 53.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.776 0.798 . . . . 0.0 111.585 -179.918 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.5 mm -99.5 114.88 38.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.67 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.523 HG22 HG23 ' A' ' 96' ' ' VAL . 4.1 t -90.45 108.2 19.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.714 0.292 . . . . 0.0 111.383 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -95.08 113.67 25.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.147 0.499 . . . . 0.0 111.326 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 21.8 t0 -99.32 103.72 15.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.5 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.25 97.66 4.24 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.176 0.512 . . . . 0.0 111.723 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.66 -42.1 10.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.482 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.455 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.2 t70 -99.47 131.75 24.39 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.837 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -80.73 39.63 0.88 Allowed 'Trans proline' 0 C--N 1.348 0.526 0 C-N-CA 123.16 2.573 . . . . 0.0 113.162 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 30.7 t -69.77 136.18 87.84 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.326 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -63.95 -27.95 66.63 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.576 2.184 . . . . 0.0 112.443 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 80.6 m -81.05 -6.89 59.33 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.059 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.563 HD22 HG13 ' A' ' 45' ' ' VAL . 50.9 mt -118.31 14.92 13.92 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.208 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -68.37 -35.89 78.39 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 120.95 0.405 . . . . 0.0 111.557 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -129.34 165.68 21.0 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.047 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.08 131.82 42.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.245 0.545 . . . . 0.0 110.98 179.156 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.9 128.63 43.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.455 0.645 . . . . 0.0 111.179 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -90.81 102.21 4.95 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.422 178.848 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -65.24 -14.2 43.83 Favored 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.583 2.188 . . . . 0.0 113.583 -178.547 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -101.05 -10.24 20.68 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 111.906 0.335 . . . . 0.0 111.906 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 59.0 m-85 -119.84 -23.69 6.37 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -179.644 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 87.92 1.28 82.57 Favored Glycine 0 CA--C 1.521 0.458 0 C-N-CA 121.291 -0.48 . . . . 0.0 112.175 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.506 HG11 HG13 ' A' ' 97' ' ' VAL . 53.6 t -81.48 116.27 25.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.892 0.377 . . . . 0.0 111.348 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 20.3 p-80 -131.51 120.86 23.53 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.959 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -140.18 173.79 11.16 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.759 -179.028 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 8.1 p-10 -106.54 145.54 31.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.738 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 36.2 mt -103.97 130.17 23.89 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 120.924 0.393 . . . . 0.0 111.203 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.425 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.7 Cg_endo -80.86 126.11 5.69 Favored 'Trans proline' 0 CA--C 1.532 0.382 0 C-N-CA 122.706 2.271 . . . . 0.0 112.325 179.26 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.0 tpt -64.01 123.95 20.34 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.092 0.473 . . . . 0.0 111.764 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.02 3.59 87.62 Favored Glycine 0 CA--C 1.522 0.508 0 CA-C-N 115.866 -0.606 . . . . 0.0 113.283 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.425 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 47.8 mt-10 -131.86 176.86 7.99 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 120.886 0.374 . . . . 0.0 111.196 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -113.38 135.55 53.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.083 0.468 . . . . 0.0 111.985 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -120.07 124.26 45.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.807 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.523 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -98.7 137.94 24.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.63 0.728 . . . . 0.0 112.666 -178.879 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.506 HG13 HG11 ' A' ' 85' ' ' VAL . 46.1 t -114.99 110.46 32.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.055 178.78 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -93.56 117.09 29.64 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.854 0.359 . . . . 0.0 111.481 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 pt -132.05 158.05 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.213 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -121.38 96.24 47.97 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.501 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.451 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.7 Cg_endo -71.19 99.59 0.91 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.724 2.283 . . . . 0.0 112.276 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -94.22 3.65 54.96 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -132.01 135.95 46.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.79 0.329 . . . . 0.0 110.754 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.46 124.11 34.19 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.962 179.752 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 168.76 -159.44 32.56 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.839 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -100.61 125.93 47.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.155 0.503 . . . . 0.0 111.556 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.467 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 95.5 m-85 -121.42 164.86 16.44 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.831 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -151.21 157.43 42.63 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.251 0.548 . . . . 0.0 112.244 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -142.92 140.42 31.14 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.913 179.099 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.21 177.69 9.42 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.356 -179.757 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 39.1 t -143.68 128.18 17.99 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 120.849 0.356 . . . . 0.0 111.262 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 72.85 -142.55 32.19 Favored Glycine 0 CA--C 1.521 0.415 0 C-N-CA 121.08 -0.581 . . . . 0.0 113.196 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -131.01 104.23 6.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.846 0.355 . . . . 0.0 110.923 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.25 -179.91 6.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.984 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.66 -28.82 30.41 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.441 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 1.6 ptm -67.85 116.87 9.01 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.156 0.503 . . . . 0.0 111.221 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 49.6 p-80 -151.82 157.73 42.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.771 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -114.23 148.84 18.79 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.468 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 4.1 ttmm -120.85 147.3 45.57 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.947 0.403 . . . . 0.0 111.209 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.467 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 3.4 ttm -131.1 135.13 47.24 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.926 179.496 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.16 117.87 55.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.045 0.45 . . . . 0.0 110.527 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.1 t -99.95 123.58 52.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.349 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 118.186 -0.912 . . . . 0.0 111.46 -179.844 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.647 0 CA-C-O 121.282 0.379 . . . . 0.0 112.28 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.87 2.79 17.2 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.439 -0.381 . . . . 0.0 111.383 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 19.6 mtm -82.9 52.05 2.06 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-O 121.007 0.432 . . . . 0.0 111.623 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.65 160.39 35.74 Favored Glycine 0 CA--C 1.518 0.278 0 C-N-CA 121.051 -0.595 . . . . 0.0 113.007 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -124.04 129.31 50.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.069 0.461 . . . . 0.0 111.268 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 5.3 mtpt -90.12 129.25 36.43 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.733 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.99 149.21 43.49 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.636 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.602 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.8 pt20 -74.81 138.02 42.3 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.907 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -97.55 113.36 25.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.871 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -95.41 -156.17 0.5 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.368 -179.682 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -81.89 79.26 8.47 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 112.29 0.478 . . . . 0.0 112.29 -179.182 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.74 -9.98 66.36 Favored Glycine 0 CA--C 1.522 0.508 0 C-N-CA 120.799 -0.715 . . . . 0.0 114.298 178.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 28.9 p90 -142.01 164.07 31.17 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 117.098 0.449 . . . . 0.0 111.193 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.13 155.41 26.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.012 0.434 . . . . 0.0 111.182 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.602 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.9 tt0 -144.49 143.19 30.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.33 -179.28 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.11 129.44 17.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.082 0.468 . . . . 0.0 111.327 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 ttm180 -88.7 106.97 18.69 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.221 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.587 HG13 ' HD2' ' A' ' 51' ' ' PRO . 45.6 t -100.39 102.31 13.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.496 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -73.6 119.38 17.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.711 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.552 HG13 HD22 ' A' ' 75' ' ' LEU . 53.2 t -98.86 99.44 8.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.517 -178.723 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.493 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.2 ptm -143.8 88.24 1.97 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.537 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.31 -0.36 84.61 Favored Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.575 -178.555 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.437 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 163.41 -163.45 35.6 Favored Glycine 0 N--CA 1.447 -0.586 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -98.58 126.36 44.13 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.768 0.284 . . . . 0.0 110.321 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.537 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 47.8 m -65.24 -64.3 2.73 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 121.196 -0.202 . . . . 0.0 111.267 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.587 ' HD2' HG13 ' A' ' 43' ' ' VAL . 60.8 Cg_endo -74.62 96.58 1.0 Allowed 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 121.358 1.372 . . . . 0.0 111.198 177.693 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.36 -42.86 61.61 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.096 -0.502 . . . . 0.0 112.195 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.485 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.88 118.68 20.16 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.696 0.284 . . . . 0.0 110.606 179.513 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.9 pt -98.0 127.48 50.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-O 121.03 0.443 . . . . 0.0 111.092 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.1 t -98.68 126.72 51.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.597 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.0 mt -136.41 165.32 26.08 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.264 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -90.97 171.42 9.29 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.797 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.5 ttpp -101.74 148.47 25.24 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.999 0.428 . . . . 0.0 112.066 -179.325 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.0 t 65.42 20.14 11.71 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.931 179.567 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.436 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.8 p -123.78 135.91 26.77 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.866 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -64.36 122.2 10.06 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.202 1.935 . . . . 0.0 111.68 178.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.46 138.65 54.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.995 0.426 . . . . 0.0 111.546 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.474 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.2 ptt180 -120.72 126.85 51.21 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-O 121.776 0.798 . . . . 0.0 111.343 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.8 mm -97.73 115.01 36.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.81 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.452 HG22 HG23 ' A' ' 96' ' ' VAL . 3.6 t -91.99 110.52 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.376 -179.271 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -96.2 114.69 26.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.041 0.448 . . . . 0.0 111.289 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -100.38 104.5 15.93 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.181 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.407 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 0.1 OUTLIER -76.64 104.66 7.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.289 0.566 . . . . 0.0 111.958 -179.093 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.73 -39.84 9.26 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.093 179.212 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.493 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.1 t70 -105.71 133.86 19.99 Favored Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.929 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -80.97 39.53 0.87 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.994 2.463 . . . . 0.0 112.861 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.07 133.87 91.74 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.451 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.67 -32.37 57.67 Favored 'Trans proline' 0 C--N 1.348 0.527 0 C-N-CA 122.771 2.314 . . . . 0.0 112.63 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.15 -2.69 32.3 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.56 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.552 HD22 HG13 ' A' ' 45' ' ' VAL . 34.9 mt -118.74 12.99 13.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.275 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -70.55 -43.46 69.46 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.931 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.55 140.14 51.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.026 0.441 . . . . 0.0 111.54 -179.476 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -120.64 127.64 75.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.525 178.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -130.11 130.58 65.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.349 0.595 . . . . 0.0 111.475 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -92.65 102.12 6.26 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.374 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -66.67 -16.66 51.18 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.667 2.245 . . . . 0.0 113.7 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -100.57 -7.44 24.06 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -120.58 -21.82 6.61 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.9 29.82 45.53 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.077 -179.369 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.1 t -110.85 117.98 56.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.81 0.338 . . . . 0.0 111.753 -178.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -119.93 121.0 38.03 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.226 179.117 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.48 158.92 43.37 Favored 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 112.521 0.564 . . . . 0.0 112.521 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -104.01 137.0 42.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.477 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 45.0 mt -99.76 127.84 32.8 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.968 0.413 . . . . 0.0 111.466 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.433 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 70.8 Cg_endo -82.05 130.36 6.46 Favored 'Trans proline' 0 CA--C 1.533 0.426 0 C-N-CA 122.689 2.259 . . . . 0.0 112.441 179.241 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' MET . . . . . 0.407 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 10.7 tpt -68.06 125.57 26.77 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-O 121.072 0.463 . . . . 0.0 111.644 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.51 13.11 79.16 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-N 115.855 -0.611 . . . . 0.0 112.866 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.433 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.5 mm-40 -138.5 176.93 8.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.878 0.371 . . . . 0.0 111.125 -179.482 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -114.0 134.21 55.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.049 0.452 . . . . 0.0 111.661 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.7 t80 -123.05 124.84 44.03 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.029 178.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.452 HG23 HG22 ' A' ' 65' ' ' VAL . 2.1 p -105.04 136.73 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 CA-C-O 121.544 0.688 . . . . 0.0 112.439 -178.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.7 t -113.17 112.92 42.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.113 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -93.84 119.49 32.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.951 0.405 . . . . 0.0 111.476 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -135.46 156.6 38.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.145 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -119.96 97.57 49.45 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.614 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.4 Cg_endo -72.75 100.28 1.16 Allowed 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 122.806 2.338 . . . . 0.0 112.309 179.502 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -95.46 5.34 51.85 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -131.97 133.29 44.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.798 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.89 127.74 35.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.0 0.429 . . . . 0.0 111.223 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 162.47 -156.56 28.25 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.764 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.02 126.13 48.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.198 0.523 . . . . 0.0 111.488 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.439 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 84.0 m-85 -118.15 173.41 6.81 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.904 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 83.2 p -151.22 158.13 43.51 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -178.859 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -149.69 130.46 14.15 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.334 178.756 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' ALA . . . . . 0.419 ' HB1' ' HB3' ' A' ' 116' ' ' MET . . . -162.33 172.91 14.9 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.964 0.411 . . . . 0.0 112.001 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 41.2 t -120.58 130.41 54.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.627 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -77.0 70.34 2.34 Favored Glycine 0 CA--C 1.522 0.489 0 C-N-CA 120.923 -0.655 . . . . 0.0 113.084 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.86 -31.53 0.55 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.777 0.322 . . . . 0.0 111.593 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -156.14 -159.78 0.93 Allowed 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.116 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 1.7 ttp -78.16 77.94 4.65 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-O 120.999 0.428 . . . . 0.0 111.302 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' MET . . . . . 0.419 ' HB3' ' HB1' ' A' ' 110' ' ' ALA . 0.0 OUTLIER -87.19 149.56 24.54 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.151 -179.954 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.4 105.21 3.58 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.8 0.333 . . . . 0.0 111.822 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -146.06 121.15 1.42 Allowed Glycine 0 CA--C 1.521 0.444 0 C-N-CA 121.185 -0.531 . . . . 0.0 112.269 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 12.4 ttmt -123.09 151.57 41.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.106 0.479 . . . . 0.0 111.898 -179.255 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.439 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -134.52 139.79 45.69 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.735 179.479 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.0 mp -123.24 120.16 59.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.997 0.427 . . . . 0.0 110.81 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 85.2 t -104.16 123.19 57.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.202 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.237 0 CA-C-O 118.102 -0.951 . . . . 0.0 111.505 -179.691 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.699 0 N-CA-C 112.237 -0.345 . . . . 0.0 112.237 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -114.15 8.71 17.0 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.934 0.397 . . . . 0.0 111.464 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -88.01 89.94 8.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.985 0.421 . . . . 0.0 111.274 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.98 -168.59 12.64 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.788 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.11 128.41 24.13 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.042 0.449 . . . . 0.0 111.237 179.573 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.2 mtpt -91.34 129.24 37.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.874 179.794 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.65 152.36 40.51 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.317 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.563 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.5 pt20 -80.84 141.26 34.83 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-O 121.152 0.501 . . . . 0.0 111.444 -179.352 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 58.4 mt-30 -96.9 114.84 26.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.594 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.39 -149.82 0.31 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.456 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -82.01 72.72 9.06 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -179.104 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.76 -5.21 66.57 Favored Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.788 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.4 p90 -141.36 160.3 40.41 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.905 0.352 . . . . 0.0 110.746 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.18 155.66 21.68 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.988 0.423 . . . . 0.0 111.423 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.563 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.7 tt0 -144.53 143.84 31.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.545 -179.317 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -145.15 129.63 12.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.2 179.144 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 7.3 ttt180 -89.96 108.14 19.53 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.071 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.475 HG13 ' HD2' ' A' ' 51' ' ' PRO . 49.0 t -99.99 107.85 21.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.705 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -73.6 122.46 22.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.013 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.55 HG13 HD22 ' A' ' 75' ' ' LEU . 53.8 t -103.08 95.33 3.77 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-O 121.535 0.683 . . . . 0.0 111.052 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.449 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 3.8 ptm -146.16 89.45 1.87 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.405 179.562 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.55 0.24 89.8 Favored Glycine 0 CA--C 1.521 0.454 0 C-N-CA 120.811 -0.709 . . . . 0.0 111.545 -178.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.478 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.66 -140.6 6.81 Favored Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 111.649 -0.581 . . . . 0.0 111.649 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -121.86 129.46 52.61 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.741 0.27 . . . . 0.0 110.543 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.49 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 20.8 m -68.84 -62.0 3.17 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 120.997 -0.281 . . . . 0.0 111.176 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.49 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 63.5 Cg_endo -75.62 97.6 1.11 Allowed 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 121.417 1.411 . . . . 0.0 111.064 177.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -52.11 -43.34 63.9 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.125 -0.489 . . . . 0.0 112.062 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -134.17 118.45 17.67 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.711 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.488 HG13 ' HG3' ' A' ' 120' ' ' MET . 9.6 pt -96.91 127.35 49.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.134 0.492 . . . . 0.0 110.939 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 98.9 t -95.51 125.86 48.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.601 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 23.6 mt -133.69 167.68 20.07 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.263 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.2 mttt -96.59 168.84 10.29 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.685 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -98.67 146.72 25.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.928 0.395 . . . . 0.0 111.927 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.5 t 66.06 19.7 11.19 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.89 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 5.7 p -123.53 135.2 25.84 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.002 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -64.3 122.7 10.74 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.051 1.834 . . . . 0.0 111.711 178.761 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.1 138.98 54.36 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.79 0.328 . . . . 0.0 111.622 -179.628 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.447 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -120.92 125.33 47.17 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.719 0.771 . . . . 0.0 111.494 179.947 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 5.7 mm -97.66 115.25 37.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.654 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.518 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.9 109.8 21.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.375 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -95.5 111.81 23.65 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.016 0.436 . . . . 0.0 111.296 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -98.11 106.03 18.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.52 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.406 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 0.2 OUTLIER -78.19 105.16 9.24 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.282 0.563 . . . . 0.0 111.91 -179.448 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.05 -37.36 9.38 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.19 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.449 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 5.2 t70 -103.78 129.88 24.48 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.922 179.544 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -80.52 39.13 0.81 Allowed 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.113 2.542 . . . . 0.0 112.881 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.2 m -72.04 135.84 82.46 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.349 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -64.08 -31.21 65.65 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.617 2.211 . . . . 0.0 112.583 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 5.2 p -76.79 -5.29 47.58 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.587 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.55 HD22 HG13 ' A' ' 45' ' ' VAL . 30.2 mt -120.12 15.94 12.38 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.964 179.642 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -67.82 -35.56 78.82 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 116.096 -0.502 . . . . 0.0 112.243 -179.332 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 -133.7 165.91 23.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.914 0.388 . . . . 0.0 111.583 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ILE . . . . . 0.417 HG13 ' N ' ' A' ' 79' ' ' VAL . 0.5 OUTLIER -137.72 141.37 39.22 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.115 179.858 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.417 ' N ' HG13 ' A' ' 78' ' ' ILE . 0.2 OUTLIER -139.9 134.14 36.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.364 0.602 . . . . 0.0 111.359 179.054 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -97.57 101.68 10.97 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.84 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.56 -13.79 40.14 Favored 'Trans proline' 0 C--N 1.347 0.481 0 C-N-CA 122.613 2.209 . . . . 0.0 113.431 -178.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -100.57 -9.11 22.32 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -123.02 -19.93 5.92 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.353 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.71 28.97 49.7 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.86 -0.685 . . . . 0.0 112.226 -179.605 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.4 t -110.75 116.87 53.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.745 0.307 . . . . 0.0 111.535 -179.052 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 4.3 t60 -127.12 117.72 22.95 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.87 0.367 . . . . 0.0 110.45 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.12 170.48 15.61 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 121.09 0.471 . . . . 0.0 111.858 -179.394 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -106.24 145.84 31.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.477 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 34.8 mt -105.47 129.35 24.85 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.867 0.365 . . . . 0.0 111.412 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.445 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.7 Cg_endo -81.86 129.21 6.18 Favored 'Trans proline' 0 CA--C 1.532 0.409 0 C-N-CA 122.752 2.301 . . . . 0.0 112.486 179.265 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' MET . . . . . 0.406 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 10.3 tpt -67.07 125.27 25.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.138 0.494 . . . . 0.0 111.699 -179.575 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.66 6.37 85.64 Favored Glycine 0 C--N 1.333 0.367 0 CA-C-N 115.864 -0.607 . . . . 0.0 113.077 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.445 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 45.7 mt-10 -134.29 176.82 8.26 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 120.988 0.423 . . . . 0.0 111.018 -179.533 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -115.06 132.49 56.58 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.0 0.429 . . . . 0.0 111.767 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.4 t80 -116.47 123.9 48.64 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.968 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.518 HG23 HG22 ' A' ' 65' ' ' VAL . 1.6 p -101.28 137.1 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 CA-C-O 121.651 0.739 . . . . 0.0 112.51 -178.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.98 110.21 31.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.154 178.823 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -92.67 118.82 31.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.373 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -135.84 154.52 34.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.361 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -119.22 97.43 50.46 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.272 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.449 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 74.2 Cg_endo -73.47 101.92 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.845 2.363 . . . . 0.0 112.72 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -97.71 19.9 12.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.984 0.421 . . . . 0.0 111.483 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -146.97 129.93 16.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.774 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -86.1 126.28 34.08 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.903 0.382 . . . . 0.0 111.269 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.09 -168.29 41.36 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.816 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -99.76 112.02 24.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.141 0.496 . . . . 0.0 110.774 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -110.94 172.4 6.9 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.292 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 54.2 p -153.69 163.39 40.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.132 0.491 . . . . 0.0 112.274 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 31.2 p90 -145.58 140.63 27.54 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.518 179.067 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.39 178.48 8.62 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 121.332 0.587 . . . . 0.0 112.273 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 49.6 t -122.35 137.18 54.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.108 178.818 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -73.93 74.16 1.19 Allowed Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.008 -0.615 . . . . 0.0 113.474 -179.365 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 3.4 ttm -164.3 -39.26 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.275 0 CA-C-O 120.694 0.283 . . . . 0.0 111.443 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -114.69 177.19 4.74 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.205 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -95.77 -16.08 22.15 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.491 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.9 146.38 44.06 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-O 121.008 0.432 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 22.9 p80 -153.54 157.98 40.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.92 0.39 . . . . 0.0 111.611 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -107.49 151.92 16.92 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 179.381 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 1.2 ttpt -115.94 151.9 34.5 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.957 0.408 . . . . 0.0 111.476 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.488 ' HG3' HG13 ' A' ' 54' ' ' ILE . 9.2 ttp -133.96 122.18 22.71 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.048 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -109.69 116.08 51.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.101 0.477 . . . . 0.0 110.88 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 98.3 t -100.05 120.07 48.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.077 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 24.1 mt-10 . . . . . 0 C--O 1.253 1.247 0 CA-C-O 118.13 -0.938 . . . . 0.0 111.491 -179.542 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.684 0 CA-C-O 121.227 0.348 . . . . 0.0 112.315 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.9 24.59 9.55 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.98 0.419 . . . . 0.0 111.26 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.53 72.2 10.29 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 121.041 0.448 . . . . 0.0 111.443 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 118.19 167.36 14.04 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.88 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 19.8 mp0 -117.14 123.85 47.74 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.175 0.512 . . . . 0.0 111.114 -179.533 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 3.4 ttmt -89.5 127.52 35.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.909 -179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.16 155.95 39.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.052 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.575 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 10.9 pt20 -79.68 132.8 36.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.295 0.569 . . . . 0.0 111.248 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.0 mt-30 -92.79 109.11 20.53 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.83 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.03 -157.07 0.47 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.352 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -83.09 80.3 9.09 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.203 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.05 -7.18 67.01 Favored Glycine 0 CA--C 1.523 0.534 0 C-N-CA 120.846 -0.692 . . . . 0.0 114.178 178.762 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' TYR . . . . . 0.452 ' HB2' ' O ' ' A' ' 61' ' ' PRO . 24.6 p90 -144.15 165.53 27.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 117.191 0.496 . . . . 0.0 111.075 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.89 154.96 33.61 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.901 0.382 . . . . 0.0 111.201 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.575 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.5 tt0 -145.21 143.13 30.12 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.43 -179.533 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.71 129.2 13.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.93 0.395 . . . . 0.0 110.714 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.58 111.45 22.76 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.317 0.58 . . . . 0.0 111.127 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.652 HG13 ' HD2' ' A' ' 51' ' ' PRO . 42.6 t -100.05 102.82 13.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.571 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.414 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.4 OUTLIER -72.56 113.61 9.79 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.607 179.874 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.604 HG13 HD22 ' A' ' 75' ' ' LEU . 43.1 t -94.66 97.45 6.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.674 -0.693 . . . . 0.0 111.336 -178.87 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.474 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.7 ptm -141.68 85.27 1.94 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.532 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.94 1.42 90.63 Favored Glycine 0 CA--C 1.521 0.41 0 C-N-CA 120.958 -0.639 . . . . 0.0 111.516 -178.598 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.427 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.94 -166.95 35.79 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -93.75 123.75 37.29 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.86 0.33 . . . . 0.0 110.44 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.501 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 25.5 m -63.67 -62.17 5.81 Favored Pre-proline 0 CA--C 1.538 0.489 0 CA-C-O 119.594 -0.241 . . . . 0.0 111.07 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.652 ' HD2' HG13 ' A' ' 43' ' ' VAL . 61.2 Cg_endo -75.23 98.73 1.19 Allowed 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 121.211 1.274 . . . . 0.0 110.974 177.366 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.54 -45.31 62.94 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.3 -179.066 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.461 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -133.18 118.28 18.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.53 179.704 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.435 HG13 ' HG3' ' A' ' 120' ' ' MET . 5.0 pt -96.92 126.12 49.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.141 0.495 . . . . 0.0 111.273 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 88.9 t -99.07 125.65 52.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.413 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.57 HD22 ' HB1' ' A' ' 62' ' ' ALA . 2.3 mt -136.27 166.19 24.0 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.354 -179.588 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.0 177.18 7.67 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.263 179.382 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 12.2 ttpt -106.05 147.36 28.99 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 111.842 0.312 . . . . 0.0 111.842 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.8 t 62.35 26.9 16.08 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.646 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -123.57 137.06 27.97 Favored Pre-proline 0 CA--C 1.538 0.508 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.435 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' PRO . . . . . 0.452 ' O ' ' HB2' ' A' ' 38' ' ' TYR . 36.2 Cg_endo -67.25 93.44 0.35 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.773 2.316 . . . . 0.0 112.206 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.57 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -97.99 138.78 34.8 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.911 0.386 . . . . 0.0 111.988 -179.083 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.491 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.5 OUTLIER -121.51 129.09 52.71 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 121.736 0.779 . . . . 0.0 111.644 179.747 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.6 mm -100.63 114.78 40.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.285 -0.871 . . . . 0.0 110.695 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.501 HG22 HG23 ' A' ' 96' ' ' VAL . 3.3 t -91.65 109.86 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.677 -0.238 . . . . 0.0 111.411 -179.396 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -95.44 113.63 25.32 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.034 0.445 . . . . 0.0 111.278 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -100.18 106.6 18.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.142 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.05 105.98 9.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.312 0.577 . . . . 0.0 112.12 -179.143 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.2 tptp -99.9 -34.56 10.07 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.084 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.474 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.6 t70 -109.6 132.68 21.2 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.779 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -81.13 40.43 0.99 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.085 2.524 . . . . 0.0 113.306 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.514 ' HB3' HD12 ' A' ' 75' ' ' LEU . 36.2 t -68.65 134.7 90.41 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.331 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -64.43 -27.96 62.56 Favored 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 122.652 2.234 . . . . 0.0 112.647 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.1 m -78.92 -10.75 59.91 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.168 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.604 HD22 HG13 ' A' ' 45' ' ' VAL . 40.9 mt -110.57 10.21 23.04 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.497 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -68.23 -40.53 82.0 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 120.87 0.367 . . . . 0.0 111.81 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -123.54 148.64 46.11 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.359 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -130.53 129.88 64.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.13 0.49 . . . . 0.0 110.374 178.653 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 2.4 p -133.98 132.45 56.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.2 0.524 . . . . 0.0 111.18 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -93.07 101.76 5.99 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.259 178.647 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 109' ' ' PHE . 38.2 Cg_endo -66.57 -15.71 48.52 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.662 2.241 . . . . 0.0 113.527 -178.391 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -100.58 -7.59 23.87 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -121.36 -20.9 6.5 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 112.026 0.38 . . . . 0.0 112.026 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.95 29.43 46.84 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.105 -179.524 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 50.9 t -110.89 115.71 50.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.881 0.372 . . . . 0.0 111.753 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.6 p80 -118.75 124.95 48.53 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.429 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.04 160.06 41.09 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -104.08 139.55 39.02 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.471 179.594 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 42.3 mt -101.63 127.23 31.87 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.904 0.383 . . . . 0.0 111.438 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.438 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 68.9 Cg_endo -81.0 128.14 6.4 Favored 'Trans proline' 0 CA--C 1.532 0.383 0 C-N-CA 122.667 2.245 . . . . 0.0 112.479 179.441 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.0 tpt -66.75 125.49 26.01 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.993 0.425 . . . . 0.0 111.583 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.84 7.88 83.4 Favored Glycine 0 CA--C 1.52 0.393 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.889 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.438 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 52.4 mm-40 -135.58 176.9 8.25 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.014 0.435 . . . . 0.0 111.14 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -114.63 134.34 55.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.033 0.444 . . . . 0.0 111.669 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -121.95 126.15 47.96 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.108 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.501 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -103.81 139.28 25.21 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 CA-C-O 121.516 0.674 . . . . 0.0 112.674 -178.873 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.8 t -116.41 110.82 32.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.123 178.68 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -93.67 119.37 32.6 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.255 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -133.31 157.57 42.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.086 0.469 . . . . 0.0 111.186 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.5 m -122.3 95.57 46.99 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.317 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.68 101.2 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.816 2.344 . . . . 0.0 112.649 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -95.02 23.73 5.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.922 0.391 . . . . 0.0 111.64 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -149.25 130.43 14.54 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.764 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.51 127.21 35.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.04 0.448 . . . . 0.0 111.438 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 165.01 -160.38 33.66 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.659 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -101.58 125.58 48.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.051 0.453 . . . . 0.0 111.275 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.439 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 91.7 m-85 -118.31 167.54 11.45 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.198 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.6 p -143.53 154.88 44.07 Favored 'General case' 0 C--O 1.234 0.26 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.415 ' HA ' ' HD2' ' A' ' 81' ' ' PRO . 44.4 p90 -148.73 129.46 14.16 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.916 178.869 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.81 158.09 22.3 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.116 -179.703 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 6.7 t -156.51 162.82 39.93 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.921 0.391 . . . . 0.0 111.188 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 87.08 -77.29 1.99 Allowed Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.924 -0.655 . . . . 0.0 113.237 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -135.0 177.59 7.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.005 0.431 . . . . 0.0 111.418 -179.674 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -85.2 2.03 45.52 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.508 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 6.9 mtm -85.26 -7.66 58.91 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-O 120.875 0.369 . . . . 0.0 111.324 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -76.34 155.95 33.73 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.119 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -144.89 106.25 4.22 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.987 0.423 . . . . 0.0 111.858 -179.51 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -141.34 115.69 1.03 Allowed Glycine 0 CA--C 1.519 0.316 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.969 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.461 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.9 ttpt -119.4 149.7 41.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.304 0.573 . . . . 0.0 111.729 -179.181 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.439 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 12.0 ttp -133.93 135.16 43.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.734 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.1 mp -119.38 119.29 60.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.952 0.406 . . . . 0.0 110.856 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 89.6 t -104.12 120.16 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.135 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.227 -0.892 . . . . 0.0 111.464 -179.773 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.706 0 N-CA-C 112.529 -0.229 . . . . 0.0 112.529 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . 63.47 -91.23 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 123.408 0.683 . . . . 0.0 112.127 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -137.15 111.23 8.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.951 0.405 . . . . 0.0 111.39 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -84.67 167.8 42.96 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.993 -0.623 . . . . 0.0 112.962 179.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.09 132.19 55.99 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.134 0.493 . . . . 0.0 111.223 -179.768 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.42 126.1 37.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.808 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.36 153.19 42.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.24 179.681 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -81.42 141.2 34.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.163 0.506 . . . . 0.0 111.52 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -97.16 115.71 28.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.596 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.51 -149.88 0.34 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.513 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -81.74 73.0 8.8 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -179.149 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.68 -6.54 67.62 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.65 -0.786 . . . . 0.0 113.898 179.006 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 38.9 p90 -139.89 163.7 31.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.767 0.283 . . . . 0.0 110.799 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.92 153.1 29.83 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.111 0.481 . . . . 0.0 111.283 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.409 ' HG3' ' HE ' ' A' ' 63' ' ' ARG . 3.3 tt0 -142.16 141.6 32.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.606 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.19 128.95 22.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.116 179.203 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -89.1 107.46 19.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.159 0.504 . . . . 0.0 111.017 179.574 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.587 HG13 ' HD2' ' A' ' 51' ' ' PRO . 47.3 t -100.28 103.29 14.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.416 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -73.29 116.87 14.35 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.025 -179.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.558 HG13 HD22 ' A' ' 75' ' ' LEU . 42.0 t -98.01 99.08 8.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 CA-C-O 121.52 0.676 . . . . 0.0 111.423 -179.013 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.497 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.0 ptm -143.88 86.93 1.88 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.462 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.98 2.28 90.67 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.447 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.65 -154.01 24.97 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 65.3 m-85 -107.43 127.62 53.76 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.85 0.325 . . . . 0.0 110.407 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.517 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 40.7 m -66.92 -64.46 2.16 Favored Pre-proline 0 CA--C 1.539 0.522 0 CA-C-O 119.529 -0.272 . . . . 0.0 111.389 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.587 ' HD2' HG13 ' A' ' 43' ' ' VAL . 65.1 Cg_endo -75.0 98.65 1.18 Allowed 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.329 1.353 . . . . 0.0 111.028 177.789 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.89 -44.67 59.92 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.33 -179.346 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.506 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.04 119.2 20.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.645 0.259 . . . . 0.0 110.913 179.788 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.1 pt -97.1 125.71 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 120.976 0.417 . . . . 0.0 111.102 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 88.4 t -98.27 126.77 51.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.535 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.412 HD22 ' HB1' ' A' ' 62' ' ' ALA . 2.9 mt -136.93 166.79 22.82 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.384 -179.602 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.2 mtmm -90.38 172.49 8.71 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.915 179.322 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.6 ttpp -103.38 148.76 25.49 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 37.3 t 65.45 20.12 11.68 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.779 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.44 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.9 p -123.73 136.01 26.85 Favored Pre-proline 0 CA--C 1.535 0.371 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.868 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -64.2 122.9 11.03 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.105 1.87 . . . . 0.0 111.561 178.7 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.412 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -124.46 137.85 54.4 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.007 0.432 . . . . 0.0 111.632 -179.539 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.423 ' HB2' HG22 ' A' ' 96' ' ' VAL . 5.6 ptt180 -119.65 125.55 49.01 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.714 0.769 . . . . 0.0 111.286 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.5 mm -98.35 115.58 38.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.61 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.538 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.79 109.21 20.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.558 -179.177 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -97.83 107.8 20.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.898 0.38 . . . . 0.0 111.386 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -93.47 107.28 19.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.533 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.404 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 1.2 tpt180 -77.07 101.3 6.01 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.183 0.516 . . . . 0.0 111.776 -179.509 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 21.0 tptt -96.38 -34.28 11.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.413 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.497 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.8 t70 -108.93 131.39 21.82 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.693 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -79.6 39.54 0.84 Allowed 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 123.163 2.575 . . . . 0.0 113.246 -179.374 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.41 ' HB3' HD12 ' A' ' 75' ' ' LEU . 30.0 t -68.23 136.05 91.37 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.095 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.29 -26.98 55.95 Favored 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 122.684 2.256 . . . . 0.0 112.584 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -81.65 -7.98 59.65 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.243 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.558 HD22 HG13 ' A' ' 45' ' ' VAL . 40.5 mt -115.02 8.28 15.72 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.472 -179.811 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.61 -38.18 90.14 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.899 0.38 . . . . 0.0 111.933 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 3.9 mp0 -124.86 160.35 29.0 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.092 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -135.95 131.8 50.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.167 0.508 . . . . 0.0 110.83 179.202 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.417 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 1.0 OUTLIER -135.79 130.53 49.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.279 0.561 . . . . 0.0 111.199 179.757 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -93.89 101.9 7.05 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.393 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.7 -15.94 48.92 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.616 2.211 . . . . 0.0 113.578 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 55.7 m-20 -100.53 -7.13 24.46 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -121.17 -23.45 5.77 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.26 26.94 41.82 Favored Glycine 0 CA--C 1.52 0.363 0 C-N-CA 120.892 -0.671 . . . . 0.0 112.234 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 50.1 t -107.62 119.58 57.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.772 0.32 . . . . 0.0 111.605 -178.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -124.14 120.59 32.77 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.667 179.569 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -139.6 173.57 11.4 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-O 121.004 0.431 . . . . 0.0 112.109 -179.433 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -114.92 142.18 46.94 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.972 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 31.0 mt -102.77 124.09 40.12 Favored Pre-proline 0 CA--C 1.531 0.25 0 CA-C-O 120.949 0.404 . . . . 0.0 111.53 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.414 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 61.1 Cg_endo -77.07 129.48 10.56 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.753 2.302 . . . . 0.0 112.725 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' MET . . . . . 0.404 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 10.2 tpt -66.36 125.01 24.3 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.039 0.447 . . . . 0.0 111.803 -179.46 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.03 1.25 82.35 Favored Glycine 0 C--N 1.332 0.336 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.838 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.414 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 42.1 mt-10 -133.93 177.13 7.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.955 0.407 . . . . 0.0 110.802 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -119.01 134.73 55.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.135 0.493 . . . . 0.0 111.596 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.406 ' HB2' ' HD2' ' A' ' 90' ' ' PRO . 12.5 t80 -113.77 127.91 56.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.171 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.538 HG23 HG22 ' A' ' 65' ' ' VAL . 1.8 p -99.87 136.3 31.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.588 0.708 . . . . 0.0 112.504 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 65.7 t -113.84 112.17 39.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.203 178.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -93.53 118.89 31.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.584 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.88 158.05 41.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.255 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -120.48 97.08 48.94 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.663 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.44 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 65.8 Cg_endo -72.5 99.73 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.915 2.41 . . . . 0.0 112.336 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -95.07 3.73 54.5 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 111.868 0.321 . . . . 0.0 111.868 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -130.82 133.37 45.89 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.77 0.319 . . . . 0.0 110.812 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.75 128.08 35.62 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.98 0.419 . . . . 0.0 111.241 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.11 -157.9 30.1 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.709 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -101.42 125.64 48.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.21 0.528 . . . . 0.0 111.605 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.452 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 85.8 m-85 -118.46 172.81 7.22 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.868 179.602 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 93.4 p -155.03 158.74 39.59 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.1 p90 -147.23 133.43 19.42 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.542 -0.754 . . . . 0.0 111.088 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.43 162.56 27.71 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.994 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 5.8 t -143.97 135.22 25.68 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 120.875 0.369 . . . . 0.0 111.562 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.59 -172.67 54.58 Favored Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.173 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 4.1 tpt -103.39 88.43 3.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.03 0.443 . . . . 0.0 110.733 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -148.48 175.8 10.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.181 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -88.09 -30.38 19.92 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.275 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.53 121.43 14.89 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 121.104 0.478 . . . . 0.0 111.295 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 56.2 p-80 -149.94 154.14 37.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.879 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -109.46 146.68 16.9 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.757 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.506 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 13.4 ttmt -118.05 148.8 41.91 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.958 0.409 . . . . 0.0 110.852 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.452 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -131.25 138.48 49.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.062 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.1 mp -121.84 118.49 55.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.964 0.411 . . . . 0.0 110.775 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.5 t -102.06 121.84 53.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.301 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 . . . . . 0 C--O 1.252 1.235 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.441 -179.802 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.609 0 CA-C-O 121.155 0.308 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -83.42 66.18 8.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.1 0.476 . . . . 0.0 111.472 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 1.4 mpp? -95.69 90.88 5.85 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.204 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.74 -176.69 19.52 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.981 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.69 129.73 53.79 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.107 0.479 . . . . 0.0 111.166 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.2 ttmt -91.93 125.48 36.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.995 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -70.94 150.89 45.25 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.189 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.557 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 3.8 pt20 -80.71 139.68 36.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.131 0.491 . . . . 0.0 111.422 -179.385 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 6.9 mp0 -95.66 115.33 27.28 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.776 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.75 -149.79 0.3 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.256 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -83.6 75.84 10.01 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 94.75 -5.97 69.92 Favored Glycine 0 CA--C 1.523 0.536 0 C-N-CA 120.88 -0.676 . . . . 0.0 113.928 179.016 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -142.32 160.54 40.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.912 0.356 . . . . 0.0 110.859 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -109.98 157.29 19.44 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.094 0.473 . . . . 0.0 111.45 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.557 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.0 OUTLIER -145.88 143.13 29.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.474 -179.539 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -142.7 129.05 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.064 0.459 . . . . 0.0 111.024 179.079 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.5 ttt180 -89.45 106.98 18.81 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.192 0.52 . . . . 0.0 111.028 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.584 HG13 ' HD2' ' A' ' 51' ' ' PRO . 47.0 t -99.82 103.0 14.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.474 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.403 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.5 OUTLIER -73.07 116.66 13.85 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.08 -179.906 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.57 HG13 HD22 ' A' ' 75' ' ' LEU . 48.5 t -97.52 98.91 7.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.466 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.446 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.6 ptm -143.06 85.83 1.89 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.453 179.111 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.04 3.37 87.75 Favored Glycine 0 CA--C 1.52 0.356 0 C-N-CA 120.941 -0.647 . . . . 0.0 111.509 -178.522 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.447 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 159.81 -143.32 8.99 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -116.2 127.89 55.16 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.687 0.244 . . . . 0.0 110.56 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.521 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 42.6 m -67.7 -64.67 1.85 Allowed Pre-proline 0 CA--C 1.54 0.58 0 CA-C-O 119.548 -0.263 . . . . 0.0 111.481 -179.649 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.584 ' HD2' HG13 ' A' ' 43' ' ' VAL . 66.7 Cg_endo -75.0 98.88 1.2 Allowed 'Trans proline' 0 C--N 1.356 0.941 0 C-N-CA 121.288 1.325 . . . . 0.0 111.044 177.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -51.45 -44.51 62.41 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.333 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.498 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.72 118.99 20.71 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.635 0.255 . . . . 0.0 110.944 179.77 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.0 pt -97.65 125.08 50.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.033 0.444 . . . . 0.0 111.087 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.7 t -95.98 126.38 48.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.497 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 10.2 mt -134.83 169.61 17.1 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.403 -179.683 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -97.66 166.98 11.24 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.56 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.3 ttpp -96.92 147.87 23.54 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -179.302 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.6 t 65.92 20.2 11.33 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.953 179.439 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.451 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 5.6 p -123.59 134.93 25.61 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.991 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -64.41 123.77 12.3 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.1 1.867 . . . . 0.0 111.596 178.618 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.95 137.23 53.68 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.908 0.385 . . . . 0.0 111.748 -179.527 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.485 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -117.5 125.9 51.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.705 0.764 . . . . 0.0 111.414 179.827 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.1 mm -98.08 114.78 36.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.726 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.528 HG22 HG23 ' A' ' 96' ' ' VAL . 4.1 t -90.53 107.73 18.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.35 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 61.9 m-85 -95.71 102.78 14.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.912 0.387 . . . . 0.0 111.479 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -89.66 105.84 18.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.178 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.77 101.98 8.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.237 0.541 . . . . 0.0 112.12 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.3 tppt? -96.49 -36.65 10.71 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.636 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.446 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.6 t70 -102.32 130.52 23.99 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.932 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -80.62 39.25 0.83 Allowed 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.089 2.526 . . . . 0.0 113.112 -179.543 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.428 ' HB2' HD12 ' A' ' 75' ' ' LEU . 2.5 m -70.07 137.77 87.2 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.299 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -63.01 -33.55 73.75 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 122.814 2.343 . . . . 0.0 112.982 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.9 p -75.54 -9.87 58.95 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.388 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.57 HD22 HG13 ' A' ' 45' ' ' VAL . 57.3 mt -112.93 14.62 19.77 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.469 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -68.33 -35.35 77.65 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-O 120.91 0.386 . . . . 0.0 111.461 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -131.62 165.9 22.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.932 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -139.13 133.68 40.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.945 0.402 . . . . 0.0 111.116 179.301 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -136.46 132.27 48.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.34 0.59 . . . . 0.0 111.403 179.378 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -94.35 102.08 7.85 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.136 -0.938 . . . . 0.0 109.466 178.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 109' ' ' PHE . 37.6 Cg_endo -65.92 -16.4 52.57 Favored 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.696 2.264 . . . . 0.0 113.696 -178.34 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -100.46 -7.38 24.31 Favored 'General case' 0 CA--C 1.535 0.394 0 N-CA-C 111.933 0.345 . . . . 0.0 111.933 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -120.44 -22.04 6.62 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.69 31.0 41.84 Favored Glycine 0 C--N 1.333 0.378 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.922 -179.325 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.3 t -114.46 117.06 54.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.633 0.254 . . . . 0.0 111.659 -178.71 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 -126.13 122.76 36.61 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.892 0.377 . . . . 0.0 110.617 179.244 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.77 171.21 14.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.655 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -106.32 143.54 34.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.73 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 38.7 mt -104.65 128.3 27.15 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.972 0.415 . . . . 0.0 111.359 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.417 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.5 Cg_endo -80.64 126.7 6.08 Favored 'Trans proline' 0 CA--C 1.532 0.421 0 C-N-CA 122.726 2.284 . . . . 0.0 112.507 179.284 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.4 tpt -65.35 124.93 23.55 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-O 120.974 0.416 . . . . 0.0 111.64 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.29 1.66 81.15 Favored Glycine 0 CA--C 1.52 0.387 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.959 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.417 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 42.6 mt-10 -134.04 177.37 7.79 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 120.885 0.374 . . . . 0.0 110.857 -179.567 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -117.55 134.24 55.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.179 0.514 . . . . 0.0 111.658 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -113.78 126.84 55.65 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.142 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.528 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -98.4 136.92 27.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 CA-C-O 121.55 0.69 . . . . 0.0 112.613 -179.053 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 62.0 t -115.52 111.4 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.132 178.837 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -92.66 118.42 31.03 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.52 -179.305 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.68 157.07 40.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.142 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.8 m -121.14 98.3 47.2 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.533 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.451 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.1 Cg_endo -72.79 100.62 1.21 Allowed 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.781 2.321 . . . . 0.0 112.376 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -95.34 6.7 48.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.791 0.329 . . . . 0.0 111.783 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.12 133.75 43.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.528 -0.305 . . . . 0.0 110.706 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.32 127.49 35.8 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.918 0.39 . . . . 0.0 111.29 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.08 -157.08 29.09 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.716 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -101.68 125.13 48.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.166 0.508 . . . . 0.0 111.684 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.456 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 82.6 m-85 -117.64 172.27 7.47 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.666 179.495 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 86.9 p -153.72 158.62 41.27 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -178.795 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' PHE . . . . . 0.404 ' HA ' ' HD2' ' A' ' 81' ' ' PRO . 37.5 p90 -148.71 134.46 18.88 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.87 178.666 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.31 162.92 28.22 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.903 0.383 . . . . 0.0 111.564 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 3.2 t -154.75 157.49 38.09 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.949 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 85.8 -5.56 83.43 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.931 -0.652 . . . . 0.0 113.538 179.655 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 56.82 50.83 11.74 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 121.063 0.459 . . . . 0.0 111.722 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -120.66 -173.11 2.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.361 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -73.82 -34.09 64.42 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.477 -179.846 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -65.32 119.79 11.6 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 121.122 0.487 . . . . 0.0 111.242 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 56.5 p-80 -149.23 151.5 34.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.242 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -110.02 148.8 17.41 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.433 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 0.9 OUTLIER -119.32 148.81 42.76 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.955 0.407 . . . . 0.0 111.033 -179.926 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.456 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 3.0 ttm -130.58 137.68 49.78 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.09 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -120.92 118.32 55.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.024 0.44 . . . . 0.0 110.639 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 88.9 t -101.79 122.96 54.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.307 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 . . . . . 0 C--O 1.253 1.249 0 CA-C-O 118.163 -0.922 . . . . 0.0 111.462 -179.645 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.753 0 CA-C-O 121.15 0.305 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -84.07 71.19 10.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.032 0.444 . . . . 0.0 111.443 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -116.63 119.05 34.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.173 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.55 -176.89 26.72 Favored Glycine 0 CA--C 1.52 0.377 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.905 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.63 143.6 33.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.163 0.506 . . . . 0.0 111.579 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.1 ttmt -101.38 129.62 47.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.619 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.09 152.84 39.83 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 111.187 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.516 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 22.8 pt20 -85.49 142.96 28.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.155 0.502 . . . . 0.0 111.791 -179.25 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -94.96 114.92 26.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.785 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -94.97 -150.72 0.31 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.024 0.44 . . . . 0.0 111.362 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -82.69 70.54 9.69 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.55 -9.83 59.05 Favored Glycine 0 CA--C 1.521 0.411 0 C-N-CA 120.771 -0.728 . . . . 0.0 113.713 178.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 32.8 p90 -137.93 165.64 26.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.953 0.376 . . . . 0.0 110.895 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.7 152.45 31.96 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.912 0.387 . . . . 0.0 111.103 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.516 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.9 tt0 -143.27 139.94 30.41 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.576 -179.325 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.0 128.42 22.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.975 179.185 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 11.0 ttt180 -89.28 108.85 19.85 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.297 0.57 . . . . 0.0 111.114 179.616 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.617 HG13 ' HD2' ' A' ' 51' ' ' PRO . 44.3 t -100.1 103.61 15.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.583 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -72.91 117.03 14.13 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.979 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.537 HG13 HD22 ' A' ' 75' ' ' LEU . 52.3 t -99.59 99.18 8.03 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.558 -178.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.486 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.7 ptm -145.86 86.68 1.73 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.182 179.112 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.22 -0.42 88.75 Favored Glycine 0 CA--C 1.52 0.368 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -178.243 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.441 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.8 -161.4 32.76 Favored Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 47.4 m-85 -101.99 126.39 48.91 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 117.046 0.423 . . . . 0.0 110.418 179.53 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.514 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 40.3 m -63.82 -63.49 3.87 Favored Pre-proline 0 CA--C 1.54 0.569 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.566 -179.547 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.617 ' HD2' HG13 ' A' ' 43' ' ' VAL . 68.2 Cg_endo -75.48 95.86 1.02 Allowed 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 121.301 1.334 . . . . 0.0 111.036 177.653 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -49.6 -43.54 46.47 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.32 -179.371 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.427 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.94 118.69 19.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.476 179.56 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.8 pt -97.45 126.4 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 121.086 0.469 . . . . 0.0 111.172 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 78.0 t -96.07 127.31 48.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.283 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 10.4 mt -135.0 171.51 14.33 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.558 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -97.13 173.26 7.34 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.739 179.453 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.0 ttpp -104.8 147.93 27.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.829 0.347 . . . . 0.0 111.926 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.4 t 65.49 20.7 11.74 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.751 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.438 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.95 136.46 27.49 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.169 -179.769 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -64.28 122.46 10.42 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.096 1.864 . . . . 0.0 111.47 178.242 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.91 138.04 54.26 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.99 0.424 . . . . 0.0 111.775 -179.45 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.418 HH11 ' HD2' ' A' ' 63' ' ' ARG . 6.7 ptt85 -120.67 126.55 50.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.789 0.804 . . . . 0.0 111.081 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.4 mm -100.07 114.16 37.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.759 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.507 HG22 HG23 ' A' ' 96' ' ' VAL . 3.0 t -89.93 107.49 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.467 -179.057 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -96.53 106.96 19.3 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.918 0.389 . . . . 0.0 111.318 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -91.54 105.79 18.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.633 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.45 96.2 5.32 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.204 0.526 . . . . 0.0 111.596 -179.338 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 17.4 tptt -90.95 -37.92 13.19 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.69 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.486 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.6 t70 -102.73 130.95 22.86 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.785 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -79.75 38.57 0.75 Allowed 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 123.151 2.567 . . . . 0.0 113.235 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.9 t -69.67 135.55 88.1 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.046 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.33 -28.21 63.4 Favored 'Trans proline' 0 C--N 1.349 0.556 0 C-N-CA 122.63 2.22 . . . . 0.0 112.42 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 22.7 m -78.75 -9.23 59.36 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.081 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.537 HD22 HG13 ' A' ' 45' ' ' VAL . 46.0 mt -116.05 17.27 15.9 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.456 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -71.7 -32.19 67.55 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -133.29 165.87 23.81 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.967 0.413 . . . . 0.0 111.393 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -140.57 130.14 26.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.98 179.296 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -130.27 132.7 64.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.481 0.657 . . . . 0.0 111.157 179.349 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -95.91 101.96 9.43 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.662 179.05 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.56 -15.19 46.93 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.59 2.193 . . . . 0.0 113.624 -178.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -100.71 -7.16 24.09 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -122.45 -22.06 5.58 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 112.017 0.376 . . . . 0.0 112.017 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.49 31.4 41.39 Favored Glycine 0 C--N 1.332 0.355 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.028 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.1 t -114.69 119.62 62.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.654 0.264 . . . . 0.0 111.657 -178.721 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 13.7 t-80 -126.37 119.8 28.23 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.841 0.353 . . . . 0.0 110.427 179.251 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.8 173.23 11.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.754 -179.474 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -110.07 151.44 27.2 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.046 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 28.0 mt -111.25 125.04 31.31 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-O 120.945 0.402 . . . . 0.0 111.386 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.427 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 64.5 Cg_endo -78.18 131.06 10.57 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 122.826 2.351 . . . . 0.0 112.708 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.6 tpt -66.81 124.43 22.92 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.799 -179.415 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 86.64 3.59 83.65 Favored Glycine 0 CA--C 1.52 0.345 0 CA-C-N 115.814 -0.63 . . . . 0.0 113.012 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.427 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 43.4 mt-10 -134.96 177.09 8.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.862 0.363 . . . . 0.0 110.905 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.56 134.8 54.82 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.231 0.539 . . . . 0.0 111.546 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -113.54 125.35 54.1 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.221 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.507 HG23 HG22 ' A' ' 65' ' ' VAL . 2.3 p -99.08 135.2 35.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.552 0.691 . . . . 0.0 112.489 -178.983 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 66.7 t -110.77 112.24 39.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.055 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -94.09 118.6 31.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.95 0.405 . . . . 0.0 111.475 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.99 166.5 28.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.146 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.2 m -129.66 97.51 24.32 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.486 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.438 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 70.2 Cg_endo -72.99 100.58 1.22 Allowed 'Trans proline' 0 CA--C 1.532 0.423 0 C-N-CA 122.844 2.363 . . . . 0.0 112.447 179.774 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -95.32 3.8 54.09 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.665 -179.586 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -132.16 134.68 45.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.735 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.32 124.24 34.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.974 0.416 . . . . 0.0 111.272 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 171.42 -165.34 38.32 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.884 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.25 115.47 27.67 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.19 0.519 . . . . 0.0 110.721 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.413 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 20.5 m-85 -111.4 173.03 6.54 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.971 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 85.5 p -152.58 165.1 36.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.307 0.575 . . . . 0.0 112.549 -178.573 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.2 p90 -152.07 136.86 17.09 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.441 178.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -161.92 176.89 10.33 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.834 0.349 . . . . 0.0 111.825 -179.32 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 48.6 t -131.98 133.15 44.14 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.064 179.195 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 95.67 -135.8 12.54 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.832 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -122.69 -96.98 0.46 Allowed 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 120.649 0.261 . . . . 0.0 110.979 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -86.72 59.82 5.86 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.035 0.445 . . . . 0.0 111.346 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -154.9 179.35 9.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.04 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER 69.5 174.18 0.29 Allowed 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.289 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 56.4 t-80 -164.9 103.74 0.79 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.009 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -150.55 122.59 1.41 Allowed Glycine 0 CA--C 1.517 0.193 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.361 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.427 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.0 ttmm -122.84 151.44 41.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.069 0.462 . . . . 0.0 111.828 -179.4 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.413 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.6 ttm -134.74 131.22 37.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.773 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.7 mp -116.03 117.79 56.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.024 0.44 . . . . 0.0 110.67 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 74.8 t -101.8 122.53 54.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.288 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 . . . . . 0 C--O 1.252 1.213 0 CA-C-O 118.112 -0.947 . . . . 0.0 111.387 -179.583 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.688 0 CA-C-O 121.073 0.263 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -82.21 91.66 6.77 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.143 0.497 . . . . 0.0 111.547 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 4.8 tpp -81.4 101.0 9.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.143 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.92 168.34 53.41 Favored Glycine 0 CA--C 1.519 0.304 0 C-N-CA 120.963 -0.637 . . . . 0.0 113.115 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.96 130.43 48.39 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.096 0.474 . . . . 0.0 111.402 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.8 mtpt -91.67 130.85 37.4 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.79 179.56 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.25 151.37 39.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.488 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.587 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.6 pt20 -79.04 139.4 38.16 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.142 0.496 . . . . 0.0 111.089 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -97.31 114.47 26.24 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.766 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -94.89 -154.5 0.43 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.256 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -82.11 74.23 9.1 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.14 -9.14 59.48 Favored Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.655 -0.783 . . . . 0.0 113.986 178.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 27.5 p90 -140.96 164.66 29.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 117.036 0.418 . . . . 0.0 111.066 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.67 153.65 29.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.974 0.416 . . . . 0.0 111.353 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.587 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.9 tt0 -143.36 143.08 31.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.46 -179.579 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.51 128.53 17.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.011 0.434 . . . . 0.0 111.08 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.63 106.12 18.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.213 0.53 . . . . 0.0 111.168 179.71 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.604 HG13 ' HD2' ' A' ' 51' ' ' PRO . 46.1 t -99.01 103.29 14.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.65 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.416 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.9 OUTLIER -73.09 118.2 15.75 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.789 -179.961 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.617 HG13 HD22 ' A' ' 75' ' ' LEU . 53.9 t -100.23 97.82 6.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.472 -178.852 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.473 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.9 ptm -143.27 85.02 1.84 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.372 179.273 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.08 0.24 88.9 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 -178.451 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.413 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.38 -169.29 36.15 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -92.17 125.73 36.96 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.924 0.362 . . . . 0.0 110.348 179.511 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.522 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 43.3 m -65.27 -63.97 3.02 Favored Pre-proline 0 CA--C 1.54 0.587 0 CA-C-O 119.557 -0.259 . . . . 0.0 111.293 -179.657 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.604 ' HD2' HG13 ' A' ' 43' ' ' VAL . 64.3 Cg_endo -75.03 96.55 1.03 Allowed 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 121.244 1.296 . . . . 0.0 111.205 177.815 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -51.36 -42.51 61.36 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.182 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.509 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -130.96 118.74 21.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.763 179.617 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.2 pt -99.16 126.93 52.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.951 0.405 . . . . 0.0 111.098 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 85.2 t -98.25 127.03 51.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.473 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.2 mt -135.95 165.52 25.47 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.318 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.6 mttt -90.12 176.26 6.84 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.728 179.164 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.2 ttpp -107.0 148.64 28.44 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -179.108 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.9 t 64.93 20.38 12.1 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.771 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.45 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.0 p -123.93 136.75 27.82 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.064 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.75 122.46 10.31 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.164 1.91 . . . . 0.0 111.639 178.607 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.45 139.8 53.65 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.969 0.414 . . . . 0.0 111.53 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.451 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.8 ptt180 -121.5 126.92 50.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.764 0.792 . . . . 0.0 111.344 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.7 mm -98.4 114.71 36.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.726 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.424 HG22 HG23 ' A' ' 96' ' ' VAL . 4.5 t -90.62 113.44 26.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.35 -179.391 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -100.31 114.87 28.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.077 0.465 . . . . 0.0 111.5 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -99.45 102.99 14.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.065 179.31 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.55 98.42 6.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.176 0.513 . . . . 0.0 111.998 -179.148 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.9 tptp -94.29 -35.69 12.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.536 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.473 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.8 t70 -106.17 130.79 22.43 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.931 179.579 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -81.2 39.39 0.85 Allowed 'Trans proline' 0 C--N 1.349 0.598 0 C-N-CA 123.059 2.506 . . . . 0.0 113.302 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -70.4 138.33 86.49 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.186 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -62.75 -32.73 78.08 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 122.924 2.416 . . . . 0.0 113.257 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.4 p -76.08 -8.06 56.13 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.779 0.323 . . . . 0.0 111.5 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.617 HD22 HG13 ' A' ' 45' ' ' VAL . 53.0 mt -114.88 13.67 17.15 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.356 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -68.49 -36.88 79.56 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-O 120.913 0.387 . . . . 0.0 111.643 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -132.23 161.58 33.08 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.066 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -136.96 131.22 46.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.038 0.446 . . . . 0.0 111.083 179.521 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -133.09 132.96 58.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 121.362 0.601 . . . . 0.0 111.31 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -94.76 102.14 8.39 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.509 178.842 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.25 -16.55 52.14 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.67 2.246 . . . . 0.0 113.668 -178.381 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -100.38 -7.04 24.83 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -120.52 -20.78 7.03 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 77.37 32.31 48.02 Favored Glycine 0 C--N 1.333 0.398 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.944 -179.198 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.1 t -116.72 117.98 57.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 -178.581 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 22.3 t-80 -123.79 122.03 36.98 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.802 0.334 . . . . 0.0 110.402 179.042 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.9 163.64 28.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.704 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.88 139.04 40.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.481 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 45.7 mt -101.34 128.45 29.22 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 120.856 0.36 . . . . 0.0 111.541 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.433 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 72.7 Cg_endo -82.91 128.65 5.19 Favored 'Trans proline' 0 CA--C 1.532 0.415 0 C-N-CA 122.71 2.273 . . . . 0.0 112.388 179.198 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -66.45 125.12 24.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.08 0.467 . . . . 0.0 111.725 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.88 11.77 80.9 Favored Glycine 0 CA--C 1.52 0.364 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.98 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.433 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.6 mm-40 -137.64 176.97 8.23 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.89 0.376 . . . . 0.0 111.083 -179.604 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -113.37 134.73 54.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.025 0.441 . . . . 0.0 111.733 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.1 t80 -123.98 127.86 48.54 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.935 178.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.424 HG23 HG22 ' A' ' 65' ' ' VAL . 2.3 p -107.0 137.18 39.16 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 CA-C-O 121.417 0.627 . . . . 0.0 112.628 -178.865 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 67.2 t -112.93 113.19 43.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.134 178.907 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -94.11 120.15 33.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.95 0.405 . . . . 0.0 111.516 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -136.0 157.9 38.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.82 97.79 48.14 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.682 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 67.1 Cg_endo -72.82 101.31 1.29 Allowed 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.814 2.343 . . . . 0.0 112.15 179.539 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -95.51 1.96 54.15 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -179.393 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -129.81 134.84 47.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.762 0.315 . . . . 0.0 110.74 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.93 124.25 34.56 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.007 0.432 . . . . 0.0 111.273 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 166.82 -157.3 29.71 Favored Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.63 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -101.64 125.72 48.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.187 0.518 . . . . 0.0 111.487 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.446 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 84.9 m-85 -117.34 171.44 7.97 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.013 179.731 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.3 p -150.22 158.31 44.02 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 -178.765 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -150.4 131.46 14.37 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.957 178.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.36 165.09 26.95 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.075 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.453 ' O ' ' HG3' ' A' ' 116' ' ' MET . 4.1 t -147.74 157.68 43.66 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.008 0.432 . . . . 0.0 111.405 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 88.81 -90.77 1.67 Allowed Glycine 0 CA--C 1.52 0.349 0 C-N-CA 120.893 -0.67 . . . . 0.0 113.195 179.658 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -145.09 -170.03 3.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.745 0.307 . . . . 0.0 111.111 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.56 52.38 1.17 Allowed 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 120.925 0.393 . . . . 0.0 111.676 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -126.59 -17.54 5.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.078 179.776 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' MET . . . . . 0.453 ' HG3' ' O ' ' A' ' 111' ' ' CYS . 0.3 OUTLIER -84.93 164.57 18.27 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.169 179.953 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.36 105.47 3.75 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 111.963 0.357 . . . . 0.0 111.963 -179.757 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -142.95 116.96 1.06 Allowed Glycine 0 CA--C 1.52 0.403 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.882 179.349 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.509 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.7 ttpt -122.15 148.71 44.58 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.204 0.526 . . . . 0.0 111.904 -179.089 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.446 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.6 ttm -132.4 139.15 47.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.686 179.439 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -122.39 119.72 59.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.116 0.484 . . . . 0.0 110.854 179.586 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 90.9 t -102.97 123.08 56.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.272 -179.695 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 . . . . . 0 C--O 1.252 1.201 0 CA-C-O 118.169 -0.92 . . . . 0.0 111.42 -179.774 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.935 ' N ' ' HZ1' ' A' ' 31' ' ' LYS . . . . . . . . 0 N--CA 1.498 2.789 0 CA-C-O 121.147 0.304 . . . . 0.0 112.387 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -96.49 -12.19 24.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.918 0.39 . . . . 0.0 111.382 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -132.11 -51.32 0.96 Allowed 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.231 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -103.0 -163.15 25.76 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.851 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 18.4 mm-40 -133.14 130.27 38.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.128 0.489 . . . . 0.0 111.328 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' LYS . . . . . 0.935 ' HZ1' ' N ' ' A' ' 26' ' ' GLY . 0.2 OUTLIER -89.97 125.59 35.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.709 179.823 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -70.93 152.07 44.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.238 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.53 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 7.3 pt20 -81.27 137.99 35.77 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.214 0.531 . . . . 0.0 111.448 -179.328 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.2 mp0 -94.53 113.2 25.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.865 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.63 -151.32 0.28 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.191 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -83.81 77.51 9.87 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 112.03 0.382 . . . . 0.0 112.03 -179.223 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.15 -6.49 68.98 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 120.812 -0.709 . . . . 0.0 114.047 178.869 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.7 p90 -143.54 161.34 38.72 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.045 0.423 . . . . 0.0 111.072 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.19 156.63 21.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.058 0.456 . . . . 0.0 111.349 179.744 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.53 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.4 tt0 -145.75 144.45 30.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.434 -179.566 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -146.96 129.04 7.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.732 179.135 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.417 HH11 ' HD2' ' A' ' 42' ' ' ARG . 0.1 OUTLIER -90.9 110.18 21.41 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.252 0.548 . . . . 0.0 110.938 179.305 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.491 HG13 ' HD2' ' A' ' 51' ' ' PRO . 60.6 t -100.42 108.21 22.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.757 -179.668 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -72.68 124.97 26.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.648 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.569 HG13 HD22 ' A' ' 75' ' ' LEU . 53.7 t -104.64 96.44 4.6 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 CA-C-O 121.475 0.655 . . . . 0.0 111.262 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.484 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.0 ptp -141.97 87.74 2.06 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.373 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.11 -15.88 36.27 Favored Glycine 0 CA--C 1.522 0.482 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.127 -178.035 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 178.79 -138.72 3.71 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.483 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -121.09 129.59 53.38 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.862 0.331 . . . . 0.0 110.59 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.489 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 20.2 m -65.84 -60.93 6.34 Favored Pre-proline 0 CA--C 1.538 0.519 0 C-N-CA 121.027 -0.269 . . . . 0.0 110.911 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.491 ' HD2' HG13 ' A' ' 43' ' ' VAL . 74.4 Cg_endo -76.79 95.77 1.07 Allowed 'Trans proline' 0 C--N 1.358 1.045 0 C-N-CA 121.333 1.355 . . . . 0.0 110.968 177.575 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.77 -42.73 58.11 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.331 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.482 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.73 118.52 20.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.782 179.52 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.8 pt -97.32 124.45 50.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.085 0.469 . . . . 0.0 110.888 179.501 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.5 t -97.25 126.73 49.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.509 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.3 mt -134.21 170.12 16.17 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.357 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.28 173.73 7.57 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.684 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.6 ttpt -104.29 146.7 28.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.779 0.323 . . . . 0.0 111.844 -179.206 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.4 t 64.97 20.86 12.21 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.832 179.627 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.45 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 7.9 p -123.44 135.61 26.26 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.935 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.6 Cg_endo -64.34 122.49 10.45 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 122.076 1.85 . . . . 0.0 111.668 178.588 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.25 138.86 54.35 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.877 0.37 . . . . 0.0 111.577 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.413 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -121.57 126.79 49.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.769 0.795 . . . . 0.0 111.439 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.0 mm -99.0 115.82 40.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.836 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.483 HG22 HG23 ' A' ' 96' ' ' VAL . 3.2 t -91.71 110.25 22.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.216 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -95.59 114.77 26.56 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.076 0.465 . . . . 0.0 111.467 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -99.93 104.48 16.11 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.398 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.4 ' HA ' ' HB ' ' A' ' 45' ' ' VAL . 0.1 OUTLIER -77.6 106.54 9.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.274 0.559 . . . . 0.0 112.144 -179.155 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -101.23 -33.83 9.91 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.415 179.293 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.484 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.0 t70 -110.6 133.87 21.04 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.862 179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -81.67 40.29 0.96 Allowed 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 123.086 2.524 . . . . 0.0 112.975 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.41 137.29 93.56 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.308 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -63.03 -35.02 68.24 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.938 2.426 . . . . 0.0 112.941 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.35 -6.68 54.16 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.595 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.569 HD22 HG13 ' A' ' 45' ' ' VAL . 58.2 mt -114.32 7.75 16.5 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.426 -179.777 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -66.18 -38.46 88.09 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.089 0.471 . . . . 0.0 111.451 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -124.74 158.72 32.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.576 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -133.23 127.79 54.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.379 0.609 . . . . 0.0 110.937 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.68 129.63 58.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.294 0.568 . . . . 0.0 111.105 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -92.9 102.02 6.29 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.402 178.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.26 -16.35 51.42 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.626 2.217 . . . . 0.0 113.77 -178.315 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 46.5 m-20 -100.71 -6.83 24.48 Favored 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.0 m-85 -120.97 -22.54 6.14 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 81.7 25.45 53.37 Favored Glycine 0 C--N 1.332 0.348 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.07 -179.442 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.1 t -106.48 117.95 53.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.844 0.354 . . . . 0.0 111.663 -178.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -121.16 118.9 30.84 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.598 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.79 167.17 21.36 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.172 0.51 . . . . 0.0 111.945 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 4.4 m-80 -109.38 138.66 45.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.621 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 51.8 mt -101.13 128.46 29.39 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.89 0.376 . . . . 0.0 111.39 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.435 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 74.4 Cg_endo -82.0 128.15 5.68 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 122.768 2.312 . . . . 0.0 112.428 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.4 tpt -66.3 124.55 23.0 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.046 0.451 . . . . 0.0 111.623 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.53 9.3 81.74 Favored Glycine 0 CA--C 1.521 0.418 0 CA-C-N 115.857 -0.611 . . . . 0.0 113.075 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.435 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 50.1 mm-40 -136.9 176.75 8.43 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.903 0.382 . . . . 0.0 111.342 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -112.9 136.32 52.68 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.036 0.446 . . . . 0.0 111.744 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -124.23 126.25 45.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.039 178.975 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.483 HG23 HG22 ' A' ' 65' ' ' VAL . 1.8 p -102.99 138.19 28.2 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-O 121.58 0.705 . . . . 0.0 112.511 -178.778 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 64.5 t -115.51 112.34 39.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.188 178.782 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -93.8 118.99 32.18 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.934 0.397 . . . . 0.0 111.576 -179.307 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.11 156.33 39.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.073 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.4 m -120.03 98.32 49.21 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.461 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.9 Cg_endo -71.88 99.14 0.94 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.713 2.275 . . . . 0.0 112.561 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -97.7 22.79 8.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.09 0.471 . . . . 0.0 111.515 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.15 131.78 14.89 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.464 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.29 127.29 35.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.983 0.421 . . . . 0.0 111.407 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 164.42 -157.33 29.64 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.759 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.18 126.59 49.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.168 0.509 . . . . 0.0 111.544 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.446 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 86.4 m-85 -119.32 171.99 7.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.891 179.641 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 87.8 p -153.73 159.85 42.11 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.909 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -150.53 131.14 13.95 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.093 178.866 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.7 168.49 21.49 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.295 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 5.9 t -146.14 128.38 15.76 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.263 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 73.06 -152.97 47.82 Favored Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.936 -0.65 . . . . 0.0 113.15 179.717 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -135.77 110.28 8.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.839 0.352 . . . . 0.0 111.14 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -163.31 -170.38 2.25 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.903 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -85.35 48.86 1.64 Allowed 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.0 0.429 . . . . 0.0 111.916 -179.672 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -145.22 142.37 29.48 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.053 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -162.21 139.19 8.14 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.851 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -116.75 136.75 13.0 Favored Glycine 0 CA--C 1.52 0.35 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.639 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 4.5 ttmm -120.01 149.48 42.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.053 0.454 . . . . 0.0 111.229 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.446 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -132.83 140.42 47.95 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.994 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.95 119.77 56.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.061 0.458 . . . . 0.0 110.877 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.9 t -101.89 124.68 55.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.079 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.251 1.158 0 CA-C-O 118.045 -0.979 . . . . 0.0 111.898 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.722 0 N-CA-C 112.4 -0.28 . . . . 0.0 112.4 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -82.96 73.94 9.96 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.148 0.499 . . . . 0.0 111.504 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -100.17 160.3 14.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.368 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -91.06 175.18 39.59 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.831 -0.699 . . . . 0.0 113.063 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -118.97 128.62 54.57 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.187 0.517 . . . . 0.0 111.168 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -88.27 126.58 35.24 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.631 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.03 150.56 45.47 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.141 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.551 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 19.8 pt20 -79.44 137.5 37.27 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.297 0.57 . . . . 0.0 111.283 -179.323 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.5 mp0 -94.52 114.02 25.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.963 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -93.03 -156.08 0.46 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.072 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -83.56 76.91 9.92 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-O 120.851 0.358 . . . . 0.0 111.948 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.25 -12.71 57.19 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 120.806 -0.712 . . . . 0.0 114.151 178.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -140.69 167.47 22.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 117.16 0.48 . . . . 0.0 111.353 -179.595 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.93 155.0 28.78 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.863 0.363 . . . . 0.0 111.119 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.551 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 5.8 tt0 -145.35 142.23 29.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.562 -179.271 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.39 129.84 17.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.312 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -91.67 110.22 21.54 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.239 0.542 . . . . 0.0 111.058 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.62 HG13 ' HD2' ' A' ' 51' ' ' PRO . 46.4 t -100.48 104.01 15.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.589 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.427 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.9 OUTLIER -73.16 116.98 14.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.845 -179.91 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.556 HG13 HD22 ' A' ' 75' ' ' LEU . 41.1 t -97.41 98.46 7.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.365 -178.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.466 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.8 ptp -139.6 81.93 1.85 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.383 179.383 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 88.01 -8.98 76.39 Favored Glycine 0 CA--C 1.521 0.429 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 -178.342 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 172.85 -153.36 18.35 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -105.42 125.65 51.23 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.825 0.313 . . . . 0.0 110.54 179.648 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.516 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 45.2 m -65.13 -64.48 2.61 Favored Pre-proline 0 CA--C 1.538 0.518 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.407 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.62 ' HD2' HG13 ' A' ' 43' ' ' VAL . 60.1 Cg_endo -74.11 97.91 1.05 Allowed 'Trans proline' 0 C--N 1.358 1.039 0 C-N-CA 121.266 1.311 . . . . 0.0 111.001 177.684 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.63 -44.04 57.18 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.163 -179.236 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.453 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.6 118.99 19.88 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.605 0.241 . . . . 0.0 110.959 179.57 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.0 pt -97.07 126.96 49.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 121.054 0.454 . . . . 0.0 110.747 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 84.6 t -98.09 126.93 50.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.505 -179.649 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.8 mt -135.63 166.52 23.05 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.567 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.7 tttt -93.1 170.24 9.8 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.709 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.5 ttpp -100.45 148.25 24.96 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.403 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.2 t 65.84 20.14 11.38 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.917 179.393 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.434 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.2 p -123.8 135.88 26.74 Favored Pre-proline 0 CA--C 1.537 0.445 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.977 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -64.4 122.77 10.8 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.198 1.932 . . . . 0.0 111.575 178.637 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.67 138.51 53.9 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.956 0.408 . . . . 0.0 111.728 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.433 ' CG ' ' HG3' ' A' ' 40' ' ' GLU . 0.0 OUTLIER -121.06 129.4 53.33 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.767 0.794 . . . . 0.0 111.517 179.739 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.4 mm -100.76 115.69 42.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.817 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.435 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.77 111.69 24.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 120.766 0.317 . . . . 0.0 111.326 -179.3 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -97.7 113.22 24.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.053 0.454 . . . . 0.0 111.354 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -98.96 105.19 17.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.215 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -79.09 104.8 9.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.29 0.566 . . . . 0.0 112.22 -178.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.2 tppt? -99.35 -36.09 9.72 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.086 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.466 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 6.4 t70 -103.79 129.86 24.53 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.852 179.562 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -80.49 39.47 0.85 Allowed 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.998 2.465 . . . . 0.0 112.939 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.493 ' HB2' HD12 ' A' ' 75' ' ' LEU . 2.1 m -69.95 135.67 87.47 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.382 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -64.05 -29.9 66.06 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.901 2.401 . . . . 0.0 112.811 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.71 -9.38 58.63 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.599 179.761 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.556 HD22 HG13 ' A' ' 45' ' ' VAL . 29.1 mt -113.17 12.52 19.07 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 120.784 0.326 . . . . 0.0 111.321 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -67.44 -35.18 78.72 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.785 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -129.48 160.68 32.42 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.805 0.336 . . . . 0.0 111.21 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.67 129.01 33.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.181 0.515 . . . . 0.0 110.85 179.292 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.5 p -132.04 132.4 61.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.276 0.56 . . . . 0.0 111.257 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 15.7 m-85 -94.93 101.92 8.11 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.725 179.032 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -67.09 -15.23 46.05 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.722 2.281 . . . . 0.0 113.562 -178.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 -99.62 -7.34 25.88 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -122.67 -22.13 5.46 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.092 0.405 . . . . 0.0 112.092 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 81.45 26.43 51.33 Favored Glycine 0 CA--C 1.52 0.374 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.044 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.6 t -107.69 117.37 53.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.746 0.307 . . . . 0.0 111.709 -178.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -119.12 117.94 30.05 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.519 179.214 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.67 167.54 19.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.156 0.503 . . . . 0.0 112.222 -179.157 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -111.69 141.2 45.6 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.319 179.562 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 53.1 mt -103.56 127.75 28.89 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.005 0.431 . . . . 0.0 111.566 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.443 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 72.5 Cg_endo -82.94 129.85 5.53 Favored 'Trans proline' 0 CA--C 1.532 0.411 0 C-N-CA 122.846 2.364 . . . . 0.0 112.481 179.271 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.5 tpt -67.58 125.24 25.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.008 0.432 . . . . 0.0 111.71 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 83.29 11.61 80.3 Favored Glycine 0 CA--C 1.52 0.405 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.877 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.443 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 53.7 mm-40 -137.46 176.86 8.33 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.007 0.432 . . . . 0.0 111.157 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -113.37 132.77 55.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.78 -179.716 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -121.75 125.11 45.8 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.967 178.876 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.435 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -105.16 137.06 36.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.549 0.69 . . . . 0.0 112.472 -178.887 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -112.79 112.11 39.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.153 178.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -93.67 119.22 32.4 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.953 0.406 . . . . 0.0 111.416 -179.469 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.91 158.24 38.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.339 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -121.67 96.81 47.11 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.469 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.434 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.9 Cg_endo -71.59 99.44 0.94 Allowed 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.823 2.349 . . . . 0.0 112.294 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -94.07 4.47 53.85 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.995 0.368 . . . . 0.0 111.995 -179.3 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -133.88 135.63 43.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.756 0.313 . . . . 0.0 110.933 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.59 124.9 34.5 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.837 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.35 -167.56 40.51 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.796 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -97.9 114.72 26.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.105 0.479 . . . . 0.0 110.631 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.402 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 20.7 m-85 -111.4 172.42 6.9 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.177 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 87.1 p -158.17 164.88 36.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.155 0.502 . . . . 0.0 112.196 -178.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -148.26 137.39 21.92 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.762 179.017 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -161.85 153.74 19.12 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.277 -179.719 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 4.7 t -159.22 161.25 36.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.945 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 84.44 -118.87 4.82 Favored Glycine 0 CA--C 1.52 0.378 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.237 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -154.46 -160.9 1.13 Allowed 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 122.013 0.125 . . . . 0.0 110.85 -179.585 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 68.33 -170.63 0.19 Allowed 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 122.898 0.479 . . . . 0.0 111.828 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.21 65.04 0.95 Allowed 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.933 0.396 . . . . 0.0 111.69 -179.626 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -135.9 136.49 40.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.863 0.363 . . . . 0.0 111.066 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 20.2 p80 -165.5 154.47 12.01 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.24 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -113.15 150.31 18.48 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.047 -0.596 . . . . 0.0 112.055 179.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.453 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.8 ttmt -119.09 150.32 40.2 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.974 0.416 . . . . 0.0 111.359 -179.869 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.402 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -133.68 133.62 42.1 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.896 179.685 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.13 117.36 53.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.071 0.463 . . . . 0.0 110.753 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 94.7 t -101.65 121.94 53.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.155 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.277 -0.868 . . . . 0.0 111.538 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.703 0 CA-C-O 121.192 0.329 . . . . 0.0 112.347 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.99 37.19 3.91 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.1 0.476 . . . . 0.0 111.439 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 14.5 mtp -82.57 66.33 8.12 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-O 121.056 0.455 . . . . 0.0 111.385 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.69 171.83 23.67 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.854 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -123.83 124.88 43.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.959 0.409 . . . . 0.0 111.502 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.6 ttmt -90.37 126.71 35.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.501 179.565 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.36 151.11 46.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.028 0.442 . . . . 0.0 111.464 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.578 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.7 pt20 -78.28 143.52 36.95 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.379 -179.544 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -98.68 115.33 28.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.855 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.63 -151.62 0.36 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.484 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -81.65 75.52 8.6 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -179.171 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.4 -7.47 68.82 Favored Glycine 0 CA--C 1.523 0.573 0 C-N-CA 120.72 -0.753 . . . . 0.0 114.047 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -141.35 161.48 37.78 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.959 0.38 . . . . 0.0 110.981 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.06 155.71 22.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.102 0.477 . . . . 0.0 111.154 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.578 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.9 tt0 -144.53 143.89 31.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.616 -179.382 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.17 128.71 16.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.081 0.467 . . . . 0.0 110.963 178.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.69 109.03 20.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.33 0.586 . . . . 0.0 110.962 179.535 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.628 HG13 ' HD2' ' A' ' 51' ' ' PRO . 45.1 t -99.75 103.95 15.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.599 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.415 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 1.1 tp10 -73.17 117.62 15.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.857 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.592 HG13 HD22 ' A' ' 75' ' ' LEU . 54.3 t -99.52 98.55 7.18 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.526 -178.792 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.491 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.3 ptm -145.25 86.97 1.78 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.4 179.304 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 83.66 -2.51 87.25 Favored Glycine 0 CA--C 1.521 0.407 0 C-N-CA 120.824 -0.703 . . . . 0.0 111.468 -178.429 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.421 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 162.9 -171.17 38.63 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 30.3 m-85 -91.78 124.94 36.29 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.816 0.308 . . . . 0.0 110.354 179.534 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.524 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 45.0 m -63.99 -64.35 2.95 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 119.638 -0.22 . . . . 0.0 111.407 -179.42 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.628 ' HD2' HG13 ' A' ' 43' ' ' VAL . 62.1 Cg_endo -74.98 96.88 1.04 Allowed 'Trans proline' 0 C--N 1.357 0.977 0 C-N-CA 121.299 1.333 . . . . 0.0 111.075 177.729 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.84 -43.19 59.12 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.261 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.36 118.52 20.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.622 -0.263 . . . . 0.0 110.708 179.667 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.7 pt -98.3 125.43 51.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.031 0.443 . . . . 0.0 111.15 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 75.9 t -98.62 126.71 51.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.425 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.423 HD22 ' HB1' ' A' ' 62' ' ' ALA . 5.4 mt -132.74 171.5 13.79 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.472 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.95 170.02 9.72 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.549 179.403 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.6 ttpp -102.43 147.06 27.19 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.86 0.362 . . . . 0.0 111.909 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.4 t 65.27 20.46 11.89 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.527 -0.76 . . . . 0.0 111.701 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.425 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 7.4 p -123.66 136.41 27.26 Favored Pre-proline 0 CA--C 1.534 0.356 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.003 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -64.33 122.7 10.72 Favored 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 121.984 1.79 . . . . 0.0 111.412 178.442 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.423 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -125.29 138.49 54.08 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.017 0.437 . . . . 0.0 111.582 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.438 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.9 ptt180 -120.55 127.74 52.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.727 0.775 . . . . 0.0 111.418 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.0 mm -99.4 114.68 38.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.628 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.495 HG22 HG23 ' A' ' 96' ' ' VAL . 3.3 t -92.01 110.53 22.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.697 0.284 . . . . 0.0 111.553 -179.284 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -97.1 120.05 36.72 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.013 0.435 . . . . 0.0 111.233 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -103.93 105.18 15.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.433 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.401 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 2.0 tpt180 -77.77 97.81 5.32 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.161 0.505 . . . . 0.0 111.605 -179.427 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.8 tptp -93.71 -32.93 13.83 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.412 179.428 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.491 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.9 t70 -111.28 131.66 22.13 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.741 179.661 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -80.24 39.33 0.83 Allowed 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 123.075 2.516 . . . . 0.0 112.978 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.13 135.76 91.57 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.159 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.26 -33.28 60.34 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.764 2.309 . . . . 0.0 112.875 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -77.37 -1.97 32.71 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.55 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.592 HD22 HG13 ' A' ' 45' ' ' VAL . 28.8 mt -119.01 9.13 11.76 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.457 -179.749 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.9 -41.04 78.76 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -122.09 149.37 43.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.028 0.442 . . . . 0.0 111.591 -179.495 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -131.51 129.18 61.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.54 179.238 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 p -132.7 131.35 59.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.439 0.637 . . . . 0.0 111.44 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -92.86 101.93 6.1 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.448 178.649 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.41 -15.52 45.64 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.631 2.221 . . . . 0.0 113.657 -178.465 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -100.12 -9.61 22.38 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.5 m-85 -119.46 -21.41 7.43 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 80.95 28.33 46.34 Favored Glycine 0 CA--C 1.52 0.346 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.074 -179.589 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.4 t -109.44 117.58 54.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.786 0.327 . . . . 0.0 111.731 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -120.59 119.74 33.76 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.428 179.481 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.72 167.92 20.72 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 121.182 0.515 . . . . 0.0 112.344 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -113.3 143.27 44.72 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.316 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 30.7 mt -103.53 124.35 38.34 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.451 . . . . 0.0 111.599 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.421 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 68.6 Cg_endo -79.09 130.38 9.33 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.771 2.314 . . . . 0.0 112.662 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 91' ' ' MET . . . . . 0.401 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 11.2 tpt -67.47 124.77 24.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.138 0.494 . . . . 0.0 111.748 -179.597 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 83.53 9.68 82.98 Favored Glycine 0 CA--C 1.521 0.411 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.975 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.421 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.4 mm-40 -136.21 176.69 8.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.865 0.364 . . . . 0.0 111.284 -179.537 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -114.07 134.72 54.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.013 0.435 . . . . 0.0 111.574 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' TYR . . . . . 0.4 ' HB2' ' HD2' ' A' ' 90' ' ' PRO . 8.7 t80 -122.52 124.09 42.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.036 178.918 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.495 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -104.37 136.99 35.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 CA-C-O 121.563 0.697 . . . . 0.0 112.533 -178.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 54.2 t -112.98 112.11 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.16 179.02 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -93.52 119.57 32.75 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.517 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.6 158.28 39.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.207 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 m -121.51 96.79 47.44 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.525 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.425 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.8 Cg_endo -72.93 101.18 1.29 Allowed 'Trans proline' 0 CA--C 1.532 0.399 0 C-N-CA 122.855 2.37 . . . . 0.0 112.349 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -95.51 5.53 51.31 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 111.898 0.333 . . . . 0.0 111.898 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -132.4 133.97 44.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.763 0.316 . . . . 0.0 110.751 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -90.61 128.26 36.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.983 0.42 . . . . 0.0 111.301 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 162.64 -155.88 27.36 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.694 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -102.19 126.91 49.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.21 0.529 . . . . 0.0 111.468 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.435 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 89.9 m-85 -120.69 173.28 7.3 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.885 179.733 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 14.9 m -154.9 156.91 36.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.197 0.523 . . . . 0.0 112.399 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -146.26 142.21 28.12 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.726 179.246 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.4 178.19 8.87 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.961 0.41 . . . . 0.0 111.68 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 38.3 t -106.78 127.3 53.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.057 0.456 . . . . 0.0 110.76 179.005 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.15 -2.7 74.91 Favored Glycine 0 CA--C 1.525 0.686 0 C-N-CA 121.1 -0.572 . . . . 0.0 113.417 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.7 mtm 58.13 38.49 26.44 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 122.857 0.463 . . . . 0.0 111.805 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -156.16 -48.24 0.08 Allowed 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.044 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -96.08 -175.58 3.43 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.972 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 79.1 mmm 68.5 -179.36 0.22 Allowed 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.052 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -158.17 105.21 1.91 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.875 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -142.23 123.75 2.27 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 111.776 -0.529 . . . . 0.0 111.776 179.309 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.1 ttpt -119.9 151.68 38.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.122 0.487 . . . . 0.0 112.054 -178.952 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.435 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.4 ttm -135.73 139.76 43.86 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.805 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.32 120.64 59.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.027 0.441 . . . . 0.0 110.667 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 90.2 t -102.88 123.31 56.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.272 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 . . . . . 0 C--O 1.252 1.191 0 CA-C-O 118.184 -0.913 . . . . 0.0 111.416 -179.554 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.669 0 N-CA-C 112.42 -0.272 . . . . 0.0 112.42 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . 58.59 -124.0 1.39 Allowed 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 123.082 0.553 . . . . 0.0 111.961 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER 56.68 49.98 13.49 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 120.99 0.424 . . . . 0.0 111.735 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.99 174.64 52.83 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.91 -0.662 . . . . 0.0 113.302 -179.65 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.53 130.33 50.37 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.026 0.441 . . . . 0.0 111.297 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.22 126.12 35.72 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.753 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.4 148.97 46.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.257 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.585 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 18.6 pt20 -76.49 140.21 41.12 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.269 0.557 . . . . 0.0 111.217 -179.461 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -97.45 115.94 28.72 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.92 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -95.33 -151.91 0.35 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.522 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -82.46 72.88 9.52 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -179.275 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.12 -8.74 61.06 Favored Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.678 -0.773 . . . . 0.0 113.902 178.971 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -139.1 165.29 27.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 117.03 0.415 . . . . 0.0 110.932 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.2 153.07 31.52 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.994 0.426 . . . . 0.0 111.058 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.585 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 6.7 tt0 -144.42 140.49 29.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.412 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.01 130.24 24.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.131 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -90.6 110.06 21.21 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.178 0.513 . . . . 0.0 110.999 179.463 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.511 HG13 ' HD2' ' A' ' 51' ' ' PRO . 53.1 t -102.1 109.84 27.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.738 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.98 123.16 23.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.727 179.793 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.543 HG13 HD22 ' A' ' 75' ' ' LEU . 67.2 t -104.25 95.78 4.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-O 121.479 0.656 . . . . 0.0 111.376 -179.372 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.467 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 6.2 ptm -146.58 87.89 1.74 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.281 179.27 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.52 -0.84 89.22 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.432 -178.321 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.45 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.57 -144.36 9.88 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 111.5 -0.64 . . . . 0.0 111.5 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -119.1 128.61 54.46 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.774 0.287 . . . . 0.0 110.636 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.504 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 22.0 m -65.61 -61.66 5.52 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-O 119.572 -0.252 . . . . 0.0 110.958 179.775 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.511 ' HD2' HG13 ' A' ' 43' ' ' VAL . 68.9 Cg_endo -75.91 95.75 1.03 Allowed 'Trans proline' 0 C--N 1.357 0.998 0 C-N-CA 121.325 1.35 . . . . 0.0 111.038 177.742 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.6 -42.13 55.56 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.162 -179.206 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.441 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -133.8 118.99 18.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.83 179.477 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.472 HG13 ' HG3' ' A' ' 120' ' ' MET . 6.0 pt -96.67 126.62 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-O 121.062 0.458 . . . . 0.0 110.969 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 94.8 t -97.72 125.94 50.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.443 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.461 HD22 ' HB1' ' A' ' 62' ' ' ALA . 3.5 mt -135.67 165.03 26.52 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.307 -179.662 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.6 mmtt -89.01 176.41 7.01 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 120.769 0.318 . . . . 0.0 111.046 179.415 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.8 ttpp -106.93 148.26 28.84 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.834 0.349 . . . . 0.0 111.929 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.4 t 64.73 20.85 12.26 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.644 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.413 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.8 p -123.88 136.17 27.13 Favored Pre-proline 0 CA--C 1.537 0.457 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.998 -179.776 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -63.57 120.87 8.43 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.111 1.874 . . . . 0.0 111.688 178.595 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.461 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -123.82 138.29 54.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.845 0.355 . . . . 0.0 111.598 -179.425 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.414 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.4 OUTLIER -123.19 128.42 50.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.784 0.802 . . . . 0.0 111.537 179.867 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.2 mm -99.69 116.31 42.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.883 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.431 HG22 HG23 ' A' ' 96' ' ' VAL . 3.6 t -91.63 112.56 25.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.812 0.339 . . . . 0.0 111.246 -179.501 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -98.21 116.84 31.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.116 0.484 . . . . 0.0 111.528 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -100.78 103.31 14.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.387 179.468 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.54 102.85 7.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.247 0.546 . . . . 0.0 112.157 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.5 tptp -97.44 -38.37 9.63 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.588 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.467 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.0 t70 -103.0 130.72 23.13 Favored Pre-proline 0 CA--C 1.535 0.375 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.95 179.68 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -81.31 39.43 0.86 Allowed 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 123.099 2.532 . . . . 0.0 113.209 -179.394 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 29.1 t -70.5 135.16 86.35 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.263 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.15 -26.85 64.91 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.673 2.249 . . . . 0.0 112.519 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.3 m -80.24 -10.93 59.77 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.131 179.631 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.543 HD22 HG13 ' A' ' 45' ' ' VAL . 24.0 mt -113.9 13.7 18.39 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.213 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -70.21 -34.15 72.57 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.575 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -127.21 161.88 27.5 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.969 0.414 . . . . 0.0 111.511 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -138.76 127.97 30.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.338 178.477 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 1.5 p -131.72 130.08 61.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.282 0.563 . . . . 0.0 111.545 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -92.65 101.84 5.8 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.279 178.576 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.94 -13.32 38.04 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 122.566 2.177 . . . . 0.0 113.64 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -100.49 -11.72 19.92 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 111.929 0.344 . . . . 0.0 111.929 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -120.77 -17.82 7.85 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -178.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.78 29.24 52.68 Favored Glycine 0 C--N 1.333 0.371 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.541 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 54.2 t -109.06 113.59 44.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.81 0.338 . . . . 0.0 111.748 -179.113 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -117.93 117.44 29.27 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.401 179.368 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.57 167.59 20.19 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-O 121.342 0.591 . . . . 0.0 112.44 -179.044 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -110.1 139.8 44.86 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.257 179.512 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 46.3 mt -102.89 126.61 32.08 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.943 0.402 . . . . 0.0 111.481 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.443 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 70.1 Cg_endo -81.03 128.79 6.63 Favored 'Trans proline' 0 CA--C 1.532 0.393 0 C-N-CA 122.794 2.33 . . . . 0.0 112.414 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -65.92 124.83 23.56 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 121.042 0.449 . . . . 0.0 111.837 -179.497 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.94 9.6 84.17 Favored Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.923 -0.581 . . . . 0.0 113.055 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.443 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 47.5 mt-10 -135.14 176.79 8.34 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-O 120.94 0.4 . . . . 0.0 111.08 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -113.12 134.63 54.46 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.981 0.42 . . . . 0.0 111.799 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.9 t80 -123.22 126.59 47.23 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.899 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.431 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -106.15 138.87 29.47 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 CA-C-O 121.527 0.679 . . . . 0.0 112.64 -178.721 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 63' ' ' ARG . 53.8 t -114.22 112.3 39.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.164 178.789 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -94.76 119.1 32.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.018 0.437 . . . . 0.0 111.626 -179.532 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.03 157.57 40.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.273 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.8 m -120.73 96.67 48.75 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.326 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.413 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 71.6 Cg_endo -73.31 102.68 1.5 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.81 2.34 . . . . 0.0 112.434 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -97.71 10.6 39.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.902 0.382 . . . . 0.0 111.9 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.26 130.25 30.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.851 0.358 . . . . 0.0 110.874 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.07 128.22 35.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.372 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 165.79 -155.15 26.26 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.847 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -107.96 125.63 51.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.122 0.487 . . . . 0.0 111.012 -179.639 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -124.29 166.92 15.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.305 -179.74 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.19 157.9 43.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.182 0.515 . . . . 0.0 112.29 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -146.36 135.57 22.75 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.623 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.2 164.81 27.57 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 120.799 0.333 . . . . 0.0 111.406 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 1.2 t -151.92 178.84 9.0 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.059 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 97.35 -160.29 21.29 Favored Glycine 0 CA--C 1.519 0.326 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.879 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -100.71 -28.08 13.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.843 0.354 . . . . 0.0 111.506 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.87 178.0 9.33 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.814 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 2.4 ttm 62.8 -141.68 0.39 Allowed 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.43 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 73.35 151.13 0.11 Allowed 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.239 0.616 . . . . 0.0 112.038 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 5.4 t-80 -157.88 105.06 1.96 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.549 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -140.97 115.18 1.0 Allowed Glycine 0 CA--C 1.521 0.434 0 C-N-CA 121.115 -0.564 . . . . 0.0 111.794 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.441 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.0 ttpt -118.28 149.7 40.7 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.223 0.535 . . . . 0.0 111.783 -179.414 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.472 ' HG3' HG13 ' A' ' 54' ' ' ILE . 10.1 ttp -134.36 130.73 37.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.657 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -117.61 118.78 59.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.038 0.447 . . . . 0.0 111.097 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 57.8 t -101.29 119.83 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.886 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.005 -0.998 . . . . 0.0 112.063 -179.622 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.67 0 CA-C-O 121.191 0.328 . . . . 0.0 112.339 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.16 -38.31 12.22 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.904 0.383 . . . . 0.0 111.325 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 4.1 mmm -91.09 57.58 3.49 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 121.071 0.462 . . . . 0.0 111.272 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.2 -172.37 25.35 Favored Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.765 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.91 128.65 26.86 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.066 0.46 . . . . 0.0 111.454 179.819 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 8.4 ttmt -91.43 128.45 37.26 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.788 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.8 152.22 41.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.163 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 -82.75 141.51 32.32 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.206 0.527 . . . . 0.0 111.555 -179.403 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -95.34 115.69 27.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.805 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.71 -150.87 0.33 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.245 -179.831 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -83.11 78.0 9.66 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.85 -6.34 73.31 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.94 -0.648 . . . . 0.0 114.111 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -143.35 161.88 37.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 117.039 0.419 . . . . 0.0 111.094 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.11 155.56 21.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.982 0.42 . . . . 0.0 111.081 179.603 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -146.01 140.31 26.76 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.7 -179.17 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.06 130.12 21.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.791 179.108 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.411 HH11 ' HD2' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -91.5 111.05 22.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.192 0.52 . . . . 0.0 111.113 179.535 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.646 HG13 ' HD2' ' A' ' 51' ' ' PRO . 44.9 t -100.54 103.8 15.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.681 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -72.27 115.31 11.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.602 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.53 HG13 HD22 ' A' ' 75' ' ' LEU . 53.8 t -97.68 98.74 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.489 0.662 . . . . 0.0 111.432 -178.686 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.555 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.6 ptm -145.76 89.51 1.91 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.502 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.3 -0.89 83.26 Favored Glycine 0 CA--C 1.521 0.418 0 C-N-CA 120.869 -0.681 . . . . 0.0 111.59 -178.402 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.453 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 161.83 -173.29 38.16 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -90.14 124.66 35.01 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.896 0.348 . . . . 0.0 110.17 179.479 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.515 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 31.7 m -63.36 -63.9 3.54 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 119.648 -0.215 . . . . 0.0 111.317 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.646 ' HD2' HG13 ' A' ' 43' ' ' VAL . 63.5 Cg_endo -75.63 96.97 1.07 Allowed 'Trans proline' 0 C--N 1.358 1.038 0 C-N-CA 121.267 1.312 . . . . 0.0 111.068 177.506 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.61 -43.31 56.77 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 116.057 -0.519 . . . . 0.0 112.38 -179.222 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.465 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.39 118.58 19.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.655 179.684 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.436 HG13 ' HG3' ' A' ' 120' ' ' MET . 5.6 pt -97.67 125.72 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-O 121.085 0.469 . . . . 0.0 111.037 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 83.9 t -97.76 126.67 50.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.36 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' LEU . . . . . 0.442 HD22 ' HB1' ' A' ' 62' ' ' ALA . 3.3 mt -135.76 171.42 14.49 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.494 -179.647 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 14.5 mttt -93.63 174.58 7.12 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.978 179.638 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' LYS . . . . . 0.521 ' HD3' ' HB2' ' A' ' 104' ' ' ALA . 2.8 ttpt -106.46 147.88 28.81 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.852 0.358 . . . . 0.0 111.891 -179.296 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.0 t 65.08 19.72 11.88 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.641 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.421 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.5 135.93 26.64 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -63.45 122.35 10.47 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.118 1.878 . . . . 0.0 111.464 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ALA . . . . . 0.442 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -123.85 139.41 54.0 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.931 0.396 . . . . 0.0 111.728 -179.528 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.473 ' HB2' HG22 ' A' ' 96' ' ' VAL . 3.3 ptt180 -122.3 128.29 50.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.769 0.795 . . . . 0.0 111.389 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.6 mm -101.58 113.62 38.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.759 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.513 HG22 HG23 ' A' ' 96' ' ' VAL . 3.0 t -88.82 106.91 17.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.507 -179.192 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -94.03 113.24 25.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.016 0.436 . . . . 0.0 111.258 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -99.52 104.35 16.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.522 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.7 94.97 5.17 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.231 0.539 . . . . 0.0 111.498 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -88.6 -35.05 17.09 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.829 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.555 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 0.2 OUTLIER -111.55 136.82 21.03 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.083 179.906 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -81.01 39.47 0.87 Allowed 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 123.105 2.537 . . . . 0.0 113.288 -179.371 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.9 m -67.46 133.68 92.94 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.175 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -63.03 -32.23 75.89 Favored 'Trans proline' 0 C--N 1.348 0.551 0 C-N-CA 122.693 2.262 . . . . 0.0 112.776 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.58 -2.48 32.73 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.547 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.53 HD22 HG13 ' A' ' 45' ' ' VAL . 49.9 mt -121.21 13.77 11.23 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.291 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -70.63 -41.59 72.01 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.764 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -124.72 138.48 54.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.892 0.377 . . . . 0.0 111.586 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -118.78 130.35 73.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.593 179.287 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' VAL . . . . . 0.608 ' O ' ' HD3' ' A' ' 81' ' ' PRO . 0.2 OUTLIER -134.83 131.79 53.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.386 0.612 . . . . 0.0 111.316 179.978 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -92.84 101.59 5.53 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.42 178.653 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' PRO . . . . . 0.608 ' HD3' ' O ' ' A' ' 79' ' ' VAL . 25.5 Cg_exo -61.82 -17.66 56.42 Favored 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 123.024 2.482 . . . . 0.0 113.748 -178.716 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -101.2 -10.22 20.58 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -119.55 -21.38 7.39 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 85.66 1.49 87.43 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 121.248 -0.501 . . . . 0.0 112.226 -179.449 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.9 t -80.72 115.24 22.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.893 0.378 . . . . 0.0 111.41 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' HIS . . . . . 0.42 ' HB3' ' HB ' ' A' ' 79' ' ' VAL . 20.5 p-80 -131.29 121.63 25.06 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.602 179.831 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -141.15 161.91 36.75 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.722 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -99.53 127.11 45.6 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.115 179.208 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 57.5 mt -84.4 130.22 54.71 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-O 121.059 0.457 . . . . 0.0 111.844 -178.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -79.04 123.54 5.72 Favored 'Trans proline' 0 CA--C 1.533 0.461 0 C-N-CA 122.704 2.27 . . . . 0.0 112.236 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.1 tpt -64.16 124.96 23.01 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.7 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.86 6.25 85.43 Favored Glycine 0 CA--C 1.521 0.426 0 CA-C-N 115.886 -0.597 . . . . 0.0 113.081 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -132.96 176.87 8.11 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.984 0.421 . . . . 0.0 111.081 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.6 mp0 -115.97 132.17 56.73 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.478 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -120.51 117.95 28.98 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.333 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.513 HG23 HG22 ' A' ' 65' ' ' VAL . 3.4 p -96.0 130.34 44.83 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 CA-C-O 121.764 0.792 . . . . 0.0 112.062 -179.429 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 63' ' ' ARG . 52.9 t -106.17 115.24 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.426 179.167 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -95.81 119.17 33.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.871 0.367 . . . . 0.0 111.631 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -134.09 157.15 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.107 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.4 m -120.0 97.06 49.5 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.517 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.421 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.9 Cg_endo -73.22 98.06 0.99 Allowed 'Trans proline' 0 CA--C 1.532 0.402 0 C-N-CA 122.78 2.32 . . . . 0.0 112.531 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -96.51 23.44 6.83 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.014 0.435 . . . . 0.0 111.481 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.5 131.91 14.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.521 179.66 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ALA . . . . . 0.521 ' HB2' ' HD3' ' A' ' 58' ' ' LYS . . . -89.71 128.46 36.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.986 0.422 . . . . 0.0 111.495 -179.855 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.57 -158.64 31.15 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.632 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -101.82 123.46 45.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.048 0.452 . . . . 0.0 111.352 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.434 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 88.2 m-85 -115.9 166.19 12.24 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.019 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 95.5 p -141.57 155.73 45.75 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -178.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -151.57 129.56 11.78 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.389 178.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.59 177.77 9.14 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 121.123 0.487 . . . . 0.0 111.904 -179.346 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 34.6 t -116.33 132.12 56.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.615 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -77.24 75.65 1.74 Allowed Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.191 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.78 -60.31 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.774 0.321 . . . . 0.0 111.437 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -151.36 -86.08 0.07 Allowed 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 120.689 0.28 . . . . 0.0 111.458 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 2.1 ttm -124.8 111.99 16.17 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.923 0.392 . . . . 0.0 111.362 -179.72 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 1.8 mmt -131.49 156.81 45.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.835 179.723 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.14 105.34 3.5 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 120.902 0.382 . . . . 0.0 111.874 -179.835 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -144.64 115.05 0.83 Allowed Glycine 0 CA--C 1.519 0.334 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.946 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.465 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 6.8 ttpt -120.88 149.82 42.01 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.265 0.555 . . . . 0.0 111.785 -179.201 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.436 ' HG3' HG13 ' A' ' 54' ' ' ILE . 17.2 ttp -133.02 133.65 43.37 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.701 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -118.82 119.66 61.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.111 0.481 . . . . 0.0 111.08 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 92.5 t -102.61 121.86 54.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.946 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.25 1.106 0 CA-C-O 118.147 -0.93 . . . . 0.0 111.937 -179.428 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.711 0 N-CA-C 112.328 -0.309 . . . . 0.0 112.328 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -89.49 -36.18 15.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.754 -0.223 . . . . 0.0 111.447 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 59.88 -160.62 0.29 Allowed 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.95 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.86 152.54 30.16 Favored Glycine 0 C--N 1.331 0.293 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.663 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -116.32 128.93 55.98 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.321 0.582 . . . . 0.0 111.527 -179.452 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.4 mtpt -89.19 130.17 35.65 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.736 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.41 151.85 41.01 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.388 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLN . . . . . 0.575 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.6 pt20 -80.33 141.06 35.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.036 0.445 . . . . 0.0 111.4 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 56.4 mt-30 -96.83 115.03 26.73 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.73 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.76 -149.99 0.31 Allowed 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.454 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -81.58 72.68 8.63 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -179.132 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.03 -6.11 66.44 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 120.806 -0.711 . . . . 0.0 113.875 178.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -140.92 160.67 39.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.894 0.347 . . . . 0.0 110.788 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.15 156.08 21.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.136 0.493 . . . . 0.0 111.379 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.575 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.5 tt0 -144.31 143.2 30.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.513 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -143.73 128.42 14.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.065 0.459 . . . . 0.0 111.053 179.089 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.75 106.5 18.5 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.152 0.501 . . . . 0.0 111.078 179.689 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.598 HG13 ' HD2' ' A' ' 51' ' ' PRO . 49.0 t -98.09 101.99 12.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.557 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -71.59 117.81 13.63 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.796 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' VAL . . . . . 0.66 HG13 HD22 ' A' ' 75' ' ' LEU . 31.8 t -99.49 98.22 6.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.394 -178.782 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' MET . . . . . 0.492 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 10.8 ptp -140.38 82.3 1.85 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.333 179.499 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 88.0 -12.14 64.97 Favored Glycine 0 CA--C 1.517 0.194 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -178.017 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . 0.446 ' HA2' ' SD ' ' A' ' 116' ' ' MET . . . 173.27 -171.43 44.46 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 179.502 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -88.41 123.02 32.55 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.973 0.386 . . . . 0.0 110.265 179.58 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' THR . . . . . 0.515 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 35.5 m -61.99 -63.45 4.23 Favored Pre-proline 0 CA--C 1.54 0.558 0 CA-C-O 119.559 -0.257 . . . . 0.0 111.359 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' PRO . . . . . 0.598 ' HD2' HG13 ' A' ' 43' ' ' VAL . 73.6 Cg_endo -75.76 96.74 1.06 Allowed 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 121.296 1.331 . . . . 0.0 111.013 177.501 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -50.57 -43.13 56.26 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -179.252 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.439 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -130.41 118.8 21.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.659 0.266 . . . . 0.0 110.866 179.775 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.0 pt -98.8 126.31 52.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.079 0.466 . . . . 0.0 110.984 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 91.9 t -97.13 126.46 49.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.925 0.393 . . . . 0.0 111.532 -179.704 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 8.3 mt -133.98 168.33 18.99 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.38 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.6 tttt -95.09 168.28 10.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.508 179.43 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 4.6 ttpp -99.18 147.89 24.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 111.964 -179.423 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.4 t 65.78 19.83 11.39 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.874 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 6.3 p -123.71 135.63 26.41 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.895 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -64.52 123.36 11.64 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.104 1.869 . . . . 0.0 111.53 178.621 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.61 138.82 54.29 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.893 0.378 . . . . 0.0 111.703 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' ARG . . . . . 0.41 ' HB2' HG22 ' A' ' 96' ' ' VAL . 5.8 ptt180 -120.4 126.63 50.94 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-O 121.706 0.765 . . . . 0.0 111.274 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.2 mm -99.42 115.48 40.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.801 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' VAL . . . . . 0.484 HG22 HG23 ' A' ' 96' ' ' VAL . 4.0 t -91.17 109.55 21.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.825 0.345 . . . . 0.0 111.287 -179.342 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -96.78 112.23 24.07 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.075 0.464 . . . . 0.0 111.431 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -96.74 101.63 13.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.281 179.517 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.77 97.91 4.64 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 121.281 0.563 . . . . 0.0 111.918 -179.12 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -95.98 -29.56 14.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.828 179.715 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ASP . . . . . 0.492 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.8 t70 -111.75 131.79 22.23 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.922 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -80.63 39.45 0.86 Allowed 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.085 2.523 . . . . 0.0 113.121 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.528 ' HB2' HD12 ' A' ' 75' ' ' LEU . 2.7 m -69.75 139.1 88.33 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.289 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -62.61 -33.85 76.41 Favored 'Trans proline' 0 C--N 1.348 0.553 0 C-N-CA 122.883 2.389 . . . . 0.0 112.863 -179.6 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 10.7 p -78.59 -2.57 39.56 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.45 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.66 HD22 HG13 ' A' ' 45' ' ' VAL . 37.9 mt -121.14 9.94 10.59 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.32 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.93 -37.29 78.8 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.059 0.457 . . . . 0.0 111.118 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -129.34 160.06 34.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.515 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -133.49 128.5 54.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.339 0.59 . . . . 0.0 111.018 179.44 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -132.39 128.83 58.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 121.312 0.577 . . . . 0.0 111.071 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -92.54 102.08 6.1 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.47 -0.787 . . . . 0.0 109.537 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.79 -16.24 49.58 Favored 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.581 2.187 . . . . 0.0 113.598 -178.436 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -100.68 -6.37 25.22 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 111.984 0.364 . . . . 0.0 111.984 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -121.38 -22.98 5.8 Favored 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.25 25.33 51.95 Favored Glycine 0 CA--C 1.52 0.355 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.032 -179.473 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.0 t -106.6 117.7 52.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.813 0.339 . . . . 0.0 111.684 -178.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -121.1 117.52 27.38 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.52 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.82 165.83 24.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.138 0.494 . . . . 0.0 112.025 -179.292 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -107.38 140.56 40.11 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.474 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 58.9 mt -102.07 129.56 26.11 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.986 0.422 . . . . 0.0 111.363 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' PRO . . . . . 0.438 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 74.3 Cg_endo -82.7 126.2 4.53 Favored 'Trans proline' 0 CA--C 1.533 0.426 0 C-N-CA 122.723 2.282 . . . . 0.0 112.341 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.7 tpt -64.72 124.23 21.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.023 0.439 . . . . 0.0 111.789 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.65 5.23 84.6 Favored Glycine 0 CA--C 1.521 0.424 0 CA-C-N 115.87 -0.605 . . . . 0.0 113.195 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.438 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 44.8 mt-10 -133.29 176.78 8.21 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.959 0.409 . . . . 0.0 111.181 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.74 132.63 55.13 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.834 -179.747 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -118.98 125.43 49.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.982 178.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' VAL . . . . . 0.484 HG23 HG22 ' A' ' 65' ' ' VAL . 1.8 p -101.68 136.31 34.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.672 0.749 . . . . 0.0 112.462 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 61.5 t -113.26 112.31 39.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.069 178.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -93.27 118.72 31.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.511 -179.498 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -135.23 156.98 39.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.215 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.36 97.4 48.97 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.573 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' PRO . . . . . 0.449 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 66.7 Cg_endo -72.19 100.06 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.794 2.329 . . . . 0.0 112.36 179.544 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -96.11 10.36 37.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.854 0.359 . . . . 0.0 111.9 -179.521 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.03 132.45 32.22 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.51 -0.314 . . . . 0.0 110.779 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.38 127.3 35.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.018 0.437 . . . . 0.0 111.314 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.78 -157.24 29.41 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.624 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -101.73 126.81 48.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.127 0.489 . . . . 0.0 111.668 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' PHE . . . . . 0.443 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 86.0 m-85 -119.64 173.76 6.82 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.67 -0.696 . . . . 0.0 109.815 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 41.9 p -154.7 160.86 41.64 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -178.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.8 p90 -152.79 133.99 14.23 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.89 178.994 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -163.62 177.73 8.52 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-O 121.05 0.452 . . . . 0.0 111.879 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 33.7 t -148.65 127.45 12.59 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.553 179.017 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 68.51 -145.48 44.03 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.949 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 2.7 tpt -153.47 75.55 1.06 Allowed 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 121.043 0.449 . . . . 0.0 111.062 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -119.35 41.3 3.13 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.363 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 1.6 ttp 59.11 37.73 24.06 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.109 0.481 . . . . 0.0 111.714 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' MET . . . . . 0.446 ' SD ' ' HA2' ' A' ' 48' ' ' GLY . 2.5 ttp -139.55 135.64 33.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.654 -179.773 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -158.24 135.31 9.96 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.383 -179.6 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -102.05 150.01 18.12 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 121.087 -0.578 . . . . 0.0 111.748 178.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' LYS . . . . . 0.439 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.4 ttpt -126.84 150.82 49.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.071 0.463 . . . . 0.0 111.568 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 120' ' ' MET . . . . . 0.443 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -134.22 141.01 46.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.043 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.7 mp -124.66 120.22 58.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.984 0.421 . . . . 0.0 110.706 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.0 t -103.25 124.34 57.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.238 -179.675 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 . . . . . 0 C--O 1.252 1.216 0 CA-C-O 118.106 -0.949 . . . . 0.0 111.46 -179.601 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 . . . . . 0 C--O 1.232 0.144 0 CA-C-O 121.105 0.479 . . . . 0.0 111.325 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.34 129.36 35.89 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.525 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.46 153.58 40.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.187 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.572 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 4.5 pt20 -80.74 135.53 36.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.185 0.517 . . . . 0.0 111.279 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 19.7 mt-30 -94.05 112.39 24.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.601 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.42 -154.28 0.4 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.389 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -81.95 75.81 8.87 Favored 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.12 -5.36 63.23 Favored Glycine 0 CA--C 1.522 0.518 0 C-N-CA 120.772 -0.728 . . . . 0.0 114.121 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 26.9 p90 -144.35 163.76 32.79 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 117.063 0.431 . . . . 0.0 110.958 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.13 154.81 28.26 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.991 0.424 . . . . 0.0 111.452 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.572 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.6 tt0 -145.26 141.59 28.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.515 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.63 128.59 14.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.863 179.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.3 109.97 21.26 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.207 0.527 . . . . 0.0 111.117 179.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.647 HG13 ' HD2' ' A' ' 51' ' ' PRO . 44.9 t -98.22 103.37 14.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.488 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.424 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.8 OUTLIER -70.93 114.23 8.78 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.792 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.59 HG13 HD22 ' A' ' 75' ' ' LEU . 49.3 t -96.61 97.73 6.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.461 -178.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.496 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.2 ptm -144.25 86.98 1.86 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.52 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.47 -0.53 89.06 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.833 -0.698 . . . . 0.0 111.434 -178.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.427 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 161.9 -170.33 37.55 Favored Glycine 0 N--CA 1.448 -0.522 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -93.07 124.24 36.9 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.793 0.297 . . . . 0.0 110.213 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.509 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 37.1 m -63.42 -63.65 3.8 Favored Pre-proline 0 CA--C 1.539 0.527 0 CA-C-O 119.642 -0.218 . . . . 0.0 111.431 -179.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.647 ' HD2' HG13 ' A' ' 43' ' ' VAL . 60.7 Cg_endo -74.99 96.58 1.02 Allowed 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 121.312 1.341 . . . . 0.0 111.055 177.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.65 -43.44 57.17 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.069 -179.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.39 118.68 19.68 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.654 179.443 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.3 pt -97.8 126.78 50.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.913 0.387 . . . . 0.0 110.929 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 95.9 t -100.09 127.24 53.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.953 0.406 . . . . 0.0 111.557 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.438 HD22 ' HB1' ' A' ' 62' ' ' ALA . 2.3 mt -136.87 166.92 22.48 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.279 -179.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -89.62 176.89 6.69 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 120.745 0.307 . . . . 0.0 110.897 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.9 ttpp -107.55 149.53 27.9 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 111.972 0.36 . . . . 0.0 111.972 -179.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.7 t 65.55 19.51 11.51 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.725 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.44 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.5 p -123.82 136.26 27.19 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.11 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -64.26 122.61 10.62 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.247 1.965 . . . . 0.0 111.641 178.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.438 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -124.66 138.34 54.31 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.926 0.394 . . . . 0.0 111.723 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.502 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -120.49 127.42 52.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.643 0.735 . . . . 0.0 111.626 179.825 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.4 mm -100.2 114.23 38.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.623 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.511 HG22 HG23 ' A' ' 96' ' ' VAL . 2.8 t -90.64 107.41 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.739 0.304 . . . . 0.0 111.492 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -94.77 102.62 14.51 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.918 0.39 . . . . 0.0 111.279 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -91.17 106.94 18.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.435 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -77.46 105.28 8.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.287 0.565 . . . . 0.0 111.903 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.3 tptp -97.76 -34.28 10.96 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.256 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.496 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.7 t70 -110.27 134.38 20.8 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.848 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -81.42 40.1 0.94 Allowed 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.111 2.54 . . . . 0.0 112.995 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.61 135.37 90.47 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.387 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.27 -32.88 61.41 Favored 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 122.772 2.315 . . . . 0.0 112.802 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.1 p -77.09 -2.15 32.73 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.364 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.59 HD22 HG13 ' A' ' 45' ' ' VAL . 33.4 mt -119.29 13.56 12.8 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.242 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.14 -36.38 72.06 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.078 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.84 152.67 48.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.896 0.379 . . . . 0.0 111.503 -179.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -132.79 128.48 57.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.103 0.478 . . . . 0.0 110.727 179.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.4 130.61 65.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 121.258 0.551 . . . . 0.0 111.346 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -93.17 102.12 6.72 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.715 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.55 -14.36 41.96 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.621 2.214 . . . . 0.0 113.593 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -100.65 -7.57 23.77 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 111.809 0.299 . . . . 0.0 111.809 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -122.63 -22.77 5.3 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 112.058 0.392 . . . . 0.0 112.058 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.25 25.75 50.44 Favored Glycine 0 C--N 1.331 0.302 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.025 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.7 t -106.5 117.79 52.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.887 0.375 . . . . 0.0 111.71 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -121.67 118.52 29.37 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.388 179.323 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.38 162.53 34.19 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.084 0.468 . . . . 0.0 112.257 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 14.2 p-10 -104.19 148.28 26.48 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.679 179.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 29.5 mt -107.18 130.8 22.33 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.938 0.399 . . . . 0.0 111.716 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.418 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.3 Cg_endo -82.34 127.99 5.37 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.743 2.296 . . . . 0.0 112.434 179.176 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.5 tpt -66.62 125.4 25.65 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-O 121.025 0.441 . . . . 0.0 111.693 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.81 1.37 80.21 Favored Glycine 0 CA--C 1.52 0.344 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.842 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.418 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 41.7 mt-10 -134.24 177.17 7.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.895 0.379 . . . . 0.0 110.787 -179.484 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -118.14 133.33 56.0 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.197 0.522 . . . . 0.0 111.639 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.1 t80 -112.16 123.28 49.92 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.127 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.511 HG23 HG22 ' A' ' 65' ' ' VAL . 1.5 p -97.78 135.24 33.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.609 0.719 . . . . 0.0 112.304 -179.207 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 62.6 t -112.49 109.69 29.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.027 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -92.08 117.17 29.58 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.228 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -131.58 165.8 30.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.237 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.3 m -128.1 96.22 32.04 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.426 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.44 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.4 Cg_endo -72.2 98.88 0.95 Allowed 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.803 2.336 . . . . 0.0 112.454 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -95.27 7.78 45.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.832 0.349 . . . . 0.0 111.838 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.39 130.97 31.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.753 0.311 . . . . 0.0 110.931 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -85.3 124.8 32.34 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.199 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 171.71 -166.53 39.51 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.863 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.76 114.89 27.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.036 0.446 . . . . 0.0 110.732 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -110.49 174.84 5.67 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.233 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 91.6 p -153.45 164.15 38.69 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.419 0.525 . . . . 0.0 112.419 -178.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 36.8 p90 -150.85 137.67 19.0 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.481 178.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.261 0 CA-C-O 120.982 0.42 . . . . 0.0 111.708 -179.311 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.8 ttmm . . . . . 0 CA--C 1.53 0.177 0 CA-C-O 121.235 0.54 . . . . 0.0 111.891 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 2.2 ttm -134.65 136.26 42.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.797 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -120.99 118.2 55.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.006 0.432 . . . . 0.0 110.804 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 71.9 t -102.82 121.33 53.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.177 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.254 1.306 0 CA-C-O 118.335 -0.84 . . . . 0.0 111.396 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.531 0.217 0 CA-C-O 121.018 0.437 . . . . 0.0 111.289 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -90.49 126.67 35.99 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.787 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.26 151.88 43.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.15 179.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.586 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 7.7 pt20 -82.24 140.18 33.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.178 0.513 . . . . 0.0 111.545 -179.183 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 6.8 mp0 -95.46 113.25 24.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.488 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 6.1 mmtt -93.2 -148.68 0.25 Allowed 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.474 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -81.64 72.81 8.69 Favored 'General case' 0 CA--C 1.535 0.373 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.19 -5.71 68.37 Favored Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.845 178.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -141.27 160.46 40.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.864 0.332 . . . . 0.0 110.751 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.98 156.23 19.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.197 0.522 . . . . 0.0 111.351 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.586 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 4.2 tt0 -145.9 142.44 28.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.445 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.5 129.61 16.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.194 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -90.23 106.56 18.57 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.012 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.58 HG13 ' HD2' ' A' ' 51' ' ' PRO . 46.1 t -97.81 103.01 14.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.604 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.47 117.48 14.18 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.974 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.545 HG13 HD22 ' A' ' 75' ' ' LEU . 42.3 t -100.4 99.04 7.69 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 CA-C-O 121.535 0.683 . . . . 0.0 111.484 -178.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.448 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.5 ptp -141.27 85.63 1.98 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.222 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 87.56 -14.65 57.6 Favored Glycine 0 CA--C 1.519 0.313 0 N-CA-C 111.104 -0.798 . . . . 0.0 111.104 -177.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 176.89 -152.5 12.37 Favored Glycine 0 N--CA 1.449 -0.452 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -104.91 127.98 52.96 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.82 0.31 . . . . 0.0 110.56 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.513 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 43.0 m -69.15 -63.72 1.97 Allowed Pre-proline 0 CA--C 1.539 0.535 0 CA-C-O 119.571 -0.252 . . . . 0.0 111.368 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.58 ' HD2' HG13 ' A' ' 43' ' ' VAL . 61.9 Cg_endo -74.39 98.09 1.08 Allowed 'Trans proline' 0 C--N 1.357 1.012 0 C-N-CA 121.295 1.33 . . . . 0.0 111.121 177.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.25 -43.86 61.62 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.991 -0.549 . . . . 0.0 112.326 -179.181 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -133.89 118.53 18.05 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.559 0.218 . . . . 0.0 110.776 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.493 HG13 ' HG3' ' A' ' 120' ' ' MET . 8.6 pt -97.33 127.55 49.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.1 0.476 . . . . 0.0 111.004 179.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.5 t -96.04 126.43 48.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.472 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 24.3 mt -133.44 166.4 22.62 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.425 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 18.6 mttt -96.74 166.75 11.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.563 179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.3 ttpp -97.52 147.74 23.95 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.9 t 66.73 18.8 10.74 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.861 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.45 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 6.0 p -123.56 135.16 25.82 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.914 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -64.58 122.73 10.71 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.051 1.834 . . . . 0.0 111.611 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.24 138.94 54.34 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.834 0.35 . . . . 0.0 111.561 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.486 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.5 ptt180 -121.15 126.76 50.54 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.638 0.732 . . . . 0.0 111.394 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.8 mm -98.64 114.36 36.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.822 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.501 HG22 HG23 ' A' ' 96' ' ' VAL . 3.2 t -91.47 109.84 21.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.375 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -96.15 117.37 30.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.132 0.491 . . . . 0.0 111.332 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.6 t0 -99.94 100.31 11.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.412 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.37 93.0 3.41 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 121.225 0.536 . . . . 0.0 111.455 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -88.74 -37.43 15.49 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.752 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.448 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.2 t70 -101.75 129.44 26.61 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.763 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -79.23 38.63 0.74 Allowed 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 123.088 2.525 . . . . 0.0 113.014 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -70.52 135.35 86.27 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.015 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -63.47 -31.57 71.68 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.789 2.326 . . . . 0.0 112.888 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -75.85 -9.45 58.61 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.46 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.545 HD22 HG13 ' A' ' 45' ' ' VAL . 36.7 mt -113.22 13.99 19.3 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.466 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -70.13 -38.44 75.55 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.782 0.325 . . . . 0.0 111.709 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -122.64 158.82 29.17 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.113 0.482 . . . . 0.0 111.435 -179.586 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.86 130.12 35.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.444 178.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 2.0 p -133.27 132.3 58.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.314 0.578 . . . . 0.0 111.43 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -94.08 101.89 7.21 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.516 178.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -67.32 -14.03 41.44 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.589 2.193 . . . . 0.0 113.566 -178.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 33.1 m-20 -100.23 -9.14 22.75 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -122.87 -20.07 5.96 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.76 30.65 42.91 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.353 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 49.8 t -110.8 116.44 52.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.828 0.347 . . . . 0.0 111.733 -179.018 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -119.86 121.12 38.37 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.47 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.92 172.19 13.38 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 -112.66 142.36 45.36 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.461 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 41.0 mt -105.73 122.79 41.39 Favored Pre-proline 0 CA--C 1.531 0.246 0 CA-C-O 121.094 0.473 . . . . 0.0 111.544 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.426 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 67.2 Cg_endo -78.13 132.72 11.72 Favored 'Trans proline' 0 CA--C 1.531 0.326 0 C-N-CA 122.921 2.414 . . . . 0.0 112.713 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.8 tpt -68.55 124.89 24.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.082 0.467 . . . . 0.0 111.733 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.06 9.23 85.52 Favored Glycine 0 C--N 1.333 0.395 0 CA-C-N 115.863 -0.608 . . . . 0.0 113.101 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 45.4 mt-10 -134.28 176.82 8.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.979 0.419 . . . . 0.0 111.13 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -115.2 133.31 56.15 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.137 0.494 . . . . 0.0 111.647 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 14.1 t80 -119.89 123.64 44.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.977 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.501 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -102.99 137.21 32.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.65 0.738 . . . . 0.0 112.643 -178.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 54.9 t -112.86 112.03 38.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.18 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -93.16 119.52 32.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.507 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -136.49 155.6 34.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.227 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 2.9 m -119.37 97.81 50.3 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.514 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 73.2 Cg_endo -74.24 100.82 1.34 Allowed 'Trans proline' 0 CA--C 1.531 0.344 0 C-N-CA 122.86 2.373 . . . . 0.0 112.503 179.719 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -95.63 3.76 53.7 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.919 0.39 . . . . 0.0 111.657 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -130.4 133.63 46.52 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.867 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -90.07 128.8 36.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.908 0.385 . . . . 0.0 111.255 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 168.05 -166.75 39.67 Favored Glycine 0 CA--C 1.517 0.185 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.813 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -99.89 112.83 25.08 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.168 0.509 . . . . 0.0 110.746 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.408 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 22.6 m-85 -110.67 168.61 9.34 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.009 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 63.5 p -150.64 160.89 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.138 0.494 . . . . 0.0 112.047 -179.379 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 36.3 p90 -146.21 136.08 23.41 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.913 179.083 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.462 0.157 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.231 -179.673 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.17 0 CA-C-O 120.966 0.412 . . . . 0.0 111.083 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.493 ' HG3' HG13 ' A' ' 54' ' ' ILE . 8.9 ttp -131.71 119.52 21.46 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.012 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.7 mp -107.16 116.24 50.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.031 0.443 . . . . 0.0 110.793 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.2 t -101.23 120.43 50.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.168 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 . . . . . 0 C--O 1.252 1.224 0 CA-C-O 118.146 -0.93 . . . . 0.0 111.458 -179.646 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 . . . . . 0 C--O 1.232 0.133 0 CA-C-O 121.161 0.505 . . . . 0.0 111.066 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.82 129.23 35.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.606 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.71 156.1 39.3 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.403 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.549 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 5.9 pt20 -82.0 142.81 32.05 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.125 0.488 . . . . 0.0 111.259 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -98.47 112.99 24.84 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.657 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 5.6 mmtt -95.34 -150.28 0.31 Allowed 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.557 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -80.71 74.99 7.63 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.98 -5.82 76.11 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.867 -0.682 . . . . 0.0 113.974 178.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.4 p90 -140.59 163.96 31.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.923 0.361 . . . . 0.0 110.85 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.65 154.57 27.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.975 0.417 . . . . 0.0 111.457 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.549 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 4.0 tt0 -143.82 141.3 30.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.572 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.71 128.97 17.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.915 179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 ttt180 -90.73 110.9 22.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.253 0.549 . . . . 0.0 111.123 179.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.57 HG13 ' HD2' ' A' ' 51' ' ' PRO . 45.2 t -101.04 103.87 15.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.517 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.411 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 1.3 tp10 -71.49 117.01 12.5 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.029 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.557 HG13 HD22 ' A' ' 75' ' ' LEU . 53.2 t -98.76 99.93 9.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.451 -178.76 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.564 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.3 ptm -147.09 90.77 1.92 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.568 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 79.28 1.04 85.25 Favored Glycine 0 CA--C 1.52 0.396 0 C-N-CA 120.774 -0.727 . . . . 0.0 111.733 -178.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.481 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 163.54 -148.61 15.19 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 111.314 -0.715 . . . . 0.0 111.314 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -115.64 129.65 56.57 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.718 0.259 . . . . 0.0 110.309 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.504 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 41.0 m -68.76 -64.6 1.65 Allowed Pre-proline 0 CA--C 1.538 0.515 0 CA-C-O 119.468 -0.301 . . . . 0.0 111.497 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.57 ' HD2' HG13 ' A' ' 43' ' ' VAL . 62.4 Cg_endo -74.9 98.88 1.19 Allowed 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.271 1.314 . . . . 0.0 111.119 177.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -51.84 -44.55 63.64 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.917 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.85 119.09 20.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.864 179.78 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.2 pt -97.1 126.98 49.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 121.08 0.467 . . . . 0.0 110.943 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 60.1 t -98.58 126.67 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.642 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.3 mt -136.22 165.37 25.91 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.363 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -88.85 176.01 7.22 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.82 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.452 ' HD3' ' HB2' ' A' ' 104' ' ' ALA . 2.6 ttpt -106.7 147.95 28.98 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 111.872 -179.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.0 t 65.13 20.2 11.95 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.737 179.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.444 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.3 p -123.61 136.4 27.22 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.989 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -64.47 123.43 11.76 Favored 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.099 1.866 . . . . 0.0 111.736 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.05 139.37 53.86 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.954 0.407 . . . . 0.0 111.682 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.515 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.6 ptt180 -121.78 127.06 50.21 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.744 0.783 . . . . 0.0 111.335 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.5 mm -99.87 115.78 41.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.838 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.517 HG22 HG23 ' A' ' 96' ' ' VAL . 3.2 t -91.24 107.59 18.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.853 0.359 . . . . 0.0 111.463 -179.229 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -95.09 103.57 15.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.909 0.385 . . . . 0.0 111.466 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -90.59 105.9 18.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.377 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.55 100.1 7.6 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.157 0.503 . . . . 0.0 111.882 -179.197 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.0 tmtt? -91.42 -39.19 12.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.852 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.564 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 0.1 OUTLIER -107.1 137.8 19.66 Favored Pre-proline 0 CA--C 1.534 0.354 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.149 -179.913 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -81.87 39.66 0.88 Allowed 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 123.229 2.619 . . . . 0.0 113.405 -179.279 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -67.73 135.66 92.48 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.991 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -62.42 -34.3 76.93 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.872 2.382 . . . . 0.0 113.106 -179.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.02 -3.29 38.33 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.518 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.557 HD22 HG13 ' A' ' 45' ' ' VAL . 56.3 mt -120.01 12.88 12.07 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.446 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -68.78 -39.27 80.25 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 120.915 0.388 . . . . 0.0 111.379 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 31.0 mt-30 -123.66 166.15 16.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.034 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -140.93 130.45 25.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.296 0.57 . . . . 0.0 110.836 178.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.582 ' O ' ' HD3' ' A' ' 81' ' ' PRO . 0.2 OUTLIER -133.9 132.33 56.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.216 0.532 . . . . 0.0 110.981 179.68 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 -96.01 101.72 9.01 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.721 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.582 ' HD3' ' O ' ' A' ' 79' ' ' VAL . 23.2 Cg_exo -63.46 -19.02 67.1 Favored 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.072 2.515 . . . . 0.0 113.791 -178.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -100.66 -5.94 25.88 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -121.44 -23.03 5.76 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.11 22.8 56.69 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.151 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.1 t -102.53 120.34 52.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.674 0.274 . . . . 0.0 111.552 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -125.74 119.69 28.62 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.633 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.78 169.35 17.94 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.112 0.482 . . . . 0.0 112.249 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -109.05 140.67 42.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.548 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 38.6 mt -100.69 129.44 27.6 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.851 0.358 . . . . 0.0 111.356 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.426 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.9 Cg_endo -80.64 128.25 6.76 Favored 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.813 2.342 . . . . 0.0 112.452 179.164 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -66.16 124.85 23.74 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.087 0.47 . . . . 0.0 111.681 -179.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 87.11 3.46 82.56 Favored Glycine 0 CA--C 1.521 0.446 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.951 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 41.9 mt-10 -134.65 177.05 8.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.009 0.433 . . . . 0.0 110.913 -179.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -117.27 133.35 56.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.211 0.529 . . . . 0.0 111.564 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -113.21 125.49 54.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.222 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.517 HG23 HG22 ' A' ' 65' ' ' VAL . 1.7 p -98.09 135.19 33.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.715 0.769 . . . . 0.0 112.334 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.0 t -112.82 112.92 42.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.199 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -93.73 119.76 33.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.035 0.445 . . . . 0.0 111.518 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -136.4 156.44 36.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.125 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.26 97.74 48.99 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.452 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.444 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 58.6 Cg_endo -71.14 98.42 0.82 Allowed 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.734 2.289 . . . . 0.0 112.618 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -97.6 22.72 8.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.004 0.43 . . . . 0.0 111.482 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.35 131.23 14.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.539 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . 0.452 ' HB2' ' HD3' ' A' ' 58' ' ' LYS . . . -88.11 127.1 35.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.071 0.462 . . . . 0.0 111.41 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 164.99 -157.6 30.13 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.714 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -101.55 126.01 48.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.172 0.51 . . . . 0.0 111.535 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.443 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 87.9 m-85 -119.58 171.93 8.02 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.783 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 84.8 p -157.81 160.54 37.88 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.211 0.529 . . . . 0.0 112.418 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -143.77 140.46 29.94 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.496 178.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.282 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.662 -179.196 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 0.2 OUTLIER . . . . . 0 CA--C 1.529 0.143 0 CA-C-O 120.884 0.373 . . . . 0.0 111.112 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.443 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -132.56 140.12 48.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.059 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.5 118.74 54.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 121.048 0.451 . . . . 0.0 110.823 179.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.3 t -100.21 123.86 53.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.062 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.251 1.168 0 CA-C-O 118.155 -0.926 . . . . 0.0 111.973 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.158 0 CA-C-O 121.155 0.502 . . . . 0.0 111.375 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -88.57 126.59 35.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.626 179.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.27 153.84 41.32 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.297 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.72 140.67 34.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.243 0.544 . . . . 0.0 111.187 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 22.0 mt-30 -96.38 116.83 29.69 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.595 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.1 -153.07 0.41 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.119 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -83.73 76.82 9.96 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -179.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.6 -8.84 64.2 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.767 -0.73 . . . . 0.0 114.007 178.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -141.21 164.99 28.77 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 117.093 0.446 . . . . 0.0 111.091 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.44 154.28 27.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.924 0.392 . . . . 0.0 111.177 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -143.28 142.07 31.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.891 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.54 128.69 15.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.972 179.027 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -90.18 110.18 21.22 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.208 0.528 . . . . 0.0 110.93 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.566 HG13 ' HD2' ' A' ' 51' ' ' PRO . 47.9 t -102.37 107.2 21.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.663 -0.698 . . . . 0.0 110.74 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.42 ' HG2' ' SD ' ' A' ' 46' ' ' MET . 0.7 OUTLIER -75.93 117.76 17.99 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.002 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.491 HG13 HD22 ' A' ' 75' ' ' LEU . 50.6 t -96.62 99.03 8.31 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.416 -178.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.496 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.4 ptm -144.72 90.3 2.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.487 179.023 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 81.85 2.05 90.43 Favored Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.72 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.448 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 159.61 -131.28 2.67 Favored Glycine 0 N--CA 1.449 -0.471 0 N-CA-C 111.601 -0.6 . . . . 0.0 111.601 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -126.09 134.57 51.33 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.729 -0.277 . . . . 0.0 110.754 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.521 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 32.4 m -73.57 -63.98 0.87 Allowed Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 121.066 -0.253 . . . . 0.0 110.93 179.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.566 ' HD2' HG13 ' A' ' 43' ' ' VAL . 61.2 Cg_endo -74.53 100.51 1.33 Allowed 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 121.409 1.406 . . . . 0.0 111.226 177.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.63 -45.42 63.27 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.28 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.511 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.76 119.06 19.82 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.561 0.22 . . . . 0.0 110.999 179.783 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.1 pt -96.58 126.04 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.128 0.489 . . . . 0.0 110.896 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 84.0 t -97.8 126.43 50.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.567 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.5 mt -136.15 164.37 28.21 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.248 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.74 170.9 10.04 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 120.757 0.313 . . . . 0.0 110.935 179.24 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 12.7 ttpt -100.65 147.81 25.57 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.7 t 65.72 19.63 11.42 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.936 179.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.5 p -123.63 135.74 26.49 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.964 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_endo -64.11 123.28 11.64 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.133 1.889 . . . . 0.0 111.722 178.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.23 136.56 54.24 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.938 0.399 . . . . 0.0 111.542 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.434 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -118.53 125.51 50.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.855 0.836 . . . . 0.0 111.545 179.965 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.1 mm -98.38 114.93 37.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.626 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.543 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.34 107.83 19.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.768 0.318 . . . . 0.0 111.357 -179.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -94.16 118.53 31.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.081 0.467 . . . . 0.0 111.381 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -102.18 106.97 17.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.469 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.7 tpt180 -76.35 96.69 4.05 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 121.13 0.491 . . . . 0.0 111.42 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 23.4 tptt -91.89 -35.91 13.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.451 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.496 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.7 t70 -107.08 131.15 21.92 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.731 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -80.18 38.48 0.75 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.001 2.467 . . . . 0.0 113.027 -179.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -68.91 132.74 90.37 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.945 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -64.32 -30.92 63.5 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.668 2.245 . . . . 0.0 112.894 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.75 -3.13 42.78 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.544 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.491 HD22 HG13 ' A' ' 45' ' ' VAL . 16.6 mt -117.67 10.15 13.29 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 120.751 0.31 . . . . 0.0 111.19 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.18 -42.61 79.71 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -179.412 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 16.8 mt-30 -116.83 138.01 51.81 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.829 0.347 . . . . 0.0 111.584 -179.56 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -118.21 131.7 70.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.654 179.432 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.416 ' HB ' ' HB3' ' A' ' 86' ' ' HIS . 0.2 OUTLIER -137.42 129.44 41.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.397 0.618 . . . . 0.0 111.579 179.947 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -89.95 102.18 4.39 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.252 178.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 109' ' ' PHE . 36.4 Cg_endo -64.99 -14.16 43.72 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.606 2.204 . . . . 0.0 113.637 -178.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -101.02 -11.25 19.82 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -119.15 -24.29 6.52 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 111.945 0.35 . . . . 0.0 111.945 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 88.84 1.17 80.46 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.143 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.521 HG11 HG13 ' A' ' 97' ' ' VAL . 54.8 t -80.36 117.02 25.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.886 0.374 . . . . 0.0 111.396 -178.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . 0.416 ' HB3' ' HB ' ' A' ' 79' ' ' VAL . 19.2 p-80 -132.05 122.59 25.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.835 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.48 174.23 10.94 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 121.112 0.482 . . . . 0.0 111.91 -178.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -108.23 141.89 39.31 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.656 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 33.9 mt -100.71 124.49 42.06 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 120.906 0.384 . . . . 0.0 111.467 -179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.434 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 63.6 Cg_endo -78.57 128.63 8.82 Favored 'Trans proline' 0 CA--C 1.53 0.313 0 C-N-CA 122.786 2.324 . . . . 0.0 112.684 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 12.3 tpt -66.19 124.94 23.99 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.151 0.501 . . . . 0.0 111.677 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.38 6.76 85.69 Favored Glycine 0 CA--C 1.52 0.398 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.923 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.434 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 48.3 mm-40 -134.13 176.78 8.28 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-O 120.943 0.401 . . . . 0.0 111.292 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -114.58 132.32 56.38 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.983 0.42 . . . . 0.0 111.834 -179.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.415 ' HB2' ' HD2' ' A' ' 90' ' ' PRO . 9.6 t80 -118.06 121.63 41.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.778 178.632 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.543 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -98.52 138.46 23.04 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 CA-C-O 121.629 0.728 . . . . 0.0 112.577 -178.715 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.521 HG13 HG11 ' A' ' 85' ' ' VAL . 43.8 t -115.6 110.34 31.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.053 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -93.98 117.39 30.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.034 0.445 . . . . 0.0 111.551 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -132.73 156.52 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.18 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.3 m -119.9 96.74 49.55 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.437 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.449 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.1 Cg_endo -72.07 99.49 1.0 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.706 2.271 . . . . 0.0 112.494 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -97.3 22.92 8.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.023 0.439 . . . . 0.0 111.553 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.17 127.76 11.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.749 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -83.84 122.96 29.4 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.975 0.417 . . . . 0.0 111.326 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 169.2 -158.76 31.44 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.729 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -101.99 126.7 48.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.182 0.515 . . . . 0.0 111.576 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.447 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 85.7 m-85 -119.69 169.7 9.86 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.918 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 99.1 p -149.81 157.38 43.15 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.408 ' HA ' ' HD2' ' A' ' 81' ' ' PRO . 32.9 p90 -148.29 138.48 22.6 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.995 178.778 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.38 0 CA-C-O 121.05 0.452 . . . . 0.0 111.655 -179.73 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 14.6 ttpt . . . . . 0 CA--C 1.528 0.119 0 CA-C-O 121.03 0.443 . . . . 0.0 111.098 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.447 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.7 ttm -128.39 136.22 50.61 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.908 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -120.02 118.42 56.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.981 0.42 . . . . 0.0 110.846 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 76.0 t -99.78 121.78 50.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.146 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.103 -0.951 . . . . 0.0 111.531 -179.702 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 . . . . . 0 N--CA 1.462 0.168 0 CA-C-O 121.207 0.527 . . . . 0.0 111.477 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 3.1 ttpt -90.17 129.5 36.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.747 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.22 153.51 40.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.441 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 3.7 pt20 -84.48 139.33 32.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.132 0.491 . . . . 0.0 111.393 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -94.82 115.29 27.31 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.769 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.89 -151.14 0.32 Allowed 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.248 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.6 m120 -82.94 73.29 9.98 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.68 -4.76 61.75 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 120.817 -0.706 . . . . 0.0 114.061 178.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 30.2 p90 -143.62 162.57 35.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.909 0.355 . . . . 0.0 110.915 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.42 153.33 27.51 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.006 0.432 . . . . 0.0 111.475 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.441 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.6 tt0 -142.14 142.81 32.78 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.567 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.56 129.07 13.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -90.74 110.12 21.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.239 0.542 . . . . 0.0 110.939 179.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.582 HG13 ' HD2' ' A' ' 51' ' ' PRO . 43.5 t -102.16 103.91 15.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.774 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.468 ' HG2' ' SD ' ' A' ' 46' ' ' MET . 0.8 OUTLIER -75.25 118.13 17.82 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.614 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.563 HG13 HD22 ' A' ' 75' ' ' LEU . 53.5 t -96.9 98.41 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.649 -178.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.468 ' SD ' ' HG2' ' A' ' 44' ' ' GLU . 6.4 ptm -142.55 90.81 2.26 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.642 179.124 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 81.7 0.72 89.68 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.901 -0.666 . . . . 0.0 111.684 -178.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.464 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 162.79 -133.66 3.16 Favored Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -124.8 130.77 53.04 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.743 0.272 . . . . 0.0 110.599 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.537 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 49.7 m -70.15 -64.99 1.2 Allowed Pre-proline 0 CA--C 1.538 0.51 0 CA-C-O 119.508 -0.282 . . . . 0.0 111.391 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.582 ' HD2' HG13 ' A' ' 43' ' ' VAL . 58.7 Cg_endo -73.95 100.32 1.27 Allowed 'Trans proline' 0 C--N 1.358 1.058 0 C-N-CA 121.278 1.319 . . . . 0.0 111.249 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.84 -47.16 60.25 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.951 -0.568 . . . . 0.0 112.285 -179.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.56 119.06 20.01 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.638 0.256 . . . . 0.0 110.752 179.897 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.4 pt -97.04 129.37 47.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.093 0.473 . . . . 0.0 111.062 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 96.3 t -96.18 124.95 49.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.509 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.0 157.24 42.87 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.087 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -89.85 168.99 11.63 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 110.163 -0.31 . . . . 0.0 110.163 178.31 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.9 ttpp -98.77 146.95 25.39 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 112.305 0.484 . . . . 0.0 112.305 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.6 t 65.66 19.78 11.48 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.86 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.451 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.95 135.9 26.84 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.976 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -64.29 122.74 10.8 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.128 1.885 . . . . 0.0 111.812 178.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.7 134.68 53.67 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.856 0.36 . . . . 0.0 111.47 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.46 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -116.59 126.32 53.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.776 0.798 . . . . 0.0 111.585 -179.918 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.5 mm -99.5 114.88 38.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.67 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.523 HG22 HG23 ' A' ' 96' ' ' VAL . 4.1 t -90.45 108.2 19.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.714 0.292 . . . . 0.0 111.383 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -95.08 113.67 25.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.147 0.499 . . . . 0.0 111.326 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 21.8 t0 -99.32 103.72 15.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.5 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.25 97.66 4.24 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.176 0.512 . . . . 0.0 111.723 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.66 -42.1 10.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.482 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.455 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.2 t70 -99.47 131.75 24.39 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.837 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -80.73 39.63 0.88 Allowed 'Trans proline' 0 C--N 1.348 0.526 0 C-N-CA 123.16 2.573 . . . . 0.0 113.162 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 30.7 t -69.77 136.18 87.84 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.326 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -63.95 -27.95 66.63 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.576 2.184 . . . . 0.0 112.443 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 80.6 m -81.05 -6.89 59.33 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.059 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.563 HD22 HG13 ' A' ' 45' ' ' VAL . 50.9 mt -118.31 14.92 13.92 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.208 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -68.37 -35.89 78.39 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 120.95 0.405 . . . . 0.0 111.557 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -129.34 165.68 21.0 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.047 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.08 131.82 42.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.245 0.545 . . . . 0.0 110.98 179.156 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.9 128.63 43.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.455 0.645 . . . . 0.0 111.179 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -90.81 102.21 4.95 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.422 178.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -65.24 -14.2 43.83 Favored 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.583 2.188 . . . . 0.0 113.583 -178.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -101.05 -10.24 20.68 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 111.906 0.335 . . . . 0.0 111.906 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 59.0 m-85 -119.84 -23.69 6.37 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -179.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 87.92 1.28 82.57 Favored Glycine 0 CA--C 1.521 0.458 0 C-N-CA 121.291 -0.48 . . . . 0.0 112.175 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.506 HG11 HG13 ' A' ' 97' ' ' VAL . 53.6 t -81.48 116.27 25.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.892 0.377 . . . . 0.0 111.348 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 20.3 p-80 -131.51 120.86 23.53 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.959 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -140.18 173.79 11.16 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.759 -179.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 8.1 p-10 -106.54 145.54 31.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.738 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 36.2 mt -103.97 130.17 23.89 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 120.924 0.393 . . . . 0.0 111.203 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.425 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.7 Cg_endo -80.86 126.11 5.69 Favored 'Trans proline' 0 CA--C 1.532 0.382 0 C-N-CA 122.706 2.271 . . . . 0.0 112.325 179.26 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.0 tpt -64.01 123.95 20.34 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.092 0.473 . . . . 0.0 111.764 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.02 3.59 87.62 Favored Glycine 0 CA--C 1.522 0.508 0 CA-C-N 115.866 -0.606 . . . . 0.0 113.283 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.425 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 47.8 mt-10 -131.86 176.86 7.99 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 120.886 0.374 . . . . 0.0 111.196 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -113.38 135.55 53.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.083 0.468 . . . . 0.0 111.985 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -120.07 124.26 45.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.807 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.523 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -98.7 137.94 24.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.63 0.728 . . . . 0.0 112.666 -178.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.506 HG13 HG11 ' A' ' 85' ' ' VAL . 46.1 t -114.99 110.46 32.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.055 178.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -93.56 117.09 29.64 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.854 0.359 . . . . 0.0 111.481 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 pt -132.05 158.05 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.213 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -121.38 96.24 47.97 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.501 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.451 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.7 Cg_endo -71.19 99.59 0.91 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.724 2.283 . . . . 0.0 112.276 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -94.22 3.65 54.96 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -132.01 135.95 46.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.79 0.329 . . . . 0.0 110.754 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.46 124.11 34.19 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.962 179.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 168.76 -159.44 32.56 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.839 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -100.61 125.93 47.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.155 0.503 . . . . 0.0 111.556 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.467 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 95.5 m-85 -121.42 164.86 16.44 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.831 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -151.21 157.43 42.63 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.251 0.548 . . . . 0.0 112.244 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -142.92 140.42 31.14 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.913 179.099 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.356 -179.757 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 4.1 ttmm . . . . . 0 CA--C 1.528 0.097 0 CA-C-O 120.947 0.403 . . . . 0.0 111.209 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.467 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 3.4 ttm -131.1 135.13 47.24 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.926 179.496 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.16 117.87 55.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.045 0.45 . . . . 0.0 110.527 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.1 t -99.95 123.58 52.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.349 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 118.186 -0.912 . . . . 0.0 111.46 -179.844 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 . . . . . 0 CA--C 1.53 0.177 0 CA-C-O 121.069 0.461 . . . . 0.0 111.268 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 5.3 mtpt -90.12 129.25 36.43 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.733 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.99 149.21 43.49 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.636 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.602 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.8 pt20 -74.81 138.02 42.3 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.907 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -97.55 113.36 25.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.871 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -95.41 -156.17 0.5 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.368 -179.682 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -81.89 79.26 8.47 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 112.29 0.478 . . . . 0.0 112.29 -179.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.74 -9.98 66.36 Favored Glycine 0 CA--C 1.522 0.508 0 C-N-CA 120.799 -0.715 . . . . 0.0 114.298 178.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 28.9 p90 -142.01 164.07 31.17 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 117.098 0.449 . . . . 0.0 111.193 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.13 155.41 26.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.012 0.434 . . . . 0.0 111.182 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.602 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.9 tt0 -144.49 143.19 30.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.33 -179.28 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.11 129.44 17.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.082 0.468 . . . . 0.0 111.327 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 ttm180 -88.7 106.97 18.69 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.221 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.587 HG13 ' HD2' ' A' ' 51' ' ' PRO . 45.6 t -100.39 102.31 13.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.496 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -73.6 119.38 17.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.711 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.552 HG13 HD22 ' A' ' 75' ' ' LEU . 53.2 t -98.86 99.44 8.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.517 -178.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.493 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.2 ptm -143.8 88.24 1.97 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.537 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.31 -0.36 84.61 Favored Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.575 -178.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.437 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 163.41 -163.45 35.6 Favored Glycine 0 N--CA 1.447 -0.586 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -98.58 126.36 44.13 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.768 0.284 . . . . 0.0 110.321 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.537 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 47.8 m -65.24 -64.3 2.73 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 121.196 -0.202 . . . . 0.0 111.267 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.587 ' HD2' HG13 ' A' ' 43' ' ' VAL . 60.8 Cg_endo -74.62 96.58 1.0 Allowed 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 121.358 1.372 . . . . 0.0 111.198 177.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.36 -42.86 61.61 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.096 -0.502 . . . . 0.0 112.195 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.485 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.88 118.68 20.16 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.696 0.284 . . . . 0.0 110.606 179.513 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.9 pt -98.0 127.48 50.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-O 121.03 0.443 . . . . 0.0 111.092 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.1 t -98.68 126.72 51.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.597 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.0 mt -136.41 165.32 26.08 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.264 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -90.97 171.42 9.29 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.797 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.5 ttpp -101.74 148.47 25.24 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.999 0.428 . . . . 0.0 112.066 -179.325 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.0 t 65.42 20.14 11.71 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.931 179.567 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.436 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.8 p -123.78 135.91 26.77 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.866 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -64.36 122.2 10.06 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.202 1.935 . . . . 0.0 111.68 178.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.46 138.65 54.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.995 0.426 . . . . 0.0 111.546 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.474 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.2 ptt180 -120.72 126.85 51.21 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-O 121.776 0.798 . . . . 0.0 111.343 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.8 mm -97.73 115.01 36.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.81 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.452 HG22 HG23 ' A' ' 96' ' ' VAL . 3.6 t -91.99 110.52 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.376 -179.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -96.2 114.69 26.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.041 0.448 . . . . 0.0 111.289 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -100.38 104.5 15.93 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.181 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.407 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 0.1 OUTLIER -76.64 104.66 7.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.289 0.566 . . . . 0.0 111.958 -179.093 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.73 -39.84 9.26 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.093 179.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.493 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.1 t70 -105.71 133.86 19.99 Favored Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.929 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -80.97 39.53 0.87 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.994 2.463 . . . . 0.0 112.861 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.07 133.87 91.74 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.451 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.67 -32.37 57.67 Favored 'Trans proline' 0 C--N 1.348 0.527 0 C-N-CA 122.771 2.314 . . . . 0.0 112.63 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.15 -2.69 32.3 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.56 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.552 HD22 HG13 ' A' ' 45' ' ' VAL . 34.9 mt -118.74 12.99 13.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.275 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -70.55 -43.46 69.46 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.931 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.55 140.14 51.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.026 0.441 . . . . 0.0 111.54 -179.476 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -120.64 127.64 75.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.525 178.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -130.11 130.58 65.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.349 0.595 . . . . 0.0 111.475 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -92.65 102.12 6.26 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.374 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -66.67 -16.66 51.18 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.667 2.245 . . . . 0.0 113.7 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -100.57 -7.44 24.06 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -120.58 -21.82 6.61 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.9 29.82 45.53 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.077 -179.369 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.1 t -110.85 117.98 56.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.81 0.338 . . . . 0.0 111.753 -178.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -119.93 121.0 38.03 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.226 179.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.48 158.92 43.37 Favored 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 112.521 0.564 . . . . 0.0 112.521 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -104.01 137.0 42.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.477 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 45.0 mt -99.76 127.84 32.8 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.968 0.413 . . . . 0.0 111.466 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.433 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 70.8 Cg_endo -82.05 130.36 6.46 Favored 'Trans proline' 0 CA--C 1.533 0.426 0 C-N-CA 122.689 2.259 . . . . 0.0 112.441 179.241 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . 0.407 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 10.7 tpt -68.06 125.57 26.77 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-O 121.072 0.463 . . . . 0.0 111.644 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.51 13.11 79.16 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-N 115.855 -0.611 . . . . 0.0 112.866 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.433 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.5 mm-40 -138.5 176.93 8.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.878 0.371 . . . . 0.0 111.125 -179.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -114.0 134.21 55.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.049 0.452 . . . . 0.0 111.661 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.7 t80 -123.05 124.84 44.03 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.029 178.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.452 HG23 HG22 ' A' ' 65' ' ' VAL . 2.1 p -105.04 136.73 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 CA-C-O 121.544 0.688 . . . . 0.0 112.439 -178.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.7 t -113.17 112.92 42.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.113 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -93.84 119.49 32.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.951 0.405 . . . . 0.0 111.476 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -135.46 156.6 38.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.145 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -119.96 97.57 49.45 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.614 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.4 Cg_endo -72.75 100.28 1.16 Allowed 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 122.806 2.338 . . . . 0.0 112.309 179.502 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -95.46 5.34 51.85 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -131.97 133.29 44.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.798 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.89 127.74 35.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.0 0.429 . . . . 0.0 111.223 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 162.47 -156.56 28.25 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.764 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.02 126.13 48.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.198 0.523 . . . . 0.0 111.488 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.439 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 84.0 m-85 -118.15 173.41 6.81 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.904 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 83.2 p -151.22 158.13 43.51 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -178.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -149.69 130.46 14.15 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.334 178.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.215 0 CA-C-O 120.964 0.411 . . . . 0.0 112.001 -179.381 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 12.4 ttmt . . . . . 0 CA--C 1.532 0.271 0 CA-C-O 121.106 0.479 . . . . 0.0 111.898 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.439 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -134.52 139.79 45.69 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.735 179.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.0 mp -123.24 120.16 59.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.997 0.427 . . . . 0.0 110.81 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 85.2 t -104.16 123.19 57.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.202 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.237 0 CA-C-O 118.102 -0.951 . . . . 0.0 111.505 -179.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.135 0 CA-C-O 121.042 0.449 . . . . 0.0 111.237 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.2 mtpt -91.34 129.24 37.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.874 179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.65 152.36 40.51 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.317 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.563 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.5 pt20 -80.84 141.26 34.83 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-O 121.152 0.501 . . . . 0.0 111.444 -179.352 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 58.4 mt-30 -96.9 114.84 26.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.594 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.39 -149.82 0.31 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.456 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -82.01 72.72 9.06 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -179.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.76 -5.21 66.57 Favored Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.788 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.4 p90 -141.36 160.3 40.41 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.905 0.352 . . . . 0.0 110.746 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.18 155.66 21.68 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.988 0.423 . . . . 0.0 111.423 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.563 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.7 tt0 -144.53 143.84 31.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.545 -179.317 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -145.15 129.63 12.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.2 179.144 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 7.3 ttt180 -89.96 108.14 19.53 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.071 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.475 HG13 ' HD2' ' A' ' 51' ' ' PRO . 49.0 t -99.99 107.85 21.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.705 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -73.6 122.46 22.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.013 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.55 HG13 HD22 ' A' ' 75' ' ' LEU . 53.8 t -103.08 95.33 3.77 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-O 121.535 0.683 . . . . 0.0 111.052 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.449 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 3.8 ptm -146.16 89.45 1.87 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.405 179.562 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.55 0.24 89.8 Favored Glycine 0 CA--C 1.521 0.454 0 C-N-CA 120.811 -0.709 . . . . 0.0 111.545 -178.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.478 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.66 -140.6 6.81 Favored Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 111.649 -0.581 . . . . 0.0 111.649 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -121.86 129.46 52.61 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.741 0.27 . . . . 0.0 110.543 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.49 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 20.8 m -68.84 -62.0 3.17 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 120.997 -0.281 . . . . 0.0 111.176 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.49 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 63.5 Cg_endo -75.62 97.6 1.11 Allowed 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 121.417 1.411 . . . . 0.0 111.064 177.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -52.11 -43.34 63.9 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.125 -0.489 . . . . 0.0 112.062 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -134.17 118.45 17.67 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.711 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.488 HG13 ' HG3' ' A' ' 120' ' ' MET . 9.6 pt -96.91 127.35 49.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.134 0.492 . . . . 0.0 110.939 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 98.9 t -95.51 125.86 48.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.601 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 23.6 mt -133.69 167.68 20.07 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.263 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.2 mttt -96.59 168.84 10.29 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.685 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -98.67 146.72 25.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.928 0.395 . . . . 0.0 111.927 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.5 t 66.06 19.7 11.19 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.89 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 5.7 p -123.53 135.2 25.84 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.002 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -64.3 122.7 10.74 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.051 1.834 . . . . 0.0 111.711 178.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.1 138.98 54.36 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.79 0.328 . . . . 0.0 111.622 -179.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.447 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -120.92 125.33 47.17 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.719 0.771 . . . . 0.0 111.494 179.947 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 5.7 mm -97.66 115.25 37.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.654 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.518 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.9 109.8 21.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.375 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -95.5 111.81 23.65 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.016 0.436 . . . . 0.0 111.296 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -98.11 106.03 18.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.52 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.406 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 0.2 OUTLIER -78.19 105.16 9.24 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.282 0.563 . . . . 0.0 111.91 -179.448 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.05 -37.36 9.38 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.19 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.449 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 5.2 t70 -103.78 129.88 24.48 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.922 179.544 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -80.52 39.13 0.81 Allowed 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.113 2.542 . . . . 0.0 112.881 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.2 m -72.04 135.84 82.46 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.349 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -64.08 -31.21 65.65 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.617 2.211 . . . . 0.0 112.583 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 5.2 p -76.79 -5.29 47.58 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.587 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.55 HD22 HG13 ' A' ' 45' ' ' VAL . 30.2 mt -120.12 15.94 12.38 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.964 179.642 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -67.82 -35.56 78.82 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 116.096 -0.502 . . . . 0.0 112.243 -179.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 -133.7 165.91 23.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.914 0.388 . . . . 0.0 111.583 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . 0.417 HG13 ' N ' ' A' ' 79' ' ' VAL . 0.5 OUTLIER -137.72 141.37 39.22 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.115 179.858 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.417 ' N ' HG13 ' A' ' 78' ' ' ILE . 0.2 OUTLIER -139.9 134.14 36.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.364 0.602 . . . . 0.0 111.359 179.054 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -97.57 101.68 10.97 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.84 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.56 -13.79 40.14 Favored 'Trans proline' 0 C--N 1.347 0.481 0 C-N-CA 122.613 2.209 . . . . 0.0 113.431 -178.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -100.57 -9.11 22.32 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -123.02 -19.93 5.92 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.71 28.97 49.7 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.86 -0.685 . . . . 0.0 112.226 -179.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.4 t -110.75 116.87 53.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.745 0.307 . . . . 0.0 111.535 -179.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 4.3 t60 -127.12 117.72 22.95 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.87 0.367 . . . . 0.0 110.45 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.12 170.48 15.61 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 121.09 0.471 . . . . 0.0 111.858 -179.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -106.24 145.84 31.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.477 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 34.8 mt -105.47 129.35 24.85 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.867 0.365 . . . . 0.0 111.412 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.445 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.7 Cg_endo -81.86 129.21 6.18 Favored 'Trans proline' 0 CA--C 1.532 0.409 0 C-N-CA 122.752 2.301 . . . . 0.0 112.486 179.265 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . 0.406 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 10.3 tpt -67.07 125.27 25.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.138 0.494 . . . . 0.0 111.699 -179.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.66 6.37 85.64 Favored Glycine 0 C--N 1.333 0.367 0 CA-C-N 115.864 -0.607 . . . . 0.0 113.077 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.445 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 45.7 mt-10 -134.29 176.82 8.26 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 120.988 0.423 . . . . 0.0 111.018 -179.533 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -115.06 132.49 56.58 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.0 0.429 . . . . 0.0 111.767 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.4 t80 -116.47 123.9 48.64 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.968 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.518 HG23 HG22 ' A' ' 65' ' ' VAL . 1.6 p -101.28 137.1 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 CA-C-O 121.651 0.739 . . . . 0.0 112.51 -178.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.98 110.21 31.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.154 178.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -92.67 118.82 31.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.373 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -135.84 154.52 34.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.361 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -119.22 97.43 50.46 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.272 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.449 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 74.2 Cg_endo -73.47 101.92 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.845 2.363 . . . . 0.0 112.72 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -97.71 19.9 12.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.984 0.421 . . . . 0.0 111.483 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -146.97 129.93 16.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.774 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -86.1 126.28 34.08 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.903 0.382 . . . . 0.0 111.269 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.09 -168.29 41.36 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.816 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -99.76 112.02 24.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.141 0.496 . . . . 0.0 110.774 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -110.94 172.4 6.9 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.292 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 54.2 p -153.69 163.39 40.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.132 0.491 . . . . 0.0 112.274 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 31.2 p90 -145.58 140.63 27.54 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.518 179.067 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.466 0.371 0 CA-C-O 121.332 0.587 . . . . 0.0 112.273 -179.222 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 1.2 ttpt . . . . . 0 CA--C 1.53 0.175 0 CA-C-O 120.957 0.408 . . . . 0.0 111.476 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.488 ' HG3' HG13 ' A' ' 54' ' ' ILE . 9.2 ttp -133.96 122.18 22.71 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.048 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -109.69 116.08 51.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.101 0.477 . . . . 0.0 110.88 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 98.3 t -100.05 120.07 48.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.077 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 24.1 mt-10 . . . . . 0 C--O 1.253 1.247 0 CA-C-O 118.13 -0.938 . . . . 0.0 111.491 -179.542 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 19.8 mp0 . . . . . 0 C--O 1.232 0.164 0 CA-C-O 121.175 0.512 . . . . 0.0 111.114 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 3.4 ttmt -89.5 127.52 35.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.909 -179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.16 155.95 39.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.052 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.575 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 10.9 pt20 -79.68 132.8 36.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.295 0.569 . . . . 0.0 111.248 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.0 mt-30 -92.79 109.11 20.53 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.83 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.03 -157.07 0.47 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.352 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -83.09 80.3 9.09 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.05 -7.18 67.01 Favored Glycine 0 CA--C 1.523 0.534 0 C-N-CA 120.846 -0.692 . . . . 0.0 114.178 178.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . 0.452 ' HB2' ' O ' ' A' ' 61' ' ' PRO . 24.6 p90 -144.15 165.53 27.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 117.191 0.496 . . . . 0.0 111.075 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.89 154.96 33.61 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.901 0.382 . . . . 0.0 111.201 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.575 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.5 tt0 -145.21 143.13 30.12 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.43 -179.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.71 129.2 13.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.93 0.395 . . . . 0.0 110.714 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.58 111.45 22.76 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.317 0.58 . . . . 0.0 111.127 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.652 HG13 ' HD2' ' A' ' 51' ' ' PRO . 42.6 t -100.05 102.82 13.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.571 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.414 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.4 OUTLIER -72.56 113.61 9.79 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.607 179.874 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.604 HG13 HD22 ' A' ' 75' ' ' LEU . 43.1 t -94.66 97.45 6.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.674 -0.693 . . . . 0.0 111.336 -178.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.474 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.7 ptm -141.68 85.27 1.94 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.532 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.94 1.42 90.63 Favored Glycine 0 CA--C 1.521 0.41 0 C-N-CA 120.958 -0.639 . . . . 0.0 111.516 -178.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.427 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.94 -166.95 35.79 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -93.75 123.75 37.29 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.86 0.33 . . . . 0.0 110.44 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.501 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 25.5 m -63.67 -62.17 5.81 Favored Pre-proline 0 CA--C 1.538 0.489 0 CA-C-O 119.594 -0.241 . . . . 0.0 111.07 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.652 ' HD2' HG13 ' A' ' 43' ' ' VAL . 61.2 Cg_endo -75.23 98.73 1.19 Allowed 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 121.211 1.274 . . . . 0.0 110.974 177.366 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.54 -45.31 62.94 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.3 -179.066 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.461 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -133.18 118.28 18.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.53 179.704 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.435 HG13 ' HG3' ' A' ' 120' ' ' MET . 5.0 pt -96.92 126.12 49.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.141 0.495 . . . . 0.0 111.273 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 88.9 t -99.07 125.65 52.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.413 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.57 HD22 ' HB1' ' A' ' 62' ' ' ALA . 2.3 mt -136.27 166.19 24.0 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.354 -179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.0 177.18 7.67 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.263 179.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 12.2 ttpt -106.05 147.36 28.99 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 111.842 0.312 . . . . 0.0 111.842 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.8 t 62.35 26.9 16.08 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.646 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -123.57 137.06 27.97 Favored Pre-proline 0 CA--C 1.538 0.508 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.435 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . 0.452 ' O ' ' HB2' ' A' ' 38' ' ' TYR . 36.2 Cg_endo -67.25 93.44 0.35 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.773 2.316 . . . . 0.0 112.206 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.57 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -97.99 138.78 34.8 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.911 0.386 . . . . 0.0 111.988 -179.083 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.491 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.5 OUTLIER -121.51 129.09 52.71 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 121.736 0.779 . . . . 0.0 111.644 179.747 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.6 mm -100.63 114.78 40.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.285 -0.871 . . . . 0.0 110.695 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.501 HG22 HG23 ' A' ' 96' ' ' VAL . 3.3 t -91.65 109.86 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.677 -0.238 . . . . 0.0 111.411 -179.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -95.44 113.63 25.32 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.034 0.445 . . . . 0.0 111.278 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -100.18 106.6 18.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.142 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.05 105.98 9.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.312 0.577 . . . . 0.0 112.12 -179.143 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.2 tptp -99.9 -34.56 10.07 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.084 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.474 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.6 t70 -109.6 132.68 21.2 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.779 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -81.13 40.43 0.99 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.085 2.524 . . . . 0.0 113.306 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.514 ' HB3' HD12 ' A' ' 75' ' ' LEU . 36.2 t -68.65 134.7 90.41 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.331 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -64.43 -27.96 62.56 Favored 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 122.652 2.234 . . . . 0.0 112.647 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.1 m -78.92 -10.75 59.91 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.168 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.604 HD22 HG13 ' A' ' 45' ' ' VAL . 40.9 mt -110.57 10.21 23.04 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.497 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -68.23 -40.53 82.0 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 120.87 0.367 . . . . 0.0 111.81 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -123.54 148.64 46.11 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.359 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -130.53 129.88 64.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.13 0.49 . . . . 0.0 110.374 178.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 2.4 p -133.98 132.45 56.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.2 0.524 . . . . 0.0 111.18 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -93.07 101.76 5.99 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.259 178.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 109' ' ' PHE . 38.2 Cg_endo -66.57 -15.71 48.52 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.662 2.241 . . . . 0.0 113.527 -178.391 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -100.58 -7.59 23.87 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -121.36 -20.9 6.5 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 112.026 0.38 . . . . 0.0 112.026 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.95 29.43 46.84 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.105 -179.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 50.9 t -110.89 115.71 50.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.881 0.372 . . . . 0.0 111.753 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.6 p80 -118.75 124.95 48.53 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.429 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.04 160.06 41.09 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -104.08 139.55 39.02 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.471 179.594 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 42.3 mt -101.63 127.23 31.87 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.904 0.383 . . . . 0.0 111.438 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.438 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 68.9 Cg_endo -81.0 128.14 6.4 Favored 'Trans proline' 0 CA--C 1.532 0.383 0 C-N-CA 122.667 2.245 . . . . 0.0 112.479 179.441 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.0 tpt -66.75 125.49 26.01 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.993 0.425 . . . . 0.0 111.583 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.84 7.88 83.4 Favored Glycine 0 CA--C 1.52 0.393 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.889 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.438 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 52.4 mm-40 -135.58 176.9 8.25 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.014 0.435 . . . . 0.0 111.14 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -114.63 134.34 55.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.033 0.444 . . . . 0.0 111.669 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -121.95 126.15 47.96 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.108 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.501 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -103.81 139.28 25.21 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 CA-C-O 121.516 0.674 . . . . 0.0 112.674 -178.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.8 t -116.41 110.82 32.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.123 178.68 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -93.67 119.37 32.6 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.255 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -133.31 157.57 42.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.086 0.469 . . . . 0.0 111.186 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.5 m -122.3 95.57 46.99 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.317 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.68 101.2 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.816 2.344 . . . . 0.0 112.649 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -95.02 23.73 5.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.922 0.391 . . . . 0.0 111.64 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -149.25 130.43 14.54 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.764 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.51 127.21 35.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.04 0.448 . . . . 0.0 111.438 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 165.01 -160.38 33.66 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.659 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -101.58 125.58 48.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.051 0.453 . . . . 0.0 111.275 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.439 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 91.7 m-85 -118.31 167.54 11.45 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.198 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.6 p -143.53 154.88 44.07 Favored 'General case' 0 C--O 1.234 0.26 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.415 ' HA ' ' HD2' ' A' ' 81' ' ' PRO . 44.4 p90 -148.73 129.46 14.16 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.916 178.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.249 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.116 -179.703 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.461 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.9 ttpt . . . . . 0 CA--C 1.53 0.184 0 CA-C-O 121.304 0.573 . . . . 0.0 111.729 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.439 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 12.0 ttp -133.93 135.16 43.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.734 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.1 mp -119.38 119.29 60.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.952 0.406 . . . . 0.0 110.856 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 89.6 t -104.12 120.16 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.135 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.227 -0.892 . . . . 0.0 111.464 -179.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.16 0 CA-C-O 121.134 0.493 . . . . 0.0 111.223 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.42 126.1 37.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.808 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.36 153.19 42.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.24 179.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -81.42 141.2 34.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.163 0.506 . . . . 0.0 111.52 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -97.16 115.71 28.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.596 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.51 -149.88 0.34 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.513 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -81.74 73.0 8.8 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -179.149 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.68 -6.54 67.62 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.65 -0.786 . . . . 0.0 113.898 179.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 38.9 p90 -139.89 163.7 31.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.767 0.283 . . . . 0.0 110.799 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.92 153.1 29.83 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.111 0.481 . . . . 0.0 111.283 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.409 ' HG3' ' HE ' ' A' ' 63' ' ' ARG . 3.3 tt0 -142.16 141.6 32.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.606 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.19 128.95 22.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.116 179.203 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -89.1 107.46 19.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.159 0.504 . . . . 0.0 111.017 179.574 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.587 HG13 ' HD2' ' A' ' 51' ' ' PRO . 47.3 t -100.28 103.29 14.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.416 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -73.29 116.87 14.35 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.025 -179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.558 HG13 HD22 ' A' ' 75' ' ' LEU . 42.0 t -98.01 99.08 8.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 CA-C-O 121.52 0.676 . . . . 0.0 111.423 -179.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.497 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.0 ptm -143.88 86.93 1.88 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.462 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.98 2.28 90.67 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.447 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.65 -154.01 24.97 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 65.3 m-85 -107.43 127.62 53.76 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.85 0.325 . . . . 0.0 110.407 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.517 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 40.7 m -66.92 -64.46 2.16 Favored Pre-proline 0 CA--C 1.539 0.522 0 CA-C-O 119.529 -0.272 . . . . 0.0 111.389 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.587 ' HD2' HG13 ' A' ' 43' ' ' VAL . 65.1 Cg_endo -75.0 98.65 1.18 Allowed 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.329 1.353 . . . . 0.0 111.028 177.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.89 -44.67 59.92 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.33 -179.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.506 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.04 119.2 20.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.645 0.259 . . . . 0.0 110.913 179.788 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.1 pt -97.1 125.71 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 120.976 0.417 . . . . 0.0 111.102 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 88.4 t -98.27 126.77 51.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.535 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.412 HD22 ' HB1' ' A' ' 62' ' ' ALA . 2.9 mt -136.93 166.79 22.82 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.384 -179.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.2 mtmm -90.38 172.49 8.71 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.915 179.322 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.6 ttpp -103.38 148.76 25.49 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 37.3 t 65.45 20.12 11.68 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.779 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.44 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.9 p -123.73 136.01 26.85 Favored Pre-proline 0 CA--C 1.535 0.371 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.868 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -64.2 122.9 11.03 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.105 1.87 . . . . 0.0 111.561 178.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.412 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -124.46 137.85 54.4 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.007 0.432 . . . . 0.0 111.632 -179.539 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.423 ' HB2' HG22 ' A' ' 96' ' ' VAL . 5.6 ptt180 -119.65 125.55 49.01 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.714 0.769 . . . . 0.0 111.286 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.5 mm -98.35 115.58 38.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.61 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.538 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.79 109.21 20.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.558 -179.177 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -97.83 107.8 20.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.898 0.38 . . . . 0.0 111.386 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -93.47 107.28 19.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.533 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.404 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 1.2 tpt180 -77.07 101.3 6.01 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.183 0.516 . . . . 0.0 111.776 -179.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 21.0 tptt -96.38 -34.28 11.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.413 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.497 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.8 t70 -108.93 131.39 21.82 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.693 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -79.6 39.54 0.84 Allowed 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 123.163 2.575 . . . . 0.0 113.246 -179.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.41 ' HB3' HD12 ' A' ' 75' ' ' LEU . 30.0 t -68.23 136.05 91.37 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.095 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.29 -26.98 55.95 Favored 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 122.684 2.256 . . . . 0.0 112.584 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -81.65 -7.98 59.65 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.243 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.558 HD22 HG13 ' A' ' 45' ' ' VAL . 40.5 mt -115.02 8.28 15.72 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.472 -179.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.61 -38.18 90.14 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.899 0.38 . . . . 0.0 111.933 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 3.9 mp0 -124.86 160.35 29.0 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.092 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -135.95 131.8 50.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.167 0.508 . . . . 0.0 110.83 179.202 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.417 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 1.0 OUTLIER -135.79 130.53 49.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.279 0.561 . . . . 0.0 111.199 179.757 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -93.89 101.9 7.05 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.393 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.7 -15.94 48.92 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.616 2.211 . . . . 0.0 113.578 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 55.7 m-20 -100.53 -7.13 24.46 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -121.17 -23.45 5.77 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.26 26.94 41.82 Favored Glycine 0 CA--C 1.52 0.363 0 C-N-CA 120.892 -0.671 . . . . 0.0 112.234 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 50.1 t -107.62 119.58 57.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.772 0.32 . . . . 0.0 111.605 -178.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -124.14 120.59 32.77 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.667 179.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -139.6 173.57 11.4 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-O 121.004 0.431 . . . . 0.0 112.109 -179.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -114.92 142.18 46.94 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.972 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 31.0 mt -102.77 124.09 40.12 Favored Pre-proline 0 CA--C 1.531 0.25 0 CA-C-O 120.949 0.404 . . . . 0.0 111.53 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.414 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 61.1 Cg_endo -77.07 129.48 10.56 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.753 2.302 . . . . 0.0 112.725 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . 0.404 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 10.2 tpt -66.36 125.01 24.3 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.039 0.447 . . . . 0.0 111.803 -179.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.03 1.25 82.35 Favored Glycine 0 C--N 1.332 0.336 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.838 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.414 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 42.1 mt-10 -133.93 177.13 7.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.955 0.407 . . . . 0.0 110.802 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -119.01 134.73 55.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.135 0.493 . . . . 0.0 111.596 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.406 ' HB2' ' HD2' ' A' ' 90' ' ' PRO . 12.5 t80 -113.77 127.91 56.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.171 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.538 HG23 HG22 ' A' ' 65' ' ' VAL . 1.8 p -99.87 136.3 31.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.588 0.708 . . . . 0.0 112.504 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 65.7 t -113.84 112.17 39.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.203 178.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -93.53 118.89 31.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.584 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.88 158.05 41.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.255 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -120.48 97.08 48.94 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.663 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.44 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 65.8 Cg_endo -72.5 99.73 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.915 2.41 . . . . 0.0 112.336 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -95.07 3.73 54.5 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 111.868 0.321 . . . . 0.0 111.868 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -130.82 133.37 45.89 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.77 0.319 . . . . 0.0 110.812 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.75 128.08 35.62 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.98 0.419 . . . . 0.0 111.241 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.11 -157.9 30.1 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.709 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -101.42 125.64 48.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.21 0.528 . . . . 0.0 111.605 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.452 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 85.8 m-85 -118.46 172.81 7.22 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.868 179.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 93.4 p -155.03 158.74 39.59 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.1 p90 -147.23 133.43 19.42 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.542 -0.754 . . . . 0.0 111.088 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.309 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.994 -179.887 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.506 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 13.4 ttmt . . . . . 0 CA--C 1.53 0.204 0 CA-C-O 120.958 0.409 . . . . 0.0 110.852 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.452 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -131.25 138.48 49.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.062 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.1 mp -121.84 118.49 55.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.964 0.411 . . . . 0.0 110.775 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.5 t -102.06 121.84 53.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.301 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 . . . . . 0 C--O 1.252 1.235 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.441 -179.802 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.181 0 CA-C-O 121.107 0.479 . . . . 0.0 111.166 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.2 ttmt -91.93 125.48 36.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.995 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -70.94 150.89 45.25 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.189 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.557 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 3.8 pt20 -80.71 139.68 36.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.131 0.491 . . . . 0.0 111.422 -179.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 6.9 mp0 -95.66 115.33 27.28 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.776 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.75 -149.79 0.3 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.256 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -83.6 75.84 10.01 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 94.75 -5.97 69.92 Favored Glycine 0 CA--C 1.523 0.536 0 C-N-CA 120.88 -0.676 . . . . 0.0 113.928 179.016 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -142.32 160.54 40.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.912 0.356 . . . . 0.0 110.859 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -109.98 157.29 19.44 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.094 0.473 . . . . 0.0 111.45 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.557 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.0 OUTLIER -145.88 143.13 29.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.474 -179.539 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -142.7 129.05 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.064 0.459 . . . . 0.0 111.024 179.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.5 ttt180 -89.45 106.98 18.81 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.192 0.52 . . . . 0.0 111.028 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.584 HG13 ' HD2' ' A' ' 51' ' ' PRO . 47.0 t -99.82 103.0 14.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.474 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.403 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.5 OUTLIER -73.07 116.66 13.85 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.08 -179.906 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.57 HG13 HD22 ' A' ' 75' ' ' LEU . 48.5 t -97.52 98.91 7.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.466 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.446 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.6 ptm -143.06 85.83 1.89 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.453 179.111 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.04 3.37 87.75 Favored Glycine 0 CA--C 1.52 0.356 0 C-N-CA 120.941 -0.647 . . . . 0.0 111.509 -178.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.447 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 159.81 -143.32 8.99 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -116.2 127.89 55.16 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.687 0.244 . . . . 0.0 110.56 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.521 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 42.6 m -67.7 -64.67 1.85 Allowed Pre-proline 0 CA--C 1.54 0.58 0 CA-C-O 119.548 -0.263 . . . . 0.0 111.481 -179.649 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.584 ' HD2' HG13 ' A' ' 43' ' ' VAL . 66.7 Cg_endo -75.0 98.88 1.2 Allowed 'Trans proline' 0 C--N 1.356 0.941 0 C-N-CA 121.288 1.325 . . . . 0.0 111.044 177.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -51.45 -44.51 62.41 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.333 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.498 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.72 118.99 20.71 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.635 0.255 . . . . 0.0 110.944 179.77 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.0 pt -97.65 125.08 50.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.033 0.444 . . . . 0.0 111.087 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.7 t -95.98 126.38 48.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.497 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 10.2 mt -134.83 169.61 17.1 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.403 -179.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -97.66 166.98 11.24 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.56 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.3 ttpp -96.92 147.87 23.54 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -179.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.6 t 65.92 20.2 11.33 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.953 179.439 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.451 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 5.6 p -123.59 134.93 25.61 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.991 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -64.41 123.77 12.3 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.1 1.867 . . . . 0.0 111.596 178.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.95 137.23 53.68 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.908 0.385 . . . . 0.0 111.748 -179.527 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.485 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -117.5 125.9 51.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.705 0.764 . . . . 0.0 111.414 179.827 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.1 mm -98.08 114.78 36.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.726 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.528 HG22 HG23 ' A' ' 96' ' ' VAL . 4.1 t -90.53 107.73 18.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.35 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 61.9 m-85 -95.71 102.78 14.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.912 0.387 . . . . 0.0 111.479 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -89.66 105.84 18.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.178 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.77 101.98 8.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.237 0.541 . . . . 0.0 112.12 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.3 tppt? -96.49 -36.65 10.71 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.636 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.446 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.6 t70 -102.32 130.52 23.99 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.932 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -80.62 39.25 0.83 Allowed 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.089 2.526 . . . . 0.0 113.112 -179.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.428 ' HB2' HD12 ' A' ' 75' ' ' LEU . 2.5 m -70.07 137.77 87.2 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.299 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -63.01 -33.55 73.75 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 122.814 2.343 . . . . 0.0 112.982 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.9 p -75.54 -9.87 58.95 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.388 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.57 HD22 HG13 ' A' ' 45' ' ' VAL . 57.3 mt -112.93 14.62 19.77 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.469 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -68.33 -35.35 77.65 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-O 120.91 0.386 . . . . 0.0 111.461 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -131.62 165.9 22.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.932 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -139.13 133.68 40.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.945 0.402 . . . . 0.0 111.116 179.301 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -136.46 132.27 48.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.34 0.59 . . . . 0.0 111.403 179.378 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -94.35 102.08 7.85 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.136 -0.938 . . . . 0.0 109.466 178.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 109' ' ' PHE . 37.6 Cg_endo -65.92 -16.4 52.57 Favored 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.696 2.264 . . . . 0.0 113.696 -178.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -100.46 -7.38 24.31 Favored 'General case' 0 CA--C 1.535 0.394 0 N-CA-C 111.933 0.345 . . . . 0.0 111.933 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -120.44 -22.04 6.62 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.69 31.0 41.84 Favored Glycine 0 C--N 1.333 0.378 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.922 -179.325 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.3 t -114.46 117.06 54.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.633 0.254 . . . . 0.0 111.659 -178.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 -126.13 122.76 36.61 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.892 0.377 . . . . 0.0 110.617 179.244 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.77 171.21 14.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.655 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -106.32 143.54 34.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.73 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 38.7 mt -104.65 128.3 27.15 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.972 0.415 . . . . 0.0 111.359 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.417 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.5 Cg_endo -80.64 126.7 6.08 Favored 'Trans proline' 0 CA--C 1.532 0.421 0 C-N-CA 122.726 2.284 . . . . 0.0 112.507 179.284 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.4 tpt -65.35 124.93 23.55 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-O 120.974 0.416 . . . . 0.0 111.64 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.29 1.66 81.15 Favored Glycine 0 CA--C 1.52 0.387 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.959 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.417 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 42.6 mt-10 -134.04 177.37 7.79 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 120.885 0.374 . . . . 0.0 110.857 -179.567 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -117.55 134.24 55.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.179 0.514 . . . . 0.0 111.658 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -113.78 126.84 55.65 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.142 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.528 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -98.4 136.92 27.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 CA-C-O 121.55 0.69 . . . . 0.0 112.613 -179.053 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 62.0 t -115.52 111.4 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.132 178.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -92.66 118.42 31.03 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.52 -179.305 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.68 157.07 40.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.142 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.8 m -121.14 98.3 47.2 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.533 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.451 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.1 Cg_endo -72.79 100.62 1.21 Allowed 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.781 2.321 . . . . 0.0 112.376 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -95.34 6.7 48.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.791 0.329 . . . . 0.0 111.783 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.12 133.75 43.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.528 -0.305 . . . . 0.0 110.706 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.32 127.49 35.8 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.918 0.39 . . . . 0.0 111.29 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.08 -157.08 29.09 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.716 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -101.68 125.13 48.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.166 0.508 . . . . 0.0 111.684 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.456 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 82.6 m-85 -117.64 172.27 7.47 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.666 179.495 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 86.9 p -153.72 158.62 41.27 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -178.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . 0.404 ' HA ' ' HD2' ' A' ' 81' ' ' PRO . 37.5 p90 -148.71 134.46 18.88 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.87 178.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.264 0 CA-C-O 120.903 0.383 . . . . 0.0 111.564 -179.72 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 0.9 OUTLIER . . . . . 0 CA--C 1.53 0.182 0 CA-C-O 120.955 0.407 . . . . 0.0 111.033 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.456 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 3.0 ttm -130.58 137.68 49.78 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.09 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -120.92 118.32 55.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.024 0.44 . . . . 0.0 110.639 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 88.9 t -101.79 122.96 54.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.307 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 . . . . . 0 C--O 1.253 1.249 0 CA-C-O 118.163 -0.922 . . . . 0.0 111.462 -179.645 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.53 0.196 0 CA-C-O 121.163 0.506 . . . . 0.0 111.579 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.1 ttmt -101.38 129.62 47.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.619 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.09 152.84 39.83 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 111.187 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.516 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 22.8 pt20 -85.49 142.96 28.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.155 0.502 . . . . 0.0 111.791 -179.25 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -94.96 114.92 26.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.785 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -94.97 -150.72 0.31 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.024 0.44 . . . . 0.0 111.362 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -82.69 70.54 9.69 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.55 -9.83 59.05 Favored Glycine 0 CA--C 1.521 0.411 0 C-N-CA 120.771 -0.728 . . . . 0.0 113.713 178.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 32.8 p90 -137.93 165.64 26.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.953 0.376 . . . . 0.0 110.895 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.7 152.45 31.96 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.912 0.387 . . . . 0.0 111.103 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.516 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.9 tt0 -143.27 139.94 30.41 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.576 -179.325 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.0 128.42 22.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.975 179.185 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 11.0 ttt180 -89.28 108.85 19.85 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.297 0.57 . . . . 0.0 111.114 179.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.617 HG13 ' HD2' ' A' ' 51' ' ' PRO . 44.3 t -100.1 103.61 15.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.583 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -72.91 117.03 14.13 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.979 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.537 HG13 HD22 ' A' ' 75' ' ' LEU . 52.3 t -99.59 99.18 8.03 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.558 -178.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.486 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.7 ptm -145.86 86.68 1.73 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.182 179.112 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.22 -0.42 88.75 Favored Glycine 0 CA--C 1.52 0.368 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -178.243 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.441 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.8 -161.4 32.76 Favored Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 47.4 m-85 -101.99 126.39 48.91 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 117.046 0.423 . . . . 0.0 110.418 179.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.514 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 40.3 m -63.82 -63.49 3.87 Favored Pre-proline 0 CA--C 1.54 0.569 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.566 -179.547 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.617 ' HD2' HG13 ' A' ' 43' ' ' VAL . 68.2 Cg_endo -75.48 95.86 1.02 Allowed 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 121.301 1.334 . . . . 0.0 111.036 177.653 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -49.6 -43.54 46.47 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.32 -179.371 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.427 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.94 118.69 19.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.476 179.56 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.8 pt -97.45 126.4 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 121.086 0.469 . . . . 0.0 111.172 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 78.0 t -96.07 127.31 48.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.283 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 10.4 mt -135.0 171.51 14.33 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.558 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -97.13 173.26 7.34 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.739 179.453 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.0 ttpp -104.8 147.93 27.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.829 0.347 . . . . 0.0 111.926 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.4 t 65.49 20.7 11.74 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.751 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.438 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.95 136.46 27.49 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.169 -179.769 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -64.28 122.46 10.42 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.096 1.864 . . . . 0.0 111.47 178.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.91 138.04 54.26 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.99 0.424 . . . . 0.0 111.775 -179.45 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.418 HH11 ' HD2' ' A' ' 63' ' ' ARG . 6.7 ptt85 -120.67 126.55 50.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.789 0.804 . . . . 0.0 111.081 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.4 mm -100.07 114.16 37.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.759 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.507 HG22 HG23 ' A' ' 96' ' ' VAL . 3.0 t -89.93 107.49 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.467 -179.057 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -96.53 106.96 19.3 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.918 0.389 . . . . 0.0 111.318 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -91.54 105.79 18.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.633 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.45 96.2 5.32 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.204 0.526 . . . . 0.0 111.596 -179.338 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 17.4 tptt -90.95 -37.92 13.19 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.69 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.486 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.6 t70 -102.73 130.95 22.86 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.785 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -79.75 38.57 0.75 Allowed 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 123.151 2.567 . . . . 0.0 113.235 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.9 t -69.67 135.55 88.1 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.046 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.33 -28.21 63.4 Favored 'Trans proline' 0 C--N 1.349 0.556 0 C-N-CA 122.63 2.22 . . . . 0.0 112.42 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 22.7 m -78.75 -9.23 59.36 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.081 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.537 HD22 HG13 ' A' ' 45' ' ' VAL . 46.0 mt -116.05 17.27 15.9 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.456 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -71.7 -32.19 67.55 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -133.29 165.87 23.81 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.967 0.413 . . . . 0.0 111.393 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -140.57 130.14 26.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.98 179.296 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -130.27 132.7 64.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.481 0.657 . . . . 0.0 111.157 179.349 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -95.91 101.96 9.43 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.662 179.05 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.56 -15.19 46.93 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.59 2.193 . . . . 0.0 113.624 -178.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -100.71 -7.16 24.09 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -122.45 -22.06 5.58 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 112.017 0.376 . . . . 0.0 112.017 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.49 31.4 41.39 Favored Glycine 0 C--N 1.332 0.355 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.028 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.1 t -114.69 119.62 62.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.654 0.264 . . . . 0.0 111.657 -178.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 13.7 t-80 -126.37 119.8 28.23 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.841 0.353 . . . . 0.0 110.427 179.251 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.8 173.23 11.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.754 -179.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -110.07 151.44 27.2 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.046 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 28.0 mt -111.25 125.04 31.31 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-O 120.945 0.402 . . . . 0.0 111.386 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.427 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 64.5 Cg_endo -78.18 131.06 10.57 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 122.826 2.351 . . . . 0.0 112.708 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.6 tpt -66.81 124.43 22.92 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.799 -179.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 86.64 3.59 83.65 Favored Glycine 0 CA--C 1.52 0.345 0 CA-C-N 115.814 -0.63 . . . . 0.0 113.012 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.427 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 43.4 mt-10 -134.96 177.09 8.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.862 0.363 . . . . 0.0 110.905 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.56 134.8 54.82 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.231 0.539 . . . . 0.0 111.546 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -113.54 125.35 54.1 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.221 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.507 HG23 HG22 ' A' ' 65' ' ' VAL . 2.3 p -99.08 135.2 35.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.552 0.691 . . . . 0.0 112.489 -178.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 66.7 t -110.77 112.24 39.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.055 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -94.09 118.6 31.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.95 0.405 . . . . 0.0 111.475 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.99 166.5 28.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.146 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.2 m -129.66 97.51 24.32 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.486 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.438 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 70.2 Cg_endo -72.99 100.58 1.22 Allowed 'Trans proline' 0 CA--C 1.532 0.423 0 C-N-CA 122.844 2.363 . . . . 0.0 112.447 179.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -95.32 3.8 54.09 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.665 -179.586 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -132.16 134.68 45.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.735 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.32 124.24 34.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.974 0.416 . . . . 0.0 111.272 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 171.42 -165.34 38.32 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.884 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.25 115.47 27.67 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.19 0.519 . . . . 0.0 110.721 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.413 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 20.5 m-85 -111.4 173.03 6.54 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.971 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 85.5 p -152.58 165.1 36.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.307 0.575 . . . . 0.0 112.549 -178.573 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.2 p90 -152.07 136.86 17.09 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.441 178.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.256 0 CA-C-O 120.834 0.349 . . . . 0.0 111.825 -179.32 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.427 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.0 ttmm . . . . . 0 CA--C 1.529 0.164 0 CA-C-O 121.069 0.462 . . . . 0.0 111.828 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.413 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.6 ttm -134.74 131.22 37.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.773 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.7 mp -116.03 117.79 56.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.024 0.44 . . . . 0.0 110.67 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 74.8 t -101.8 122.53 54.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.288 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 . . . . . 0 C--O 1.252 1.213 0 CA-C-O 118.112 -0.947 . . . . 0.0 111.387 -179.583 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.53 0.203 0 CA-C-O 121.096 0.474 . . . . 0.0 111.402 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.8 mtpt -91.67 130.85 37.4 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.79 179.56 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.25 151.37 39.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.488 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.587 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.6 pt20 -79.04 139.4 38.16 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.142 0.496 . . . . 0.0 111.089 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -97.31 114.47 26.24 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.766 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -94.89 -154.5 0.43 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.256 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -82.11 74.23 9.1 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.14 -9.14 59.48 Favored Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.655 -0.783 . . . . 0.0 113.986 178.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 27.5 p90 -140.96 164.66 29.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 117.036 0.418 . . . . 0.0 111.066 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.67 153.65 29.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.974 0.416 . . . . 0.0 111.353 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.587 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.9 tt0 -143.36 143.08 31.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.46 -179.579 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.51 128.53 17.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.011 0.434 . . . . 0.0 111.08 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.63 106.12 18.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.213 0.53 . . . . 0.0 111.168 179.71 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.604 HG13 ' HD2' ' A' ' 51' ' ' PRO . 46.1 t -99.01 103.29 14.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.65 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.416 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.9 OUTLIER -73.09 118.2 15.75 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.789 -179.961 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.617 HG13 HD22 ' A' ' 75' ' ' LEU . 53.9 t -100.23 97.82 6.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.472 -178.852 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.473 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.9 ptm -143.27 85.02 1.84 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.372 179.273 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.08 0.24 88.9 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 -178.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.413 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.38 -169.29 36.15 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -92.17 125.73 36.96 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.924 0.362 . . . . 0.0 110.348 179.511 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.522 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 43.3 m -65.27 -63.97 3.02 Favored Pre-proline 0 CA--C 1.54 0.587 0 CA-C-O 119.557 -0.259 . . . . 0.0 111.293 -179.657 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.604 ' HD2' HG13 ' A' ' 43' ' ' VAL . 64.3 Cg_endo -75.03 96.55 1.03 Allowed 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 121.244 1.296 . . . . 0.0 111.205 177.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -51.36 -42.51 61.36 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.182 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.509 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -130.96 118.74 21.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.763 179.617 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.2 pt -99.16 126.93 52.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.951 0.405 . . . . 0.0 111.098 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 85.2 t -98.25 127.03 51.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.473 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.2 mt -135.95 165.52 25.47 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.318 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.6 mttt -90.12 176.26 6.84 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.728 179.164 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.2 ttpp -107.0 148.64 28.44 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -179.108 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.9 t 64.93 20.38 12.1 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.771 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.45 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.0 p -123.93 136.75 27.82 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.064 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.75 122.46 10.31 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.164 1.91 . . . . 0.0 111.639 178.607 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.45 139.8 53.65 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.969 0.414 . . . . 0.0 111.53 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.451 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.8 ptt180 -121.5 126.92 50.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.764 0.792 . . . . 0.0 111.344 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.7 mm -98.4 114.71 36.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.726 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.424 HG22 HG23 ' A' ' 96' ' ' VAL . 4.5 t -90.62 113.44 26.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.35 -179.391 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -100.31 114.87 28.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.077 0.465 . . . . 0.0 111.5 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -99.45 102.99 14.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.065 179.31 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.55 98.42 6.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.176 0.513 . . . . 0.0 111.998 -179.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.9 tptp -94.29 -35.69 12.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.536 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.473 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.8 t70 -106.17 130.79 22.43 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.931 179.579 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -81.2 39.39 0.85 Allowed 'Trans proline' 0 C--N 1.349 0.598 0 C-N-CA 123.059 2.506 . . . . 0.0 113.302 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -70.4 138.33 86.49 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.186 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -62.75 -32.73 78.08 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 122.924 2.416 . . . . 0.0 113.257 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.4 p -76.08 -8.06 56.13 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.779 0.323 . . . . 0.0 111.5 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.617 HD22 HG13 ' A' ' 45' ' ' VAL . 53.0 mt -114.88 13.67 17.15 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.356 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -68.49 -36.88 79.56 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-O 120.913 0.387 . . . . 0.0 111.643 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -132.23 161.58 33.08 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.066 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -136.96 131.22 46.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.038 0.446 . . . . 0.0 111.083 179.521 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -133.09 132.96 58.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 121.362 0.601 . . . . 0.0 111.31 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -94.76 102.14 8.39 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.509 178.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.25 -16.55 52.14 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.67 2.246 . . . . 0.0 113.668 -178.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -100.38 -7.04 24.83 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -120.52 -20.78 7.03 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 77.37 32.31 48.02 Favored Glycine 0 C--N 1.333 0.398 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.944 -179.198 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.1 t -116.72 117.98 57.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 -178.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 22.3 t-80 -123.79 122.03 36.98 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.802 0.334 . . . . 0.0 110.402 179.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.9 163.64 28.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.704 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.88 139.04 40.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.481 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 45.7 mt -101.34 128.45 29.22 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 120.856 0.36 . . . . 0.0 111.541 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.433 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 72.7 Cg_endo -82.91 128.65 5.19 Favored 'Trans proline' 0 CA--C 1.532 0.415 0 C-N-CA 122.71 2.273 . . . . 0.0 112.388 179.198 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -66.45 125.12 24.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.08 0.467 . . . . 0.0 111.725 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.88 11.77 80.9 Favored Glycine 0 CA--C 1.52 0.364 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.98 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.433 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.6 mm-40 -137.64 176.97 8.23 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.89 0.376 . . . . 0.0 111.083 -179.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -113.37 134.73 54.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.025 0.441 . . . . 0.0 111.733 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.1 t80 -123.98 127.86 48.54 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.935 178.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.424 HG23 HG22 ' A' ' 65' ' ' VAL . 2.3 p -107.0 137.18 39.16 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 CA-C-O 121.417 0.627 . . . . 0.0 112.628 -178.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 67.2 t -112.93 113.19 43.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.134 178.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -94.11 120.15 33.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.95 0.405 . . . . 0.0 111.516 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -136.0 157.9 38.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.82 97.79 48.14 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.682 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 67.1 Cg_endo -72.82 101.31 1.29 Allowed 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.814 2.343 . . . . 0.0 112.15 179.539 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -95.51 1.96 54.15 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -179.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -129.81 134.84 47.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.762 0.315 . . . . 0.0 110.74 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.93 124.25 34.56 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.007 0.432 . . . . 0.0 111.273 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 166.82 -157.3 29.71 Favored Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.63 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -101.64 125.72 48.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.187 0.518 . . . . 0.0 111.487 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.446 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 84.9 m-85 -117.34 171.44 7.97 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.013 179.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.3 p -150.22 158.31 44.02 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 -178.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -150.4 131.46 14.37 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.957 178.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.075 -179.858 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.509 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.7 ttpt . . . . . 0 CA--C 1.53 0.181 0 CA-C-O 121.204 0.526 . . . . 0.0 111.904 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.446 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.6 ttm -132.4 139.15 47.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.686 179.439 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -122.39 119.72 59.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.116 0.484 . . . . 0.0 110.854 179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 90.9 t -102.97 123.08 56.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.272 -179.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 . . . . . 0 C--O 1.252 1.201 0 CA-C-O 118.169 -0.92 . . . . 0.0 111.42 -179.774 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 18.4 mm-40 . . . . . 0 C--O 1.233 0.195 0 CA-C-O 121.128 0.489 . . . . 0.0 111.328 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -89.97 125.59 35.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.709 179.823 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -70.93 152.07 44.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.238 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.53 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 17.2 pt20 -81.27 137.99 35.77 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.214 0.531 . . . . 0.0 111.448 -179.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.2 mp0 -94.53 113.2 25.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.865 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.63 -151.32 0.28 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.191 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -83.81 77.51 9.87 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 112.03 0.382 . . . . 0.0 112.03 -179.223 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.15 -6.49 68.98 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 120.812 -0.709 . . . . 0.0 114.047 178.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.7 p90 -143.54 161.34 38.72 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.045 0.423 . . . . 0.0 111.072 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.19 156.63 21.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.058 0.456 . . . . 0.0 111.349 179.744 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.53 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.4 tt0 -145.75 144.45 30.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.434 -179.566 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -146.96 129.04 7.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.732 179.135 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.417 HH11 ' HD2' ' A' ' 42' ' ' ARG . 0.1 OUTLIER -90.9 110.18 21.41 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.252 0.548 . . . . 0.0 110.938 179.305 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.491 HG13 ' HD2' ' A' ' 51' ' ' PRO . 60.6 t -100.42 108.21 22.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.757 -179.668 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -72.68 124.97 26.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.648 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.569 HG13 HD22 ' A' ' 75' ' ' LEU . 53.7 t -104.64 96.44 4.6 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 CA-C-O 121.475 0.655 . . . . 0.0 111.262 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.484 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.0 ptp -141.97 87.74 2.06 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.373 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.11 -15.88 36.27 Favored Glycine 0 CA--C 1.522 0.482 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.127 -178.035 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 178.79 -138.72 3.71 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.483 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -121.09 129.59 53.38 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.862 0.331 . . . . 0.0 110.59 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.489 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 20.2 m -65.84 -60.93 6.34 Favored Pre-proline 0 CA--C 1.538 0.519 0 C-N-CA 121.027 -0.269 . . . . 0.0 110.911 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.491 ' HD2' HG13 ' A' ' 43' ' ' VAL . 74.4 Cg_endo -76.79 95.77 1.07 Allowed 'Trans proline' 0 C--N 1.358 1.045 0 C-N-CA 121.333 1.355 . . . . 0.0 110.968 177.575 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.77 -42.73 58.11 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.331 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.482 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.73 118.52 20.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.782 179.52 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.8 pt -97.32 124.45 50.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.085 0.469 . . . . 0.0 110.888 179.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.5 t -97.25 126.73 49.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.509 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.3 mt -134.21 170.12 16.17 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.357 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.28 173.73 7.57 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.684 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.6 ttpt -104.29 146.7 28.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.779 0.323 . . . . 0.0 111.844 -179.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.4 t 64.97 20.86 12.21 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.832 179.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.45 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 7.9 p -123.44 135.61 26.26 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.935 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.6 Cg_endo -64.34 122.49 10.45 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 122.076 1.85 . . . . 0.0 111.668 178.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.25 138.86 54.35 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.877 0.37 . . . . 0.0 111.577 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.413 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -121.57 126.79 49.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.769 0.795 . . . . 0.0 111.439 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.0 mm -99.0 115.82 40.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.836 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.483 HG22 HG23 ' A' ' 96' ' ' VAL . 3.2 t -91.71 110.25 22.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.216 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -95.59 114.77 26.56 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.076 0.465 . . . . 0.0 111.467 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -99.93 104.48 16.11 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.398 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.4 ' HA ' ' HB ' ' A' ' 45' ' ' VAL . 0.1 OUTLIER -77.6 106.54 9.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.274 0.559 . . . . 0.0 112.144 -179.155 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -101.23 -33.83 9.91 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.415 179.293 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.484 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.0 t70 -110.6 133.87 21.04 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.862 179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -81.67 40.29 0.96 Allowed 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 123.086 2.524 . . . . 0.0 112.975 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.41 137.29 93.56 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.308 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -63.03 -35.02 68.24 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.938 2.426 . . . . 0.0 112.941 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.35 -6.68 54.16 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.595 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.569 HD22 HG13 ' A' ' 45' ' ' VAL . 58.2 mt -114.32 7.75 16.5 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.426 -179.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -66.18 -38.46 88.09 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.089 0.471 . . . . 0.0 111.451 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 16.5 mt-30 -124.74 158.72 32.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.576 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -133.23 127.79 54.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.379 0.609 . . . . 0.0 110.937 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.68 129.63 58.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.294 0.568 . . . . 0.0 111.105 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -92.9 102.02 6.29 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.402 178.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.26 -16.35 51.42 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.626 2.217 . . . . 0.0 113.77 -178.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 46.5 m-20 -100.71 -6.83 24.48 Favored 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.0 m-85 -120.97 -22.54 6.14 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 81.7 25.45 53.37 Favored Glycine 0 C--N 1.332 0.348 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.07 -179.442 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.1 t -106.48 117.95 53.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.844 0.354 . . . . 0.0 111.663 -178.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -121.16 118.9 30.84 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.598 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.79 167.17 21.36 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.172 0.51 . . . . 0.0 111.945 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -109.38 138.66 45.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.621 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 51.8 mt -101.13 128.46 29.39 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.89 0.376 . . . . 0.0 111.39 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.435 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 74.4 Cg_endo -82.0 128.15 5.68 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 122.768 2.312 . . . . 0.0 112.428 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.4 tpt -66.3 124.55 23.0 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.046 0.451 . . . . 0.0 111.623 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.53 9.3 81.74 Favored Glycine 0 CA--C 1.521 0.418 0 CA-C-N 115.857 -0.611 . . . . 0.0 113.075 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.435 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 50.1 mm-40 -136.9 176.75 8.43 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.903 0.382 . . . . 0.0 111.342 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -112.9 136.32 52.68 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.036 0.446 . . . . 0.0 111.744 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -124.23 126.25 45.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.039 178.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.483 HG23 HG22 ' A' ' 65' ' ' VAL . 1.8 p -102.99 138.19 28.2 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-O 121.58 0.705 . . . . 0.0 112.511 -178.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 64.5 t -115.51 112.34 39.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.188 178.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -93.8 118.99 32.18 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.934 0.397 . . . . 0.0 111.576 -179.307 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.11 156.33 39.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.073 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.4 m -120.03 98.32 49.21 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.461 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.9 Cg_endo -71.88 99.14 0.94 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.713 2.275 . . . . 0.0 112.561 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -97.7 22.79 8.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.09 0.471 . . . . 0.0 111.515 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.15 131.78 14.89 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.464 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.29 127.29 35.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.983 0.421 . . . . 0.0 111.407 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 164.42 -157.33 29.64 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.759 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.18 126.59 49.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.168 0.509 . . . . 0.0 111.544 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.446 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 86.4 m-85 -119.32 171.99 7.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.891 179.641 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 87.8 p -153.73 159.85 42.11 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -150.53 131.14 13.95 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.093 178.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.325 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.295 -179.774 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 4.5 ttmm . . . . . 0 CA--C 1.531 0.244 0 CA-C-O 121.053 0.454 . . . . 0.0 111.229 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.446 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -132.83 140.42 47.95 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.994 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.95 119.77 56.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.061 0.458 . . . . 0.0 110.877 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.9 t -101.89 124.68 55.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.079 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.251 1.158 0 CA-C-O 118.045 -0.979 . . . . 0.0 111.898 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.232 0.168 0 CA-C-O 121.187 0.517 . . . . 0.0 111.168 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -88.27 126.58 35.24 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.631 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.03 150.56 45.47 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.141 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.551 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 19.8 pt20 -79.44 137.5 37.27 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.297 0.57 . . . . 0.0 111.283 -179.323 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.5 mp0 -94.52 114.02 25.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.963 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -93.03 -156.08 0.46 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.072 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -83.56 76.91 9.92 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-O 120.851 0.358 . . . . 0.0 111.948 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.25 -12.71 57.19 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 120.806 -0.712 . . . . 0.0 114.151 178.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -140.69 167.47 22.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 117.16 0.48 . . . . 0.0 111.353 -179.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.93 155.0 28.78 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.863 0.363 . . . . 0.0 111.119 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.551 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 5.8 tt0 -145.35 142.23 29.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.562 -179.271 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.39 129.84 17.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.312 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -91.67 110.22 21.54 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.239 0.542 . . . . 0.0 111.058 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.62 HG13 ' HD2' ' A' ' 51' ' ' PRO . 46.4 t -100.48 104.01 15.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.589 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.427 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.9 OUTLIER -73.16 116.98 14.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.845 -179.91 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.556 HG13 HD22 ' A' ' 75' ' ' LEU . 41.1 t -97.41 98.46 7.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.365 -178.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.466 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.8 ptp -139.6 81.93 1.85 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.383 179.383 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 88.01 -8.98 76.39 Favored Glycine 0 CA--C 1.521 0.429 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 -178.342 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 172.85 -153.36 18.35 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -105.42 125.65 51.23 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.825 0.313 . . . . 0.0 110.54 179.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.516 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 45.2 m -65.13 -64.48 2.61 Favored Pre-proline 0 CA--C 1.538 0.518 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.407 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.62 ' HD2' HG13 ' A' ' 43' ' ' VAL . 60.1 Cg_endo -74.11 97.91 1.05 Allowed 'Trans proline' 0 C--N 1.358 1.039 0 C-N-CA 121.266 1.311 . . . . 0.0 111.001 177.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.63 -44.04 57.18 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.163 -179.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.453 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.6 118.99 19.88 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.605 0.241 . . . . 0.0 110.959 179.57 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.0 pt -97.07 126.96 49.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 121.054 0.454 . . . . 0.0 110.747 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 84.6 t -98.09 126.93 50.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.505 -179.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.8 mt -135.63 166.52 23.05 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.567 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.7 tttt -93.1 170.24 9.8 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.709 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.5 ttpp -100.45 148.25 24.96 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.403 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.2 t 65.84 20.14 11.38 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.917 179.393 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.434 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.2 p -123.8 135.88 26.74 Favored Pre-proline 0 CA--C 1.537 0.445 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.977 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -64.4 122.77 10.8 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.198 1.932 . . . . 0.0 111.575 178.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.67 138.51 53.9 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.956 0.408 . . . . 0.0 111.728 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.433 ' CG ' ' HG3' ' A' ' 40' ' ' GLU . 0.0 OUTLIER -121.06 129.4 53.33 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.767 0.794 . . . . 0.0 111.517 179.739 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.4 mm -100.76 115.69 42.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.817 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.435 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.77 111.69 24.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 120.766 0.317 . . . . 0.0 111.326 -179.3 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -97.7 113.22 24.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.053 0.454 . . . . 0.0 111.354 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -98.96 105.19 17.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.215 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -79.09 104.8 9.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.29 0.566 . . . . 0.0 112.22 -178.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.2 tppt? -99.35 -36.09 9.72 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.086 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.466 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 6.4 t70 -103.79 129.86 24.53 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.852 179.562 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -80.49 39.47 0.85 Allowed 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.998 2.465 . . . . 0.0 112.939 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.493 ' HB2' HD12 ' A' ' 75' ' ' LEU . 2.1 m -69.95 135.67 87.47 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.382 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -64.05 -29.9 66.06 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.901 2.401 . . . . 0.0 112.811 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.71 -9.38 58.63 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.599 179.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.556 HD22 HG13 ' A' ' 45' ' ' VAL . 29.1 mt -113.17 12.52 19.07 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 120.784 0.326 . . . . 0.0 111.321 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -67.44 -35.18 78.72 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.785 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -129.48 160.68 32.42 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.805 0.336 . . . . 0.0 111.21 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.67 129.01 33.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.181 0.515 . . . . 0.0 110.85 179.292 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.5 p -132.04 132.4 61.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.276 0.56 . . . . 0.0 111.257 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 15.7 m-85 -94.93 101.92 8.11 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.725 179.032 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -67.09 -15.23 46.05 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.722 2.281 . . . . 0.0 113.562 -178.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 -99.62 -7.34 25.88 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -122.67 -22.13 5.46 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.092 0.405 . . . . 0.0 112.092 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 81.45 26.43 51.33 Favored Glycine 0 CA--C 1.52 0.374 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.044 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.6 t -107.69 117.37 53.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.746 0.307 . . . . 0.0 111.709 -178.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -119.12 117.94 30.05 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.519 179.214 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.67 167.54 19.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.156 0.503 . . . . 0.0 112.222 -179.157 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -111.69 141.2 45.6 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.319 179.562 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 53.1 mt -103.56 127.75 28.89 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.005 0.431 . . . . 0.0 111.566 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.443 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 72.5 Cg_endo -82.94 129.85 5.53 Favored 'Trans proline' 0 CA--C 1.532 0.411 0 C-N-CA 122.846 2.364 . . . . 0.0 112.481 179.271 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.5 tpt -67.58 125.24 25.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.008 0.432 . . . . 0.0 111.71 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 83.29 11.61 80.3 Favored Glycine 0 CA--C 1.52 0.405 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.877 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.443 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 53.7 mm-40 -137.46 176.86 8.33 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.007 0.432 . . . . 0.0 111.157 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -113.37 132.77 55.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.78 -179.716 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -121.75 125.11 45.8 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.967 178.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.435 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -105.16 137.06 36.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.549 0.69 . . . . 0.0 112.472 -178.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -112.79 112.11 39.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.153 178.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -93.67 119.22 32.4 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.953 0.406 . . . . 0.0 111.416 -179.469 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.91 158.24 38.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.339 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -121.67 96.81 47.11 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.469 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.434 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.9 Cg_endo -71.59 99.44 0.94 Allowed 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.823 2.349 . . . . 0.0 112.294 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -94.07 4.47 53.85 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.995 0.368 . . . . 0.0 111.995 -179.3 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -133.88 135.63 43.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.756 0.313 . . . . 0.0 110.933 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.59 124.9 34.5 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.837 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.35 -167.56 40.51 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.796 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -97.9 114.72 26.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.105 0.479 . . . . 0.0 110.631 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.402 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 20.7 m-85 -111.4 172.42 6.9 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.177 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 87.1 p -158.17 164.88 36.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.155 0.502 . . . . 0.0 112.196 -178.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -148.26 137.39 21.92 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.762 179.017 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.219 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.277 -179.719 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.453 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.8 ttmt . . . . . 0 CA--C 1.53 0.194 0 CA-C-O 120.974 0.416 . . . . 0.0 111.359 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.402 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -133.68 133.62 42.1 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.896 179.685 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.13 117.36 53.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.071 0.463 . . . . 0.0 110.753 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 94.7 t -101.65 121.94 53.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.155 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.277 -0.868 . . . . 0.0 111.538 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.233 0.235 0 CA-C-O 120.959 0.409 . . . . 0.0 111.502 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.6 ttmt -90.37 126.71 35.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.501 179.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.36 151.11 46.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.028 0.442 . . . . 0.0 111.464 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.578 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.7 pt20 -78.28 143.52 36.95 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.379 -179.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -98.68 115.33 28.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.855 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.63 -151.62 0.36 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.484 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -81.65 75.52 8.6 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -179.171 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.4 -7.47 68.82 Favored Glycine 0 CA--C 1.523 0.573 0 C-N-CA 120.72 -0.753 . . . . 0.0 114.047 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -141.35 161.48 37.78 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.959 0.38 . . . . 0.0 110.981 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.06 155.71 22.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.102 0.477 . . . . 0.0 111.154 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.578 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.9 tt0 -144.53 143.89 31.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.616 -179.382 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.17 128.71 16.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.081 0.467 . . . . 0.0 110.963 178.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.69 109.03 20.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.33 0.586 . . . . 0.0 110.962 179.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.628 HG13 ' HD2' ' A' ' 51' ' ' PRO . 45.1 t -99.75 103.95 15.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.599 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.415 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 1.1 tp10 -73.17 117.62 15.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.857 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.592 HG13 HD22 ' A' ' 75' ' ' LEU . 54.3 t -99.52 98.55 7.18 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.526 -178.792 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.491 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.3 ptm -145.25 86.97 1.78 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.4 179.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 83.66 -2.51 87.25 Favored Glycine 0 CA--C 1.521 0.407 0 C-N-CA 120.824 -0.703 . . . . 0.0 111.468 -178.429 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.421 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 162.9 -171.17 38.63 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 30.3 m-85 -91.78 124.94 36.29 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.816 0.308 . . . . 0.0 110.354 179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.524 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 45.0 m -63.99 -64.35 2.95 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 119.638 -0.22 . . . . 0.0 111.407 -179.42 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.628 ' HD2' HG13 ' A' ' 43' ' ' VAL . 62.1 Cg_endo -74.98 96.88 1.04 Allowed 'Trans proline' 0 C--N 1.357 0.977 0 C-N-CA 121.299 1.333 . . . . 0.0 111.075 177.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.84 -43.19 59.12 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.261 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.36 118.52 20.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.622 -0.263 . . . . 0.0 110.708 179.667 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.7 pt -98.3 125.43 51.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.031 0.443 . . . . 0.0 111.15 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 75.9 t -98.62 126.71 51.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.425 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.423 HD22 ' HB1' ' A' ' 62' ' ' ALA . 5.4 mt -132.74 171.5 13.79 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.472 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.95 170.02 9.72 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.549 179.403 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.6 ttpp -102.43 147.06 27.19 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.86 0.362 . . . . 0.0 111.909 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.4 t 65.27 20.46 11.89 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.527 -0.76 . . . . 0.0 111.701 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.425 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 7.4 p -123.66 136.41 27.26 Favored Pre-proline 0 CA--C 1.534 0.356 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.003 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -64.33 122.7 10.72 Favored 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 121.984 1.79 . . . . 0.0 111.412 178.442 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.423 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -125.29 138.49 54.08 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.017 0.437 . . . . 0.0 111.582 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.438 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.9 ptt180 -120.55 127.74 52.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.727 0.775 . . . . 0.0 111.418 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.0 mm -99.4 114.68 38.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.628 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.495 HG22 HG23 ' A' ' 96' ' ' VAL . 3.3 t -92.01 110.53 22.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.697 0.284 . . . . 0.0 111.553 -179.284 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -97.1 120.05 36.72 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.013 0.435 . . . . 0.0 111.233 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -103.93 105.18 15.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.433 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . 0.401 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 2.0 tpt180 -77.77 97.81 5.32 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.161 0.505 . . . . 0.0 111.605 -179.427 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.8 tptp -93.71 -32.93 13.83 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.412 179.428 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.491 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.9 t70 -111.28 131.66 22.13 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.741 179.661 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -80.24 39.33 0.83 Allowed 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 123.075 2.516 . . . . 0.0 112.978 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.13 135.76 91.57 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.159 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.26 -33.28 60.34 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.764 2.309 . . . . 0.0 112.875 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -77.37 -1.97 32.71 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.55 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.592 HD22 HG13 ' A' ' 45' ' ' VAL . 28.8 mt -119.01 9.13 11.76 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.457 -179.749 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.9 -41.04 78.76 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -122.09 149.37 43.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.028 0.442 . . . . 0.0 111.591 -179.495 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -131.51 129.18 61.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.54 179.238 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 p -132.7 131.35 59.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.439 0.637 . . . . 0.0 111.44 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -92.86 101.93 6.1 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.448 178.649 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.41 -15.52 45.64 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.631 2.221 . . . . 0.0 113.657 -178.465 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -100.12 -9.61 22.38 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.5 m-85 -119.46 -21.41 7.43 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 80.95 28.33 46.34 Favored Glycine 0 CA--C 1.52 0.346 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.074 -179.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.4 t -109.44 117.58 54.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.786 0.327 . . . . 0.0 111.731 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -120.59 119.74 33.76 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.428 179.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.72 167.92 20.72 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 121.182 0.515 . . . . 0.0 112.344 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -113.3 143.27 44.72 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.316 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 30.7 mt -103.53 124.35 38.34 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.451 . . . . 0.0 111.599 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.421 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 68.6 Cg_endo -79.09 130.38 9.33 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.771 2.314 . . . . 0.0 112.662 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . 0.401 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 11.2 tpt -67.47 124.77 24.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.138 0.494 . . . . 0.0 111.748 -179.597 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 83.53 9.68 82.98 Favored Glycine 0 CA--C 1.521 0.411 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.975 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.421 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.4 mm-40 -136.21 176.69 8.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.865 0.364 . . . . 0.0 111.284 -179.537 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -114.07 134.72 54.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.013 0.435 . . . . 0.0 111.574 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . 0.4 ' HB2' ' HD2' ' A' ' 90' ' ' PRO . 8.7 t80 -122.52 124.09 42.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.036 178.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.495 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -104.37 136.99 35.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 CA-C-O 121.563 0.697 . . . . 0.0 112.533 -178.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 54.2 t -112.98 112.11 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.16 179.02 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -93.52 119.57 32.75 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.517 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.6 158.28 39.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.207 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 m -121.51 96.79 47.44 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.525 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.425 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.8 Cg_endo -72.93 101.18 1.29 Allowed 'Trans proline' 0 CA--C 1.532 0.399 0 C-N-CA 122.855 2.37 . . . . 0.0 112.349 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -95.51 5.53 51.31 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 111.898 0.333 . . . . 0.0 111.898 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -132.4 133.97 44.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.763 0.316 . . . . 0.0 110.751 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -90.61 128.26 36.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.983 0.42 . . . . 0.0 111.301 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 162.64 -155.88 27.36 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.694 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -102.19 126.91 49.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.21 0.529 . . . . 0.0 111.468 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.435 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 89.9 m-85 -120.69 173.28 7.3 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.885 179.733 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 14.9 m -154.9 156.91 36.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.197 0.523 . . . . 0.0 112.399 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -146.26 142.21 28.12 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.726 179.246 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.331 -0.215 0 CA-C-O 120.961 0.41 . . . . 0.0 111.68 -179.487 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.1 ttpt . . . . . 0 CA--C 1.531 0.222 0 CA-C-O 121.122 0.487 . . . . 0.0 112.054 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.435 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.4 ttm -135.73 139.76 43.86 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.805 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.32 120.64 59.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.027 0.441 . . . . 0.0 110.667 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 90.2 t -102.88 123.31 56.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.272 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 . . . . . 0 C--O 1.252 1.191 0 CA-C-O 118.184 -0.913 . . . . 0.0 111.416 -179.554 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.529 0.139 0 CA-C-O 121.026 0.441 . . . . 0.0 111.297 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.22 126.12 35.72 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.753 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.4 148.97 46.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.257 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.585 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 18.6 pt20 -76.49 140.21 41.12 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.269 0.557 . . . . 0.0 111.217 -179.461 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -97.45 115.94 28.72 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.92 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -95.33 -151.91 0.35 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.522 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -82.46 72.88 9.52 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -179.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.12 -8.74 61.06 Favored Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.678 -0.773 . . . . 0.0 113.902 178.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -139.1 165.29 27.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 117.03 0.415 . . . . 0.0 110.932 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.2 153.07 31.52 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.994 0.426 . . . . 0.0 111.058 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.585 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 6.7 tt0 -144.42 140.49 29.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.412 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.01 130.24 24.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.131 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -90.6 110.06 21.21 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.178 0.513 . . . . 0.0 110.999 179.463 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.511 HG13 ' HD2' ' A' ' 51' ' ' PRO . 53.1 t -102.1 109.84 27.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.738 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.98 123.16 23.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.727 179.793 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.543 HG13 HD22 ' A' ' 75' ' ' LEU . 67.2 t -104.25 95.78 4.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-O 121.479 0.656 . . . . 0.0 111.376 -179.372 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.467 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 6.2 ptm -146.58 87.89 1.74 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.281 179.27 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.52 -0.84 89.22 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.432 -178.321 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.45 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.57 -144.36 9.88 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 111.5 -0.64 . . . . 0.0 111.5 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -119.1 128.61 54.46 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.774 0.287 . . . . 0.0 110.636 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.504 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 22.0 m -65.61 -61.66 5.52 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-O 119.572 -0.252 . . . . 0.0 110.958 179.775 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.511 ' HD2' HG13 ' A' ' 43' ' ' VAL . 68.9 Cg_endo -75.91 95.75 1.03 Allowed 'Trans proline' 0 C--N 1.357 0.998 0 C-N-CA 121.325 1.35 . . . . 0.0 111.038 177.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.6 -42.13 55.56 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.162 -179.206 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.441 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -133.8 118.99 18.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.83 179.477 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.472 HG13 ' HG3' ' A' ' 120' ' ' MET . 6.0 pt -96.67 126.62 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-O 121.062 0.458 . . . . 0.0 110.969 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 94.8 t -97.72 125.94 50.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.443 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.461 HD22 ' HB1' ' A' ' 62' ' ' ALA . 3.5 mt -135.67 165.03 26.52 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.307 -179.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.6 mmtt -89.01 176.41 7.01 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 120.769 0.318 . . . . 0.0 111.046 179.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.8 ttpp -106.93 148.26 28.84 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.834 0.349 . . . . 0.0 111.929 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.4 t 64.73 20.85 12.26 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.644 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.413 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.8 p -123.88 136.17 27.13 Favored Pre-proline 0 CA--C 1.537 0.457 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.998 -179.776 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -63.57 120.87 8.43 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.111 1.874 . . . . 0.0 111.688 178.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.461 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -123.82 138.29 54.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.845 0.355 . . . . 0.0 111.598 -179.425 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.414 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.4 OUTLIER -123.19 128.42 50.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.784 0.802 . . . . 0.0 111.537 179.867 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.2 mm -99.69 116.31 42.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.883 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.431 HG22 HG23 ' A' ' 96' ' ' VAL . 3.6 t -91.63 112.56 25.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.812 0.339 . . . . 0.0 111.246 -179.501 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -98.21 116.84 31.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.116 0.484 . . . . 0.0 111.528 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -100.78 103.31 14.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.387 179.468 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.54 102.85 7.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.247 0.546 . . . . 0.0 112.157 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.5 tptp -97.44 -38.37 9.63 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.588 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.467 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.0 t70 -103.0 130.72 23.13 Favored Pre-proline 0 CA--C 1.535 0.375 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.95 179.68 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -81.31 39.43 0.86 Allowed 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 123.099 2.532 . . . . 0.0 113.209 -179.394 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 29.1 t -70.5 135.16 86.35 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.263 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.15 -26.85 64.91 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.673 2.249 . . . . 0.0 112.519 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.3 m -80.24 -10.93 59.77 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.131 179.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.543 HD22 HG13 ' A' ' 45' ' ' VAL . 24.0 mt -113.9 13.7 18.39 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.213 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -70.21 -34.15 72.57 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.575 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . 0.435 ' HG3' HD22 ' A' ' 88' ' ' ASN . 0.6 OUTLIER -127.21 161.88 27.5 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.969 0.414 . . . . 0.0 111.511 -179.494 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -138.76 127.97 30.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.338 178.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 1.5 p -131.72 130.08 61.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.282 0.563 . . . . 0.0 111.545 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -92.65 101.84 5.8 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.279 178.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.94 -13.32 38.04 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 122.566 2.177 . . . . 0.0 113.64 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -100.49 -11.72 19.92 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 111.929 0.344 . . . . 0.0 111.929 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -120.77 -17.82 7.85 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -178.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.78 29.24 52.68 Favored Glycine 0 C--N 1.333 0.371 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.541 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 54.2 t -109.06 113.59 44.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.81 0.338 . . . . 0.0 111.748 -179.113 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -117.93 117.44 29.27 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.401 179.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.57 167.59 20.19 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-O 121.342 0.591 . . . . 0.0 112.44 -179.044 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . 0.435 HD22 ' HG3' ' A' ' 77' ' ' GLN . 28.7 t-20 -110.1 139.8 44.86 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.257 179.512 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 46.3 mt -102.89 126.61 32.08 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.943 0.402 . . . . 0.0 111.481 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.443 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 70.1 Cg_endo -81.03 128.79 6.63 Favored 'Trans proline' 0 CA--C 1.532 0.393 0 C-N-CA 122.794 2.33 . . . . 0.0 112.414 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -65.92 124.83 23.56 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 121.042 0.449 . . . . 0.0 111.837 -179.497 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.94 9.6 84.17 Favored Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.923 -0.581 . . . . 0.0 113.055 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.443 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 47.5 mt-10 -135.14 176.79 8.34 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-O 120.94 0.4 . . . . 0.0 111.08 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -113.12 134.63 54.46 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.981 0.42 . . . . 0.0 111.799 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.9 t80 -123.22 126.59 47.23 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.899 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.431 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -106.15 138.87 29.47 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 CA-C-O 121.527 0.679 . . . . 0.0 112.64 -178.721 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 63' ' ' ARG . 53.8 t -114.22 112.3 39.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.164 178.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -94.76 119.1 32.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.018 0.437 . . . . 0.0 111.626 -179.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.03 157.57 40.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.273 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.8 m -120.73 96.67 48.75 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.326 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.413 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 71.6 Cg_endo -73.31 102.68 1.5 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.81 2.34 . . . . 0.0 112.434 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -97.71 10.6 39.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.902 0.382 . . . . 0.0 111.9 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.26 130.25 30.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.851 0.358 . . . . 0.0 110.874 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.07 128.22 35.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.372 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 165.79 -155.15 26.26 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.847 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -107.96 125.63 51.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.122 0.487 . . . . 0.0 111.012 -179.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -124.29 166.92 15.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.305 -179.74 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.19 157.9 43.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.182 0.515 . . . . 0.0 112.29 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -146.36 135.57 22.75 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.623 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.278 0 CA-C-O 120.799 0.333 . . . . 0.0 111.406 -179.627 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.441 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.0 ttpt . . . . . 0 CA--C 1.53 0.199 0 CA-C-O 121.223 0.535 . . . . 0.0 111.783 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.472 ' HG3' HG13 ' A' ' 54' ' ' ILE . 10.1 ttp -134.36 130.73 37.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.657 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -117.61 118.78 59.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.038 0.447 . . . . 0.0 111.097 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 57.8 t -101.29 119.83 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.886 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.005 -0.998 . . . . 0.0 112.063 -179.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.174 0 CA-C-O 121.066 0.46 . . . . 0.0 111.454 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 8.4 ttmt -91.43 128.45 37.26 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.788 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.8 152.22 41.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.163 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 -82.75 141.51 32.32 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.206 0.527 . . . . 0.0 111.555 -179.403 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -95.34 115.69 27.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.805 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.71 -150.87 0.33 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.245 -179.831 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -83.11 78.0 9.66 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.85 -6.34 73.31 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.94 -0.648 . . . . 0.0 114.111 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -143.35 161.88 37.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 117.039 0.419 . . . . 0.0 111.094 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.11 155.56 21.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.982 0.42 . . . . 0.0 111.081 179.603 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -146.01 140.31 26.76 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.7 -179.17 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.06 130.12 21.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.791 179.108 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . 0.411 HH11 ' HD2' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -91.5 111.05 22.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.192 0.52 . . . . 0.0 111.113 179.535 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.646 HG13 ' HD2' ' A' ' 51' ' ' PRO . 44.9 t -100.54 103.8 15.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.681 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -72.27 115.31 11.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.602 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.53 HG13 HD22 ' A' ' 75' ' ' LEU . 53.8 t -97.68 98.74 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.489 0.662 . . . . 0.0 111.432 -178.686 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.555 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.6 ptm -145.76 89.51 1.91 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.502 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.3 -0.89 83.26 Favored Glycine 0 CA--C 1.521 0.418 0 C-N-CA 120.869 -0.681 . . . . 0.0 111.59 -178.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . 0.453 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 161.83 -173.29 38.16 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -90.14 124.66 35.01 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.896 0.348 . . . . 0.0 110.17 179.479 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.515 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 31.7 m -63.36 -63.9 3.54 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 119.648 -0.215 . . . . 0.0 111.317 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.646 ' HD2' HG13 ' A' ' 43' ' ' VAL . 63.5 Cg_endo -75.63 96.97 1.07 Allowed 'Trans proline' 0 C--N 1.358 1.038 0 C-N-CA 121.267 1.312 . . . . 0.0 111.068 177.506 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.61 -43.31 56.77 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 116.057 -0.519 . . . . 0.0 112.38 -179.222 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.465 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.39 118.58 19.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.655 179.684 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.436 HG13 ' HG3' ' A' ' 120' ' ' MET . 5.6 pt -97.67 125.72 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-O 121.085 0.469 . . . . 0.0 111.037 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 83.9 t -97.76 126.67 50.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.36 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . 0.442 HD22 ' HB1' ' A' ' 62' ' ' ALA . 3.3 mt -135.76 171.42 14.49 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.494 -179.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 14.5 mttt -93.63 174.58 7.12 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.978 179.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . 0.521 ' HD3' ' HB2' ' A' ' 104' ' ' ALA . 2.8 ttpt -106.46 147.88 28.81 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.852 0.358 . . . . 0.0 111.891 -179.296 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.0 t 65.08 19.72 11.88 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.641 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.421 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.5 135.93 26.64 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -63.45 122.35 10.47 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.118 1.878 . . . . 0.0 111.464 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . 0.442 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -123.85 139.41 54.0 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.931 0.396 . . . . 0.0 111.728 -179.528 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.473 ' HB2' HG22 ' A' ' 96' ' ' VAL . 3.3 ptt180 -122.3 128.29 50.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.769 0.795 . . . . 0.0 111.389 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.6 mm -101.58 113.62 38.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.759 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.513 HG22 HG23 ' A' ' 96' ' ' VAL . 3.0 t -88.82 106.91 17.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.507 -179.192 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -94.03 113.24 25.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.016 0.436 . . . . 0.0 111.258 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -99.52 104.35 16.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.522 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.7 94.97 5.17 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.231 0.539 . . . . 0.0 111.498 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -88.6 -35.05 17.09 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.829 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.555 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 0.2 OUTLIER -111.55 136.82 21.03 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.083 179.906 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -81.01 39.47 0.87 Allowed 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 123.105 2.537 . . . . 0.0 113.288 -179.371 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.9 m -67.46 133.68 92.94 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.175 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -63.03 -32.23 75.89 Favored 'Trans proline' 0 C--N 1.348 0.551 0 C-N-CA 122.693 2.262 . . . . 0.0 112.776 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.58 -2.48 32.73 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.547 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.53 HD22 HG13 ' A' ' 45' ' ' VAL . 49.9 mt -121.21 13.77 11.23 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.291 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -70.63 -41.59 72.01 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.764 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -124.72 138.48 54.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.892 0.377 . . . . 0.0 111.586 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -118.78 130.35 73.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.593 179.287 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . 0.608 ' O ' ' HD3' ' A' ' 81' ' ' PRO . 0.2 OUTLIER -134.83 131.79 53.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.386 0.612 . . . . 0.0 111.316 179.978 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -92.84 101.59 5.53 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.42 178.653 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . 0.608 ' HD3' ' O ' ' A' ' 79' ' ' VAL . 25.5 Cg_exo -61.82 -17.66 56.42 Favored 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 123.024 2.482 . . . . 0.0 113.748 -178.716 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -101.2 -10.22 20.58 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -119.55 -21.38 7.39 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 85.66 1.49 87.43 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 121.248 -0.501 . . . . 0.0 112.226 -179.449 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.9 t -80.72 115.24 22.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.893 0.378 . . . . 0.0 111.41 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . 0.42 ' HB3' ' HB ' ' A' ' 79' ' ' VAL . 20.5 p-80 -131.29 121.63 25.06 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.602 179.831 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -141.15 161.91 36.75 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -99.53 127.11 45.6 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.115 179.208 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 57.5 mt -84.4 130.22 54.71 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-O 121.059 0.457 . . . . 0.0 111.844 -178.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -79.04 123.54 5.72 Favored 'Trans proline' 0 CA--C 1.533 0.461 0 C-N-CA 122.704 2.27 . . . . 0.0 112.236 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.1 tpt -64.16 124.96 23.01 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.7 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.86 6.25 85.43 Favored Glycine 0 CA--C 1.521 0.426 0 CA-C-N 115.886 -0.597 . . . . 0.0 113.081 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -132.96 176.87 8.11 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.984 0.421 . . . . 0.0 111.081 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.6 mp0 -115.97 132.17 56.73 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.478 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -120.51 117.95 28.98 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.333 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.513 HG23 HG22 ' A' ' 65' ' ' VAL . 3.4 p -96.0 130.34 44.83 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 CA-C-O 121.764 0.792 . . . . 0.0 112.062 -179.429 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 63' ' ' ARG . 52.9 t -106.17 115.24 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.426 179.167 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -95.81 119.17 33.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.871 0.367 . . . . 0.0 111.631 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -134.09 157.15 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.107 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.4 m -120.0 97.06 49.5 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.517 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.421 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.9 Cg_endo -73.22 98.06 0.99 Allowed 'Trans proline' 0 CA--C 1.532 0.402 0 C-N-CA 122.78 2.32 . . . . 0.0 112.531 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -96.51 23.44 6.83 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.014 0.435 . . . . 0.0 111.481 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.5 131.91 14.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.521 179.66 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . 0.521 ' HB2' ' HD3' ' A' ' 58' ' ' LYS . . . -89.71 128.46 36.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.986 0.422 . . . . 0.0 111.495 -179.855 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.57 -158.64 31.15 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.632 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -101.82 123.46 45.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.048 0.452 . . . . 0.0 111.352 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.434 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 88.2 m-85 -115.9 166.19 12.24 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.019 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 95.5 p -141.57 155.73 45.75 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -178.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -151.57 129.56 11.78 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.389 178.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.188 0 CA-C-O 121.123 0.487 . . . . 0.0 111.904 -179.346 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.465 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 6.8 ttpt . . . . . 0 CA--C 1.53 0.207 0 CA-C-O 121.265 0.555 . . . . 0.0 111.785 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.436 ' HG3' HG13 ' A' ' 54' ' ' ILE . 17.2 ttp -133.02 133.65 43.37 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.701 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -118.82 119.66 61.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.111 0.481 . . . . 0.0 111.08 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 92.5 t -102.61 121.86 54.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.946 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.25 1.106 0 CA-C-O 118.147 -0.93 . . . . 0.0 111.937 -179.428 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.232 0.157 0 CA-C-O 121.321 0.582 . . . . 0.0 111.527 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.4 mtpt -89.19 130.17 35.65 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.736 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.41 151.85 41.01 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.388 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLN . . . . . 0.575 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.6 pt20 -80.33 141.06 35.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.036 0.445 . . . . 0.0 111.4 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 56.4 mt-30 -96.83 115.03 26.73 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.73 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.76 -149.99 0.31 Allowed 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.454 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -81.58 72.68 8.63 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -179.132 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.03 -6.11 66.44 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 120.806 -0.711 . . . . 0.0 113.875 178.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -140.92 160.67 39.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.894 0.347 . . . . 0.0 110.788 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.15 156.08 21.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.136 0.493 . . . . 0.0 111.379 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.575 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.5 tt0 -144.31 143.2 30.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.513 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -143.73 128.42 14.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.065 0.459 . . . . 0.0 111.053 179.089 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.75 106.5 18.5 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.152 0.501 . . . . 0.0 111.078 179.689 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.598 HG13 ' HD2' ' A' ' 51' ' ' PRO . 49.0 t -98.09 101.99 12.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.557 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -71.59 117.81 13.63 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.796 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' VAL . . . . . 0.66 HG13 HD22 ' A' ' 75' ' ' LEU . 31.8 t -99.49 98.22 6.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.394 -178.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' MET . . . . . 0.492 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 10.8 ptp -140.38 82.3 1.85 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.333 179.499 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 88.0 -12.14 64.97 Favored Glycine 0 CA--C 1.517 0.194 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -178.017 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 173.27 -171.43 44.46 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -88.41 123.02 32.55 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.973 0.386 . . . . 0.0 110.265 179.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' THR . . . . . 0.515 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 35.5 m -61.99 -63.45 4.23 Favored Pre-proline 0 CA--C 1.54 0.558 0 CA-C-O 119.559 -0.257 . . . . 0.0 111.359 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' PRO . . . . . 0.598 ' HD2' HG13 ' A' ' 43' ' ' VAL . 73.6 Cg_endo -75.76 96.74 1.06 Allowed 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 121.296 1.331 . . . . 0.0 111.013 177.501 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -50.57 -43.13 56.26 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -179.252 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.439 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -130.41 118.8 21.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.659 0.266 . . . . 0.0 110.866 179.775 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.0 pt -98.8 126.31 52.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.079 0.466 . . . . 0.0 110.984 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 91.9 t -97.13 126.46 49.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.925 0.393 . . . . 0.0 111.532 -179.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 8.3 mt -133.98 168.33 18.99 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.38 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.6 tttt -95.09 168.28 10.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.508 179.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 4.6 ttpp -99.18 147.89 24.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 111.964 -179.423 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.4 t 65.78 19.83 11.39 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.874 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 6.3 p -123.71 135.63 26.41 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.895 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -64.52 123.36 11.64 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.104 1.869 . . . . 0.0 111.53 178.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.61 138.82 54.29 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.893 0.378 . . . . 0.0 111.703 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' ARG . . . . . 0.41 ' HB2' HG22 ' A' ' 96' ' ' VAL . 5.8 ptt180 -120.4 126.63 50.94 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-O 121.706 0.765 . . . . 0.0 111.274 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.2 mm -99.42 115.48 40.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.801 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' VAL . . . . . 0.484 HG22 HG23 ' A' ' 96' ' ' VAL . 4.0 t -91.17 109.55 21.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.825 0.345 . . . . 0.0 111.287 -179.342 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -96.78 112.23 24.07 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.075 0.464 . . . . 0.0 111.431 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -96.74 101.63 13.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.281 179.517 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.77 97.91 4.64 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 121.281 0.563 . . . . 0.0 111.918 -179.12 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -95.98 -29.56 14.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.828 179.715 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ASP . . . . . 0.492 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.8 t70 -111.75 131.79 22.23 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.922 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -80.63 39.45 0.86 Allowed 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.085 2.523 . . . . 0.0 113.121 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.528 ' HB2' HD12 ' A' ' 75' ' ' LEU . 2.7 m -69.75 139.1 88.33 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.289 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -62.61 -33.85 76.41 Favored 'Trans proline' 0 C--N 1.348 0.553 0 C-N-CA 122.883 2.389 . . . . 0.0 112.863 -179.6 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 10.7 p -78.59 -2.57 39.56 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.45 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.66 HD22 HG13 ' A' ' 45' ' ' VAL . 37.9 mt -121.14 9.94 10.59 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.32 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.93 -37.29 78.8 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.059 0.457 . . . . 0.0 111.118 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -129.34 160.06 34.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.515 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -133.49 128.5 54.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.339 0.59 . . . . 0.0 111.018 179.44 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -132.39 128.83 58.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 121.312 0.577 . . . . 0.0 111.071 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -92.54 102.08 6.1 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.47 -0.787 . . . . 0.0 109.537 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.79 -16.24 49.58 Favored 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.581 2.187 . . . . 0.0 113.598 -178.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -100.68 -6.37 25.22 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 111.984 0.364 . . . . 0.0 111.984 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -121.38 -22.98 5.8 Favored 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.25 25.33 51.95 Favored Glycine 0 CA--C 1.52 0.355 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.032 -179.473 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.0 t -106.6 117.7 52.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.813 0.339 . . . . 0.0 111.684 -178.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -121.1 117.52 27.38 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.52 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.82 165.83 24.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.138 0.494 . . . . 0.0 112.025 -179.292 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -107.38 140.56 40.11 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.474 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 58.9 mt -102.07 129.56 26.11 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.986 0.422 . . . . 0.0 111.363 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' PRO . . . . . 0.438 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 74.3 Cg_endo -82.7 126.2 4.53 Favored 'Trans proline' 0 CA--C 1.533 0.426 0 C-N-CA 122.723 2.282 . . . . 0.0 112.341 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.7 tpt -64.72 124.23 21.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.023 0.439 . . . . 0.0 111.789 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.65 5.23 84.6 Favored Glycine 0 CA--C 1.521 0.424 0 CA-C-N 115.87 -0.605 . . . . 0.0 113.195 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.438 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 44.8 mt-10 -133.29 176.78 8.21 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.959 0.409 . . . . 0.0 111.181 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.74 132.63 55.13 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.834 -179.747 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -118.98 125.43 49.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.982 178.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' VAL . . . . . 0.484 HG23 HG22 ' A' ' 65' ' ' VAL . 1.8 p -101.68 136.31 34.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.672 0.749 . . . . 0.0 112.462 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 61.5 t -113.26 112.31 39.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.069 178.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -93.27 118.72 31.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.511 -179.498 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -135.23 156.98 39.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.215 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.36 97.4 48.97 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.573 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' PRO . . . . . 0.449 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 66.7 Cg_endo -72.19 100.06 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.794 2.329 . . . . 0.0 112.36 179.544 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -96.11 10.36 37.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.854 0.359 . . . . 0.0 111.9 -179.521 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.03 132.45 32.22 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.51 -0.314 . . . . 0.0 110.779 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.38 127.3 35.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.018 0.437 . . . . 0.0 111.314 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.78 -157.24 29.41 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.624 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -101.73 126.81 48.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.127 0.489 . . . . 0.0 111.668 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' PHE . . . . . 0.443 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 86.0 m-85 -119.64 173.76 6.82 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.67 -0.696 . . . . 0.0 109.815 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 41.9 p -154.7 160.86 41.64 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -178.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.8 p90 -152.79 133.99 14.23 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.89 178.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.39 0 CA-C-O 121.05 0.452 . . . . 0.0 111.879 179.758 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' LYS . . . . . 0.439 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.4 ttpt . . . . . 0 CA--C 1.531 0.233 0 CA-C-O 121.071 0.463 . . . . 0.0 111.568 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' MET . . . . . 0.443 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -134.22 141.01 46.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.043 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.7 mp -124.66 120.22 58.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.984 0.421 . . . . 0.0 110.706 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.0 t -103.25 124.34 57.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.238 -179.675 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 . . . . . 0 C--O 1.252 1.216 0 CA-C-O 118.106 -0.949 . . . . 0.0 111.46 -179.601 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.667 0 N-CA-C 112.452 -0.259 . . . . 0.0 112.452 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -82.38 75.08 9.31 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 121.109 0.48 . . . . 0.0 111.471 -179.799 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -89.92 142.24 27.89 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.366 179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -86.57 170.1 41.9 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.887 -0.673 . . . . 0.0 113.041 179.871 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 3.3 mt-30 -118.6 128.74 54.83 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.105 0.479 . . . . 0.0 111.325 -179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -89.34 129.36 35.89 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.525 179.637 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.46 153.58 40.31 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.359 -0.382 . . . . 0.0 111.187 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.572 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 4.5 pt20 -80.74 135.53 36.0 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.185 0.517 . . . . 0.0 111.279 -179.56 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 19.7 mt-30 -94.05 112.39 24.21 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.601 179.938 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -93.42 -154.28 0.4 Allowed 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.389 -179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -81.95 75.81 8.87 Favored 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 112.339 0.496 . . . . 0.0 112.339 -179.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.12 -5.36 63.23 Favored Glycine 0 CA--C 1.522 0.518 0 C-N-CA 120.772 -0.728 . . . . 0.0 114.121 178.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 26.9 p90 -144.35 163.76 32.79 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 117.063 0.431 . . . . 0.0 110.958 -179.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.13 154.81 28.26 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-O 120.991 0.424 . . . . 0.0 111.452 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.572 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.6 tt0 -145.26 141.59 28.74 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.515 -179.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.63 128.59 14.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.863 179.024 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.3 109.97 21.26 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 121.207 0.527 . . . . 0.0 111.117 179.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.647 HG13 ' HD2' ' A' ' 51' ' ' PRO . 44.9 t -98.22 103.37 14.61 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.488 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.424 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.8 OUTLIER -70.93 114.23 8.78 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.792 -179.969 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.59 HG13 HD22 ' A' ' 75' ' ' LEU . 49.3 t -96.61 97.73 6.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.706 -0.679 . . . . 0.0 111.461 -178.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.496 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.2 ptm -144.25 86.98 1.86 Allowed 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.52 179.23 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.47 -0.53 89.06 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.833 -0.698 . . . . 0.0 111.434 -178.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.427 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 161.9 -170.33 37.55 Favored Glycine 0 N--CA 1.448 -0.522 0 N-CA-C 111.158 -0.777 . . . . 0.0 111.158 -179.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -93.07 124.24 36.9 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.793 0.297 . . . . 0.0 110.213 179.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.509 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 37.1 m -63.42 -63.65 3.8 Favored Pre-proline 0 CA--C 1.539 0.527 0 CA-C-O 119.642 -0.218 . . . . 0.0 111.431 -179.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.647 ' HD2' HG13 ' A' ' 43' ' ' VAL . 60.7 Cg_endo -74.99 96.58 1.02 Allowed 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 121.312 1.341 . . . . 0.0 111.055 177.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.65 -43.44 57.17 Favored 'General case' 0 N--CA 1.47 0.543 0 CA-C-N 116.062 -0.517 . . . . 0.0 112.069 -179.351 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.39 118.68 19.68 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.523 -0.308 . . . . 0.0 110.654 179.443 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.3 pt -97.8 126.78 50.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.913 0.387 . . . . 0.0 110.929 179.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 95.9 t -100.09 127.24 53.23 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.953 0.406 . . . . 0.0 111.557 -179.612 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.438 HD22 ' HB1' ' A' ' 62' ' ' ALA . 2.3 mt -136.87 166.92 22.48 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.279 -179.633 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -89.62 176.89 6.69 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 120.745 0.307 . . . . 0.0 110.897 179.259 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.9 ttpp -107.55 149.53 27.9 Favored 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 111.972 0.36 . . . . 0.0 111.972 -179.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.7 t 65.55 19.51 11.51 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-N 115.676 -0.693 . . . . 0.0 111.725 179.692 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.44 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.5 p -123.82 136.26 27.19 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.11 -179.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.5 Cg_endo -64.26 122.61 10.62 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.247 1.965 . . . . 0.0 111.641 178.528 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.438 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -124.66 138.34 54.31 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.926 0.394 . . . . 0.0 111.723 -179.337 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.502 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -120.49 127.42 52.18 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.643 0.735 . . . . 0.0 111.626 179.825 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.4 mm -100.2 114.23 38.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.519 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.623 179.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.511 HG22 HG23 ' A' ' 96' ' ' VAL . 2.8 t -90.64 107.41 18.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.302 0 CA-C-O 120.739 0.304 . . . . 0.0 111.492 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.9 m-85 -94.77 102.62 14.51 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 120.918 0.39 . . . . 0.0 111.279 179.941 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -91.17 106.94 18.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.435 179.78 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -77.46 105.28 8.49 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.287 0.565 . . . . 0.0 111.903 -179.463 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.3 tptp -97.76 -34.28 10.96 Favored 'General case' 0 CA--C 1.534 0.364 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.256 179.332 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.496 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.7 t70 -110.27 134.38 20.8 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.848 179.566 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 89.2 Cg_endo -81.42 40.1 0.94 Allowed 'Trans proline' 0 C--N 1.349 0.572 0 C-N-CA 123.111 2.54 . . . . 0.0 112.995 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.61 135.37 90.47 Favored Pre-proline 0 C--N 1.328 -0.327 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.387 -179.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.27 -32.88 61.41 Favored 'Trans proline' 0 C--N 1.35 0.648 0 C-N-CA 122.772 2.315 . . . . 0.0 112.802 -179.914 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.1 p -77.09 -2.15 32.73 Favored 'General case' 0 N--CA 1.464 0.26 0 CA-C-N 116.297 -0.411 . . . . 0.0 111.364 179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.59 HD22 HG13 ' A' ' 45' ' ' VAL . 33.4 mt -119.29 13.56 12.8 Favored 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.242 -179.993 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -71.14 -36.38 72.06 Favored 'General case' 0 CA--C 1.535 0.383 0 CA-C-N 116.289 -0.414 . . . . 0.0 112.078 -179.583 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.7 OUTLIER -128.84 152.67 48.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.896 0.379 . . . . 0.0 111.503 -179.447 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -132.79 128.48 57.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 121.103 0.478 . . . . 0.0 110.727 179.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -130.4 130.61 65.35 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 CA-C-O 121.258 0.551 . . . . 0.0 111.346 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -93.17 102.12 6.72 Favored Pre-proline 0 C--N 1.326 -0.416 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.715 179.08 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 41.4 Cg_endo -67.55 -14.36 41.96 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 122.621 2.214 . . . . 0.0 113.593 -178.617 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 28.7 m-20 -100.65 -7.57 23.77 Favored 'General case' 0 CA--C 1.535 0.391 0 N-CA-C 111.809 0.299 . . . . 0.0 111.809 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 64.5 m-85 -122.63 -22.77 5.3 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 112.058 0.392 . . . . 0.0 112.058 -179.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.25 25.75 50.44 Favored Glycine 0 C--N 1.331 0.302 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.025 -179.366 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.7 t -106.5 117.79 52.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.887 0.375 . . . . 0.0 111.71 -178.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -121.67 118.52 29.37 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.388 179.323 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.38 162.53 34.19 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-O 121.084 0.468 . . . . 0.0 112.257 -179.133 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 14.2 p-10 -104.19 148.28 26.48 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.679 179.604 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 29.5 mt -107.18 130.8 22.33 Favored Pre-proline 0 C--N 1.328 -0.352 0 CA-C-O 120.938 0.399 . . . . 0.0 111.716 -179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.418 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.3 Cg_endo -82.34 127.99 5.37 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.743 2.296 . . . . 0.0 112.434 179.176 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.5 tpt -66.62 125.4 25.65 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-O 121.025 0.441 . . . . 0.0 111.693 -179.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.81 1.37 80.21 Favored Glycine 0 CA--C 1.52 0.344 0 CA-C-N 115.937 -0.574 . . . . 0.0 112.842 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.418 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 41.7 mt-10 -134.24 177.17 7.96 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.895 0.379 . . . . 0.0 110.787 -179.484 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.2 pt-20 -118.14 133.33 56.0 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 121.197 0.522 . . . . 0.0 111.639 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.1 t80 -112.16 123.28 49.92 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.127 179.46 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.511 HG23 HG22 ' A' ' 65' ' ' VAL . 1.5 p -97.78 135.24 33.0 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.609 0.719 . . . . 0.0 112.304 -179.207 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 62.6 t -112.49 109.69 29.48 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.027 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.5 mt-10 -92.08 117.17 29.58 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.228 -179.54 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -131.58 165.8 30.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.086 -0.506 . . . . 0.0 111.237 179.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.3 m -128.1 96.22 32.04 Favored Pre-proline 0 C--N 1.328 -0.343 0 CA-C-N 116.398 -0.365 . . . . 0.0 111.426 -179.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.44 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.4 Cg_endo -72.2 98.88 0.95 Allowed 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.803 2.336 . . . . 0.0 112.454 179.631 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 5.7 mt-10 -95.27 7.78 45.12 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.832 0.349 . . . . 0.0 111.838 -179.588 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.39 130.97 31.37 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.753 0.311 . . . . 0.0 110.931 179.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -85.3 124.8 32.34 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.199 -179.876 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 171.71 -166.53 39.51 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.863 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.76 114.89 27.0 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.036 0.446 . . . . 0.0 110.732 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 20.2 m-85 -110.49 174.84 5.67 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.233 -179.779 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 91.6 p -153.45 164.15 38.69 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.419 0.525 . . . . 0.0 112.419 -178.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 36.8 p90 -150.85 137.67 19.0 Favored 'General case' 0 CA--C 1.533 0.318 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.481 178.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.22 178.65 8.55 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-O 120.982 0.42 . . . . 0.0 111.708 -179.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 41.6 t -115.55 127.84 55.55 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.933 179.309 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 87.71 -115.31 4.32 Favored Glycine 0 CA--C 1.52 0.361 0 C-N-CA 120.925 -0.655 . . . . 0.0 112.837 -179.962 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 3.8 mtm -137.97 -90.85 0.22 Allowed 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.868 0.366 . . . . 0.0 111.058 179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 2.2 p-10 -88.85 58.82 4.78 Favored 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 121.017 0.437 . . . . 0.0 111.342 179.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -149.38 165.52 31.78 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.109 -179.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 77.7 mmm 66.17 -177.51 0.19 Allowed 'General case' 0 N--CA 1.471 0.607 0 CA-C-N 115.885 -0.598 . . . . 0.0 112.097 179.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -159.31 104.93 1.67 Allowed 'General case' 0 N--CA 1.466 0.365 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.446 179.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -145.93 122.31 1.64 Allowed Glycine 0 CA--C 1.52 0.346 0 C-N-CA 121.093 -0.575 . . . . 0.0 112.108 179.587 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.8 ttmm -121.36 150.82 40.89 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 121.235 0.54 . . . . 0.0 111.891 -179.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . . . . . . . . . 2.2 ttm -134.65 136.26 42.7 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.797 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -120.99 118.2 55.46 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.006 0.432 . . . . 0.0 110.804 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 71.9 t -102.82 121.33 53.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.177 -179.714 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.254 1.306 0 CA-C-O 118.335 -0.84 . . . . 0.0 111.396 -179.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.613 0 CA-C-O 121.112 0.285 . . . . 0.0 112.465 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -83.19 71.0 10.2 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.183 0.516 . . . . 0.0 111.562 -179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 1.9 mtm -82.15 64.29 6.76 Favored 'General case' 0 CA--C 1.532 0.284 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.359 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 94.38 -168.83 28.5 Favored Glycine 0 CA--C 1.52 0.372 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.797 179.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.27 127.93 20.25 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.018 0.437 . . . . 0.0 111.289 179.74 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.4 ttmt -90.49 126.67 35.99 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.787 179.786 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.26 151.88 43.83 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.356 -0.384 . . . . 0.0 111.15 179.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.586 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 7.7 pt20 -82.24 140.18 33.81 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.178 0.513 . . . . 0.0 111.545 -179.183 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 6.8 mp0 -95.46 113.25 24.89 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.488 179.422 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 6.1 mmtt -93.2 -148.68 0.25 Allowed 'General case' 0 CA--C 1.536 0.425 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.474 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -81.64 72.81 8.69 Favored 'General case' 0 CA--C 1.535 0.373 0 N-CA-C 112.416 0.525 . . . . 0.0 112.416 -179.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.19 -5.71 68.37 Favored Glycine 0 CA--C 1.522 0.48 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.845 178.978 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.1 p90 -141.27 160.46 40.07 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.864 0.332 . . . . 0.0 110.751 -179.862 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -108.98 156.23 19.96 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.197 0.522 . . . . 0.0 111.351 179.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.586 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 4.2 tt0 -145.9 142.44 28.75 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.445 -179.43 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.5 129.61 16.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.194 179.429 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.2 ttt180 -90.23 106.56 18.57 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.012 179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.58 HG13 ' HD2' ' A' ' 51' ' ' PRO . 46.1 t -97.81 103.01 14.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.466 0 CA-C-N 115.877 -0.602 . . . . 0.0 110.604 -179.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -72.47 117.48 14.18 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-N 115.733 -0.667 . . . . 0.0 110.974 179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.545 HG13 HD22 ' A' ' 75' ' ' LEU . 42.3 t -100.4 99.04 7.69 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 CA-C-O 121.535 0.683 . . . . 0.0 111.484 -178.798 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.448 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.5 ptp -141.27 85.63 1.98 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.608 -0.724 . . . . 0.0 110.222 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 87.56 -14.65 57.6 Favored Glycine 0 CA--C 1.519 0.313 0 N-CA-C 111.104 -0.798 . . . . 0.0 111.104 -177.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 176.89 -152.5 12.37 Favored Glycine 0 N--CA 1.449 -0.452 0 N-CA-C 111.357 -0.697 . . . . 0.0 111.357 179.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 61.0 m-85 -104.91 127.98 52.96 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 116.82 0.31 . . . . 0.0 110.56 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.513 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 43.0 m -69.15 -63.72 1.97 Allowed Pre-proline 0 CA--C 1.539 0.535 0 CA-C-O 119.571 -0.252 . . . . 0.0 111.368 -179.664 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.58 ' HD2' HG13 ' A' ' 43' ' ' VAL . 61.9 Cg_endo -74.39 98.09 1.08 Allowed 'Trans proline' 0 C--N 1.357 1.012 0 C-N-CA 121.295 1.33 . . . . 0.0 111.121 177.817 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.25 -43.86 61.62 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-N 115.991 -0.549 . . . . 0.0 112.326 -179.181 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -133.89 118.53 18.05 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-O 120.559 0.218 . . . . 0.0 110.776 179.643 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.493 HG13 ' HG3' ' A' ' 120' ' ' MET . 8.6 pt -97.33 127.55 49.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 121.1 0.476 . . . . 0.0 111.004 179.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.5 t -96.04 126.43 48.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.472 -179.635 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 24.3 mt -133.44 166.4 22.62 Favored 'General case' 0 CA--C 1.533 0.289 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.425 -179.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 18.6 mttt -96.74 166.75 11.5 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.563 179.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.3 ttpp -97.52 147.74 23.95 Favored 'General case' 0 C--N 1.328 -0.339 0 N-CA-C 111.912 0.338 . . . . 0.0 111.912 -179.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.9 t 66.73 18.8 10.74 Favored 'General case' 0 N--CA 1.471 0.582 0 CA-C-N 115.548 -0.751 . . . . 0.0 111.861 179.518 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.45 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 6.0 p -123.56 135.16 25.82 Favored Pre-proline 0 CA--C 1.535 0.368 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.914 179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -64.58 122.73 10.71 Favored 'Trans proline' 0 C--N 1.346 0.422 0 C-N-CA 122.051 1.834 . . . . 0.0 111.611 178.687 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.24 138.94 54.34 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 120.834 0.35 . . . . 0.0 111.561 -179.572 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.486 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.5 ptt180 -121.15 126.76 50.54 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.638 0.732 . . . . 0.0 111.394 179.932 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.8 mm -98.64 114.36 36.04 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.822 -179.829 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.501 HG22 HG23 ' A' ' 96' ' ' VAL . 3.2 t -91.47 109.84 21.72 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 CA-C-N 116.437 -0.347 . . . . 0.0 111.375 -179.372 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 70.5 m-85 -96.15 117.37 30.6 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.132 0.491 . . . . 0.0 111.332 179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.6 t0 -99.94 100.31 11.19 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.412 179.545 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.37 93.0 3.41 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 121.225 0.536 . . . . 0.0 111.455 -179.389 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -88.74 -37.43 15.49 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.752 179.781 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.448 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.2 t70 -101.75 129.44 26.61 Favored Pre-proline 0 C--N 1.328 -0.354 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.763 179.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 93.4 Cg_endo -79.23 38.63 0.74 Allowed 'Trans proline' 0 C--N 1.349 0.563 0 C-N-CA 123.088 2.525 . . . . 0.0 113.014 -179.641 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.3 m -70.52 135.35 86.27 Favored Pre-proline 0 C--N 1.329 -0.295 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.015 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -63.47 -31.57 71.68 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.789 2.326 . . . . 0.0 112.888 -179.663 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -75.85 -9.45 58.61 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.503 -0.317 . . . . 0.0 111.46 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.545 HD22 HG13 ' A' ' 45' ' ' VAL . 36.7 mt -113.22 13.99 19.3 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.571 -0.286 . . . . 0.0 111.466 -179.913 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.4 t70 -70.13 -38.44 75.55 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-O 120.782 0.325 . . . . 0.0 111.709 -179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 1.7 mt-30 -122.64 158.82 29.17 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.113 0.482 . . . . 0.0 111.435 -179.586 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.86 130.12 35.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.444 178.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.436 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 2.0 p -133.27 132.3 58.22 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 CA-C-O 121.314 0.578 . . . . 0.0 111.43 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.0 m-85 -94.08 101.89 7.21 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-N 115.385 -0.825 . . . . 0.0 109.516 178.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_endo -67.32 -14.03 41.44 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 122.589 2.193 . . . . 0.0 113.566 -178.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 33.1 m-20 -100.23 -9.14 22.75 Favored 'General case' 0 CA--C 1.536 0.423 0 N-CA-C 111.789 0.292 . . . . 0.0 111.789 179.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 50.3 m-85 -122.87 -20.07 5.96 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.353 0.501 . . . . 0.0 112.353 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.76 30.65 42.91 Favored Glycine 0 C--N 1.333 0.389 0 C-N-CA 120.962 -0.637 . . . . 0.0 112.353 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 49.8 t -110.8 116.44 52.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.828 0.347 . . . . 0.0 111.733 -179.018 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -119.86 121.12 38.37 Favored 'General case' 0 N--CA 1.468 0.473 0 CA-C-N 116.341 -0.391 . . . . 0.0 110.47 179.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.92 172.19 13.38 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 112.539 0.57 . . . . 0.0 112.539 -179.036 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 17.3 t-20 -112.66 142.36 45.36 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.461 179.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 41.0 mt -105.73 122.79 41.39 Favored Pre-proline 0 CA--C 1.531 0.246 0 CA-C-O 121.094 0.473 . . . . 0.0 111.544 -179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.426 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 67.2 Cg_endo -78.13 132.72 11.72 Favored 'Trans proline' 0 CA--C 1.531 0.326 0 C-N-CA 122.921 2.414 . . . . 0.0 112.713 -179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.8 tpt -68.55 124.89 24.81 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.082 0.467 . . . . 0.0 111.733 -179.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.06 9.23 85.52 Favored Glycine 0 C--N 1.333 0.395 0 CA-C-N 115.863 -0.608 . . . . 0.0 113.101 179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 45.4 mt-10 -134.28 176.82 8.26 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.979 0.419 . . . . 0.0 111.13 -179.527 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -115.2 133.31 56.15 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-O 121.137 0.494 . . . . 0.0 111.647 -179.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 14.1 t80 -119.89 123.64 44.09 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.865 -0.607 . . . . 0.0 109.977 178.809 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.501 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -102.99 137.21 32.03 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.42 0 CA-C-O 121.65 0.738 . . . . 0.0 112.643 -178.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 54.9 t -112.86 112.03 38.67 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.491 -0.777 . . . . 0.0 110.18 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 10.2 mt-10 -93.16 119.52 32.45 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.507 -179.495 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -136.49 155.6 34.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.227 -179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 2.9 m -119.37 97.81 50.3 Favored Pre-proline 0 C--N 1.328 -0.351 0 CA-C-N 116.113 -0.494 . . . . 0.0 111.514 -179.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 73.2 Cg_endo -74.24 100.82 1.34 Allowed 'Trans proline' 0 CA--C 1.531 0.344 0 C-N-CA 122.86 2.373 . . . . 0.0 112.503 179.719 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -95.63 3.76 53.7 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.919 0.39 . . . . 0.0 111.657 -179.927 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -130.4 133.63 46.52 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.867 179.88 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -90.07 128.8 36.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.908 0.385 . . . . 0.0 111.255 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 168.05 -166.75 39.67 Favored Glycine 0 CA--C 1.517 0.185 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.813 -179.831 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -99.89 112.83 25.08 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.168 0.509 . . . . 0.0 110.746 179.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.408 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 22.6 m-85 -110.67 168.61 9.34 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.009 -179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 63.5 p -150.64 160.89 43.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.138 0.494 . . . . 0.0 112.047 -179.379 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 36.3 p90 -146.21 136.08 23.41 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.913 179.083 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.15 156.2 21.56 Favored 'General case' 0 N--CA 1.462 0.157 0 CA-C-N 116.361 -0.382 . . . . 0.0 111.231 -179.673 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 4.8 t -160.97 165.89 29.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.44 -0.346 . . . . 0.0 111.004 179.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 83.55 -77.65 2.1 Favored Glycine 0 CA--C 1.52 0.398 0 C-N-CA 120.934 -0.65 . . . . 0.0 113.308 179.494 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -127.83 153.72 46.27 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.929 0.395 . . . . 0.0 111.4 -179.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -83.51 54.53 2.87 Favored 'General case' 0 CA--C 1.535 0.371 0 CA-C-N 116.304 -0.407 . . . . 0.0 111.474 -179.794 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 1.5 mpp? -126.94 -92.6 0.49 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.62 179.907 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -68.37 141.93 55.6 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-O 120.971 0.415 . . . . 0.0 110.279 179.51 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 34.2 p-80 -155.08 158.05 38.47 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.495 -0.32 . . . . 0.0 111.488 -179.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -110.73 145.99 17.46 Favored Glycine 0 N--CA 1.449 -0.437 0 C-N-CA 120.989 -0.624 . . . . 0.0 112.497 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -111.85 149.69 31.44 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 120.966 0.412 . . . . 0.0 111.083 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.493 ' HG3' HG13 ' A' ' 54' ' ' ILE . 8.9 ttp -131.71 119.52 21.46 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.115 -0.493 . . . . 0.0 111.012 -179.849 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.7 mp -107.16 116.24 50.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.031 0.443 . . . . 0.0 110.793 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.2 t -101.23 120.43 50.78 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.168 -179.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 . . . . . 0 C--O 1.252 1.224 0 CA-C-O 118.146 -0.93 . . . . 0.0 111.458 -179.646 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.631 0 N-CA-C 112.168 -0.373 . . . . 0.0 112.168 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -70.95 -18.54 62.63 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.795 0.331 . . . . 0.0 111.655 -179.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 50.7 mmm -86.77 -10.03 54.52 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.303 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.05 164.56 20.42 Favored Glycine 0 CA--C 1.519 0.287 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.868 179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 1.2 mt-30 -112.4 123.23 49.83 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.161 0.505 . . . . 0.0 111.066 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.82 129.23 35.26 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.971 -0.558 . . . . 0.0 110.606 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.71 156.1 39.3 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.403 179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.549 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 5.9 pt20 -82.0 142.81 32.05 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-O 121.125 0.488 . . . . 0.0 111.259 -179.611 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -98.47 112.99 24.84 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.657 179.628 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 5.6 mmtt -95.34 -150.28 0.31 Allowed 'General case' 0 CA--C 1.536 0.436 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.557 -179.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.6 t30 -80.71 74.99 7.63 Favored 'General case' 0 CA--C 1.534 0.347 0 N-CA-C 112.376 0.51 . . . . 0.0 112.376 -179.073 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 92.98 -5.82 76.11 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.867 -0.682 . . . . 0.0 113.974 178.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.4 p90 -140.59 163.96 31.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.923 0.361 . . . . 0.0 110.85 -179.906 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.65 154.57 27.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.975 0.417 . . . . 0.0 111.457 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.549 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 4.0 tt0 -143.82 141.3 30.3 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.572 -179.344 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.71 128.97 17.75 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.915 179.109 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 ttt180 -90.73 110.9 22.08 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.253 0.549 . . . . 0.0 111.123 179.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.57 HG13 ' HD2' ' A' ' 51' ' ' PRO . 45.2 t -101.04 103.87 15.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.517 -179.933 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.411 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 1.3 tp10 -71.49 117.01 12.5 Favored 'General case' 0 C--O 1.235 0.311 0 CA-C-N 115.77 -0.65 . . . . 0.0 111.029 -179.899 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.557 HG13 HD22 ' A' ' 75' ' ' LEU . 53.2 t -98.76 99.93 9.55 Favored 'Isoleucine or valine' 0 C--O 1.234 0.284 0 CA-C-N 115.681 -0.69 . . . . 0.0 111.451 -178.76 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.564 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.3 ptm -147.09 90.77 1.92 Allowed 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.603 -0.726 . . . . 0.0 110.568 179.142 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 79.28 1.04 85.25 Favored Glycine 0 CA--C 1.52 0.396 0 C-N-CA 120.774 -0.727 . . . . 0.0 111.733 -178.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.481 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 163.54 -148.61 15.19 Favored Glycine 0 N--CA 1.449 -0.472 0 N-CA-C 111.314 -0.715 . . . . 0.0 111.314 179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.4 m-85 -115.64 129.65 56.57 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.718 0.259 . . . . 0.0 110.309 179.695 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.504 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 41.0 m -68.76 -64.6 1.65 Allowed Pre-proline 0 CA--C 1.538 0.515 0 CA-C-O 119.468 -0.301 . . . . 0.0 111.497 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.57 ' HD2' HG13 ' A' ' 43' ' ' VAL . 62.4 Cg_endo -74.9 98.88 1.19 Allowed 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.271 1.314 . . . . 0.0 111.119 177.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -51.84 -44.55 63.64 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.917 -179.583 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.467 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.85 119.09 20.72 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.864 179.78 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.2 pt -97.1 126.98 49.74 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 121.08 0.467 . . . . 0.0 110.943 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 60.1 t -98.58 126.67 51.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.642 -179.613 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.3 mt -136.22 165.37 25.91 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 115.8 -0.636 . . . . 0.0 111.363 -179.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 24.5 mttt -88.85 176.01 7.22 Favored 'General case' 0 CA--C 1.532 0.252 0 CA-C-N 116.383 -0.371 . . . . 0.0 110.82 179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.452 ' HD3' ' HB2' ' A' ' 104' ' ' ALA . 2.6 ttpt -106.7 147.95 28.98 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-O 120.812 0.339 . . . . 0.0 111.872 -179.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.0 t 65.13 20.2 11.95 Favored 'General case' 0 N--CA 1.472 0.631 0 CA-C-N 115.605 -0.725 . . . . 0.0 111.737 179.596 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.444 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.3 p -123.61 136.4 27.22 Favored Pre-proline 0 CA--C 1.535 0.388 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.989 -179.821 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.4 Cg_endo -64.47 123.43 11.76 Favored 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.099 1.866 . . . . 0.0 111.736 178.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.05 139.37 53.86 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.954 0.407 . . . . 0.0 111.682 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.515 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.6 ptt180 -121.78 127.06 50.21 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-O 121.744 0.783 . . . . 0.0 111.335 179.806 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.5 mm -99.87 115.78 41.69 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.838 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.517 HG22 HG23 ' A' ' 96' ' ' VAL . 3.2 t -91.24 107.59 18.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 120.853 0.359 . . . . 0.0 111.463 -179.229 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -95.09 103.57 15.42 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 120.909 0.385 . . . . 0.0 111.466 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 2.4 t0 -90.59 105.9 18.14 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.074 -0.512 . . . . 0.0 110.377 179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.55 100.1 7.6 Favored 'General case' 0 N--CA 1.464 0.226 0 CA-C-O 121.157 0.503 . . . . 0.0 111.882 -179.197 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.0 tmtt? -91.42 -39.19 12.12 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.852 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.564 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 0.1 OUTLIER -107.1 137.8 19.66 Favored Pre-proline 0 CA--C 1.534 0.354 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.149 -179.913 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 79.4 Cg_endo -81.87 39.66 0.88 Allowed 'Trans proline' 0 C--N 1.349 0.573 0 C-N-CA 123.229 2.619 . . . . 0.0 113.405 -179.279 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.5 m -67.73 135.66 92.48 Favored Pre-proline 0 C--N 1.329 -0.326 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.991 179.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_endo -62.42 -34.3 76.93 Favored 'Trans proline' 0 C--N 1.349 0.588 0 C-N-CA 122.872 2.382 . . . . 0.0 113.106 -179.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.02 -3.29 38.33 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.518 179.937 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.557 HD22 HG13 ' A' ' 45' ' ' VAL . 56.3 mt -120.01 12.88 12.07 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.446 -179.89 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -68.78 -39.27 80.25 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-O 120.915 0.388 . . . . 0.0 111.379 179.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 31.0 mt-30 -123.66 166.15 16.0 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.334 -0.394 . . . . 0.0 111.034 -179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -140.93 130.45 25.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.296 0.57 . . . . 0.0 110.836 178.764 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.582 ' O ' ' HD3' ' A' ' 81' ' ' PRO . 0.2 OUTLIER -133.9 132.33 56.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.413 0 CA-C-O 121.216 0.532 . . . . 0.0 110.981 179.68 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.5 m-85 -96.01 101.72 9.01 Favored Pre-proline 0 C--N 1.325 -0.465 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.721 178.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.582 ' HD3' ' O ' ' A' ' 79' ' ' VAL . 23.2 Cg_exo -63.46 -19.02 67.1 Favored 'Trans proline' 0 CA--C 1.53 0.32 0 C-N-CA 123.072 2.515 . . . . 0.0 113.791 -178.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -100.66 -5.94 25.88 Favored 'General case' 0 CA--C 1.537 0.469 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -179.605 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -121.44 -23.03 5.76 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 112.167 0.432 . . . . 0.0 112.167 -179.984 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.11 22.8 56.69 Favored Glycine 0 C--N 1.332 0.349 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.151 -179.503 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.1 t -102.53 120.34 52.15 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-O 120.674 0.274 . . . . 0.0 111.552 -179.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -125.74 119.69 28.62 Favored 'General case' 0 N--CA 1.468 0.445 0 CA-C-N 116.467 -0.333 . . . . 0.0 110.633 179.532 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -138.78 169.35 17.94 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-O 121.112 0.482 . . . . 0.0 112.249 -179.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -109.05 140.67 42.27 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.548 179.673 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 38.6 mt -100.69 129.44 27.6 Favored Pre-proline 0 C--N 1.329 -0.29 0 CA-C-O 120.851 0.358 . . . . 0.0 111.356 -179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.426 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.9 Cg_endo -80.64 128.25 6.76 Favored 'Trans proline' 0 CA--C 1.533 0.452 0 C-N-CA 122.813 2.342 . . . . 0.0 112.452 179.164 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -66.16 124.85 23.74 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-O 121.087 0.47 . . . . 0.0 111.681 -179.541 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 87.11 3.46 82.56 Favored Glycine 0 CA--C 1.521 0.446 0 CA-C-N 115.878 -0.601 . . . . 0.0 112.951 -179.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 41.9 mt-10 -134.65 177.05 8.09 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 121.009 0.433 . . . . 0.0 110.913 -179.593 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 3.8 pt-20 -117.27 133.35 56.09 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 121.211 0.529 . . . . 0.0 111.564 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 12.8 t80 -113.21 125.49 54.38 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.222 179.497 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.517 HG23 HG22 ' A' ' 65' ' ' VAL . 1.7 p -98.09 135.19 33.64 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-O 121.715 0.769 . . . . 0.0 112.334 -179.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.0 t -112.82 112.92 42.5 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.199 178.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.6 mt-10 -93.73 119.76 33.13 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-O 121.035 0.445 . . . . 0.0 111.518 -179.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -136.4 156.44 36.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.208 0 CA-C-N 116.033 -0.531 . . . . 0.0 111.125 179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.26 97.74 48.99 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.452 -179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.444 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 58.6 Cg_endo -71.14 98.42 0.82 Allowed 'Trans proline' 0 C--N 1.346 0.437 0 C-N-CA 122.734 2.289 . . . . 0.0 112.618 179.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.4 mt-10 -97.6 22.72 8.6 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.004 0.43 . . . . 0.0 111.482 -179.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.35 131.23 14.21 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.539 179.681 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . 0.452 ' HB2' ' HD3' ' A' ' 58' ' ' LYS . . . -88.11 127.1 35.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.071 0.462 . . . . 0.0 111.41 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 164.99 -157.6 30.13 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.965 -0.636 . . . . 0.0 112.714 -179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.8 tt0 -101.55 126.01 48.29 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 121.172 0.51 . . . . 0.0 111.535 -179.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.443 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 87.9 m-85 -119.58 171.93 8.02 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.711 -0.677 . . . . 0.0 109.783 179.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 84.8 p -157.81 160.54 37.88 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.211 0.529 . . . . 0.0 112.418 -179.09 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 27.5 p90 -143.77 140.46 29.94 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-N 115.442 -0.799 . . . . 0.0 110.496 178.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.602 ' HB2' ' HB2' ' A' ' 117' ' ' HIS . . . -157.43 177.84 10.98 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.443 -0.344 . . . . 0.0 111.662 -179.196 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 7.3 t -163.41 138.87 6.55 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.301 179.344 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 84.84 -78.8 1.97 Allowed Glycine 0 CA--C 1.521 0.447 0 C-N-CA 120.833 -0.698 . . . . 0.0 113.413 179.533 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -116.54 -178.74 3.49 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.066 0.46 . . . . 0.0 111.455 -179.409 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -85.89 -22.45 27.5 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 116.06 -0.518 . . . . 0.0 111.189 179.649 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -87.3 157.56 19.26 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.541 179.527 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 11.0 ttp 61.75 73.22 0.48 Allowed 'General case' 0 N--CA 1.468 0.444 0 CA-C-O 121.295 0.569 . . . . 0.0 110.922 -179.484 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . 0.602 ' HB2' ' HB2' ' A' ' 110' ' ' ALA . 18.8 p80 -133.67 169.86 16.39 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.685 -179.431 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -106.5 160.92 14.26 Favored Glycine 0 N--CA 1.447 -0.624 0 C-N-CA 120.952 -0.642 . . . . 0.0 112.178 179.499 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.467 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 0.2 OUTLIER -128.51 149.85 50.42 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 120.884 0.373 . . . . 0.0 111.112 179.68 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.443 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -132.56 140.12 48.14 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.059 179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.5 118.74 54.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 121.048 0.451 . . . . 0.0 110.823 179.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.3 t -100.21 123.86 53.34 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.022 -0.536 . . . . 0.0 111.062 -179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.251 1.168 0 CA-C-O 118.155 -0.926 . . . . 0.0 111.973 -179.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.946 ' N ' ' HZ1' ' A' ' 31' ' ' LYS . . . . . . . . 0 N--CA 1.498 2.784 0 CA-C-O 121.159 0.311 . . . . 0.0 112.457 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -93.8 -27.14 16.63 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 120.93 0.395 . . . . 0.0 111.441 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 4.9 tpt -133.51 93.35 3.13 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.039 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 110.28 -162.84 12.48 Favored Glycine 0 CA--C 1.517 0.163 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.615 -179.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.29 125.12 19.65 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-O 121.155 0.502 . . . . 0.0 111.375 179.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.946 ' HZ1' ' N ' ' A' ' 26' ' ' GLY . 0.5 OUTLIER -88.57 126.59 35.35 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.626 179.784 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.27 153.84 41.32 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.297 179.929 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -81.72 140.67 34.17 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.243 0.544 . . . . 0.0 111.187 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 22.0 mt-30 -96.38 116.83 29.69 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.595 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.1 -153.07 0.41 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.119 -179.989 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 -83.73 76.82 9.96 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 112.037 0.384 . . . . 0.0 112.037 -179.271 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.6 -8.84 64.2 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.767 -0.73 . . . . 0.0 114.007 178.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 40.9 p90 -141.21 164.99 28.77 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 117.093 0.446 . . . . 0.0 111.091 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.44 154.28 27.25 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.924 0.392 . . . . 0.0 111.177 179.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -143.28 142.07 31.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.891 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.54 128.69 15.3 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.972 179.027 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -90.18 110.18 21.22 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 121.208 0.528 . . . . 0.0 110.93 179.436 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.566 HG13 ' HD2' ' A' ' 51' ' ' PRO . 47.9 t -102.37 107.2 21.31 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.663 -0.698 . . . . 0.0 110.74 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.42 ' HG2' ' SD ' ' A' ' 46' ' ' MET . 0.7 OUTLIER -75.93 117.76 17.99 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.88 -0.6 . . . . 0.0 111.002 -179.922 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.491 HG13 HD22 ' A' ' 75' ' ' LEU . 50.6 t -96.62 99.03 8.31 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.31 0 CA-C-N 115.72 -0.673 . . . . 0.0 111.416 -178.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.496 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.4 ptm -144.72 90.3 2.06 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.487 179.023 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 81.85 2.05 90.43 Favored Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.72 -178.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.448 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 159.61 -131.28 2.67 Favored Glycine 0 N--CA 1.449 -0.471 0 N-CA-C 111.601 -0.6 . . . . 0.0 111.601 -179.862 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 76.9 m-85 -126.09 134.57 51.33 Favored 'General case' 0 C--N 1.328 -0.346 0 O-C-N 122.729 -0.277 . . . . 0.0 110.754 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.521 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 32.4 m -73.57 -63.98 0.87 Allowed Pre-proline 0 CA--C 1.539 0.536 0 C-N-CA 121.066 -0.253 . . . . 0.0 110.93 179.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.566 ' HD2' HG13 ' A' ' 43' ' ' VAL . 61.2 Cg_endo -74.53 100.51 1.33 Allowed 'Trans proline' 0 C--N 1.358 1.078 0 C-N-CA 121.409 1.406 . . . . 0.0 111.226 177.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.63 -45.42 63.27 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-N 116.034 -0.53 . . . . 0.0 112.28 -179.255 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.511 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.76 119.06 19.82 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.561 0.22 . . . . 0.0 110.999 179.783 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.1 pt -96.58 126.04 49.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 121.128 0.489 . . . . 0.0 110.896 179.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 84.0 t -97.8 126.43 50.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.567 -179.709 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.5 mt -136.15 164.37 28.21 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.248 -179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.74 170.9 10.04 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-O 120.757 0.313 . . . . 0.0 110.935 179.24 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 12.7 ttpt -100.65 147.81 25.57 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 111.993 0.368 . . . . 0.0 111.993 -179.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.7 t 65.72 19.63 11.42 Favored 'General case' 0 N--CA 1.471 0.601 0 CA-C-N 115.641 -0.708 . . . . 0.0 111.936 179.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.5 p -123.63 135.74 26.49 Favored Pre-proline 0 C--N 1.327 -0.394 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.964 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_endo -64.11 123.28 11.64 Favored 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.133 1.889 . . . . 0.0 111.722 178.642 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.23 136.56 54.24 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.938 0.399 . . . . 0.0 111.542 -179.539 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.434 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -118.53 125.51 50.0 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.855 0.836 . . . . 0.0 111.545 179.965 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.1 mm -98.38 114.93 37.31 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-N 115.209 -0.905 . . . . 0.0 110.626 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.543 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.34 107.83 19.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.768 0.318 . . . . 0.0 111.357 -179.38 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.1 m-85 -94.16 118.53 31.69 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.081 0.467 . . . . 0.0 111.381 -179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 6.1 t0 -102.18 106.97 17.89 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.469 179.713 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 2.7 tpt180 -76.35 96.69 4.05 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 121.13 0.491 . . . . 0.0 111.42 -179.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 23.4 tptt -91.89 -35.91 13.77 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.675 -0.693 . . . . 0.0 110.451 179.725 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.496 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.7 t70 -107.08 131.15 21.92 Favored Pre-proline 0 C--N 1.328 -0.365 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.731 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -80.18 38.48 0.75 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.001 2.467 . . . . 0.0 113.027 -179.631 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -68.91 132.74 90.37 Favored Pre-proline 0 C--N 1.329 -0.324 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.945 179.854 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -64.32 -30.92 63.5 Favored 'Trans proline' 0 C--N 1.347 0.492 0 C-N-CA 122.668 2.245 . . . . 0.0 112.894 -179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.75 -3.13 42.78 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.544 179.875 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.491 HD22 HG13 ' A' ' 45' ' ' VAL . 16.6 mt -117.67 10.15 13.29 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-O 120.751 0.31 . . . . 0.0 111.19 -179.938 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -68.18 -42.61 79.71 Favored 'General case' 0 CA--C 1.534 0.343 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -179.412 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . 0.426 ' O ' ' HB3' ' A' ' 111' ' ' CYS . 16.8 mt-30 -116.83 138.01 51.81 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.829 0.347 . . . . 0.0 111.584 -179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -118.21 131.7 70.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.654 179.432 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.416 ' HB ' ' HB3' ' A' ' 86' ' ' HIS . 0.2 OUTLIER -137.42 129.44 41.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-O 121.397 0.618 . . . . 0.0 111.579 179.947 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.5 m-85 -89.95 102.18 4.39 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 115.14 -0.936 . . . . 0.0 109.252 178.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 109' ' ' PHE . 36.4 Cg_endo -64.99 -14.16 43.72 Favored 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.606 2.204 . . . . 0.0 113.637 -178.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 50.6 m-20 -101.02 -11.25 19.82 Favored 'General case' 0 CA--C 1.538 0.488 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 61.3 m-85 -119.15 -24.29 6.52 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 111.945 0.35 . . . . 0.0 111.945 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 88.84 1.17 80.46 Favored Glycine 0 CA--C 1.521 0.467 0 C-N-CA 121.129 -0.558 . . . . 0.0 112.143 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.521 HG11 HG13 ' A' ' 97' ' ' VAL . 54.8 t -80.36 117.02 25.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.886 0.374 . . . . 0.0 111.396 -178.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . 0.416 ' HB3' ' HB ' ' A' ' 79' ' ' VAL . 19.2 p-80 -132.05 122.59 25.69 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.835 179.891 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.48 174.23 10.94 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 121.112 0.482 . . . . 0.0 111.91 -178.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -108.23 141.89 39.31 Favored 'General case' 0 N--CA 1.464 0.244 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.656 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 33.9 mt -100.71 124.49 42.06 Favored Pre-proline 0 C--N 1.328 -0.33 0 CA-C-O 120.906 0.384 . . . . 0.0 111.467 -179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.434 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 63.6 Cg_endo -78.57 128.63 8.82 Favored 'Trans proline' 0 CA--C 1.53 0.313 0 C-N-CA 122.786 2.324 . . . . 0.0 112.684 -179.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 12.3 tpt -66.19 124.94 23.99 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-O 121.151 0.501 . . . . 0.0 111.677 -179.635 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.38 6.76 85.69 Favored Glycine 0 CA--C 1.52 0.398 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.923 -179.917 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.434 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 48.3 mm-40 -134.13 176.78 8.28 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-O 120.943 0.401 . . . . 0.0 111.292 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -114.58 132.32 56.38 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-O 120.983 0.42 . . . . 0.0 111.834 -179.665 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.415 ' HB2' ' HD2' ' A' ' 90' ' ' PRO . 9.6 t80 -118.06 121.63 41.09 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.125 -0.489 . . . . 0.0 109.778 178.632 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.543 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -98.52 138.46 23.04 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.387 0 CA-C-O 121.629 0.728 . . . . 0.0 112.577 -178.715 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.521 HG13 HG11 ' A' ' 85' ' ' VAL . 43.8 t -115.6 110.34 31.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.053 178.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.4 mt-10 -93.98 117.39 30.04 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.034 0.445 . . . . 0.0 111.551 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -132.73 156.52 42.4 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.193 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.18 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.3 m -119.9 96.74 49.55 Favored Pre-proline 0 C--N 1.327 -0.376 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.437 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.449 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.1 Cg_endo -72.07 99.49 1.0 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.706 2.271 . . . . 0.0 112.494 179.882 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -97.3 22.92 8.05 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.023 0.439 . . . . 0.0 111.553 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.17 127.76 11.58 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.749 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -83.84 122.96 29.4 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.975 0.417 . . . . 0.0 111.326 -179.907 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 169.2 -158.76 31.44 Favored Glycine 0 CA--C 1.518 0.279 0 C-N-CA 120.86 -0.686 . . . . 0.0 112.729 -179.84 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.9 mt-10 -101.99 126.7 48.98 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.182 0.515 . . . . 0.0 111.576 -179.819 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.447 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 85.7 m-85 -119.69 169.7 9.86 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.918 179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 99.1 p -149.81 157.38 43.15 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.408 ' HA ' ' HD2' ' A' ' 81' ' ' PRO . 32.9 p90 -148.29 138.48 22.6 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.507 -0.769 . . . . 0.0 110.995 178.778 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.42 178.27 8.79 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.05 0.452 . . . . 0.0 111.655 -179.73 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.426 ' HB3' ' O ' ' A' ' 77' ' ' GLN . 0.0 OUTLIER -123.9 126.74 46.91 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.882 179.407 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 62.22 -103.75 0.65 Allowed Glycine 0 CA--C 1.522 0.484 0 C-N-CA 121.179 -0.534 . . . . 0.0 113.066 -179.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -139.3 -107.06 0.17 Allowed 'General case' 0 CA--C 1.535 0.393 0 N-CA-C 110.504 -0.184 . . . . 0.0 110.504 179.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.5 t-20 59.05 -160.13 0.28 Allowed 'General case' 0 CA--C 1.539 0.528 0 CA-C-O 121.099 0.476 . . . . 0.0 111.923 179.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . 0.409 ' H ' ' HG3' ' A' ' 115' ' ' MET . 0.0 OUTLIER -113.9 -27.87 7.59 Favored 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.19 179.408 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 1.2 ptm -68.39 117.77 10.6 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-O 121.032 0.444 . . . . 0.0 111.219 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 53.1 p-80 -150.18 152.91 35.4 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.164 -179.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -105.64 148.3 16.46 Favored Glycine 0 N--CA 1.451 -0.354 0 C-N-CA 120.877 -0.678 . . . . 0.0 112.251 179.896 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.511 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 14.6 ttpt -117.62 146.14 43.86 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.03 0.443 . . . . 0.0 111.098 -179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.447 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.7 ttm -128.39 136.22 50.61 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.908 179.655 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -120.02 118.42 56.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.393 0 CA-C-O 120.981 0.42 . . . . 0.0 110.846 179.537 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 76.0 t -99.78 121.78 50.86 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.012 -0.54 . . . . 0.0 111.146 -179.673 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 . . . . . 0 C--O 1.25 1.11 0 CA-C-O 118.103 -0.951 . . . . 0.0 111.531 -179.702 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.646 0 CA-C-O 121.259 0.366 . . . . 0.0 112.241 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.18 0.21 11.17 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.511 -0.344 . . . . 0.0 111.415 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -124.95 -74.36 0.61 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.415 -0.357 . . . . 0.0 111.441 -179.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 93.4 171.09 39.49 Favored Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.797 -0.716 . . . . 0.0 112.801 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 2.1 mp0 -133.1 128.17 35.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 121.207 0.527 . . . . 0.0 111.477 -179.737 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 3.1 ttpt -90.17 129.5 36.43 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.747 179.495 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.22 153.51 40.62 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.124 179.905 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.441 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 3.7 pt20 -84.48 139.33 32.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.132 0.491 . . . . 0.0 111.393 -179.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -94.82 115.29 27.31 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.769 -179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.89 -151.14 0.32 Allowed 'General case' 0 CA--C 1.535 0.368 0 CA-C-N 115.918 -0.583 . . . . 0.0 111.248 -179.982 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.6 m120 -82.94 73.29 9.98 Favored 'General case' 0 CA--C 1.534 0.332 0 N-CA-C 112.263 0.468 . . . . 0.0 112.263 -179.131 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 97.68 -4.76 61.75 Favored Glycine 0 CA--C 1.522 0.53 0 C-N-CA 120.817 -0.706 . . . . 0.0 114.061 178.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 30.2 p90 -143.62 162.57 35.58 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.909 0.355 . . . . 0.0 110.915 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.42 153.33 27.51 Favored 'General case' 0 N--CA 1.466 0.354 0 CA-C-O 121.006 0.432 . . . . 0.0 111.475 179.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.441 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.6 tt0 -142.14 142.81 32.78 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.067 -0.515 . . . . 0.0 111.567 -179.961 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.56 129.07 13.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 179.188 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -90.74 110.12 21.31 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.239 0.542 . . . . 0.0 110.939 179.639 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.582 HG13 ' HD2' ' A' ' 51' ' ' PRO . 43.5 t -102.16 103.91 15.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.774 -179.706 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.468 ' HG2' ' SD ' ' A' ' 46' ' ' MET . 0.8 OUTLIER -75.25 118.13 17.82 Favored 'General case' 0 C--O 1.235 0.34 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.614 -179.999 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.563 HG13 HD22 ' A' ' 75' ' ' LEU . 53.5 t -96.9 98.41 7.5 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.327 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.649 -178.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.468 ' SD ' ' HG2' ' A' ' 44' ' ' GLU . 6.4 ptm -142.55 90.81 2.26 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.672 -0.695 . . . . 0.0 110.642 179.124 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 81.7 0.72 89.68 Favored Glycine 0 CA--C 1.521 0.431 0 C-N-CA 120.901 -0.666 . . . . 0.0 111.684 -178.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.464 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 162.79 -133.66 3.16 Favored Glycine 0 N--CA 1.448 -0.519 0 N-CA-C 111.484 -0.646 . . . . 0.0 111.484 179.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 78.2 m-85 -124.8 130.77 53.04 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.743 0.272 . . . . 0.0 110.599 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.537 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 49.7 m -70.15 -64.99 1.2 Allowed Pre-proline 0 CA--C 1.538 0.51 0 CA-C-O 119.508 -0.282 . . . . 0.0 111.391 -179.837 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.582 ' HD2' HG13 ' A' ' 43' ' ' VAL . 58.7 Cg_endo -73.95 100.32 1.27 Allowed 'Trans proline' 0 C--N 1.358 1.058 0 C-N-CA 121.278 1.319 . . . . 0.0 111.249 177.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.84 -47.16 60.25 Favored 'General case' 0 N--CA 1.468 0.467 0 CA-C-N 115.951 -0.568 . . . . 0.0 112.285 -179.365 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.473 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.56 119.06 20.01 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.638 0.256 . . . . 0.0 110.752 179.897 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 10.4 pt -97.04 129.37 47.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 121.093 0.473 . . . . 0.0 111.062 179.816 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 96.3 t -96.18 124.95 49.12 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.509 -179.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.0 157.24 42.87 Favored 'General case' 0 N--CA 1.467 0.417 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.087 -179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 23.9 mttt -89.85 168.99 11.63 Favored 'General case' 0 C--N 1.329 -0.309 0 N-CA-C 110.163 -0.31 . . . . 0.0 110.163 178.31 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.9 ttpp -98.77 146.95 25.39 Favored 'General case' 0 C--N 1.328 -0.362 0 N-CA-C 112.305 0.484 . . . . 0.0 112.305 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.6 t 65.66 19.78 11.48 Favored 'General case' 0 N--CA 1.471 0.62 0 CA-C-N 115.354 -0.839 . . . . 0.0 111.86 179.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.451 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.95 135.9 26.84 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.976 -179.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -64.29 122.74 10.8 Favored 'Trans proline' 0 C--N 1.346 0.403 0 C-N-CA 122.128 1.885 . . . . 0.0 111.812 178.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.7 134.68 53.67 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.856 0.36 . . . . 0.0 111.47 -179.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.46 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -116.59 126.32 53.1 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.776 0.798 . . . . 0.0 111.585 -179.918 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.5 mm -99.5 114.88 38.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.192 -0.913 . . . . 0.0 110.67 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.523 HG22 HG23 ' A' ' 96' ' ' VAL . 4.1 t -90.45 108.2 19.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.239 0 CA-C-O 120.714 0.292 . . . . 0.0 111.383 -179.505 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 62.9 m-85 -95.08 113.67 25.38 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.147 0.499 . . . . 0.0 111.326 -179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 21.8 t0 -99.32 103.72 15.57 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.5 179.759 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.25 97.66 4.24 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-O 121.176 0.512 . . . . 0.0 111.723 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.66 -42.1 10.37 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.482 179.731 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.455 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.2 t70 -99.47 131.75 24.39 Favored Pre-proline 0 C--N 1.328 -0.346 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.837 179.522 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -80.73 39.63 0.88 Allowed 'Trans proline' 0 C--N 1.348 0.526 0 C-N-CA 123.16 2.573 . . . . 0.0 113.162 -179.534 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 30.7 t -69.77 136.18 87.84 Favored Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.401 -0.363 . . . . 0.0 111.326 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -63.95 -27.95 66.63 Favored 'Trans proline' 0 C--N 1.348 0.512 0 C-N-CA 122.576 2.184 . . . . 0.0 112.443 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 80.6 m -81.05 -6.89 59.33 Favored 'General case' 0 CA--C 1.532 0.253 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.059 179.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.563 HD22 HG13 ' A' ' 45' ' ' VAL . 50.9 mt -118.31 14.92 13.92 Favored 'General case' 0 CA--C 1.533 0.292 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.208 179.83 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -68.37 -35.89 78.39 Favored 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 120.95 0.405 . . . . 0.0 111.557 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 4.3 mt-30 -129.34 165.68 21.0 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.047 -179.843 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.08 131.82 42.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 121.245 0.545 . . . . 0.0 110.98 179.156 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -136.9 128.63 43.05 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 CA-C-O 121.455 0.645 . . . . 0.0 111.179 179.793 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.2 m-85 -90.81 102.21 4.95 Favored Pre-proline 0 C--N 1.325 -0.491 0 CA-C-N 115.095 -0.957 . . . . 0.0 109.422 178.848 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -65.24 -14.2 43.83 Favored 'Trans proline' 0 C--N 1.348 0.518 0 C-N-CA 122.583 2.188 . . . . 0.0 113.583 -178.547 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 67.6 m-20 -101.05 -10.24 20.68 Favored 'General case' 0 CA--C 1.535 0.383 0 N-CA-C 111.906 0.335 . . . . 0.0 111.906 179.951 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 59.0 m-85 -119.84 -23.69 6.37 Favored 'General case' 0 N--CA 1.466 0.329 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -179.644 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 87.92 1.28 82.57 Favored Glycine 0 CA--C 1.521 0.458 0 C-N-CA 121.291 -0.48 . . . . 0.0 112.175 -179.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.506 HG11 HG13 ' A' ' 97' ' ' VAL . 53.6 t -81.48 116.27 25.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.892 0.377 . . . . 0.0 111.348 -178.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 20.3 p-80 -131.51 120.86 23.53 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.386 -0.37 . . . . 0.0 110.959 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -140.18 173.79 11.16 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.759 -179.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 8.1 p-10 -106.54 145.54 31.73 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.738 179.725 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 36.2 mt -103.97 130.17 23.89 Favored Pre-proline 0 C--N 1.329 -0.321 0 CA-C-O 120.924 0.393 . . . . 0.0 111.203 -179.733 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.425 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.7 Cg_endo -80.86 126.11 5.69 Favored 'Trans proline' 0 CA--C 1.532 0.382 0 C-N-CA 122.706 2.271 . . . . 0.0 112.325 179.26 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.0 tpt -64.01 123.95 20.34 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-O 121.092 0.473 . . . . 0.0 111.764 -179.479 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.02 3.59 87.62 Favored Glycine 0 CA--C 1.522 0.508 0 CA-C-N 115.866 -0.606 . . . . 0.0 113.283 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.425 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 47.8 mt-10 -131.86 176.86 7.99 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 120.886 0.374 . . . . 0.0 111.196 -179.581 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -113.38 135.55 53.74 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.083 0.468 . . . . 0.0 111.985 -179.555 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 10.3 t80 -120.07 124.26 45.41 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.807 178.749 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.523 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -98.7 137.94 24.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-O 121.63 0.728 . . . . 0.0 112.666 -178.879 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.506 HG13 HG11 ' A' ' 85' ' ' VAL . 46.1 t -114.99 110.46 32.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.055 178.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 -93.56 117.09 29.64 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.854 0.359 . . . . 0.0 111.481 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.6 pt -132.05 158.05 43.22 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.213 179.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -121.38 96.24 47.97 Favored Pre-proline 0 C--N 1.329 -0.285 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.501 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.451 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.7 Cg_endo -71.19 99.59 0.91 Allowed 'Trans proline' 0 C--N 1.346 0.431 0 C-N-CA 122.724 2.283 . . . . 0.0 112.276 179.563 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -94.22 3.65 54.96 Favored 'General case' 0 CA--C 1.533 0.305 0 N-CA-C 111.996 0.369 . . . . 0.0 111.996 -179.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -132.01 135.95 46.9 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.79 0.329 . . . . 0.0 110.754 179.791 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.46 124.11 34.19 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.249 -0.432 . . . . 0.0 110.962 179.752 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 168.76 -159.44 32.56 Favored Glycine 0 N--CA 1.452 -0.235 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.839 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -100.61 125.93 47.05 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 121.155 0.503 . . . . 0.0 111.556 -179.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.467 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 95.5 m-85 -121.42 164.86 16.44 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.831 179.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -151.21 157.43 42.63 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 121.251 0.548 . . . . 0.0 112.244 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 30.1 p90 -142.92 140.42 31.14 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.913 179.099 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.21 177.69 9.42 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.356 -179.757 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 39.1 t -143.68 128.18 17.99 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 120.849 0.356 . . . . 0.0 111.262 179.558 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 72.85 -142.55 32.19 Favored Glycine 0 CA--C 1.521 0.415 0 C-N-CA 121.08 -0.581 . . . . 0.0 113.196 179.799 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -131.01 104.23 6.99 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.846 0.355 . . . . 0.0 110.923 179.896 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -163.25 -179.91 6.95 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.984 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -82.66 -28.82 30.41 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.441 179.936 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 1.6 ptm -67.85 116.87 9.01 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-O 121.156 0.503 . . . . 0.0 111.221 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 49.6 p-80 -151.82 157.73 42.32 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.771 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -114.23 148.84 18.79 Favored Glycine 0 N--CA 1.45 -0.382 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.468 -179.802 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 4.1 ttmm -120.85 147.3 45.57 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 120.947 0.403 . . . . 0.0 111.209 179.949 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.467 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 3.4 ttm -131.1 135.13 47.24 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.926 179.496 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.16 117.87 55.65 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 121.045 0.45 . . . . 0.0 110.527 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 87.1 t -99.95 123.58 52.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.349 -179.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 . . . . . 0 C--O 1.251 1.159 0 CA-C-O 118.186 -0.912 . . . . 0.0 111.46 -179.844 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.647 0 CA-C-O 121.282 0.379 . . . . 0.0 112.28 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.87 2.79 17.2 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.439 -0.381 . . . . 0.0 111.383 179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 19.6 mtm -82.9 52.05 2.06 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-O 121.007 0.432 . . . . 0.0 111.623 -179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 92.65 160.39 35.74 Favored Glycine 0 CA--C 1.518 0.278 0 C-N-CA 121.051 -0.595 . . . . 0.0 113.007 -179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 2.3 mt-30 -124.04 129.31 50.69 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.069 0.461 . . . . 0.0 111.268 -179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 5.3 mtpt -90.12 129.25 36.43 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.733 179.471 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.99 149.21 43.49 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.943 -0.571 . . . . 0.0 111.636 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.602 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.8 pt20 -74.81 138.02 42.3 Favored 'General case' 0 C--O 1.234 0.289 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.907 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -97.55 113.36 25.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.871 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -95.41 -156.17 0.5 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.048 -0.524 . . . . 0.0 111.368 -179.682 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t-20 -81.89 79.26 8.47 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 112.29 0.478 . . . . 0.0 112.29 -179.182 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.74 -9.98 66.36 Favored Glycine 0 CA--C 1.522 0.508 0 C-N-CA 120.799 -0.715 . . . . 0.0 114.298 178.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 28.9 p90 -142.01 164.07 31.17 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 117.098 0.449 . . . . 0.0 111.193 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.13 155.41 26.07 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.012 0.434 . . . . 0.0 111.182 -179.99 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.602 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.9 tt0 -144.49 143.19 30.74 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.981 -0.554 . . . . 0.0 111.33 -179.28 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.11 129.44 17.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.404 0 CA-C-O 121.082 0.468 . . . . 0.0 111.327 179.384 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 ttm180 -88.7 106.97 18.69 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 116.062 -0.517 . . . . 0.0 111.221 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.587 HG13 ' HD2' ' A' ' 51' ' ' PRO . 45.6 t -100.39 102.31 13.27 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.496 179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 3.3 tp10 -73.6 119.38 17.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.711 -179.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.552 HG13 HD22 ' A' ' 75' ' ' LEU . 53.2 t -98.86 99.44 8.6 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.371 0 CA-C-N 115.521 -0.763 . . . . 0.0 111.517 -178.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.493 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.2 ptm -143.8 88.24 1.97 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.537 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.31 -0.36 84.61 Favored Glycine 0 CA--C 1.521 0.425 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.575 -178.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.437 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 163.41 -163.45 35.6 Favored Glycine 0 N--CA 1.447 -0.586 0 N-CA-C 111.203 -0.759 . . . . 0.0 111.203 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 43.2 m-85 -98.58 126.36 44.13 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.768 0.284 . . . . 0.0 110.321 179.654 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.537 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 47.8 m -65.24 -64.3 2.73 Favored Pre-proline 0 CA--C 1.539 0.529 0 C-N-CA 121.196 -0.202 . . . . 0.0 111.267 -179.639 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.587 ' HD2' HG13 ' A' ' 43' ' ' VAL . 60.8 Cg_endo -74.62 96.58 1.0 Allowed 'Trans proline' 0 C--N 1.358 1.062 0 C-N-CA 121.358 1.372 . . . . 0.0 111.198 177.693 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.36 -42.86 61.61 Favored 'General case' 0 N--CA 1.469 0.487 0 CA-C-N 116.096 -0.502 . . . . 0.0 112.195 -179.265 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.485 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.88 118.68 20.16 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-O 120.696 0.284 . . . . 0.0 110.606 179.513 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.9 pt -98.0 127.48 50.37 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.294 0 CA-C-O 121.03 0.443 . . . . 0.0 111.092 179.698 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.1 t -98.68 126.72 51.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.345 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.597 -179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.0 mt -136.41 165.32 26.08 Favored 'General case' 0 CA--C 1.533 0.321 0 CA-C-N 115.802 -0.636 . . . . 0.0 111.264 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.6 mttt -90.97 171.42 9.29 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.797 179.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.5 ttpp -101.74 148.47 25.24 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 120.999 0.428 . . . . 0.0 112.066 -179.325 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.0 t 65.42 20.14 11.71 Favored 'General case' 0 N--CA 1.472 0.67 0 CA-C-N 115.414 -0.812 . . . . 0.0 111.931 179.567 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.436 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.8 p -123.78 135.91 26.77 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.866 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.9 Cg_endo -64.36 122.2 10.06 Favored 'Trans proline' 0 C--N 1.345 0.371 0 C-N-CA 122.202 1.935 . . . . 0.0 111.68 178.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.46 138.65 54.54 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.995 0.426 . . . . 0.0 111.546 -179.55 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.474 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.2 ptt180 -120.72 126.85 51.21 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-O 121.776 0.798 . . . . 0.0 111.343 179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.8 mm -97.73 115.01 36.54 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.81 -179.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.452 HG22 HG23 ' A' ' 96' ' ' VAL . 3.6 t -91.99 110.52 22.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.274 0 CA-C-N 116.492 -0.322 . . . . 0.0 111.376 -179.271 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -96.2 114.69 26.41 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.041 0.448 . . . . 0.0 111.289 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -100.38 104.5 15.93 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.181 179.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.407 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 0.1 OUTLIER -76.64 104.66 7.27 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.289 0.566 . . . . 0.0 111.958 -179.093 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -96.73 -39.84 9.26 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.093 179.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.493 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.1 t70 -105.71 133.86 19.99 Favored Pre-proline 0 CA--C 1.535 0.378 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.929 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -80.97 39.53 0.87 Allowed 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.994 2.463 . . . . 0.0 112.861 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.07 133.87 91.74 Favored Pre-proline 0 C--N 1.328 -0.332 0 CA-C-N 116.107 -0.497 . . . . 0.0 111.451 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.67 -32.37 57.67 Favored 'Trans proline' 0 C--N 1.348 0.527 0 C-N-CA 122.771 2.314 . . . . 0.0 112.63 -179.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.15 -2.69 32.3 Favored 'General case' 0 N--CA 1.465 0.311 0 CA-C-N 116.323 -0.398 . . . . 0.0 111.56 179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.552 HD22 HG13 ' A' ' 45' ' ' VAL . 34.9 mt -118.74 12.99 13.17 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.39 -0.368 . . . . 0.0 111.275 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -70.55 -43.46 69.46 Favored 'General case' 0 CA--C 1.534 0.334 0 CA-C-N 116.322 -0.399 . . . . 0.0 111.931 -179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.55 140.14 51.92 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.026 0.441 . . . . 0.0 111.54 -179.476 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -120.64 127.64 75.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.525 178.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -130.11 130.58 65.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-O 121.349 0.595 . . . . 0.0 111.475 -179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.9 m-85 -92.65 102.12 6.26 Favored Pre-proline 0 C--N 1.326 -0.436 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.374 178.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -66.67 -16.66 51.18 Favored 'Trans proline' 0 C--N 1.346 0.447 0 C-N-CA 122.667 2.245 . . . . 0.0 113.7 -178.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 46.4 m-20 -100.57 -7.44 24.06 Favored 'General case' 0 CA--C 1.535 0.386 0 N-CA-C 112.033 0.383 . . . . 0.0 112.033 179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 57.0 m-85 -120.58 -21.82 6.61 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -179.897 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.9 29.82 45.53 Favored Glycine 0 C--N 1.332 0.333 0 C-N-CA 121.026 -0.607 . . . . 0.0 112.077 -179.369 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 51.1 t -110.85 117.98 56.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.81 0.338 . . . . 0.0 111.753 -178.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -119.93 121.0 38.03 Favored 'General case' 0 N--CA 1.468 0.443 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.226 179.117 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.48 158.92 43.37 Favored 'General case' 0 N--CA 1.463 0.208 0 N-CA-C 112.521 0.564 . . . . 0.0 112.521 -179.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 15.0 t-20 -104.01 137.0 42.61 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.477 179.596 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 45.0 mt -99.76 127.84 32.8 Favored Pre-proline 0 C--N 1.329 -0.287 0 CA-C-O 120.968 0.413 . . . . 0.0 111.466 -179.511 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.433 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 70.8 Cg_endo -82.05 130.36 6.46 Favored 'Trans proline' 0 CA--C 1.533 0.426 0 C-N-CA 122.689 2.259 . . . . 0.0 112.441 179.241 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . 0.407 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 10.7 tpt -68.06 125.57 26.77 Favored 'General case' 0 CA--C 1.533 0.291 0 CA-C-O 121.072 0.463 . . . . 0.0 111.644 -179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.51 13.11 79.16 Favored Glycine 0 CA--C 1.52 0.388 0 CA-C-N 115.855 -0.611 . . . . 0.0 112.866 179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.433 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.5 mm-40 -138.5 176.93 8.27 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.878 0.371 . . . . 0.0 111.125 -179.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -114.0 134.21 55.0 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.049 0.452 . . . . 0.0 111.661 -179.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.7 t80 -123.05 124.84 44.03 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.029 178.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.452 HG23 HG22 ' A' ' 65' ' ' VAL . 2.1 p -105.04 136.73 37.56 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.459 0 CA-C-O 121.544 0.688 . . . . 0.0 112.439 -178.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.7 t -113.17 112.92 42.44 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.498 -0.774 . . . . 0.0 110.113 179.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -93.84 119.49 32.85 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.951 0.405 . . . . 0.0 111.476 -179.333 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -135.46 156.6 38.74 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.145 179.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -119.96 97.57 49.45 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.393 -0.367 . . . . 0.0 111.614 -179.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.436 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.4 Cg_endo -72.75 100.28 1.16 Allowed 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 122.806 2.338 . . . . 0.0 112.309 179.502 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -95.46 5.34 51.85 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.435 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -131.97 133.29 44.32 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.798 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.89 127.74 35.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.0 0.429 . . . . 0.0 111.223 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 162.47 -156.56 28.25 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.93 -0.652 . . . . 0.0 112.764 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.02 126.13 48.88 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 121.198 0.523 . . . . 0.0 111.488 -179.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.439 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 84.0 m-85 -118.15 173.41 6.81 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.639 -0.71 . . . . 0.0 109.904 179.558 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 83.2 p -151.22 158.13 43.51 Favored 'General case' 0 C--N 1.33 -0.272 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -178.859 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 39.0 p90 -149.69 130.46 14.15 Favored 'General case' 0 CA--C 1.531 0.235 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.334 178.756 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . 0.419 ' HB1' ' HB3' ' A' ' 116' ' ' MET . . . -162.33 172.91 14.9 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.964 0.411 . . . . 0.0 112.001 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 41.2 t -120.58 130.41 54.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.627 179.233 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -77.0 70.34 2.34 Favored Glycine 0 CA--C 1.522 0.489 0 C-N-CA 120.923 -0.655 . . . . 0.0 113.084 -179.702 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -141.86 -31.53 0.55 Allowed 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.777 0.322 . . . . 0.0 111.593 179.914 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -156.14 -159.78 0.93 Allowed 'General case' 0 CA--C 1.532 0.268 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.116 179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 1.7 ttp -78.16 77.94 4.65 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-O 120.999 0.428 . . . . 0.0 111.302 179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . 0.419 ' HB3' ' HB1' ' A' ' 110' ' ' ALA . 0.0 OUTLIER -87.19 149.56 24.54 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.151 -179.954 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -148.4 105.21 3.58 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.8 0.333 . . . . 0.0 111.822 -179.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -146.06 121.15 1.42 Allowed Glycine 0 CA--C 1.521 0.444 0 C-N-CA 121.185 -0.531 . . . . 0.0 112.269 179.679 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.485 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 12.4 ttmt -123.09 151.57 41.89 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.106 0.479 . . . . 0.0 111.898 -179.255 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.439 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -134.52 139.79 45.69 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.735 179.479 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.0 mp -123.24 120.16 59.56 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-O 120.997 0.427 . . . . 0.0 110.81 179.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 85.2 t -104.16 123.19 57.8 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.202 -179.723 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.253 1.237 0 CA-C-O 118.102 -0.951 . . . . 0.0 111.505 -179.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.699 0 N-CA-C 112.237 -0.345 . . . . 0.0 112.237 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -114.15 8.71 17.0 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.934 0.397 . . . . 0.0 111.464 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -88.01 89.94 8.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.985 0.421 . . . . 0.0 111.274 -179.915 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 112.98 -168.59 12.64 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.788 179.856 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.11 128.41 24.13 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.042 0.449 . . . . 0.0 111.237 179.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.2 mtpt -91.34 129.24 37.36 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.874 179.794 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.65 152.36 40.51 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.908 -0.587 . . . . 0.0 111.317 179.804 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.563 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.5 pt20 -80.84 141.26 34.83 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-O 121.152 0.501 . . . . 0.0 111.444 -179.352 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 58.4 mt-30 -96.9 114.84 26.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.594 179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.39 -149.82 0.31 Allowed 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.456 -179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -82.01 72.72 9.06 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 112.425 0.528 . . . . 0.0 112.425 -179.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.76 -5.21 66.57 Favored Glycine 0 CA--C 1.522 0.471 0 C-N-CA 120.879 -0.677 . . . . 0.0 113.788 178.935 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.4 p90 -141.36 160.3 40.41 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.905 0.352 . . . . 0.0 110.746 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.18 155.66 21.68 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 120.988 0.423 . . . . 0.0 111.423 179.906 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.563 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.7 tt0 -144.53 143.84 31.03 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.545 -179.317 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -145.15 129.63 12.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.2 179.144 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 7.3 ttt180 -89.96 108.14 19.53 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.071 179.558 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.475 HG13 ' HD2' ' A' ' 51' ' ' PRO . 49.0 t -99.99 107.85 21.67 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.705 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -73.6 122.46 22.29 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.878 -0.601 . . . . 0.0 111.013 179.978 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.55 HG13 HD22 ' A' ' 75' ' ' LEU . 53.8 t -103.08 95.33 3.77 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 CA-C-O 121.535 0.683 . . . . 0.0 111.052 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.449 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 3.8 ptm -146.16 89.45 1.87 Allowed 'General case' 0 N--CA 1.464 0.257 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.405 179.562 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.55 0.24 89.8 Favored Glycine 0 CA--C 1.521 0.454 0 C-N-CA 120.811 -0.709 . . . . 0.0 111.545 -178.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.478 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.66 -140.6 6.81 Favored Glycine 0 N--CA 1.447 -0.572 0 N-CA-C 111.649 -0.581 . . . . 0.0 111.649 -179.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 62.3 m-85 -121.86 129.46 52.61 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.741 0.27 . . . . 0.0 110.543 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.49 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 20.8 m -68.84 -62.0 3.17 Favored Pre-proline 0 CA--C 1.538 0.49 0 C-N-CA 120.997 -0.281 . . . . 0.0 111.176 179.851 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.49 ' HD3' ' HB ' ' A' ' 50' ' ' THR . 63.5 Cg_endo -75.62 97.6 1.11 Allowed 'Trans proline' 0 C--N 1.356 0.927 0 C-N-CA 121.417 1.411 . . . . 0.0 111.064 177.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -52.11 -43.34 63.9 Favored 'General case' 0 N--CA 1.467 0.382 0 CA-C-N 116.125 -0.489 . . . . 0.0 112.062 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -134.17 118.45 17.67 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.711 179.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.488 HG13 ' HG3' ' A' ' 120' ' ' MET . 9.6 pt -96.91 127.35 49.17 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.218 0 CA-C-O 121.134 0.492 . . . . 0.0 110.939 179.569 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 98.9 t -95.51 125.86 48.15 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.601 -179.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 23.6 mt -133.69 167.68 20.07 Favored 'General case' 0 CA--C 1.531 0.24 0 CA-C-N 115.968 -0.56 . . . . 0.0 111.263 -179.943 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.2 mttt -96.59 168.84 10.29 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 116.395 -0.366 . . . . 0.0 110.685 179.593 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 13.5 ttpt -98.67 146.72 25.57 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.928 0.395 . . . . 0.0 111.927 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.5 t 66.06 19.7 11.19 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 115.587 -0.733 . . . . 0.0 111.89 179.624 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 5.7 p -123.53 135.2 25.84 Favored Pre-proline 0 CA--C 1.535 0.397 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.002 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.7 Cg_endo -64.3 122.7 10.74 Favored 'Trans proline' 0 C--N 1.346 0.398 0 C-N-CA 122.051 1.834 . . . . 0.0 111.711 178.761 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.1 138.98 54.36 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.79 0.328 . . . . 0.0 111.622 -179.628 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.447 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -120.92 125.33 47.17 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.719 0.771 . . . . 0.0 111.494 179.947 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 5.7 mm -97.66 115.25 37.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.654 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.518 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.9 109.8 21.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.535 -0.302 . . . . 0.0 111.375 -179.238 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 63.8 m-85 -95.5 111.81 23.65 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.016 0.436 . . . . 0.0 111.296 179.904 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -98.11 106.03 18.27 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.958 -0.564 . . . . 0.0 110.52 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.406 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 0.2 OUTLIER -78.19 105.16 9.24 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.282 0.563 . . . . 0.0 111.91 -179.448 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.05 -37.36 9.38 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.19 179.303 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.449 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 5.2 t70 -103.78 129.88 24.48 Favored Pre-proline 0 CA--C 1.535 0.379 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.922 179.544 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.5 Cg_endo -80.52 39.13 0.81 Allowed 'Trans proline' 0 C--N 1.347 0.452 0 C-N-CA 123.113 2.542 . . . . 0.0 112.881 -179.908 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 1.2 m -72.04 135.84 82.46 Favored Pre-proline 0 C--N 1.326 -0.432 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.349 -179.768 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.8 Cg_endo -64.08 -31.21 65.65 Favored 'Trans proline' 0 C--N 1.349 0.576 0 C-N-CA 122.617 2.211 . . . . 0.0 112.583 -179.992 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 5.2 p -76.79 -5.29 47.58 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-N 116.324 -0.398 . . . . 0.0 111.587 179.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.55 HD22 HG13 ' A' ' 45' ' ' VAL . 30.2 mt -120.12 15.94 12.38 Favored 'General case' 0 CA--C 1.531 0.226 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.964 179.642 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -67.82 -35.56 78.82 Favored 'General case' 0 CA--C 1.534 0.355 0 CA-C-N 116.096 -0.502 . . . . 0.0 112.243 -179.332 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 10.5 mt-30 -133.7 165.91 23.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.914 0.388 . . . . 0.0 111.583 -179.508 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . 0.417 HG13 ' N ' ' A' ' 79' ' ' VAL . 0.5 OUTLIER -137.72 141.37 39.22 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.337 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.115 179.858 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.417 ' N ' HG13 ' A' ' 78' ' ' ILE . 0.2 OUTLIER -139.9 134.14 36.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 121.364 0.602 . . . . 0.0 111.359 179.054 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -97.57 101.68 10.97 Favored Pre-proline 0 C--N 1.326 -0.44 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.84 178.958 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_endo -67.56 -13.79 40.14 Favored 'Trans proline' 0 C--N 1.347 0.481 0 C-N-CA 122.613 2.209 . . . . 0.0 113.431 -178.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 35.6 m-20 -100.57 -9.11 22.32 Favored 'General case' 0 CA--C 1.535 0.399 0 N-CA-C 111.947 0.351 . . . . 0.0 111.947 -179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.2 m-85 -123.02 -19.93 5.92 Favored 'General case' 0 N--CA 1.467 0.39 0 N-CA-C 112.226 0.454 . . . . 0.0 112.226 -179.353 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.71 28.97 49.7 Favored Glycine 0 C--N 1.332 0.347 0 C-N-CA 120.86 -0.685 . . . . 0.0 112.226 -179.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 54.4 t -110.75 116.87 53.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.745 0.307 . . . . 0.0 111.535 -179.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 4.3 t60 -127.12 117.72 22.95 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.87 0.367 . . . . 0.0 110.45 179.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.12 170.48 15.61 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 121.09 0.471 . . . . 0.0 111.858 -179.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -106.24 145.84 31.08 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.477 179.65 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 34.8 mt -105.47 129.35 24.85 Favored Pre-proline 0 C--N 1.329 -0.296 0 CA-C-O 120.867 0.365 . . . . 0.0 111.412 -179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.445 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.7 Cg_endo -81.86 129.21 6.18 Favored 'Trans proline' 0 CA--C 1.532 0.409 0 C-N-CA 122.752 2.301 . . . . 0.0 112.486 179.265 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . 0.406 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 10.3 tpt -67.07 125.27 25.47 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.138 0.494 . . . . 0.0 111.699 -179.575 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.66 6.37 85.64 Favored Glycine 0 C--N 1.333 0.367 0 CA-C-N 115.864 -0.607 . . . . 0.0 113.077 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.445 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 45.7 mt-10 -134.29 176.82 8.26 Favored 'General case' 0 C--O 1.234 0.258 0 CA-C-O 120.988 0.423 . . . . 0.0 111.018 -179.533 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -115.06 132.49 56.58 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.0 0.429 . . . . 0.0 111.767 -179.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.4 t80 -116.47 123.9 48.64 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.968 178.727 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.518 HG23 HG22 ' A' ' 65' ' ' VAL . 1.6 p -101.28 137.1 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.378 0 CA-C-O 121.651 0.739 . . . . 0.0 112.51 -178.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.5 t -113.98 110.21 31.3 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.154 178.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 8.2 mt-10 -92.67 118.82 31.45 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.373 -179.458 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -135.84 154.52 34.35 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.361 -179.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -119.22 97.43 50.46 Favored Pre-proline 0 C--N 1.329 -0.314 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.272 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.449 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 74.2 Cg_endo -73.47 101.92 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.364 0 C-N-CA 122.845 2.363 . . . . 0.0 112.72 179.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -97.71 19.9 12.84 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.984 0.421 . . . . 0.0 111.483 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -146.97 129.93 16.31 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.774 179.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -86.1 126.28 34.08 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.903 0.382 . . . . 0.0 111.269 179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.09 -168.29 41.36 Favored Glycine 0 CA--C 1.519 0.306 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.816 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -99.76 112.02 24.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.141 0.496 . . . . 0.0 110.774 179.797 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 22.3 m-85 -110.94 172.4 6.9 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.76 -0.655 . . . . 0.0 110.292 -179.539 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 54.2 p -153.69 163.39 40.08 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.132 0.491 . . . . 0.0 112.274 -179.543 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 31.2 p90 -145.58 140.63 27.54 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-N 115.562 -0.745 . . . . 0.0 110.518 179.067 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.39 178.48 8.62 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-O 121.332 0.587 . . . . 0.0 112.273 -179.222 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 49.6 t -122.35 137.18 54.94 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.108 178.818 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -73.93 74.16 1.19 Allowed Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.008 -0.615 . . . . 0.0 113.474 -179.365 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 3.4 ttm -164.3 -39.26 0.03 OUTLIER 'General case' 0 CA--C 1.532 0.275 0 CA-C-O 120.694 0.283 . . . . 0.0 111.443 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -114.69 177.19 4.74 Favored 'General case' 0 CA--C 1.533 0.306 0 CA-C-O 120.948 0.404 . . . . 0.0 111.205 -179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -95.77 -16.08 22.15 Favored 'General case' 0 CA--C 1.531 0.25 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.491 -179.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -73.9 146.38 44.06 Favored 'General case' 0 CA--C 1.533 0.319 0 CA-C-O 121.008 0.432 . . . . 0.0 110.891 179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 22.9 p80 -153.54 157.98 40.57 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.92 0.39 . . . . 0.0 111.611 -179.634 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -107.49 151.92 16.92 Favored Glycine 0 N--CA 1.451 -0.36 0 N-CA-C 111.646 -0.582 . . . . 0.0 111.646 179.381 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . . . . . . . . . 1.2 ttpt -115.94 151.9 34.5 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 120.957 0.408 . . . . 0.0 111.476 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.488 ' HG3' HG13 ' A' ' 54' ' ' ILE . 9.2 ttp -133.96 122.18 22.71 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 116.056 -0.52 . . . . 0.0 111.048 -179.814 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -109.69 116.08 51.28 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 121.101 0.477 . . . . 0.0 110.88 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 98.3 t -100.05 120.07 48.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.077 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 24.1 mt-10 . . . . . 0 C--O 1.253 1.247 0 CA-C-O 118.13 -0.938 . . . . 0.0 111.491 -179.542 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.684 0 CA-C-O 121.227 0.348 . . . . 0.0 112.315 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -121.9 24.59 9.55 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 120.98 0.419 . . . . 0.0 111.26 179.959 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -83.53 72.2 10.29 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 121.041 0.448 . . . . 0.0 111.443 -179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 118.19 167.36 14.04 Favored Glycine 0 CA--C 1.518 0.256 0 C-N-CA 121.087 -0.578 . . . . 0.0 112.88 179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 19.8 mp0 -117.14 123.85 47.74 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 121.175 0.512 . . . . 0.0 111.114 -179.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 3.4 ttmt -89.5 127.52 35.87 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.909 -179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.16 155.95 39.11 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.052 179.747 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.575 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 10.9 pt20 -79.68 132.8 36.31 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.295 0.569 . . . . 0.0 111.248 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.0 mt-30 -92.79 109.11 20.53 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.83 179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.03 -157.07 0.47 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.352 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.5 t-20 -83.09 80.3 9.09 Favored 'General case' 0 CA--C 1.533 0.321 0 N-CA-C 112.172 0.434 . . . . 0.0 112.172 -179.203 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.05 -7.18 67.01 Favored Glycine 0 CA--C 1.523 0.534 0 C-N-CA 120.846 -0.692 . . . . 0.0 114.178 178.762 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . 0.452 ' HB2' ' O ' ' A' ' 61' ' ' PRO . 24.6 p90 -144.15 165.53 27.57 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 117.191 0.496 . . . . 0.0 111.075 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.89 154.96 33.61 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.901 0.382 . . . . 0.0 111.201 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.575 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.5 tt0 -145.21 143.13 30.12 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.43 -179.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -144.71 129.2 13.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-O 120.93 0.395 . . . . 0.0 110.714 178.841 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -90.58 111.45 22.76 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.317 0.58 . . . . 0.0 111.127 179.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.652 HG13 ' HD2' ' A' ' 51' ' ' PRO . 42.6 t -100.05 102.82 13.95 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.551 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.571 -179.877 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.414 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.4 OUTLIER -72.56 113.61 9.79 Favored 'General case' 0 C--O 1.234 0.279 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.607 179.874 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.604 HG13 HD22 ' A' ' 75' ' ' LEU . 43.1 t -94.66 97.45 6.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.367 0 CA-C-N 115.674 -0.693 . . . . 0.0 111.336 -178.87 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.474 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.7 ptm -141.68 85.27 1.94 Allowed 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.532 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.94 1.42 90.63 Favored Glycine 0 CA--C 1.521 0.41 0 C-N-CA 120.958 -0.639 . . . . 0.0 111.516 -178.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.427 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.94 -166.95 35.79 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.014 -0.834 . . . . 0.0 111.014 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 24.0 m-85 -93.75 123.75 37.29 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.86 0.33 . . . . 0.0 110.44 179.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.501 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 25.5 m -63.67 -62.17 5.81 Favored Pre-proline 0 CA--C 1.538 0.489 0 CA-C-O 119.594 -0.241 . . . . 0.0 111.07 -179.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.652 ' HD2' HG13 ' A' ' 43' ' ' VAL . 61.2 Cg_endo -75.23 98.73 1.19 Allowed 'Trans proline' 0 C--N 1.356 0.945 0 C-N-CA 121.211 1.274 . . . . 0.0 110.974 177.366 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -51.54 -45.31 62.94 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-N 115.845 -0.616 . . . . 0.0 112.3 -179.066 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.461 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -133.18 118.28 18.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.53 179.704 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.435 HG13 ' HG3' ' A' ' 120' ' ' MET . 5.0 pt -96.92 126.12 49.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 121.141 0.495 . . . . 0.0 111.273 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 88.9 t -99.07 125.65 52.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.362 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.413 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.57 HD22 ' HB1' ' A' ' 62' ' ' ALA . 2.3 mt -136.27 166.19 24.0 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.759 -0.655 . . . . 0.0 111.354 -179.588 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -86.0 177.18 7.67 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.411 -0.358 . . . . 0.0 111.263 179.382 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 12.2 ttpt -106.05 147.36 28.99 Favored 'General case' 0 N--CA 1.465 0.277 0 N-CA-C 111.842 0.312 . . . . 0.0 111.842 -179.313 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.8 t 62.35 26.9 16.08 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.704 -0.68 . . . . 0.0 111.646 179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 7.9 p -123.57 137.06 27.97 Favored Pre-proline 0 CA--C 1.538 0.508 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.435 -179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . 0.452 ' O ' ' HB2' ' A' ' 38' ' ' TYR . 36.2 Cg_endo -67.25 93.44 0.35 Allowed 'Trans proline' 0 C--N 1.348 0.504 0 C-N-CA 122.773 2.316 . . . . 0.0 112.206 178.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.57 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -97.99 138.78 34.8 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 120.911 0.386 . . . . 0.0 111.988 -179.083 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.491 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.5 OUTLIER -121.51 129.09 52.71 Favored 'General case' 0 C--O 1.233 0.218 0 CA-C-O 121.736 0.779 . . . . 0.0 111.644 179.747 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.6 mm -100.63 114.78 40.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-N 115.285 -0.871 . . . . 0.0 110.695 179.857 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.501 HG22 HG23 ' A' ' 96' ' ' VAL . 3.3 t -91.65 109.86 21.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.677 -0.238 . . . . 0.0 111.411 -179.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 74.1 m-85 -95.44 113.63 25.32 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.034 0.445 . . . . 0.0 111.278 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -100.18 106.6 18.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.883 -0.599 . . . . 0.0 110.142 179.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -78.05 105.98 9.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.312 0.577 . . . . 0.0 112.12 -179.143 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.2 tptp -99.9 -34.56 10.07 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.084 179.202 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.474 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.6 t70 -109.6 132.68 21.2 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.779 179.426 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 87.3 Cg_endo -81.13 40.43 0.99 Allowed 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.085 2.524 . . . . 0.0 113.306 -179.388 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.514 ' HB3' HD12 ' A' ' 75' ' ' LEU . 36.2 t -68.65 134.7 90.41 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.394 -0.366 . . . . 0.0 111.331 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -64.43 -27.96 62.56 Favored 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 122.652 2.234 . . . . 0.0 112.647 179.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.1 m -78.92 -10.75 59.91 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.308 -0.406 . . . . 0.0 111.168 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.604 HD22 HG13 ' A' ' 45' ' ' VAL . 40.9 mt -110.57 10.21 23.04 Favored 'General case' 0 CA--C 1.531 0.239 0 CA-C-N 116.367 -0.379 . . . . 0.0 111.497 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.4 t70 -68.23 -40.53 82.0 Favored 'General case' 0 CA--C 1.534 0.342 0 CA-C-O 120.87 0.367 . . . . 0.0 111.81 -179.782 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -123.54 148.64 46.11 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.442 -0.345 . . . . 0.0 111.359 -179.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -130.53 129.88 64.7 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.465 0 CA-C-O 121.13 0.49 . . . . 0.0 110.374 178.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.414 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 2.4 p -133.98 132.45 56.23 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 CA-C-O 121.2 0.524 . . . . 0.0 111.18 179.811 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 14.8 m-85 -93.07 101.76 5.99 Favored Pre-proline 0 C--N 1.324 -0.524 0 CA-C-N 115.42 -0.809 . . . . 0.0 109.259 178.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.415 ' HD2' ' HA ' ' A' ' 109' ' ' PHE . 38.2 Cg_endo -66.57 -15.71 48.52 Favored 'Trans proline' 0 C--N 1.347 0.485 0 C-N-CA 122.662 2.241 . . . . 0.0 113.527 -178.391 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 64.4 m-20 -100.58 -7.59 23.87 Favored 'General case' 0 CA--C 1.537 0.443 0 N-CA-C 111.815 0.302 . . . . 0.0 111.815 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 49.0 m-85 -121.36 -20.9 6.5 Favored 'General case' 0 N--CA 1.466 0.362 0 N-CA-C 112.026 0.38 . . . . 0.0 112.026 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.95 29.43 46.84 Favored Glycine 0 CA--C 1.519 0.307 0 C-N-CA 120.999 -0.619 . . . . 0.0 112.105 -179.524 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.414 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 50.9 t -110.89 115.71 50.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-O 120.881 0.372 . . . . 0.0 111.753 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.6 p80 -118.75 124.95 48.53 Favored 'General case' 0 N--CA 1.469 0.506 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.429 179.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -143.04 160.06 41.09 Favored 'General case' 0 N--CA 1.464 0.27 0 N-CA-C 112.312 0.486 . . . . 0.0 112.312 -179.057 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 20.9 t-20 -104.08 139.55 39.02 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.471 179.594 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 42.3 mt -101.63 127.23 31.87 Favored Pre-proline 0 C--N 1.328 -0.337 0 CA-C-O 120.904 0.383 . . . . 0.0 111.438 -179.561 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.438 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 68.9 Cg_endo -81.0 128.14 6.4 Favored 'Trans proline' 0 CA--C 1.532 0.383 0 C-N-CA 122.667 2.245 . . . . 0.0 112.479 179.441 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.0 tpt -66.75 125.49 26.01 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.993 0.425 . . . . 0.0 111.583 -179.603 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.84 7.88 83.4 Favored Glycine 0 CA--C 1.52 0.393 0 CA-C-N 115.887 -0.597 . . . . 0.0 112.889 -179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.438 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 52.4 mm-40 -135.58 176.9 8.25 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-O 121.014 0.435 . . . . 0.0 111.14 -179.734 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.0 mp0 -114.63 134.34 55.14 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.033 0.444 . . . . 0.0 111.669 -179.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 10.9 t80 -121.95 126.15 47.96 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.108 179.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.501 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -103.81 139.28 25.21 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.402 0 CA-C-O 121.516 0.674 . . . . 0.0 112.674 -178.873 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 53.8 t -116.41 110.82 32.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.123 178.68 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.3 mt-10 -93.67 119.37 32.6 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.255 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -133.31 157.57 42.69 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-O 121.086 0.469 . . . . 0.0 111.186 -179.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.5 m -122.3 95.57 46.99 Favored Pre-proline 0 C--N 1.328 -0.334 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.317 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -74.68 101.2 1.42 Allowed 'Trans proline' 0 C--N 1.345 0.387 0 C-N-CA 122.816 2.344 . . . . 0.0 112.649 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.4 mt-10 -95.02 23.73 5.39 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.922 0.391 . . . . 0.0 111.64 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -149.25 130.43 14.54 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.764 179.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.51 127.21 35.25 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.04 0.448 . . . . 0.0 111.438 -179.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 165.01 -160.38 33.66 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.659 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 -101.58 125.58 48.26 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.051 0.453 . . . . 0.0 111.275 -179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.439 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 91.7 m-85 -118.31 167.54 11.45 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.198 179.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.6 p -143.53 154.88 44.07 Favored 'General case' 0 C--O 1.234 0.26 0 N-CA-C 112.275 0.472 . . . . 0.0 112.275 -179.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.415 ' HA ' ' HD2' ' A' ' 81' ' ' PRO . 44.4 p90 -148.73 129.46 14.16 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.916 178.869 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.81 158.09 22.3 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.116 -179.703 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 6.7 t -156.51 162.82 39.93 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.921 0.391 . . . . 0.0 111.188 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 87.08 -77.29 1.99 Allowed Glycine 0 CA--C 1.52 0.385 0 C-N-CA 120.924 -0.655 . . . . 0.0 113.237 179.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -135.0 177.59 7.69 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.005 0.431 . . . . 0.0 111.418 -179.674 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 2.1 p30 -85.2 2.03 45.52 Favored 'General case' 0 CA--C 1.533 0.325 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.508 -179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 6.9 mtm -85.26 -7.66 58.91 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-O 120.875 0.369 . . . . 0.0 111.324 179.685 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -76.34 155.95 33.73 Favored 'General case' 0 C--O 1.233 0.19 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.119 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -144.89 106.25 4.22 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-O 120.987 0.423 . . . . 0.0 111.858 -179.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -141.34 115.69 1.03 Allowed Glycine 0 CA--C 1.519 0.316 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.969 179.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.461 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.9 ttpt -119.4 149.7 41.41 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.304 0.573 . . . . 0.0 111.729 -179.181 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.439 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 12.0 ttp -133.93 135.16 43.39 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.734 179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.1 mp -119.38 119.29 60.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-O 120.952 0.406 . . . . 0.0 110.856 179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 89.6 t -104.12 120.16 53.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.135 -179.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.227 -0.892 . . . . 0.0 111.464 -179.773 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.706 0 N-CA-C 112.529 -0.229 . . . . 0.0 112.529 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . 63.47 -91.23 0.03 OUTLIER 'General case' 0 N--CA 1.47 0.528 0 C-N-CA 123.408 0.683 . . . . 0.0 112.127 179.91 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -137.15 111.23 8.34 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 120.951 0.405 . . . . 0.0 111.39 -179.693 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -84.67 167.8 42.96 Favored Glycine 0 CA--C 1.519 0.339 0 C-N-CA 120.993 -0.623 . . . . 0.0 112.962 179.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -119.09 132.19 55.99 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-O 121.134 0.493 . . . . 0.0 111.223 -179.768 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -92.42 126.1 37.35 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.808 179.747 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.36 153.19 42.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.275 -0.42 . . . . 0.0 111.24 179.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 1.4 pt20 -81.42 141.2 34.14 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.163 0.506 . . . . 0.0 111.52 -179.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 31.1 mt-30 -97.16 115.71 28.05 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.88 -0.6 . . . . 0.0 110.596 179.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -97.51 -149.88 0.34 Allowed 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.147 -0.479 . . . . 0.0 111.513 -179.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -81.74 73.0 8.8 Favored 'General case' 0 CA--C 1.535 0.376 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -179.149 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.68 -6.54 67.62 Favored Glycine 0 CA--C 1.522 0.498 0 C-N-CA 120.65 -0.786 . . . . 0.0 113.898 179.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 38.9 p90 -139.89 163.7 31.96 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.767 0.283 . . . . 0.0 110.799 -179.901 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -113.92 153.1 29.83 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-O 121.111 0.481 . . . . 0.0 111.283 -179.928 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.409 ' HG3' ' HE ' ' A' ' 63' ' ' ARG . 3.3 tt0 -142.16 141.6 32.64 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.606 -179.653 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.19 128.95 22.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.116 179.203 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -89.1 107.46 19.05 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.159 0.504 . . . . 0.0 111.017 179.574 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.587 HG13 ' HD2' ' A' ' 51' ' ' PRO . 47.3 t -100.28 103.29 14.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.416 -179.97 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -73.29 116.87 14.35 Favored 'General case' 0 C--O 1.235 0.342 0 CA-C-N 115.799 -0.637 . . . . 0.0 111.025 -179.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.558 HG13 HD22 ' A' ' 75' ' ' LEU . 42.0 t -98.01 99.08 8.11 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 CA-C-O 121.52 0.676 . . . . 0.0 111.423 -179.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.497 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.0 ptm -143.88 86.93 1.88 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.584 -0.735 . . . . 0.0 110.462 179.137 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 82.98 2.28 90.67 Favored Glycine 0 CA--C 1.521 0.435 0 N-CA-C 111.453 -0.659 . . . . 0.0 111.453 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.447 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.65 -154.01 24.97 Favored Glycine 0 N--CA 1.447 -0.571 0 N-CA-C 111.151 -0.779 . . . . 0.0 111.151 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 65.3 m-85 -107.43 127.62 53.76 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 116.85 0.325 . . . . 0.0 110.407 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.517 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 40.7 m -66.92 -64.46 2.16 Favored Pre-proline 0 CA--C 1.539 0.522 0 CA-C-O 119.529 -0.272 . . . . 0.0 111.389 -179.665 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.587 ' HD2' HG13 ' A' ' 43' ' ' VAL . 65.1 Cg_endo -75.0 98.65 1.18 Allowed 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.329 1.353 . . . . 0.0 111.028 177.789 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.89 -44.67 59.92 Favored 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 116.083 -0.508 . . . . 0.0 112.33 -179.346 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.506 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.04 119.2 20.7 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.645 0.259 . . . . 0.0 110.913 179.788 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 7.1 pt -97.1 125.71 50.06 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.315 0 CA-C-O 120.976 0.417 . . . . 0.0 111.102 179.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 88.4 t -98.27 126.77 51.24 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.535 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.412 HD22 ' HB1' ' A' ' 62' ' ' ALA . 2.9 mt -136.93 166.79 22.82 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 115.934 -0.576 . . . . 0.0 111.384 -179.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.2 mtmm -90.38 172.49 8.71 Favored 'General case' 0 CA--C 1.534 0.338 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.915 179.322 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.6 ttpp -103.38 148.76 25.49 Favored 'General case' 0 C--N 1.33 -0.239 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.534 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 37.3 t 65.45 20.12 11.68 Favored 'General case' 0 N--CA 1.472 0.635 0 CA-C-N 115.537 -0.756 . . . . 0.0 111.779 179.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.44 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.9 p -123.73 136.01 26.85 Favored Pre-proline 0 CA--C 1.535 0.371 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.868 -179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 24.2 Cg_endo -64.2 122.9 11.03 Favored 'Trans proline' 0 C--N 1.347 0.476 0 C-N-CA 122.105 1.87 . . . . 0.0 111.561 178.7 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.412 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -124.46 137.85 54.4 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.007 0.432 . . . . 0.0 111.632 -179.539 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.423 ' HB2' HG22 ' A' ' 96' ' ' VAL . 5.6 ptt180 -119.65 125.55 49.01 Favored 'General case' 0 C--O 1.236 0.358 0 CA-C-O 121.714 0.769 . . . . 0.0 111.286 179.807 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.5 mm -98.35 115.58 38.94 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.61 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.538 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.79 109.21 20.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-O 120.798 0.332 . . . . 0.0 111.558 -179.177 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.7 m-85 -97.83 107.8 20.37 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.898 0.38 . . . . 0.0 111.386 179.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.8 t70 -93.47 107.28 19.15 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.533 179.807 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.404 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 1.2 tpt180 -77.07 101.3 6.01 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-O 121.183 0.516 . . . . 0.0 111.776 -179.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 21.0 tptt -96.38 -34.28 11.61 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.678 -0.692 . . . . 0.0 110.413 179.455 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.497 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.8 t70 -108.93 131.39 21.82 Favored Pre-proline 0 C--N 1.328 -0.341 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.693 179.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -79.6 39.54 0.84 Allowed 'Trans proline' 0 C--N 1.349 0.578 0 C-N-CA 123.163 2.575 . . . . 0.0 113.246 -179.374 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.41 ' HB3' HD12 ' A' ' 75' ' ' LEU . 30.0 t -68.23 136.05 91.37 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.41 -0.359 . . . . 0.0 111.095 179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -65.29 -26.98 55.95 Favored 'Trans proline' 0 C--N 1.348 0.53 0 C-N-CA 122.684 2.256 . . . . 0.0 112.584 179.713 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -81.65 -7.98 59.65 Favored 'General case' 0 CA--C 1.531 0.232 0 CA-C-N 116.354 -0.385 . . . . 0.0 111.243 179.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.558 HD22 HG13 ' A' ' 45' ' ' VAL . 40.5 mt -115.02 8.28 15.72 Favored 'General case' 0 CA--C 1.531 0.231 0 CA-C-N 116.46 -0.336 . . . . 0.0 111.472 -179.811 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.61 -38.18 90.14 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-O 120.899 0.38 . . . . 0.0 111.933 -179.583 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 3.9 mp0 -124.86 160.35 29.0 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.343 -0.39 . . . . 0.0 111.092 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -135.95 131.8 50.0 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.417 0 CA-C-O 121.167 0.508 . . . . 0.0 110.83 179.202 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.417 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 1.0 OUTLIER -135.79 130.53 49.46 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.279 0.561 . . . . 0.0 111.199 179.757 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -93.89 101.9 7.05 Favored Pre-proline 0 C--N 1.326 -0.437 0 CA-C-N 115.402 -0.817 . . . . 0.0 109.393 178.849 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -66.7 -15.94 48.92 Favored 'Trans proline' 0 C--N 1.348 0.507 0 C-N-CA 122.616 2.211 . . . . 0.0 113.578 -178.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 55.7 m-20 -100.53 -7.13 24.46 Favored 'General case' 0 CA--C 1.536 0.416 0 N-CA-C 111.97 0.359 . . . . 0.0 111.97 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.4 m-85 -121.17 -23.45 5.77 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.004 0.372 . . . . 0.0 112.004 -179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 83.26 26.94 41.82 Favored Glycine 0 CA--C 1.52 0.363 0 C-N-CA 120.892 -0.671 . . . . 0.0 112.234 -179.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.417 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 50.1 t -107.62 119.58 57.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-O 120.772 0.32 . . . . 0.0 111.605 -178.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -124.14 120.59 32.77 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.436 -0.347 . . . . 0.0 110.667 179.569 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -139.6 173.57 11.4 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-O 121.004 0.431 . . . . 0.0 112.109 -179.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -114.92 142.18 46.94 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.972 179.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 31.0 mt -102.77 124.09 40.12 Favored Pre-proline 0 CA--C 1.531 0.25 0 CA-C-O 120.949 0.404 . . . . 0.0 111.53 -179.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.414 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 61.1 Cg_endo -77.07 129.48 10.56 Favored 'Trans proline' 0 C--N 1.344 0.322 0 C-N-CA 122.753 2.302 . . . . 0.0 112.725 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . 0.404 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 10.2 tpt -66.36 125.01 24.3 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.039 0.447 . . . . 0.0 111.803 -179.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.03 1.25 82.35 Favored Glycine 0 C--N 1.332 0.336 0 CA-C-N 115.886 -0.597 . . . . 0.0 112.838 -179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.414 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 42.1 mt-10 -133.93 177.13 7.97 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.955 0.407 . . . . 0.0 110.802 -179.568 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -119.01 134.73 55.01 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.135 0.493 . . . . 0.0 111.596 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.406 ' HB2' ' HD2' ' A' ' 90' ' ' PRO . 12.5 t80 -113.77 127.91 56.2 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.171 179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.538 HG23 HG22 ' A' ' 65' ' ' VAL . 1.8 p -99.87 136.3 31.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 CA-C-O 121.588 0.708 . . . . 0.0 112.504 -179.036 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 65.7 t -113.84 112.17 39.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.226 0 CA-C-N 115.436 -0.802 . . . . 0.0 110.203 178.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 8.0 mt-10 -93.53 118.89 31.92 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.352 -0.386 . . . . 0.0 111.584 -179.454 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.88 158.05 41.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.255 179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -120.48 97.08 48.94 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.326 -0.397 . . . . 0.0 111.663 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.44 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 65.8 Cg_endo -72.5 99.73 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.399 0 C-N-CA 122.915 2.41 . . . . 0.0 112.336 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -95.07 3.73 54.5 Favored 'General case' 0 CA--C 1.534 0.339 0 N-CA-C 111.868 0.321 . . . . 0.0 111.868 -179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 1.4 tt0 -130.82 133.37 45.89 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.77 0.319 . . . . 0.0 110.812 179.892 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.75 128.08 35.62 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.98 0.419 . . . . 0.0 111.241 -179.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.11 -157.9 30.1 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.833 -0.698 . . . . 0.0 112.709 -179.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -101.42 125.64 48.09 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.21 0.528 . . . . 0.0 111.605 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.452 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 85.8 m-85 -118.46 172.81 7.22 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.868 179.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 93.4 p -155.03 158.74 39.59 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 112.572 0.582 . . . . 0.0 112.572 -178.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 32.1 p90 -147.23 133.43 19.42 Favored 'General case' 0 CA--C 1.533 0.308 0 CA-C-N 115.542 -0.754 . . . . 0.0 111.088 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.43 162.56 27.71 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.994 -179.887 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 5.8 t -143.97 135.22 25.68 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-O 120.875 0.369 . . . . 0.0 111.562 179.89 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.59 -172.67 54.58 Favored Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.012 -0.613 . . . . 0.0 113.173 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 4.1 tpt -103.39 88.43 3.11 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.03 0.443 . . . . 0.0 110.733 179.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -148.48 175.8 10.84 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.054 -0.521 . . . . 0.0 111.181 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -88.09 -30.38 19.92 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.275 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.53 121.43 14.89 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-O 121.104 0.478 . . . . 0.0 111.295 179.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 56.2 p-80 -149.94 154.14 37.78 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.879 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -109.46 146.68 16.9 Favored Glycine 0 N--CA 1.451 -0.362 0 C-N-CA 120.625 -0.797 . . . . 0.0 112.757 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.506 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 13.4 ttmt -118.05 148.8 41.91 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 120.958 0.409 . . . . 0.0 110.852 179.89 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.452 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -131.25 138.48 49.34 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.062 179.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.1 mp -121.84 118.49 55.85 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.364 0 CA-C-O 120.964 0.411 . . . . 0.0 110.775 179.479 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.5 t -102.06 121.84 53.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 116.094 -0.503 . . . . 0.0 111.301 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 . . . . . 0 C--O 1.252 1.235 0 CA-C-O 118.273 -0.87 . . . . 0.0 111.441 -179.802 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.495 2.609 0 CA-C-O 121.155 0.308 . . . . 0.0 112.506 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -83.42 66.18 8.73 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.1 0.476 . . . . 0.0 111.472 -179.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 1.4 mpp? -95.69 90.88 5.85 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.204 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 109.74 -176.69 19.52 Favored Glycine 0 CA--C 1.519 0.338 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.981 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -120.69 129.73 53.79 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.107 0.479 . . . . 0.0 111.166 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.2 ttmt -91.93 125.48 36.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.995 179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -70.94 150.89 45.25 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.189 179.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.557 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 3.8 pt20 -80.71 139.68 36.0 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.131 0.491 . . . . 0.0 111.422 -179.385 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 6.9 mp0 -95.66 115.33 27.28 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.929 -0.578 . . . . 0.0 110.776 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.75 -149.79 0.3 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.256 179.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -83.6 75.84 10.01 Favored 'General case' 0 CA--C 1.533 0.317 0 N-CA-C 112.252 0.464 . . . . 0.0 112.252 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 94.75 -5.97 69.92 Favored Glycine 0 CA--C 1.523 0.536 0 C-N-CA 120.88 -0.676 . . . . 0.0 113.928 179.016 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -142.32 160.54 40.06 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.912 0.356 . . . . 0.0 110.859 -179.781 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -109.98 157.29 19.44 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-O 121.094 0.473 . . . . 0.0 111.45 -179.912 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.557 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 1.0 OUTLIER -145.88 143.13 29.4 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.838 -0.619 . . . . 0.0 111.474 -179.539 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -142.7 129.05 17.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 121.064 0.459 . . . . 0.0 111.024 179.079 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 10.5 ttt180 -89.45 106.98 18.81 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.192 0.52 . . . . 0.0 111.028 179.602 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.584 HG13 ' HD2' ' A' ' 51' ' ' PRO . 47.0 t -99.82 103.0 14.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.499 0 CA-C-N 115.813 -0.63 . . . . 0.0 110.474 -179.871 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.403 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.5 OUTLIER -73.07 116.66 13.85 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.08 -179.906 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.57 HG13 HD22 ' A' ' 75' ' ' LEU . 48.5 t -97.52 98.91 7.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.639 -0.709 . . . . 0.0 111.466 -179.001 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.446 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.6 ptm -143.06 85.83 1.89 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.453 179.111 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.04 3.37 87.75 Favored Glycine 0 CA--C 1.52 0.356 0 C-N-CA 120.941 -0.647 . . . . 0.0 111.509 -178.522 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.447 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 159.81 -143.32 8.99 Favored Glycine 0 N--CA 1.449 -0.467 0 N-CA-C 111.333 -0.707 . . . . 0.0 111.333 -179.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 60.7 m-85 -116.2 127.89 55.16 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 116.687 0.244 . . . . 0.0 110.56 179.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.521 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 42.6 m -67.7 -64.67 1.85 Allowed Pre-proline 0 CA--C 1.54 0.58 0 CA-C-O 119.548 -0.263 . . . . 0.0 111.481 -179.649 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.584 ' HD2' HG13 ' A' ' 43' ' ' VAL . 66.7 Cg_endo -75.0 98.88 1.2 Allowed 'Trans proline' 0 C--N 1.356 0.941 0 C-N-CA 121.288 1.325 . . . . 0.0 111.044 177.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -51.45 -44.51 62.41 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 116.066 -0.516 . . . . 0.0 112.333 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.498 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.72 118.99 20.71 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.635 0.255 . . . . 0.0 110.944 179.77 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 9.0 pt -97.65 125.08 50.9 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-O 121.033 0.444 . . . . 0.0 111.087 179.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.7 t -95.98 126.38 48.58 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.222 -0.444 . . . . 0.0 111.497 -179.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 10.2 mt -134.83 169.61 17.1 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.928 -0.578 . . . . 0.0 111.403 -179.683 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -97.66 166.98 11.24 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.328 -0.397 . . . . 0.0 110.56 179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.3 ttpp -96.92 147.87 23.54 Favored 'General case' 0 C--N 1.33 -0.266 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 -179.302 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.6 t 65.92 20.2 11.33 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.459 -0.791 . . . . 0.0 111.953 179.439 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.451 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 5.6 p -123.59 134.93 25.61 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.468 -0.333 . . . . 0.0 110.991 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -64.41 123.77 12.3 Favored 'Trans proline' 0 C--N 1.346 0.408 0 C-N-CA 122.1 1.867 . . . . 0.0 111.596 178.618 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.95 137.23 53.68 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.908 0.385 . . . . 0.0 111.748 -179.527 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.485 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.1 OUTLIER -117.5 125.9 51.67 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.705 0.764 . . . . 0.0 111.414 179.827 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.1 mm -98.08 114.78 36.43 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.726 179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.528 HG22 HG23 ' A' ' 96' ' ' VAL . 4.1 t -90.53 107.73 18.81 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.35 -179.249 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 61.9 m-85 -95.71 102.78 14.61 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.912 0.387 . . . . 0.0 111.479 -179.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.2 t70 -89.66 105.84 18.06 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.178 179.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -79.77 101.98 8.78 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 121.237 0.541 . . . . 0.0 112.12 -179.084 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.3 tppt? -96.49 -36.65 10.71 Favored 'General case' 0 CA--C 1.533 0.311 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.636 179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.446 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.6 t70 -102.32 130.52 23.99 Favored Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.932 179.765 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -80.62 39.25 0.83 Allowed 'Trans proline' 0 C--N 1.349 0.577 0 C-N-CA 123.089 2.526 . . . . 0.0 113.112 -179.543 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.428 ' HB2' HD12 ' A' ' 75' ' ' LEU . 2.5 m -70.07 137.77 87.2 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.281 -0.418 . . . . 0.0 111.299 179.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_endo -63.01 -33.55 73.75 Favored 'Trans proline' 0 C--N 1.349 0.562 0 C-N-CA 122.814 2.343 . . . . 0.0 112.982 -179.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.9 p -75.54 -9.87 58.95 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 116.482 -0.326 . . . . 0.0 111.388 179.851 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.57 HD22 HG13 ' A' ' 45' ' ' VAL . 57.3 mt -112.93 14.62 19.77 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 116.408 -0.36 . . . . 0.0 111.469 -179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -68.33 -35.35 77.65 Favored 'General case' 0 CA--C 1.534 0.337 0 CA-C-O 120.91 0.386 . . . . 0.0 111.461 179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 76.7 mt-30 -131.62 165.9 22.63 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.932 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -139.13 133.68 40.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 120.945 0.402 . . . . 0.0 111.116 179.301 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -136.46 132.27 48.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.369 0 CA-C-O 121.34 0.59 . . . . 0.0 111.403 179.378 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.6 m-85 -94.35 102.08 7.85 Favored Pre-proline 0 C--N 1.325 -0.486 0 CA-C-N 115.136 -0.938 . . . . 0.0 109.466 178.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 109' ' ' PHE . 37.6 Cg_endo -65.92 -16.4 52.57 Favored 'Trans proline' 0 C--N 1.348 0.501 0 C-N-CA 122.696 2.264 . . . . 0.0 113.696 -178.34 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 48.9 m-20 -100.46 -7.38 24.31 Favored 'General case' 0 CA--C 1.535 0.394 0 N-CA-C 111.933 0.345 . . . . 0.0 111.933 -179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 56.1 m-85 -120.44 -22.04 6.62 Favored 'General case' 0 N--CA 1.466 0.353 0 N-CA-C 111.872 0.323 . . . . 0.0 111.872 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.69 31.0 41.84 Favored Glycine 0 C--N 1.333 0.378 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.922 -179.325 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.3 t -114.46 117.06 54.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.633 0.254 . . . . 0.0 111.659 -178.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 16.7 t-80 -126.13 122.76 36.61 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-O 120.892 0.377 . . . . 0.0 110.617 179.244 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -136.77 171.21 14.83 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.019 -0.537 . . . . 0.0 111.655 -179.566 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 1.1 m-80 -106.32 143.54 34.29 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.73 179.81 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 38.7 mt -104.65 128.3 27.15 Favored Pre-proline 0 C--N 1.33 -0.267 0 CA-C-O 120.972 0.415 . . . . 0.0 111.359 -179.73 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.417 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 73.5 Cg_endo -80.64 126.7 6.08 Favored 'Trans proline' 0 CA--C 1.532 0.421 0 C-N-CA 122.726 2.284 . . . . 0.0 112.507 179.284 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.4 tpt -65.35 124.93 23.55 Favored 'General case' 0 CA--C 1.532 0.274 0 CA-C-O 120.974 0.416 . . . . 0.0 111.64 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 88.29 1.66 81.15 Favored Glycine 0 CA--C 1.52 0.387 0 CA-C-N 115.961 -0.563 . . . . 0.0 112.959 -179.936 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.417 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 42.6 mt-10 -134.04 177.37 7.79 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 120.885 0.374 . . . . 0.0 110.857 -179.567 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -117.55 134.24 55.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.179 0.514 . . . . 0.0 111.658 -179.947 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 13.0 t80 -113.78 126.84 55.65 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.142 179.545 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.528 HG23 HG22 ' A' ' 65' ' ' VAL . 1.4 p -98.4 136.92 27.51 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 CA-C-O 121.55 0.69 . . . . 0.0 112.613 -179.053 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 62.0 t -115.52 111.4 35.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.132 178.837 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.3 mt-10 -92.66 118.42 31.03 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.275 -0.421 . . . . 0.0 111.52 -179.305 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.68 157.07 40.95 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.142 179.953 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.8 m -121.14 98.3 47.2 Favored Pre-proline 0 C--N 1.33 -0.266 0 CA-C-N 116.317 -0.401 . . . . 0.0 111.533 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.451 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.1 Cg_endo -72.79 100.62 1.21 Allowed 'Trans proline' 0 C--N 1.346 0.417 0 C-N-CA 122.781 2.321 . . . . 0.0 112.376 179.563 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -95.34 6.7 48.3 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-O 120.791 0.329 . . . . 0.0 111.783 -179.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -133.12 133.75 43.31 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.528 -0.305 . . . . 0.0 110.706 179.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.32 127.49 35.8 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.918 0.39 . . . . 0.0 111.29 -179.884 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.08 -157.08 29.09 Favored Glycine 0 N--CA 1.453 -0.219 0 C-N-CA 120.83 -0.7 . . . . 0.0 112.716 -179.805 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -101.68 125.13 48.29 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.166 0.508 . . . . 0.0 111.684 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.456 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 82.6 m-85 -117.64 172.27 7.47 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.622 -0.717 . . . . 0.0 109.666 179.495 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 86.9 p -153.72 158.62 41.27 Favored 'General case' 0 C--N 1.33 -0.268 0 N-CA-C 112.594 0.59 . . . . 0.0 112.594 -178.795 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . 0.404 ' HA ' ' HD2' ' A' ' 81' ' ' PRO . 37.5 p90 -148.71 134.46 18.88 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 115.424 -0.807 . . . . 0.0 110.87 178.666 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.31 162.92 28.22 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-O 120.903 0.383 . . . . 0.0 111.564 -179.72 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 3.2 t -154.75 157.49 38.09 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.949 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 85.8 -5.56 83.43 Favored Glycine 0 CA--C 1.522 0.475 0 C-N-CA 120.931 -0.652 . . . . 0.0 113.538 179.655 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 56.82 50.83 11.74 Favored 'General case' 0 N--CA 1.47 0.564 0 CA-C-O 121.063 0.459 . . . . 0.0 111.722 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.3 t-20 -120.66 -173.11 2.51 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.361 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -73.82 -34.09 64.42 Favored 'General case' 0 C--O 1.235 0.31 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.477 -179.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -65.32 119.79 11.6 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-O 121.122 0.487 . . . . 0.0 111.242 179.928 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 56.5 p-80 -149.23 151.5 34.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.242 -179.771 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -110.02 148.8 17.41 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.936 -0.649 . . . . 0.0 112.433 179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.498 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 0.9 OUTLIER -119.32 148.81 42.76 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.955 0.407 . . . . 0.0 111.033 -179.926 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.456 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 3.0 ttm -130.58 137.68 49.78 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.09 179.664 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -120.92 118.32 55.93 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.406 0 CA-C-O 121.024 0.44 . . . . 0.0 110.639 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 88.9 t -101.79 122.96 54.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.307 -179.656 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 3.0 mm-40 . . . . . 0 C--O 1.253 1.249 0 CA-C-O 118.163 -0.922 . . . . 0.0 111.462 -179.645 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.753 0 CA-C-O 121.15 0.305 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -84.07 71.19 10.57 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.032 0.444 . . . . 0.0 111.443 -179.912 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.2 OUTLIER -116.63 119.05 34.31 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.173 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 101.55 -176.89 26.72 Favored Glycine 0 CA--C 1.52 0.377 0 C-N-CA 120.735 -0.745 . . . . 0.0 112.905 179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -141.63 143.6 33.73 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.163 0.506 . . . . 0.0 111.579 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 2.1 ttmt -101.38 129.62 47.42 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.619 179.749 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.09 152.84 39.83 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.813 0.34 . . . . 0.0 111.187 179.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.516 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 22.8 pt20 -85.49 142.96 28.82 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.155 0.502 . . . . 0.0 111.791 -179.25 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.7 mt-30 -94.96 114.92 26.8 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.785 179.661 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 1.9 mmtp -94.97 -150.72 0.31 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.024 0.44 . . . . 0.0 111.362 179.859 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.9 t30 -82.69 70.54 9.69 Favored 'General case' 0 CA--C 1.534 0.363 0 N-CA-C 112.129 0.418 . . . . 0.0 112.129 -179.302 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.55 -9.83 59.05 Favored Glycine 0 CA--C 1.521 0.411 0 C-N-CA 120.771 -0.728 . . . . 0.0 113.713 178.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 32.8 p90 -137.93 165.64 26.02 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.953 0.376 . . . . 0.0 110.895 -179.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.7 152.45 31.96 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-O 120.912 0.387 . . . . 0.0 111.103 179.552 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.516 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.9 tt0 -143.27 139.94 30.41 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.069 -0.514 . . . . 0.0 111.576 -179.325 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.0 128.42 22.01 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.975 179.185 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 11.0 ttt180 -89.28 108.85 19.85 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.297 0.57 . . . . 0.0 111.114 179.616 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.617 HG13 ' HD2' ' A' ' 51' ' ' PRO . 44.3 t -100.1 103.61 15.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.583 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -72.91 117.03 14.13 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.979 -179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.537 HG13 HD22 ' A' ' 75' ' ' LEU . 52.3 t -99.59 99.18 8.03 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.328 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.558 -178.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.486 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.7 ptm -145.86 86.68 1.73 Allowed 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.182 179.112 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.22 -0.42 88.75 Favored Glycine 0 CA--C 1.52 0.368 0 N-CA-C 111.327 -0.709 . . . . 0.0 111.327 -178.243 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.441 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.8 -161.4 32.76 Favored Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 -179.869 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 47.4 m-85 -101.99 126.39 48.91 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 117.046 0.423 . . . . 0.0 110.418 179.53 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.514 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 40.3 m -63.82 -63.49 3.87 Favored Pre-proline 0 CA--C 1.54 0.569 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.566 -179.547 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.617 ' HD2' HG13 ' A' ' 43' ' ' VAL . 68.2 Cg_endo -75.48 95.86 1.02 Allowed 'Trans proline' 0 C--N 1.356 0.961 0 C-N-CA 121.301 1.334 . . . . 0.0 111.036 177.653 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -49.6 -43.54 46.47 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-N 115.904 -0.589 . . . . 0.0 112.32 -179.371 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.427 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.94 118.69 19.19 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.677 -0.238 . . . . 0.0 110.476 179.56 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.8 pt -97.45 126.4 50.31 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.301 0 CA-C-O 121.086 0.469 . . . . 0.0 111.172 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 78.0 t -96.07 127.31 48.26 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.283 -179.945 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 10.4 mt -135.0 171.51 14.33 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.558 -179.63 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -97.13 173.26 7.34 Favored 'General case' 0 CA--C 1.531 0.227 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.739 179.453 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 6.0 ttpp -104.8 147.93 27.19 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.829 0.347 . . . . 0.0 111.926 -179.434 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.4 t 65.49 20.7 11.74 Favored 'General case' 0 N--CA 1.472 0.658 0 CA-C-N 115.555 -0.748 . . . . 0.0 111.751 179.672 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.438 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.95 136.46 27.49 Favored Pre-proline 0 CA--C 1.534 0.361 0 CA-C-N 116.246 -0.433 . . . . 0.0 111.169 -179.769 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_endo -64.28 122.46 10.42 Favored 'Trans proline' 0 C--N 1.346 0.439 0 C-N-CA 122.096 1.864 . . . . 0.0 111.47 178.242 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.91 138.04 54.26 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 120.99 0.424 . . . . 0.0 111.775 -179.45 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.418 HH11 ' HD2' ' A' ' 63' ' ' ARG . 6.7 ptt85 -120.67 126.55 50.5 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.789 0.804 . . . . 0.0 111.081 179.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.4 mm -100.07 114.16 37.76 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.759 179.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.507 HG22 HG23 ' A' ' 96' ' ' VAL . 3.0 t -89.93 107.49 18.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.467 -179.057 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -96.53 106.96 19.3 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 120.918 0.389 . . . . 0.0 111.318 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -91.54 105.79 18.01 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.309 -0.405 . . . . 0.0 110.633 179.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.45 96.2 5.32 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-O 121.204 0.526 . . . . 0.0 111.596 -179.338 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 17.4 tptt -90.95 -37.92 13.19 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.69 179.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.486 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.6 t70 -102.73 130.95 22.86 Favored Pre-proline 0 C--N 1.328 -0.348 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.785 179.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -79.75 38.57 0.75 Allowed 'Trans proline' 0 C--N 1.348 0.552 0 C-N-CA 123.151 2.567 . . . . 0.0 113.235 -179.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 36.9 t -69.67 135.55 88.1 Favored Pre-proline 0 C--N 1.328 -0.331 0 CA-C-N 116.378 -0.374 . . . . 0.0 111.046 179.779 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -64.33 -28.21 63.4 Favored 'Trans proline' 0 C--N 1.349 0.556 0 C-N-CA 122.63 2.22 . . . . 0.0 112.42 179.698 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 22.7 m -78.75 -9.23 59.36 Favored 'General case' 0 N--CA 1.462 0.171 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.081 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.537 HD22 HG13 ' A' ' 45' ' ' VAL . 46.0 mt -116.05 17.27 15.9 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.456 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.6 t70 -71.7 -32.19 67.55 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.044 0.387 . . . . 0.0 112.044 -179.654 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 6.8 mt-30 -133.29 165.87 23.81 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.967 0.413 . . . . 0.0 111.393 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -140.57 130.14 26.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.98 179.296 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -130.27 132.7 64.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 121.481 0.657 . . . . 0.0 111.157 179.349 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.3 m-85 -95.91 101.96 9.43 Favored Pre-proline 0 C--N 1.325 -0.458 0 CA-C-N 115.017 -0.992 . . . . 0.0 109.662 179.05 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -66.56 -15.19 46.93 Favored 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.59 2.193 . . . . 0.0 113.624 -178.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -100.71 -7.16 24.09 Favored 'General case' 0 CA--C 1.536 0.41 0 N-CA-C 111.981 0.363 . . . . 0.0 111.981 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 66.7 m-85 -122.45 -22.06 5.58 Favored 'General case' 0 N--CA 1.465 0.301 0 N-CA-C 112.017 0.376 . . . . 0.0 112.017 -179.774 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 79.49 31.4 41.39 Favored Glycine 0 C--N 1.332 0.355 0 C-N-CA 120.942 -0.647 . . . . 0.0 112.028 -179.186 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.1 t -114.69 119.62 62.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.654 0.264 . . . . 0.0 111.657 -178.721 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 13.7 t-80 -126.37 119.8 28.23 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.841 0.353 . . . . 0.0 110.427 179.251 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.8 173.23 11.76 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.754 -179.474 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -110.07 151.44 27.2 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-N 116.097 -0.502 . . . . 0.0 111.046 179.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 28.0 mt -111.25 125.04 31.31 Favored Pre-proline 0 CA--C 1.532 0.261 0 CA-C-O 120.945 0.402 . . . . 0.0 111.386 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.427 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 64.5 Cg_endo -78.18 131.06 10.57 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 122.826 2.351 . . . . 0.0 112.708 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.6 tpt -66.81 124.43 22.92 Favored 'General case' 0 CA--C 1.531 0.247 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.799 -179.415 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 86.64 3.59 83.65 Favored Glycine 0 CA--C 1.52 0.345 0 CA-C-N 115.814 -0.63 . . . . 0.0 113.012 179.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.427 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 43.4 mt-10 -134.96 177.09 8.08 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.862 0.363 . . . . 0.0 110.905 -179.509 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -118.56 134.8 54.82 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.231 0.539 . . . . 0.0 111.546 179.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.5 t80 -113.54 125.35 54.1 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.221 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.507 HG23 HG22 ' A' ' 65' ' ' VAL . 2.3 p -99.08 135.2 35.16 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.552 0.691 . . . . 0.0 112.489 -178.983 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 66.7 t -110.77 112.24 39.71 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.055 178.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.0 mt-10 -94.09 118.6 31.76 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.95 0.405 . . . . 0.0 111.475 -179.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -134.99 166.5 28.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.0 -0.545 . . . . 0.0 111.146 -179.956 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 5.2 m -129.66 97.51 24.32 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.473 -0.331 . . . . 0.0 111.486 179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.438 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 70.2 Cg_endo -72.99 100.58 1.22 Allowed 'Trans proline' 0 CA--C 1.532 0.423 0 C-N-CA 122.844 2.363 . . . . 0.0 112.447 179.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -95.32 3.8 54.09 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-N 116.556 -0.293 . . . . 0.0 111.665 -179.586 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 2.9 mt-30 -132.16 134.68 45.68 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.735 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.32 124.24 34.24 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.974 0.416 . . . . 0.0 111.272 -179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 171.42 -165.34 38.32 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.884 -179.789 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -97.25 115.47 27.67 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.19 0.519 . . . . 0.0 110.721 179.757 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.413 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 20.5 m-85 -111.4 173.03 6.54 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.691 -0.686 . . . . 0.0 109.971 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 85.5 p -152.58 165.1 36.24 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 121.307 0.575 . . . . 0.0 112.549 -178.573 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.2 p90 -152.07 136.86 17.09 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.441 178.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -161.92 176.89 10.33 Favored 'General case' 0 N--CA 1.464 0.256 0 CA-C-O 120.834 0.349 . . . . 0.0 111.825 -179.32 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 48.6 t -131.98 133.15 44.14 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.064 179.195 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 95.67 -135.8 12.54 Favored Glycine 0 CA--C 1.519 0.313 0 C-N-CA 120.807 -0.711 . . . . 0.0 112.832 179.899 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER -122.69 -96.98 0.46 Allowed 'General case' 0 CA--C 1.534 0.334 0 CA-C-O 120.649 0.261 . . . . 0.0 110.979 -179.907 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.8 p-10 -86.72 59.82 5.86 Favored 'General case' 0 CA--C 1.533 0.322 0 CA-C-O 121.035 0.445 . . . . 0.0 111.346 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -154.9 179.35 9.2 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.04 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.7 OUTLIER 69.5 174.18 0.29 Allowed 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 115.811 -0.631 . . . . 0.0 112.289 179.651 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 56.4 t-80 -164.9 103.74 0.79 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.87 -0.605 . . . . 0.0 111.009 179.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -150.55 122.59 1.41 Allowed Glycine 0 CA--C 1.517 0.193 0 C-N-CA 120.89 -0.671 . . . . 0.0 112.361 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.427 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.0 ttmm -122.84 151.44 41.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.069 0.462 . . . . 0.0 111.828 -179.4 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.413 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.6 ttm -134.74 131.22 37.34 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.773 179.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.7 mp -116.03 117.79 56.68 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.444 0 CA-C-O 121.024 0.44 . . . . 0.0 110.67 179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 74.8 t -101.8 122.53 54.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.001 -0.545 . . . . 0.0 111.288 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 . . . . . 0 C--O 1.252 1.213 0 CA-C-O 118.112 -0.947 . . . . 0.0 111.387 -179.583 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.688 0 CA-C-O 121.073 0.263 . . . . 0.0 112.47 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -82.21 91.66 6.77 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.143 0.497 . . . . 0.0 111.547 -179.942 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 4.8 tpp -81.4 101.0 9.56 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.09 -0.505 . . . . 0.0 111.143 -179.926 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -78.92 168.34 53.41 Favored Glycine 0 CA--C 1.519 0.304 0 C-N-CA 120.963 -0.637 . . . . 0.0 113.115 -179.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -127.96 130.43 48.39 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-O 121.096 0.474 . . . . 0.0 111.402 -179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.8 mtpt -91.67 130.85 37.4 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.79 179.56 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -74.25 151.37 39.92 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.488 -179.873 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.587 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.6 pt20 -79.04 139.4 38.16 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.142 0.496 . . . . 0.0 111.089 -179.712 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 2.5 mt-30 -97.31 114.47 26.24 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.959 -0.564 . . . . 0.0 110.766 179.993 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -94.89 -154.5 0.43 Allowed 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.0 -0.546 . . . . 0.0 111.256 -179.739 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.7 t30 -82.11 74.23 9.1 Favored 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -179.032 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 100.14 -9.14 59.48 Favored Glycine 0 CA--C 1.521 0.44 0 C-N-CA 120.655 -0.783 . . . . 0.0 113.986 178.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 27.5 p90 -140.96 164.66 29.66 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 117.036 0.418 . . . . 0.0 111.066 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -114.67 153.65 29.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.974 0.416 . . . . 0.0 111.353 -179.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.587 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.9 tt0 -143.36 143.08 31.51 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.98 -0.554 . . . . 0.0 111.46 -179.579 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.51 128.53 17.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-O 121.011 0.434 . . . . 0.0 111.08 179.238 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.63 106.12 18.11 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 121.213 0.53 . . . . 0.0 111.168 179.71 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.604 HG13 ' HD2' ' A' ' 51' ' ' PRO . 46.1 t -99.01 103.29 14.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 CA-C-N 115.743 -0.662 . . . . 0.0 110.65 -179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.416 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.9 OUTLIER -73.09 118.2 15.75 Favored 'General case' 0 C--O 1.236 0.35 0 CA-C-N 115.844 -0.616 . . . . 0.0 110.789 -179.961 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.617 HG13 HD22 ' A' ' 75' ' ' LEU . 53.9 t -100.23 97.82 6.25 Favored 'Isoleucine or valine' 0 C--O 1.236 0.364 0 CA-C-N 115.729 -0.669 . . . . 0.0 111.472 -178.852 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.473 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.9 ptm -143.27 85.02 1.84 Allowed 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.372 179.273 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 85.08 0.24 88.9 Favored Glycine 0 CA--C 1.519 0.338 0 N-CA-C 111.347 -0.701 . . . . 0.0 111.347 -178.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.413 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.38 -169.29 36.15 Favored Glycine 0 N--CA 1.446 -0.677 0 N-CA-C 111.234 -0.746 . . . . 0.0 111.234 -179.954 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 26.3 m-85 -92.17 125.73 36.96 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.924 0.362 . . . . 0.0 110.348 179.511 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.522 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 43.3 m -65.27 -63.97 3.02 Favored Pre-proline 0 CA--C 1.54 0.587 0 CA-C-O 119.557 -0.259 . . . . 0.0 111.293 -179.657 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.604 ' HD2' HG13 ' A' ' 43' ' ' VAL . 64.3 Cg_endo -75.03 96.55 1.03 Allowed 'Trans proline' 0 C--N 1.357 0.995 0 C-N-CA 121.244 1.296 . . . . 0.0 111.205 177.815 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 -51.36 -42.51 61.36 Favored 'General case' 0 N--CA 1.47 0.535 0 CA-C-N 116.144 -0.48 . . . . 0.0 112.182 -179.342 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.509 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -130.96 118.74 21.09 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.559 -0.292 . . . . 0.0 110.763 179.617 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.2 pt -99.16 126.93 52.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.951 0.405 . . . . 0.0 111.098 179.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 85.2 t -98.25 127.03 51.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.309 -0.405 . . . . 0.0 111.473 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.2 mt -135.95 165.52 25.47 Favored 'General case' 0 CA--C 1.534 0.336 0 CA-C-N 115.953 -0.567 . . . . 0.0 111.318 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 13.6 mttt -90.12 176.26 6.84 Favored 'General case' 0 CA--C 1.532 0.255 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.728 179.164 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.2 ttpp -107.0 148.64 28.44 Favored 'General case' 0 N--CA 1.464 0.269 0 N-CA-C 112.333 0.494 . . . . 0.0 112.333 -179.108 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.9 t 64.93 20.38 12.1 Favored 'General case' 0 N--CA 1.472 0.654 0 CA-C-N 115.494 -0.775 . . . . 0.0 111.771 179.602 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.45 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 8.0 p -123.93 136.75 27.82 Favored Pre-proline 0 C--N 1.325 -0.461 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.064 -179.74 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 28.6 Cg_endo -64.75 122.46 10.31 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 122.164 1.91 . . . . 0.0 111.639 178.607 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -123.45 139.8 53.65 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-O 120.969 0.414 . . . . 0.0 111.53 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.451 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 5.8 ptt180 -121.5 126.92 50.39 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-O 121.764 0.792 . . . . 0.0 111.344 179.898 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.7 mm -98.4 114.71 36.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.726 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.424 HG22 HG23 ' A' ' 96' ' ' VAL . 4.5 t -90.62 113.44 26.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 CA-C-N 116.517 -0.31 . . . . 0.0 111.35 -179.391 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.5 m-85 -100.31 114.87 28.7 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.077 0.465 . . . . 0.0 111.5 -179.812 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.5 t70 -99.45 102.99 14.73 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.943 -0.572 . . . . 0.0 110.065 179.31 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.55 98.42 6.11 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.176 0.513 . . . . 0.0 111.998 -179.148 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 8.9 tptp -94.29 -35.69 12.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.536 179.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.473 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.8 t70 -106.17 130.79 22.43 Favored Pre-proline 0 CA--C 1.534 0.341 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.931 179.579 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 90.9 Cg_endo -81.2 39.39 0.85 Allowed 'Trans proline' 0 C--N 1.349 0.598 0 C-N-CA 123.059 2.506 . . . . 0.0 113.302 -179.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -70.4 138.33 86.49 Favored Pre-proline 0 C--N 1.329 -0.311 0 CA-C-N 116.53 -0.305 . . . . 0.0 111.186 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.4 Cg_endo -62.75 -32.73 78.08 Favored 'Trans proline' 0 C--N 1.35 0.63 0 C-N-CA 122.924 2.416 . . . . 0.0 113.257 -179.353 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.4 p -76.08 -8.06 56.13 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 120.779 0.323 . . . . 0.0 111.5 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.617 HD22 HG13 ' A' ' 45' ' ' VAL . 53.0 mt -114.88 13.67 17.15 Favored 'General case' 0 CA--C 1.533 0.314 0 CA-C-N 116.45 -0.341 . . . . 0.0 111.356 -179.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -68.49 -36.88 79.56 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-O 120.913 0.387 . . . . 0.0 111.643 -179.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 11.0 mt-30 -132.23 161.58 33.08 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.376 -0.375 . . . . 0.0 111.066 -179.802 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -136.96 131.22 46.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 121.038 0.446 . . . . 0.0 111.083 179.521 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -133.09 132.96 58.79 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 121.362 0.601 . . . . 0.0 111.31 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.0 m-85 -94.76 102.14 8.39 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-N 115.142 -0.935 . . . . 0.0 109.509 178.842 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.25 -16.55 52.14 Favored 'Trans proline' 0 C--N 1.348 0.525 0 C-N-CA 122.67 2.246 . . . . 0.0 113.668 -178.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 48.2 m-20 -100.38 -7.04 24.83 Favored 'General case' 0 CA--C 1.536 0.411 0 N-CA-C 111.848 0.314 . . . . 0.0 111.848 -179.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 56.5 m-85 -120.52 -20.78 7.03 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 111.924 0.342 . . . . 0.0 111.924 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 77.37 32.31 48.02 Favored Glycine 0 C--N 1.333 0.398 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.944 -179.198 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 49.1 t -116.72 117.98 57.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 -178.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 22.3 t-80 -123.79 122.03 36.98 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.802 0.334 . . . . 0.0 110.402 179.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.9 163.64 28.69 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.704 -179.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -104.88 139.04 40.21 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.481 179.794 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 45.7 mt -101.34 128.45 29.22 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-O 120.856 0.36 . . . . 0.0 111.541 -179.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.433 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 72.7 Cg_endo -82.91 128.65 5.19 Favored 'Trans proline' 0 CA--C 1.532 0.415 0 C-N-CA 122.71 2.273 . . . . 0.0 112.388 179.198 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -66.45 125.12 24.67 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.08 0.467 . . . . 0.0 111.725 -179.577 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.88 11.77 80.9 Favored Glycine 0 CA--C 1.52 0.364 0 CA-C-N 115.898 -0.592 . . . . 0.0 112.98 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.433 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.6 mm-40 -137.64 176.97 8.23 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 120.89 0.376 . . . . 0.0 111.083 -179.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -113.37 134.73 54.48 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.025 0.441 . . . . 0.0 111.733 -179.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.1 t80 -123.98 127.86 48.54 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.935 178.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.424 HG23 HG22 ' A' ' 65' ' ' VAL . 2.3 p -107.0 137.18 39.16 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.454 0 CA-C-O 121.417 0.627 . . . . 0.0 112.628 -178.865 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 67.2 t -112.93 113.19 43.37 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.134 178.907 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.7 mt-10 -94.11 120.15 33.96 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.95 0.405 . . . . 0.0 111.516 -179.44 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -136.0 157.9 38.53 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.121 179.782 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.82 97.79 48.14 Favored Pre-proline 0 C--N 1.33 -0.279 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.682 -179.747 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 67.1 Cg_endo -72.82 101.31 1.29 Allowed 'Trans proline' 0 C--N 1.347 0.498 0 C-N-CA 122.814 2.343 . . . . 0.0 112.15 179.539 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.9 mt-10 -95.51 1.96 54.15 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -179.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -129.81 134.84 47.8 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.762 0.315 . . . . 0.0 110.74 179.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -89.93 124.25 34.56 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-O 121.007 0.432 . . . . 0.0 111.273 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 166.82 -157.3 29.71 Favored Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.844 -0.693 . . . . 0.0 112.63 -179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 -101.64 125.72 48.35 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.187 0.518 . . . . 0.0 111.487 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.446 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 84.9 m-85 -117.34 171.44 7.97 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.593 -0.73 . . . . 0.0 110.013 179.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 88.3 p -150.22 158.31 44.02 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 112.448 0.536 . . . . 0.0 112.448 -178.765 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.3 p90 -150.4 131.46 14.37 Favored 'General case' 0 CA--C 1.535 0.377 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.957 178.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.36 165.09 26.95 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.075 -179.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.453 ' O ' ' HG3' ' A' ' 116' ' ' MET . 4.1 t -147.74 157.68 43.66 Favored 'General case' 0 N--CA 1.464 0.259 0 CA-C-O 121.008 0.432 . . . . 0.0 111.405 179.915 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 88.81 -90.77 1.67 Allowed Glycine 0 CA--C 1.52 0.349 0 C-N-CA 120.893 -0.67 . . . . 0.0 113.195 179.658 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -145.09 -170.03 3.33 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 120.745 0.307 . . . . 0.0 111.111 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -78.56 52.38 1.17 Allowed 'General case' 0 CA--C 1.536 0.418 0 CA-C-O 120.925 0.393 . . . . 0.0 111.676 -179.838 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -126.59 -17.54 5.03 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.078 179.776 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . 0.453 ' HG3' ' O ' ' A' ' 111' ' ' CYS . 0.3 OUTLIER -84.93 164.57 18.27 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.169 179.953 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -147.36 105.47 3.75 Favored 'General case' 0 C--N 1.331 -0.198 0 N-CA-C 111.963 0.357 . . . . 0.0 111.963 -179.757 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -142.95 116.96 1.06 Allowed Glycine 0 CA--C 1.52 0.403 0 CA-C-N 115.967 -0.561 . . . . 0.0 111.882 179.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.509 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.7 ttpt -122.15 148.71 44.58 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.204 0.526 . . . . 0.0 111.904 -179.089 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.446 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.6 ttm -132.4 139.15 47.96 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.686 179.439 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -122.39 119.72 59.07 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 CA-C-O 121.116 0.484 . . . . 0.0 110.854 179.586 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 90.9 t -102.97 123.08 56.13 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 116.034 -0.53 . . . . 0.0 111.272 -179.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 19.5 mt-10 . . . . . 0 C--O 1.252 1.201 0 CA-C-O 118.169 -0.92 . . . . 0.0 111.42 -179.774 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.935 ' N ' ' HZ1' ' A' ' 31' ' ' LYS . . . . . . . . 0 N--CA 1.498 2.789 0 CA-C-O 121.147 0.304 . . . . 0.0 112.387 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -96.49 -12.19 24.48 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.918 0.39 . . . . 0.0 111.382 179.845 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -132.11 -51.32 0.96 Allowed 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.231 179.965 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -103.0 -163.15 25.76 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.926 -0.654 . . . . 0.0 112.851 179.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 18.4 mm-40 -133.14 130.27 38.98 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.128 0.489 . . . . 0.0 111.328 179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . 0.935 ' HZ1' ' N ' ' A' ' 26' ' ' GLY . 0.2 OUTLIER -89.97 125.59 35.43 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.936 -0.574 . . . . 0.0 110.709 179.823 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -70.93 152.07 44.03 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.376 -0.374 . . . . 0.0 111.238 179.755 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.53 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 17.2 pt20 -81.27 137.99 35.77 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 121.214 0.531 . . . . 0.0 111.448 -179.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 7.2 mp0 -94.53 113.2 25.0 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.865 179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -92.63 -151.32 0.28 Allowed 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.191 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 3.1 t-20 -83.81 77.51 9.87 Favored 'General case' 0 CA--C 1.535 0.379 0 N-CA-C 112.03 0.382 . . . . 0.0 112.03 -179.223 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.15 -6.49 68.98 Favored Glycine 0 CA--C 1.523 0.557 0 C-N-CA 120.812 -0.709 . . . . 0.0 114.047 178.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.7 p90 -143.54 161.34 38.72 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 117.045 0.423 . . . . 0.0 111.072 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.19 156.63 21.14 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.058 0.456 . . . . 0.0 111.349 179.744 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.53 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 3.4 tt0 -145.75 144.45 30.33 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.434 -179.566 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -146.96 129.04 7.02 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.732 179.135 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.417 HH11 ' HD2' ' A' ' 42' ' ' ARG . 0.1 OUTLIER -90.9 110.18 21.41 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-O 121.252 0.548 . . . . 0.0 110.938 179.305 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.491 HG13 ' HD2' ' A' ' 51' ' ' PRO . 60.6 t -100.42 108.21 22.57 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.757 -179.668 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -72.68 124.97 26.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.648 179.64 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.569 HG13 HD22 ' A' ' 75' ' ' LEU . 53.7 t -104.64 96.44 4.6 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.406 0 CA-C-O 121.475 0.655 . . . . 0.0 111.262 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.484 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.0 ptp -141.97 87.74 2.06 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 115.515 -0.766 . . . . 0.0 110.373 179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.11 -15.88 36.27 Favored Glycine 0 CA--C 1.522 0.482 0 C-N-CA 120.523 -0.846 . . . . 0.0 111.127 -178.035 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 178.79 -138.72 3.71 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.483 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 56.4 m-85 -121.09 129.59 53.38 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.862 0.331 . . . . 0.0 110.59 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.489 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 20.2 m -65.84 -60.93 6.34 Favored Pre-proline 0 CA--C 1.538 0.519 0 C-N-CA 121.027 -0.269 . . . . 0.0 110.911 179.537 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.491 ' HD2' HG13 ' A' ' 43' ' ' VAL . 74.4 Cg_endo -76.79 95.77 1.07 Allowed 'Trans proline' 0 C--N 1.358 1.045 0 C-N-CA 121.333 1.355 . . . . 0.0 110.968 177.575 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.77 -42.73 58.11 Favored 'General case' 0 N--CA 1.469 0.487 0 N-CA-C 112.198 0.444 . . . . 0.0 112.198 -179.331 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.482 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.73 118.52 20.07 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.648 -0.251 . . . . 0.0 110.782 179.52 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.8 pt -97.32 124.45 50.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 121.085 0.469 . . . . 0.0 110.888 179.501 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 86.5 t -97.25 126.73 49.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.426 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.509 -179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 5.3 mt -134.21 170.12 16.17 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.844 -0.616 . . . . 0.0 111.357 -179.724 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -93.28 173.73 7.57 Favored 'General case' 0 CA--C 1.532 0.254 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.684 179.461 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 2.6 ttpt -104.29 146.7 28.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.779 0.323 . . . . 0.0 111.844 -179.206 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 33.4 t 64.97 20.86 12.21 Favored 'General case' 0 N--CA 1.471 0.615 0 CA-C-N 115.545 -0.752 . . . . 0.0 111.832 179.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.45 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 7.9 p -123.44 135.61 26.26 Favored Pre-proline 0 C--N 1.327 -0.398 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.935 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.6 Cg_endo -64.34 122.49 10.45 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 122.076 1.85 . . . . 0.0 111.668 178.588 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.25 138.86 54.35 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.877 0.37 . . . . 0.0 111.577 -179.553 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.413 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.0 OUTLIER -121.57 126.79 49.98 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.769 0.795 . . . . 0.0 111.439 179.932 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.0 mm -99.0 115.82 40.5 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.836 -179.85 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.483 HG22 HG23 ' A' ' 96' ' ' VAL . 3.2 t -91.71 110.25 22.35 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 116.472 -0.331 . . . . 0.0 111.216 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 66.8 m-85 -95.59 114.77 26.56 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.076 0.465 . . . . 0.0 111.467 -179.669 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 34.9 t70 -99.93 104.48 16.11 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.398 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.4 ' HA ' ' HB ' ' A' ' 45' ' ' VAL . 0.1 OUTLIER -77.6 106.54 9.45 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.274 0.559 . . . . 0.0 112.144 -179.155 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -101.23 -33.83 9.91 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.415 179.293 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.484 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 2.0 t70 -110.6 133.87 21.04 Favored Pre-proline 0 CA--C 1.535 0.392 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.862 179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -81.67 40.29 0.96 Allowed 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 123.086 2.524 . . . . 0.0 112.975 -179.8 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -67.41 137.29 93.56 Favored Pre-proline 0 C--N 1.33 -0.254 0 CA-C-N 116.321 -0.399 . . . . 0.0 111.308 179.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -63.03 -35.02 68.24 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.938 2.426 . . . . 0.0 112.941 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.35 -6.68 54.16 Favored 'General case' 0 CA--C 1.531 0.225 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.595 179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.569 HD22 HG13 ' A' ' 45' ' ' VAL . 58.2 mt -114.32 7.75 16.5 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.426 -179.777 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.7 t70 -66.18 -38.46 88.09 Favored 'General case' 0 N--CA 1.465 0.294 0 CA-C-O 121.089 0.471 . . . . 0.0 111.451 -179.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 16.5 mt-30 -124.74 158.72 32.59 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.576 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -133.23 127.79 54.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.424 0 CA-C-O 121.379 0.609 . . . . 0.0 110.937 179.06 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.7 OUTLIER -132.68 129.63 58.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-O 121.294 0.568 . . . . 0.0 111.105 179.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 17.4 m-85 -92.9 102.02 6.29 Favored Pre-proline 0 C--N 1.326 -0.421 0 CA-C-N 115.438 -0.801 . . . . 0.0 109.402 178.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -66.26 -16.35 51.42 Favored 'Trans proline' 0 C--N 1.348 0.515 0 C-N-CA 122.626 2.217 . . . . 0.0 113.77 -178.315 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 46.5 m-20 -100.71 -6.83 24.48 Favored 'General case' 0 CA--C 1.537 0.457 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.0 m-85 -120.97 -22.54 6.14 Favored 'General case' 0 N--CA 1.466 0.371 0 N-CA-C 111.913 0.338 . . . . 0.0 111.913 -179.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 81.7 25.45 53.37 Favored Glycine 0 C--N 1.332 0.348 0 C-N-CA 120.943 -0.646 . . . . 0.0 112.07 -179.442 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.1 t -106.48 117.95 53.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.844 0.354 . . . . 0.0 111.663 -178.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -121.16 118.9 30.84 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.598 179.402 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -134.79 167.17 21.36 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 121.172 0.51 . . . . 0.0 111.945 -179.409 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 7.4 m120 -109.38 138.66 45.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.981 -0.554 . . . . 0.0 110.621 179.667 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 51.8 mt -101.13 128.46 29.39 Favored Pre-proline 0 C--N 1.329 -0.286 0 CA-C-O 120.89 0.376 . . . . 0.0 111.39 -179.687 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.435 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 74.4 Cg_endo -82.0 128.15 5.68 Favored 'Trans proline' 0 CA--C 1.531 0.366 0 C-N-CA 122.768 2.312 . . . . 0.0 112.428 179.213 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 11.4 tpt -66.3 124.55 23.0 Favored 'General case' 0 CA--C 1.532 0.257 0 CA-C-O 121.046 0.451 . . . . 0.0 111.623 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.53 9.3 81.74 Favored Glycine 0 CA--C 1.521 0.418 0 CA-C-N 115.857 -0.611 . . . . 0.0 113.075 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.435 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 50.1 mm-40 -136.9 176.75 8.43 Favored 'General case' 0 C--O 1.234 0.267 0 CA-C-O 120.903 0.382 . . . . 0.0 111.342 -179.616 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -112.9 136.32 52.68 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 121.036 0.446 . . . . 0.0 111.744 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -124.23 126.25 45.78 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.039 178.975 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.483 HG23 HG22 ' A' ' 65' ' ' VAL . 1.8 p -102.99 138.19 28.2 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.486 0 CA-C-O 121.58 0.705 . . . . 0.0 112.511 -178.778 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 64.5 t -115.51 112.34 39.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.188 178.782 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -93.8 118.99 32.18 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.934 0.397 . . . . 0.0 111.576 -179.307 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.11 156.33 39.21 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.073 -179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.4 m -120.03 98.32 49.21 Favored Pre-proline 0 C--N 1.328 -0.366 0 CA-C-N 116.22 -0.445 . . . . 0.0 111.461 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.45 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.9 Cg_endo -71.88 99.14 0.94 Allowed 'Trans proline' 0 C--N 1.347 0.457 0 C-N-CA 122.713 2.275 . . . . 0.0 112.561 179.715 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.6 mt-10 -97.7 22.79 8.59 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.09 0.471 . . . . 0.0 111.515 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.15 131.78 14.89 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.464 179.652 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.29 127.29 35.47 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.983 0.421 . . . . 0.0 111.407 -179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 164.42 -157.33 29.64 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.859 -0.686 . . . . 0.0 112.759 -179.821 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -102.18 126.59 49.19 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.168 0.509 . . . . 0.0 111.544 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.446 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 86.4 m-85 -119.32 171.99 7.92 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.674 -0.694 . . . . 0.0 109.891 179.641 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 87.8 p -153.73 159.85 42.11 Favored 'General case' 0 C--N 1.331 -0.223 0 N-CA-C 112.406 0.521 . . . . 0.0 112.406 -178.909 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -150.53 131.14 13.95 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.501 -0.772 . . . . 0.0 111.093 178.866 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.7 168.49 21.49 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.295 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 5.9 t -146.14 128.38 15.76 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.4 -0.364 . . . . 0.0 111.263 179.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 73.06 -152.97 47.82 Favored Glycine 0 CA--C 1.52 0.4 0 C-N-CA 120.936 -0.65 . . . . 0.0 113.15 179.717 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -135.77 110.28 8.55 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.839 0.352 . . . . 0.0 111.14 179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -163.31 -170.38 2.25 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.903 179.88 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER -85.35 48.86 1.64 Allowed 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.0 0.429 . . . . 0.0 111.916 -179.672 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -145.22 142.37 29.48 Favored 'General case' 0 C--O 1.233 0.213 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.053 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -162.21 139.19 8.14 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.851 179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -116.75 136.75 13.0 Favored Glycine 0 CA--C 1.52 0.35 0 C-N-CA 120.813 -0.708 . . . . 0.0 112.639 179.696 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 4.5 ttmm -120.01 149.48 42.1 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 121.053 0.454 . . . . 0.0 111.229 -179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.446 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -132.83 140.42 47.95 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.994 179.723 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.95 119.77 56.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-O 121.061 0.458 . . . . 0.0 110.877 179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 97.9 t -101.89 124.68 55.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.124 -0.489 . . . . 0.0 111.079 -179.777 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.251 1.158 0 CA-C-O 118.045 -0.979 . . . . 0.0 111.898 -179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.722 0 N-CA-C 112.4 -0.28 . . . . 0.0 112.4 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -82.96 73.94 9.96 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.148 0.499 . . . . 0.0 111.504 -179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.8 OUTLIER -100.17 160.3 14.43 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.098 -0.501 . . . . 0.0 111.368 179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -91.06 175.18 39.59 Favored Glycine 0 CA--C 1.518 0.262 0 C-N-CA 120.831 -0.699 . . . . 0.0 113.063 179.807 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -118.97 128.62 54.57 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.187 0.517 . . . . 0.0 111.168 -179.76 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -88.27 126.58 35.24 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.631 179.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.03 150.56 45.47 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.141 179.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.551 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 19.8 pt20 -79.44 137.5 37.27 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 121.297 0.57 . . . . 0.0 111.283 -179.323 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 4.5 mp0 -94.52 114.02 25.94 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.963 -179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -93.03 -156.08 0.46 Allowed 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.072 179.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.4 t-20 -83.56 76.91 9.92 Favored 'General case' 0 CA--C 1.533 0.307 0 CA-C-O 120.851 0.358 . . . . 0.0 111.948 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 102.25 -12.71 57.19 Favored Glycine 0 CA--C 1.523 0.561 0 C-N-CA 120.806 -0.712 . . . . 0.0 114.151 178.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 36.1 p90 -140.69 167.47 22.1 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 117.16 0.48 . . . . 0.0 111.353 -179.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.93 155.0 28.78 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.863 0.363 . . . . 0.0 111.119 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.551 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 5.8 tt0 -145.35 142.23 29.2 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.562 -179.271 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.39 129.84 17.02 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.44 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.096 179.312 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -91.67 110.22 21.54 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-O 121.239 0.542 . . . . 0.0 111.058 179.504 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.62 HG13 ' HD2' ' A' ' 51' ' ' PRO . 46.4 t -100.48 104.01 15.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.589 -179.86 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.427 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 0.9 OUTLIER -73.16 116.98 14.34 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.845 -179.91 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.556 HG13 HD22 ' A' ' 75' ' ' LEU . 41.1 t -97.41 98.46 7.45 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.365 -178.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.466 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 9.8 ptp -139.6 81.93 1.85 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.383 179.383 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 88.01 -8.98 76.39 Favored Glycine 0 CA--C 1.521 0.429 0 N-CA-C 111.16 -0.776 . . . . 0.0 111.16 -178.342 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 172.85 -153.36 18.35 Favored Glycine 0 N--CA 1.448 -0.559 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 179.654 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -105.42 125.65 51.23 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.825 0.313 . . . . 0.0 110.54 179.648 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.516 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 45.2 m -65.13 -64.48 2.61 Favored Pre-proline 0 CA--C 1.538 0.518 0 CA-C-O 119.575 -0.25 . . . . 0.0 111.407 -179.675 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.62 ' HD2' HG13 ' A' ' 43' ' ' VAL . 60.1 Cg_endo -74.11 97.91 1.05 Allowed 'Trans proline' 0 C--N 1.358 1.039 0 C-N-CA 121.266 1.311 . . . . 0.0 111.001 177.684 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.63 -44.04 57.18 Favored 'General case' 0 N--CA 1.47 0.552 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.163 -179.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.453 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.6 118.99 19.88 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 120.605 0.241 . . . . 0.0 110.959 179.57 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 6.0 pt -97.07 126.96 49.7 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 CA-C-O 121.054 0.454 . . . . 0.0 110.747 179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 84.6 t -98.09 126.93 50.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.505 -179.649 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 7.8 mt -135.63 166.52 23.05 Favored 'General case' 0 CA--C 1.534 0.331 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.567 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 4.7 tttt -93.1 170.24 9.8 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.709 179.206 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.5 ttpp -100.45 148.25 24.96 Favored 'General case' 0 CA--C 1.532 0.262 0 N-CA-C 112.106 0.41 . . . . 0.0 112.106 -179.403 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 36.2 t 65.84 20.14 11.38 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 115.482 -0.781 . . . . 0.0 111.917 179.393 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.434 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.2 p -123.8 135.88 26.74 Favored Pre-proline 0 CA--C 1.537 0.445 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.977 -179.844 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_endo -64.4 122.77 10.8 Favored 'Trans proline' 0 C--N 1.347 0.462 0 C-N-CA 122.198 1.932 . . . . 0.0 111.575 178.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -125.67 138.51 53.9 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 120.956 0.408 . . . . 0.0 111.728 -179.567 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.433 ' CG ' ' HG3' ' A' ' 40' ' ' GLU . 0.0 OUTLIER -121.06 129.4 53.33 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.767 0.794 . . . . 0.0 111.517 179.739 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.4 mm -100.76 115.69 42.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.484 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.817 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.435 HG22 HG23 ' A' ' 96' ' ' VAL . 3.5 t -91.77 111.69 24.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.297 0 CA-C-O 120.766 0.317 . . . . 0.0 111.326 -179.3 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 71.6 m-85 -97.7 113.22 24.94 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.053 0.454 . . . . 0.0 111.354 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -98.96 105.19 17.31 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.881 -0.599 . . . . 0.0 110.215 179.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -79.09 104.8 9.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.29 0.566 . . . . 0.0 112.22 -178.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 6.2 tppt? -99.35 -36.09 9.72 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.086 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.466 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 6.4 t70 -103.79 129.86 24.53 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.852 179.562 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.1 Cg_endo -80.49 39.47 0.85 Allowed 'Trans proline' 0 C--N 1.348 0.502 0 C-N-CA 122.998 2.465 . . . . 0.0 112.939 -179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.493 ' HB2' HD12 ' A' ' 75' ' ' LEU . 2.1 m -69.95 135.67 87.47 Favored Pre-proline 0 C--N 1.328 -0.336 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.382 -179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -64.05 -29.9 66.06 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 122.901 2.401 . . . . 0.0 112.811 -179.752 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.71 -9.38 58.63 Favored 'General case' 0 CA--C 1.532 0.256 0 CA-C-N 116.33 -0.396 . . . . 0.0 111.599 179.761 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.556 HD22 HG13 ' A' ' 45' ' ' VAL . 29.1 mt -113.17 12.52 19.07 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 120.784 0.326 . . . . 0.0 111.321 -179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -67.44 -35.18 78.72 Favored 'General case' 0 CA--C 1.533 0.312 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.785 -179.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 81.9 mt-30 -129.48 160.68 32.42 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-O 120.805 0.336 . . . . 0.0 111.21 -179.785 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -138.67 129.01 33.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 121.181 0.515 . . . . 0.0 110.85 179.292 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.5 p -132.04 132.4 61.25 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.473 0 CA-C-O 121.276 0.56 . . . . 0.0 111.257 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 15.7 m-85 -94.93 101.92 8.11 Favored Pre-proline 0 C--N 1.326 -0.429 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.725 179.032 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -67.09 -15.23 46.05 Favored 'Trans proline' 0 C--N 1.348 0.52 0 C-N-CA 122.722 2.281 . . . . 0.0 113.562 -178.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 38.3 m-20 -99.62 -7.34 25.88 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 111.782 0.29 . . . . 0.0 111.782 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 58.6 m-85 -122.67 -22.13 5.46 Favored 'General case' 0 CA--C 1.534 0.349 0 N-CA-C 112.092 0.405 . . . . 0.0 112.092 -179.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 81.45 26.43 51.33 Favored Glycine 0 CA--C 1.52 0.374 0 C-N-CA 120.877 -0.677 . . . . 0.0 112.044 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.6 t -107.69 117.37 53.23 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-O 120.746 0.307 . . . . 0.0 111.709 -178.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -119.12 117.94 30.05 Favored 'General case' 0 N--CA 1.467 0.42 0 CA-C-N 116.426 -0.352 . . . . 0.0 110.519 179.214 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -132.67 167.54 19.9 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 121.156 0.503 . . . . 0.0 112.222 -179.157 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -111.69 141.2 45.6 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.319 179.562 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 53.1 mt -103.56 127.75 28.89 Favored Pre-proline 0 C--N 1.33 -0.281 0 CA-C-O 121.005 0.431 . . . . 0.0 111.566 -179.625 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.443 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 72.5 Cg_endo -82.94 129.85 5.53 Favored 'Trans proline' 0 CA--C 1.532 0.411 0 C-N-CA 122.846 2.364 . . . . 0.0 112.481 179.271 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.5 tpt -67.58 125.24 25.56 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.008 0.432 . . . . 0.0 111.71 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 83.29 11.61 80.3 Favored Glycine 0 CA--C 1.52 0.405 0 CA-C-N 115.913 -0.585 . . . . 0.0 112.877 179.931 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.443 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 53.7 mm-40 -137.46 176.86 8.33 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-O 121.007 0.432 . . . . 0.0 111.157 -179.544 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -113.37 132.77 55.47 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.78 -179.716 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 8.4 t80 -121.75 125.11 45.8 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.077 -0.51 . . . . 0.0 109.967 178.876 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.435 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -105.16 137.06 36.34 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-O 121.549 0.69 . . . . 0.0 112.472 -178.887 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 60.1 t -112.79 112.11 39.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 115.56 -0.745 . . . . 0.0 110.153 178.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 11.5 mt-10 -93.67 119.22 32.4 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.953 0.406 . . . . 0.0 111.416 -179.469 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.91 158.24 38.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.339 -179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.6 m -121.67 96.81 47.11 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.469 -179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.434 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 60.9 Cg_endo -71.59 99.44 0.94 Allowed 'Trans proline' 0 C--N 1.346 0.425 0 C-N-CA 122.823 2.349 . . . . 0.0 112.294 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.3 mt-10 -94.07 4.47 53.85 Favored 'General case' 0 C--N 1.329 -0.297 0 N-CA-C 111.995 0.368 . . . . 0.0 111.995 -179.3 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -133.88 135.63 43.79 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.756 0.313 . . . . 0.0 110.933 179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -88.59 124.9 34.5 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.837 179.594 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 172.35 -167.56 40.51 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.796 -179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 -97.9 114.72 26.89 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.105 0.479 . . . . 0.0 110.631 179.733 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.402 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 20.7 m-85 -111.4 172.42 6.9 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.727 -0.67 . . . . 0.0 110.177 -179.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 87.1 p -158.17 164.88 36.13 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.155 0.502 . . . . 0.0 112.196 -178.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 28.9 p90 -148.26 137.39 21.92 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.762 179.017 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -161.85 153.74 19.12 Favored 'General case' 0 N--CA 1.463 0.219 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.277 -179.719 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 4.7 t -159.22 161.25 36.06 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.945 179.795 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 84.44 -118.87 4.82 Favored Glycine 0 CA--C 1.52 0.378 0 C-N-CA 120.861 -0.685 . . . . 0.0 113.237 179.545 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -154.46 -160.9 1.13 Allowed 'General case' 0 CA--C 1.531 0.242 0 C-N-CA 122.013 0.125 . . . . 0.0 110.85 -179.585 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 68.33 -170.63 0.19 Allowed 'General case' 0 N--CA 1.47 0.529 0 C-N-CA 122.898 0.479 . . . . 0.0 111.828 179.853 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.9 OUTLIER -102.21 65.04 0.95 Allowed 'General case' 0 CA--C 1.532 0.276 0 CA-C-O 120.933 0.396 . . . . 0.0 111.69 -179.626 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -135.9 136.49 40.55 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.863 0.363 . . . . 0.0 111.066 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 20.2 p80 -165.5 154.47 12.01 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 116.276 -0.42 . . . . 0.0 111.24 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -113.15 150.31 18.48 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 121.047 -0.596 . . . . 0.0 112.055 179.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.453 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 2.8 ttmt -119.09 150.32 40.2 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 120.974 0.416 . . . . 0.0 111.359 -179.869 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.402 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.8 ttm -133.68 133.62 42.1 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.896 179.685 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.5 mp -119.13 117.36 53.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.451 0 CA-C-O 121.071 0.463 . . . . 0.0 110.753 179.689 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 94.7 t -101.65 121.94 53.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.155 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.277 -0.868 . . . . 0.0 111.538 -179.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.703 0 CA-C-O 121.192 0.329 . . . . 0.0 112.347 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.99 37.19 3.91 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 121.1 0.476 . . . . 0.0 111.439 -179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 14.5 mtp -82.57 66.33 8.12 Favored 'General case' 0 CA--C 1.533 0.316 0 CA-C-O 121.056 0.455 . . . . 0.0 111.385 -179.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 105.69 171.83 23.67 Favored Glycine 0 CA--C 1.52 0.354 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.854 179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.1 OUTLIER -123.83 124.88 43.63 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 120.959 0.409 . . . . 0.0 111.502 179.987 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.6 ttmt -90.37 126.71 35.97 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.501 179.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -69.36 151.11 46.57 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 121.028 0.442 . . . . 0.0 111.464 -179.663 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.578 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.7 pt20 -78.28 143.52 36.95 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.379 -179.544 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 24.6 mt-30 -98.68 115.33 28.46 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.855 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -96.63 -151.62 0.36 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.484 -179.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.5 m120 -81.65 75.52 8.6 Favored 'General case' 0 CA--C 1.534 0.346 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -179.171 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 95.4 -7.47 68.82 Favored Glycine 0 CA--C 1.523 0.573 0 C-N-CA 120.72 -0.753 . . . . 0.0 114.047 178.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 35.3 p90 -141.35 161.48 37.78 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.959 0.38 . . . . 0.0 110.981 -179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -111.06 155.71 22.38 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 121.102 0.477 . . . . 0.0 111.154 179.843 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.578 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.9 tt0 -144.53 143.89 31.05 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.616 -179.382 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.17 128.71 16.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 121.081 0.467 . . . . 0.0 110.963 178.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.69 109.03 20.21 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.33 0.586 . . . . 0.0 110.962 179.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.628 HG13 ' HD2' ' A' ' 51' ' ' PRO . 45.1 t -99.75 103.95 15.43 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.599 -179.931 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.415 ' HB3' ' OG1' ' A' ' 50' ' ' THR . 1.1 tp10 -73.17 117.62 15.12 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.857 179.98 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.592 HG13 HD22 ' A' ' 75' ' ' LEU . 54.3 t -99.52 98.55 7.18 Favored 'Isoleucine or valine' 0 C--O 1.236 0.368 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.526 -178.792 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.491 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 5.3 ptm -145.25 86.97 1.78 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.4 179.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 83.66 -2.51 87.25 Favored Glycine 0 CA--C 1.521 0.407 0 C-N-CA 120.824 -0.703 . . . . 0.0 111.468 -178.429 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.421 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 162.9 -171.17 38.63 Favored Glycine 0 N--CA 1.447 -0.592 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 30.3 m-85 -91.78 124.94 36.29 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 116.816 0.308 . . . . 0.0 110.354 179.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.524 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 45.0 m -63.99 -64.35 2.95 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 119.638 -0.22 . . . . 0.0 111.407 -179.42 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.628 ' HD2' HG13 ' A' ' 43' ' ' VAL . 62.1 Cg_endo -74.98 96.88 1.04 Allowed 'Trans proline' 0 C--N 1.357 0.977 0 C-N-CA 121.299 1.333 . . . . 0.0 111.075 177.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.84 -43.19 59.12 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.261 -179.342 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.438 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -131.36 118.52 20.4 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.622 -0.263 . . . . 0.0 110.708 179.667 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 5.7 pt -98.3 125.43 51.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-O 121.031 0.443 . . . . 0.0 111.15 179.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 75.9 t -98.62 126.71 51.7 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.425 0 CA-C-N 116.251 -0.431 . . . . 0.0 111.425 -179.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.423 HD22 ' HB1' ' A' ' 62' ' ' ALA . 5.4 mt -132.74 171.5 13.79 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-N 115.811 -0.631 . . . . 0.0 111.472 -179.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.95 170.02 9.72 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.549 179.403 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 5.6 ttpp -102.43 147.06 27.19 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-O 120.86 0.362 . . . . 0.0 111.909 -179.601 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 35.4 t 65.27 20.46 11.89 Favored 'General case' 0 N--CA 1.472 0.671 0 CA-C-N 115.527 -0.76 . . . . 0.0 111.701 179.763 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.425 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 7.4 p -123.66 136.41 27.26 Favored Pre-proline 0 CA--C 1.534 0.356 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.003 -179.855 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 25.4 Cg_endo -64.33 122.7 10.72 Favored 'Trans proline' 0 C--N 1.346 0.44 0 C-N-CA 121.984 1.79 . . . . 0.0 111.412 178.442 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.423 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -125.29 138.49 54.08 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.017 0.437 . . . . 0.0 111.582 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.438 ' HE ' ' HG3' ' A' ' 40' ' ' GLU . 7.9 ptt180 -120.55 127.74 52.44 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.727 0.775 . . . . 0.0 111.418 -179.981 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.0 mm -99.4 114.68 38.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.628 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.495 HG22 HG23 ' A' ' 96' ' ' VAL . 3.3 t -92.01 110.53 22.85 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-O 120.697 0.284 . . . . 0.0 111.553 -179.284 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 79.2 m-85 -97.1 120.05 36.72 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.013 0.435 . . . . 0.0 111.233 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.8 t0 -103.93 105.18 15.28 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.433 179.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.401 ' HG2' ' HA ' ' A' ' 91' ' ' MET . 2.0 tpt180 -77.77 97.81 5.32 Favored 'General case' 0 N--CA 1.464 0.272 0 CA-C-O 121.161 0.505 . . . . 0.0 111.605 -179.427 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 9.8 tptp -93.71 -32.93 13.83 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.412 179.428 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.491 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 1.9 t70 -111.28 131.66 22.13 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.741 179.661 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -80.24 39.33 0.83 Allowed 'Trans proline' 0 C--N 1.348 0.534 0 C-N-CA 123.075 2.516 . . . . 0.0 112.978 -179.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -68.13 135.76 91.57 Favored Pre-proline 0 C--N 1.327 -0.371 0 CA-C-N 116.294 -0.412 . . . . 0.0 111.159 179.879 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -64.26 -33.28 60.34 Favored 'Trans proline' 0 C--N 1.349 0.569 0 C-N-CA 122.764 2.309 . . . . 0.0 112.875 -179.676 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -77.37 -1.97 32.71 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 116.352 -0.385 . . . . 0.0 111.55 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.592 HD22 HG13 ' A' ' 45' ' ' VAL . 28.8 mt -119.01 9.13 11.76 Favored 'General case' 0 CA--C 1.533 0.298 0 CA-C-N 116.387 -0.369 . . . . 0.0 111.457 -179.749 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -68.9 -41.04 78.76 Favored 'General case' 0 N--CA 1.466 0.347 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -179.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 32.4 mt-30 -122.09 149.37 43.66 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.028 0.442 . . . . 0.0 111.591 -179.495 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.6 OUTLIER -131.51 129.18 61.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.952 -0.567 . . . . 0.0 110.54 179.238 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 1.2 p -132.7 131.35 59.69 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-O 121.439 0.637 . . . . 0.0 111.44 -179.92 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 21.0 m-85 -92.86 101.93 6.1 Favored Pre-proline 0 C--N 1.327 -0.385 0 CA-C-N 115.29 -0.868 . . . . 0.0 109.448 178.649 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.41 -15.52 45.64 Favored 'Trans proline' 0 C--N 1.348 0.538 0 C-N-CA 122.631 2.221 . . . . 0.0 113.657 -178.465 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 66.6 m-20 -100.12 -9.61 22.38 Favored 'General case' 0 CA--C 1.536 0.406 0 N-CA-C 111.928 0.344 . . . . 0.0 111.928 -179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 55.5 m-85 -119.46 -21.41 7.43 Favored 'General case' 0 CA--C 1.534 0.333 0 N-CA-C 111.988 0.366 . . . . 0.0 111.988 -179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 80.95 28.33 46.34 Favored Glycine 0 CA--C 1.52 0.346 0 C-N-CA 120.935 -0.65 . . . . 0.0 112.074 -179.589 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.4 t -109.44 117.58 54.84 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-O 120.786 0.327 . . . . 0.0 111.731 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -120.59 119.74 33.76 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.428 179.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -137.72 167.92 20.72 Favored 'General case' 0 CA--C 1.53 0.198 0 CA-C-O 121.182 0.515 . . . . 0.0 112.344 -179.268 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -113.3 143.27 44.72 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.316 179.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 30.7 mt -103.53 124.35 38.34 Favored Pre-proline 0 C--N 1.329 -0.283 0 CA-C-O 121.046 0.451 . . . . 0.0 111.599 -179.397 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.421 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 68.6 Cg_endo -79.09 130.38 9.33 Favored 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 122.771 2.314 . . . . 0.0 112.662 179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . 0.401 ' HA ' ' HG2' ' A' ' 68' ' ' ARG . 11.2 tpt -67.47 124.77 24.12 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 121.138 0.494 . . . . 0.0 111.748 -179.597 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 83.53 9.68 82.98 Favored Glycine 0 CA--C 1.521 0.411 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.975 -179.977 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.421 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 51.4 mm-40 -136.21 176.69 8.47 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.865 0.364 . . . . 0.0 111.284 -179.537 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -114.07 134.72 54.68 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 121.013 0.435 . . . . 0.0 111.574 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . 0.4 ' HB2' ' HD2' ' A' ' 90' ' ' PRO . 8.7 t80 -122.52 124.09 42.76 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.036 178.918 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.495 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -104.37 136.99 35.29 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 CA-C-O 121.563 0.697 . . . . 0.0 112.533 -178.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 54.2 t -112.98 112.11 39.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.16 179.02 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -93.52 119.57 32.75 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.397 -0.365 . . . . 0.0 111.517 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.6 158.28 39.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.207 179.917 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 4.2 m -121.51 96.79 47.44 Favored Pre-proline 0 C--N 1.328 -0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.525 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.425 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 69.8 Cg_endo -72.93 101.18 1.29 Allowed 'Trans proline' 0 CA--C 1.532 0.399 0 C-N-CA 122.855 2.37 . . . . 0.0 112.349 179.698 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -95.51 5.53 51.31 Favored 'General case' 0 N--CA 1.466 0.34 0 N-CA-C 111.898 0.333 . . . . 0.0 111.898 -179.448 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -132.4 133.97 44.57 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 120.763 0.316 . . . . 0.0 110.751 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -90.61 128.26 36.54 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.983 0.42 . . . . 0.0 111.301 -179.838 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 162.64 -155.88 27.36 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.806 -0.711 . . . . 0.0 112.694 -179.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -102.19 126.91 49.3 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-O 121.21 0.529 . . . . 0.0 111.468 -179.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.435 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 89.9 m-85 -120.69 173.28 7.3 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.885 179.733 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 14.9 m -154.9 156.91 36.97 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 121.197 0.523 . . . . 0.0 112.399 -179.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 41.2 p90 -146.26 142.21 28.12 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.726 179.246 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.4 178.19 8.87 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.961 0.41 . . . . 0.0 111.68 -179.487 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 38.3 t -106.78 127.3 53.27 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.057 0.456 . . . . 0.0 110.76 179.005 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 80.15 -2.7 74.91 Favored Glycine 0 CA--C 1.525 0.686 0 C-N-CA 121.1 -0.572 . . . . 0.0 113.417 179.791 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 7.7 mtm 58.13 38.49 26.44 Favored 'General case' 0 N--CA 1.471 0.606 0 C-N-CA 122.857 0.463 . . . . 0.0 111.805 -179.735 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -156.16 -48.24 0.08 Allowed 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.044 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -96.08 -175.58 3.43 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.972 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 79.1 mmm 68.5 -179.36 0.22 Allowed 'General case' 0 N--CA 1.472 0.661 0 CA-C-N 116.029 -0.532 . . . . 0.0 112.052 179.824 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -158.17 105.21 1.91 Allowed 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 116.341 -0.39 . . . . 0.0 111.875 -179.874 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -142.23 123.75 2.27 Favored Glycine 0 CA--C 1.521 0.467 0 N-CA-C 111.776 -0.529 . . . . 0.0 111.776 179.309 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.438 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.1 ttpt -119.9 151.68 38.53 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.122 0.487 . . . . 0.0 112.054 -178.952 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.435 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.4 ttm -135.73 139.76 43.86 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.805 179.637 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.8 mp -124.32 120.64 59.76 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 121.027 0.441 . . . . 0.0 110.667 179.593 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 90.2 t -102.88 123.31 56.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.272 -179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 21.1 mt-10 . . . . . 0 C--O 1.252 1.191 0 CA-C-O 118.184 -0.913 . . . . 0.0 111.416 -179.554 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.669 0 N-CA-C 112.42 -0.272 . . . . 0.0 112.42 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . 58.59 -124.0 1.39 Allowed 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 123.082 0.553 . . . . 0.0 111.961 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER 56.68 49.98 13.49 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 120.99 0.424 . . . . 0.0 111.735 -179.977 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.99 174.64 52.83 Favored Glycine 0 CA--C 1.519 0.314 0 C-N-CA 120.91 -0.662 . . . . 0.0 113.302 -179.65 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -126.53 130.33 50.37 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.026 0.441 . . . . 0.0 111.297 179.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -90.22 126.12 35.72 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.753 179.973 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -71.4 148.97 46.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.257 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.585 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 18.6 pt20 -76.49 140.21 41.12 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-O 121.269 0.557 . . . . 0.0 111.217 -179.461 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -97.45 115.94 28.72 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.848 -0.614 . . . . 0.0 110.92 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -95.33 -151.91 0.35 Allowed 'General case' 0 CA--C 1.535 0.379 0 CA-C-N 116.032 -0.531 . . . . 0.0 111.522 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.0 t30 -82.46 72.88 9.52 Favored 'General case' 0 CA--C 1.534 0.33 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 -179.275 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 99.12 -8.74 61.06 Favored Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.678 -0.773 . . . . 0.0 113.902 178.971 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 37.3 p90 -139.1 165.29 27.54 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 117.03 0.415 . . . . 0.0 110.932 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.2 153.07 31.52 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.994 0.426 . . . . 0.0 111.058 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.585 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 6.7 tt0 -144.42 140.49 29.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.412 -179.305 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -141.01 130.24 24.92 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.262 -0.427 . . . . 0.0 111.131 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -90.6 110.06 21.21 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-O 121.178 0.513 . . . . 0.0 110.999 179.463 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.511 HG13 ' HD2' ' A' ' 51' ' ' PRO . 53.1 t -102.1 109.84 27.28 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.738 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -73.98 123.16 23.79 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.727 179.793 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.543 HG13 HD22 ' A' ' 75' ' ' LEU . 67.2 t -104.25 95.78 4.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.353 0 CA-C-O 121.479 0.656 . . . . 0.0 111.376 -179.372 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.467 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 6.2 ptm -146.58 87.89 1.74 Allowed 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.281 179.27 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.52 -0.84 89.22 Favored Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.873 -0.679 . . . . 0.0 111.432 -178.321 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.45 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 160.57 -144.36 9.88 Favored Glycine 0 N--CA 1.448 -0.509 0 N-CA-C 111.5 -0.64 . . . . 0.0 111.5 -179.889 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 32.7 m-85 -119.1 128.61 54.46 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.774 0.287 . . . . 0.0 110.636 179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.504 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 22.0 m -65.61 -61.66 5.52 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-O 119.572 -0.252 . . . . 0.0 110.958 179.775 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.511 ' HD2' HG13 ' A' ' 43' ' ' VAL . 68.9 Cg_endo -75.91 95.75 1.03 Allowed 'Trans proline' 0 C--N 1.357 0.998 0 C-N-CA 121.325 1.35 . . . . 0.0 111.038 177.742 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -50.6 -42.13 55.56 Favored 'General case' 0 N--CA 1.47 0.54 0 CA-C-N 116.1 -0.5 . . . . 0.0 112.162 -179.206 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.441 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -133.8 118.99 18.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.556 -0.293 . . . . 0.0 110.83 179.477 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.472 HG13 ' HG3' ' A' ' 120' ' ' MET . 6.0 pt -96.67 126.62 49.32 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.273 0 CA-C-O 121.062 0.458 . . . . 0.0 110.969 179.655 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 94.8 t -97.72 125.94 50.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.443 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.461 HD22 ' HB1' ' A' ' 62' ' ' ALA . 3.5 mt -135.67 165.03 26.52 Favored 'General case' 0 CA--C 1.534 0.351 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.307 -179.662 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 1.6 mmtt -89.01 176.41 7.01 Favored 'General case' 0 N--CA 1.464 0.263 0 CA-C-O 120.769 0.318 . . . . 0.0 111.046 179.415 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 3.8 ttpp -106.93 148.26 28.84 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-O 120.834 0.349 . . . . 0.0 111.929 -179.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.4 t 64.73 20.85 12.26 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-N 115.64 -0.709 . . . . 0.0 111.644 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.413 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.8 p -123.88 136.17 27.13 Favored Pre-proline 0 CA--C 1.537 0.457 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.998 -179.776 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 22.1 Cg_endo -63.57 120.87 8.43 Favored 'Trans proline' 0 C--N 1.346 0.433 0 C-N-CA 122.111 1.874 . . . . 0.0 111.688 178.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.461 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -123.82 138.29 54.52 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 120.845 0.355 . . . . 0.0 111.598 -179.425 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.414 ' HB2' HG22 ' A' ' 96' ' ' VAL . 0.4 OUTLIER -123.19 128.42 50.0 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 121.784 0.802 . . . . 0.0 111.537 179.867 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 4.2 mm -99.69 116.31 42.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.883 179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.431 HG22 HG23 ' A' ' 96' ' ' VAL . 3.6 t -91.63 112.56 25.69 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.217 0 CA-C-O 120.812 0.339 . . . . 0.0 111.246 -179.501 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 67.5 m-85 -98.21 116.84 31.28 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.116 0.484 . . . . 0.0 111.528 -179.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.0 t0 -100.78 103.31 14.53 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.387 179.468 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.54 102.85 7.14 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.247 0.546 . . . . 0.0 112.157 -179.004 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 3.5 tptp -97.44 -38.37 9.63 Favored 'General case' 0 CA--C 1.534 0.33 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.588 179.633 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.467 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 3.0 t70 -103.0 130.72 23.13 Favored Pre-proline 0 CA--C 1.535 0.375 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.95 179.68 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 87.1 Cg_endo -81.31 39.43 0.86 Allowed 'Trans proline' 0 C--N 1.346 0.438 0 C-N-CA 123.099 2.532 . . . . 0.0 113.209 -179.394 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 29.1 t -70.5 135.16 86.35 Favored Pre-proline 0 C--N 1.328 -0.326 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.263 179.773 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -64.15 -26.85 64.91 Favored 'Trans proline' 0 C--N 1.348 0.529 0 C-N-CA 122.673 2.249 . . . . 0.0 112.519 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 1.3 m -80.24 -10.93 59.77 Favored 'General case' 0 CA--C 1.53 0.192 0 CA-C-N 116.31 -0.404 . . . . 0.0 111.131 179.631 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.543 HD22 HG13 ' A' ' 45' ' ' VAL . 24.0 mt -113.9 13.7 18.39 Favored 'General case' 0 CA--C 1.532 0.265 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.213 -180.0 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 2.2 t70 -70.21 -34.15 72.57 Favored 'General case' 0 CA--C 1.533 0.309 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.575 -179.827 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . 0.435 ' HG3' HD22 ' A' ' 88' ' ' ASN . 0.6 OUTLIER -127.21 161.88 27.5 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.969 0.414 . . . . 0.0 111.511 -179.494 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -138.76 127.97 30.86 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.338 178.477 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.409 ' HA ' ' O ' ' A' ' 85' ' ' VAL . 1.5 p -131.72 130.08 61.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-O 121.282 0.563 . . . . 0.0 111.545 179.943 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -92.65 101.84 5.8 Favored Pre-proline 0 C--N 1.326 -0.414 0 CA-C-N 115.441 -0.8 . . . . 0.0 109.279 178.576 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.94 -13.32 38.04 Favored 'Trans proline' 0 C--N 1.348 0.542 0 C-N-CA 122.566 2.177 . . . . 0.0 113.64 -178.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -100.49 -11.72 19.92 Favored 'General case' 0 C--N 1.328 -0.334 0 N-CA-C 111.929 0.344 . . . . 0.0 111.929 -179.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 46.7 m-85 -120.77 -17.82 7.85 Favored 'General case' 0 N--CA 1.465 0.292 0 N-CA-C 112.157 0.428 . . . . 0.0 112.157 -178.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 78.78 29.24 52.68 Favored Glycine 0 C--N 1.333 0.371 0 C-N-CA 121.015 -0.612 . . . . 0.0 112.541 -179.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 79' ' ' VAL . 54.2 t -109.06 113.59 44.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.81 0.338 . . . . 0.0 111.748 -179.113 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.9 p80 -117.93 117.44 29.27 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.401 179.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.57 167.59 20.19 Favored 'General case' 0 CA--C 1.532 0.263 0 CA-C-O 121.342 0.591 . . . . 0.0 112.44 -179.044 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . 0.435 HD22 ' HG3' ' A' ' 77' ' ' GLN . 28.7 t-20 -110.1 139.8 44.86 Favored 'General case' 0 CA--C 1.53 0.207 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.257 179.512 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 46.3 mt -102.89 126.61 32.08 Favored Pre-proline 0 C--N 1.33 -0.272 0 CA-C-O 120.943 0.402 . . . . 0.0 111.481 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.443 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 70.1 Cg_endo -81.03 128.79 6.63 Favored 'Trans proline' 0 CA--C 1.532 0.393 0 C-N-CA 122.794 2.33 . . . . 0.0 112.414 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.9 tpt -65.92 124.83 23.56 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 121.042 0.449 . . . . 0.0 111.837 -179.497 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 82.94 9.6 84.17 Favored Glycine 0 CA--C 1.521 0.429 0 CA-C-N 115.923 -0.581 . . . . 0.0 113.055 179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.443 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 47.5 mt-10 -135.14 176.79 8.34 Favored 'General case' 0 CA--C 1.532 0.272 0 CA-C-O 120.94 0.4 . . . . 0.0 111.08 -179.553 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 -113.12 134.63 54.46 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.981 0.42 . . . . 0.0 111.799 -179.607 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 9.9 t80 -123.22 126.59 47.23 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.899 178.794 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.431 HG23 HG22 ' A' ' 65' ' ' VAL . 2.2 p -106.15 138.87 29.47 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 CA-C-O 121.527 0.679 . . . . 0.0 112.64 -178.721 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.413 ' O ' ' HA ' ' A' ' 63' ' ' ARG . 53.8 t -114.22 112.3 39.57 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.207 0 CA-C-N 115.398 -0.819 . . . . 0.0 110.164 178.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 10.7 mt-10 -94.76 119.1 32.81 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-O 121.018 0.437 . . . . 0.0 111.626 -179.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.2 pt -135.03 157.57 40.77 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.238 0 CA-C-N 115.97 -0.559 . . . . 0.0 111.273 -179.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.8 m -120.73 96.67 48.75 Favored Pre-proline 0 C--N 1.327 -0.395 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.326 -179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.413 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 71.6 Cg_endo -73.31 102.68 1.5 Allowed 'Trans proline' 0 C--N 1.345 0.349 0 C-N-CA 122.81 2.34 . . . . 0.0 112.434 179.816 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -97.71 10.6 39.6 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.902 0.382 . . . . 0.0 111.9 -179.666 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.26 130.25 30.6 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.851 0.358 . . . . 0.0 110.874 179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.07 128.22 35.1 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.372 -179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 165.79 -155.15 26.26 Favored Glycine 0 N--CA 1.452 -0.253 0 C-N-CA 120.856 -0.688 . . . . 0.0 112.847 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -107.96 125.63 51.74 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.122 0.487 . . . . 0.0 111.012 -179.639 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . . . . . . . . . 95.1 m-85 -124.29 166.92 15.06 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.305 -179.74 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -147.19 157.9 43.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 121.182 0.515 . . . . 0.0 112.29 -179.494 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 40.0 p90 -146.36 135.57 22.75 Favored 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.623 179.232 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.2 164.81 27.57 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-O 120.799 0.333 . . . . 0.0 111.406 -179.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 1.2 t -151.92 178.84 9.0 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.338 -0.392 . . . . 0.0 111.059 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 97.35 -160.29 21.29 Favored Glycine 0 CA--C 1.519 0.326 0 C-N-CA 120.831 -0.7 . . . . 0.0 112.879 179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -100.71 -28.08 13.02 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.843 0.354 . . . . 0.0 111.506 -179.947 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -161.87 178.0 9.33 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 116.285 -0.416 . . . . 0.0 110.814 -179.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 2.4 ttm 62.8 -141.68 0.39 Allowed 'General case' 0 CA--C 1.538 0.484 0 CA-C-N 116.111 -0.495 . . . . 0.0 111.43 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 73.35 151.13 0.11 Allowed 'General case' 0 N--CA 1.473 0.723 0 C-N-CA 123.239 0.616 . . . . 0.0 112.038 179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 5.4 t-80 -157.88 105.06 1.96 Allowed 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.549 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -140.97 115.18 1.0 Allowed Glycine 0 CA--C 1.521 0.434 0 C-N-CA 121.115 -0.564 . . . . 0.0 111.794 179.476 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.441 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 9.0 ttpt -118.28 149.7 40.7 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.223 0.535 . . . . 0.0 111.783 -179.414 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.472 ' HG3' HG13 ' A' ' 54' ' ' ILE . 10.1 ttp -134.36 130.73 37.36 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.657 179.853 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -117.61 118.78 59.61 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.403 0 CA-C-O 121.038 0.447 . . . . 0.0 111.097 179.81 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 57.8 t -101.29 119.83 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.886 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.25 1.08 0 CA-C-O 118.005 -0.998 . . . . 0.0 112.063 -179.622 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.496 2.67 0 CA-C-O 121.191 0.328 . . . . 0.0 112.339 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -92.16 -38.31 12.22 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.904 0.383 . . . . 0.0 111.325 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 4.1 mmm -91.09 57.58 3.49 Favored 'General case' 0 CA--C 1.531 0.237 0 CA-C-O 121.071 0.462 . . . . 0.0 111.272 -179.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . 99.2 -172.37 25.35 Favored Glycine 0 CA--C 1.519 0.325 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.765 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -137.91 128.65 26.86 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.066 0.46 . . . . 0.0 111.454 179.819 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 8.4 ttmt -91.43 128.45 37.26 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.788 179.6 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -72.8 152.22 41.67 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.163 179.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . . . . . . . . . 19.1 pt20 -82.75 141.51 32.32 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.206 0.527 . . . . 0.0 111.555 -179.403 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -95.34 115.69 27.76 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.769 -0.651 . . . . 0.0 110.805 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -95.71 -150.87 0.33 Allowed 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.245 -179.831 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -83.11 78.0 9.66 Favored 'General case' 0 CA--C 1.534 0.328 0 N-CA-C 112.199 0.444 . . . . 0.0 112.199 -179.239 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 93.85 -6.34 73.31 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.94 -0.648 . . . . 0.0 114.111 178.872 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 39.7 p90 -143.35 161.88 37.2 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 117.039 0.419 . . . . 0.0 111.094 -179.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.11 155.56 21.74 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 120.982 0.42 . . . . 0.0 111.081 179.603 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 4.9 tt0 -146.01 140.31 26.76 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.7 -179.17 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.06 130.12 21.31 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.791 179.108 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.411 HH11 ' HD2' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -91.5 111.05 22.39 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.192 0.52 . . . . 0.0 111.113 179.535 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.646 HG13 ' HD2' ' A' ' 51' ' ' PRO . 44.9 t -100.54 103.8 15.3 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.512 0 CA-C-N 115.782 -0.645 . . . . 0.0 110.681 -179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -72.27 115.31 11.35 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.602 179.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.53 HG13 HD22 ' A' ' 75' ' ' LEU . 53.8 t -97.68 98.74 7.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 121.489 0.662 . . . . 0.0 111.432 -178.686 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.555 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 4.6 ptm -145.76 89.51 1.91 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.502 179.107 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 80.3 -0.89 83.26 Favored Glycine 0 CA--C 1.521 0.418 0 C-N-CA 120.869 -0.681 . . . . 0.0 111.59 -178.402 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.453 ' N ' HD11 ' A' ' 75' ' ' LEU . . . 161.83 -173.29 38.16 Favored Glycine 0 N--CA 1.447 -0.574 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 31.7 m-85 -90.14 124.66 35.01 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.896 0.348 . . . . 0.0 110.17 179.479 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.515 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 31.7 m -63.36 -63.9 3.54 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-O 119.648 -0.215 . . . . 0.0 111.317 -179.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.646 ' HD2' HG13 ' A' ' 43' ' ' VAL . 63.5 Cg_endo -75.63 96.97 1.07 Allowed 'Trans proline' 0 C--N 1.358 1.038 0 C-N-CA 121.267 1.312 . . . . 0.0 111.068 177.506 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -50.61 -43.31 56.77 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 116.057 -0.519 . . . . 0.0 112.38 -179.222 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.465 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -132.39 118.58 19.56 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.607 -0.27 . . . . 0.0 110.655 179.684 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.436 HG13 ' HG3' ' A' ' 120' ' ' MET . 5.6 pt -97.67 125.72 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.27 0 CA-C-O 121.085 0.469 . . . . 0.0 111.037 179.777 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 83.9 t -97.76 126.67 50.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.36 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . 0.442 HD22 ' HB1' ' A' ' 62' ' ' ALA . 3.3 mt -135.76 171.42 14.49 Favored 'General case' 0 CA--C 1.533 0.302 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.494 -179.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 14.5 mttt -93.63 174.58 7.12 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-N 116.448 -0.342 . . . . 0.0 110.978 179.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . 0.521 ' HD3' ' HB2' ' A' ' 104' ' ' ALA . 2.8 ttpt -106.46 147.88 28.81 Favored 'General case' 0 N--CA 1.464 0.238 0 CA-C-O 120.852 0.358 . . . . 0.0 111.891 -179.296 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 38.0 t 65.08 19.72 11.88 Favored 'General case' 0 N--CA 1.473 0.685 0 CA-C-N 115.685 -0.689 . . . . 0.0 111.641 179.773 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.421 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 9.6 p -123.5 135.93 26.64 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.918 -179.844 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_endo -63.45 122.35 10.47 Favored 'Trans proline' 0 C--N 1.345 0.382 0 C-N-CA 122.118 1.878 . . . . 0.0 111.464 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . 0.442 ' HB1' HD22 ' A' ' 56' ' ' LEU . . . -123.85 139.41 54.0 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.931 0.396 . . . . 0.0 111.728 -179.528 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.473 ' HB2' HG22 ' A' ' 96' ' ' VAL . 3.3 ptt180 -122.3 128.29 50.88 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 121.769 0.795 . . . . 0.0 111.389 179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.6 mm -101.58 113.62 38.39 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.759 179.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.513 HG22 HG23 ' A' ' 96' ' ' VAL . 3.0 t -88.82 106.91 17.25 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.242 0 CA-C-N 116.554 -0.294 . . . . 0.0 111.507 -179.192 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 64.2 m-85 -94.03 113.24 25.18 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.016 0.436 . . . . 0.0 111.258 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -99.52 104.35 16.16 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.522 179.812 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.7 94.97 5.17 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 121.231 0.539 . . . . 0.0 111.498 -179.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -88.6 -35.05 17.09 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.829 179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.555 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 0.2 OUTLIER -111.55 136.82 21.03 Favored Pre-proline 0 C--N 1.327 -0.374 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.083 179.906 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -81.01 39.47 0.87 Allowed 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 123.105 2.537 . . . . 0.0 113.288 -179.371 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 2.9 m -67.46 133.68 92.94 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.175 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 34.0 Cg_endo -63.03 -32.23 75.89 Favored 'Trans proline' 0 C--N 1.348 0.551 0 C-N-CA 122.693 2.262 . . . . 0.0 112.776 -179.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -76.58 -2.48 32.73 Favored 'General case' 0 CA--C 1.531 0.222 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.547 179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.53 HD22 HG13 ' A' ' 45' ' ' VAL . 49.9 mt -121.21 13.77 11.23 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.291 -179.954 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 3.7 t70 -70.63 -41.59 72.01 Favored 'General case' 0 CA--C 1.534 0.343 0 CA-C-N 116.421 -0.354 . . . . 0.0 111.764 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 0.8 OUTLIER -124.72 138.48 54.29 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 120.892 0.377 . . . . 0.0 111.586 -179.721 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -118.78 130.35 73.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.593 179.287 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . 0.608 ' O ' ' HD3' ' A' ' 81' ' ' PRO . 0.2 OUTLIER -134.83 131.79 53.52 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 CA-C-O 121.386 0.612 . . . . 0.0 111.316 179.978 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 16.8 m-85 -92.84 101.59 5.53 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.202 -0.908 . . . . 0.0 109.42 178.653 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . 0.608 ' HD3' ' O ' ' A' ' 79' ' ' VAL . 25.5 Cg_exo -61.82 -17.66 56.42 Favored 'Trans proline' 0 CA--C 1.531 0.327 0 C-N-CA 123.024 2.482 . . . . 0.0 113.748 -178.716 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 39.7 m-20 -101.2 -10.22 20.58 Favored 'General case' 0 CA--C 1.537 0.45 0 N-CA-C 112.359 0.503 . . . . 0.0 112.359 -179.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -119.55 -21.38 7.39 Favored 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 111.969 0.359 . . . . 0.0 111.969 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 85.66 1.49 87.43 Favored Glycine 0 CA--C 1.521 0.436 0 C-N-CA 121.248 -0.501 . . . . 0.0 112.226 -179.449 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 53.9 t -80.72 115.24 22.94 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 120.893 0.378 . . . . 0.0 111.41 -178.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . 0.42 ' HB3' ' HB ' ' A' ' 79' ' ' VAL . 20.5 p-80 -131.29 121.63 25.06 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.602 179.831 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -141.15 161.91 36.75 Favored 'General case' 0 C--N 1.332 -0.195 0 N-CA-C 112.396 0.517 . . . . 0.0 112.396 -178.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -99.53 127.11 45.6 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.115 179.208 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 57.5 mt -84.4 130.22 54.71 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-O 121.059 0.457 . . . . 0.0 111.844 -178.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . . . . . . . . . 61.4 Cg_endo -79.04 123.54 5.72 Favored 'Trans proline' 0 CA--C 1.533 0.461 0 C-N-CA 122.704 2.27 . . . . 0.0 112.236 179.205 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 9.1 tpt -64.16 124.96 23.01 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.7 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 84.86 6.25 85.43 Favored Glycine 0 CA--C 1.521 0.426 0 CA-C-N 115.886 -0.597 . . . . 0.0 113.081 179.972 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -132.96 176.87 8.11 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-O 120.984 0.421 . . . . 0.0 111.081 -179.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 6.6 mp0 -115.97 132.17 56.73 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.478 -179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 1.0 OUTLIER -120.51 117.95 28.98 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.333 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.513 HG23 HG22 ' A' ' 65' ' ' VAL . 3.4 p -96.0 130.34 44.83 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.41 0 CA-C-O 121.764 0.792 . . . . 0.0 112.062 -179.429 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.404 ' O ' ' HA ' ' A' ' 63' ' ' ARG . 52.9 t -106.17 115.24 47.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.426 179.167 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -95.81 119.17 33.84 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.871 0.367 . . . . 0.0 111.631 -179.542 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -134.09 157.15 41.67 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.281 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.107 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.4 m -120.0 97.06 49.5 Favored Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.278 -0.419 . . . . 0.0 111.517 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.421 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 62.9 Cg_endo -73.22 98.06 0.99 Allowed 'Trans proline' 0 CA--C 1.532 0.402 0 C-N-CA 122.78 2.32 . . . . 0.0 112.531 179.89 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 2.8 mt-10 -96.51 23.44 6.83 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.014 0.435 . . . . 0.0 111.481 -179.9 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.5 131.91 14.68 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.521 179.66 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . 0.521 ' HB2' ' HD3' ' A' ' 58' ' ' LYS . . . -89.71 128.46 36.1 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.986 0.422 . . . . 0.0 111.495 -179.855 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.57 -158.64 31.15 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.632 -179.978 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -101.82 123.46 45.81 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.048 0.452 . . . . 0.0 111.352 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.434 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 88.2 m-85 -115.9 166.19 12.24 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.019 179.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 95.5 p -141.57 155.73 45.75 Favored 'General case' 0 C--N 1.328 -0.346 0 N-CA-C 112.484 0.55 . . . . 0.0 112.484 -178.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 49.1 p90 -151.57 129.56 11.78 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.389 178.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -162.59 177.77 9.14 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-O 121.123 0.487 . . . . 0.0 111.904 -179.346 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 34.6 t -116.33 132.12 56.76 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.615 179.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -77.24 75.65 1.74 Allowed Glycine 0 CA--C 1.52 0.366 0 C-N-CA 120.943 -0.646 . . . . 0.0 113.191 -179.866 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -126.78 -60.31 1.23 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 120.774 0.321 . . . . 0.0 111.437 179.872 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -151.36 -86.08 0.07 Allowed 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 120.689 0.28 . . . . 0.0 111.458 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 2.1 ttm -124.8 111.99 16.17 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-O 120.923 0.392 . . . . 0.0 111.362 -179.72 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . . . . . . . . . 1.8 mmt -131.49 156.81 45.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.835 179.723 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -149.14 105.34 3.5 Favored 'General case' 0 N--CA 1.465 0.315 0 CA-C-O 120.902 0.382 . . . . 0.0 111.874 -179.835 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -144.64 115.05 0.83 Allowed Glycine 0 CA--C 1.519 0.334 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.946 179.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.465 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 6.8 ttpt -120.88 149.82 42.01 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-O 121.265 0.555 . . . . 0.0 111.785 -179.201 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.436 ' HG3' HG13 ' A' ' 54' ' ' ILE . 17.2 ttp -133.02 133.65 43.37 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.701 179.823 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 4.2 mp -118.82 119.66 61.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.462 0 CA-C-O 121.111 0.481 . . . . 0.0 111.08 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 92.5 t -102.61 121.86 54.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.946 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.25 1.106 0 CA-C-O 118.147 -0.93 . . . . 0.0 111.937 -179.428 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 2.711 0 N-CA-C 112.328 -0.309 . . . . 0.0 112.328 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -89.49 -36.18 15.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.754 -0.223 . . . . 0.0 111.447 179.973 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER 59.88 -160.62 0.29 Allowed 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 116.08 -0.509 . . . . 0.0 111.95 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLY . . . . . . . . . . . . . . . -82.86 152.54 30.16 Favored Glycine 0 C--N 1.331 0.293 0 C-N-CA 120.682 -0.771 . . . . 0.0 112.663 179.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -116.32 128.93 55.98 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 121.321 0.582 . . . . 0.0 111.527 -179.452 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' LYS . . . . . . . . . . . . . 4.4 mtpt -89.19 130.17 35.65 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.736 179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -73.41 151.85 41.01 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.998 -0.546 . . . . 0.0 111.388 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLN . . . . . 0.575 ' HG2' ' O ' ' A' ' 40' ' ' GLU . 2.6 pt20 -80.33 141.06 35.81 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.036 0.445 . . . . 0.0 111.4 -179.487 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . . . . . . . . . 56.4 mt-30 -96.83 115.03 26.73 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.73 179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -95.76 -149.99 0.31 Allowed 'General case' 0 CA--C 1.536 0.42 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.454 -179.781 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ASN . . . . . . . . . . . . . 2.2 t30 -81.58 72.68 8.63 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -179.132 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 96.03 -6.11 66.44 Favored Glycine 0 CA--C 1.52 0.395 0 C-N-CA 120.806 -0.711 . . . . 0.0 113.875 178.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' TYR . . . . . . . . . . . . . 34.4 p90 -140.92 160.67 39.56 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.894 0.347 . . . . 0.0 110.788 -179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -110.15 156.08 21.09 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 121.136 0.493 . . . . 0.0 111.379 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.575 ' O ' ' HG2' ' A' ' 33' ' ' GLN . 2.5 tt0 -144.31 143.2 30.87 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.785 -0.643 . . . . 0.0 111.513 -179.529 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -143.73 128.42 14.52 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.375 0 CA-C-O 121.065 0.459 . . . . 0.0 111.053 179.089 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.75 106.5 18.5 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 121.152 0.501 . . . . 0.0 111.078 179.689 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.598 HG13 ' HD2' ' A' ' 51' ' ' PRO . 49.0 t -98.09 101.99 12.87 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.557 -179.922 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -71.59 117.81 13.63 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.796 179.913 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' VAL . . . . . 0.66 HG13 HD22 ' A' ' 75' ' ' LEU . 31.8 t -99.49 98.22 6.8 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.377 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.394 -178.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' MET . . . . . 0.492 ' HA ' ' HB2' ' A' ' 70' ' ' ASP . 10.8 ptp -140.38 82.3 1.85 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.333 179.499 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 88.0 -12.14 64.97 Favored Glycine 0 CA--C 1.517 0.194 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 -178.017 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . 0.446 ' HA2' ' SD ' ' A' ' 116' ' ' MET . . . 173.27 -171.43 44.46 Favored Glycine 0 N--CA 1.446 -0.685 0 N-CA-C 111.186 -0.766 . . . . 0.0 111.186 179.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . . . . . . . . . 36.5 m-85 -88.41 123.02 32.55 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.973 0.386 . . . . 0.0 110.265 179.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' THR . . . . . 0.515 ' HB ' ' HD3' ' A' ' 51' ' ' PRO . 35.5 m -61.99 -63.45 4.23 Favored Pre-proline 0 CA--C 1.54 0.558 0 CA-C-O 119.559 -0.257 . . . . 0.0 111.359 -179.684 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' PRO . . . . . 0.598 ' HD2' HG13 ' A' ' 43' ' ' VAL . 73.6 Cg_endo -75.76 96.74 1.06 Allowed 'Trans proline' 0 C--N 1.355 0.896 0 C-N-CA 121.296 1.331 . . . . 0.0 111.013 177.501 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.7 pm0 -50.57 -43.13 56.26 Favored 'General case' 0 N--CA 1.469 0.515 0 N-CA-C 112.279 0.474 . . . . 0.0 112.279 -179.252 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.439 ' HA ' ' O ' ' A' ' 119' ' ' LYS . 0.0 OUTLIER -130.41 118.8 21.73 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.659 0.266 . . . . 0.0 110.866 179.775 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 8.0 pt -98.8 126.31 52.02 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-O 121.079 0.466 . . . . 0.0 110.984 179.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 91.9 t -97.13 126.46 49.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.925 0.393 . . . . 0.0 111.532 -179.704 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' LEU . . . . . . . . . . . . . 8.3 mt -133.98 168.33 18.99 Favored 'General case' 0 CA--C 1.534 0.328 0 CA-C-N 115.886 -0.597 . . . . 0.0 111.38 -179.92 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 8.6 tttt -95.09 168.28 10.86 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.327 -0.397 . . . . 0.0 110.508 179.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' LYS . . . . . . . . . . . . . 4.6 ttpp -99.18 147.89 24.65 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.888 0.375 . . . . 0.0 111.964 -179.423 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 34.4 t 65.78 19.83 11.39 Favored 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 115.493 -0.776 . . . . 0.0 111.874 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.449 ' O ' ' HD2' ' A' ' 101' ' ' PRO . 6.3 p -123.71 135.63 26.41 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.895 -179.892 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' PRO . . . . . . . . . . . . . 26.3 Cg_endo -64.52 123.36 11.64 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 122.104 1.869 . . . . 0.0 111.53 178.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ALA . . . . . . . . . . . . . . . -124.61 138.82 54.29 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-O 120.893 0.378 . . . . 0.0 111.703 -179.454 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' ARG . . . . . 0.41 ' HB2' HG22 ' A' ' 96' ' ' VAL . 5.8 ptt180 -120.4 126.63 50.94 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-O 121.706 0.765 . . . . 0.0 111.274 179.875 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ILE . . . . . . . . . . . . . 3.2 mm -99.42 115.48 40.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.801 -179.911 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' VAL . . . . . 0.484 HG22 HG23 ' A' ' 96' ' ' VAL . 4.0 t -91.17 109.55 21.23 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-O 120.825 0.345 . . . . 0.0 111.287 -179.342 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . . . . . . . . . 65.9 m-85 -96.78 112.23 24.07 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.075 0.464 . . . . 0.0 111.431 -179.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -96.74 101.63 13.26 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.281 179.517 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -76.77 97.91 4.64 Favored 'General case' 0 N--CA 1.463 0.203 0 CA-C-O 121.281 0.563 . . . . 0.0 111.918 -179.12 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -95.98 -29.56 14.09 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.828 179.715 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ASP . . . . . 0.492 ' HB2' ' HA ' ' A' ' 46' ' ' MET . 7.8 t70 -111.75 131.79 22.23 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.922 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 94.4 Cg_endo -80.63 39.45 0.86 Allowed 'Trans proline' 0 C--N 1.348 0.521 0 C-N-CA 123.085 2.523 . . . . 0.0 113.121 -179.644 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.528 ' HB2' HD12 ' A' ' 75' ' ' LEU . 2.7 m -69.75 139.1 88.33 Favored Pre-proline 0 C--N 1.329 -0.307 0 CA-C-N 116.349 -0.387 . . . . 0.0 111.289 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_endo -62.61 -33.85 76.41 Favored 'Trans proline' 0 C--N 1.348 0.553 0 C-N-CA 122.883 2.389 . . . . 0.0 112.863 -179.6 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' CYS . . . . . . . . . . . . . 10.7 p -78.59 -2.57 39.56 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.385 -0.37 . . . . 0.0 111.45 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.66 HD22 HG13 ' A' ' 45' ' ' VAL . 37.9 mt -121.14 9.94 10.59 Favored 'General case' 0 CA--C 1.531 0.234 0 CA-C-N 116.525 -0.307 . . . . 0.0 111.32 -179.918 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -68.93 -37.29 78.8 Favored 'General case' 0 CA--C 1.533 0.294 0 CA-C-O 121.059 0.457 . . . . 0.0 111.118 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -129.34 160.06 34.21 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.515 179.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ILE . . . . . . . . . . . . . 0.5 OUTLIER -133.49 128.5 54.89 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-O 121.339 0.59 . . . . 0.0 111.018 179.44 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -132.39 128.83 58.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.516 0 CA-C-O 121.312 0.577 . . . . 0.0 111.071 179.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' PHE . . . . . . . . . . . . . 19.7 m-85 -92.54 102.08 6.1 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.47 -0.787 . . . . 0.0 109.537 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -66.79 -16.24 49.58 Favored 'Trans proline' 0 C--N 1.348 0.514 0 C-N-CA 122.581 2.187 . . . . 0.0 113.598 -178.436 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ASP . . . . . . . . . . . . . 37.3 m-20 -100.68 -6.37 25.22 Favored 'General case' 0 CA--C 1.535 0.396 0 N-CA-C 111.984 0.364 . . . . 0.0 111.984 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -121.38 -22.98 5.8 Favored 'General case' 0 CA--C 1.533 0.318 0 N-CA-C 111.998 0.37 . . . . 0.0 111.998 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' GLY . . . . . . . . . . . . . . . 82.25 25.33 51.95 Favored Glycine 0 CA--C 1.52 0.355 0 C-N-CA 120.96 -0.638 . . . . 0.0 112.032 -179.473 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' VAL . . . . . . . . . . . . . 52.0 t -106.6 117.7 52.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.813 0.339 . . . . 0.0 111.684 -178.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' HIS . . . . . . . . . . . . . 1.8 p80 -121.1 117.52 27.38 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.52 179.389 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' ALA . . . . . . . . . . . . . . . -133.82 165.83 24.08 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 121.138 0.494 . . . . 0.0 112.025 -179.292 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -107.38 140.56 40.11 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.948 -0.569 . . . . 0.0 110.474 179.62 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 58.9 mt -102.07 129.56 26.11 Favored Pre-proline 0 C--N 1.328 -0.328 0 CA-C-O 120.986 0.422 . . . . 0.0 111.363 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' PRO . . . . . 0.438 ' HG2' ' HB2' ' A' ' 93' ' ' GLU . 74.3 Cg_endo -82.7 126.2 4.53 Favored 'Trans proline' 0 CA--C 1.533 0.426 0 C-N-CA 122.723 2.282 . . . . 0.0 112.341 179.284 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' MET . . . . . . . . . . . . . 10.7 tpt -64.72 124.23 21.4 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 121.023 0.439 . . . . 0.0 111.789 -179.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . 85.65 5.23 84.6 Favored Glycine 0 CA--C 1.521 0.424 0 CA-C-N 115.87 -0.605 . . . . 0.0 113.195 179.987 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.438 ' HB2' ' HG2' ' A' ' 90' ' ' PRO . 44.8 mt-10 -133.29 176.78 8.21 Favored 'General case' 0 CA--C 1.532 0.251 0 CA-C-O 120.959 0.409 . . . . 0.0 111.181 -179.613 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -112.74 132.63 55.13 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.239 -0.437 . . . . 0.0 111.834 -179.747 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' TYR . . . . . . . . . . . . . 11.1 t80 -118.98 125.43 49.39 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.982 178.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' VAL . . . . . 0.484 HG23 HG22 ' A' ' 65' ' ' VAL . 1.8 p -101.68 136.31 34.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 121.672 0.749 . . . . 0.0 112.462 -178.851 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 61.5 t -113.26 112.31 39.82 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.069 178.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' GLU . . . . . . . . . . . . . 6.4 mt-10 -93.27 118.72 31.59 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.318 -0.401 . . . . 0.0 111.511 -179.498 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 1.1 pt -135.23 156.98 39.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 116.071 -0.513 . . . . 0.0 111.215 179.863 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' THR . . . . . . . . . . . . . 3.5 m -120.36 97.4 48.97 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.289 -0.414 . . . . 0.0 111.573 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' PRO . . . . . 0.449 ' HD2' ' O ' ' A' ' 60' ' ' VAL . 66.7 Cg_endo -72.19 100.06 1.07 Allowed 'Trans proline' 0 C--N 1.346 0.427 0 C-N-CA 122.794 2.329 . . . . 0.0 112.36 179.544 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 3.1 mt-10 -96.11 10.36 37.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.854 0.359 . . . . 0.0 111.9 -179.521 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -138.03 132.45 32.22 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.51 -0.314 . . . . 0.0 110.779 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ALA . . . . . . . . . . . . . . . -87.38 127.3 35.21 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.018 0.437 . . . . 0.0 111.314 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 163.78 -157.24 29.41 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.827 -0.702 . . . . 0.0 112.624 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLU . . . . . . . . . . . . . 2.0 mt-10 -101.73 126.81 48.65 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.127 0.489 . . . . 0.0 111.668 -179.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' PHE . . . . . 0.443 ' HB2' ' HB3' ' A' ' 120' ' ' MET . 86.0 m-85 -119.64 173.76 6.82 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.67 -0.696 . . . . 0.0 109.815 179.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' SER . . . . . . . . . . . . . 41.9 p -154.7 160.86 41.64 Favored 'General case' 0 C--N 1.33 -0.243 0 N-CA-C 112.593 0.59 . . . . 0.0 112.593 -178.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' PHE . . . . . . . . . . . . . 35.8 p90 -152.79 133.99 14.23 Favored 'General case' 0 N--CA 1.468 0.449 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.89 178.994 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' ALA . . . . . . . . . . . . . . . -163.62 177.73 8.52 Favored 'General case' 0 N--CA 1.467 0.39 0 CA-C-O 121.05 0.452 . . . . 0.0 111.879 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 33.7 t -148.65 127.45 12.59 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.9 -0.591 . . . . 0.0 110.553 179.017 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 68.51 -145.48 44.03 Favored Glycine 0 CA--C 1.522 0.506 0 C-N-CA 120.823 -0.703 . . . . 0.0 112.949 -179.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' MET . . . . . . . . . . . . . 2.7 tpt -153.47 75.55 1.06 Allowed 'General case' 0 CA--C 1.531 0.234 0 CA-C-O 121.043 0.449 . . . . 0.0 111.062 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -119.35 41.3 3.13 Favored 'General case' 0 CA--C 1.533 0.297 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.363 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' MET . . . . . . . . . . . . . 1.6 ttp 59.11 37.73 24.06 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.109 0.481 . . . . 0.0 111.714 -179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' MET . . . . . 0.446 ' SD ' ' HA2' ' A' ' 48' ' ' GLY . 2.5 ttp -139.55 135.64 33.63 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.654 -179.773 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' HIS . . . . . . . . . . . . . 4.7 t-80 -158.24 135.31 9.96 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.414 -0.357 . . . . 0.0 111.383 -179.6 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' GLY . . . . . . . . . . . . . . . -102.05 150.01 18.12 Favored Glycine 0 CA--C 1.519 0.312 0 C-N-CA 121.087 -0.578 . . . . 0.0 111.748 178.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' LYS . . . . . 0.439 ' O ' ' HA ' ' A' ' 53' ' ' LEU . 5.4 ttpt -126.84 150.82 49.01 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-O 121.071 0.463 . . . . 0.0 111.568 -179.849 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' MET . . . . . 0.443 ' HB3' ' HB2' ' A' ' 107' ' ' PHE . 2.5 ttm -134.22 141.01 46.87 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.043 179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 3.7 mp -124.66 120.22 58.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-O 120.984 0.421 . . . . 0.0 110.706 179.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' VAL . . . . . . . . . . . . . 86.0 t -103.25 124.34 57.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.238 -179.675 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' GLU . . . . . . . . . . . . . 2.0 mm-40 . . . . . 0 C--O 1.252 1.216 0 CA-C-O 118.106 -0.949 . . . . 0.0 111.46 -179.601 . . . . . . . . 0 0 . 1 stop_ save_